0000917520-20-000047.txt : 20201029 0000917520-20-000047.hdr.sgml : 20201029 20201029162700 ACCESSION NUMBER: 0000917520-20-000047 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 97 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201029 DATE AS OF CHANGE: 20201029 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTEGRA LIFESCIENCES HOLDINGS CORP CENTRAL INDEX KEY: 0000917520 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 510317849 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-26224 FILM NUMBER: 201273010 BUSINESS ADDRESS: STREET 1: 1100 CAMPUS ROAD CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 6092750500 MAIL ADDRESS: STREET 1: 1100 CAMPUS ROAD CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: INTEGRA LIFESCIENCES CORP DATE OF NAME CHANGE: 19950614 10-Q 1 iart-2020093010q.htm 10-Q Document
false--12-31Q320200000917520P3Y5.505.004.504.00P1Mus-gaap:AccountingStandardsUpdate201613Member430300067270000.010.0124000000024000000088735000891910008775000002000001000000150000001500000000P3MP6Y28650004915000 0000917520 2020-01-01 2020-09-30 0000917520 2020-10-27 0000917520 2019-01-01 2019-09-30 0000917520 2020-07-01 2020-09-30 0000917520 2019-07-01 2019-09-30 0000917520 2020-09-30 0000917520 2019-12-31 0000917520 2018-12-31 0000917520 2019-09-30 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000917520 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0000917520 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000917520 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000917520 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000917520 us-gaap:RetainedEarningsMember 2019-09-30 0000917520 2019-04-01 2019-06-30 0000917520 us-gaap:CommonStockMember 2019-03-31 0000917520 2019-01-01 2019-03-31 0000917520 us-gaap:TreasuryStockMember 2019-04-01 2019-06-30 0000917520 2019-06-30 0000917520 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0000917520 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000917520 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000917520 us-gaap:CommonStockMember 2019-09-30 0000917520 us-gaap:TreasuryStockMember 2019-09-30 0000917520 us-gaap:RetainedEarningsMember 2019-06-30 0000917520 us-gaap:RetainedEarningsMember 2018-12-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000917520 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000917520 us-gaap:CommonStockMember 2018-12-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000917520 us-gaap:TreasuryStockMember 2019-03-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000917520 us-gaap:TreasuryStockMember 2019-06-30 0000917520 us-gaap:CommonStockMember 2019-06-30 0000917520 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000917520 us-gaap:TreasuryStockMember 2018-12-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000917520 us-gaap:RetainedEarningsMember 2019-03-31 0000917520 2019-03-31 0000917520 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000917520 2020-01-01 2020-03-31 0000917520 2020-04-01 2020-06-30 0000917520 us-gaap:CommonStockMember 2020-09-30 0000917520 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000917520 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000917520 us-gaap:TreasuryStockMember 2020-06-30 0000917520 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0000917520 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0000917520 us-gaap:TreasuryStockMember 2020-04-01 2020-06-30 0000917520 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000917520 us-gaap:TreasuryStockMember 2019-12-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000917520 us-gaap:RetainedEarningsMember 2020-09-30 0000917520 us-gaap:CommonStockMember 2019-12-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000917520 us-gaap:CommonStockMember 2020-03-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000917520 us-gaap:CommonStockMember 2020-06-30 0000917520 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000917520 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000917520 us-gaap:RetainedEarningsMember 2020-03-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000917520 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0000917520 us-gaap:TreasuryStockMember 2020-03-31 0000917520 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-12-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000917520 us-gaap:RetainedEarningsMember 2020-06-30 0000917520 2020-03-31 0000917520 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000917520 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000917520 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0000917520 us-gaap:TreasuryStockMember 2020-09-30 0000917520 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000917520 us-gaap:RetainedEarningsMember 2019-12-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000917520 2020-06-30 0000917520 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000917520 2019-01-01 2019-12-31 0000917520 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember iart:SmithNephewUSDLimitedMember 2020-09-30 0000917520 srt:ScenarioForecastMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember iart:SmithNephewUSDLimitedMember us-gaap:SubsequentEventMember 2020-12-31 0000917520 iart:ConsortiumofFocusedOrthopedistsLLCMember srt:ScenarioForecastMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember iart:SmithNephewUSDLimitedMember us-gaap:SubsequentEventMember 2020-12-31 2020-12-31 0000917520 iart:IntegratedShoulderCollaborationInc.Member 2019-01-01 2019-03-31 0000917520 iart:ArkisBioSciencesInc.Member 2019-07-29 0000917520 iart:ReboundTherapeuticsCorporationMember 2019-01-01 2019-12-31 0000917520 iart:IntegratedShoulderCollaborationInc.Member us-gaap:LicensingAgreementsMember 2019-01-04 2019-01-04 0000917520 iart:ArkisBioSciencesInc.Member 2019-07-29 2019-07-29 0000917520 iart:ReboundTherapeuticsCorporationMember us-gaap:InProcessResearchAndDevelopmentMember 2019-09-09 2019-09-09 0000917520 iart:ReboundTherapeuticsCorporationMember 2019-09-09 2019-09-09 0000917520 iart:ArkisBioSciencesInc.Member 2020-09-30 0000917520 iart:ReboundTherapeuticsCorporationMember iart:DeferredTaxAssetMember 2019-09-09 2019-09-09 0000917520 iart:ReboundTherapeuticsCorporationMember us-gaap:CashAndCashEquivalentsMember 2019-09-09 2019-09-09 0000917520 iart:ReboundTherapeuticsCorporationMember 2019-12-31 0000917520 iart:ArkisBioSciencesInc.Member iart:MilestonePaymentOneMember 2019-07-29 0000917520 iart:ArkisBioSciencesInc.Member iart:MilestonePaymentTwoMember 2019-07-29 0000917520 iart:ReboundTherapeuticsCorporationMember 2019-09-09 0000917520 iart:IntegratedShoulderCollaborationInc.Member 2019-01-04 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:LicensingAgreementsMember 2019-07-29 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:DevelopedTechnologyRightsMember 2019-07-29 2019-07-29 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:LicensingAgreementsMember 2019-07-29 2019-07-29 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:DevelopedTechnologyRightsMember 2019-07-29 0000917520 2020-10-01 2020-09-30 0000917520 srt:MaximumMember 2020-01-01 2020-09-30 0000917520 iart:RegenerativeSkinAndWoundMember iart:OrthopedicsandTissueTechnologiesMember 2020-01-01 2020-09-30 0000917520 iart:InstrumentsMember iart:CodmanSpecialtySurgicalMember 2020-01-01 2020-09-30 0000917520 iart:RegenerativeSkinAndWoundMember iart:OrthopedicsandTissueTechnologiesMember 2019-01-01 2019-09-30 0000917520 iart:NeurosurgeryMember iart:CodmanSpecialtySurgicalMember 2019-07-01 2019-09-30 0000917520 iart:RegenerativeSkinAndWoundMember iart:OrthopedicsandTissueTechnologiesMember 2020-07-01 2020-09-30 0000917520 iart:CodmanSpecialtySurgicalMember 2020-07-01 2020-09-30 0000917520 iart:OrthopedicsandTissueTechnologiesMember 2020-01-01 2020-09-30 0000917520 iart:NeurosurgeryMember iart:CodmanSpecialtySurgicalMember 2020-01-01 2020-09-30 0000917520 iart:NeurosurgeryMember iart:CodmanSpecialtySurgicalMember 2020-07-01 2020-09-30 0000917520 iart:ExtremityOrthopedicsMember iart:OrthopedicsandTissueTechnologiesMember 2020-07-01 2020-09-30 0000917520 iart:InstrumentsMember iart:CodmanSpecialtySurgicalMember 2019-07-01 2019-09-30 0000917520 iart:OrthopedicsandTissueTechnologiesMember 2019-01-01 2019-09-30 0000917520 iart:CodmanSpecialtySurgicalMember 2020-01-01 2020-09-30 0000917520 iart:PrivateLabelMember iart:OrthopedicsandTissueTechnologiesMember 2019-07-01 2019-09-30 0000917520 iart:RegenerativeSkinAndWoundMember iart:OrthopedicsandTissueTechnologiesMember 2019-07-01 2019-09-30 0000917520 iart:PrivateLabelMember iart:OrthopedicsandTissueTechnologiesMember 2020-07-01 2020-09-30 0000917520 iart:ExtremityOrthopedicsMember iart:OrthopedicsandTissueTechnologiesMember 2019-07-01 2019-09-30 0000917520 iart:PrivateLabelMember iart:OrthopedicsandTissueTechnologiesMember 2019-01-01 2019-09-30 0000917520 iart:InstrumentsMember iart:CodmanSpecialtySurgicalMember 2019-01-01 2019-09-30 0000917520 iart:OrthopedicsandTissueTechnologiesMember 2019-07-01 2019-09-30 0000917520 iart:ExtremityOrthopedicsMember iart:OrthopedicsandTissueTechnologiesMember 2020-01-01 2020-09-30 0000917520 iart:InstrumentsMember iart:CodmanSpecialtySurgicalMember 2020-07-01 2020-09-30 0000917520 iart:CodmanSpecialtySurgicalMember 2019-07-01 2019-09-30 0000917520 iart:NeurosurgeryMember iart:CodmanSpecialtySurgicalMember 2019-01-01 2019-09-30 0000917520 iart:CodmanSpecialtySurgicalMember 2019-01-01 2019-09-30 0000917520 iart:OrthopedicsandTissueTechnologiesMember 2020-07-01 2020-09-30 0000917520 iart:PrivateLabelMember iart:OrthopedicsandTissueTechnologiesMember 2020-01-01 2020-09-30 0000917520 iart:ExtremityOrthopedicsMember iart:OrthopedicsandTissueTechnologiesMember 2019-01-01 2019-09-30 0000917520 srt:MinimumMember 2020-01-01 2020-09-30 0000917520 us-gaap:CustomerRelationshipsMember 2019-12-31 0000917520 us-gaap:CustomerRelationshipsMember 2019-01-01 2019-12-31 0000917520 iart:CompletedTechnologyMember 2019-12-31 0000917520 iart:CompletedTechnologyMember 2019-01-01 2019-12-31 0000917520 iart:SupplierRelationShipsMember 2019-12-31 0000917520 iart:SupplierRelationShipsMember 2019-01-01 2019-12-31 0000917520 iart:TrademarksBrandNamesMember 2019-12-31 0000917520 iart:TrademarksBrandNamesMember 2019-01-01 2019-12-31 0000917520 us-gaap:TradeNamesMember 2019-12-31 0000917520 iart:AllOtherMember 2019-12-31 0000917520 iart:AllOtherMember 2019-01-01 2019-12-31 0000917520 iart:OrthopedicsandTissueTechnologiesMember 2019-12-31 0000917520 iart:OrthopedicsandTissueTechnologiesMember 2020-09-30 0000917520 iart:CodmanSpecialtySurgicalMember 2020-09-30 0000917520 iart:CodmanSpecialtySurgicalMember 2019-12-31 0000917520 iart:AllOtherMember 2020-01-01 2020-09-30 0000917520 iart:SupplierRelationShipsMember 2020-09-30 0000917520 iart:TransferToAssetsHeldForSaleMember 2020-09-30 0000917520 iart:TrademarksBrandNamesMember 2020-01-01 2020-09-30 0000917520 iart:AllOtherMember 2020-09-30 0000917520 iart:CompletedTechnologyMember 2020-09-30 0000917520 us-gaap:CustomerRelationshipsMember 2020-09-30 0000917520 iart:TrademarksBrandNamesMember 2020-09-30 0000917520 us-gaap:TradeNamesMember 2020-09-30 0000917520 iart:SupplierRelationShipsMember 2020-01-01 2020-09-30 0000917520 us-gaap:CustomerRelationshipsMember 2020-01-01 2020-09-30 0000917520 iart:CompletedTechnologyMember 2020-01-01 2020-09-30 0000917520 us-gaap:InProcessResearchAndDevelopmentMember 2020-09-30 0000917520 us-gaap:InProcessResearchAndDevelopmentMember 2019-12-31 0000917520 us-gaap:StandbyLettersOfCreditMember iart:SeniorCreditFacilityMember 2020-09-30 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-01-01 2020-09-30 0000917520 iart:SeniorCreditFacilityMember 2020-02-03 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-09-30 0000917520 us-gaap:SecuredDebtMember iart:TermLoanFacilityMember 2020-02-03 0000917520 us-gaap:RevolvingCreditFacilityMember 2019-12-31 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember us-gaap:CallOptionMember 2020-01-01 2020-09-30 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-02-04 0000917520 us-gaap:SecuredDebtMember iart:TermLoanFacilityMember 2020-09-30 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember us-gaap:CallOptionMember 2020-02-04 2020-02-04 0000917520 srt:MinimumMember iart:SeniorCreditFacilityMember us-gaap:EurodollarMember 2020-01-01 2020-09-30 0000917520 srt:MinimumMember iart:SeniorCreditFacilityMember 2020-01-01 2020-09-30 0000917520 us-gaap:RevolvingCreditFacilityMember 2020-09-30 0000917520 us-gaap:SecuredDebtMember iart:TermLoanFacilityMember 2019-12-31 0000917520 us-gaap:FairValueInputsLevel2Member 2020-09-30 0000917520 iart:SeniorCreditFacilityMember us-gaap:FederalFundsEffectiveSwapRateMember 2020-01-01 2020-09-30 0000917520 iart:SeniorCreditFacilityMember iart:OneMonthEurodollarRateMember 2020-01-01 2020-09-30 0000917520 us-gaap:StandbyLettersOfCreditMember 2020-02-03 0000917520 srt:MaximumMember iart:SeniorCreditFacilityMember us-gaap:EurodollarMember 2020-01-01 2020-09-30 0000917520 us-gaap:RevolvingCreditFacilityMember us-gaap:FairValueInputsLevel2Member 2020-09-30 0000917520 us-gaap:StandbyLettersOfCreditMember iart:SeniorCreditFacilityMember 2019-12-31 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-02-04 2020-02-04 0000917520 us-gaap:SecuredDebtMember iart:TermLoanFacilityMember us-gaap:FairValueInputsLevel2Member 2020-09-30 0000917520 srt:MaximumMember iart:SeniorCreditFacilityMember 2020-01-01 2020-09-30 0000917520 iart:SeniorCreditFacilityMember 2020-07-01 2020-09-30 0000917520 iart:SwinglineLoanMember 2020-02-03 0000917520 us-gaap:RevolvingCreditFacilityMember 2020-02-03 0000917520 iart:SeniorCreditFacilityMember 2020-01-01 2020-03-31 0000917520 2018-10-01 2018-12-31 0000917520 iart:DebtCovenantPeriod8Member iart:SeniorCreditFacilityMember 2020-07-14 0000917520 iart:DebtCovenantPeriod6Member iart:SeniorCreditFacilityMember 2020-07-14 0000917520 iart:DebtCovenantPeriod7Member iart:SeniorCreditFacilityMember 2020-07-14 0000917520 iart:DebtCovenantPeriod9Member iart:SeniorCreditFacilityMember 2020-07-14 0000917520 us-gaap:OtherAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 us-gaap:OtherAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-09-30 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:ShortMember 2017-10-02 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-07-01 2019-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-09-30 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-07-01 2020-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-07-01 2019-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-07-01 2020-09-30 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SubsequentEventMember 2020-10-02 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:LongMember 2017-10-02 0000917520 iart:SwapTwoMember iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:SwapTwoMember iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-09-30 0000917520 iart:SwapThreeMember iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 iart:SwapOneMember iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-09-30 0000917520 iart:SwapThreeMember iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-09-30 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:SwapOneMember iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-09-30 0000917520 iart:SwapOneMember iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 iart:SwapOneMember iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:SwapThreeMember iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-09-30 0000917520 iart:SwapTwoMember iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-09-30 0000917520 iart:SwapTwoMember iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 iart:SwapThreeMember iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-01-01 2020-09-30 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-07-01 2019-09-30 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-07-01 2020-09-30 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-06-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-06-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2020-01-01 2020-09-30 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-07-01 2019-09-30 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2019-07-01 2019-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2019-06-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-09-30 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2020-09-30 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-06-30 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-07-01 2020-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2019-12-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-06-30 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-09-30 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2020-07-01 2020-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-09-30 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2019-01-01 2019-09-30 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2019-09-30 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2019-07-01 2019-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2020-06-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2020-07-01 2020-09-30 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-12-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2018-12-31 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:CrossCurrencyInterestRateContractFourMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractFourMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractFiveMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractFiveMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractFiveMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractFiveMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractFourMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:CrossCurrencyInterestRateContractFourMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche5Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche3Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedDecember182018Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2019-12-31 0000917520 iart:InterestRateSwapDesignatedDecember182018Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedFebruary62017Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:ThreeMonthUSDLIBORMember 2019-12-31 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche5Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2019-12-31 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2019-12-31 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche4Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2019-12-31 0000917520 iart:InterestRateSwapDesignatedDecember182018Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2019-12-31 0000917520 iart:InterestRateSwapDesignatedFebruary62017Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:ThreeMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedDecember182018Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche4Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche3Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2019-12-31 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche3Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2019-12-31 0000917520 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche3Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedFebruary62017Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2019-12-31 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedFebruary62017Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2019-12-31 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedMarch272017Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2019-12-31 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2019-12-31 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedMarch272017Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2019-12-31 0000917520 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 iart:PerformanceStockAndRestrictedStockAwardsMember 2020-01-01 2020-09-30 0000917520 srt:DirectorMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000917520 us-gaap:RestrictedStockMember 2020-01-01 2020-09-30 0000917520 us-gaap:EmployeeStockOptionMember 2020-09-30 0000917520 us-gaap:PerformanceSharesMember 2020-01-01 2020-09-30 0000917520 us-gaap:RestrictedStockMember 2020-09-30 0000917520 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000917520 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000917520 iart:EmployeeMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000917520 srt:MaximumMember iart:DirectorsandCertainExecutiveOfficersMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000917520 srt:MinimumMember iart:DirectorsandCertainExecutiveOfficersMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000917520 2019-05-01 2019-05-31 0000917520 iart:ThirdPartiesMember 2020-09-30 0000917520 iart:RelatedPartiesMember 2020-09-30 0000917520 us-gaap:BuildingMember 2020-09-30 0000917520 us-gaap:VehiclesMember 2020-09-30 0000917520 iart:FiveYearOptionLeasePeriodOneMember srt:AffiliatedEntityMember 2020-01-01 2020-09-30 0000917520 iart:FiveYearOptionLeasePeriodTwoMember srt:AffiliatedEntityMember 2020-01-01 2020-09-30 0000917520 srt:AffiliatedEntityMember 2020-01-01 2020-09-30 0000917520 srt:AffiliatedEntityMember 2019-01-01 2019-09-30 0000917520 2020-02-05 2020-02-05 0000917520 2018-12-11 0000917520 us-gaap:ConvertibleDebtMember 2020-01-01 2020-09-30 0000917520 2020-02-05 0000917520 2020-06-01 2020-06-30 0000917520 iart:CertainPurchasersMember us-gaap:ConvertibleDebtMember 2020-01-01 2020-09-30 0000917520 us-gaap:ForeignCountryMember us-gaap:SwissFederalTaxAdministrationFTAMember 2019-01-01 2019-09-30 0000917520 us-gaap:ForeignCountryMember us-gaap:SwissFederalTaxAdministrationFTAMember 2019-01-01 2019-03-31 0000917520 iart:ReboundTherapeuticsCorporationMember 2019-07-01 2019-09-30 0000917520 us-gaap:ForeignCountryMember us-gaap:MinistryOfTheEconomyFinanceAndIndustryFranceMember 2020-07-01 2020-09-30 0000917520 iart:ReboundTherapeuticsCorporationMember 2019-01-01 2019-09-30 0000917520 iart:PerformanceSharesandRestrictedUnitsMember 2020-09-30 0000917520 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-09-30 0000917520 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-09-30 0000917520 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000917520 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0000917520 us-gaap:AccumulatedTranslationAdjustmentMember 2020-09-30 0000917520 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000917520 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-09-30 0000917520 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-09-30 0000917520 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-09-30 0000917520 us-gaap:InterestIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-09-30 0000917520 us-gaap:OtherExpenseMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-09-30 0000917520 country:US 2020-07-01 2020-09-30 0000917520 srt:EuropeMember 2019-07-01 2019-09-30 0000917520 srt:AsiaPacificMember 2020-07-01 2020-09-30 0000917520 iart:RestOfWorldMember 2019-01-01 2019-09-30 0000917520 srt:AsiaPacificMember 2019-07-01 2019-09-30 0000917520 iart:RestOfWorldMember 2020-01-01 2020-09-30 0000917520 country:US 2019-07-01 2019-09-30 0000917520 srt:EuropeMember 2019-01-01 2019-09-30 0000917520 srt:EuropeMember 2020-07-01 2020-09-30 0000917520 country:US 2019-01-01 2019-09-30 0000917520 iart:RestOfWorldMember 2019-07-01 2019-09-30 0000917520 srt:AsiaPacificMember 2019-01-01 2019-09-30 0000917520 country:US 2020-01-01 2020-09-30 0000917520 srt:EuropeMember 2020-01-01 2020-09-30 0000917520 iart:RestOfWorldMember 2020-07-01 2020-09-30 0000917520 srt:AsiaPacificMember 2020-01-01 2020-09-30 0000917520 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-09-30 0000917520 us-gaap:OperatingSegmentsMember iart:CodmanSpecialtySurgicalMember 2020-07-01 2020-09-30 0000917520 us-gaap:OperatingSegmentsMember iart:OrthopedicsandTissueTechnologiesMember 2019-07-01 2019-09-30 0000917520 us-gaap:CorporateNonSegmentMember 2020-07-01 2020-09-30 0000917520 us-gaap:OperatingSegmentsMember iart:CodmanSpecialtySurgicalMember 2020-01-01 2020-09-30 0000917520 us-gaap:OperatingSegmentsMember iart:OrthopedicsandTissueTechnologiesMember 2020-07-01 2020-09-30 0000917520 us-gaap:OperatingSegmentsMember 2020-07-01 2020-09-30 0000917520 us-gaap:CorporateNonSegmentMember 2019-07-01 2019-09-30 0000917520 us-gaap:OperatingSegmentsMember iart:OrthopedicsandTissueTechnologiesMember 2019-01-01 2019-09-30 0000917520 us-gaap:OperatingSegmentsMember iart:OrthopedicsandTissueTechnologiesMember 2020-01-01 2020-09-30 0000917520 us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0000917520 us-gaap:OperatingSegmentsMember 2020-01-01 2020-09-30 0000917520 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-09-30 0000917520 us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0000917520 us-gaap:OperatingSegmentsMember iart:CodmanSpecialtySurgicalMember 2019-07-01 2019-09-30 0000917520 us-gaap:OperatingSegmentsMember iart:CodmanSpecialtySurgicalMember 2019-01-01 2019-09-30 0000917520 iart:DermaSciencesMember 2020-09-30 0000917520 iart:DermaSciencesMember iart:BioDEarnoutPaymentsandMedihoneyEarnoutPaymentsMember 2020-01-01 2020-09-30 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2019-12-31 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2020-01-01 2020-09-30 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2020-09-30 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2019-12-31 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2020-01-01 2020-09-30 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2020-09-30 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2019-01-01 2019-09-30 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2018-12-31 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2019-09-30 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2018-12-31 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2019-09-30 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2019-01-01 2019-09-30 xbrli:pure iart:asset iso4217:CHF iso4217:USD xbrli:shares iso4217:USD xbrli:shares iart:plan iso4217:GBP iart:liability iart:renewal_option iart:Segment iso4217:EUR iart:product
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 10-Q
 
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             
COMMISSION FILE NO. 0-26224
 
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
 
Delaware
 
51-0317849
(STATE OR OTHER JURISDICTION OF
INCORPORATION OR ORGANIZATION)
 
(I.R.S. EMPLOYER
IDENTIFICATION NO.)
 
 
1100 Campus Road
 
08540
Princeton
,
New Jersey
 
(ZIP CODE)
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
 
Registrant's Telephone Number, Including Area Code: (609275-0500
Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report:
Securities registered pursuant to Section 12(b) of the Act:
TITLE OF EACH CLASS
TRADING SYMBOL
NAME OF EACH EXCHANGE ON WHICH REGISTERED
Common Stock, Par Value $.01 Per Share
IART
Nasdaq Global Select Market
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and "emerging growth company" in Rule 12b-2 of the Exchange Act.





Large accelerated filer
Accelerated filer
 
 
 
 
Non-accelerated filer
  
Smaller reporting company
 
 
 
 
Emerging growth company
 
 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes      No  
Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.  Yes      No  
The number of shares of the registrant’s Common Stock, $0.01 par value, outstanding as of October 27, 2020 was 84,272,671.
















































INTEGRA LIFESCIENCES HOLDINGS CORPORATION
INDEX
 

 
Page
Number
 
 
 
 
 


 
 
 
 

 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EX-101 INSTANCE DOCUMENT
 
EX-101 SCHEMA DOCUMENT
 
EX-101 CALCULATION LINKBASE DOCUMENT
 
EX-101 DEFINITION LINKBASE DOCUMENT
 
EX-101 LABELS LINKBASE DOCUMENT
 
EX-101 PRESENTATION LINKBASE DOCUMENT
 




PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE INCOME / (LOSS)
(UNAUDITED)
(In thousands, except per share amounts)
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2020
 
2019
 
2020
 
2019
Total revenue, net
$
370,232

 
$
379,095

 
$
983,221

 
$
1,122,430

Costs and expenses:
 
 
 
 
 
 
 
Cost of goods sold
134,811

 
142,636

 
373,765

 
415,219

Research and development
19,460

 
19,003

 
55,202

 
54,957

    In-process research and development

 
59,889

 

 
59,889

Selling, general and administrative
150,076

 
173,098

 
432,136

 
513,345

Intangible asset amortization
8,343

 
5,056

 
23,393

 
21,340

Total costs and expenses
312,690

 
399,682

 
884,496

 
1,064,750

Operating income (loss)
57,542

 
(20,587
)
 
98,725

 
57,680

Interest income
2,273

 
2,913

 
7,124

 
8,051

Interest expense
(20,796
)
 
(13,962
)
 
(54,230
)
 
(40,495
)
Other income, net
2,492

 
4,127

 
2,985

 
8,461

Income (loss) before income taxes
41,511

 
(27,509
)
 
54,604

 
33,697

Provision (benefit) for income taxes
9,174

 
101

 
13,456

 
(1,185
)
Net income (loss)
$
32,337

 
$
(27,610
)
 
$
41,148

 
$
34,882

 
 
 
 
 
 
 
 
Net income (loss) per share
 
 
 
 
 
 
 
Basic
$
0.38

 
$
(0.32
)
 
$
0.49

 
$
0.41

Diluted
$
0.38

 
$
(0.32
)
 
$
0.48

 
$
0.40

 
 
 
 
 
 
 
 
Weighted average common shares outstanding (See Note 14):
 
 
 
 
 
 
 
Basic
84,325

 
85,688

 
84,745

 
85,536

Diluted
84,752

 
85,688

 
85,303

 
86,581

Comprehensive income (loss) (See Note 15)
$
43,548

 
$
(46,521
)
 
$
25,637

 
$
(7,288
)


The accompanying unaudited notes are an integral part of these condensed consolidated financial statements.

4


INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(In thousands, except per share amounts) 
 
September 30, 2020
 
December 31, 2019
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
396,279

 
$
198,911

Trade accounts receivable, net of allowances of $6,727 and $4,303
218,184

 
275,296

Inventories, net
307,839

 
316,054

Assets held for sale
159,977

 

Prepaid expenses and other current assets
69,817

 
67,907

  Total current assets
1,152,096

 
858,168

Property, plant and equipment, net
294,439

 
337,404

Right of use asset - operating leases
84,916

 
94,530

Intangible assets, net
973,685

 
1,031,591

Goodwill
919,556

 
954,280

Deferred tax assets, net
8,150

 
12,623

Other assets
20,679

 
14,644

Total assets
$
3,453,521

 
$
3,303,240

LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Current portion of borrowings under senior credit facility
$
22,500

 
$
45,000

Current portion of lease liability - operating leases
12,518

 
12,253

Accounts payable, trade
50,254

 
113,090

Contract liabilities
4,875

 
4,772

Accrued compensation
71,712

 
79,385

Liabilities held for sale
12,349

 

Accrued expenses and other current liabilities
80,938

 
76,809

  Total current liabilities
255,146

 
331,309

Long-term borrowings under senior credit facility
944,102

 
1,198,561

Long-term borrowings under securitization facility
92,300

 
104,500

Long-term convertible securities
469,898

 

Lease liability - operating leases
88,778

 
97,504

Deferred tax liabilities
27,780

 
36,553

Other liabilities
177,530

 
118,077

Total liabilities
2,055,534

 
1,886,504

Stockholders’ equity:
 
 
 
Preferred stock; no par value; 15,000 authorized shares; none outstanding

 

Common stock; $0.01 par value; 240,000 authorized shares; 89,191 and 88,735 issued at September 30, 2020 and December 31, 2019, respectively
892

 
887

Additional paid-in capital
1,284,711

 
1,213,620

Treasury stock, at cost; 4,915 shares and 2,865 shares at September 30, 2020 and December 31, 2019, respectively
(235,224
)
 
(119,943
)
Accumulated other comprehensive loss
(91,913
)
 
(76,402
)
Retained earnings
439,521

 
398,574

Total stockholders’ equity
1,397,987

 
1,416,736

Total liabilities and stockholders’ equity
$
3,453,521

 
$
3,303,240



The accompanying unaudited notes are an integral part of these condensed consolidated financial statements.

5



INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(In thousands)
 
Nine Months Ended September 30,
 
2020
 
2019
OPERATING ACTIVITIES:
 
 
 
Net income
$
41,148

 
$
34,882

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
Depreciation and amortization
89,853

 
81,584

Non-cash in-process research and development expense

 
59,889

Non-cash impairment charges

 
5,764

Income tax expense (benefit)
4,784

 
(10,536
)
Share-based compensation
14,333

 
15,744

Amortization of debt issuance costs and expenses associated with debt refinancing
10,499

 
4,084

Non-cash lease expense
2,172

 
3,473

Accretion of bond issuance discount
11,075

 

Loss on disposal of property and equipment
559

 
844

Change in fair value of contingent consideration and others
(45
)
 
10

Changes in assets and liabilities:
 
 
 
Accounts receivable
57,863

 
(17,519
)
Inventories
(45,531
)
 
(30,553
)
Prepaid expenses and other current assets
(865
)
 
(8,162
)
Other non-current assets
10,868

 
6,650

Accounts payable, accrued expenses and other current liabilities
(67,178
)
 
366

Contract liabilities
(548
)
 
(1,395
)
Other non-current liabilities
(5,417
)
 
(2,876
)
Net cash provided by operating activities
123,570

 
142,249

INVESTING ACTIVITIES:
 
 
 
Purchases of property and equipment
(30,463
)
 
(47,343
)
Acquired in-process research and development milestone

(5,000
)
 

Proceeds from note receivable

 
752

Proceeds from sale of property and equipment
3,311

 
36

Cash (paid) provided for business acquisitions, net of cash acquired

 
(30,509
)
Acquired in-process research and development

 
(64,995
)
Net cash used in investing activities
(32,152
)
 
(142,059
)
FINANCING ACTIVITIES:
 
 
 
Proceeds from borrowings of long-term indebtedness
151,300

 
215,800

Payments on debt
(441,000
)
 
(143,250
)
Purchase of option hedge on convertible notes
(104,248
)
 

Proceeds from convertible notes issuance
575,000

 

Proceeds from sale of stock purchase warrants
44,563

 

Payment of debt issuance costs
(24,347
)
 

Purchases of treasury stock
(100,000
)
 

Proceeds from exercised stock options
3,821

 
6,948

Cash taxes paid in net equity settlement
(4,686
)
 
(6,272
)
Net cash provided by financing activities
100,403

 
73,226

Effect of exchange rate changes on cash and cash equivalents
5,547

 
(4,273
)
Net increase in cash and cash equivalents
197,368

 
69,143

Cash and cash equivalents at beginning of period
198,911

 
138,838

Cash and cash equivalents at end of period
$
396,279

 
$
207,981


The accompanying unaudited notes are an integral part of these condensed consolidated financial statements.

6


INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDER'S EQUITY
(UNAUDITED)
(In thousands, except per share amounts) 

 
Nine Months Ended September 30, 2020
 
Common Stock
 
Treasury Stock
 
Additional Paid-In Capital
 
Accumulated Other Comprehensive Loss
 
Retained Earnings
 
Total Equity
Shares
 
Amount
Shares
 
Amount
 
(In thousands)
Balance, January 1, 2020
88,735

 
$
887

 
(2,865
)
 
$
(119,943
)
 
$
1,213,620

 
$
(76,402
)
 
$
398,574

 
$
1,416,736

Net income

 

 

 

 

 

 
9,180

 
9,180

Other comprehensive loss, net of tax

 

 

 

 

 
(28,187
)
 

 
(28,187
)
Issuance of common stock through employee stock purchase plan
13

 

 

 

 
694

 

 

 
694

Issuance of common stock for vesting of share based awards, net of shares withheld for taxes
357

 
2

 
10

 
476

 
(3,217
)
 

 

 
(2,739
)
Share-based compensation
 
 

 

 

 
3,781

 

 

 
3,781

Share repurchase and equity component of the convertible note issuance, net

 

 
(135
)
 
(7,632
)
 
42,538

 

 

 
34,906

Accelerated shares repurchased

 

 
(1,304
)
 
(75,407
)
 
(16,961
)
 

 

 
(92,368
)
Adoption of Update No. 2016-13

 

 

 

 

 

 
(200
)
 
(200
)
Balance, March 31, 2020
89,105

 
$
889

 
(4,294
)
 
$
(202,506
)
 
$
1,240,455

 
$
(104,589
)
 
$
407,553

 
$
1,341,802

Net loss

 

 

 

 

 

 
(369
)
 
(369
)
Other comprehensive income, net of tax

 

 

 

 

 
1,464

 

 
1,464

Issuance of common stock for vesting of share based awards, net of shares withheld for taxes
84

 
3

 

 
(35
)
 
1,282

 

 

 
1,250

Share-based compensation

 

 

 

 
4,948

 

 

 
4,948

Accelerated shares repurchased

 

 
(621
)
 
(32,685
)
 
32,685

 

 

 

Balance, June 30, 2020
89,189

 
$
892

 
(4,915
)
 
$
(235,226
)
 
$
1,279,370

 
$
(103,125
)
 
$
407,184

 
$
1,349,095

Net income

 

 

 

 

 

 
32,337

 
32,337

Other comprehensive income, net of tax

 

 

 

 

 
11,212

 

 
11,212

Issuance of common stock for vesting of share based awards, net of shares withheld for taxes
2

 

 

 
2

 
(69
)
 

 

 
(67
)
Share-based compensation

 

 

 

 
5,410

 

 

 
5,410

Balance, September 30, 2020
89,191


$
892


(4,915
)

$
(235,224
)

$
1,284,711


$
(91,913
)

$
439,521


$
1,397,987



7


 
Nine Months Ended September 30, 2019
 
Common Stock
 
Treasury Stock
 
Additional Paid-In Capital
 
Accumulated Other Comprehensive Loss
 
Retained Earnings
 
Total Equity
Shares
 
Amount
Shares
 
Amount
 
(In thousands)
Balance, January 1, 2019
88,044

 
$
880

 
(2,881
)
 
$
(120,615
)
 
$
1,192,601

 
$
(45,443
)
 
$
348,373

 
$
1,375,796

Net income

 

 

 

 

 

 
32,756

 
32,756

Other comprehensive loss, net of tax

 

 

 

 

 
(11,236
)
 

 
(11,236
)
Issuance of common stock through employee stock purchase plan
17

 

 

 

 
716

 

 

 
716

Issuance of common stock for vesting of share based awards, net of shares withheld for taxes
243

 
2

 
12

 
506

 
(5,629
)
 

 

 
(5,121
)
Share-based compensation

 

 

 

 
4,119

 

 

 
4,119

Balance, March 31, 2019
88,304

 
$
882

 
(2,869
)
 
$
(120,109
)
 
$
1,191,807

 
$
(56,679
)
 
$
381,129

 
$
1,397,030

Net income

 

 

 

 

 

 
29,736

 
29,736

Other comprehensive loss, net of tax

 

 

 

 

 
(12,021
)
 

 
(12,021
)
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes
47

 
1

 

 
2

 
405

 

 

 
408

Share-based compensation

 

 

 

 
5,798

 

 

 
5,798

Balance, June 30, 2019
88,351

 
$
883

 
(2,869
)
 
$
(120,107
)
 
$
1,198,010

 
$
(68,700
)
 
$
410,865

 
$
1,420,951

Net loss

 

 

 

 

 

 
(27,610
)
 
(27,610
)
Other comprehensive loss, net of tax

 

 

 

 

 
(18,915
)
 

 
(18,915
)
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes
338

 
3

 

 
6

 
4,665

 

 

 
4,674

Share-based compensation

 

 

 

 
5,874

 

 

 
5,874

Balance, September 30, 2019
88,689

 
$
886

 
(2,869
)
 
$
(120,101
)
 
$
1,208,549

 
$
(87,615
)
 
$
383,255

 
$
1,384,974


The accompanying unaudited notes are an integral part of these condensed consolidated financial statements.

8


INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. BASIS OF PRESENTATION
General
The terms “we,” “our,” “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise.
In the opinion of management, the September 30, 2020 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, statement of changes in shareholder's equity, results of operations and cash flows of the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K. The December 31, 2019 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States. Operating results for the three and nine month period ended September 30, 2020 are not necessarily indicative of the results to be expected for the entire year.
The preparation of consolidated financial statements is in conformity with generally accepted accounting principles in the United States ("GAAP") which requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of derivative instruments, valuation of the equity component of convertible debt instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates. The novel coronavirus (“COVID-19”) pandemic and the resulting adverse impacts to global economic conditions, as well as our operations, may impact future estimates including, but not limited to, inventory valuations, fair value measurements, goodwill and long-lived asset impairments, the effectiveness of the Company’s hedging instruments, deferred tax valuation allowances, and allowances for doubtful accounts receivable.
Risks and Uncertainties
The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company's business is highly uncertain and difficult to predict, as the responses to the pandemic and information is rapidly evolving. From late March, the Company's customers diverted resources to treat COVID-19 patients and deferred or canceled elective or non-emergent surgical procedures, all of which impacted hospitals' abilities to meet their obligations, including to the Company. Beginning in May 2020 and through the end of the third quarter of 2020, procedural volumes relevant to the Company’s products steadily increased and, in some geographic areas, began to approach normalized levels. However, on-going uncertainty persists about the continuing sustainability of those procedural volumes as virus outbreaks constrain healthcare networks. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is possible that it could cause a local and/or global economic recession. Such economic disruption has had an adverse effect on the Company's business as customers curtailed and reduced capital and overall spending. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and the economy as a whole. The magnitude and overall effectiveness of these actions remains uncertain. The severity of the impact of the COVID-19 pandemic on the Company's business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company's customers, all of which are uncertain and cannot be predicted with certainty. The Company's future results of operations and liquidity could be adversely impacted by delays in payments of outstanding receivable amounts beyond normal payment terms, supply chain disruptions and uncertain demand, and the impact of any initiatives or programs that the Company may undertake to address financial and operations challenges faced by its customers. The COVID-19 pandemic continues to cause a financial strain on healthcare systems which varies by location, and as a result we do not expect the same level of spending in the fourth quarter that we experienced last year. Even after the COVID-19 pandemic and government responses thereto have subsided, residual economic and other effects may have an impact on the demand for post-pandemic surgery levels that are difficult to predict. If the downturn is more severe and prolonged than currently expected, the Company may need to take further steps to reduce costs.

9

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)



Recently Issued Accounting Standards
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The ASU is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financial assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. The ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted this guidance on January 1, 2020 using a modified retrospective transition method which requires a cumulative-effect adjustment to the opening balance of retained earnings to be recognized on the date of adoption with no change to financial results reported in prior periods. The cumulative-effect adjustment recorded on January 1, 2020, is not material. The adoption of this ASU did not have a significant impact on the Company's consolidated financial statements and related disclosures.
The Company's exposure to credit losses may increase if its customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. Although the Company has historically not experienced significant credit losses, it is possible that there could be an adverse impact as hospital's cash flows are impacted by their response to the COVID-19 pandemic.
In August 2018, the FASB issued ASU 2018-14, Compensation-Retirement Benefits-Defined Benefit Plans-General (Subtopic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans. The new guidance modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans, including removing certain previous disclosure requirements, adding certain new disclosure requirements, and clarifying certain other disclosure requirements. The ASU will be effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Early adoption is permitted. The adoption is not expected to have a material impact on the Company's consolidated financial statements and related disclosures.
In August 2018, the FASB issued ASU No. 2018-15, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40), relating to a customer's accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement that is hosted by a vendor (e.g., a service contract). Under the new guidance, a customer will apply the same criteria for capitalizing implementation costs as it would for an arrangement that has a software license. The new guidance also prescribes the balance sheet, income statement, and cash flow classification of the capitalized implementation costs and related amortization expense, and requires additional quantitative and qualitative disclosures. The ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted this guidance on January 1, 2020 using a prospective transition method. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements and related disclosures.
In December 2019, the FASB issued ASU No. 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes intended to simplify the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The Company is currently assessing the impact of this standard on its financial condition and results of operations.
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform, which provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. This amendment applies to all entities, subject to meeting certain criteria, that have contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This ASU is effective immediately and may be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before December 31, 2022. The Company is currently assessing the impact that this ASU will have on its consolidated financial statements and related disclosures.

In August 2020, the FASB issued ASU No. 2020-06 Debt- Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40)-Accounting For Convertible Instruments and Contracts in an Entity's Own Equity . The guidance simplifies accounting for convertible instruments by removing major

10

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify. The guidance also simplifies the diluted net income per share calculation in certain areas. The ASU will be effective for annual and interim periods beginning after December 15, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact of this standard on its consolidated financial statements and related disclosures.
There are no other recently issued accounting pronouncements that are expected to have any significant effect on the Company's financial position, results of operations or cash flows.
2. ASSETS AND LIABILITIES HELD FOR SALE
On September 29, 2020, the Company and certain of its subsidiaries entered into an agreement to sell its Extremity Orthopedics business to Smith & Nephew USD Limited for approximately $240 million in cash. The transaction includes the sale of the Company’s upper and lower Extremity Orthopedics product portfolio, including ankle and shoulder arthroplasty and hand and wrist product lines. In connection with the transaction, the Company will pay $41.5 million to the Consortium of Focused Orthopedists, LLC (“CFO”) pursuant to the terms of certain agreements between Integra and CFO relating to the development of shoulder arthroplasty products. The transaction is expected to close at or around the end of 2020, subject to the satisfaction of customary conditions, including regulatory approvals and consultation with employee representative bodies.
The Company considered the assets and liabilities associated with the Extremity Orthopedics business to be accounted as held-for-sale as the six criteria under ASC 260 were met during the third quarter of 2020. Upon designation of the assets and liabilities as held for sale, the Company recorded the assets at the lower of their carrying value or their estimated fair value, less estimated costs to sell. Goodwill was allocated to the assets and liabilities held for sale using the relative fair value method of the Extremity Orthopedics business to the Company's Orthopedics and Tissue Technologies reporting unit. The fair value of the business less costs to sell exceeded the related carrying value.

The Extremity Orthopedics business was treated as a single disposal group and presented separately in the condensed consolidated balance sheet as assets and liabilities held for sale as of September 30, 2020. These balances are presented as current assets and liabilities as they are expected to be sold within twelve months. The major classes of assets and liabilities classified as a held for sale consisted of the following as of September 30, 2020 (amounts in thousands):
Prepaid and other current assets
$
748

Other assets
4,448

Deferred tax assets
6,927

Intangible assets
13,332

Property, plant and equipment, net
36,714

Goodwill
47,117

Inventories
50,691

Total assets held for sale
$
159,977

Other liabilities
241

Current portion of lease liability - operating leases

1,060

Accrued compensation
1,584

Deferred tax liabilities
3,035

Lease liability - operating leases

6,429

Total liabilities held for sale

$
12,349



3. BUSINESS DEVELOPMENT
Arkis BioSciences Inc.
On July 29, 2019, the Company acquired Arkis BioSciences Inc. ("Arkis") for an acquisition purchase price of $30.6 million (the "Arkis Acquisition") plus contingent consideration of up to $25.5 million, that may be payable based on the successful completion of certain development and commercial milestones. The contingent consideration had an acquisition date fair value of $13.1 million. Arkis was a privately-held company that marketed the CerebroFlo® external ventricular drainage (EVD) catheter with Endexo® technology, a permanent additive designed to reduce the potential for catheter obstruction due to thrombus formation.

11

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Assets Acquired and Liabilities Assumed at Fair Value
The Arkis Acquisition has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination to be recognized at their fair values as of the acquisition date.
The following table summarizes the final fair values of the assets acquired and liabilities assumed at the acquisition date:
 
Final Valuation as of
September 30, 2019
 
Weighted Average Life
 
(Dollars in thousands)
 
 
Cash
$
90

 
 
Other current assets
751

 
 
Property, plant and equipment
457

 
 
Deferred tax assets
1,697

 
 
Intangible assets:
 
 
 
CerebroFlo developed technology
20,100

 
15 years
Enabling technology license
1,980

 
14 years
Goodwill
27,153

 
 
Total assets acquired
52,228

 
 
 
 
 
 
Accounts payable, accrued expenses and other liabilities
2,926

 
 
Contingent consideration
13,100

 
 
Deferred tax liabilities
5,603

 
 
     Net assets acquired
$
30,599

 
 

Intangible Assets
The estimated fair value of the intangible assets was determined using the income approach, which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each asset (including net revenues, cost of sales, R&D costs, selling and marketing costs, and working capital/contributory asset charges), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, and competitive trends impacting the asset and each cash flow stream.
The Company used a discount rate of 14.5% to arrive at the present value for the acquired intangible assets to reflect the rate of return a market participant would expect to earn and incremental commercial uncertainty in the cash flow projections. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results.  
Goodwill
The Company allocated goodwill related to the Arkis Acquisition to the Codman Specialty Surgical segment. Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected revenue and cost synergies of the combined company and assembled workforce. One of the key factors that contributes to the recognition of goodwill, and a driver for the Company's acquisition of Arkis, is the planned expansion of the Endexo technology with the existing products within the Codman Specialty Surgical segment. Goodwill recognized as a result of this acquisition is non-deductible for income tax purposes.
Contingent Consideration
The Company determines the acquisition date fair value of contingent consideration obligations based on a probability-weighted income approach derived from revenue estimates and a probability assessment with respect to the likelihood of achieving contingent obligations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined using the fair value concepts in ASC 820. The resultant probability-weighted cash flows are discounted using an appropriate effective annual interest rate. At each reporting date, the contingent consideration obligation will be revalued to estimated fair value and changes in fair value will be reflected as income or expense in the Company's consolidated statement of operations. Changes in the fair value of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of revenue estimates and changes in probability assumptions with respect to the likelihood of achieving the various contingent payment obligations.

12

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

As part of the acquisition, the Company is required to pay the former shareholders of Arkis up to $25.5 million based on the timing of certain development milestones of $10.0 million and commercial sales milestones of $15.5 million, respectively. The Company used a probability weighted income approach to calculate the fair value of the contingent consideration that considered the possible outcomes of scenarios related to each specified milestone. The Company estimated the fair value of the contingent consideration to be $13.1 million at the acquisition date. The estimated fair value as of September 30, 2020 was $14.2 million. This amount is included in other liabilities at September 30, 2020 in the consolidated balance sheets of the Company.
Deferred Tax Liabilities
Deferred tax liabilities result from identifiable intangible assets’ fair value adjustments. These adjustments create excess book basis over tax basis which is tax-effected by the statutory tax rates of applicable jurisdictions.
The pro forma results are not presented for this acquisition as they are not material.
Rebound Therapeutics Corporation
On September 9, 2019, the Company acquired Rebound Therapeutics Corporation (“Rebound”), developers of a single-use medical device known as the AURORA Surgiscope® System ("Aurora") which enables minimally invasive access, using optics and illumination, for visualization, diagnostic and therapeutic use in neurosurgery (the “Rebound transaction”). Under the terms of the Rebound transaction, the Company made an upfront payment of $67.1 million and are committed to pay up to $35.0 million of contingent development milestones upon achievement of certain regulatory milestones. The acquisition of Rebound was primarily concentrated in one single identifiable asset and thus, for accounting purposes, the Company has concluded that the acquired assets do not meet the accounting definition of a business. The initial payment was allocated primarily to Aurora, resulting in a $59.9 million in-process research and development (IPR&D) expense. The balance of approximately $7.2 million, which included $2.1 million of cash and cash equivalents and a net deferred tax asset of $4.2 million, was allocated to the remaining net assets acquired. The deferred tax asset primarily resulted from a federal net operating loss carry forward.
During the fourth quarter of 2019, the Company achieved the first developmental milestone which triggered a $5.0 million obligation to be paid to former shareholders of Rebound. The Company recorded $5.0 million as IPR&D expense in the consolidated statements of operations during the year ended December 31, 2019. The obligation was included in accrued expenses and other current liabilities at December 31, 2019 in the consolidated balance sheets. The milestone was paid during the first quarter of 2020.
Integrated Shoulder Collaboration, Inc.
On January 4, 2019, the Company entered into a licensing agreement with Integrated Shoulder Collaboration, Inc ("ISC"). Under the terms of the agreement, the Company paid ISC $1.7 million for the exclusive, worldwide license to commercialize its short stem and stemless shoulder system. A patent related to short stem and stemless shoulder systems was issued to ISC during the first quarter of 2019. ISC is eligible to receive royalties on sales of the short stem and stemless shoulder system. The Company has the option to acquire ISC at a date four years subsequent to the first commercial sale, which becomes mandatory upon the achievement of a certain sales thresholds of the short stem and stemless shoulder system, for an amount not to exceed $80.0 million. The transaction was accounted for as an asset acquisition as the Company concluded that it acquired primarily one asset. During the quarter ended March 31, 2019, the total upfront payment of $1.7 million was expensed as a component of research and development expense and the future milestone and option payments will be recorded if the corresponding events become probable.
In connection with the sale of the Company's Extremity Orthopedic business, the Company will pay $41.5 million to CFO pursuant to the terms of certain agreements between Integra and CFO relating to the sale of shares of ISC which includes the development of shoulder arthroplasty products effectively terminating our licensing agreement with ISC. See Note 2, Assets and Liabilities Held for Sale, for details of the transaction.
4. REVENUES FROM CONTRACTS WITH CUSTOMERS
Summary of Accounting Policies on Revenue Recognition
Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services.
Total revenue, net, includes product sales, product royalties and other revenues, such as fees received for services.
For products shipped with FOB shipping point terms, the control of the product passes to the customer at the time of shipment. For shipments in which the control of the product is transferred when the customer receives the product, the Company recognizes revenue upon receipt by the customer. Certain products that the Company produces for private label customers have no alternative use and the Company has a right of payment for performance to date. Revenues from those products are recognized over the period

13

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

that the Company manufactures these products, which is typically one to three months. The Company uses the input method to measure the manufacturing activities completed to date, which depicts the progress of the Company's performance obligation of transferring control of goods being manufactured for private label customers.
A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and distributors, and also from inventory physically held by field sales representatives. For these types of product sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized.   
Revenues from sale of products and services are evidenced by either a contract with the customer or a valid purchase order and an invoice which includes all relevant terms of sale. For product sales, invoices are generally issued upon the transfer of control (or upon the completion of the manufacturing in the case of the private label transactions recognized over time) and are typically payable thirty days after the invoice date. The Company performs a review of each specific customer's creditworthiness and ability to pay prior to acceptance as a customer. Further, the Company performs periodic reviews of its customers' creditworthiness prospectively.
Performance Obligations
The Company's performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders, or invoices. The Company has no significant multi-element contracts with customers.
Significant Judgments
Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company and the Company's strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information, and expected sales trends. Differences between actual reported licensee sales and those that were estimated are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant.
The Company estimates returns, price concessions, and discount allowances using the expected value method based on historical trends and other known factors. Rebate allowances are estimated using the most likely method based on each customer contract.
The Company's return policy, as set forth in its product catalogs and sales invoices, requires review and authorization in advance prior to the return of product. Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally ninety days.
The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less. The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.
Contract Asset and Liability
Revenues recognized from the Company's private label business that are not invoiced to the customers as a result of recognizing revenue over time are recorded as a contract asset included in the prepaid expenses and other current assets account in the consolidated balance sheet.
Other operating revenues may include fees received under service agreements. Non-refundable fees received under multiple-period service agreements are recognized as revenue as the Company satisfies the performance obligations to the other party. A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability.












14

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

The following table summarizes the changes in the contract asset and liability balances for the nine months ended September 30, 2020:
Contract Asset
 
Contract asset, January 1, 2020
$
8,680

Transferred to trade receivable of contract asset included
     in beginning of the year contract asset
(8,680
)
Contract asset, net of transferred to trade receivables on contracts during the period
6,653

Contract asset, September 30, 2020
$
6,653

 
 
Contract Liability
 
Contract liability, January 1, 2020
$
11,946

Recognition of revenue included in beginning of year contract liability
(3,150
)
Contract liability, net of revenue recognized on contracts during the period

2,631

Foreign currency translation
(42
)
Contract liability, September 30, 2020
$
11,385


At September 30, 2020, the short-term portion of the contract liability of $4.9 million and the long-term portion of $6.5 million were included in accrued expenses and other current liabilities and other liabilities in the consolidated balance sheet.
As of September 30, 2020, the Company is expected to recognize approximately 43% of unsatisfied (or partially unsatisfied) performance obligations as revenue through 2020, with the remaining balance to be recognized in 2021 and thereafter.
Shipping and Handling Fees
The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in the cost of goods sold.
Product Warranties
Certain of the Company's medical devices, including monitoring systems and neurosurgical systems, are designed to operate over long periods of time. These products are sold with warranties which may extend for up to two years from the date of purchase. The warranties are not considered a separate performance obligation. The Company estimates its product warranties using the expected value method based on historical trends and other known factors. The Company includes them in accrued expenses and other current liabilities in the consolidated balance sheet.
Taxes Collected from Customers
The Company elected to exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer.













15

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Disaggregated Revenue
The following table presents revenues disaggregated by the major sources of revenues for the three and nine months ended September 30, 2020 and 2019 (amounts in thousands):
 
Three Months Ended September 30, 2020
Three Months Ended September 30, 2019
 
Nine Months Ended September 30, 2020
Nine Months Ended September 30, 2019
 
 
 
 
 
Neurosurgery
$
189,674

$
195,330

 
$
516,048

$
567,779

Instruments
49,649

57,654

 
124,493

169,031

Total Codman Specialty Surgical
239,323

252,984

 
640,541

736,810

 
 
 
 
 
 
Wound Reconstruction and Care
82,115

82,213

 
210,673

239,458

Extremity Orthopedics
21,922

20,852

 
54,556

65,299

Private Label
26,872

23,046

 
77,451

80,863

Total Orthopedics and Tissue Technologies
130,909

126,111

 
342,680

385,620

Total revenue
$
370,232

$
379,095

 
$
983,221

$
1,122,430


Prior period amounts were reclassified between categories within the Codman Specialty Surgical segment to conform to the current period presentation.
See Note 16, Segment and Geographical Information, for details of revenues based on the location of the customer.
5. INVENTORIES
Inventories, net consisted of the following:
 
September 30, 2020
 
December 31, 2019
 
(In thousands)
Finished goods
$
223,726

 
$
201,870

Work in process
57,037

 
48,333

Raw materials
77,767

 
$
65,851

Transfer to assets held for sale (See Note 2. Assets Held for Sale)

(50,691
)
 

Total inventories
$
307,839

 
$
316,054



6. GOODWILL AND OTHER INTANGIBLE ASSETS
Goodwill
Changes in the carrying amount of goodwill for the nine-month period ended September 30, 2020 were as follows:
 
Codman Specialty
Surgical
 
Orthopedics and
Tissue Technologies
 
Total
 
(In thousands)
Goodwill at December 31, 2019
$
653,500

 
$
300,780

 
$
954,280

Transfer to assets held for sale (See Note 2. Assets Held for Sale)

 
(47,117
)
 
(47,117
)
Foreign currency translation
8,928

 
3,465

 
12,393

Goodwill at September 30, 2020
$
662,428

 
$
257,128

 
$
919,556









16

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

The components of the Company’s identifiable intangible assets were as follows:
 
September 30, 2020
 
Weighted
Average
Life
 
Cost
 
Accumulated
Amortization
 
Net
 
(Dollars in thousands)
Completed technology
19 years
 
$
891,554

 
$
(250,609
)
 
$
640,945

Customer relationships
12 years
 
223,512

 
(138,989
)
 
84,523

Trademarks/brand names
28 years
 
104,404

 
(31,425
)
 
72,979

Codman tradename
Indefinite
 
167,013

 

 
167,013

Supplier relationships
27 years
 
34,721

 
(19,018
)
 
15,703

All other(1)
4 years
 
11,101

 
(5,247
)
 
5,854

Transfer to assets held for sale (See Note 2. Assets Held for Sale)

 
 
(39,821
)
 
26,489

 
(13,332
)
 
 
 
$
1,392,484

 
$
(418,799
)
 
$
973,685


 
December 31, 2019
 
Weighted
Average
Life
 
Cost
 
Accumulated
Amortization
 
Net
 
(Dollars in thousands)
Completed technology
19 years
 
$
880,623

 
$
(213,702
)
 
$
666,921

Customer relationships
12 years
 
222,575

 
(119,393
)
 
103,182

Trademarks/brand names
28 years
 
103,873

 
(28,514
)
 
75,359

Codman tradename
Indefinite
 
163,126

 

 
163,126

Supplier relationships
27 years
 
34,721

 
(17,947
)
 
16,774

All other (1)
4 years
 
10,869

 
(4,640
)
 
6,229

 
 
 
$
1,415,787

 
$
(384,196
)
 
$
1,031,591


(1)
At September 30, 2020 and December 31, 2019, all other included IPR&D of $1.0 million, which was indefinite-lived. At September 30, 2020, this IPR&D asset was presented separately as "assets held for sale" in conjunction with the sale of the Extremity Orthopedics business which is expected to be sold within twelve months. See Note 2, Assets and Liabilities Held for Sale, for details.
Goodwill and Intangible Assets with Indefinite Lives

The Company tests goodwill and intangible assets with indefinite lives for impairment annually in the third quarter in accordance with ASC Topic 350. Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit or indefinite lived intangible asset below its carrying amount. The carrying value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units.

The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including reporting unit specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of a reporting unit is less than its carrying amount, including goodwill. The Company may elect to bypass this qualitative evaluation for some or all of its reporting units and perform a quantitative test. During the third quarter of 2020, the Company began with the qualitative evaluation, which was sufficient to find no impairment.

For intangible assets with indefinite lives, the Company elected to bypass the qualitative evaluation for its Codman tradename intangible asset and perform a quantitative test during the third quarter 2020. In performing this test, the Company utilized a discount rate of 11.5%. The assumptions used in evaluating the Codman tradename for impairment are subject to change and are tracked against historical results by management. Based on the results of the quantitative test, the Company recorded no impairment to the Codman tradename intangible asset.


17

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Based on quarter-end exchange rates, amortization expense (including amounts reported in cost of product revenues) is expected to be approximately $15.7 million for the remainder of 2020, $62.1 million in 2021, $59.7 million in 2022, $58.9 million in 2023, $58.4 million in 2024, $58.4 million in 2025 and $494.9 million thereafter.
7. DEBT
Amendment to the Sixth Amended and Restated Senior Credit Agreement
On February 3, 2020, the Company entered into the sixth amendment and restatement (the "February 2020 Amendment") of its Senior Credit Facility (the "Senior Credit Facility") with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. The February 2020 Amendment extended the maturity date to February 3, 2025. The Company continues to have the aggregate principal amount of up to approximately $2.2 billion available to it through the following facilities: (i) a $877.5 million Term Loan facility, and (ii) a $1.3 billion revolving credit facility, which includes a $60 million sublimit for the issuance of standby letters of credit and a $60 million sublimit for swingline loans.

On July 14, 2020, the Company entered into an amendment (the "July 2020 Amendment") to the February 2020 Amendment of the Senior Credit Facility to increase financial flexibility in light of the unprecedented impact and uncertainty of the COVID-19 pandemic on the global economy. The July 2020 amendment does not increase the Company’s total indebtedness.
In connection with the July 14, 2020 amendment, the Company’s maximum consolidated total leverage ratio in the financial covenants (as defined in the Senior Credit Facility) was modified to the following:
Fiscal Quarter
 
Maximum Consolidated Total Leverage Ratio
 
 
 
Execution of July 2020 Amendment through June 30, 2021
 
5.50 to 1.00
September 30, 2021 through June 30, 2022
 
5.00 to 1.00
September 30, 2022 through June 30, 2023
 
4.50 to 1.00
September 30, 2023 and the last day of each fiscal quarter thereafter
 
4.00 to 1.00

Borrowings under the Senior Credit Facility bear interest, at the Company’s option, at a rate equal to the following:
i.
the Eurodollar Rate (as defined in the amendment and restatement) in effect from time to time plus the applicable rate (ranging from 1.00% to 2.25%), or
ii.
the highest of:
1.
the weighted average overnight Federal funds rate, as published by the Federal Reserve Bank of New York, plus 0.50%
2.
the prime lending rate of Bank of America, N.A. or
3.
the one-month Eurodollar Rate plus 1.00%

The applicable rates are based on the Company’s consolidated total leverage ratio (defined as the ratio of (a) consolidated funded indebtedness as of such date less cash that is not subject to any restriction on the use or investment thereof to (b) consolidated EBITDA as defined by the July 2020 amendment, for the period of four consecutive fiscal quarters ending on such date).
The Company will pay an annual commitment fee (ranging from 0.15% to 0.30%), based on the Company's consolidated total leverage ratio, on the amount available for borrowing under the revolving credit facility.
The Senior Credit Facility is collateralized by substantially all of the assets of the Company’s U.S. subsidiaries, excluding intangible assets. The Senior Credit Facility is subject to various financial and negative covenants and at September 30, 2020, the Company was in compliance with all such covenants. In connection with the February 2020 Amendment, the Company capitalized $4.6 million of financing costs in connection with modification of the Senior Credit Facility and wrote off $1.2 million of previously capitalized financing costs during the first quarter of 2020. In connection with the July 2020 amendment, the Company expensed $3.3 million of incremental financing costs in connection with the modification of the Senior Credit Facility during the third quarter of 2020.
At September 30, 2020 and December 31, 2019, there was $97.5 million and $375.0 million outstanding, respectively, under the revolving credit component of the Senior Credit Facility at weighted average interest rates of 1.5% and 3.2%, respectively. At September 30, 2020 and December 31, 2019, there was $877.5 million outstanding, respectively, under the Term Loan component of the Senior Credit Facility at a weighted average interest rate of 1.5% and 3.2%, respectively. At September 30, 2020, $22.5

18

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

million of the Term Loan component of the Senior Credit Facility is classified as current on the consolidated balance sheet as the first mandatory repayment is due June 30, 2021.
The fair value of outstanding borrowings of the Senior Credit Facility's revolving credit and Term Loan components at September 30, 2020 were $94.6 million and $853.7 million, respectively. These fair values were determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable inputs that reflect unadjusted quoted prices for identical assets or liabilities.
Letters of credit outstanding as of September 30, 2020 and December 31, 2019 totaled $1.6 million and $0.8 million. There were no amounts drawn as of September 30, 2020.
Contractual repayments of the Term Loan component of the Senior Credit Facility are due as follows:
Quarter Ended September 30, 2020
 
Principal Repayment
 
 
(In thousands)
Remainder of 2020
 
$

2021
 
33,750

2022
 
45,000

2023
 
61,875

2024
 
67,500

2025
 
669,375

 
 
$
877,500


The outstanding balance of the revolving credit component of the Senior Credit Facility is due on February 3, 2025.
Convertible Senior Notes
On February 4, 2020, the Company issued $575.0 million aggregate principal amount of its 0.5% Convertible Senior Notes due 2025 (the "2025 Notes"). The 2025 Notes will mature on August 15, 2025 and bear interest at a rate of 0.5% per annum payable semi-annually in arrears, unless earlier converted, repurchased or redeemed in accordance with the terms of the Notes. The portion of debt proceeds that was classified as equity at the time of the offering was $104.5 million, and that amount is being amortized to interest expense using the effective interest method through August 2025. The effective interest rate implicit in the liability component is 4.2%. In connection with this offering, the Company capitalized $13.2 million of financing fees. At September 30, 2020, the carrying amount of the liability component was $481.5 million, the remaining unamortized discount was $93.5 million, and the principal amount outstanding was $575.0 million. The fair value of the 2025 Notes at September 30, 2020 was $541.8 million.
The 2025 Notes are senior, unsecured obligations of the Company, and are convertible into cash and shares of its common stock based on initial conversion rate, subject to adjustment of 13.5739 shares per $1,000 principal amounts of the 2025 Notes (which represents an initial conversion price of $73.67 per share). The 2025 Notes convert only in the following circumstances: (1) if the closing price of the Company's common stock has been at least 130% of the conversion price during the period; (2) if the average trading price per $1000 principal amount of the 2025 Notes is less than or equal to 98% of the average conversion value of the 2025 Notes during a period as defined in the indenture; (3) at any time on or after February 20, 2023; or (4) if specified corporate transactions occur. As of September 30, 2020, none of these conditions existed with respect to the 2025 Notes and as a result the 2025 Notes are classified as long term.
Holders of the Notes will have the right to require the Company to repurchase for cash all or a portion of their Notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of a fundamental change (as defined in the indenture relating to the Notes). The Company will also be required to increase the conversion rate for holders who convert their Notes in connection with certain fundamental changes occurring prior to the maturity date or following delivery by the Company of a notice of redemption.

In connection with the issuance of the 2025 Notes, the Company entered into call transactions and warrant transactions, primarily with affiliates of the initial purchasers of the 2025 Notes (the “hedge participants”). The cost of the call transactions was $104.2 million for the 2025 Notes. The Company received $44.5 million of proceeds from the warrant transactions for the 2025 Notes. The call transactions involved purchasing call options from the hedge participants, and the warrant transactions involved selling call options to the hedge participants with a higher strike price than the purchased call options. The initial strike price of the call transactions was $73.67, subject to anti-dilution adjustments substantially similar to those in the 2025

19

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Notes. The initial strike price of the warrant transactions was $113.34 for the 2025 Notes, subject to customary anti-dilution adjustments.
During the nine months ended September 30, 2020, the Company recognized cash interest related to the contractual interest coupon of $1.9 million and amortization of the discount on the liability component of $11.1 million for a total interest charge of $13.0 million on the 2025 Notes.
Securitization Facility
During the fourth quarter of 2018, the Company entered into an accounts receivable securitization facility (the "Securitization Facility") under which accounts receivable of certain domestic subsidiaries are sold on a non-recourse basis to a special purpose entity (“SPE”), which is a bankruptcy-remote, consolidated subsidiary of the Company. Accordingly, the assets of the SPE are not available to satisfy the obligations of the Company or any of its subsidiaries. From time to time, the SPE may finance such accounts receivable with a revolving loan facility secured by a pledge of such accounts receivable. The amount of outstanding borrowings on the Securitization Facility at any one time is limited to $150.0 million. The Securitization Facility Agreement ("Securitization Agreement") is for an initial three-year term and may be extended. The Securitization Agreement governing the Securitization Facility contains certain covenants and termination events. An occurrence of an event of default or a termination event under this Securitization Agreement may give rise to the right of its counterparty to terminate this facility. As of September 30, 2020, the Company was in compliance with the covenants and none of the termination events had occurred. At September 30, 2020 and December 31, 2019, the Company had $92.3 million and $104.5 million, respectively, of outstanding borrowings under its Securitization Facility at a weighted average interest rate of 1.4% and 2.8%, respectively.
The fair value of the outstanding borrowing of the Securitization Facility at September 30, 2020 was $92.8 million.
8. DERIVATIVE INSTRUMENTS
Interest Rate Hedging
The Company’s interest rate risk relates to U.S. dollar denominated variable interest rate borrowings. The Company uses interest rate swap derivative instruments to manage earnings and cash flow exposure resulting from changes in interest rates. These interest rate swaps apply a fixed interest rate on a portion of the Company's expected LIBOR-indexed floating-rate borrowings.
The Company held the following interest rate swaps as of September 30, 2020 and December 31, 2019 (dollar amounts in thousands):
 
 
September 30, 2020
 
December 31, 2019
 
 
 
 
 
 
 
 
 
September 30, 2020
 
December 31, 2019
Hedged Item
 
Notional Amount
 
Notional Amount
 
Designation Date
 
Effective Date
 
Termination Date
 
Fixed Interest Rate
 
Estimated Fair Value
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Asset (Liability)
3-month USD LIBOR Loan
 

 
50,000

 
February 6, 2017
 
June 30, 2017
 
June 30, 2020
 
1.834
%
 
$

 
$
(2
)
1-month USD LIBOR Loan
 

 
100,000

 
February 6, 2017
 
June 30, 2017
 
June 30, 2020
 
1.652
%
 

 
12

1-month USD LIBOR Loan
 
100,000

 
100,000

 
March 27, 2017
 
December 31, 2017
 
June 30, 2021
 
1.971
%
 
(1,377
)
 
(581
)
1-month USD LIBOR Loan
 
150,000

 
150,000

 
December 13, 2017
 
January 1, 2018
 
December 31, 2022
 
2.201
%
 
(6,901
)
 
(2,880
)
1-month USD LIBOR Loan
 
150,000

 
150,000

 
December 13, 2017
 
January 1, 2018
 
December 31, 2022
 
2.201
%
 
(6,922
)
 
(2,880
)
1-month USD LIBOR Loan
 
100,000

 
100,000

 
December 13, 2017
 
July 1, 2019
 
June 30, 2024
 
2.423
%
 
(8,454
)
 
(3,517
)
1-month USD LIBOR Loan
 
50,000

 
50,000

 
December 13, 2017
 
July 1, 2019
 
June 30, 2024
 
2.423
%
 
(4,064
)
 
(1,778
)
1-month USD LIBOR Loan
 
200,000

 
200,000

 
December 13, 2017
 
January 1, 2018
 
December 31, 2024
 
2.313
%
 
(18,188
)
 
(6,595
)
1-month USD LIBOR Loan
 
75,000

 
75,000

 
October 10, 2018
 
July 1, 2020
 
June 30, 2025
 
3.220
%
 
(10,608
)
 
(5,750
)
1-month USD LIBOR Loan
 
75,000

 
75,000

 
October 10, 2018
 
July 1, 2020
 
June 30, 2025
 
3.199
%
 
(10,871
)
 
(5,747
)
1-month USD LIBOR Loan
 
75,000

 
75,000

 
October 10, 2018
 
July 1, 2020
 
June 30, 2025
 
3.209
%
 
(10,586
)
 
(5,807
)
1-month USD LIBOR Loan
 
100,000

 
100,000

 
December 18, 2018
 
December 30, 2022
 
December 31, 2027
 
2.885
%
 
(11,282
)
 
(4,930
)
1-month USD LIBOR Loan
 
100,000

 
100,000

 
December 18, 2018
 
December 30, 2022
 
December 31, 2027
 
2.867
%
 
(11,127
)
 
(4,691
)
Total interest rate derivatives designated as cash flow hedge
 
$
1,175,000

 
$
1,325,000

 
 
 
 
 
 
 
 
 
$
(100,380
)
 
$
(45,145
)

The Company has designated these derivative instruments as cash flow hedges. The Company assesses the effectiveness of these derivative instruments and has recorded the changes in the fair value of the derivative instrument designated as a cash flow hedge as unrealized gains or losses in accumulated other comprehensive loss (“AOCL”), net of tax, until the hedged item affected earnings, at which point any gain or loss was reclassified to earnings. If the hedged cash flow does not occur, or if it becomes probable that it will not occur, the Company will reclassify the remaining amount of any gain or loss on the related cash flow hedge recorded in AOCL to interest expense at that time.

20

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Foreign Currency Hedging
From time to time the Company enters into foreign currency hedge contracts intended to protect the U.S. dollar value of certain forecasted foreign currency denominated transactions. The Company assesses the effectiveness of the contracts that are designated as hedging instruments. The changes in fair value of foreign currency cash flow hedges are recorded in AOCL, net of tax, until the hedged item affects earnings. Once the related hedged item affects earnings, the Company reclassifies amounts recorded in AOCL to earnings. If the hedged forecasted transaction does not occur, or if it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. For contracts not designated as hedging instruments, the changes in fair value of the contracts are recognized in other income (expense), net in the consolidated statements of operation, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities.
The success of the Company’s hedging program depends, in part, on forecasts of certain activity denominated in foreign currency. The Company may experience unanticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activities during periods of currency volatility. In addition, changes in currency exchange rates related to any unhedged transactions may affect earnings and cash flows.
Cross-Currency Rate Swaps
On October 2, 2017, the Company entered into cross-currency swap agreements to convert a notional amount of $300.0 million equivalent to 291.2 million of CHF denominated intercompany loans into U.S. dollars. The CHF-denominated intercompany loans were the result of the purchase of intellectual property by a subsidiary in Switzerland as part of an acquisition. The objective of these cross-currency swaps is to reduce volatility of earnings and cash flows associated with changes in the foreign currency exchange rate. Under the terms of these contracts, which have been designated as cash flow hedges, the Company will make interest payments in Swiss Francs and receive interest in U.S. dollars. Upon the maturity of these contracts, the Company will pay the principal amount of the loans in Swiss Francs and receive U.S. dollars from the counterparties.
The Company held the following cross-currency rate swaps as of September 30, 2020 and December 31, 2019 (dollar amounts in thousands):
 
 
 
 
 
 
 
 
 
 
 
September 30, 2020
 
December 31, 2019
 
 
Effective Date
 
Termination Date
 
Fixed Rate
 
Aggregate Notional Amount
 
Fair Value
Asset (Liability)
 
 
 
 
 
 
 
 
 
 
 
 
 
Pay CHF
 
October 2, 2017
 
October 2, 2020
 
1.75%
 
CHF
32,355

 
$
(1,565
)
 
$
(101
)
Receive U.S.$
 
 
4.38%
 
$
33,333

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pay CHF
 
October 2, 2017
 
October 2, 2021
 
1.85%
 
CHF
48,533

 
(2,003
)
 
(119
)
Receive U.S.$
 
 
4.46%
 
$
50,000

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pay CHF
 
October 2, 2017
 
October 2, 2022
 
1.95%
 
CHF
145,598

 
(4,167
)
 
(289
)
Receive U.S.$
 
 
4.52%
 
$
150,000

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total
 
 
 
 
 
 
 
 
 
 
$
(7,735
)
 
$
(509
)


On October 2, 2020 in accordance with the termination date, the Company settled a cross-currency swap designated as a cash flow hedge of an intercompany loan with an aggregate notional amount of $33.3 million.
The cross- currency swaps are carried on the consolidated balance sheet at fair value, and changes in the fair values are recorded as unrealized gains or losses in AOCL. For the three and nine months ended September 30, 2020, the Company recorded losses of $6.9 million and $12.0 million, respectively, in other income, net related to change in fair value related to the foreign currency rate translation to offset the gains recognized on the intercompany loans. For the three and nine months ended September 30, 2019, the Company recorded gains of $5.7 million and $3.9 million, respectively, in other income, net related to change in fair value related to the foreign currency rate translation to offset the losses recognized on the intercompany loans.
For the three and nine months ended September 30, 2020, the Company recorded a loss of $6.3 million and a gain of $2.7 million in AOCL, respectively, related to change in fair value of the cross-currency swaps. For the three and nine months ended September 30, 2019, the Company recorded gains of $9.7 million and $15.4 million in AOCL, respectively, related to change in fair value of the cross-currency swaps.
For the three and nine months ended September 30, 2020, the Company recorded gains of $1.5 million and $4.5 million, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps. For the three and nine months ended September 30, 2019, the Company recorded gains of $1.8 million and

21

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

$5.5 million, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps.
The estimated gain that is expected to be reclassified to other income (expense), net from AOCL as of September 30, 2020 within the next twelve months is $3.0 million. As of September 30, 2020, the Company does not expect any gains or losses will be reclassified into earnings as a result of the discontinuance of these cash flow hedges because the original forecasted transaction will not occur.
Net Investment Hedges
The Company manages certain foreign exchange risks through a variety of strategies, including hedging. The Company is exposed to foreign exchange risk from its international operations through foreign currency purchases, net investments in foreign subsidiaries, and foreign currency assets and liabilities created in the normal course of business. On October 1, 2018, the Company entered into cross-currency swap agreements designated as net investment hedges to partially offset the effects of foreign currency on foreign subsidiaries.
The Company held the following cross-currency rate swaps designated as net investment hedges as of September 30, 2020 and December 31, 2019, respectively (dollar amounts in thousands):
 
 
 
 
 
 
 
 
 
 
 
September 30, 2020
 
December 31, 2019
 
 
Effective Date
 
Termination Date
 
Fixed Rate
 
Aggregate Notional Amount
 
Fair Value
Asset (Liability)
 
 
 
 
 
 
 
 
 
 
 
 
 
Pay EUR
 
October 3, 2018
 
September 30, 2021
 
%
 
EUR
44,859

 
$
589

 
$
2,459

Receive U.S.$
 
 
 
3.01%
 
$
52,000

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pay EUR
 
October 3, 2018
 
September 30, 2023
 
%
 
EUR
51,760

 
2,443

 
3,087

Receive U.S.$
 
 
 
2.57%
 
$
60,000

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pay EUR
 
October 3, 2018
 
September 30, 2025
 
%
 
EUR
38,820

 
2,398

 
2,032

Receive U.S.$
 
 
 
2.19%
 
$
45,000

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pay GBP
 
October 3, 2018
 
September 30, 2025
 
1.67%
 
GBP
128,284

 
8,580

 
(154
)
Receive U.S.$
 
 
 
2.71%
 
$
167,500

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pay CHF
 
October 3, 2018
 
September 30, 2025
 
%
 
CHF
165,172

 
(6,828
)
 
1,221

Receive GBP
 
 
 
1.67%
 
GBP
128,284

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total
 
 
 
 
 
 
 
 
 
 
$
7,182

 
$
8,645


The cross-currency swaps were carried on the consolidated balance sheet at fair value and changes in the fair values were recorded as unrealized gains or losses in AOCL. For the three and nine months ended September 30, 2020, the Company recorded loss of $11.3 million and a gain of $5.1 million in AOCL related to the change in fair value of the cross-currency swaps. For the three and nine months ended September 30, 2019, the Company recorded gains of $17.1 million and $26.6 million in AOCL related to the change in fair value of the cross-currency swaps.
For the three and nine months ended September 30, 2020, the Company recorded gains of $2.2 million and $6.6 million in interest income included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps. For the three and nine months ended September 30, 2019, the Company recorded gains of $2.5 million and $7.2 million, respectively, in interest income included in the consolidation statements of operations related to the interest rate differential of the cross-currency swaps.
The estimated gain that is expected to be reclassified to interest income from AOCL as of September 30, 2020 within the next twelve months is $7.7 million.
Counterparty Credit Risk
The Company manages its concentration of counterparty credit risk on its derivative instruments by limiting acceptable counterparties to a group of major financial institutions with investment grade credit ratings, and by actively monitoring their credit ratings and outstanding positions on an ongoing basis. Therefore, the Company considers the credit risk of the counterparties to be low. Furthermore, none of the Company’s derivative transactions are subject to collateral or other security arrangements, and none contain provisions that depend upon the Company’s credit ratings from any credit rating agency.

22

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Fair Value of Derivative Instruments
The Company has classified all of its derivative instruments within Level 2 of the fair value hierarchy because observable inputs are available for substantially the full term of the derivative instruments. The fair values of the interest rate swaps and cross-currency swaps were developed using a market approach based on publicly available market yield curves and the terms of the swap. The Company performs ongoing assessments of counterparty credit risk.

The following table summarizes the fair value for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of September 30, 2020 and December 31, 2019:
 
 
Fair Value as of
Location on Balance Sheet (1):
 
September 30, 2020
 
December 31, 2019
 
 
(In thousands)
Derivatives designated as hedges — Assets:
 
 
 
 
Prepaid expenses and other current assets
 
 
 
 
Cash Flow Hedges
 
 
 
 
Interest rate swap
 
$

 
$
12

Cross-currency swap
 
4,608

 
5,032

Net Investment Hedges
 
 
 
 
Cross-currency swap
 
7,717

 
7,952

Other assets
 
 
 
 
Net Investment Hedges
 
 
 
 
Cross-currency swap
 
9,071

 
3,465

Total derivatives designated as hedges — Assets
 
$
21,396

 
$
16,461

 
 
 
 
 
Derivatives designated as hedges — Liabilities:
 
 
 
 
Accrued expenses and other current liabilities
 
 
 
 
Cash Flow Hedges
 
 
 
 
Interest rate swap
 
$
22,324

 
$
6,635

Cross-currency swap
 
1,565

 
101

Other liabilities
 
 
 
 
Cash Flow Hedges
 
 
 
 
Interest rate swap
 
78,056

 
38,522

Cross-currency swap
 
10,777

 
5,440

Net Investment Hedges
 
 
 
 
Cross-currency swap
 
9,605

 
2,772

Total derivatives designated as hedges — Liabilities
 
$
122,327

 
$
53,470

 
(1) 
The Company classifies derivative assets and liabilities as non-current based on the cash flows expected to be incurred within the following 12 months.


23

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

The following presents the effect of derivative instruments designated as cash flow hedges on the accompanying condensed consolidated statement of operations during the three and nine months ended September 30, 2020 and 2019:
 
Balance in AOCL
Beginning of
Quarter
 
Amount of
Gain (Loss)
Recognized in
AOCL
 
Amount of Gain (Loss)
Reclassified from
AOCL into
Earnings
 
Balance in AOCL
End of Quarter
 
Location in
Statements of
Operations
 
(In thousands)
Three Months Ended September 30, 2020
 
 
 
 
 
 
 
 
 
Cash Flow Hedges
 
 
 
 
 
 
 
 
 
Interest rate swap
$
(102,128
)
 
$
(3,971
)
 
$
(5,718
)
 
$
(100,381
)
 
Interest expense
Cross-currency swap
5,843

 
(6,272
)
 
(5,353
)
 
4,924

 
Other income (expense),net
Net Investment Hedges
 
 
 
 
 
 
 
 
 
Cross-currency swap
22,223

 
(11,254
)
 
2,202

 
8,767

 
Interest income
 
$
(74,062
)
 
$
(21,497
)
 
$
(8,869
)
 
$
(86,690
)
 
 
Three Months Ended September 30, 2019
 
 
 
 
 
 
 
 
 
Cash Flow Hedges
 
 
 
 
 
 
 
 
 
Interest rate swap
$
(43,161
)
 
$
(13,788
)
 
$
237

 
$
(57,186
)
 
Interest expense
Cross-currency swap
(2,284
)
 
9,661

 
7,520

 
(143
)
 
Other income (expense),net
Net Investment Hedges
 
 
 
 
 
 
 
 
 
Cross-currency swap
4,054

 
17,136

 
2,489

 
18,701

 
Interest income
 
$
(41,391
)
 
$
13,009

 
$
10,246

 
$
(38,628
)
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance in AOCL
Beginning of
Year
 
Amount of
Gain (Loss)
Recognized in
AOCL
 
Amount of Gain (Loss)
Reclassified from
AOCL into
Earnings
 
Balance in AOCL
End of Quarter
 
Location in
Statements of
Operations
 
(In thousands)
Nine Months Ended September 30, 2020
 
 
 
 
 
 
 
 
 
Cash Flow Hedges
 
 
 
 
 
 
 
 
 
Interest rate swap
$
(45,146
)
 
$
(65,608
)
 
$
(10,373
)
 
$
(100,381
)
 
Interest expense
Cross-currency swap
177

 
(2,688
)
 
(7,435
)
 
4,924

 
Other income (expense),net
Net Investment Hedges
 
 
 
 
 
 
 
 
 
Cross-currency swap
10,229

 
5,102

 
6,564

 
8,767

 
Interest income
 
$
(34,740
)
 
$
(63,194
)
 
$
(11,244
)
 
$
(86,690
)
 
 
Nine months ended September 30, 2019
 
 
 
 
 
 
 
 
 
Cash Flow Hedges
 
 
 
 
 
 
 
 
 
Interest rate swap
$
619

 
$
(54,841
)
 
$
2,964

 
$
(57,186
)
 
Interest expense
Cross-currency swap
(6,190
)
 
15,418

 
9,371

 
(143
)
 
Other income (expense), net
Net Investment Hedges
 
 
 
 
 
 
 
 
 
Cross-currency swap
(632
)
 
26,558

 
7,225

 
18,701

 
Interest income
 
$
(6,203
)
 
$
(12,865
)
 
$
19,560

 
$
(38,628
)
 
 


 
9. STOCK-BASED COMPENSATION
As of September 30, 2020, the Company had stock options, restricted stock awards, performance stock units, contract stock awards and restricted stock unit awards outstanding under two plans, the 2001 Equity Incentive Plan (the “2001 Plan”) and the 2003 Equity Incentive Plan (the “2003 Plan,” and collectively, the “Plans”).
Stock options issued under the Plans become exercisable over specified periods, generally within four years from the date of grant for officers and employees, and within one year from date of grant for directors and generally expire eight years from the grant

24

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

date for employees, and from six to ten years for directors and certain executive officers. The Company values stock option grants using the binomial distribution model. Restricted stock issued under the Plans vests over specified periods, generally three years after the date of grant. The vesting of performance stock issued under the Plans is subject to service and performance conditions.
Stock Options
As of September 30, 2020, there were approximately $6.0 million of total unrecognized compensation costs related to unvested stock options. These costs are expected to be recognized over a weighted-average period of approximately three years. There were 348,587 stock options granted during the nine months ended September 30, 2020. For the nine months ended September 30, 2020, the weighted average grant date fair value for stock options was $13.03 per option.
Awards of Restricted Stock and Performance Stock
Performance stock and restricted stock awards generally have requisite service periods of three years. Performance stock units are subject to graded vesting conditions based on revenue goals of the Company. The Company expenses the fair value of restricted stock awards on a straight-line basis over the requisite service period. As of September 30, 2020, there was approximately $27.5 million of total unrecognized compensation costs related to these unvested awards. The Company expects to recognize these costs over a weighted-average period of approximately two years. The Company granted 322,485 restricted stock awards and 180,875 performance stock awards during the nine months ended September 30, 2020. For the nine months ended September 30, 2020, the weighted average grant date fair value for restricted stock awards and performance stock units was $44.08 and $43.39 per award, respectively.
The Company also maintains an Employee Stock Purchase Plan (the “ESPP”), which provides eligible employees with the opportunity to acquire shares of common stock at periodic intervals by means of accumulated payroll deductions. The ESPP is a non-compensatory plan based on its terms.
10. RETIREMENT PLANS
The Company maintains defined benefit pension plans that cover certain employees in France, Japan, Germany and Switzerland.
Net periodic benefit costs for the Company’s defined benefit pension plans for the three and nine months ended September 30, 2020 were $1.0 million and $3.0 million, respectively. The components of the net periodic benefit costs other than the service cost component of $1.0 million and $2.9 million for the three and nine months ended September 30, 2020, respectively, are included in other income (expense), net in the consolidated statements of operations.
Net periodic benefit costs for the Company’s defined benefit pension plans for the three and nine months ended September 30, 2019 was $1.0 million and $2.1 million, respectively. The components of the net periodic benefit costs other than the service cost component of $0.7 million and $2.0 million for the three and nine months ended September 30, 2019, respectively, are included in other income (expense), net in the consolidated statements of operations.
The estimated fair values of plan assets were $33.2 million and $30.8 million as of September 30, 2020 and December 31, 2019, respectively. The net plan assets of the pension plans are invested in common trusts as of September 30, 2020 and December 31, 2019. Common trusts are classified as Level 2 in the fair value hierarchy. The fair value of common trusts is valued at the net asset value based on the fair values of the underlying investments of the trusts as determined by the sponsor of the trusts. The investment strategy of the Company's defined benefit plans is both to meet the liabilities of the plans as they fall due and to maximize the return on invested assets within an appropriate risk profile.
Deferred Compensation Plan
In May 2019, the Company adopted the Integra LifeSciences Deferred Compensation Plan (the “Plan”). Under the Plan, certain employees of the Company may defer the payment and taxation of up to 75% of their base salary and up to 100% of bonus amounts and other eligible cash compensation.
During the first quarter of 2020, employees participating in the Plan began to defer their compensation. This deferred compensation is invested in funds offered under the Plan and is valued based on Level 1 measurements in the fair value hierarchy. The purpose of the Plan is to retain key employees by providing them with an opportunity to defer a portion of their compensation as elected by the participant in accordance with the Plan. Any amounts set aside to defray the liabilities assumed by the Company will remain the general assets of the Company until such amounts are distributed to the participants. Assets of the Company's deferred compensation plan are included in Other current assets and recorded at fair value based on their quoted market prices. The fair value of these assets at September 30, 2020 was $1.7 million. Offsetting liabilities relating to the deferred compensation plan are included in Other liabilities.

25

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

11. LEASES AND RELATED PARTY LEASES
The Company leases administrative, manufacturing, research and distribution facilities and vehicles through operating lease agreements. The Company has no finance leases as of September 30, 2020. Many of the Company's leases include both lease (e.g., fixed payments including rent) and non-lease components (e.g., common-area or other maintenance costs). For vehicles, the Company has elected the practical expedient to group lease and non-lease components. 
Most facility leases include one or more options to renew. The exercise of lease renewal options is typically at the Company's sole discretion, therefore, the majority of renewals to extend the lease terms are not included in the Right of Use ("ROU") assets and lease liabilities as they are not reasonably certain of exercise. The Company regularly evaluates renewal options and when they are reasonably certain of exercise, the renewal period is included in the lease term.
As most of the Company's leases do not provide an implicit rate, the Company uses a collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments.
Total operating lease expense for the nine months ended September 30, 2020 and September 30, 2019, was $14.6 million and $14.2 million respectively, which includes $0.2 million, in related party operating lease expense.
Supplemental balance sheet information related to operating leases at September 30, 2020 were as follows:
 
September 30, 2020
 
(In thousands, except lease term and discount rate)
Weighted average remaining lease term (in years):
 
 
 
Leased facilities
11.8

Leased vehicles
1.4

 
 
Weighted average discount rate:
 
Leased facilities
4.6
%
Leased vehicles
2.2
%

Supplemental cash flow information related to leases for the nine months ended September 30, 2020 and September 30, 2019 were as follows:
 
September 30, 2020
 
September 30, 2019
 
(In thousands)
 
(In thousands)
Cash paid for amounts included in the measurement of lease liabilities:
 
 
 
Operating cash flows from operating leases
$
10,976

 
$
10,680

 
 
 
 
ROU assets obtained in exchange for lease liabilities:
 
 
 
Operating leases
$
6,007

 
$
41,860













26

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Future minimum lease payments under operating leases at September 30, 2020 were as follows:
 
Related Parties
 
Third Parties
 
Total
 
(In thousands)
2020
$
74

 
$
3,742

 
$
3,816

2021
296

 
13,209

 
13,505

2022
296

 
13,224

 
13,520

2023
296

 
10,782

 
11,078

2024
296

 
9,996

 
10,292

Thereafter
1,426

 
86,750

 
88,176

Total minimum lease payments
$
2,684

 
$
137,703

 
$
140,387

Less: Imputed interest
 
 
 
 
39,091

Total lease liabilities
 
 
 
 
101,296

Less: Current lease liabilities
 
 
 
 
12,518

Long-term lease liabilities
 
 
 
 
88,778


Related Party Leases
The Company leases its manufacturing facility in Plainsboro, New Jersey, from a general partnership that is 50% owned by a corporation whose shareholders are trusts, whose beneficiaries include family members of the Company’s principal stockholder and former director. The term of the current lease agreement is through October 31, 2029 at an annual rate of approximately $0.3 million per year. The current lease agreement also provides (i) a 5-year renewal option for the Company to extend the lease from November 1, 2029 through October 31, 2034 at the fair market rental rate of the premises, and (ii) another 5-year renewal option to extend the lease from November 1, 2034 through October 31, 2039 at the fair market rental rate of the premises.
12. TREASURY STOCK
As of September 30, 2020 and December 31, 2019, there were 4.9 million and 2.9 million shares of treasury stock outstanding with a cost of $235.2 million and $119.9 million, at a weighted average cost per share of $47.86 and $41.87, respectively.
On December 11, 2018, the board of directors of the Company (the “Board”) authorized the Company to repurchase up to $225.0 million of the Company’s common stock. The program allows the Company to repurchase its shares opportunistically from time to time. The repurchase authorization expires in December 2020.

During the nine months ended September 30, 2020, the Company repurchased 2.1 million shares of Integra’s common stock as part of the existing share repurchase authorization. The Company utilized $100.0 million of net proceeds from the offering of the Convertible Senior Notes to execute the share repurchase transactions. This included $7.6 million from certain purchasers of the convertible notes in conjunction with the closing of the offering. On February 5, 2020, the Company entered into a
$92.4 million accelerated share repurchase ("ASR") to complete the remaining $100.0 million of share repurchase. The Company received 1.3 million shares at inception of the ASR, which represented approximately 80% of the expected total shares. Upon settlement of the ASR in June 2020, the Company received an additional 0.6 million shares determined using the volume-weighted average price of the Company's common stock during the term of the transaction.

The Company has $125.0 million remaining under the share repurchase of its Common Stock. The price and timing of any future purchases under the share repurchase program will depend on factors such as levels of cash generation from operations, the volume of stock option exercises by employees, cash requirements for acquisitions, dividends, economic and market conditions and stock price.

13. INCOME TAXES
The following table provides a summary of the Company's effective tax rate:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2020
 
2019
 
2020
 
2019
Reported tax rate
22.1
%
 
(0.4
)%
 
24.6
%
 
(3.5
)%



27

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

The Company’s effective income tax rates for the three months ended September 30, 2020 and 2019 were 22.1% and (0.4)%, respectively. For the three months ended September 30, 2020, the primary drivers of the higher tax rate are the jurisdictional mix of income along with a $4.2 million recognition of a deferred tax liability related to an outside tax basis from the sale of the Extremity Orthopedics business, offset by a $3.2 million benefit from the reversal of the French valuation allowance. For the three months ended September 30, 2019, the rate was primarily driven by the impact of the Rebound transaction, which resulted in a $59.9 million IPR&D expense. This amount was not deductible for tax purposes.

The Company's effective income tax rates for the nine months ended September 30, 2020 and September 30, 2019 were 24.6% and (3.5)%, respectively. For the nine months ended September 30, 2020, the primary drivers of the higher tax rate are the jurisdictional mix of income along with a $4.2 million recognition of a deferred tax liability related to an outside tax basis from the sale of the Extremity Orthopedics business. For the nine months ended September 30, 2019, the primary driver of the tax rate is the impact of the Rebound transaction, which resulted in a $59.9 million IPR&D expense. This amount is not deductible for tax purposes. This was offset by a tax benefit of $10.8 million related to a federal tax holiday in Switzerland, which was finalized during the quarter ended March 31, 2019. The Company received a federal tax credit in Switzerland of 12 million CHF, which may be used over a seven year period, ending in 2024.
As of September 30, 2020, the Company has not provided deferred income taxes on unrepatriated earnings from foreign subsidiaries as they are deemed indefinitely reinvested. Such taxes would primarily be attributable to foreign withholding taxes and local income taxes when such earnings are distributed. As such, the Company has determined the tax impact of repatriating these earnings would not be material as of September 30, 2020. The Company does not anticipate the need to repatriate earnings from foreign subsidiaries as a result of the impact of the COVID-19 pandemic.
On March 27, 2020, the Coronavirus Aid Relief, and Economic Security Act (CARES Act) was signed into law. The CARES Act included certain income tax provisions for corporations and individuals, among other provisions. The Company does not expect the CARES Act provisions to have a significant impact on the Company's income taxes. The Company continues to monitor the issuance of new legislation, regulations, and case law that may impact federal, state, and international tax positions.

14. NET INCOME (LOSS) PER SHARE
Basic and diluted net income (loss) per share was as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2020
 
2019
 
2020
 
2019
 
(In thousands, except per share amounts)
 
(In thousands, except per share amounts)
Basic net income (loss) per share:
 
 
 
 
 
 
 
Net income (loss)
$
32,337

 
$
(27,610
)
 
$
41,148

 
$
34,882

Weighted average common shares outstanding
84,325

 
85,688

 
84,745

 
85,536

Basic net income (loss) per common share
$
0.38

 
$
(0.32
)
 
$
0.49

 
$
0.41

 
 
 
 
 
 
 
 
Diluted net income (loss) per share:
 
 
 
 
 
 
 
Net income (loss)
$
32,337

 
$
(27,610
)
 
$
41,148

 
$
34,882

 
 
 
 
 
 
 
 
Weighted average common shares outstanding — Basic
84,325

 
85,688

 
84,745

 
85,536

Effect of dilutive securities:
 
 
 
 
 
 
 
Stock options and restricted stock
427

 

 
558

 
1,045

Weighted average common shares for diluted earnings per share
84,752

 
85,688

 
85,303

 
86,581

 
 
 
 
 
 
 
 
Diluted net income (loss) per common share
$
0.38

 
$
(0.32
)
 
$
0.48

 
$
0.40



Common stock of approximately 0.3 million and 0.6 million shares at September 30, 2020, and 2019, respectively that are issuable through exercise of dilutive securities were not included in the computation of diluted net income (loss) per share because their effect would have been anti-dilutive.

28

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Performance Shares and Restricted Units that entitle the holders to approximately 0.5 million shares of common stock are included in the basic and diluted weighted average shares outstanding calculation from their date of issuance because no further consideration is due related to the issuance of the underlying common shares.

15. COMPREHENSIVE INCOME (LOSS)

Comprehensive income (loss) was as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2020
 
2019
 
2020
 
2019
 
(In thousands)
 
(In thousands)
Net income (loss)
$
32,337

 
$
(27,610
)
 
$
41,148

 
$
34,882

Foreign currency translation adjustment
21,181

 
(18,651
)
 
24,801

 
(17,960
)
Change in unrealized loss on derivatives, net of tax
(9,679
)
 
(775
)
 
(39,814
)
 
(24,714
)
Pension liability adjustment, net of tax
(291
)
 
515

 
(498
)
 
504

Comprehensive income (loss), net
$
43,548

 
$
(46,521
)
 
$
25,637

 
$
(7,288
)

Changes in accumulated other comprehensive loss by component between December 31, 2019 and September 30, 2020 are presented in the table below, net of tax:
 
 
Gains and Losses on Derivatives
 
Defined Benefit Pension Items
 
Foreign Currency Items
 
Total
 
 
(In thousands)
Balance at January 1, 2020
 
$
(26,625
)
 
$
(9,709
)
 
$
(40,068
)
 
$
(76,402
)
Other comprehensive income (loss)
 
(48,429
)
 
(498
)
 
24,801

 
(24,126
)
Less: Amounts reclassified from accumulated other comprehensive loss
 
(8,615
)
 

 

 
(8,615
)
Net current-period other comprehensive income (loss)
 
(39,814
)
 
(498
)
 
24,801

 
(15,511
)
Balance at September 30, 2020
 
$
(66,439
)
 
$
(10,207
)
 
$
(15,267
)
 
$
(91,913
)

For the nine months ended September 30, 2020, the Company reclassified a loss of $5.7 million and $2.9 million from accumulated other comprehensive loss to other income (expense), net and interest income, respectively.
16. SEGMENT AND GEOGRAPHIC INFORMATION
The Company internally manages two global reportable segments and reports the results of its businesses to its chief operating decision maker. The two reportable segments and their activities are described below.
The Codman Specialty Surgical segment includes (i) the Neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment and (ii) the instruments business, which sells more than 40,000 instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices.
The Orthopedics and Tissue Technologies segment includes such offerings as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair products.
The Corporate and other category includes (i) various executive, finance, human resource, information systems and legal functions, (ii) brand management, and (iii) share-based compensation costs.
The operating results of the various reportable segments as presented are not comparable to one another because (i) certain operating segments are more dependent than others on corporate functions for unallocated general and administrative and/or operational manufacturing functions and (ii) the Company does not allocate certain manufacturing costs and general and administrative costs to the operating segment results. Net sales and profit by each reportable segment for the three and nine months ended September 30, 2020 and 2019 are as follows:

29

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2020
 
2019
 
2020
 
2019
 
(In thousands)
 
(In thousands)
Segment Net Sales
 
 
 
 
 
 
 
Codman Specialty Surgical
$
239,323

 
$
252,984

 
$
640,541

 
$
736,810

Orthopedics and Tissue Technologies 
130,909

 
126,111

 
342,680

 
385,620

Total revenues
$
370,232

 
$
379,095

 
$
983,221

 
$
1,122,430

Segment Profit
 
 
 
 
 
 
 
Codman Specialty Surgical
$
97,061

 
$
101,129

 
$
249,552

 
$
291,750

Orthopedics and Tissue Technologies 
50,132

 
30,383

 
110,091

 
112,664

Segment profit
147,193

 
131,512

 
359,643

 
$
404,414

Amortization
(8,343
)
 
(5,056)

 
$
(23,393
)
 
(21,340)

Corporate and other
(81,308
)
 
(147,043
)
 
(237,525
)
 
(325,394
)
Operating income
$
57,542

 
$
(20,587
)
 
$
98,725

 
$
57,680


The Company does not allocate any assets to the reportable segments. No asset information is reported to the chief operating decision maker and disclosed in the financial information for each segment.
The Company attributes revenues to geographic areas based on the location of the customer. Total revenue by major geographic area consisted of the following:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2020
 
2019
 
2020
 
2019
 
(In thousands)
 
(In thousands)
United States
$
266,477

 
$
266,280

 
$
695,179

 
$
796,397

Europe
45,995

 
49,242

 
123,917

 
148,753

Asia Pacific
40,473

 
42,079

 
113,934

 
114,810

Rest of World
17,287

 
21,494

 
50,191

 
62,470

Total Revenues
$
370,232

 
$
379,095

 
$
983,221

 
$
1,122,430



17. COMMITMENTS AND CONTINGENCIES
In consideration for certain technology, manufacturing, distribution, and selling rights and licenses granted to the Company, the Company has agreed to pay royalties on sales of certain products that it sells. The royalty payments that the Company made under these agreements were not significant for any of the periods presented.
The Company is subject to various claims, lawsuits and proceedings in the ordinary course of the Company's business, including claims by current or former employees, distributors and competitors and with respect to its products and product liability claims, lawsuits and proceedings, some of which have been settled by the Company. In the opinion of management, such claims are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material, adverse effect on the Company's financial condition. However, it is possible that the Company's results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies.
The Company accrues for loss contingencies when it is deemed probable that a loss has been incurred and that loss is estimable. The amounts accrued are based on the full amount of the estimated loss before considering insurance proceeds and do not include an estimate for legal fees expected to be incurred in connection with the loss contingency. The Company consistently accrues legal fees expected to be incurred in connection with loss contingencies as those fees are incurred by outside counsel as a period cost.





30

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Contingent Consideration
The Company determined the fair value of contingent consideration during the nine month period ended September 30, 2020 and September 30, 2019 to reflect the change in estimates, additions, payments, transfers and the time value of money during the period.
A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the nine months ended September 30, 2020 and September 30, 2019 is as follows (in thousands):
Nine Months Ended September 30, 2020
Contingent Consideration Liability Related to Acquisition of Arkis (See Note 3)
 
Contingent Consideration
 Liability Related to Acquisition of Derma Sciences
Location in Financial Statements
 
Long-term
 
Long-term
 
Balance as of January 1, 2020
$
14,210

 
$
230

 
Loss from change in fair value of contingent consideration liabilities
(45
)
 

Research and development
Balance as of September 30, 2020
$
14,165

 
$
230

 

Nine Months Ended September 30, 2019
Contingent Consideration Liability Related to Acquisition of Arkis (See Note 3)
 
Contingent Consideration
 Liability Related to Acquisition of Derma Sciences
Location in Financial Statements
 
Long-term
 
Long-term
 
Balance as of January 1, 2019
$

 
$
230

 
Additions from acquisition of Arkis
13,100

 

 
Balance as of September 30, 2019
$
13,100

 
$
230

 

Derma Sciences
The Company assumed contingent consideration incurred by Derma Sciences, Inc. ("Derma Sciences") related to its acquisitions of BioD and the intellectual property related to Medihoney products. The Company accounted for the contingent liabilities by recording their fair value on the date of the acquisition based on a probability weighted income approach. The Company has already paid $33.3 million related to the aforementioned contingent liabilities. One contingent liability remains which relates to net sales of Medihoney products exceeding certain amounts defined in the agreement between the Company and Derma Sciences. The potential maximum undiscounted payment amounts to $3.0 million. The estimated fair value as of September 30, 2020 and September 30, 2019 was $0.2 million.
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of the Company's financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the related notes thereto appearing elsewhere in this report and our consolidated financial statements for the year ended December 31, 2019 included in our Annual Report on Form 10-K.
We have made statements in this report which constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). These forward-looking statements are subject to a number of risks, uncertainties and assumptions about the Company and other matters. These forward-looking statements include, but are not limited to, statements related to the Company's expectations regarding the potential impacts of the COVID-19 pandemic on our business, financial condition, and results of operations. These statements should, therefore, be considered in light of various important factors, including, but not limited to, the following: The Company's ability to obtain accurate procedure volume in the midst of the COVID-19 pandemic; the risk that the COVID-19 pandemic could lead to further material delays and cancellations of, or reduced demand for, procedures; curtailed or delayed capital spending by the Company's customers; disruption to the Company's supply chain; closures of our facilities; delays in gathering clinical evidence; diversion of management and other resources to respond to the COVID-19 outbreak; the impact of global and regional economic and credit market conditions on healthcare spending; the risk that the COVID-19 virus disrupts local economies and causes economies in our key markets to enter prolonged recessions. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors, including but not limited to those set forth under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019, and under the heading "Risk Factors" in this

31


report. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
You can identify these forward-looking statements by forward-looking words such as “believe,” “may,” “might,” “could,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “seek,” “plan,” “expect,” “should,” “would” and similar expressions in this report.
GENERAL
Integra, headquartered in Princeton, New Jersey, is a world leader in medical technologies. The Company was founded in 1989 with the acquisition of an engineered collagen technology platform used to repair and regenerate tissue. Since then, Integra has developed numerous product lines from this technology for applications ranging from burn and deep tissue wounds, to the repair of dura mater in the brain, and repair of nerves and tendons. The Company has expanded its base regenerative technology business to include surgical instruments, neurosurgical products, advanced wound care, collagen matrix products for hernia and plastic & reconstructive surgery, and orthopedic hardware, through a combination of several global acquisitions and internally developed products to further meet the needs of its customers and impact patient care.
We manufacture and sell our products in two reportable global business segments: Codman Specialty Surgical and Orthopedics and Tissue Technologies. Our Codman Specialty Surgical products comprise of specialty surgical implants and instrumentation for a broad range of specialties. This segment includes products and solutions for dural access and repair, instruments, advanced energy, cerebral spinal fluid ("CSF") management and neuro monitoring including market-leading product portfolios used in neurosurgery operation suites and critical care units. Our Orthopedics and Tissue Technologies product portfolios consist of differentiated regenerative technology products for soft tissue repair and tissue regeneration products, surgical reconstruction, and small bone fixation and joint replacement hardware products for both upper extremities and lower extremities. This business also includes private label sales of a broad set of our regenerative and wound care medical technologies.
We have key manufacturing and research facilities located in California, Massachusetts, New Jersey, Ohio, Tennessee, Texas, Canada, France, Germany, Ireland, Puerto Rico and Switzerland. We also source most of our handheld surgical instruments, specialty metal and pyrocarbon implants, and dural sealant products through specialized third-party vendors.
Codman Specialty Surgical products are sold through a combination of directly employed sales representatives, distributors and wholesalers, depending on the customer call point.
Orthopedics and Tissue Technologies products are sold through directly employed sales representatives, distributors focused on their respective surgical specialties, and strategic partners.
Integra is committed to delivering high quality products that positively impact the lives of millions of patients and their families. We focus on four key pillars of our strategy: 1) building an execution-focused culture, 2) achieving relevant scale, 3) improving agility and innovation, and 4) leading in customer experience. We believe that by sharpening our focus on these areas through improved planning and communication, optimization of our infrastructure, and strategically aligned tuck-in acquisitions, we can build scale, increase competitiveness and achieve our long-term goals.
To this end, the executive leadership team has established the following key priorities aligned to the following areas of focus:
Strategic Acquisitions. An important part of the Company's strategy is pursuing strategic transactions and licensing agreements that increase relevant scale in the clinical areas in which Integra competes. We successfully completed the Codman Neurosurgery integration, the most significant acquisition in the Company's history, as we exited 45 transition service agreements, across 90 countries. This acquisition expanded the Company's portfolio of neurosurgery products and established us as the world leader in neurosurgery. It has also enabled us to expand our international footprint and customer reach, thereby providing access to our entire product portfolio globally. In 2020, we continue to invest in our two most recent acquisitions Arkis Biosciences, Inc. and Rebound Therapeutics Corporation, both of which are developing innovative technologies for neurosurgery.
Portfolio Optimization and New Product Introductions. We are investing in innovative product development to drive a multi-generational pipeline for our key product franchises. Our product development efforts span across our key global franchises focused on potential for significant returns on investment.  In February 2020, we launched the AmnioExcel® Plus Placental Allograft Membrane, the next generation wound care offering to support soft tissue repair. Further in 2020, we continue to reap the benefits of many of our 10 new products launches from 2019. In addition to new product development, we are funding studies to gather clinical evidence to support launches, ensure market access and improve reimbursement for existing products. We continue to identify ways of optimizing our portfolio including identifying low-growth, low-margin products and product franchises for discontinuation.

32


On September 29, 2020, we entered into an agreement to sell our Extremity Orthopedics business to Smith & Nephew USD Limited for approximately $240 million in cash. The transaction is expected to close at or around the end of 2020, subject to the satisfaction of customary conditions, including regulatory approvals and consultation with employee representative bodies. See Note 2, Assets and Liabilities Held for Sale, for details. Upon completion of the transaction, we expect Integra to be a faster growing, more profitable, and more focused company.  This will enable us to increase our investments in our core Neurosurgery and Tissue Technology businesses.Those investments will strengthen our existing leadership positions and fund pipeline opportunities to drive future growth and expand our addressable markets. We will also significantly reduce the complexity of the organization. Exiting the Orthopedics business is accretive to our organic growth and EBITDA margins which will enhance shareholder value and keep us on a path toward achieving our long-term growth and profitability targets.  Additionally, this transaction will improve our financial flexibility. We will have the ability to meaningfully reduce our consolidated total leverage ratio and to pursue strategic M&A from a stronger financial position.
Commercial Channel Investments. With acquisitions, new product introductions and a broader portfolio of products, investing in our sales channels is a core part of our strategy to create specialization and greater focus on reaching new and existing customers and addressing their needs. Internationally, we have increased our commercial resources significantly in many markets and are making investments to support our sales organization and maximize our commercial opportunities. We now have a strong international sales channel that will deliver our current portfolio as well as position us for expansion. In addition, we continue to build upon our leadership brands across our product franchises to enable us to engage customers through enterprise-wide contracts.
Customer Experience. We aspire to be ranked as a best-in-class provider and are committed to strengthen our relationships with all customers. We strive to consistently deliver outstanding customer service and continue to invest in technologies, systems and processes to improve the way our customers do business with us. Additionally, we expect to build on the success of our professional education programs to drive continued customer familiarity with our growing portfolio of medical technologies globally.
Clinical and Product Development Activities
We continue to invest in collecting clinical evidence to support the Company's existing products and new product launches, and to ensure that we obtain market access for broader and more cost-effective solutions.
Within our Codman Specialty Surgical segment, the Company received FDA clearance in July 2020 to treat malignant and benign tumors, but not limited to meningiomas and gliomas, for its CUSA® Clarity Ultrasonic Surgical Aspirator System, the first and only ultrasonic tissue ablation system with this specific indication. The FDA clearance is based on a wealth of peer-reviewed clinical publications and 40 years of surgical cases involving resection of brain and spinal tumors. Additionally, the Company continued to reap the benefits of our product launches from the prior year from the Codman Specialty Surgical segment, including our new electrosurgery generator and irrigator system, an innovative customer-centric toolkit for our Certas™ Plus Programmable Valve along with additional shunt configurations. In Japan, we are experiencing strong growth as a result of the successful launch of DuraGen® in the prior year, which is the first and only collagen xenograft approved for use as a dural substitute in the country. We are focused on the development of core clinical applications in our electromechanical technologies portfolio. Also, we updated our CUSA Clarity platform to incorporate a new ultrasonic handpiece, surgical tips and integrated electrosurgical capabilities. We continue to work with several instrument partners to bring new surgical instrument platforms to the market. This enables us to add new instruments with minimal expense and invest in ongoing development, such as our next generation of LED technology with our DUO LED Surgical Headlight System.

Within our Orthopedic and Tissue Technologies segment, we launched AmnioExcel® Plus Placental Allograft Membrane, a human placental tissue product for treatment of wounds during February 2020. We also continued to benefit from the 2019 U.S. product launches, such as, the Panta® II TTC Arthrodesis Nail System. The Panta II system is our new fusion nail used in ankle fixation. We also launched a small post baseplate in our reverse shoulder system that accommodates smaller patients. In addition, we initiated the limited market release of enhancements to our Salto Talaris® Total Ankle System.

In May 2020, the Company announced positive clinical and economic data on Integra® Bilayer Wound Matrix ("IBWM") in complex lower extremity reconstruction based on two retrospective studies recently published in Plastic and Reconstructive Surgery, the official journal of the American Society of Plastic Surgeons. As surgeons looks for ways to efficiently and effectively repair and close wounds during these challenging times, IBWM helps address the efficiency needed in operating rooms by reducing both the operating time and costs to hospitals and patients.
COVID-19 Pandemic
The Company's focus during this global crisis remains unchanged. The Company continues to support patients, provide customers with life-saving products, and protect the health and safety of its employees. The rapid and evolving spread of the

33


virus has resulted in an unprecedented challenge to the global healthcare industry, as medical resources were reallocated to fight COVID-19. During 2020, the Company was able to sustain ongoing operations by implementing contingency plans such as enabling its manufacturing and distribution sites around the world to continue operating at levels required to meet demand and to provide for the safety of its employees. During April of 2020, the Company implemented cost-savings measures, which included the following:
Reduced executive management compensation through July 2020 and director compensation
Reduced cash compensation for all other employees through reduced commissions, reduction in hours through July 2020 and/or furloughs
Hiring freeze, elimination of overtime, reduction in certain employee benefit costs, cessation of third-party services and temporary contractor relationships
Significant reduction in capital expenditures and discretionary spending including travel, events and marketing programs

The Company restored employee wages and other spending in the third quarter of 2020, as revenues sequentially increased approximately 43.1% as compared to the second quarter of 2020. The Company also continues to implement programs and strategies to drive sustainable growth, such as partnering with key opinion leaders to increase our customer engagement through educational webinars and improve the clinical components of sales training. As many surgical procedures in which our products are employed cannot be deferred for more than 90 days, this should contribute to the continued recovery of the Company's business. We cannot predict with certainty the extent to which the COVID-19 pandemic will impact procedures in the fourth quarter and beyond. We remain confident that the underlying markets in which the Company competes remain attractive over the long term. We also remain focused on managing the business for the long-term, including preserving full time jobs needed to support the rebound in surgical procedure volumes. The Company's adaptability and resiliency in the face of this unprecedented crisis is made possible in part by prior investments in technology infrastructure and operations, as well as our talented and committed global workforce. Throughout this period, we continued to prioritize and invest in critical R&D and clinical programs.

Capital markets and worldwide economies have also been significantly impacted by the COVID-19 pandemic, and it is possible that it could cause a local and/or global economic recession. Any such economic recession could have a material adverse effect on the Company's long-term business as hospitals curtail and reduce capital as well as overall spending. The COVID-19 pandemic and local actions, such as “shelter-in-place” orders and restrictions on  travel and access to our customers or temporary closures of our facilities or the facilities of our suppliers and their contract manufacturers, could further significantly impact our sales and our ability to ship our products and supply our customers. Any of these events could negatively impact the number of surgical and medical intervention procedures performed and have a material adverse effect on our business, financial condition, results of operations, or cash flows. 

Information pertaining to additional risk factors as it relates to the COVID-19 pandemic can be found in Item 1A. Risk Factors.
FDA Matters
On June 22, 2015, the FDA (the “FDA”) issued an Untitled Letter (the "Untitled Letter") alleging that BioD LLC's ("BioD") morselized amniotic membrane tissue based products do not meet the criteria for regulation as HCT/Ps solely under Section 361 of the Public Health Services Act ("Section 361") and that, as a result, BioD would need a biologics license to lawfully market those morselized products. Since the issuance of the Untitled Letter, BioD and more recently the Company have been in discussions with the FDA to communicate their disagreement with the FDA’s assertion that certain products are more than minimally manipulated. The FDA has not changed its position that certain of the BioD acquired products are not eligible for marketing solely under Section 361. In July, 2020,  the FDA issued the final guidance document related to human tissue titled, “Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use” (the “HCT/PFinal Guidance”). This Guidance document supersedes the November, 2017 guidance.
The HCT/P Final Guidance maintains the FDA’s position that products such as the Company’s morselized amniotic membrane tissue-based products do not meet the criteria for regulation solely as HCT/Ps. In addition, the FDA articulated a risk-based approach to enforcement and, while some uses for amniotic membrane tissue-based products would have as much as thirty-six months of enforcement discretion, other high risk uses could be subject to immediate enforcement action. The revised final guidance extends the discretionary enforcement period to May 31, 2021. The Company does not believe the uses for its amniotic membrane tissue-based products fall into the high-risk category.
As of September 30, 2020 the Company has not received any further notice of enforcement action from the FDA regarding its morselized amniotic tissue-based products. Nonetheless, we can make no assurances that the FDA will continue to exercise its enforcement discretion with respect to the Company’s morselized amniotic membrane tissue-based products, and any potential

34


action of the FDA could have a financial impact regarding the sales of such products. The Company has been considering and continues to consider regulatory approval pathways for its morselized amniotic membrane tissue-based products.
Revenues from BioD morselized amniotic membrane based products for the nine months ended September 30, 2020 were less than 1.0% of consolidated revenues.
On March 7, 2019, TEI Biosciences, Inc. a subsidiary of the Company received a Warning Letter (the “Warning Letter”), dated March 6, 2019, from the United States Food and Drug Administration. The warning letter relates to quality systems issues at our manufacturing facility located in Boston, Massachusetts. The letter resulted from an inspection held at that facility in October and November 2018 and did not identify any new observations that were not already provided in the Form 483 that followed the inspection. The Company submitted its initial response to the FDA Warning Letter on March 28, 2019 and provides regular progress reports to the FDA as to its corrective actions on a monthly basis and, since the conclusion of the inspection, has undertaken significant efforts to remediate the observations and continues to do so. The warning letter does not restrict the Company’s ability to manufacture or ship products or require the recall of any products. Nor does it restrict our ability to seek FDA 510(k) clearance of products. The letter states that requests for Certificates to Foreign Governments will not be granted, however, due to our progress reports, FDA has agreed to resume issuing Certificates to Foreign Governments to TEI due to substantial progress and the length of time it takes to resolve the Warning Letter. Additionally, premarket approval applications for Class III devices to which the Quality System regulation violations are reasonably related will not be approved until the violations have been corrected. The TEI Boston facility manufactures extracellular bovine matrix (EBM) products. The Company does not expect to incur material incremental expense for remediation activities. We cannot, however, give any assurances that the FDA will be satisfied with our response to the Warning Letter or as to the expected date of the resolution of the matters included in the letter. Until the issues cited in the letter are resolved to the FDA’s satisfaction, the FDA may initiate additional regulatory action without further notice. Any adverse regulatory action, depending on its magnitude, may restrict us from effectively manufacturing, marketing and selling our products and could have a material adverse effect on our business, financial condition and results of operations.
Revenues of products manufactured in the TEI Boston facility for the nine months ended September 30, 2020 were approximately 4.5% of consolidated revenues.
RESULTS OF OPERATIONS
Executive Summary
Net income (loss) for the three months ended September 30, 2020 was $32.3 million, or $0.38 per diluted share, as compared to $(27.6) million or $(0.32) per diluted share for the three months ended September 30, 2019.
Net income for the nine months ended September 30, 2020 was $41.1 million, or $0.48 per diluted share, as compared to $34.9 million or $0.40 per diluted share for the nine months ended September 30, 2019.
The net income for the three and nine months ended September 30, 2020 was impacted by the COVID-19 pandemic which resulted in lower revenues in addition to a decrease in the level of operating expenses due to cost-savings measures implemented by the Company during 2020. The Company also had an increase in interest expense due to the issuance of the Convertible Senior Notes. The increase in net income for the three months ended September 30, 2020 from the same period last year resulted from a $59.9 million IPR&D expense attributed to the Rebound transaction which occurred during the third quarter of 2019.
For the nine months ended September 30, 2020, total revenues were $983.2 million, representing a decline of 12.4% from prior year revenues.
First quarter revenues declined 1.5% which reflects the impact of the COVID-19 pandemic on the Company from mid-March 2020 following two and a half months of revenue trends at the higher end of the Company’s expectations. As a result of the speed and severity of the spread of COVID-19, the Company saw rapid and significant decline in surgical and medical intervention procedures as healthcare providers reallocated resources to address the increasing demands caused by the COVID-19 pandemic. By reacting swiftly in February and working with customers and distributors, we were largely able to mitigate the first quarter impact of the social and economic shutdowns that took place globally.
The second quarter finished with sales of $258.7 million, representing a decline of 32.6% from the prior year period. In April 2020, revenues were down 45% as compared to the same period in the prior year 2019, as healthcare providers around the world began to defer non-urgent medical procedures. Throughout the remainder of the second quarter of 2020, revenues improved sequentially as compared to lows experienced in April 2020, as surgical procedure restrictions began to ease.

During the third quarter, we experienced strong sequential quarterly revenue improvements across all franchises, representing an increase of 43.1% as compared to the second quarter. Third quarter revenues finished with sales of $370.2 million, representing a decline of 2.3% from the prior year period. The Company's performance varied across regions and product lines

35


based on the severity of the pandemic but continued to demonstrate strong improvement compared to the second quarter, as surgical procedure restrictions continued to ease.

In the Codman Specialty Surgical ("CSS") segment, revenues increased 41% as compared to the second quarter of 2020. Both the Neurosurgery and Instruments portfolio showed significant sequential quarterly improvement. During the three months ended September 30, 2020, CSS revenues declined 5.4% compared to the prior year. Sales in our neuro monitoring and programmable valve products increased low-single digits in the third quarter compared to the prior year. Despite showing a sequential quarterly improvement, sales in capital products, largely concentrated in our advanced energy franchise, declined mid-double digits in the third quarter compared to the prior year as hospitals and healthcare institutions continued to allocate capital budgets to manage the increase in costs associated with the COVID pandemic. The Company continues to have a strong pipeline of new capital opportunities and believes the reallocation of capital budgets is only temporary.  Additionally, sales of consumable products used in conjunction with previously sold capital equipment nearly recovered to prior year levels in the third quarter. Sales of our Instruments portfolio decreased low-double digits as compared to the prior year, as sales of some products are more closely tied to hospital budgets rather than directly correlated to procedure volumes.
In the Orthopedics and Tissue Technologies ("OTT") segment, revenues increased 47.3% as compared to the second quarter of 2020. Sales in our Wound Reconstruction, Extremity Orthopedics and Private Label portfolios all showed sequential quarterly improvement in revenues. During the three months ended September 30, 2020, OTT revenues increased 3.8% as compared to the prior year. Sales in the Wound Reconstruction portfolio remained flat as compared to the prior year led by growth in sales of Integra skin, PriMatrix and amniotic tissue products. This was offset by performance in surgical reconstruction which declined by mid-double digits as compared to the prior year. Sales of our Extremity Orthopedics portfolio increased low single digits as deferred surgical procedures were completed. Our Private Label portfolio sales also increased by low-double digits over the prior year.
We continue to closely monitor local and regional COVID-19 surges for an impact on procedures in the fourth quarter of 2020 and beyond. The reallocation of hospital resources to treat COVID-19 may continue to cause a financial strain on healthcare systems. Additionally, the Company does not expect all markets and product lines to improve at the same rate based on the level of recurrence of COVID-19 and its associated impact on the pace of procedure recovery and economic normalization.

Income before taxes includes the following special charges:
 
Three Months Ended September 30,
 
Nine Months Ended
September 30,
 
2020
 
2019
 
2020
 
2019
 
(In thousands)
 
(In thousands)
Acquisition, divestiture and integration-related charges(2)
$
7,148

 
$
74,531

 
$
19,856

 
$
106,816

Structural optimization charges
4,543

 
5,353

 
9,015

 
13,169

EU medical device regulation
2,399

 
1,978

 
5,470

 
3,200

Litigation charges

 
(2,254
)
 

 
46

Discontinued product lines charges
999

 
3,104

 
5,486

 
6,825

Impairment charges

 

 

 
5,764

COVID-19 pandemic related charges(1)
(192
)
 

 
3,644

 

Expenses related to debt refinancing
3,428

 

 
6,168

 

Convertible debt non-cash interest expense
4,295

 

 
11,075

 

  Total
$
22,620

 
$
82,712

 
$
60,714

 
$
135,820


36


(1) Charges relate to business interruptions and cost associated from the COVID-19 pandemic which impacted the Company's operations globally, partially offset by Coronavirus government relief programs.
(2) The Company included $59.9 million of IPR&D expense within acquisition, divestiture and integration-related charges as a result of the Rebound transaction in the third quarter of 2019.
The items reported above are reflected in the condensed consolidated statements of operations as follows: 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2020
 
2019
 
2020
 
2019
 
(In thousands)
 
(In thousands)
Cost of goods sold (1)
$
6,892

 
$
5,963

 
$
22,500

 
$
17,177

Research and development
859

 

 
432

 
1,650

IPR&D expense

 
59,889

 

 
59,916

Selling, general and administrative
7,146

 
19,361

 
20,539

 
53,814

Intangible asset amortization(2)

 

 

 
5,764

Interest expense
7,723

 

 
17,243

 

Other expense

 
(2,501
)
 

 
(2,501
)
  Total
$
22,620

 
$
82,712

 
$
60,714

 
$
135,820


(1) Amortization and impairment charges related to technology based intangible assets is included in cost of goods sold.

(2) Impairment charges related to non-technology based intangible assets such as customer relationships are included in Intangible asset amortization.
We typically define special charges as items for which the amounts and/or timing of such expenses may vary significantly from period to period, depending upon our acquisition, integration and restructuring activities, and for which the amounts are non-cash in nature, or for which the amounts are not expected to recur at the same magnitude. We believe that given our ongoing strategy of seeking acquisitions, our continuing focus on rationalizing our existing manufacturing and distribution infrastructure and our continuing review of various product lines in relation to our current business strategy, some of the special charges discussed above could recur with similar materiality in the future.
We believe that the separate identification of these special charges provides important supplemental information to investors regarding financial and business trends relating to our financial condition and results of operations. Investors may find this information useful in assessing comparability of our operating performance from period to period, assessing the objectives that management has established, and against other companies in our industry. We provide this information to investors so that they can analyze our operating results in the same way that management does and to use this information in their assessment of our core business and valuation of Integra.
Revenues and Gross Margin
The Company's revenues and gross margin on product revenues were as follows:
 
Three Months Ended September 30,
Nine Months Ended September 30,
 
2020
 
2019
2020
 
2019
Segment Net Sales
(Dollars in thousands)
(Dollars in thousands)
Codman Specialty Surgical
$
239,323

 
$
252,984

$
640,541

 
$
736,810

Orthopedics & Tissue Technologies
130,909

 
126,111

342,680

 
385,620

Total revenue
370,232

 
379,095

983,221

 
1,122,430

Cost of goods sold
134,811

 
142,636

373,765

 
415,219

Gross margin on total revenues
$
235,421

 
$
236,459

$
609,456

 
$
707,211

Gross margin as a percentage of total revenues
63.6
%
 
62.4
%
62.0
%
 
63.0
%


37


Three Months Ended September 30, 2020 as Compared to Three Months Ended September 30, 2019
Revenues and Gross Margin
For the three months ended September 30, 2020, total revenues decreased by $8.9 million to $370.2 million from $379.1 million for the same period in 2019. Domestic revenues increased by $0.2 million, or 0.1%, to $266.5 million and were 72.0% of total revenues for the three months ended September 30, 2020 compared to $266.3 million during the same period in the prior year. International revenues decreased by $9.1 million or 8% to $103.8 million for the three months ended September 30, 2020 compared to $112.8 million during the same period in the prior year. The net decrease of $8.9 million was a result of disruption from the COVID-19 pandemic and $6.0 million due to discontinued and divested products offset by $2.6 million due to favorable impact of foreign exchange.
Codman Specialty Surgical revenues were $239.3 million, a decrease of $13.7 million, or 5.4% from the prior-year period. Orthopedics and Tissue Technologies revenues were $130.9 million, an increase of $4.8 million, or 3.8% from the prior-year period.
Gross margin was $235.4 million for the three-month period ended September 30, 2020, a decrease of $1.0 million from $236.5 million for the same period last year. Gross margin as a percentage of total revenue increased to 63.6% for the third quarter of 2020 from 62.4% in the same period last year. This increase is primarily attributable to favorable revenue mix and lower costs as a result of cost-savings measures implemented by the Company.
Operating Expenses
The following is a summary of operating expenses as a percent of total revenues: 
 
Three Months Ended September 30,
 
2020

2019
Research and development
5.3
%

5.0
%
IPR&D expense
%
 
15.8
%
Selling, general and administrative
40.5
%

45.7
%
Intangible asset amortization
2.3
%

1.3
%
  Total operating expenses
48.0
%

67.8
%
Total operating expenses, which consist of selling, general and administrative expenses, research and development expenses, IPR&D expense and amortization expenses, decreased by $79.2 million, or 30.8% to $177.9 million in the three months ended September 30, 2020, compared to $257.0 million in the same period in 2019.
Research and development expenses for the three months ended September 30, 2020 increased by $0.5 million as compared to the prior year. The increase in research and development was driven by costs related to product development, including product development for the new acquisitions completed in 2019. The Company continues to invest in R&D programs with spending at prior year levels despite the challenges from the COVID-19 pandemic. IPR&D expense decreased by $59.9 million as compared to the prior year due to the Rebound transaction which occurred during the third quarter of 2019.
Selling, general and administrative costs decreased by $23.0 million as compared to the prior year. The decrease in selling, general and administrative expenses was driven by overall cost reduction actions along with lower commission and selling costs associated with lower revenue in the quarter.
Although expenses were still below prior year levels during the third quarter of 2020, the Company restored employee wages and began to increase other spending in line with the sequential revenue improvements during the period. Revenues for the third quarter of 2020, sequentially increased approximately 43.1% as compared to the second quarter of 2020.
Non-Operating Income and Expenses
The following is a summary of non-operating income and expenses:
 
Three Months Ended September 30,
 
2020
 
2019
 
(In thousands)
Interest income
$
2,273

 
$
2,913

Interest expense
(20,796
)
 
(13,962
)
Other income, net
2,492

 
4,127


38


Interest Expense
Interest expense for the three months ended September 30, 2020 increased by $6.8 million as compared to the same period last year primarily due to an increase in non-cash interest expense due to the issuance of the Convertible Senior Notes.
Other Income, net
Other income, net for the three months ended September 30, 2020, decreased by $1.6 million compared to the same period last year primarily driven from a legal settlement received during the three months ended September 30, 2019.
Income Taxes
 
Three Months Ended September 30,
 
2020
 
2019
 
(In thousands)
Income before income taxes
$
41,511

 
$
(27,509
)
Income tax (benefit) expense
9,174

 
101

Effective tax rate
22.1
%
 
(0.4
)%
The Company’s effective income tax rates for the three months ended September 30, 2020 and 2019 were 22.1% and (0.4)%, respectively.
For the three months ended September 30, 2020, the primary drivers of the higher tax rate are the jurisdictional mix of income along with a $4.2 million recognition of a deferred tax liability related to an outside tax basis from the sale of the Extremity Orthopedics business, offset by a $3.2 million benefit from a reversal of the French valuation allowance. For the three months ended September 30, 2019, the primary driver of the tax rate is the impact of the Rebound transaction, which resulted in a $59.9 million IPR&D expense. This amount was not deductible for tax purposes.

The effective tax rate may vary from period to period depending on, among other factors, the geographic and business mix of taxable earnings and losses, tax planning and settlements with various taxing authorities. We consider these factors and others, including the Company's history of generating taxable earnings, in assessing our ability to realize tax assets on a quarterly basis.

While it is often difficult to predict the outcome or the timing of the resolution of a particular matter with the various federal, state, and foreign tax authorities, we believe that our reserves reflect the most probable outcome of known tax contingencies. Settlement of a particular issue would usually require the use of cash. A favorable resolution would be recognized as a reduction to our annual effective tax rate in the year of resolution. The Company's tax reserves are presented in the balance sheet within other liabilities, except for amounts relating to items that we expect to pay in the coming year, which would be classified as current income taxes payable.
Nine Months Ended September 30, 2020 as Compared to Nine Months Ended September 30, 2019
Revenues and Gross Margin
For the nine months ended September 30, 2020, total revenues decreased by $139.2 million to $983.2 million from $1,122.4 million for the same period in 2019. Domestic revenues decreased by $101.2 million, or 13%, to $695.2 million and were 71% of total revenues for the nine months ended September 30, 2020. International revenues decreased by $38.0 million, or 12% to $288.0 million for the nine months ended September 30, 2020 compared to $326.0 million during the same period in the prior year. The net decrease of $139.2 million was a result of decline in both segments due to disruption from the COVID-19 pandemic and $17.3 million due to discontinued and divested product offset by $0.2 million due to favorable impact of foreign exchange.
Codman Specialty Surgical revenues were $640.5 million, a decrease of $96.3 million, or 13.1% from the prior-year period. Orthopedics and Tissue Technologies revenues were $342.7 million, a decrease of $42.9 million, or 11.1% from the prior-year period. The decrease in both segments is primarily due to disruption caused by the COVID-19 pandemic across all franchises.
Gross margin was $609.5 million for the nine-month period ended September 30, 2020, a decrease of $97.8 million from $707.2 million for the same period last year. Gross margin as a percentage of total revenue decreased to 62.0% for the nine months ended September 30, 2020 from 63.0% in the same period last year. This decrease is primarily attributable to the disruption caused by the COVID-19 pandemic partially offset by favorable revenue mix and lower costs as a result of cost-savings measures implemented by the Company during the second quarter of 2020.
Operating Expenses

39


The following is a summary of operating expenses as a percent of total revenues: 
 
Nine Months Ended September 30,
 
2020

2019
Research and development
5.6
%

4.9
%
IPR&D expense
%
 
5.3
%
Selling, general and administrative
44.0
%

45.7
%
Intangible asset amortization
2.4
%

1.9
%
  Total operating expenses
51.9
%

57.8
%
Total operating expenses, which consist of selling, general and administrative expenses, research and development expenses, IPR&D expense and amortization expenses, decreased by $138.8 million, or 21.4% to $510.7 million in the nine months ended September 30, 2020, compared to $649.5 million in the same period in 2019.
Research and development expenses for the nine months ended September 30, 2020 increased by $0.2 million as compared to the prior year. The Company continues to invest in R&D programs with spending at prior year levels despite the challenges from the COVID-19 pandemic. IPR&D expense for the nine months ended September 30, 2020 decreased $59.9 million from the same period last year as a result of an IPR&D expense attributed to the Rebound transaction which occurred during the third quarter of 2019. Selling, general and administrative costs decreased by $81.2 million as compared to the prior year resulting from less acquisition and integration related charges, lower commissions and selling costs resulting from lower revenue during the year and overall cost reduction actions resulting from cost-savings measures associated with actions taken by the Company as a result of the impact of the COVID-19 pandemic.
Non-Operating Income and Expenses
The following is a summary of non-operating income and expenses:
 
Nine Months Ended September 30,
 
2020
 
2019
 
(In thousands)
Interest income
$
7,124

 
$
8,051

Interest expense
(54,230
)
 
(40,495
)
Other income, net
2,985

 
8,461

Interest Expense
Interest expense for the nine months ended September 30, 2020 increased by $13.7 million as compared to the same period last year primarily due to an increase in non-cash interest expense due to the issuance of the Convertible Senior Notes and expenses associated with Amended and Restated Senior Credit Agreement.
Other Income, net
Other income, net for the nine months ended September 30, 2020, decreased by $5.5 million as compared to the same period last year primarily due to unfavorable impact of foreign exchange and a legal settlement received during the nine months ended September 30, 2019.
Income Taxes
 
Nine Months Ended September 30,
 
2020
 
2019
 
(In thousands)
Income before income taxes
$
54,604

 
$
33,697

Income tax (benefit) expense
13,456

 
(1,185
)
Effective tax rate
24.6
%
 
(3.5
)%
The Company’s effective income tax rates for the nine months ended September 30, 2020 and 2019 were 24.6% and (3.5)%, respectively.


40


For the nine months ended September 30, 2020, the primary drivers of the higher tax rate are the jurisdictional mix of income along with a $4.2 million recognition of a deferred tax liability related to an outside tax basis from the sale of the Extremity Orthopedics business. For the nine months ended September 30, 2019, the primary driver of the tax rate is the impact of the Rebound transaction, which resulted in a $59.9 million IPR&D expense. This amount is not deductible for tax purposes. This was offset by a tax benefit of $10.8 million related to a federal tax holiday in Switzerland, which was finalized during the quarter ended March 31, 2019. The Company received a federal tax credit in Switzerland of 12 million CHF, which may be used over a seven year period, ending in 2024.
On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act") was signed into law. The CARES Act includes certain income tax provisions for corporations and individuals, among other provisions. The Company does not expect the CARES Act to have a significant impact on the income tax provision. The Company continues to monitor the issuance of new legislation, regulations, and case law that may impact federal, state, and international tax positions.
The Company expects its effective income tax rate for the full year to be approximately 24.6%, driven primarily by the jurisdictional mix of income and the incremental impact of the $4.2 million expense related to an outside tax basis from the sale of the Extremity Orthopedics business.

The effective tax rate may vary from period to period depending on, among other factors, the geographic and business mix of taxable earnings and losses, tax planning and settlements with various taxing authorities. We consider these factors and others, including the Company's history of generating taxable earnings, in assessing our ability to realize tax assets on a quarterly basis.
While it is often difficult to predict the outcome or the timing of the resolution of a particular matter with the various federal, state, and foreign tax authorities, we believe that our reserves reflect the most probable outcome of known tax contingencies. Settlement of a particular issue would usually require the use of cash. Favorable resolution would be recognized as a reduction to our annual effective tax rate in the year of resolution. The tax reserves are presented in the balance sheet within other liabilities, except for amounts relating to items we expect to pay in the coming year, which would be classified as current income taxes payable.

GEOGRAPHIC PRODUCT REVENUES AND OPERATIONS
The Company attributes revenues to geographic areas based on the location of the customer. Total revenue by major geographic area consisted of the following:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2020
 
2019
 
2020
 
2019
 
(In thousands)
 
(In thousands)
United States
$
266,477

 
$
266,280

 
$
695,179

 
$
796,397

Europe
45,995

 
49,242

 
123,917

 
148,753

Asia Pacific
40,473

 
42,079

 
113,934

 
114,810

Rest of World
17,287

 
21,494

 
50,191

 
62,470

Total Revenues
$
370,232

 
$
379,095

 
$
983,221

 
$
1,122,430

The Company generates significant revenues outside the U.S., a portion of which are U.S. dollar-denominated transactions conducted with customers who generate revenue in currencies other than the U.S. dollar. As a result, currency fluctuations between the U.S. dollar and the currencies in which those customers do business could have an impact on the demand for the Company's products in foreign countries. Local economic conditions, regulatory compliance or political considerations, the effectiveness of our sales representatives and distributors, local competition and changes in local medical practice all may combine to affect our sales into markets outside the U.S.
Domestic revenues increased by $0.2 million for the three months ended September 30, 2020 compared to the same period last year. European sales decreased by $3.2 million for the three months ended September 30, 2020 compared to the same period last year. Sales to customers in Asia Pacific and the Rest of the World for the three months ended September 30, 2020 decreased by $5.8 million compared to the same period last year. The revenues globally continue to be impacted by the COVID-19 pandemic across all of the franchises.
Domestic revenues decreased by $101.2 million for the nine months ended September 30, 2020 compared to the same period last year. European sales decreased by $24.8 million for the nine months ended September 30, 2020 compared to the same period last year. Sales to customers in Asia Pacific and the Rest of the World for the nine months ended September 30, 2020 decreased by

41


$13.2 million compared to the same period last year. The decrease in revenues globally was primarily due to adverse effects of the COVID-19 pandemic across all franchises.
LIQUIDITY AND CAPITAL RESOURCES
Cash and Marketable Securities
The Company had cash and cash equivalents totaling approximately $396.3 million and $198.9 million at September 30, 2020 and December 31, 2019 respectively, which are valued based on Level 1 measurements in the fair value hierarchy. At September 30, 2020, our non-U.S. subsidiaries held approximately $231.4 million of cash and cash equivalents that are available for use outside the U.S. The Company asserts that it has the ability and intends to indefinitely reinvest the undistributed earnings from its foreign operations unless there is no material tax cost to remit the earnings into the U.S. The Company does not anticipate the need to repatriate earnings from foreign subsidiaries as a result of the impact of the COVID-19 pandemic.
Cash Flows
 
Nine Months Ended September 30,
 
2020
 
2019
 
(In thousands)
Net cash provided by operating activities
$
123,570

 
$
142,249

Net cash used in investing activities
(32,152
)
 
(142,059
)
Net cash provided by financing activities
100,403

 
73,226

Effect of exchange rate fluctuations on cash
5,547

 
(4,273
)
Cash Flows Provided by Operating Activities
Operating cash flows for the nine months ended September 30, 2020 decreased compared to the same period in 2019. For the nine months ended September 30, 2020, net income after non-cash adjustments decreased by approximately $21.3 million to $174.4 million from $195.7 million when compared to the same period in 2019 primarily due to adverse effects of the COVID-19 pandemic. The changes in assets and liabilities, net of business acquisitions, decreased cash flows from operating activities by $50.8 million for the nine months ended September 30, 2020 compared to a decrease of $53.5 million for the same period in 2019. The decrease in 2020 is attributable to an increase in inventory to improve safety stock of select products. In addition, decreases were also driven by reduced payables offset by decreases in accounts receivable due to lower revenue and continued collection efforts.
Cash Flows Used in Investing Activities
During the nine months ended September 30, 2020, we paid $30.5 million for capital expenditures, most of which were directed to our facilities located in Mansfield, MA; Boston, MA; Memphis, TN; and Princeton, NJ.
During the nine months ended September 30, 2019, the Company paid $47.3 million for capital expenditures, most of which were directed to our Mansfield, MA facility, Princeton, NJ facility and commercial expansion. Further, we paid $95.5 million for the Arkis Acquisition and Rebound Transaction, net of cash acquired.
Cash Flows Used in Financing Activities
Our principal sources of cash from financing activities in the nine months ended September 30, 2020 were $515.3 million proceeds from the issuance of Convertible Senior Notes including the call and warrant transactions, and $151.3 million borrowing under our Senior Credit Facility and Securitization Facility. These were offset by repayments of $441.0 million on the revolving portion of our Senior Credit Facility and Securitization Facility, $24.3 million debt issuance costs related to the Amended and Restated Senior Credit Agreement and the issuance of Convertible Senior Notes and $100.0 million purchases of treasury stock.
Our principal sources of cash from financing activities in the nine months ended September 30, 2019 were $215.8 million from borrowings under our Senior Credit Facility and Securitization Facility. These were offset by repayments of $143.3 million on the revolving portion of our Senior Credit Facility and Securitization Facility.
Amended and Restated Senior Credit Agreement, Convertible Senior Notes, Securitization and Related Hedging Activities
See Note 7 - Debt to the current period’s condensed consolidated financial statements for a discussion of our Amended and Restated Senior Credit Agreement, Convertible Senior Notes and Securitization Facility and Note 8 - Derivative Instruments for discussion of our hedging activities.
We are forecasting that for the next twelve months, sales and earnings will be sufficient to remain in compliance with our financial covenants under the terms of the February 2020 Amendment and July 2020 Amendment to the Senior Credit Facility. The Company entered into the July 2020 amendment to increase financial flexibility in light of the unprecedented impact and

42


uncertainty of the COVID-19 pandemic on the global economy. If the downturn is more severe and prolonged than we currently expect, we may need to take further steps to reduce our costs.
Share Repurchase Plan
On December 11, 2018, the Board authorized the Company to repurchase up to $225.0 million of the Company’s common stock. The program allows the Company to repurchase its shares opportunistically from time to time. The repurchase authorization expires in December 2020.
During the nine months ended September 30, 2020, the Company repurchased 2.1 million shares of Integra’s common stock as a part of our existing share repurchase authorization. The Company utilized $100.0 million of net proceeds from the offering of the Convertible Senior Notes to execute the share repurchase transactions. This included $7.6 million from certain purchasers of the convertible notes in conjunction with the closing of the offering. On February 5, 2020, the Company entered into a
$92.4 million accelerated share repurchase ("ASR") to complete the remaining $100.0 million of share repurchase. The Company received 1.3 million shares through the ASR, which represented approximately 80% of the expected total shares. Upon settlement of the ASR in June 2020, the Company received an additional 0.6 million shares determined using the volume-weighted average price of the Company's common stock during the term of the transaction.

The Company has $125.0 million remaining under the share repurchase of its Common Stock. The price and timing of any future purchases under the share repurchase program will depend on factors such as levels of cash generation from operations, the volume of stock option exercises by employees, cash requirements for acquisitions, dividends, economic and market conditions and stock price.
Dividend Policy
The Company has not paid any cash dividends on our common stock since our formation. Our Senior Credit Facility limits the amount of dividends that we may pay. Any future determinations to pay cash dividends on our common stock will be at the discretion of the Board and will depend upon our financial condition, results of operations, cash flows and other factors deemed relevant by the Board.
Capital Resources
We believe that our cash and available borrowings under the Senior Credit Facility are sufficient to finance our operations and capital expenditures for the foreseeable future. Our future capital requirements will depend on many factors, including the growth of our business, the timing and introduction of new products and investments, strategic plans and acquisitions, among others. Additional sources of liquidity available to us include short term borrowings and the issuance of long term debt and equity securities. Further, as part of our actions to manage the impacts of the COVID-19 pandemic on our business, the Company has significantly reduced our capital expenditures by approximately $16.9 million as compared to the prior year.
We currently do not anticipate disruptions to our suppliers and their supply chains due to the COVID-19 pandemic for the fourth quarter, 2020 and beyond.
Off-Balance Sheet Arrangements
The Company has no off–balance sheet financing arrangements during the nine months ended September 30, 2020 that have or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our interests.
Contractual Obligations and Commitments
As of September 30, 2020, the Company is obligated to pay the following amounts under various agreements:

43


 
 
 
Payments Due by Calendar Year

Total
 
Remaining 2020
 
2021-2022
 
2023-2024
 
Thereafter
 
(In millions)
Revolving Credit Facility (1)
$
97.5

 
$


$

 
$

 
$
97.5

Term Loan
877.5

 


78.8

 
129.4

 
669.3

Securitization Facility (1)
92.3




92.3





Convertible Debt (4)
575.0

 

 

 

 
575.0

Interest (2)
55.4

 
6.7


25.5

 
22.2

 
1.0

Employment Agreements (3)
1.2

 
0.2


1.0

 

 

Operating Leases
140.4

 
3.8


27.0

 
21.4

 
88.2

Purchase Obligations
6.4

 
1.0


4.2

 
1.2

 

Other
4.5

 
1.1


0.7

 
1.6

 
1.1

Total
$
1,850.2

 
$
12.8


$
229.5

 
$
175.8

 
$
1,432.1

(1
)
The Company may borrow and make payments against the revolving credit portion of its Senior Credit Facility and Securitization Facility from time to time and considers all of the outstanding amounts to be long term based on its current intent and ability to repay the borrowing outside of the next twelve-month period.
(2
)
Interest is calculated on the term loan portion of the Senior Credit Facility based on current interest rates paid by the Company. [As the revolving credit facility and Securitization Facility can be repaid at any time, no interest has been included in the calculation.]
(3
)
Amounts shown under Employment Agreements do not include compensation resulting from a change in control.
(4
)
On February 4, 2020, the Company issued $575.0 million aggregate principal amount of its of 0.5% Convertible Senior Notes due 2025 (the "2025 Notes"). The 2025 Notes will mature on August 15, 2025 and bear interest at a rate of 0.5% per annum payable semi-annually in arrears, unless earlier converted, repurchased or redeemed in accordance with the terms of the Notes. See Note 7, Debt, for the details on the 2025 Notes.
 
The Company has excluded its contingent consideration obligation related to a prior and current year acquisitions from the contractual obligations table above; this liability had a total estimated fair value of $14.4 million at September 30, 2020. This liability has been excluded because the amount to be paid and the potential payment date is not fixed.
The Company has excluded its option to acquire Integrated Shoulder Collaboration Inc., which becomes mandatory upon achievement of a certain sales threshold, for an amount not to exceed $80.0 million. This liability has been excluded because the amount to be paid and the potential payment date is not fixed. In connection with the sale of the Company's Extremity Orthopedic business, the Company will pay $41.5 million to CFO pursuant to the terms of certain agreements between Integra and CFO relating to the development of shoulder arthroplasty products. See Note 2, Assets and Liabilities Held for Sale, for details of the transaction.
The Company has excluded its future pension contribution obligations and deferred compensation obligations from the table above. This has been excluded because the future amounts to be paid and the potential payment dates are not fixed.
The Company has excluded the liability for uncertain tax benefits from the contractual obligations table above, including interest and penalties, totaling $1.0 million at September 30, 2020. This liability for uncertain tax benefits has been excluded because we cannot make a reliable estimate of the period in which the uncertain tax benefits may be realized.
OTHER MATTERS
Critical Accounting Estimates
The critical accounting estimates included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 have not materially changed.
Recently Issued Accounting Standards
Information regarding new accounting pronouncements is included in Note 1 - Basis of Presentation to the current period’s condensed consolidated financial statements.

44


ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are exposed to various market risks, including changes in foreign currency exchange rates and interest rates that could adversely affect our results of operations and financial condition. To manage the volatility relating to these typical business exposures, we may enter into various derivative transactions when appropriate. We do not hold or issue derivative instruments for trading or other speculative purposes.
Foreign Currency Exchange and Other Rate Risks

We operate on a global basis and are exposed to the risk that changes in foreign currency exchange rates could adversely affect our financial condition, results of operations and cash flows. We are primarily exposed to foreign currency exchange rate risk with respect to transactions and net assets denominated in Euros ("EUR"), British pounds ("GBP"), Swiss francs ("CHF"), Canadian dollars, Japanese yen, Mexican pesos, Brazilian reais, Australian dollars and Chinese yuan. We manage the foreign currency exposure centrally, on a combined basis, which allows us to net exposures and to take advantage of any natural offsets. To mitigate the impact of currency fluctuations on transactions denominated in nonfunctional currencies, we periodically enter into derivative financial instruments in the form of foreign currency exchange forward contracts with major financial institutions. We temporarily record realized and unrealized gains and losses on these contracts that qualify as cash flow hedges in other comprehensive income, and then recognize them in other income or expense when the hedged item affects net earnings.
From time to time, we enter into foreign currency forward exchange contracts to manage currency exposures for transactions denominated in a currency other than an entity’s functional currency. As a result, the impact of foreign currency gains/losses recognized in earnings are partially offset by gains/losses on the related foreign currency forward exchange contracts in the same reporting period. Refer to Note 8, Derivative Instruments for further information.
We maintain written policies and procedures governing our risk management activities. With respect to derivatives, changes in hedged items are generally expected to be completely offset by changes in the fair value of hedge instruments. Consequently, foreign currency exchange contracts would not subject us to material risk due to exchange rate movements, because gains and losses on these contracts offset gains and losses on the assets, liabilities or transactions being hedged.
The results of operations discussed herein have not been materially affected by inflation.
Interest Rate Risk
Cash and Cash Equivalents - We are exposed to the risk of interest rate fluctuations on the interest income earned on our cash and cash equivalents. A hypothetical 100 basis point movement in interest rates applicable to our cash and cash equivalents outstanding at September 30, 2020 would increase interest income by approximately $4.0 million on an annual basis. No significant decrease in interest income would be expected as our cash balances are earning interest at rates of approximately one basis point. We are subject to foreign currency exchange risk with respect to cash balances maintained in foreign currencies.
Debt - Our interest rate risk relates primarily to U.S. dollar LIBOR-indexed borrowings. We use interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates. These interest rate swaps fix the interest rate on a portion of our expected LIBOR-indexed floating-rate borrowings. See Note 8, Derivative Instruments, for the details of interest rate swaps.
The total notional amount of interest rate swaps in effect as of September 30, 2020 was $975.0 million. Based on our outstanding borrowings at September 30, 2020, a 100 basis points change in interest rates would have impacted interest expense on the unhedged portion of the debt by $0.9 million on an annualized basis.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
The Company maintains disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our Exchange Act report is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. Disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Management has designed our disclosure controls and procedures to provide reasonable assurance of achieving the desired control objectives.
As required by Exchange Act Rule 13a-15(b), the Company has carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2020. Based upon this evaluation, our

45


principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of September 30, 2020 to provide such reasonable assurance.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that occurred during the quarter ended September 30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
In response to business integration activities, the Company has and will continue to further align and streamline the design and operation of the financial control environment to be responsive to the changing business model.
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
Information pertaining to legal proceedings can be found in Note 17. Commitment and Contingencies.

ITEM 1A. RISK FACTORS
The following risk factors are in addition to the risks described in the Company’s Form 10-K under Item 1A, “Risk Factors” for its fiscal year ended December 31, 2019 and in its subsequent periodic reports filed with the Securities and Exchange Commission pursuant to the Securities Exchange Act of 1934, as amended. The risk factors described below may have the effect of heightening many of the risks contained in the Company’s Form 10-K and other periodic reports.
 
The sale of the Extremity Orthopedics business is subject to customary closing conditions, including an employee consultation process in France, and may not be completed on a timely basis, or at all.

On September 29, 2020, the Company and certain of its subsidiaries entered into an agreement to sell to Smith & Nephew USD Limited. the Company’s upper and lower extremity orthopedics product portfolio, including ankle and shoulder arthroplasty and hand and wrist product lines (See FN 2 Assets and Liabilities for Sale). We cannot assure you that the conditions to the closing of the sale will be satisfied and, if those conditions are neither satisfied nor, where permissible, waived on a timely basis or at all, we may be unable to complete the sale of the Extremity Orthopedics business, or such completion may be delayed or completed on terms that are less favorable, perhaps materially, to us than the terms currently contemplated.
 
If the proposed sale of our Extremity Orthopedics business is completed, the announcement and pendency of the sale may be disruptive to our businesses (including the Extremity Orthopedics business) and may adversely affect our existing relationships with current and prospective employees and business partners, as well as with customers. Uncertainties related to the pending sale may also impair our ability to attract, retain and motivate key personnel and could divert the attention of our management and other employees from its day-to-day business and operations in preparation for and during the sale. If we are unable to effectively manage these risks, the business, results of operations, financial condition and prospects of our businesses could be adversely affected.
 
If the proposed sale of the Extremity Orthopedics business is delayed or not completed for any reason, including due to our or Smith & Nephew's inability to satisfy the closing conditions set forth in the Definitive Agreements or industry or economic conditions outside of our control, including those related to the ongoing COVID-19 pandemic, investor confidence could decline. Moreover, in the event of a failed transaction due, for example, to our inability to successfully go through the employee consultation process in France in timely fashion, we will incur costs and will have expended significant management resources in an effort to complete the sale. Accordingly, if the proposed sale of the Extremity Orthopedics business is not completed on the timeline or terms currently contemplated, or at all, our business, results of operations, financial condition, cash flows and stock price may be adversely affected.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Information pertaining to our common stock under the repurchase program can be found in Note 12. Treasury Stock.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION

46


Not applicable.
ITEM 6. EXHIBITS
Reference is hereby made to the Exhibit Index on page 49.



47


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
 
 
 
 
 
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
 
 
 
Date:
October 29, 2020
 
/s/ Peter J. Arduini
 
 
 
Peter J. Arduini
 
 
 
President and Chief Executive Officer
 
 
 
(Principal Executive Officer)
 
 
 
Date:
October 29, 2020
 
/s/ Carrie L. Anderson
 
 
 
Carrie L. Anderson
 
 
 
Executive Vice President and Chief Financial Officer
 
 
 
(Principal Financial Officer)
 
 
 
 
Date:
October 29, 2020
 
/s/ Jeffrey A. Mosebrook
 
 
 
Jeffrey A. Mosebrook
 
 
 
Senior Vice President, Finance
 
 
 
(Principal Accounting Officer)


48



Exhibits
 
 
 
 
 
*2.1
 

*31.1
 
 
 
*31.2
 
 
 
*32.1
 
 
 
*32.2
 
 
 
 
*†101.INS
 
XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
 
 
*†101.SCH
 
XBRL Taxonomy Extension Schema Document
 
 
*†101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
*†101.DEF
 
XBRL Definition Linkbase Document
 
 
*†101.LAB
 
XBRL Taxonomy Extension Labels Linkbase Document
 
 
*†101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document
 
*
Filed herewith
#
Indicates a management contract or compensatory plan or arrangement.

† The financial information of Integra LifeSciences Holdings Corporation Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 filed on October 29, 2020 formatted in XBRL (Extensible Business Reporting Language): (i) the Condensed Consolidated Statements of Operations and Comprehensive Income, (ii) the Condensed Consolidated Balance Sheets, (iii) Parenthetical Data to the Condensed Consolidated Balance Sheets, (iv) the Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements, is furnished electronically herewith.

 




49
EX-2.1 2 iart-20200930xexx21.htm EXHIBIT 2.1 Exhibit
Execution Version


To:    The Sellers (as defined in the PSA)

PRIVATE AND CONFIDENTIAL
Date: September 29, 2020
Dear Sirs,
Project Artemis
We refer to our recent discussions relating to the contemplated acquisition by the Buyer or its applicable Buyer Designee(s) of the Ascension Shares, the ISC Shares and the Purchased Assets (the Proposed Transaction).
Capitalised terms not otherwise defined in this letter (the Offer Letter) shall have the meanings given to them in the form of purchase and sale agreement attached to this Offer Letter as Appendix 1 (the PSA) and any references in this Offer Letter to a Section shall mean a Section of the PSA. Sections 1.1 and 1.2 (Definitions and Other Defined Terms ) of the PSA are incorporated herein mutatis mutandis as if such provisions were incorporated in this Offer Letter except that any references therein to the “Agreement” shall be construed as references to this Offer Letter.
1.
PUT OPTION
1.1
In consideration of the undertakings given by the Sellers in this Offer Letter, the Buyer irrevocably grants to the Sellers a firm and binding option to require the Buyer to sign the PSA and to purchase, or cause the purchase of, the Ascension Shares, the ISC Shares and the Purchased Assets and assume the Assumed Liabilities from the Sellers and the other applicable members of the Seller Group, on the terms and subject to the conditions of the PSA and this Offer Letter (the Put Option).
1.2
The Purchase Price for the Ascension Shares, the ISC Shares and the Purchased Assets shall be determined and paid in accordance with the provisions set forth in the PSA.
1.3
The Put Option may be exercised in writing by the Sellers (a Put Option Exercise) at any time after the latest of (i) December 9, 2020 (or such other date as the Parties may agree) (ii) completion of the information and consultation process with the Social and Economic Committee of Services (the Employee Representative Body) with respect to the proposed transfer of the French Services Employees within the context of the Proposed Transaction, in accordance with applicable Law (the Consultation Process) and (iii) completion of the procedure for informing each of the French Services Employees in accordance with the provisions of Article L. 141-28 of the French Commercial Code (Code de commerce) (the Loi Hamon Process) but on or before the Option Expiry Date (as defined in paragraph 1.5 below) or, if either party exercises its extension right pursuant to paragraph 1.6, the Extended Option Expiry Date (as defined in paragraph 1.6(b) below), by written notice from the Sellers to the Buyer (the Exercise Notice).


Execution Version


1.4
For the purposes of this Offer Letter, the Consultation Process shall be deemed to have been completed if the Employee Representative Body has issued an opinion, or is deemed to have issued an opinion under applicable Law, with respect to the proposed transfer of the French Services Employees within the context of the Proposed Transaction and the Loi Hamon Process shall be completed on the date the Consultation Process will be deemed to have been completed.
1.5
The Put Option will enter into force on the date of this Offer Letter (the Option Date) and the Put Option shall remain valid until 23.59 (CET) on the date that is three months following the Option Date (the Option Expiry Date).
1.6
If the Consultation Process and the Loi Hamon Process have not been completed pursuant to paragraph 1.3 above by the Option Expiry Date:
(a)
either party that has complied in all material respects with its obligations under paragraphs 3.1 and 3.2 below, as applicable, may extend the term of the Put Option by a period of one month following the Option Expiry Date by notifying the other party in writing five calendar days before the Option Expiry Date, in which case the other party will be bound by such extension. In case of such an extension, 23:59 (CET) on the date that is one month after the Option Expiry Date shall be the “Extended Option Expiry Date”. If the Put Option is not exercised by the Sellers by the Extended Option Expiry Date, the Put Option will automatically expire at 00:00 (CET) on the Extended Option Expiry Date; or
(b)
if no extension of the Option Expiry Date is requested in accordance with paragraph 1.6(a) above, the Put Option will automatically expire at 00:00 (CET) on the Option Expiry Date.
1.7
If the Sellers fail to exercise the Put Option on or before the Option Expiry Date (or if either party exercises its extension right pursuant to paragraph 1.6, the Extended Option Expiry Date), then this Offer Letter shall terminate automatically and immediately. Additionally, this Offer Letter may be terminated upon mutual written agreement of the Buyer and the Sellers or by the Buyer upon the occurrence of a Material Adverse Effect. Section 9.3 of the PSA shall apply mutatis mutandis to the termination of this Offer Letter, except that any references therein to the “Agreement” shall be construed as references to this Offer Letter. Notwithstanding the foregoing, under circumstances where the Termination Fee is payable pursuant to paragraph 1.8, paragraphs 1.8 and 1.9 will survive the termination of this Offer Letter.
1.8
If (a) the Consultation Process and the Loi Hamon Process are completed on or prior to the Option Expiry Date (or if either party exercises its extension right pursuant to paragraph 1.6, the Extended Option Expiry Date), but the Sellers fail to exercise the Put Option on or prior to the Option Expiry Date or the Extended Option Expiry Date, as applicable, or (b) either the Consultation Process or the Loi Hamon Process has not been completed on or prior to the Option Expiry Date (or if either party exercises its extension right pursuant to paragraph 1.6, the Extended Option Expiry Date) due to a Seller’s breach of paragraph 3.1


Execution Version


hereof, then in each case, Sellers will pay to Buyer no later than three Business Days following the Option Expiry Date or Extended Option Expiry Date, as applicable, an amount equal to 5% of Base Purchase Price (the “Termination Fee”), by wire transfer of immediately available funds to an account designated in writing by Buyer.
1.9
If the Termination Fee is paid pursuant to paragraph 1.8, the maximum aggregate liability of Sellers and their Affiliates shall be limited to the amount of the Termination Fee, and in no event shall Buyer or any of its Affiliates seek any other remedies available at law or in equity. The Parties hereto acknowledge that the agreements contained in paragraph 1.8 and this paragraph 1.9 are an integral part of the Proposed Transaction, and that, without these agreements, the Parties hereto would not enter into this Offer Letter. The Parties hereto acknowledge that the Termination Fee, in the circumstances in which such fee becomes payable, constitutes liquidated damages and is not a penalty.
2.
EXECUTION OF THE PSA
2.1
Upon exercise of the Put Option, the PSA shall be legally binding immediately on the Buyer and the Sellers. For the sake of good order, the Sellers and the Buyer undertake to duly, and as soon as practicable, execute the PSA and electronically exchange signature pages thereto, within two Business Days following the day of receipt by the Buyer of the Exercise Notice.
2.2
Closing will then occur subject to and in accordance with the terms and conditions of the PSA.
3.
INFORMATION AND CONSULTATION OF THE EMPLOYEE REPRESENTATIVE BODY
3.1
Following execution of this Offer Letter, the Sellers shall:
(a)
procure that Services:
(i)
commences the Consultation Process as soon as reasonably practicable and no later than ten Business Days following the date of this Offer Letter;
(ii)
convenes a meeting of the Employee Representative Body as soon as reasonably practicable after the date of this Offer Letter and in any event by no later than ten Business Days after the date of this Offer Letter; and
(iii)
pursues diligently, and complies with all relevant obligations in respect of the Consultation Process, with a view to obtaining the Employee Representative Body’s opinion on the proposed transfer of the French Services Employees within the context of the Proposed Transaction as soon as reasonably practicable; provided, however, that the Sellers shall not be in breach of this paragraph 3.1(a)(iii) to the extent the Buyer’s failure to comply with its obligations under paragraph 3.2 materially hinders, prevents or delays the Sellers’ ability to comply with its obligations in respect of the Consultation Process;


Execution Version


(b)
procure that Services commences the Loi Hamon Process as soon as reasonably practicable and no later than ten Business Days after the date of this Offer Letter;
(c)
keep the Buyer reasonably informed in a timely manner of the progress of the Consultation Process and of the Loi Hamon Process, including notifying Buyer when the Consultation Process and Loi Hamon Process are commenced, affording Buyer with a reasonable opportunity to review and provide comments on any materials submitted to any French Services Employee or Employee Representative Body in connection with such processes, and notifying Buyer of any material feedback received from any French Services Employee or Employee Representative Body and any actual or anticipated issues or delays that arise in connection with such processes; and
(d)
not, and shall procure that their Subsidiaries shall not, without the Buyer's prior written consent, make any commitments to or for the benefit of the French Services Employees other than in the ordinary course of business.
3.2
The Buyer shall provide the Sellers with all assistance and cooperation reasonably requested in connection with the Consultation Process including, without limitation:
(a)
before the first meeting of the Employee Representative Body, the Buyer shall provide Services (to the extent reasonably required for the purposes of the Consultation Process) with details of the Buyer’s background and history, current operations in France, a structure chart and current operations in the same sector as the Business;
(b)
providing all other relevant information reasonably requested by Services for the purposes of the Consultation Process in relation to the proposed transfer of the French Services Employees within the context of the Proposed Transaction; and
(c)
procuring that a senior authorised representative of the Buyer attends meetings with the Employee Representative Body where and when so reasonably requested by Services upon reasonable prior written notice,
and, in the case of paragraphs (b) to (c), such information or assistance shall be provided by the Buyer within five Business Days of any reasonable written request by Services.
3.3
The Sellers will deliver to the Buyer a copy of the opinion (avis) rendered (or deemed to be rendered) by the Employee Representative Body of Services within two Business Days following the delivery of such opinion.
3.4
The Sellers will deliver to Buyer copies of any relevant documentation with respect to the completion of the Loi Hamon Process, within two Business Days following completion of the Consultation Process.


Execution Version


3.5
The Sellers accept the benefit of the Put Option solely as an option exercisable at the Sellers’ sole discretion, it being understood that such acceptance shall not constitute in any manner an undertaking by the Sellers to exercise the Put Option or to enter into the PSA.
3.6
The Buyer acknowledges that, until a Put Option Exercise has occurred in accordance with paragraph 1.3 above, the Sellers shall not be bound by any obligation of any nature in connection with the Proposed Transaction, other than their compliance with the exclusivity undertaking in paragraph 5 below and their other commitments under this Offer Letter.
4.
CONDITION PRECEDENT AND OTHER PROVISIONS OF THE PSA
4.1
Article VI (Covenants of Sellers) of the PSA shall apply between the Buyer and the Sellers mutatis mutandis as if set out herein and the Buyer and the Sellers agree to comply with such provisions as from the Option Date.
4.2
Sections 2.8(a) (Consents), 2.9 (Purchase Price Allocation), 7.1 (Regulatory Approvals), 7.2 (French Services Employees; French Artemis ND Employees; European Employees), 7.3 (US Employees) and 7.12 (Release of Guarantees) of the PSA shall apply mutatis mutandis between the Buyer and the Sellers as if set out herein and the Buyer and the Sellers agree to comply with such provisions as from the Option Date.
5.
EXCLUSIVITY
From (and including) the Option Date to (and including) the date that is the earlier of (i) the date of exercise of the Put Option, or (ii) if the Put Option is not exercised, the later of the Option Expiry Date and the Extended Option Expiry Date (such period, the Exclusivity Period), in consideration of the Buyer granting the Put Option, the Sellers shall not, and shall cause their Affiliates and Representatives not to, directly or indirectly:
(a)
initiate, enter into, encourage, facilitate, offer to, or continue any inquiry, proposal, offer, discussions or negotiations with, consummate, or provide any information to, any third party who may be interested in making an offer for, proposing, inquiring into or entering into an agreement to (x) acquire or invest in, directly or indirectly, the Sellers or any of their Subsidiaries, directly or indirectly, with respect to all or part of the Ascension Shares, the ISC Shares or the Purchased Assets, (y) the transfer by any means, directly or indirectly, of all or a material part of the Ascension Shares, the ISC Shares and the Purchased Assets, or (z) any other transaction similar or designed to achieve a similar economic outcome to any of the foregoing (each an “Alternative Transaction”); or
(b)
furnish any information or afford access to the business, financial position, properties, assets, or the books and records of the Sellers and the Subsidiaries of the Sellers engaged in the Business to any person or entity other than the Buyer and its Representatives in connection with an Alternative Transaction.
6.
WARRANTIES AND UNDERTAKINGS


Execution Version


6.1
The Parent hereby represents and warrants to the Buyer the statements set out in Article IV (Representations and Warranties of Parent) of the PSA as if such provisions were incorporated in this Offer Letter except that references therein to the “Agreement” shall be construed to include references to this Offer Letter.
6.2
The Buyer hereby warrants to the Sellers the statements set out in Article V (Representations and Warranties of the Buyer) of the PSA as if such provisions were incorporated in this Offer Letter except that references therein to the “Agreement” shall be construed to include references to this Offer Letter.
7.
ANNOUNCEMENTS AND CONFIDENTIALITY
The Parties agree that Section 7.10 (Public Announcements) of the PSA shall apply mutatis mutandis between the Buyer and the Sellers as if set out herein except that references in that Section to the “Agreement” shall be construed as references to the Put Option and this Offer Letter. The Parties acknowledge that the Confidentiality Agreement is in full force and effect.
8.
NOTICES
The Parties agree that Section 11.1 (Notices) of the PSA shall apply mutatis mutandis between the Buyer and the Sellers as if set out herein except that references therein to the “Agreement” shall be construed to include references to this Offer Letter.
9.
COSTS
Section 11.3 (Expenses) of the PSA shall apply mutatis mutandis between the Buyer and the Sellers as if set out herein except that references therein to the “Agreement” shall be construed to include references to this Offer Letter.
10.
GENERAL
10.1
No variation of this Offer Letter shall be valid unless it is in writing and signed by or on behalf of each party.
10.2
This Offer Letter shall be binding upon and shall inure to the benefit of the Parties to it and their respective successors and permitted assigns.
10.3
This Offer Letter is for the sole benefit of the Parties and their respective successors and permitted assigns and nothing in this Offer Letter, express or implied, is intended to or shall confer upon any other person or entity any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Offer Letter.
10.4
This Offer Letter may be executed in any number of counterparts, but shall not be effective until each party has executed and delivered at least one counterpart. Each counterpart constitutes an original, and all the counterparts together constitute one and the same agreement. If this Offer Letter is executed in duplicate, each duplicate constitutes an original.


Execution Version


This Offer Letter may be executed by manual signature, facsimile or electronic means, all of which shall be equally valid.
11.
NO WAIVER
11.1
No failure or delay in exercising any right, power or privilege under this Offer Letter will operate as a waiver of it, nor will any single or partial exercise of any right, power or privilege under this Offer Letter preclude any other or further exercise of it or of any other right, power or privilege under this letter or otherwise. Nothing contained in this Offer Letter shall be construed as prohibiting the Sellers or the Buyer from pursuing any other remedies available to it.
12.
SPECIFIC PERFORMANCE
12.1
The Parties agree that irreparable damage would occur if any provision of this Offer Letter were not performed in accordance with the terms hereof and that the Parties shall be entitled to an injunction or injunctions to prevent breaches of this Offer Letter or to enforce specifically the performance of the terms and provisions hereof, in addition to any other remedy to which they are entitled at law or in equity.
12.2
All remedies provided either under this Offer Letter or by applicable Law, in the event of breach by any party of this Offer Letter, shall be cumulative and not alternative; provided that if the Termination Fee is paid hereunder, the Termination Fee will be Buyer’s sole and exclusive remedy for any breach of this Offer Letter.
13.
GOVERNING LAW AND CONSENT TO JURISDICTION
13.1
This Offer Letter and any non-contractual obligations arising out of or in connection with it (including any non-contractual obligations arising out of the negotiation of the transaction contemplated by this Offer Letter) are governed by and interpreted and enforced in accordance with the Laws of the State of Delaware, without giving effect to any choice of Law or conflict of Laws rules or provisions (whether of the State of Delaware or any other jurisdiction) that would cause the application of the Laws of any jurisdiction other than the State of Delaware.
13.2
Section 11.7 (Consent to Jurisdiction) of the PSA shall apply mutatis mutandis between the Buyer and the Sellers as if set out herein except that references therein to the “Agreement” shall be construed to include references to this Offer Letter.
By countersigning this Offer Letter, you agree to the exclusivity undertaking and your other commitments provided for in this Offer Letter.






Yours faithfully,
By: Smith & Nephew USD Limited

/c/Susan M. Swabey
Name: Susan Margaret Swabey
Title: Director






We acknowledge and agree to the terms of, and our obligations under, this Offer Letter. Without prejudice to the rights of the Buyer and the obligations of the Sellers under this Offer Letter, such countersignature is not and shall not be construed as an agreement to execute the PSA.
Yours faithfully,

/c/Peter J. Arduini
For and on behalf of
INTEGRA LIFESCIENCES HOLDINGS CORPORATION



/c/Jeffrey Mosebrook
For and on behalf of
INTEGRA LIFESCIENCES SERVICES (FRANCE) SAS



/c/Jeffrey Mosebrook
For and on behalf of
NEWDEAL SAS



APPENDIX 1
PURCHASE AND SALE AGREEMENT



Final Form




PURCHASE AND SALE AGREEMENT

dated as of [●], 2020

by and among

Integra LifeSciences Holdings Corporation,

Integra LifeSciences Services (France) SAS,

Newdeal SAS,

and

Smith & Nephew USD Limited
 









TABLE OF CONTENTS




 
 
Page

ARTICLE I
DEFINITIONS
2
1.1
Definitions
2
1.2
Other Defined Terms
13
ARTICLE II
PURCHASE AND SALE
17
2.1
Purchase and Sale of the Business
17
2.2
Excluded Assets
19
2.3
Assumed Liabilities
19
2.4
Excluded Liabilities
20
2.5
French Business Sale Agreement; French Successor Agreement; French Closing Deliverables
20
2.6
Purchase Price; Delivery of Funds
21
2.7
Post-Closing Adjustment
22
2.8
Consents
24
2.9
Purchase Price Allocation
25
2.1
Withholding
26
ARTICLE III
CLOSING
27
3.1
Closing Date
27
3.2
Deliveries by Sellers at the Closing
27
3.3
Deliveries by Buyer at the Closing
28
3.4
The European Employees
29
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF PARENT
29
4.1
Organization and Good Standing
29
4.2
Authority and Enforceability
30
4.3
No Conflicts; Consents
30
4.4
Financial Information
31
4.5
No Undisclosed Liabilities
31
4.6
Taxes
31
4.7
Compliance with Law
34
4.8
Regulatory Matters
34
4.9
Business Authorizations
36
4.1
Acquired Company Capital Stock; Acquired Company Operations
36
4.11
Title to Assets; Sufficiency of Assets
37
4.12
Real Property
37
4.13
Intellectual Property
38
4.14
Absence of Certain Changes or Events
39
4.15
Contracts
40
4.16
Litigation
41
4.17
Employee Benefits
42
4.18
Labor and Employment Matters
44
4.19
Environmental
46
4.2
Brokers or Finders
46
4.21
Privacy and Data Security
46
4.22
Product Defects; Warnings
47
4.23
Anticorruption Matters
47
4.24
Affiliate Arrangements; Seller Guaranties
47
4.25
Inventory and Instruments
47


TABLE OF CONTENTS
(continued)
Page


ARTICLE V
REPRESENTATIONS AND WARRANTIES OF BUYER
48
5.1
Organization and Good Standing
48
5.2
Authority and Enforceability
48
5.3
No Conflicts; Consents
48
5.4
Available Funds
49
5.5
Litigation
49
5.6
Brokers or Finders
49
5.7
Investigation by Buyer
49
5.8
Acknowledgment by Buyer
50
ARTICLE VI
COVENANTS OF SELLERS
50
6.1
Conduct of Business
50
6.2
Negative Covenants
51
6.3
Access to Information Concerning Properties and Records
53
6.4
Interim Financial Statements
54
6.5
Payment of Pro-Rated Bonuses
54
6.6
Pre-Closing Assignment of Certain Contracts
54
ARTICLE VII
COVENANTS OF BUYER AND SELLERS
54
7.1
Regulatory Approvals
55
7.2
French Business Employees; European Employees
57
7.3
U.S. Employees
59
7.4
Taxes
64
7.5
Discharge of Business Obligations After Closing
70
7.6
Access to Books and Records
70
7.7
Further Assurances
71
7.8
Local Transfer Agreements
71
7.9
French Lease
72
7.1
Public Announcements
72
7.11
Confidentiality
72
7.12
Release of Guaranties
73
7.13
Termination of Affiliate Arrangements
73
7.14
Restrictive Covenants
73
7.15
Wrong Pockets
74
7.16
License
75
7.17
Post-Closing Reporting
75
ARTICLE VIII
CONDITIONS TO CLOSING
75
8.1
Conditions to Obligations of Buyer and Sellers
75
8.2
Conditions to Obligation of Buyer
76
8.3
Conditions to Obligation of Sellers
77
ARTICLE IX
TERMINATION
77
9.1
Termination
77
9.2
Effect of Termination
78
9.3
Remedies
78
ARTICLE X
INDEMNIFICATION
79
10.1
Survival
79
10.2
Indemnification Obligations of Parent
79
10.3
Indemnification Obligations of Buyer
80


TABLE OF CONTENTS
(continued)
Page


10.4
Indemnification Procedure
80
10.5
Liability Limitations
82
10.6
Exclusive Remedy
83
10.7
Materiality
83
ARTICLE XI
MISCELLANEOUS
83
11.1
Notices
83
11.2
Amendments and Waivers
84
11.3
Expenses
85
11.4
Bulk Sales Act
85
11.5
Successors and Assigns
85
11.6
Governing Law
85
11.7
Consent to Jurisdiction
85
11.8
Counterparts
86
11.9
Third Party Beneficiaries
86
11.1
Entire Agreement
86
11.11
Captions
86
11.12
Severability
87
11.13
Specific Performance
87
11.14
Disclosure Schedule
87
11.15
Interpretation
88
 
 
 





Exhibits
Exhibit A    Sample Calculation of Estimated Closing Working Capital
Exhibit B    Form of Bill of Sale, Assignment and Assumption Agreement
Exhibit C    Form of Transition Services Agreement
Exhibit D    Form of Trademark License Agreement
Exhibit E-1     French Business Sale Agreement
Exhibit E-2    French Successor Agreement
Exhibit F    Form of Tripartite Agreements
Exhibit G-1    Form of Patent Assignment
Exhibit G-2    Form of Trademark Assignment
Exhibit H    Form of Product Registration Agreement
Exhibit I    Form of Resignation and Release

Schedules

Schedule 1.1(a)    Accounting Principles
Schedule 2.1(b)(v)    Assigned Contracts
Schedule 2.2(f)    Excluded Assets and Properties
Schedule 2.2(g)    Excluded Intellectual Property
Schedule 6.2        Negative Covenants Exceptions
Schedule 6.6        Contracts to be Assigned Pre-Closing
Schedule 7.2(h)    French Business Protected Employees












PURCHASE AND SALE AGREEMENT
PURCHASE AND SALE AGREEMENT, dated as of [●], 2020 (this “Agreement”), by and among Integra LifeSciences Holdings Corporation, a Delaware corporation (“Parent”), Integra LifeSciences Services (France) SAS, a “société par actions simplifiée” organized under the Laws of France (“Services”), Newdeal SAS, a “société par actions simplifiée” organized under the Laws of France (“Artemis ND,” and collectively with Parent and Services, “Sellers”), Smith & Nephew USD Limited, a private company limited by shares organized under the Laws of England and Wales (“Buyer,” and collectively with Sellers, the “Parties,” and each individually, a “Party”).
WHEREAS, Sellers and certain Affiliates (as defined herein) of Parent are engaged in the business of the design, development, marketing, promotion, distribution, manufacturing, inspection, packaging and sale of products and devices used in the orthopedic surgical treatment of injuries and disorders of upper and lower extremities, excluding, for the avoidance of doubt, soft tissue and tendon repair and protection (the “Business”);
WHEREAS, Parent (i) indirectly owns 100% of the outstanding capital stock (the “Ascension Shares”) of Ascension Orthopedics, Inc., a Delaware corporation (“Ascension”), which is engaged in the Business, and (ii) as of the Closing, will indirectly own 100% of the outstanding capital stock (the “ISC Shares”) of ISC (as defined herein), which is engaged in the Business;
WHEREAS, the Parties desire that the Seller Group sell, assign, transfer, convey and deliver to Buyer or Buyer Designee(s), and that Buyer or Buyer Designee(s) purchase and acquire from the Seller Group, all of the right, title and interest of the Seller Group in and to the Ascension Shares, the ISC Shares and the Purchased Assets (as defined herein), and that Buyer or Buyer Designee(s) assume the Assumed Liabilities (as defined herein), upon the terms and subject to the conditions of this Agreement;
WHEREAS on [date], 2020 (the “Put Option Date”), Buyer granted to Sellers a firm and binding option to require Buyer to execute this Agreement and to purchase, or cause the purchase of, the Business, the Ascension Shares and the ISC Shares on the terms and subject to the conditions of this Agreement (the “Put Option”), and the Put Option was exercised by Sellers on [date], 2020;
WHEREAS Services’ relevant employee representative bodies have been informed and consulted with regards to the French Services Transaction contemplated by this Agreement and gave or have been deemed to give an opinion (avis) in respect thereof on [date];
WHEREAS the transfer of the French Artemis ND Assets does not trigger the obligation to inform French Artemis ND Employees under the provisions of Article L. 141-23 or L. 141-28 of the French Commercial Code (Code de Commerce);





WHEREAS Services’ employees have been informed with regards to the French Services Transaction in accordance with the provisions of Article L. 141-28 of the French Commercial Code (Code de Commerce);
NOW, THEREFORE, in consideration of the foregoing premises and the respective representations and warranties, covenants and agreements contained herein, the Parties agree as follows:
ARTICLE I

DEFINITIONS
1.1    Definitions. When used in this Agreement, the following terms shall have the meanings assigned to them in this Article I or in the applicable Section of this Agreement to which reference is made in this Article I.
Accounting Principles” means the accounting principles set forth on Schedule 1.1(a).
Action” means any, claim, action, suit, audit, investigation or proceeding by or before any Governmental Entity.
Affiliate” means, with respect to any specified Person, any other Person directly or indirectly controlling, controlled by or under common control with such specified Person, provided, that for the purposes of this definition, “control” (including, with correlative meanings, the terms “controlled by” and “under common control with”), as used with respect to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities, by Contract or otherwise.
Ancillary Agreements” means the Bill of Sale, Assignment and Assumption Agreement, the Transition Services Agreement, the Trademark License Agreement, the French Business Sale Agreement, the French Successor Agreement, the French Lease Agreement, the Local Transfer Agreements, the IP Assignments, the Product Registration Agreement and the other agreements, instruments and documents delivered at the Closing or entered into in connection with the transactions contemplated hereby (other than the ISC Purchase Agreement and any agreement contemplated thereby).
Asset Level Taxes means those Taxes imposed with respect to the ownership of the Purchased Assets or the operation of the Business; provided that for purposes of clarity such term shall not include income Taxes and Taxes payable by a Purchased Company.
Authorization” means any authorization, approval, clearance, registration, consent, certificate, license, permit or franchise of or from any Governmental Entity or pursuant to any Law.

2




Base Purchase Price” means $240,000,000.
Benefit Plan” means each “employee benefit plan” (as defined in ERISA Section 3(3)) (whether or not subject to ERISA) and all other material compensation and benefit plans, policies, trust funds, programs, arrangements or payroll practices, including severance, salary continuation, pension, profit sharing, 401(k), retirement, employee stock ownership, deferred compensation, stock purchase or other equity-based compensation plan, incentive, bonus, employment, and change in control agreement, plan, program, or arrangement maintained, sponsored or contributed to, or required to be contributed to, by any member of the Seller Group, in each case for the benefit of the Business Employees (other than any “multiemployer plan” within the meaning of Section 3(37) of ERISA).
Books and Records” means any books of account, ledgers, subsidiary ledgers general, financial, and shipping records, invoices, operating and production records, design history files, marketing and promotional materials, customer lists and price lists, credit records of customers, Tax Returns of the Purchased Companies (other than U.S. federal income and state and local group Tax Returns) and pro forma Tax Returns of the sellers reporting Asset Level Taxes of the Purchased Assets as applicable to the Business, product taxability matrices used for determining applicability of sales and use Taxes, resale and exemption certificates used for sales and use Tax purposes, records and files, in each case to the extent related to the Business, but for the avoidance of doubt, not including any Charter Documents of any Retained Companies.
Business Day” means a day other than a Saturday, Sunday or other day on which banks located in New York City are authorized or required by Law to close.
Business Employee” means only those individuals who are not Excluded Employees and who are (a) employed by a Purchased Company or (b) identified on the Business Employees Schedule (as may be updated pursuant to Section 7.3).
Buyer Designee” means any Affiliate of Buyer designated by Buyer in writing at least three (3) Business Days prior to the Closing Date as the buyer of all or any portion of the Ascension Shares, the Purchased Assets or the ISC Shares, or as the Person to whom the employment of all or any portion of the Business Employees will transfer.
Buyer Indemnified Parties” means Buyer and its Affiliates, their respective Representatives and the heirs, executors, successors and assigns of any of the foregoing.
Cash” means cash and cash equivalents of the Purchased Companies as of immediately prior to the Closing. Cash will (a) be reduced by uncleared checks and drafts issued by any Purchased Company and (b) include uncleared checks and drafts received by or deposited for the account of any Purchased Company. Cash excludes any cash subject to contractually or statutorily imposed restrictions on use of cash for any reason.
Capital Expenditures Budget” means the capital expenditures budget of the Business set forth in Section 6.2(p) of the Seller Disclosure Schedule.

1




Charter Documents” means, with respect to any entity, the certificate of incorporation, “Kbis extract” (in the case of a French entity), the certificate of formation, the articles of incorporation, “statuts” (in the case of a French entity), memorandum of association, by-laws, articles of organization, limited liability company agreement, partnership agreement, formation agreement, joint venture agreement or other similar organizational documents of such entity (in each case, as amended).
Closing Indebtedness” means the aggregate Indebtedness, as of immediately prior to the Closing, of (a) the Retained Companies, but only to the extent assumed by Buyer or a Buyer Designee pursuant to Section 2.3 and (b) the Purchased Companies.
Closing Working Capital” means an amount (which may be positive or negative) equal to the Working Capital Assets as of immediately prior to the Closing.
Closing Working Capital Adjustment” means the amount, as finally determined in accordance with Section 2.7 (which may be expressed as a negative number), equal to the Closing Working Capital, less the Target Closing Working Capital.
Code” means the Internal Revenue Code of 1986, as amended.
Contract” means any legally binding agreement, contract, license, lease, commitment, arrangement or understanding, whether written or oral.
Effect” means any state of facts, change, effect, event, occurrence or condition.
Environmental Law” means any Law relating to (a) the protection, restoration or impairment of the environment or human health and safety or (b) exposure to, or Releases of, Hazardous Substances.
Equipment” means machinery, leasehold improvements, fixtures, furniture, supplies, accessories, materials, equipment, parts, automobiles, trucks, vehicles, tooling, tools, molds, office equipment, computers, telephones and all other items of tangible personal property, in each case Related to the Business.
ERISA” means the Employee Retirement Income Security Act of 1974, as amended.
ERISA Affiliate” means any entity which is a member of a “controlled group of corporations” with, under “common control” with or a member of an “affiliated services group” with, the Seller Group, as defined in Section 414(b), (c), (m) or (o) of the Code.
Estimated Closing Working Capital Adjustment” means the amount (which may be expressed as a negative number) equal to the Estimated Closing Working Capital, less the Target Closing Working Capital.

2




European Employees” means those Business Employees who are employed by Subsidiaries of Parent and whose primary place of work is in Europe, but excluding the French Services Employees and the French Artemis ND Employees.
Excluded Employees” means those individuals who are identified as “Excluded Employees” on the Business Employees Schedule, and, to the extent such employees are employed by a Purchased Company, whose employment will be transferred to another member of the Seller Group prior to Closing.
Fraud” means, with respect to a Party, an actual and intentional fraud with respect to the making of the representations and warranties pursuant to Article IV or Article V (as applicable), provided that such actual and intentional fraud of such Party shall only be deemed to exist if such Party had actual knowledge (as opposed to imputed or constructive knowledge) that the representations and warranties made by such Party pursuant to, in the case of Parent, Article IV as qualified by the Seller Disclosure Schedule, or, in the case of Buyer, Article V, were actually breached when made.
French Artemis ND Assets” means the part of the Purchased Assets that are owned by Artemis ND, but excluding any Other Owned Intellectual Property.
French Artemis ND Business” means that part of the Business conducted by or on behalf of Artemis ND in France.
French Artemis ND Employees” means those Business Employees who are employed by Artemis ND.
French Artemis ND Liabilities” means the part of the Assumed Liabilities that are Liabilities of Artemis ND.
French Artemis ND Purchase Price” means the amount of $17,600,000, which shall be payable at the Closing in the form of Euros using the exchange rate for converting U.S. Dollars to Euros reported by Bloomberg as of the end of the day in New York time on the Business Day preceding the Closing Date.
French Business Employees” means the French Artemis ND Employees and the French Services Employees.
French Business Sale Agreement” means the agreement called “contrat de cession de fonds de commerce” substantially in the form of Exhibit E-1.
French Lease Agreement” means a commercial lease agreement to be entered into between Atlantique Mur Régions, as lessor, and Artemis ND, as lessee, in respect of that portion of the premises currently leased and occupied by Artemis ND at Bâtiment 13, 97 allée Alexandre Borodine – Parc Woodstock, Saint-Priest, France, which will be on substantially similar terms and conditions to those pursuant to which Artemis ND currently occupies such premises.

3




French Services Assets” means the part of the Purchased Assets that are owned by Services.
French Services Business” means that part of the Business conducted by or on behalf of Services in France.
French Services Employees” means those Business Employees who are employed by Services.
French Services Liabilities” means the part of the Assumed Liabilities that are Liabilities of Services.
French Services Purchase Price” means the amount of $500,000, which shall be payable at the Closing in the form of Euros using the exchange rate for converting U.S. Dollars to Euros reported by Bloomberg as of the end of the day in New York time on the Business Day preceding the Closing Date.
French Services Transaction” means the sale and purchase of the French Services Business upon and subject to the terms and conditions of this Agreement, the French Business Sale Agreement and any other applicable Local Transfer Agreement.
French Successor Agreement” means the agreement called “convention de successeur” substantially in the form of Exhibit E-2.
Fundamental Representations” means the representations and warranties set forth in Section 4.1 (Organization and Good Standing), Section 4.2 (Authority and Enforceability), Section 4.10 (Acquired Company Capital Stock; Acquired Company Operations), Section 4.11(a) (Title to Assets) and Section 4.20 (Brokers or Finders).
GAAP” means generally accepted accounting principles in the United States.
Governmental Entity” means (a) any entity or body exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to United States federal, state, local, or municipal government, foreign, international, multinational or other government, including any department, commission, board, agency, bureau, subdivision, instrumentality, official or other regulatory, administrative or judicial authority thereof, (b) any non-governmental regulatory body to the extent that the rules and regulations or orders of such body have the force of Law and (c) any arbitral body of competent jurisdiction.
Hazardous Substances” means any pollutant, contaminant, or hazardous or toxic substance, material or waste, including but not limited to petroleum, asbestos and polychlorinated biphenyls.
HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

4




Indebtedness” means any of the following: (a) any indebtedness for borrowed money, (b) any obligations evidenced by bonds, debentures, notes or other similar instruments, (c) any obligation for the reimbursement of any obligor on any letter of credit, banker’s acceptance or similar credit transaction securing obligations of an unrelated third-party, to the extent of the obligation actually drawn down or borrowed, (d) any “earn-out” obligations or other obligations to pay the deferred purchase price of property, fixed assets, Equipment or services, (e) any indebtedness created or arising under any conditional sale or other title retention agreement with respect to acquired property, (f) all obligations under leases that are required to be capitalized under GAAP (without giving effect to FASB Accounting Standards Update No. 2016-02, Leases, ASC Topic 842), (g) interest rate or currency obligations, including swaps, hedges or similar agreements, (h) any guaranty of any of the foregoing, (i) all penalty payments, premiums, charges, yield maintenance amounts and other expenses with respect to the foregoing (x) payable as a result of or in connection with the prepayment of any obligations of the types referred to in clauses (a) through (h) above (assuming for purposes of calculating such amounts that such prepayment occurs immediately prior to the Closing) or (y) in respect of obligations of the types referred to in clauses (a) through (h) above that are triggered or accelerated as a result of the transactions contemplated hereby, (j) accrued but unpaid interest expense, (k) any unpaid Liabilities for Taxes of the Purchased Companies attributable to the Pre-Closing Tax Period, (l) unpaid commissions with respect to any Transferred Employee or independent contractor of the Business, and in each case the employer portion of any Taxes arising therefrom, (m) all accounts payable and accruals of the Purchased Companies, (o) all inter-company balances between the Purchased Companies and the Parent, and (p) accrued but unused vacation pay or paid time off with respect to the Transferred Employees; provided, that any such amounts included in Transaction Expenses shall not be included as “Indebtedness.”
Indemnified Party” means the Person or Persons entitled to indemnification pursuant to Section 10.2 or 10.3, as the case may be.
Indemnifying Party” means the Person or Persons having the obligation to indemnify another Person pursuant to Section 10.2 or 10.3, as the case may be.
Instruments” means the surgical instruments that are included in kits of Products or are used in the implantation of Products, to the extent Related to the Business.
“Intellectual Property” means any and all intellectual property rights in any jurisdiction throughout the world, including the following: (a) registered and unregistered trademarks, trade names, trade dress rights and service marks, together with the goodwill connected with the use of and symbolized by the foregoing; (b) copyrights, copyrightable works and other works of authorship; (c) trade secrets, know-how and confidential or proprietary information; (d) inventions (whether or not patentable) and utility and design patents; (e) internet domain name registrations; (f) rights in or to computer programs and other software, firmware, microcode and implementations, whether in object code or source code; (g) all registration and applications for registration of any of the foregoing; and (h) any renewals, extensions, continuations, continuations-in-part, divisionals, reexaminations

5




or reissues or equivalent counterpart of any of the foregoing in any jurisdiction throughout the world.
Inventory” means all raw materials, work-in-process, finished goods, supplies, spare parts and other inventories Related to the Business, including all such items (a) located on the Leased Real Property, (b) in transit from suppliers of the Business, (c) held for delivery by suppliers of the Business, or (d) held on consignment by third parties.
ISC” means Integrated Shoulder Collaboration, Inc., a Delaware corporation.
ISC Purchase Agreement” means the Stock Purchase Agreement, dated as of the Put Option Date, among Integra LifeSciences Corporation, ISC and Consortium of Focused Orthopedists, LLC, a copy of which has been made available to Buyer.
Knowledge of Buyer”, Buyer’s Knowledge, or any similar phrase means, with respect to any fact or matter, the actual knowledge, or knowledge that would be obtained following reasonable inquiry of direct reports, of Andy Radford and Catheryn O’Rourke.
Knowledge of Sellers”, Sellers’ Knowledge, or any similar phrase means, with respect to any fact or matter, the actual knowledge, or knowledge that would be obtained following reasonable inquiry of direct reports, of Robert Davis, Chris Fedele, Jeff Mosebrook, Peter Cox, David Sirolly, Andrea Caruso, Judi O’Grady and Sandy Grosso.
Law” means any statute, law (including common law), constitution, treaty, ordinance, code, order, decree, judgment, rule, regulation and any other binding requirement or determination of any Governmental Entity.
Liability” means any liability, obligation or commitment of any nature whatsoever, asserted or unasserted, known or unknown, absolute or contingent, accrued or unaccrued, matured or unmatured.
License and Development Agreement” means the License and Development Agreement, dated January 4, 2019, by and among Integra LifeSciences Corporation, ISC and Consortium of Focused Orthopedists, LLC.
Lien” means, with respect to any property or asset, any mortgage, lien, pledge, charge, security interest, preferential purchase right, adverse claim or other encumbrance or transfer restriction in respect of such property or asset.
Lien Releases” means such agreements, certificates and other documentation (including UCC-3 termination statements, intellectual property security releases and deposit account control agreement terminations) as Buyer may reasonably request to demonstrate and evidence that the Ascension Shares, the ISC Shares, the Purchased Assets and the assets and property of the Purchased Companies are free from any and all Liens other than Permitted Liens on the Closing Date.

6




Local Transfer Agreement” means any agreement or instrument of conveyance or assumption entered into or delivered in connection with the transfer of the Purchased Assets to Buyer or an Affiliate thereof or for Buyer of an Affiliate thereof to assume the Assumed Liabilities, in any jurisdiction where the Business is organized or operates, including the French Business Sale Agreement and the French Successor Agreement.
Losses” means any and all Liabilities, Taxes, damages, losses, penalties, fines, judgments, costs and expenses (including amounts paid in settlement, costs of investigation and reasonable attorney’s fees and expenses), whenever arising or incurred, and whether or not arising out of a Third-Party Claim, but excluding any punitive or exemplary damages, except to the extent actually paid or payable to a third-party in respect of a Third-Party Claim for which indemnification hereunder is otherwise required.
Material Adverse Effect” means any Effect that, individually or in the aggregate with all other Effects, has had or would reasonably be expected to have a materially adverse Effect on the business, condition (financial or otherwise) or results of operations of the Business, taken as a whole, or on any Seller’s ability to consummate the transactions contemplated by this Agreement; provided, that no Effect resulting from any of the following shall constitute a Material Adverse Effect or be considered in determining whether a Material Adverse Effect has occurred: (a) general economic, business or political conditions; (b) conditions or changes in the securities markets, credit markets, currency markets or other financial markets in the United States or any other country or region in the world, including (i) interest rates in the United States or any other country or region in the world and exchange rates for the currencies of any countries and (ii) any suspension of trading in securities (whether equity, debt, derivative or hybrid securities) generally on any securities exchange or over-the-counter market operating in the United States or any other country or region in the world; (c) any applicable Laws or interpretations thereof by any Governmental Entity or accounting rules (or interpretations thereof); (d) changes or developments affecting generally the industry in which the Business is operated; (e) political conditions in the United States or any other country or region in the world or any natural or man-made disaster or any acts of terrorism, sabotage, military action or war (whether or not declared) or any escalation or worsening thereof; (f) epidemics, pandemics or disease outbreaks (including the COVID-19 virus), and any Action, Order, disruption or adverse impact on the Business (whether financial or otherwise) related thereto; (g) the announcement of this Agreement and the transactions contemplated hereby or any communication by Buyer to any Person of its plans or intentions with respect to the Business or any portion thereof; (h) the pendency or consummation of the transactions contemplated by this Agreement; (i) any failure by Sellers or the Business (or any portion thereof) to meet any internal or published projections, budgets, plans or forecasts of revenues, earnings or other financial performance or results of operations of all or any portion of the Business for any period (provided that this clause (i) will not prevent a determination that any Effect underlying such failure has resulted in a Material Adverse Effect); (j) any action taken or not taken at the written request of, or with the written consent or waiver of, Buyer; or (k) any matter disclosed in the Seller Disclosure Schedule; provided that in the case of clauses (a) through (f), such Effects do not have a

7




disproportionate effect on the Business, as compared to other Persons engaged in the industries in which the Business operates.
Order” means any award, injunction, judgment, decree, order, ruling, subpoena or verdict or other decision issued, promulgated or entered by or with any Governmental Entity of competent jurisdiction.
Other Antitrust Laws” means the antitrust and competition Laws of all jurisdictions other than the federal agencies of the United States. For the avoidance of doubt, “Other Antitrust Laws” excludes any Law, the primary purpose of which is to regulate foreign investment, including Articles L. 151-3 et seq. and R. 151-1 et seq. of the French Monetary and Financial Code (Code Monétaire et Financier).
Other Owned Intellectual Property” means the Intellectual Property that is owned or purported to be owned by any member of the Seller Group and is Related to the Business, other than Purchased Company Owned Intellectual Property.
Parent Indemnified Parties” means Parent and its Affiliates, their respective Representatives and the heirs, executors, successors and assigns of any of the foregoing.
Payoff Letters” means customary payoff letters with respect to all Indebtedness of the Purchased Companies as of the Closing of the type described in clauses (a) and (b) of the definition of “Indebtedness” in this Section 1.1, each in form and substance reasonably satisfactory to Buyer.
Permitted Liens” means (a) Liens for current real or personal property Taxes not yet due and payable or for Taxes being contested in good faith and, in each case, for which adequate reserves have been established in accordance with GAAP, (b) workers’, carriers’ and mechanics’ or other like Liens incurred in the ordinary course of the Business with respect to which payment is not due and that do not impair the conduct of the Business or the present or proposed use of the affected property, and (c) with respect to real property, zoning restrictions, easements or reservations of rights which are immaterial in character, amount, and extent and which do not detract from the value or interfere with the present or proposed use of the real properties they affect.
Person” means an individual, a corporation, a partnership, a limited liability company, a trust, an unincorporated association, a Governmental Entity or any other entity or body.
Personal Information” means, in addition to any definition for any similar term (e.g., “personally identifiable information” or “PII”) provided by applicable Law, all information that identifies or would reasonably be used to identify an individual person, including an individual person’s name, street address, telephone number, e-mail address, photograph, social security number, driver’s license number, passport number and customer or account number.

8




Post-Closing Tax Period means any taxable period that is not a Pre-Closing Tax Period.
Pre-Closing Tax Period means any taxable period ending before or on the Closing Date and the portion of any Straddle Period ending on the Closing Date.
Pro-Rated Bonuses” means the amount determined by Sellers in good faith, in a manner consistent with past practice and after taking into account the partial performance period, of all annual bonuses payable to the Transferred Employees with respect to the fiscal year in which the Closing Date occurs, pro-rated based on the number of days in such fiscal year that have elapsed as of the Closing Date.
Products” means all medical devices and other products designed, tested, manufactured, processed, handled, distributed, marketed, commercialized, or sold by or on behalf of the Business.
Purchase Price Adjustment” means an amount (which may be expressed as a negative number) equal to (a) the aggregate total of the Closing Working Capital Adjustment less the Estimated Closing Working Capital Adjustment, plus (b) the aggregate total of the Cash (as finally determined in accordance with Section 2.7) less the Estimated Cash, minus (c) the aggregate total of the Closing Indebtedness (as finally determined in accordance with Section 2.7) less the Estimated Closing Indebtedness, minus (d) the aggregate total of the Transaction Expenses (as finally determined in accordance with Section 2.7) less the Estimated Transaction Expenses.
Purchased Companies” means, collectively, Ascension and ISC.
Purchased Company Owned Intellectual Property means the Intellectual Property owned or purported to be owned by the Purchased Companies.
Related” with respect to the Business, means used, held for use or acquired or developed for use primarily in the Business, as applicable, or otherwise primarily relating to, or primarily arising out of, the operation of the Business, as applicable.
“Release” means, with respect to Hazardous Substances, any actual spilling, leaking, pumping, pouring, emitting, emptying, discharging, injecting, dispersing, escaping, leaching, migrating, dumping or disposing into or through the environment.
“Retained Companies” means each of the members of the Seller Group, other than the Purchased Companies.
Seller Group” means, collectively, Parent, Services, Artemis ND, Ascension, ISC, and the other Subsidiaries of Parent that are engaged in the Business or that otherwise own or hold any Purchased Asset.
Seller Guaranty” means any guaranty, letter of credit, indemnity or contribution agreement or other similar agreement entered into by a Purchased Company in favor of any

9




third party guaranteeing any obligation of Parent or any of its Affiliates (other than the Purchased Companies) or any business of Parent and its Affiliates, other than the Business.
Seller Owned Intellectual Property” means the Purchased Company Owned Intellectual Property together with the Other Owned Intellectual Property.
“Straddle Period” means any taxable period beginning on or before and ending after the Closing Date.
Subsidiary” or “Subsidiaries” means, with respect to any Party, any Person, of which (a) such Party or any other Subsidiary of such Party is a general partner (excluding partnerships, the general partnership interests of which held by such Party or any Subsidiary of such Party do not have a majority of the voting interest in such partnership) or (b) at least a majority of the securities or other interests having by their terms ordinary voting power to elect a majority of the Board of Directors or others performing similar functions with respect to such Person is directly or indirectly owned or controlled by such Party and/or by any one or more of its Subsidiaries.
“Target Closing Working Capital” means $81,000,000.
Tax” or “Taxes” means (a) any U.S. federal, national, state, local, provincial or non-U.S./foreign net income, alternative or add-on minimum, estimated, gross income, gross receipts, sales, use, ad valorem, value added, transfer, franchise, capital profits or gains, lease, service, fringe benefits, license, withholding, payroll, employment, social security, excise, severance, stamp, occupation, premium, property, escheat, unclaimed property, environmental or windfall profit tax, registration, capital stock, social security (or similar), unemployment, disability, customs duty or other tax, governmental fee or other assessment or charge that in each case is in the nature of a tax, including any interest, fines, penalties, assessments, deficiencies or additions thereto, (b) any and all liability for amounts described in clause (a) of any member of an affiliated, consolidated, combined or unitary group of which any member of the Seller Group (or any predecessor of any of the foregoing) is or was a member on or prior to the Closing Date, including pursuant to Treasury Regulations Section 1.1502-6 or any analogous or similar state, local or foreign Law or regulation, and (c) any and all liability for amounts described in clause (a) or (b) of any Person (other than a member of the Seller Group) imposed on any member of the Seller Group as a transferee or successor, by contract or pursuant to any Law, rule or regulation.
Tax Attributes” means any net operating loss, net capital loss, investment Tax credit, foreign Tax credit, charitable deduction or any other similar Tax credit, asset, deduction, basis or offset that could be carried forward or back to reduce Taxes (including deductions and credits relating to alternative minimum Taxes).
Tax Returns” means any return, declaration, report, claim for refund, or information return or statement relating to Taxes, including any schedule or attachment thereto, and including any amendment thereof.

10




Transaction Expenses” means, to the extent unpaid as of the Closing, the aggregate amount of (a) all obligations of Parent and other members of the Seller Group for all financial advisor, legal, investment banking and other expenses incurred in connection with the transactions contemplated by this Agreement as of the Closing, (b) any retention, stay, change in control or similar payments that become payable to any Business Employee prior to the Closing, (c) any severance or separation benefits arising from a termination of employment at or prior to the Closing, (d) any amounts that become payable to a Business Employee solely as a result of the transactions contemplated by this Agreement, including any amounts arising from accelerated vesting of equity or equity-based awards, (e) an amount equal to a pro-rated portion of the value of the Unvested Equity Awards set forth on Section 7.3(c) of the Seller Disclosure Schedule as of the close of trading on the Business Day immediately prior to the Closing Date (as determined in accordance with Section 7.3(c)) for the vesting year for the applicable award in which the Closing Date occurs, with such pro-ration based on the number of days that have elapsed in such vesting year as of the Closing Date, (f) the excess, if any, of the amount equal to (i) the value of the equity awards set forth on Section 7.3(c) of the Seller Disclosure Schedule (as determined in accordance with Section 7.3(c)), minus (ii) the amount set forth in clause (e) above, over $500,000, and (g) the employer portion of any payroll, social security, unemployment, or similar Taxes made in connection with the payments described under the foregoing clauses (a) through (f); provided that (i) any such amounts included in the calculation of Closing Working Capital shall not be included as “Transaction Expenses,” and (ii) any amount payable to Consortium of Focused Orthopedists, LLC under the ISC Purchase Agreement shall not be included as “Transaction Expenses” and will be paid directly by Parent or an Affiliate thereof (excluding the Purchased Companies or either of them).
Transferred Employee” means any (a) Business Employee who continues employment with a Purchased Company; and (b) Business Employee who accepts an offer of employment or otherwise with effect from Closing becomes employed by Buyer and its Affiliates in accordance with Sections 7.2 and 7.3.
Treasury Regulations” means the U.S. Federal Income Tax Regulations promulgated under the Code, as such regulations may be amended from time to time.
U.S. Employee” means any Business Employee other than a French Business Employee or a European Employee.
U.S. Transferred Employee” means any Transferred Employee who is not a French Business Employee or a European Employee.
WARN Act” means the Worker Adjustment and Retraining Notification Act of 1988.
Working Capital Assets” means the following assets: (i) Inventory and (ii) Instruments. Working Capital Assets excludes all cash and cash equivalents and all Excluded Assets. Working Capital Assets will be calculated in accordance with the Accounting Principles and consistent with the sample calculation set forth on Exhibit A.

11




$” means United States dollars.
1.2    Other Defined Terms. The following terms have the meanings assigned to such terms in the Sections of the Agreement set forth below:
Affiliate Arrangement
4.24(a)
Affiliated Group Tax Return
7.4(e)
Agreement
Preamble
Artemis ND
Preamble
Ascension
Recitals
Ascension Shares
Recitals
Assigned Contracts
2.1(b)(v)
Assumed Liabilities
2.3
Basket Amount
10.5(a)
Bill of Sale, Assignment and Assumption Agreement
3.2(a)
Business
Recitals
Business Authorizations
4.9(a)
Business Employees Schedule
4.18(a)
Buyer
Preamble
Buyer 401(k) Plan
7.3(g)
Buyer Closing Certificate
8.3(c)
Buyer’s Draft Allocation
2.9(b)
Buyer FSAs
7.3(l)
Buyer Losses
10.2
Buyer’s Proposed Calculations
2.7(a)
Closing
3.1
Closing Date
3.1

12




Closing Statement
2.7(a)
COBRA
4.17(c)(vi)
Competing Activity
7.14(a)
Confidential Information
7.11(b)
Confidentiality Agreement
6.3(a)
Direct Claim
10.4(c)
Disputed Amounts
2.7(c)
DOJ
7.1(a)
Environmental Permits
4.19(a)
Estimated Cash
2.6(a)
Estimated Closing Indebtedness
2.6(a)
Estimated Closing Statement
2.6(a)
Estimated Closing Working Capital
2.6(a)
Estimated Transaction Expenses
2.6(a)
European Employment Offer
7.2(b)
Excluded Assets
2.2
Excluded Liabilities
2.4
FDA
4.8(a)
FDCA
4.8(a)
Final Purchase Price
2.7(d)
Final Purchase Price Adjustment
2.7(d)
Financial Information
4.4(a)
FTC
7.1(a)
Health Care Laws
4.8(b)
Health Care Programs
4.8(c)

13




Imminent Tax Return
7.4(b)(iv)
In-Bound Licenses
4.13(b)
Initial Purchase Price
2.6(b)
Interim Balance Sheet
4.4(b)
Interim Balance Sheet Date
4.4(b)
IP Assignments
3.2(d)
IRS
4.17(f)
ISC Products
4.13(d)
ISC Shares
Recitals
Lease
4.12(c)
Leased Real Property
4.12(b)
Make-Whole Compensation
7.3(c)
Material Contracts
4.15(b)
Notice of Claim
10.4(c)
Notice of Objection
2.7(b)
Out-Bound Licenses
4.13(c)
Outside Date
9.1(a)(ii)(A)
Parent
Preamble
Parent Losses
10.3
Parent’s Allocation Notice
2.9(b)
Party/Parties
Preamble
Pre-Closing Asset Return
7.4(b)(iii)
Pre-Closing Tax Return
7.4(b)(ii)
Pro-Forma Asset Return
7.4(b)(iii)
Pro-Forma Tax Return
7.4(b)(ii)

14




Product Registration Agreement
3.2(e)
Product Registrations
4.9(a)
Protected Employees
7.2(h)
Purchase Price
2.6(b)
Purchased Assets
2.1(b)
Put Option
Recitals
Put Option Date
Recitals
Recall
4.8(e)
Representatives
6.3(a)
Restricted Business
7.14(a)
Seller 401(k) Plan
7.3(g)
Seller Closing Certificate
8.2(c)
Seller Disclosure Schedule
Preamble Article IV
Seller FSAs
7.3(l)
Sellers
Preamble
Services
Preamble
Straddle Period Tax Return
7.4(b)(v)
Third-Party Claim
10.4(a)
Trademark License Agreement
3.2(c)
Transition Services Agreement
3.2(b)
Unvested Equity Award
7.3(c)
Working Capital Expert
2.7(c)(i)
Wrong Pocket Asset
7.15(a)

15




ARTICLE II

PURCHASE AND SALE
2.1    Purchase and Sale of the Business. Upon the terms and subject to the conditions of this Agreement, at the Closing:
(a)    Parent shall cause the applicable member of the Seller Group to sell, convey, transfer, assign and deliver to Buyer or the applicable Buyer Designee(s), and Buyer shall, or shall cause the applicable Buyer Designee(s) to, purchase from such applicable member of the Seller Group all of such Seller Group member’s right, title and interest in and to (i) the Ascension Shares and (ii) the ISC Shares, in each case free and clear of all Liens except for transfer restrictions under applicable securities Laws; and
(b)    Sellers shall sell, assign, transfer, convey and deliver, and shall cause each other relevant Retained Company to sell, assign, transfer, convey and deliver, to Buyer or the applicable Buyer Designee(s), and Buyer shall, or shall cause the applicable Buyer Designee(s) to, purchase, acquire and accept from such Retained Companies, the entire right, title and interest of Sellers and each other such Retained Company in, to and under all of the following assets, properties and rights, other than the Excluded Assets, free and clear of all Liens other than Permitted Liens (the “Purchased Assets”):
(i)    all Inventory and Instruments;
(ii)    all Equipment;
(iii)    all fixed assets, construction in progress and leasehold improvements of (A) the facility covered by the French Lease Agreement to the extent related to the Business and (B) the Austin, Texas facility;
(iv)    the Other Owned Intellectual Property;
(v)    any Contracts or portions of Contracts, in each case to the extent related to the Business, including those entered into by any Retained Company between the Put Option Date and the Closing Date in compliance with the provisions of this Agreement, and including the Contracts set forth on Schedule 2.1(b)(v) (collectively, the “Assigned Contracts”);
(vi)    to the extent transferable, all Business Authorizations, including all Product Registrations;
(vii)    all Books and Records;
(viii)    all claims, causes of action, choses in action, rights of recovery and rights under all warranties, representations and guarantees made by suppliers of products, materials or equipment, or components thereof, solely to the extent arising from or relating to the other Purchased Assets or the Assumed Liabilities;

1




(ix)    all prepaid expenses to the extent related to the Business;
(x)    all security deposits, earnest deposits and all other forms of deposit or security placed with or by any member of the Retained Companies to the extent related to the Business;
(xi)    all goodwill of the Business, including the French Services Business and the French Artemis ND Business; and
(xii)    without duplication or modification of the assets, properties and rights set forth in items (i)-(xi) of this Section 2.1(b), all other assets, properties or rights of every kind and description, real, personal and mixed, tangible and intangible, wherever situated, to the extent related to the Business.
2.2    Excluded Assets. The Purchased Assets do not include, and neither Sellers nor any other Retained Company is selling, assigning, transferring, conveying or delivering, and neither Buyer nor any Buyer Designee is purchasing, acquiring or accepting from Sellers or any other Retained Company, any of the assets, properties or rights set forth in this Section 2.2 (collectively, the “Excluded Assets”):
(a)    all cash and cash equivalents, other than those described in Section 2.1(b)(ix) or Section 2.1(b)(x) of this Agreement;
(b)    all accounts receivable;
(c)    all Contracts or portions thereof that are not Assigned Contracts;
(d)    the corporate seals, Charter Documents, minute books, stock books, Tax Returns (other than Tax Returns of the Purchased Companies and Tax Returns reporting Asset Level Taxes), or other records relating to the corporate organization of any Retained Company;
(e)    all insurance policies and all rights and benefits thereunder;
(f)    the assets, properties and rights specifically set forth on Schedule 2.2(f);
(g)    all Intellectual Property owned by a Retained Company that is not Other Owned Intellectual Property, including the Intellectual Property set forth on Schedule 2.2(g);
(h)    all Contracts between a Retained Company, on the one hand, and Parent or any Subsidiary thereof, on the other hand;
(i)    any real property owned by a Retained Company;

2




(j)    the equity interests of any of the members of the Seller Group other than Ascension and ISC; and
(k)    the rights which accrue or will accrue to any Seller or any other Retained Company under this Agreement and the Ancillary Agreements.
2.3    Assumed Liabilities. On the terms and subject to the conditions of this Agreement, and except for the Excluded Liabilities and as otherwise provided in Section 7.2, Section 7.3 or Section 7.4, Buyer agrees, effective at the Closing, to, or to cause the applicable Buyer Designee(s) to, assume and to pay, perform and discharge when due, all Liabilities (whether known or unknown, fixed, absolute, matured, unmatured, accrued or contingent, now existing or arising after the date hereof) of Sellers and the other Retained Companies to the extent arising out of the operation or conduct of the Business, including the following (the “Assumed Liabilities”):
(a)    all Liabilities in respect of the Assigned Contracts;
(b)    subject to the provisions of Section 7.2 and Section 7.3, all Liabilities related to the Transferred Employees, including accrued but unpaid compensation expense; and
(c)    all Taxes that are the responsibility of Buyer and its Affiliates pursuant to Sections 7.4(a) (Transfer Taxes), 7.4(b)(iv) (to the extent related to the Purchased Assets), and 7.4(b)(v).
2.4    Excluded Liabilities. Neither Buyer nor any of its Affiliates shall assume any Liabilities of the Retained Companies (such unassumed Liabilities are collectively, the “Excluded Liabilities”) other than those specifically set forth in Section 2.3 and shall specifically not assume:
(a)    any Liabilities of the Business for accounts payable arising prior to the Closing;
(b)    any Liabilities for Indebtedness of any Retained Company of the type provided in clauses (a) and (b) (and clauses (h) and (i) as it relates thereto) of the definition of “Indebtedness” in Section 1.1;
(c)    any Tax Liabilities of any Retained Company, other than those set forth in Section 2.3(c); and
(d)    any Liabilities to the extent related to the Excluded Assets.
2.5    French Business Sale Agreement; French Successor Agreement; French Closing Deliverables.
(a)    On the Closing Date and without prejudice to any other provision of this Agreement, Services and Buyer or the applicable Buyer Designee(s) will enter into the

3




French language version of the French Business Sale Agreement to effect the transfer of the French Services Assets and assumption of the French Services Liabilities being transferred to and assumed by Buyer or the applicable Buyer Designee(s), provided, that, Buyer acknowledges that Services may revise the schedules to the French Business Sale Agreement to reflect updated information available prior to the Closing with the prior written consent of Buyer (not to be unreasonably withheld), and provided further, that, Services may not revise such schedules in a manner that would affect the scope of the Excluded Employees without the prior written consent of Buyer. Services and Buyer acknowledge that the transfer of the French Services Assets and assumption of the French Services Liabilities constitutes a sale of a business as a going concern regulated by Articles L. 141-2 and seq. and Articles R. 141-1 and seq. of the French Commercial Code (Code de Commerce). In the event of any conflict and/or discrepancies between this Agreement and any provision of the French Business Sale Agreement, the provisions of this Agreement shall prevail.
(b)    On the Closing Date and without prejudice to any other provision of this Agreement, Artemis ND and Buyer or the applicable Buyer Designee(s) will enter into the French language version of the French Successor Agreement to effect the transfer of the French Artemis ND Assets and assumption of the French Artemis ND Liabilities being transferred to and assumed by Buyer or the applicable Buyer Designee(s), provided, that, Buyer acknowledges that Artemis ND may revise the schedules to the French Successor Agreement to reflect updated information available prior to the Closing with the prior written consent of Buyer (not to be unreasonably withheld), and provided further, that, Artemis ND may not revise such schedules in a manner that would affect the scope of the Excluded Employees without the prior written consent of Buyer. In the event of any conflict and/or discrepancies between this Agreement and any provision of the French Successor Agreement, the provisions of this Agreement shall prevail.
2.6    Purchase Price; Delivery of Funds.
(a)    At least three (3) Business Days prior to the Closing Date, Parent shall prepare and deliver to Buyer a balance sheet of the Business and a statement (together with such balance sheet, the “Estimated Closing Statement”) setting forth Parent’s good faith estimates of the Closing Working Capital, Cash, Closing Indebtedness and Transaction Expenses. The estimates of the Closing Working Capital, Cash, Closing Indebtedness and Transaction Expenses, as set forth in the Estimated Closing Statement, are referred to herein as “Estimated Closing Working Capital,” “Estimated Cash,” “Estimated Closing Indebtedness” and “Estimated Transaction Expenses.” The Estimated Closing Statement shall (i) quantify in reasonable detail the estimates of the items constituting Estimated Closing Working Capital, Estimated Cash, Estimated Closing Indebtedness and Estimated Transaction Expenses in accordance with the terms of this Agreement and (ii) include wire instructions for the payment of any Transaction Expenses, together with copies of invoices for such amounts. The Estimated Closing Statement will be prepared in accordance with the Accounting Principles and the books and records of the Business. Exhibit A contains a sample calculation of Estimated Closing Working Capital, prepared for illustration purposes only, assuming a Closing Date of December 31, 2019. Prior to the Closing, Parent will

4




consult with Buyer with respect to the Estimated Closing Statement, and Parent will reasonably consider in good faith any of Buyer’s good faith objections thereto.
(b)    The aggregate consideration (the “Purchase Price”) to be paid by or on behalf of Buyer to Sellers for the sale of the Ascension Shares, the ISC Shares and the Purchased Assets and the assumption of the Assumed Liabilities shall be an amount equal to (i) the Base Purchase Price, plus (ii) the amount of the Estimated Closing Working Capital Adjustment, plus (iii) the amount of the Estimated Cash, minus (iv) the amount of the Estimated Closing Indebtedness, minus (v) the amount of the Estimated Transaction Expenses (collectively, the “Initial Purchase Price”), and shall be subject to further adjustment pursuant to Section 2.7 of this Agreement and payable as follows:
(i)    to Parent, the Initial Purchase Price, less the amount of the French Services Purchase Price payable pursuant to Section 2.6(b)(ii) and the amount of the French Artemis ND Purchase Price payable pursuant to Section 2.6(b)(iii), such payment to be made by wire transfer of immediately available funds to an account designated by Parent in writing to Buyer at least three (3) Business Days prior to the Closing;
(ii)    to Services, the French Services Purchase Price, such payment to be made by wire transfer of immediately available funds to an account designated by Parent in writing to Buyer at least three (3) Business Days prior to the Closing; and
(iii)    to Artemis ND, the French Artemis ND Purchase Price, such payment to be made by wire transfer of immediately available funds to an account designated by Parent in writing to Buyer at least three (3) Business Days prior to the Closing.
2.7    Post-Closing Adjustment.
(a)    Within ninety (90) days after the Closing Date, Buyer shall prepare and deliver to Parent a statement of Working Capital Assets prepared in accordance with the Accounting Principles and a statement (together with such statement of Working Capital Assets, the “Closing Statement”) setting forth Buyer’s good faith calculations (“Buyer’s Proposed Calculations”) of the Closing Working Capital, the Closing Working Capital Adjustment, Cash, Closing Indebtedness, Transaction Expenses and the Purchase Price Adjustment based on such amounts. At the request of Buyer, Parent will, and will cause its Affiliates to, provide Buyer with reasonable access to the books, records and systems of Parent and its Affiliates reasonably necessary for the purposes of preparing the Closing Statement.
(b)    If Parent does not object to Buyer’s Proposed Calculations by written notice of objection (the “Notice of Objection”) delivered to Buyer within sixty (60) days after Parent’s receipt of Buyer’s Proposed Calculations, the calculation of the Closing Working Capital Adjustment, the Purchase Price Adjustment and the components thereof pursuant to Buyer’s Proposed Calculations shall be deemed final and binding.

5




(c)    If Parent delivers a Notice of Objection to Buyer within the sixty (60) day period referred to in Section 2.7(b), then any element of Buyer’s Proposed Calculations that is not in dispute on the date such Notice of Objection is given shall be treated as final and binding, and any dispute (all such amounts, the “Disputed Amounts”) shall be resolved as set forth in this Section 2.7(c):
(i)    Parent and Buyer shall promptly endeavor in good faith to resolve the Disputed Amounts listed in the Notice of Objection. If a written agreement determining the Disputed Amounts has not been reached within thirty (30) days (or such longer period as may be agreed by Parent and Buyer) after the date of receipt by Buyer of the Notice of Objection, the resolution of such Disputed Amounts shall be submitted to Ernst & Young (the “Working Capital Expert”).
(ii)    Parent and Buyer shall use their commercially reasonable efforts to cause the Working Capital Expert to render a decision in accordance with this Section 2.7(c) along with a statement of reasons therefor within thirty (30) days of the submission of the Disputed Amounts, or a reasonable time thereafter, to the Working Capital Expert. The decision of the Working Capital Expert shall be final and binding upon each Party hereto and the decision of the Working Capital Expert shall constitute an arbitral award that is final, binding and non-appealable and upon which a judgment may be entered by a court having jurisdiction thereof.
(iii)    The Purchase Price Adjustment shall be calculated based on (A) each element of Buyer’s Proposed Calculations that is not in dispute and (B) the final determination of the Working Capital Expert with respect to the Disputed Amounts, and the Purchase Price Adjustment, as so calculated, shall be deemed to be final and binding.
(iv)    If Parent and Buyer submit any Disputed Amounts to the Working Capital Expert for resolution, Parent and Buyer shall each pay their own costs and expenses incurred under this Section 2.7(c). Parent shall be responsible for that fraction of the fees and costs of the Working Capital Expert where (A) the numerator is the absolute value of the difference between Parent’s position with respect to the Purchase Price Adjustment and the Purchase Price Adjustment as calculated based on the Working Capital Expert’s final determination with respect to the Disputed Amounts and (B) the denominator is the absolute value of the difference between Parent’s position with respect to the Purchase Price Adjustment and Buyer’s position with respect to the Purchase Price Adjustment, and Buyer shall be responsible for the remainder of such fees and costs.
(v)    The Working Capital Expert shall act as an expert and not an arbitrator to determine, based on the provisions of this Section 2.7(c), only the Disputed Amounts, and the determination of each amount of the Disputed Amounts shall be made in accordance with the procedures set forth in Section 2.7(a). The Working Capital Expert shall choose between the position of Parent or the position of Buyer with respect to each component of the Purchase Price Adjustment that constitutes a Disputed Amount.

6




(d)    The term “Final Purchase Price Adjustment” means the final and binding Purchase Price Adjustment calculated pursuant to Section 2.7(b) or 2.7(c), as the case may be. The term “Final Purchase Price” means the Initial Purchase Price, (i) plus the absolute value of the Final Purchase Price Adjustment, if such amount is a positive number, or (ii) minus the absolute value of the Final Purchase Price Adjustment, if such amount is a negative number. The Final Purchase Price Adjustment shall be treated as an adjustment to the purchase price for federal, state, territory, local and foreign income Tax purposes, unless otherwise required by applicable Law.
(i)    If the Final Purchase Price is greater than the Initial Purchase Price, then Buyer shall pay to Parent for the account of Parent the difference between the Final Purchase Price and the Initial Purchase Price within three (3) Business Days of the determination of the Final Purchase Price, such amount to be paid by wire transfer of immediately available funds to an account designated by Parent in writing to Buyer promptly after the final determination of the Final Purchase Price.
(ii)    If the Final Purchase Price is less than the Initial Purchase Price, then Parent shall pay to Buyer for the account of Buyer the difference between the Initial Purchase Price and the Final Purchase Price within three (3) Business Days of the determination of the Final Purchase Price, such amount to be paid by wire transfer of immediately available funds to an account designated by Buyer in writing to Parent promptly after the determination of the Final Purchase Price.
2.8    Consents.
(a)    Prior to the Closing, Parent shall, and shall cause the other members of the Seller Group to, use commercially reasonable efforts to obtain all consents and approvals and to deliver all notices necessary to transfer or assign the Ascension Shares, the ISC Shares and all of the Purchased Assets at the Closing.
(b)    Notwithstanding anything to the contrary contained in this Agreement, to the extent that the sale, conveyance, transfer, assignment or delivery or attempted sale, conveyance, transfer, assignment or delivery to Buyer or the applicable Buyer Designee(s) of any Purchased Asset is prohibited by any applicable Law or would require any third party or any Governmental Entity’s authorization, approval, consent, negative clearance or waiver and such authorization, approval, consent, negative clearance or waiver shall not have been obtained prior to the Closing, this Agreement shall not constitute a sale, conveyance, transfer, assignment or delivery, or an attempted sale, conveyance, transfer, assignment or delivery of such Purchased Asset. From and after the Closing until the date that is one (1) year following the Closing Date, the Parties shall have a continuing obligation to use their commercially reasonable efforts to cooperate with each other and to obtain promptly all such authorizations, approvals, consents, negative clearances or waivers. Parent shall, and shall cause its Affiliates to, (i) cooperate with Buyer in any lawful arrangement reasonably proposed by Buyer to provide that Buyer or the applicable Buyer Designee(s) shall receive the interest of the Retained Companies in the benefits under such Purchased Asset and (ii) enforce, at the reasonable request of and for the account of

7




Buyer or the applicable Buyer Designee(s), any rights of any Retained Company arising under such Purchased Asset against any third party. Upon obtaining the requisite authorization, approval, consent, negative clearance or waiver, Parent shall promptly convey, transfer, assign and deliver, or cause to be conveyed, transferred, assigned and delivered, such Purchased Asset to Buyer or the applicable Buyer Designee(s).
(c)    With respect to each Assigned Contract, Sellers will, and will cause the other members of the Seller Group to, reasonably cooperate with Buyer and its Affiliates in communicating to the counterparty(ies) to such Assigned Contract (i) that such Contract will be at the Closing (or has been) assigned to Buyer or a Buyer Designee and (ii) if applicable, payment information of Buyer or the applicable Buyer Designee.
2.9    Purchase Price Allocation.
(a)    At any time prior to the Put Option Date, Buyer may prepare and deliver to Parent a commercially reasonable written information request, detailing information such as quantity, description, and location of assets, in connection with the preparation of Buyer’s Draft Allocation (defined below).  In furtherance of the prior sentence, after the Put Option Date, Parent will, and will cause its Affiliates to, provide Buyer with access to then-existing information contained in the books, records and systems of Parent and its Affiliates as reasonably necessary for the purposes of preparing Buyer’s Draft Allocation. Buyer may supplement, at any time prior to its delivery of Buyer’s Draft Allocation, its written information request described in the first sentence of this Section 2.9(a). Parent and its Affiliates shall provide such information reasonably promptly, and in any case no later than the later of (i) the Put Option Date, or (ii) five (5) Business Days following receipt of a request for supplemental information from Buyer. 
(b)     Subject to compliance by Parent and its Affiliates with Section 2.9(a), no later than thirty-five (35) Business Days after the Put Option Date, Buyer shall deliver to Parent (i) an allocation of the Initial Purchase Price among the Ascension Shares, the ISC Shares and the Purchased Assets, and (ii) an allocation of that portion of the Initial Purchase Price (including other amounts treated as consideration for Tax purposes) allocated in clause (i) to the Purchased Assets, among such Purchased Assets in a manner consistent with Section 1060 of the Code ((i) and (ii), together, the “Buyer’s Draft Allocation”). Notwithstanding anything herein to the contrary, the Parties agree that the amount allocated to the ISC Shares will not be less than the amount paid by Parent under the ISC Purchase Agreement.
(c)    If Parent disagrees with the Buyer’s Draft Allocation, Parent may, within fifteen (15) Business Days after delivery of the Buyer’s Draft Allocation, deliver a notice (“Parent’s Allocation Notice”) to Buyer to such effect, specifying those items as to which Parent disagrees, the reasons for such disagreement, and Parent’s proposed allocation of the portion of the Initial Purchase Price. If Parent does not timely deliver a Parent’s Allocation Notice, Parent will be deemed to have agreed to the Buyer’s Draft Allocation. If Parent’s Allocation Notice is delivered to Buyer within such fifteen (15) Business Day period, Parent and Buyer will negotiate in good faith for a period not to exceed twenty (20) Business Days from the receipt of Parent’s Allocation Notice to reach agreement on the

8




disputed items or amounts in order to determine the allocation. If agreement is not reached within such twenty (20) Business Day period, the Purchase Price Allocation shall be submitted to Ernst & Young (the “Independent Accounting Firm”) for resolution; provided, however, in no event shall the amount allocated to the ISC Shares depart from the amount specified in the last sentence of Section 2.9(b). The determination of the Purchase Price Allocation by the Independent Accounting Firm shall be final and binding upon the Parties absent manifest error, and the fees imposed by the Independent Accounting Firm with regard to resolving such dispute shall be borne fifty percent (50%) by Buyer and fifty percent (50%) by Parent.
(d)    Once the Final Purchase Price is determined pursuant to Section 2.7(b) or (c), the Parties shall amend the allocation of the Initial Purchase Price, consistent with the allocations described in this Section 2.9, to reflect any post-Closing adjustments to the Initial Purchase Price pursuant to Section 2.7.
(e)    The Parties hereby undertake and agree to file timely any Tax Return that may be required to be filed pursuant to Treasury Regulations promulgated under Section 1060(b) of the Code or any other applicable Law, and shall use the allocation determined pursuant to this Section 2.9 in connection with the preparation of IRS Form 8594 or any other applicable document as such form or document relates to the transactions contemplated by this Agreement. Neither Party shall file any Tax Return or other document or otherwise take any position which is inconsistent with the allocation determined pursuant to this Section 2.9, except as may be adjusted by subsequent agreement following an audit by the IRS or any other Governmental Entity or by an Order; provided, that neither Party (nor their respective Affiliates) shall be obligated to litigate any challenge to such allocation of the Final Purchase Price by any Governmental Entity. The Parties hereto shall promptly inform one another of any challenge by any Governmental Entity to any allocation made pursuant to this Section 2.9 and agree to consult with and keep one another informed with respect to the state of, and any discussion, proposal or submission with respect to, such challenge.
2.10    Withholding. Buyer or its paying agents shall be entitled to deduct and withhold from the amounts otherwise payable under this Agreement such amounts as may be required to be deducted and withheld under any applicable Law. To the extent that amounts are so deducted and withheld by Buyer or its paying agents, such deducted and withheld amounts (a) shall be remitted by Buyer or its paying agents (or its designated Person) to the applicable Governmental Entity and (b) shall be treated for all purposes of this Agreement as having been paid to the Person in respect of which such deduction and withholding was made. If Buyer determines that any such deduction or withholding is so required, Buyer shall use reasonable best efforts to promptly (and no later than three (3) Business Days prior to the date on which such payment is made) notify each applicable Person of any intention to so deduct and withhold and provide such Person the opportunity to provide any statement, form, or other documentation that would reduce or eliminate any such requirement to deduct and withhold, and cooperate with such Person as reasonably requested with respect to the filing of any Tax Return or conduct of any claim relating to any available refund of such amount remitted. Each Seller shall reasonably cooperate with Buyer and shall provide such

9




information as reasonably necessary for Buyer to determine whether any amounts are so required to be deducted and withheld.
ARTICLE III

CLOSING
3.1    Closing Date. The closing of the transactions contemplated by this Agreement (the “Closing”) shall take place by electronic transmission of signature pages and documents at 10:00 a.m. Eastern Time on a date to be specified by the Parties which shall be no later than three (3) Business Days after satisfaction (or waiver as provided herein) of the conditions set forth in Article VIII (other than those conditions that by their nature will be satisfied at the Closing, but subject to such satisfaction), unless another time, date and/or place is agreed to in writing by the Parties; provided, that if the Closing has not occurred on or prior to November 30, 2020, then the Closing will not occur prior to January 4, 2020, unless otherwise agreed to in writing by the Parties. The date on which the Closing occurs is referred to in this Agreement as the “Closing Date.” The Closing shall be deemed to occur at 12:01 a.m. Eastern Time on the Closing Date.
3.2    Deliveries by Sellers at the Closing. At the Closing, Sellers shall deliver or cause to be delivered to Buyer the following:
(a)    a Bill of Sale, Assignment and Assumption Agreement substantially in the form of Exhibit B (the “Bill of Sale, Assignment and Assumption Agreement”), duly executed by each relevant member of the Seller Group;
(b)    the Transition Services Agreement substantially in the form of Exhibit C (the “Transition Services Agreement”), duly executed by each relevant member of the Seller Group;
(c)    the Trademark License Agreement substantially in the form of Exhibit D (the “Trademark License Agreement”), duly executed by each relevant member of the Seller Group;
(d)    the Patent Assignments and Trademark Assignments, substantially in the forms of Exhibit G-1 and G-2 (collectively, the “IP Assignments”), duly executed by each relevant Retained Company;
(e)    the Product Registration Agreement, substantially in the form of Exhibit H (the “Product Registration Agreement”), duly executed by each relevant Retained Company;
(f)    stock certificates (or similar evidence) representing the Ascension Shares and the ISC Shares, with blank transfer forms endorsed or stock powers executed in proper form for transfer, and with any required stock transfer stamps affixed thereto;

10




(g)    the Seller Closing Certificate;
(h)    a completed certification of non-foreign status pursuant to Section 1.1445-2(b)(2) of the Treasury regulations duly executed by Parent or such other Person, and an appropriate IRS Form W-9 or W-8 executed by each member of the Seller Group that is selling Purchased Assets to Buyer and its Affiliates pursuant hereto;
(i)    six (6) original copies of the French language version of the French Business Sale Agreement, duly executed by Services;
(j)    four (4) original copies of the French language version of the French Successor Agreement, duly executed by Artemis ND;
(k)    two (2) original copies of a document presenting the monthly turnover generated by the French Services Business between [January 1, 2020] and the month preceding Closing, duly executed by Services;
(l)    the Local Transfer Agreements other than the French Business Sale Agreement and the French Successor Agreement, duly executed by the applicable members of the Seller Group;
(m)    a resignation and release, substantially in the form of Exhibit I, duly executed by each director and officer of the Purchased Companies;
(n)    (A) duly executed Lien Releases and (B) Payoff Letters, if any (substantially final drafts of which will be delivered no later than two Business Days prior to the Closing Date);
(o)    all documents required by the ISC Purchase Agreement to be delivered by ISC or the seller thereunder at or prior to the closing of the transactions contemplated thereby, duly executed by the applicable parties to such documents; and
(p)    all other documents and certificates reasonably requested by Buyer to further evidence the transactions contemplated hereby.
3.3    Deliveries by Buyer at the Closing. At the Closing, Buyer shall deliver to Sellers the following:
(a)    the Initial Purchase Price, in accordance with Section 2.6(b);
(b)    the Bill of Sale, Assignment and Assumption Agreement duly executed by Buyer or the applicable Buyer Designee(s);
(c)    the Transition Services Agreement duly executed by Buyer;
(d)    the Trademark License Agreement duly executed by Buyer;

1




(e)    the IP Assignments duly executed by Buyer or the applicable Buyer Designee(s);
(f)    the Product Registration Agreement duly executed by Buyer or the applicable Buyer Designee(s);
(g)    the Buyer Closing Certificate;
(h)    six (6) original copies of the French language version of the French Business Sale Agreement, duly executed by Buyer or the applicable Buyer Designee(s);
(i)    four (4) original copies of the French language version of the French Successor Agreement, duly executed by Buyer or the applicable Buyer Designee(s);
(j)    two (2) original copies of a document presenting the monthly turnover generated by the French Services Business between January 1, 2020 and the month preceding Closing, duly executed by Buyer;
(k)    the Local Transfer Agreements other than the French Business Sale Agreement and the French Successor Agreement, each duly executed by Buyer or the applicable Buyer Designee(s); and
(l)    all other documents and certificates reasonably requested by Parent to further evidence the transactions contemplated hereby.
3.4     The European Employees. At the Closing, the applicable members of the Seller Group, Buyer or the applicable Buyer Designee(s) and the European Employees shall execute and deliver tripartite agreements substantially in the form of Exhibit F.
ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF PARENT
Parent hereby represents and warrants to Buyer that the statements contained in this Article IV are true and correct as of the Put Option Date and as of the Closing Date (as contemplated by Section 8.2(a)), except as set forth in the disclosure schedule dated and delivered as of the Put Option Date by Sellers to Buyer (the “Seller Disclosure Schedule”), which is attached to this Agreement and is designated therein as being the Seller Disclosure Schedule.
4.1    Organization and Good Standing. Each member of the Seller Group is a corporation, limited liability company or other legal entity duly organized, validly existing and in good standing (to the extent such concept is legally recognized under the laws of the jurisdiction of its incorporation or formation) under the Laws of the jurisdiction of its incorporation or formation, has all requisite power (corporate or otherwise) to own, lease and operate its properties related to the Business and to carry on the Business as now being

2




conducted, and is duly qualified to do business and is in good standing in each jurisdiction in which it owns or leases property or conducts any business related to the Business so as to require such qualification, except where the failure to be so qualified would not reasonably be expected to have a Material Adverse Effect.
4.2    Authority and Enforceability.
(a)    Each Seller has the requisite legal power and authority to enter into this Agreement and to consummate the transactions contemplated hereby. The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by all necessary legal action on the part of each Seller. Each Seller has duly executed and delivered this Agreement. This Agreement constitutes the valid and binding obligation of each Seller, enforceable against it in accordance with its terms, except as such enforceability may be limited by (i) bankruptcy, insolvency, reorganization, moratorium or other similar Laws affecting or relating to creditors’ rights generally, and (ii) the availability of injunctive relief and other equitable remedies.
(b)    Each member of the Seller Group has the requisite legal power and authority to enter into each Ancillary Agreement to which it is, or is expected to be, a party and to consummate the transactions contemplated thereby. The execution and delivery by each member of the Seller Group of each Ancillary Agreement to which it is, or is expected to be, a party and the consummation of the transactions contemplated thereby have been or will be prior to Closing duly authorized by all necessary legal action on the part of each such member of the Seller Group. Prior to the Closing, each member of the Seller Group will have duly executed and delivered each Ancillary Agreement to which it is, or is expected to be, a party. The Ancillary Agreements will constitute the valid and binding obligation of each member of the Seller Group party thereto, enforceable against it in accordance with its terms, except as such enforceability may be limited by (i) bankruptcy, insolvency, reorganization, moratorium or other similar Laws affecting or relating to creditors’ rights generally, and (ii) the availability of injunctive relief and other equitable remedies.
4.3    No Conflicts; Consents.
(a)    Except as set forth in Section 4.3(a) of the Seller Disclosure Schedule, the execution and delivery of this Agreement by each Seller do not, and the execution and delivery of each Ancillary Agreement to which each member of the Seller Group is, or is expected to be, a party, the performance by each Seller and each other member of the Seller Group of its obligations hereunder and thereunder and the consummation by each Seller and each other member of the Seller Group of the transactions contemplated hereby and thereby, will not, with or without the giving of notice or lapse of time or both, (i) violate the provisions of any of the Charter Documents of any member of the Seller Group, (ii) violate or constitute a default, an event of default or an event creating rights of acceleration, termination, cancellation, imposition of additional obligations or loss of rights, or require the consent of any Person under, any Material Contract or Lease, (iii) assuming compliance with the matters set forth in Section 4.3(b), violate or conflict with any Law, Authorization

1




or Order, or (iv) result in the creation of any Lien upon the Ascension Shares, the ISC Shares or any asset owned or used by any member of the Seller Group in the Business.
(b)    No Authorization or Order of, registration, declaration or filing with, or notice to, any Governmental Entity, is required by or with respect to any member of the Seller Group in connection with the execution and delivery of this Agreement and the Ancillary Agreements and the consummation of the transactions contemplated hereby and thereby, except for such Authorizations, consents, registrations, declarations, filings and notices as may be required under the HSR Act and the Other Antitrust Laws.
4.4    Financial Information.
(a)    Section 4.4(a) of the Seller Disclosure Schedule sets forth true and complete copies of the following financial information of the Business (the “Financial Information”):
(i)    a statement of gross profits of the Business for the twelve (12) months ended December 31, 2018;
(ii)    balance sheet information of the Business as of December 31, 2019, and a statement of gross profits of the Business for the twelve (12) months then ended; and
(iii)    balance sheet information of the Business as of June 30, 2020, and a statement of gross profits of the Business for the six (6) months then ended.
(b)    The Financial Information has been prepared in accordance with the Accounting Principles. The Financial Information is based on the books and records of the Seller Group and fairly presents the financial condition of the Business as of the respective dates it was prepared and the results of the operations of the Business for the periods indicated. The balance sheet information of the Business as of June 30, 2020 is referred to herein as the “Interim Balance Sheet” and the date thereof as the “Interim Balance Sheet Date.”
4.5    No Undisclosed Liabilities. The Purchased Companies do not have, and the Assumed Liabilities do not include, any Liabilities that would be required to be reflected or reserved against on a consolidated balance sheet of the Business dated as of the Put Option Date prepared in accordance with GAAP except (a) those which are adequately reflected or reserved against in the Interim Balance Sheet, (b) those which have been incurred in the ordinary course of the Business since the Interim Balance Sheet Date that would not, individually or in the aggregate, reasonably be expected to be material to the Business, (c) those incurred in connection with this Agreement or the transactions contemplated hereby, (d) those which are included in the Estimated Closing Statement, and (e) those set forth in Section 4.5 of the Seller Disclosure Schedule.
4.6    Taxes.

2




(a)    All material Tax Returns required to have been filed by, or with respect to, (i) each member of the Seller Group with respect to the Business or the Purchased Assets and (ii) the Purchased Companies have been duly and timely filed (and taking into account applicable extensions), and each such Tax Return is correct and complete in all material respects. All material Taxes due and owing by (i) any member of the Seller Group with respect to the Business and the Purchased Assets and (ii) the Purchased Companies have been timely paid, in each case, whether or not shown on any Tax Returns.
(b)    Except as set forth in Section 4.6(b) of the Seller Disclosure Schedule, there is no Tax audit pending against, or with respect to, (i) any member of the Seller Group with respect to the Business or the Purchased Assets or (ii) any Purchased Company. Neither any member of the Seller Group, with respect to the Business or the Purchased Assets, nor any Purchased Company is the beneficiary of any extension of time within which to file any Tax Return which has not since been filed. There are no Tax Liens imposed on the Business, the Purchased Assets, the ISC Shares, the Ascension Shares or any assets of any Purchased Company, in each case, other than Permitted Liens.
(c)    All material Taxes required to be withheld in connection with (i) the Business and the Purchased Assets and (ii) the Purchased Companies have been withheld and timely paid. There is no dispute or claim with any Governmental Entity concerning any material Liability for Taxes of any member of the Seller Group for which written notice has been provided or to Sellers’ Knowledge.
(d)    No member of the Seller Group has ever been a member of any affiliated group of corporations (as defined in Section 1504(a) of the Code or comparable Law) (other than a group of which Parent was the common parent) or filed or been included in a combined, consolidated, or unitary Tax Return (other than a combined, consolidated, or unitary Tax Return of which Parent was the common parent). No Purchased Company is a party to or bound by any Tax sharing, indemnification or allocation agreement.
(e)    No member of the Seller Group has consummated or is currently participating in any “listed transaction” as defined in Section 6707A(c)(2) of the Code and Section 1.6011-4(b)(2) of the Treasury Regulations.
(f)    No Purchased Company has been a “distributing corporation” or a “controlled corporation” (within the meaning of Section 355 of the Code) with respect to a transaction described in Section 355 of the Code within the past five (5) year period.
(g)    Except as set forth in Section 4.6(g) of the Seller Disclosure Schedule, no member of the Seller Group has waived any statute of limitations in respect of Taxes or agreed to any extension of time with respect to a Tax assessment or deficiency, in each case relating to the Business or the Purchased Assets, which period (after giving effect to such extension or waiver) has not yet expired. No member of the Seller Group has (i) granted to any Person any power of attorney that is currently in force with respect to any Tax matter, or (ii) executed or entered into a closing agreement pursuant to Section 7121 of the Code

3




or any similar provision of state, local or foreign Law, in each case, with respect to the Business or the Purchased Assets.
(h)    No Purchased Company nor any Person on behalf of a Purchased Company has waived any statute of limitations in respect of Taxes or agreed to any extension of time with respect to a Tax assessment or deficiency which period (after giving effect to such extension or waiver) has not yet expired. No Purchased Company nor any Person on behalf of a Purchased Company has (i) granted to any Person any power of attorney that is currently in force with respect to any Tax matter, or (ii) executed or entered into a closing agreement pursuant to Section 7121 of the Code or any similar provision of state, local or foreign Law.
(i)    There is no request for a private letter ruling or other formal or informal Tax guidance pending with a Governmental Entity with respect to a Purchased Company in respect of any Taxes in any jurisdiction, nor has any such private letter ruling or other such guidance ever been received with respect to any Purchased Company or a Subsidiary thereof.
(j)    No claim has been made in writing by any Governmental Entity in a jurisdiction where a Purchased Company has not filed a Tax Return that such Purchased Company is or may be subject to Tax by such jurisdiction.
(k)    No Purchased Company has participated in an international boycott as defined in Section 999 of the Code.
(l)    Except as set forth in Section 4.6(l) of the Seller Disclosure Schedule, no Purchased Company will be required to include any item of income in, or exclude any item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of (i) any change in method of accounting for a taxable period ending on or prior to the Closing Date, (ii) any installment sale or open transaction disposition made on or prior to the Closing Date, (iii) any use of an improper method of accounting for a taxable period ending on or prior to the Closing Date, (iv) any prepaid amounts received on or prior to the Closing Date, (v) any election under Section 108(i) of the Code, (vi) any election under Section 965(h) of the Code, (vii) any election under Proposed Treasury Regulations Section 1.59A-3(c)(6), or (viii) any intercompany transaction or excess loss account described in Treasury Regulations under Section 1502 of the Code (or any corresponding or similar provision of state, local, or non-U.S. income Tax Law).
(m)    No Purchased Company has ever owned, directly or indirectly, any interest in any entity that is a “passive foreign investment company” as defined under section 1297 of the Code.
(n)    No Purchased Company has (i) a permanent establishment (within the meaning of any applicable Tax treaty) outside of the United States, (ii) an office or fixed place of business in a country other than the United States, (iii) been subject to adjustment

4




under Section 482 of the Code (including any similar provision of state, local, or foreign Tax Law), (iv) entered into a gain recognition agreement pursuant to Treasury Regulations Section 1.367(a)-8, or (v) transferred an intangible the transfer of which is subject to the rules of Section 367(d) of the Code.
(o)    The Purchased companies are in compliance with the terms and conditions of any applicable Tax exemptions, Tax agreements or Tax orders of any Governmental Entity to which they may be subject or which they may have claimed, and the transactions contemplated by this Agreement will not have any adverse effect on such compliance.
(p)    Ascension does not own any interest in any entity treated as a partnership (or any other separate entity other than Ascension Orthopedics Limited) as determined under applicable Law. The shares of Ascension Orthopedics Limited will be distributed to Parent or a Subsidiary of Parent prior to the Closing.
(q)    The Purchased Assets do not include any “United States real property interest” as defined in Code section 897(c)(1). No Purchased Company is a United States Real Property Holding Corporation, as defined in Code section 897(c)(2).
4.7    Compliance with Law. Each member of the Seller Group has during the last three (3) years conducted, and is conducting, the Business in material compliance with all applicable Laws. No member of the Seller Group has received written notice regarding any actual or alleged violation of, conflict with, or failure to conduct the Business in compliance with, any applicable Law.
4.8    Regulatory Matters.
(a)    Each Product or Product candidate is being, or has been during the last five (5) years, developed, manufactured, tested, distributed or marketed in compliance in all material respects with all applicable requirements under the Federal Food, Drug, and Cosmetic Act (the “FDCA”) and the regulations of the Food and Drug Administration (the “FDA”) promulgated thereunder, and similar applicable Law, including, as applicable, those relating to investigational use, premarket clearance, registration and listing, good manufacturing practices, quality systems regulations, ISO requirements, good clinical practices, good laboratory practices, labeling, unique device identification, advertising, record keeping and filing of required reports.
(b)    Each member of the Seller Group, each director, officer and employee of any member of the Seller Group and, to Sellers’ Knowledge, any agent acting on behalf of any member of the Seller Group is, and has been during the last five (5) years, in material compliance with all applicable medical device and health care Laws with respect to the Business (collectively, “Health Care Laws”), including, to the extent applicable: (i) Laws related to the testing, clinical investigation, manufacturing, processing, labeling, distribution, marketing and sale of the Products, (ii) the requirements of the Product Registrations, (iii) Title XVIII of the Social Security Act, 42 U.S.C. §§ 1395 et seq. (the

5




Medicare statute); (iv) any joint federal or state health care or health insurance program, including, Title XIX of the Social Security Act, 42 U.S.C. §§ 1396 et seq. (the Medicaid statute); (v) TRICARE, 10 U.S.C. § 1071 et seq.; (vi) the Ethics in Patient Referrals Act, as amended, 42 U.S.C. § 1395nn, the Federal Health Care Program Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)), the Federal False Claims Act (31 U.S.C. §§ 3729-3733), the Federal Program Fraud Civil Remedies Act (31 U.S.C. §§ 3801-3812), the Federal Anti-Kickback Act of 1986 (41 U.S.C. §§ 8701-8707), the Federal Civil Monetary Penalties Law (42 U.S.C. §§ 1320a-7a and 1320a-7b), the Exclusion Laws (42 U.S.C. § 1320a-7), the Physician Payments Sunshine Act (42 U.S.C. § 1320a-7h), and any similar state laws and regulations; (vii) the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, the Health Information Technology for Economic and Clinical Health Act of the American Recovery and Reinvestment Act of 2009 (as amended and codified at 45 CFR Parts 160, 162 and 164), and their implementing regulations and similar applicable federal and state Laws; (viii) the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010; (ix) the FDCA; and (x) the Federal Trade Commission Act, 15 U.S.C. § 41 et seq. and the rules, regulations and directives promulgated thereunder. Except for the matters listed in Section 4.8(b) of the Seller Disclosure Schedule, neither any member of the Seller Group, nor any representative acting on behalf of any member of the Seller Group with respect to the Business has since January 1, 2016, been subject to any enforcement notice, communication, or correspondence from any Governmental Entity related to any Health Care Laws with respect to the Business.
(c)    There is no, and during the last five (5) years there has not been any, Action pending or, to Sellers’ Knowledge, threatened against any member of the Seller Group (with respect to the Business), any officer, director or employee or agent of any member of the Seller Group (with respect to the Business) or, to Sellers’ Knowledge, any contract manufacturer or contract supplier of the Business alleging a material violation of (i) any Law pertaining to Medicare, TRICARE or any State Medicaid program (collectively, “Health Care Programs”) or (ii) applicable Health Care Laws. No member of the Seller Group, no officer, director or employee of any member of the Seller Group and, to Sellers’ Knowledge, no agent of any member of the Seller Group has engaged in any activity with respect to the Business which is reasonably likely to be cause for civil or criminal penalties or damages under any Health Care Law. No member of the Seller Group has entered into or assumed, by Contract or operation of law or otherwise, any material obligation, Liability, order, settlement, judgment, injunction or decree relating to or arising under any Health Care Law.
(d)    No member of the Seller Group and no officer, director, employee, agent or independent contractor of any member of the Seller Group (i) is currently, or during the last five (5) years has been, excluded, debarred, or otherwise ineligible to participate in the Health Care Programs, (ii) has been convicted of a criminal offense or, to Sellers’ Knowledge, has engaged in any act or conduct that would be grounds for mandatory or permissive exclusion but has not yet been excluded, debarred, or otherwise declared ineligible to participate in any Health Care Programs, or (iii) to Sellers’ Knowledge, is under

6




investigation or otherwise aware of any circumstances which may result in being excluded from participation in the Health Care Programs.
(e)    Except as set forth in Section 4.8(e) of the Seller Disclosure Schedule, since January 1, 2016, none of the Products has been subject to a recall (whether voluntary or involuntary), removal or other field correction requiring a report under 21 C.F.R. Part 806 (collectively, a “Recall”), nor is any Product Recall currently under consideration by any member of the Seller Group or, to the Knowledge of Sellers, any Governmental Entity.
(f)    No member of the Seller Group (with respect to the Business) is, as a result of any requirement of Health Care Laws, subject to any material restriction that would restrict such member from the sale or distribution of Products in the manner in which it is selling or distributing Products as of the Put Option Date and as of the Closing Date.
4.9    Business Authorizations.
(a)    Each member of the Seller Group owns, holds or lawfully uses (either directly or through its distributors), all Authorizations which are necessary for it to conduct the Business as currently conducted (collectively, the “Business Authorizations”), including all Authorizations required for the manufacturing, packaging, marketing, promotion, testing, clinical investigation, distribution, or sale of the Products (collectively, the “Product Registrations”). Section 4.9(a) of the Seller Disclosure Schedule sets forth all material Product Registrations held by members of the Seller Group (organized by Product and country).
(b)    Each member of the Seller Group is in compliance in all material respects with the terms of the Business Authorizations. No member of the Seller Group has received written notice regarding any actual or alleged violation of, conflict with, failure to comply with the terms of, or any revocation, withdrawal, termination, cancellation or suspension of, any Business Authorization. All Business Authorizations are, and have been, in full force and effect. Except as set forth on Section 4.9(b) of the Seller Disclosure Schedule, the Business Authorizations of the Retained Companies are freely transferrable and will constitute Purchased Assets hereunder.
4.10    Acquired Company Capital Stock; Acquired Company Operations. The authorized and outstanding capital stock of the Purchased Companies and the holders thereof (both as of the Put Option Date and as of immediately prior to the Closing, assuming the consummation of the transactions contemplated by the ISC Purchase Agreement) are set forth in Section 4.10 of the Seller Disclosure Schedule. Parent or the Subsidiary thereof set forth on Section 4.10 of the Seller Disclosure Schedule (i) legally and beneficially owns all outstanding shares of Ascension, (ii) as of the Put Option Date, legally and beneficially owns one (1) share of capital stock of ISC, and (iii) as of the Closing, will legally and beneficially own all outstanding shares of capital stock of ISC. Parent or its applicable Subsidiary has good and marketable title to the Ascension Shares, and as of the Closing, will have good and marketable title to the ISC Shares, in each case free and clear of Liens, other than restrictions imposed by state and federal securities laws and Liens in favor of the Seller

7




Group’s lenders, which such Liens in favor of the Seller Group’s lenders shall be released in connection with Closing. The Ascension Shares and the ISC Shares have been duly authorized and validly issued and are fully paid and non-assessable and were not issued in violation of any Law or any preemptive or subscription rights. There are no outstanding stock appreciation, phantom stock, profit participation or similar rights with respect to any Purchased Company. Except as set forth in Section 4.10 of the Seller Disclosure Schedule, there are no options, warrants, purchase rights, subscription rights, conversion rights, rights of first refusal, preferential purchase rights, exchange rights or other Contracts that, directly or indirectly, could require a Purchased Company to issue, sell or otherwise cause to become outstanding shares of its capital stock. Except for the Stockholders’ Agreement, dated January 4, 2019, by and among Integra Lifesciences Corporation, ISC, Consortium of Focused Orthopedists, LLC and the other parties thereto, there are no Contracts with respect to the voting of shares of capital stock of any Purchased Company. ISC does not, and as of the Closing, Ascension will not, own any equity interest in any other Person. No Purchased Company has ever engaged in any business other than the Business.
4.11    Title to Assets; Sufficiency of Assets.
(a)    The Purchased Companies have good and valid title to, or a valid leasehold interest in, their assets, free and clear of all Liens, except for Permitted Liens and Liens in favor of the Seller Group’s lenders, which such Liens shall be released in connection with Closing. The Retained Companies have good and valid title to, or a valid leasehold interest in, all of the Purchased Assets, free and clear of all Liens, except for Permitted Liens and Liens in favor of the Seller Group’s lenders, which such Liens shall be released in connection with Closing.
(b)    The Purchased Assets, together with the assets of the Purchased Companies, are sufficient, and constitute all of the assets necessary, to operate the Business immediately following the Closing, in all material respects, in the same manner as it has been conducted immediately prior to the Closing, except (i) as set forth in Section 4.11(b) of the Seller Disclosure Schedule, (ii) for the services and rights to be provided or granted to Buyer and its Affiliates pursuant to the Transition Services Agreement and this Agreement, (iii) for the trademarks covered by the Trademark License Agreement and (iv) for the Business Authorizations and Product Registrations covered by the Product Registration Agreement.
4.12    Real Property.
(a)    The Purchased Companies do not own, and have never owned, any real property. There are no interests in real property owned in fee by any member of the Seller Group related to the Business. No Purchased Company is required under any Contract to acquire any interest in real property or legally bound by any unexpired option to purchase, right of first refusal, right of first offer or any other right to acquire real property, and there is no Assigned Contract that provides for any of the foregoing.

8




(b)    Section 4.12(b) of the Seller Disclosure Schedule contains a list of all real property and interests in real property leased by any member of the Seller Group related to the Business (the “Leased Real Property”).
(c)    With respect to Leased Real Property, Parent has delivered to Buyer a true and complete copy of every lease and sublease pursuant to which any member of the Seller Group is a party or by which it is bound (each, a “Lease”).
(d)    No Person other than a member of the Seller Group is in possession of any of the Leased Real Property, and except as set forth in Section 4.12(d) of the Seller Disclosure Schedule, there are no leases, subleases, licenses, concessions or other agreements granting to any Person other than the Seller Group the right of use or occupancy of the Leased Real Property.
(e)    Each Lease is in full force and effect and is valid and enforceable by the applicable member of the Seller Group, and is free and clear of all Liens, other than Permitted Liens. No member of the Seller Group has received written notice that it is in breach or default under a Lease. No event has occurred that, with or without notice or lapse of time or both, would constitute a material breach or default by a member of the Seller Group or to Sellers’ Knowledge, any other party thereto, or permit the termination, modification or acceleration of rent under a Lease by any other party thereto.
4.13    Intellectual Property.
(a)    Section 4.13(a) of the Seller Disclosure Schedule sets forth a true and correct list (by name or title, owner, jurisdiction and, where applicable, application number and filing date or registration number and registration date) of (i) all Seller Owned Intellectual Property for which applications or registrations have been filed or issued and (ii) all other Seller Owned Intellectual Property that is otherwise material to the operation of the Business. Except as described in Section 4.13(a) of the Seller Disclosure Schedule, a member of the Seller Group owns the entire right, title and interest to the Seller Owned Intellectual Property free and clear of all Liens other than Permitted Liens and Liens in favor of the Seller Group’s lenders, which such Liens shall be released in connection with Closing. The Seller Owned Intellectual Property described in clause (i) above is subsisting, has not been adjudged invalid or unenforceable, and, there is no Action pending or, to Sellers’ Knowledge, threatened that seeks to challenge the validity or enforceability of any Seller Owned Intellectual Property. The Intellectual Property licensed to members of the Seller Group for use in connection with the operation of the Business is licensed pursuant to valid and enforceable Contracts, and the members of the Seller Group are not in breach or default in any material respect under any such Contracts.
(b)    Section 4.13(b) of the Seller Disclosure Schedule sets forth a true and correct list of all material licenses, sublicenses and other agreements (“In-Bound Licenses”) pursuant to which a third party authorizes any member of the Seller Group (with respect to the Business) to use, practice any rights under, or grant sublicenses with respect to, any

9




Intellectual Property owned by a third party, other than In-Bound Licenses that consist solely of “shrink-wrap” and similar commercially available end-user licenses.
(c)    Section 4.13(c) of the Seller Disclosure Schedule sets forth a true and correct list of all material licenses, sublicenses and other agreements (“Out-Bound Licenses”) pursuant to which any member of the Seller Group authorizes a third party to use, practice any rights under, or grant sublicenses with respect to, any Seller Owned Intellectual Property or pursuant to which any member of the Seller Group (with respect to the Business) grants rights to use or practice any rights under any Intellectual Property owned by a third party other than Out-Bound Licenses that consist solely of non-exclusive licenses granted in the ordinary course of the Business.
(d)    None of the Products or services of the Business, including the Products of ISC that are or were the subject of the License and Development Agreement as designed as of the Design Freeze (as defined in the License and Development Agreement) (the “ISC Products”), infringes or misappropriates on or before the Closing, or, with respect to the ISC Products, would have infringed or misappropriated on or before the Closing, if sold by or on behalf of the Business as of the Closing, the Intellectual Property rights of any third party. For clarity, the foregoing representation and warranty applies to all features and characteristics of the Products as of the Closing (or, in the case of the ISC Products, features and characteristics as of the Design Freeze), and any change to a Product or an ISC Product made by Buyer or an Affiliate thereof to a feature or characteristic of a Product or an ISC Product will not affect Buyer’s rights to indemnification under this Agreement arising from a breach of the foregoing representation and warranty so long as the alleged infringement or misappropriation giving rise to such breach is based upon a feature or characteristic of such Product, as it exists as of the Closing, or a feature or characteristic of such ISC Product, as it exists as of the Design Freeze, and does not arise out of such change to a Product or ISC Product. No Action is pending relating to any Intellectual Property currently used by any member of the Seller Group related to the Business. Except as set forth in Section 4.13(d) of the Seller Disclosure Schedule, to Sellers’ Knowledge, no Person is infringing, misappropriating or otherwise violating, in any material respect, any Seller Owned Intellectual Property.
(e)    The members of the Seller Group have (i) taken commercially reasonable measures to maintain the confidentiality of all material trade secrets and other proprietary or confidential information used in the Business and (ii) required all employees, consultants, advisors and other Persons who have assisted in the development of Seller Owned Intellectual Property, to execute confidentiality and invention assignment agreements which provide that all right, title and interest in and to any Intellectual Property created by such Person are assigned to a member of the Seller Group.
4.14    Absence of Certain Changes or Events. Except as set forth on Section 4.14 of the Seller Disclosure Schedule, since January 1, 2019:
(a)    there has not been any event or circumstance that has had a Material Adverse Effect; and

10




(b)    no member of the Seller Group has taken any action with respect to the Business, which, if taken after the Put Option Date and prior to the Closing, would require the consent of Buyer pursuant to Section 6.1 or Section 6.2.
4.15    Contracts.
(a)    Section 4.15(a) of the Seller Disclosure Schedule sets forth a true and correct list of the following Assigned Contracts and Contracts to which a Purchased Company is a party:
(i)    any Contract or series of related Contracts for the purchase of materials, supplies, goods, services, equipment or other assets that involves annual payments by the members of the Seller Group of $250,000 or more;
(ii)    any Contract or series of related Contracts for the sale by the members of the Seller Group to any Person of materials, supplies, goods, services, equipment or other assets, in an annual sales amount of $500,000 or more;
(iii)    any distribution, dealer, representative or sales agency Contract for which a member of the Seller Group paid the applicable dealer, representative or agent more than $300,000 in the twelve months prior to the Put Option Date;
(iv)    any Contract that requires any member of the Seller Group to purchase its total requirements of any product or service from a third party or that contains “take or pay” or “most favored nation” provisions;
(v)    any note, debenture, bond, letter of credit, loan or other Contract for Indebtedness or lending of money (other than to employees for travel expenses in the ordinary course of the Business) or Contract for a line of credit or guarantee, pledge or undertaking of the Indebtedness of any other Person;
(vi)    any collective bargaining Contract or other Contract with any labor organization, union or association;
(vii)    any employment, consulting, termination or severance Contract with respect to a Business Employee, other than those Contracts with individuals where such individuals are expected to receive less than $150,000 per annum;
(viii)    any Contract with a Governmental Entity (excluding any hospitals affiliated with state-funded universities located in the United States), other than those Contracts that are terminable upon sixty (60) days’ notice or less without liability to the applicable member of the Seller Group;
(ix)    any Contract containing a covenant that restricts the Business from competing with any Person in any product line or line of business or in any geographic area;

11




(x)    any Contract granting exclusivity rights to any vendor of products or services, including any distributor, other than those Contracts that are terminable upon sixty (60) days’ notice or less without liability to the applicable member of the Seller Group;
(xi)    any Contract that provides for indemnification by a member of the Seller Group, except for any such Contract entered into in the ordinary course of business;
(xii)    any Contract for capital expenditures involving an amount greater than $200,000, other than capital expenditures reflected in the Capital Expenditures Budget;
(xiii)    any joint venture, partnership, profit sharing or similar agreement; and
(xiv)    any Contract with any Person performing any professional medical services, laboratory or research services, nursing services, behavioral health services or other clinical services, including any research investigator, physician, pharmacist, registered nurse, licensed practical nurse, advanced practice nurse, nurse practitioner, certified registered nurse practitioner, physician assistant, healthcare provider, therapist, mental health coach or other similar practitioner, in each case to the extent classified as a health care professional under applicable Law.
(b)    Each Contract listed or required to be listed in Section 4.13(b), Section 4.13(c) or Section 4.15(a) of the Seller Disclosure Schedule (other than those Contracts listed in (i) Section 4.15(a)(viii) of the Seller Disclosure Schedule, (ii) Section 4.15(a)(x) of the Seller Disclosure Schedule that are with distributors whose annual sales are less than $100,000 per annum, and (iii) Section 4.15(a)(xiv) of the Seller Disclosure Schedule) (collectively, the “Material Contracts”) is valid and enforceable in accordance with its terms. Parent has made available to Buyer a true, correct and complete copy of each Material Contract and each Contract listed in Section 4.15(a)(x) of the Seller Disclosure Schedule and Section 4.15(a)(xiv) of the Seller Disclosure Schedule (or the form of Contract for similar sets of Contracts), provided, that in some instances certain competitively sensitive terms of such Contracts were redacted. Where Parent has made available to Buyer a form of Contract, any Material Contract not made available and based on such form does not materially differ from such form. The member of the Seller Group party to such Material Contract is in compliance in all material respects with, and to Sellers’ Knowledge all other parties thereto are in compliance in all material respects with, the provisions of such Material Contracts. No party has given written notice of its intention to terminate any Material Contract, or, in any material adverse respect, has amended, cancelled or terminated any Material Contract or waived or relinquished any material right thereunder (other than the expiration of a Material Contract in accordance with its terms).
4.16    Litigation. Except as set forth on Section 4.16 of the Seller Disclosure Schedule, there is no pending, or to Sellers’ Knowledge, threatened Action against any

12




member of the Seller Group (a) related to or affecting the Business, or (b) that challenges or seeks to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement or the Ancillary Agreements. During the last three (3) years, no material adverse Action has been pending against any member of the Seller Group relating to or affecting the Business.
4.17    Employee Benefits.
(a)    Each Benefit Plan and any “multiemployer plan” (within the meaning of Section 3(37) of ERISA) subject to Title IV of ERISA, to which any Purchased Company or an ERISA Affiliate of any Purchased Company is, or within the past six (6) years was, required to make contributions is listed on Section 4.17(a) of the Seller Disclosure Schedule.
(b)    Sellers have delivered or made available to Buyer true and complete copies of (i) each Benefit Plan document, together with all amendments thereto, or a written summary of any unwritten Benefit Plan, (ii) the most recent summary plan description for each Benefit Plan for which such a summary plan description is required, (iii) the most recent favorable determination or opinion letter from the IRS with respect to any Benefit Plan intended to qualify under Section 401(a) of the Code, (iv) the annual reports on Form 5500 for the last three (3) plan years to the extent required under applicable Laws, and (v) any material correspondence with any Governmental Entity or regulatory body within three (3) years of the Put Option Date.
(c)    Except as set forth on such Section 4.17(c) of the Disclosure Schedule, or to the extent that any breach of the representations and warranties set forth in this Section 4.17(c) would not be reasonably expected to result in liability to any Purchased Company or the Buyer:
(i)    each Benefit Plan is in material compliance with applicable Law and has been administered and operated in all material respects in accordance with its terms;
(ii)    no Purchased Company nor any of their Subsidiaries, nor, to the Knowledge of Sellers, any other “disqualified person” or “party in interest” (as defined in Section 4975(e)(2) of the Code and Section 3(14) of ERISA, respectively) has engaged in any transactions in connection with any Benefit Plan that could reasonably be expected to result in the imposition of a penalty pursuant to Section 502 of ERISA, damages pursuant to Section 409 of ERISA or a Tax pursuant to Section 4975 of the Code;
(iii)     no Liability or Action has been made, commenced or, to Sellers’ Knowledge, threatened with respect to any Benefit Plan (other than routine claims for benefits payable in the ordinary course of business, and appeals of denied such claims); and
(iv)     the members of the Seller Group have complied in all material respects with the applicable requirements of Part 6 of Subtitle B of Title I of ERISA and

13




Section 4980B of the Code (“COBRA”) with respect to the Business, and no member of the Seller Group is subject to material Liability as a result of any failure to administer or operate any Benefit Plan that is a “group health plan” (as defined in COBRA) in compliance with COBRA.
(d)    The Purchased Companies offer minimum essential health coverage, satisfying the affordability and minimum value requirements, to their full time employees (as defined under Section 4980H of the Code) sufficient to prevent Liability for assessable payments under Section 4980H of the Code.
(e)    Except as set forth on such Section 4.17(e) of the Seller Disclosure Schedule, each Benefit Plan which is a “nonqualified deferred compensation plan” (within the meaning of Section 409A of the Code), to the extent it covers Business Employees, has been operated and administered in compliance with Section 409A of the Code, and no member of the Seller Group has any material obligation to provide any “gross up” payment for any income or other Taxes to any Business Employee, and neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby will entitle any Business Employee who is the recipient of any payment or benefit to receive any such “gross up” payment.
(f)    Each Benefit Plan intended to be qualified under Section 401(a) of the Code has received a favorable determination letter or opinion letter from the Internal Revenue Service (“IRS”) (or has submitted, or is within the remedial amendment period for submitting, an application for a determination letter with the IRS, and is awaiting receipt of a response) or is comprised of a master or prototype plan that has received a favorable opinion letter from the IRS, and, to the Knowledge of Sellers, no event has occurred and no condition exists that is reasonably expected to result in the revocation of any such determination letter or opinion letter, or the imposition of any material Liability or Tax under any applicable Law.
(g)    No amounts payable by a Purchased Company under the Benefit Plans in connection with the transactions contemplated by this Agreement will fail to be deductible by a Purchased Company for U.S. federal income tax purposes by virtue of Section 280G of the Code.
(h)    No Purchased Company nor any ERISA Affiliate of a Purchased Company has incurred any unsatisfied Liability under Title IV of ERISA or Section 412 of the Code or Section 302 of ERISA that would reasonably be expected to result in the imposition of any Liability on a Purchased Company and/or the Buyer. No Purchased Asset is or is currently expected to be subject to any Lien arising under Section 430(k) of the Code or Section 303(k) of ERISA. No Benefit Plan that is sponsored, maintained, or required to be contributed to by a Purchased Company, or for which a Purchased Company otherwise has any Liability, is a (i) “multiemployer plan” (as defined in Sections 3(37) or 4001(a)(3) of ERISA), (ii) “multiple employer plan” (as defined in 29 C.F.R. § 4001.2) or a plan subject to Section 413(c) of the Code, (iii) “multiple employer welfare arrangement” (as defined in Section 3(40) of ERISA or applicable state law), (iv) “voluntary employees’ beneficiary

14




association” (as defined in Section 501(c)(9) of the Code) or (v) other funded arrangement for the provision of welfare benefits.
(i)    No member of the Seller Group has any Liability or obligation to provide post-employment medical, life insurance or other welfare benefits to any (current or former) Business Employee, or any dependent or beneficiary thereof, except (i) to the extent required under applicable benefits continuation Laws and for which the individual pays the full cost of coverage, (ii) for coverage through the end of the calendar month in which a termination of employment occurs or (iii) pursuant to an applicable agreement, plan or policy that requires any member of the Seller Group to pay or subsidize COBRA premiums for a terminated employee following the employee’s termination.
(j)    Except as set forth on Section 4.17(j) of the Seller Disclosure Schedule, neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby will (either alone or in combination with another event, other than events initiated by Buyer or its Affiliates): (i) result in any payment becoming due, or increase the amount of any compensation due, to any current or former employee, officer, director or individual service provider of the Business or under any Benefit Plan; (ii) increase any benefits otherwise payable to any current or former employee, officer, director or individual service provider of the Business under any Benefit Plan; (iii) result in the acceleration of the time of payment or vesting of any such compensation or benefits; or (iv) result in the triggering or imposition of any restrictions or limitations on the rights of any Purchased Company or Buyer to amend or terminate any Benefit Plan.
(k)    Except as would not be reasonably expected to result in material Liability to any Purchased Company or Buyer, the members of the Seller Group having an obligation with respect to any Business Employee have made all contributions required to be made to or with respect to each Benefit Plan as of the Put Option Date within the time periods, if any, prescribed by ERISA, the Code or any other applicable Laws, and all contributions for any period ending on or before the Put Option Date that are not yet due have either been made to each such plan, accrued, or not accrued in accordance with the past custom and practice of the members of the Seller Group and any applicable accounting requirements.
4.18    Labor and Employment Matters.
(a)    Parent has provided to Buyer a schedule (the “Business Employees Schedule”) setting forth a list of (i) all Business Employees as of the Put Option Date, including for each such Business Employee: name, title and position, employing entity, Fair Labor Standard Act Designation (for Business Employees located in the United States), work location, current base compensation and current bonus opportunity (including any variable, incentive, or equity compensation eligibility), provided that the information in such schedule with respect to Business Employees outside the United States may be anonymized to the extent required to comply with local data protection rules, and (ii) all Excluded Employees.

15




(b)    Except as set forth on Section 4.18(b) of the Seller Disclosure Schedule, no member of the Seller Group is a party or subject to any labor union or collective bargaining agreement in connection with the Business. There have not been for the last three (3) years, and there are not pending or, to Sellers’ Knowledge, threatened, any labor disputes, work stoppages, requests for representation, pickets, work slow-downs due to labor disagreements or any Actions or arbitrations that involve Business Employees.
(c)    No member of the Seller Group has since January 1, 2019 effectuated a “plant closing” (as defined in the WARN Act) or a “mass lay-off” (as defined in the WARN Act) or been affected by any transaction or engaged in layoffs or employment terminations sufficient in number to trigger application of any state, local or foreign Law or regulation similar to the WARN Act, in each case related to the Business and without complying in all material respects with the WARN Act or any applicable Laws.
(d)    Except as would not be reasonably expected to result in material Liability to any Purchased Company or Buyer, (i) each Person who has provided services to the Business as an independent contractor, leased employee or consultant has been properly classified, and (ii) no such Person has a valid claim against any member of the Seller Group for eligibility to participate in or benefits under any Benefit Plans if such individual is later reclassified as an employee.
(e)    Each member of the Seller Group is and has been within the past three (3) years, in material compliance with all Laws governing the employment of the Business Employees and the engagement of other service providers with respect to the Business, reporting to the IRS and all other Governmental Entities, including all contractual commitments and all such Laws relating to wages, hours, affirmative action, collective bargaining, social security discrimination, civil rights, occupational health and safety, immigration, workers’ compensation, and reporting of compensation and benefits, in each case with respect to the Business Employees and other service providers with respect to the Business.
(f)    The Seller Group has delivered to Buyer accurate and complete copies of all current employee manuals and handbooks, material policy statements and other material documents relating to the employment of the Business Employees.
(g)    Except as set forth on Section 4.18(g) of the Seller Disclosure Schedule, the Business Employees, together with the employees of the Seller Group providing services pursuant to the Transition Services Agreement, are all of the employees necessary for the continued conduct of the Business after the Closing in substantially the same manner as it is currently conducted. For the avoidance of doubt, the foregoing is not a guaranty by Parent of the performance or quality of any Business Employee.
(h)    Other than the information-consultation process with the relevant employee representative bodies of Services, which is complete as of the date hereof, no member of the Seller Group is required to initiate, conduct, or complete any information, consultation or similar process with any employee representative body prior to the Closing.

16




(i)    No employment Contract with a Business Employee will entitle such Business Employee to any increase in his or her remuneration, benefits, bonuses or terms of employment as a result of, or in connection with any transaction contemplated by the Agreement.
(j)    No claims or allegations of sexual harassment have been made to a member of the Seller Group against (i) any officer or director of any member of the Seller Group with respect to any Purchased Company or any Business Employee or (ii) any Business Employee who supervises other Business Employees. No member of the Seller Group has entered into any settlement agreement related to allegations of sexual harassment or sexual misconduct by a Business Employee or any director, officer or other Representative of any member of the Seller Group or any contractor of the Business.
4.19     Environmental.
(a)    The Business, including the Purchased Assets and the Leased Real Property, is currently operated, and has been operated for the least three (3) years, in material compliance with all applicable Environmental Laws and all Authorizations required by such Environmental Laws (“Environmental Permits”).
(b)    No member of the Seller Group has received in connection with the conduct of the Business any unresolved written notice from any Governmental Entity (i) with respect to any alleged material violation by any member of the Seller Group of any Environmental Law, (ii) with respect to any failure of any member of the Seller Group to have any Environmental Permit related to the Business, or (iii) with respect to any disposal of any Hazardous Substance.
(c)    In connection with the operation of the Business, no member of the Seller Group nor, to the Knowledge of Sellers, any third party has Released any Hazardous Substance at any of the Leased Real Property or at any real property formerly owned, leased or operated by a member of the Seller Group and used in the operation of the Business.
(d)    No member of the Seller Group is subject to any Order under any Environmental Law with respect to the Business.
4.20    Brokers or Finders. Parent represents, as to itself and each member of the Seller Group, that, except as set forth in Section 4.20 of the Seller Disclosure Schedule, no agent, broker, investment banker or other firm or Person is or will be entitled to any broker’s or finder’s fee or any other commission or similar fee in connection with any of the transactions contemplated by this Agreement and the Ancillary Agreements.
4.21    Privacy and Data Security. The Retained Companies (with respect to the Business) and the Purchased Companies are, and have been for the last three (3) years, in compliance in all material respects with their respective policies and contractual obligations with respect to, and with all applicable Laws governing, the collection, use, storage, sharing or transfer of Personal Information. The Retained Companies (with respect to the Business)

17




and the Purchased Companies have reasonable safeguards in place designed to protect Personal Information and other confidential data in their possession or under their control against, loss, theft, or unauthorized disclosure. There have been no material breaches involving Personal Information in the possession or control of the Business for the last three (3) years.
4.22    Product Defects; Warnings    . There are no, and there have not been any, Actions pending, or, to the Knowledge of Sellers, threatened against or affecting any member of the Seller Group, alleging that any Products sold in the operation of the Business are defective, do not contain adequate instructions or warnings, or fail to meet any applicable product warranties, except, in each case, as would not reasonably be expected to be material to the Business.
4.23    Anticorruption Matters    .
(a)    Except as would not reasonably be expected to be materially adverse to the Business, no member of the Seller Group, no officer, director or employee thereof and, to the Knowledge of Sellers, no distributor, agent or other third party acting on behalf of any member of the Seller Group has, in any way relating to the operation of the Business during the last five (5) years, taken any action in violation of any applicable anticorruption Law, including the U.S. Foreign Corrupt Practices Act of 1977 and the UK Bribery Act 2010.
(b)    The Seller Group has a commercially reasonable compliance program adequate to ensure material compliance with applicable anticorruption Laws.
4.24    Affiliate Arrangements; Seller Guaranties.
(a)    Section 4.24(a) of the Seller Disclosure Schedule sets forth a true and correct list of (i) all Contracts or transactions between Parent or any of its Affiliates (other than a Purchased Company), on the one hand, and a Purchased Company, on the other hand, and (ii) all Contracts or transactions (other than employment, contractor or consulting Contracts) between any director or officer of Parent or any of its Affiliates (other than a Purchased Company), on the one hand, and a Purchased Company, on the other hand, in each case of clause (i) and (ii) which is currently in effect (each, an “Affiliate Arrangement”). No director or officer of Parent or any of its Affiliates owns, directly or indirectly, any material property, asset or right used by the Business, or any material interest in any Person that is a lessor, lessee, customer or supplier of the Business.
(b)    Section 4.24(b) of the Seller Disclosure Schedule sets forth a true and correct list of the Seller Guaranties.
4.25    Inventory and Instruments. Except as set forth in the Accounting Principles, the Inventory and Instruments (a) are not obsolete and are saleable or usable in the ordinary course of business for the purposes for which intended, (b) are not in excess of the quantity usable or salable by the Business in the ordinary course of business for the purposes for

18




which intended, and (c) are recorded at net realizable value and are net of all appropriate excess and obsolescence reserves as set forth in the Accounting Principles.
ARTICLE V

REPRESENTATIONS AND WARRANTIES OF BUYER
Buyer hereby represents and warrants to Sellers the following as of the date hereof and as of the Closing Date:
5.1    Organization and Good Standing. Buyer is a private company limited by shares duly organized, validly existing and in good standing under the Laws of England and Wales and has the requisite corporate or similar power to own, lease and operate its properties and to carry on its business as now being conducted.
5.2    Authority and Enforceability. Buyer has the requisite corporate or similar power and authority to enter into this Agreement and the Ancillary Agreements to which it is a party and to consummate the transactions contemplated hereby and thereby. The execution and delivery of this Agreement and the Ancillary Agreements to which Buyer is a party and the consummation of the transactions contemplated hereby and thereby have been duly authorized by all necessary corporate or similar action on the part of Buyer. This Agreement has been, and the Ancillary Agreements to which Buyer is a party will be, duly executed and delivered by Buyer and, assuming due authorization, execution and delivery by the applicable Seller, constitutes the valid and binding obligations of Buyer, enforceable against it in accordance with their respective terms, except as such enforceability may be limited by (a) bankruptcy, insolvency, reorganization, moratorium or other similar Laws affecting or relating to creditors’ rights generally, and (b) the availability of injunctive relief and other equitable remedies.
5.3    No Conflicts; Consents.
(a)    The execution and delivery of this Agreement by Buyer do not, and the execution and delivery of the Ancillary Agreements to which Buyer is a party and the consummation of the transactions contemplated hereby and thereby will not, (i) violate the provisions of any of the Charter Documents of Buyer, (ii) violate any Contract to which Buyer is a party, (iii) assuming compliance with the matters set forth in Section 5.3(b), to the Knowledge of Buyer, violate any Law of any Governmental Entity applicable to Buyer on the date hereof, or (iv) to the Knowledge of Buyer, result in the creation of any Liens upon any of the assets owned or used by Buyer, except in each such case where such violation or Lien would not reasonably be expected materially to impair or delay the ability of Buyer to perform its obligations under this Agreement or the Ancillary Agreements.
(b)    No Authorization or Order of, registration, declaration or filing with, or notice to any Governmental Entity is required by Buyer in connection with the execution and delivery of this Agreement and the Ancillary Agreements to which it is a party and the

19




consummation of the transactions contemplated hereby and thereby, except for such Authorizations, Orders, registrations, declarations, filings and notices (i) as may be required under the HSR Act and the Other Antitrust Laws, or (ii) the failure to obtain which would not reasonably be expected to materially impair the ability of Buyer to perform its obligations under this Agreement and the Ancillary Agreements to which Buyer is a party.
5.4    Available Funds. Buyer will have on the Closing Date unrestricted cash on hand and, if necessary, unrestricted cash available to it under credit facilities in place on the date hereof sufficient to pay all amounts to be paid or repaid by Buyer under this Agreement (whether payable on or after the Closing) and all of Buyer’s and its Affiliates’ fees and expenses associated with the transactions contemplated in this Agreement.
5.5    Litigation. There is no Action pending or, to the Knowledge of Buyer, threatened against, Buyer which (a) challenges or seeks to enjoin, alter or materially delay the consummation of the transactions contemplated by this Agreement, or (b) would reasonably be expected to have a material adverse effect on Buyer. Buyer is not subject to any Order which seeks to or would reasonably be expected to, individually or in the aggregate, prevent, materially delay or impair Buyer’s ability to consummate the transactions contemplated by this Agreement.
5.6    Brokers or Finders. Buyer represents, as to itself and its Affiliates, that, other than Morgan Stanley, no agent, broker, investment banker or other firm or Person is or will be entitled to any broker’s or finder’s fee or any other commission or similar fee in connection with any of the transactions contemplated by this Agreement and the Ancillary Agreements.
5.7    Investigation by Buyer. Buyer has conducted its own independent investigation, verification, review and analysis of the Business and of the Purchased Assets and the Assumed Liabilities, results of operations, financial condition, technology and prospects of the Business, which investigation, review and analysis was conducted by Buyer and its respective Affiliates and, to the extent Buyer deemed appropriate, by Buyer’s Representatives. Buyer acknowledges that it and its Representatives have been provided adequate access to the personnel, properties, premises and records of the Business and of the Purchased Assets and the Assumed Liabilities. In entering into this Agreement, Buyer acknowledges that it has relied solely upon the aforementioned investigation, review and analysis and not on any factual representations or opinions of Sellers (except the specific representations and warranties of Parent set forth in Article IV or in any Ancillary Agreement), and Buyer acknowledges and agrees, to the fullest extent permitted by Law, that:
(a)    except for the representations and warranties set forth in Article IV or in any Ancillary Agreement, none of Parent or any other member of the Seller Group or any of their respective Affiliates, Representatives or any other Person makes or has made any oral or written representation or warranty, either express or implied, as to the accuracy or completeness of any information made available or delivered to Buyer or its Affiliates and Representatives, including any information, whether oral or written (including cost estimates, financial information and projections and other projections and forward-looking

1




statements) (i) included in management presentations, “break-out” discussions, responses to questions submitted by or on behalf of Buyer or its Affiliates and Representatives, or any “data room” or (ii) delivered or made available pursuant to Section 6.3 or otherwise;
(b)    none of Parent, any member of the Seller Group or any of their Affiliates, Representatives or any other Person shall have any Liability or responsibility whatsoever to Buyer or its shareholders, Affiliates or Representatives on any basis (including in contract, tort or equity, under federal or state securities Laws or otherwise) based upon any information described in Section 5.7(a), except on the basis of the representations and warranties set forth in Article IV or in any Ancillary Agreement; and
(c)    without limiting the generality of the foregoing, except for the representations and warranties set forth in Article IV or in any Ancillary Agreement, neither Parent nor any member of the Seller Group makes any representation or warranty regarding (and Buyer disclaims) any third party beneficiary rights or other rights which Buyer might claim under any studies, reports, tests or analyses prepared by any third parties for Sellers or any of their Affiliates, even if the same were made available for review by Buyer or its Affiliates or Representatives.
5.8    Acknowledgment by Buyer. BUYER ACKNOWLEDGES THAT THE REPRESENTATIONS AND WARRANTIES BY PARENT CONTAINED IN THIS AGREEMENT AND THE ANCILLARY AGREEMENTS CONSTITUTE THE SOLE AND EXCLUSIVE REPRESENTATIONS AND WARRANTIES OF SELLERS OR THE SELLER GROUP TO BUYER IN CONNECTION WITH THE TRANSACTIONS CONTEMPLATED HEREBY. BUYER FURTHER ACKNOWLEDGES AND AGREES THAT BUYER HAS NOT RELIED ON ANY REPRESENTATION, WARRANTY OR OTHER STATEMENT BY ANY PERSON ON BEHALF OF SELLERS OR ANY MEMBER OF THE SELLER GROUP (OTHER THAN THOSE SET FORTH IN ARTICLE IV OR IN ANY ANCILLARY AGREEMENT) AND THAT ALL OTHER REPRESENTATIONS AND WARRANTIES OF ANY KIND OR NATURE EXPRESSED OR IMPLIED ARE SPECIFICALLY DISCLAIMED BY SELLERS.
ARTICLE VI

COVENANTS OF SELLERS
6.1    Conduct of Business. During the period from the Put Option Date and continuing until the earlier of the termination of this Agreement or the Closing Date, except with the prior written consent of Buyer, Sellers shall, and shall cause each other member of the Seller Group to:
(a)    (i) maintain its corporate existence, (ii) pay or perform the Liabilities related to the Business when due, (iii) carry on the Business in the usual, regular and ordinary course in a manner consistent with past practice;

2




(b)    maintain the Books and Records in accordance with past practice, and use its commercially reasonable efforts to maintain in full force and effect all Business Authorizations and policies;
(c)    use its commercially reasonable efforts to (i) keep available the services of its current officers, employees and consultants and (ii) preserve its relationships with material counterparties (including customers, suppliers, and distributors), in each case with respect to the Business;
(d)    use its commercially reasonable efforts to cause all of the conditions to the obligations of Buyer under this Agreement to be satisfied prior to the Closing Date; and
(e)    use commercially reasonable efforts to complete, or cause to be completed, the transactions contemplated by the ISC Purchase Agreement.
6.2    Negative Covenants. In furtherance and not in limitation of Section 6.1, Sellers agree that, except as (x) set forth on Schedule 6.2, (y) may be required by this Agreement or (z) required by Law, by a Governmental Entity, during the period commencing on the Put Option Date and ending on the earlier of the Closing Date and the termination of this Agreement pursuant to Section 9.1, Sellers shall not, and shall cause each Subsidiary of Parent not to, effect any of the following (as each is related to the Business) without the prior written consent of Buyer (such consent not to be unreasonably withheld, conditioned or delayed):
(a)    adopt or propose any amendment to the Charter Documents of (i) any Retained Company that could be reasonably expected to delay the consummation of the transactions contemplated by this Agreement or (ii) any Purchased Company;
(b)    authorize for issuance, issue, sell or deliver (x) any capital stock of, or other equity or voting interest in, a Purchased Company or (y) any securities convertible into, exchangeable for, or evidencing the right to subscribe for or acquire any (1) shares of capital stock of, or other equity or voting interest in any Purchased Company, (2) securities convertible into, exchangeable for, or evidencing the right to subscribe for or acquire, any shares of the capital stock of, or other equity or voting interest in, any Purchased Company (including rights, warrants or options) or (3) phantom stock or similar equity-based payment option with respect to any Purchased Company;
(c)    split, combine, redeem, reclassify, purchase or otherwise acquire directly, or indirectly, any shares of capital stock of, or other equity or voting interest in, any Purchased Company, or make any other change in the capital structure of any Purchased Company, except as contemplated by the ISC Purchase Agreement;
(d)    establish a record date for, or declare or set aside, any dividend in respect of shares of any Purchased Company, other than a cash dividend that is paid prior to the Closing;

1




(e)    (i) other than pursuant to a written agreement or Benefit Plan covering the Business Employees in effect on the Put Option Date, modify the compensation or benefits payable or to become payable by any member of the Seller Group to any Business Employee having a base salary plus projected commissions of more than $100,000 per year, (ii) hire or terminate any Business Employee having a base salary plus projected commissions in excess of $100,000 per year, other than in connection with a termination for cause, (iii) enter into any severance agreement with any Business Employee, or (iv) communicate any target bonus to any Business Employee with respect to any period following the Closing;
(f)    establish, adopt, enter into, amend or terminate any Benefit Plan or any collective bargaining, thrift, compensation or other plan, agreement, trust, fund, policy or arrangement for the benefit of any Business Employees, to the extent any such action disproportionately affects the Business Employees as compared to Sellers’ other employees, in each case other than in the ordinary course of the Business consistent with past practice, or as required by Law;
(g)    sell, lease, transfer or assign any assets, properties or rights of any member of the Seller Group related to the Business to a Person outside of the Seller Group, except (i) sales of Inventory, (ii) the grant of non-exclusive Out-Bound Licenses, (iii) the sale of obsolete Equipment or Instruments, and (iv) the sale of Excluded Assets, in each case in the ordinary course of the Business consistent with past practice;
(h)    acquire or agree to acquire any assets that would be material, individually or in the aggregate, to the Business, taken as a whole, except in the ordinary course of the Business consistent with past practice;
(i)    be party to any merger, acquisition, consolidation, recapitalization, liquidation, dissolution or similar transaction involving the Business that could be expected to delay the consummation of the transactions contemplated by this Agreement;
(j)    assume, incur or guarantee any Indebtedness or modify the terms of any existing Indebtedness, except in the ordinary course of the Business consistent with past practice;
(k)    cancel any debts or waive any claims or rights of substantial value;
(l)    mortgage, pledge or subject to Liens, other than Permitted Liens, any assets, properties or rights related to the Business or the Ascension Shares or the ISC Shares;
(m)    amend, modify, cancel or waive any material rights under any Material Contract; provided, however, that the expiration of any Material Contract in accordance with its terms shall not be deemed to be restricted under this clause (m); and provided, further, that Sellers and the members of the Seller Group may renegotiate the terms of, or otherwise extend, any Material Contract that has expired in accordance with its terms prior to the date hereof or is scheduled to expire in accordance with its terms prior to

2




the Outside Date, provided that such terms are no less favorable to the applicable member of the Seller Group than those in effect on the Put Option Date;
(n)    make any filings or registrations with any Governmental Entity, except for those contemplated by this Agreement and except for routine filings and registrations made in the ordinary course of the Business consistent with past practice;
(o)    make or change any Tax election, amend any Tax Return, settle or compromise any claim, notice, audit report or assessment in respect of Taxes, change any annual Tax accounting period, adopt or change any method of Tax accounting, enter into any tax allocation agreement, tax sharing agreement, tax indemnity agreement or closing agreement relating to any Tax, or consent to any extension or waiver of the statute of limitations period applicable to any Tax claim or assessment;
(p)    (i) make any capital expenditures in excess of $200,000 individually or in the aggregate, other than capital expenditures reflected in the Capital Expenditures Budget or (ii) fail to make any capital expenditure reflected in the Capital Expenditures Budget;
(q)    except as required by GAAP, make any change in accounting methods, principles or practices; or
(r)    agree, whether in writing or otherwise, to do any of the foregoing.
6.3    Access to Information Concerning Properties and Records.
(a)    Subject to the terms of the Confidentiality Agreement by and between Smith & Nephew, Inc. and Parent, dated July 11, 2019 (as amended, modified or supplemented from time to time, the “Confidentiality Agreement”), during the period from the Put Option Date through and including the earlier of (i) the date this Agreement is terminated in accordance with Section 9.1 and (ii) the Closing Date, Parent shall, and shall cause each other member of the Seller Group to, upon reasonable prior notice and during regular business hours, afford to Buyer’s officers, directors, employees, accountants, counsel, consultants, advisors and agents (“Representatives”) reasonable access to the personnel, properties, books and records of Sellers and the Seller Group relating to the Business, the Purchased Assets and the Assumed Liabilities to the extent Buyer reasonably believes necessary or advisable to familiarize itself with such properties and other matters; provided, that Sellers may restrict the foregoing access to the extent that, in the reasonable judgment of Sellers, any applicable Law or any health and safety policy of general application requires it to restrict such access; and provided, further, that such access shall not unreasonably disrupt the operations of Sellers or any of the Seller Group. Notwithstanding anything to the contrary contained in this Agreement, neither Sellers nor any members of the Seller Group shall be required to (x) provide any information or access to the extent that Sellers reasonably believe that providing such information or access would reasonably be likely to violate applicable Law, including the HSR Act or Other Antitrust Laws, or the terms of any Contract or cause the waiver of attorney/client or similar privilege or (y) conduct, or

3




permit Buyer or any of its Representatives, without the express written permission of Sellers, to conduct any Phase I or Phase II investigation or other environmental soil or groundwater investigation on or relating to any real property owned by or leased to Sellers and/or the Seller Group.
(b)    Nothing contained in this Agreement shall be construed to give to Buyer, directly or indirectly, rights to control or direct the Business prior to the Closing or any other business or operations of Sellers. Subject to Sections 6.1 and 6.2, prior to the Closing, Sellers shall exercise, consistent with the terms and conditions of this Agreement, complete control and supervision of the Business and shall at all times exercise complete control and supervision of all of its other businesses and operations.
(c)    Buyer hereby agrees that it is not authorized to and shall not (and shall not permit any of its respective Representatives to) contact any competitor, contractor, vendor, supplier, distributor, customer or employee of Sellers or any member of the Seller Group with respect to the Business or the transactions contemplated hereby prior to the Closing without the prior written consent of Sellers.
6.4    Interim Financial Statements. As promptly as practicable following each calendar month prior to the Closing Date, Parent will deliver to Buyer monthly revenue reports (by both SKU and dealer), trial balances with respect to the Purchased Companies, and a summary of Inventory and Instruments by location, in each case, in the form provided to Buyer prior to the Put Option Date. As promptly as practicable following each calendar quarter prior to the Closing Date, Parent will deliver to Buyer a statement of profit and loss of the Business.
6.5    Payment of Pro-Rated Bonuses. On or prior to the Closing Date (or through Parent’s or the applicable member of the Seller Group’s next payroll cycle following the Closing Date), Parent shall, or shall cause the applicable member of the Seller Group to, pay to the applicable Transferred Employees, through Parent’s or such applicable member of the Seller Group’s payroll, an amount equal to such Transferred Employee’s respective portion of the Pro-Rated Bonuses (less applicable withholding Taxes). Prior to the Closing Date, Parent will provide Buyer with the amount of the Pro-Rated Bonus paid to each Transferred Employee, as well as an explanation of how such amount was calculated.
6.6    Pre-Closing Assignment of Certain Contracts. Prior to the Closing, Parent will assign (or cause to be assigned) the Contracts set forth on Schedule 6.6 to Ascension, and will notify (or cause to be notified) the counterparty(ies) to any such Contract of such assignment.
ARTICLE VII

COVENANTS OF BUYER AND SELLERS
7.1    Regulatory Approvals.

4




(a)    Buyer and Parent shall each promptly apply for, and take all reasonably necessary actions to obtain or make, as applicable, all Orders and Authorizations of, and all filings with, any Governmental Entity or other Person required to be obtained or made by it for the consummation of the transactions contemplated by this Agreement. Each Party shall cooperate with and promptly furnish information to the other Party necessary in connection with any requirements imposed upon such other Party in connection with the consummation of the transactions contemplated by this Agreement. Without limiting the generality of the foregoing, if required, Buyer and Parent shall (i) as promptly as practicable and before the expiration of any relevant legal deadline, but in no event later than ten (10) Business Days following the Put Option Date, file with the United States Federal Trade Commission (the “FTC”) and the United States Department of Justice (“DOJ”), the Notification and Report Form required for the transactions contemplated hereby and any supplemental information requested in connection therewith pursuant to the HSR Act, which forms shall specifically request early termination of the waiting period prescribed by the HSR Act, (ii) as promptly as practicable and before the expiration of any relevant legal deadline, but in no event later than fifteen (15) Business Days following the Put Option Date, file with the the Direction Générale du Trésor of the French Ministry of Economy, the request for authorization of the purchase of the French Services Business and the French Artemis ND Business referred to in Section 8.1(c) and (iii) as promptly as practicable and before the expiration of any relevant legal deadline, file with any other Governmental Entity, any other filings, reports, information and documentation required for the transactions contemplated hereby pursuant to any Other Antitrust Laws. Each of Buyer and Parent shall furnish to each other’s counsel such necessary information (in redacted form if and to the extent necessary to comply with relevant Laws, to protect the confidentiality of commercially sensitive information or to comply with binding obligations of confidentiality to third parties) and reasonable assistance as the other may request in connection with its preparation of any filing or submission that is necessary under the HSR Act and any Other Antitrust Laws and the filing referenced in clause (ii) above. Buyer shall be responsible for all filing and other similar fees payable in connection with such filings related to Other Antitrust Laws and the filing referenced in clause (ii) above.
(b)    Buyer shall promptly take or cause to be taken any and all action necessary to obtain promptly any clearance required under the HSR Act and any Other Antitrust Laws for the consummation of the transactions contemplated by this Agreement, including agreeing to any structural or behavioral remedy with respect to the Ascension Shares, the Business or the Purchased Assets, or, at the request of Parent, to litigate in order to avoid the entry of, or to have vacated or terminated, any Order (whether temporary, preliminary or permanent) related to the HSR Act or any Other Antitrust Laws that would prevent the consummation of the transactions contemplated by this Agreement. For the avoidance of doubt, Buyer shall not take any action with respect to any Order or any applicable Law which would bind any member of the Seller Group, the Business or the Purchased Assets irrespective of whether the transactions contemplated by this Agreement occur. Each of Buyer and Parent shall keep the other apprised of the status of any communications with, and any inquiries or requests for additional information from, the FTC and the DOJ and other Governmental Entities and shall comply promptly with any

1




such inquiry or request. Each of Buyer and Parent shall instruct their respective counsels to cooperate with each other and use commercially reasonable efforts to facilitate and expedite the identification and resolution of any antitrust issues at the earliest practicable dates. Such commercially reasonable efforts and cooperation include, but are not limited to, counsel’s undertaking (i) to keep each other appropriately informed of communications from and to personnel of any Governmental Entity, and (ii) to confer with each other regarding appropriate contacts with and response to personnel of such Governmental Entity.
(c)    During the period from the date hereof and continuing until the earlier of the termination of this Agreement or the Closing Date, except with the consent of Parent (which shall not be unreasonably withheld, delayed or conditioned), Buyer and its Affiliates shall not do anything, including entering into any transaction, that would reasonably be expected to prevent or delay any filings or approvals required under the HSR Act or the applicable Other Antitrust Laws.
(d)    In connection with its application for and for the purposes of the authorization referred to in Section 8.1(c), Buyer shall:
(i)    promptly provide all additional information requested or required by any relevant Governmental Entity;
(ii)    take any lawful action reasonably required to obtain authorization for the sale and purchase of the French Services Business and the French Artemis ND Business by offering, accepting and satisfying any obligations, undertakings or conditions that any relevant Governmental Entity formally or informally reasonably indicates must be offered, accepted or satisfied in order for its authorization to be granted;
(iii)    keep the Sellers regularly and promptly informed on the status and progress of the request for authorization so as to enable the Sellers to monitor progress of the Buyer’s compliance with this Section and to provide relevant information and documents, including keeping the Sellers fully informed of the progress towards fulfilling and the satisfaction of the condition set forth in Section 8.1(c);
(iv)    not agree to any undertakings or conditions of any Governmental Entity without first, if legally possible, consulting with the Sellers in order to give the Sellers the opportunity to comment before a final decision is reached in respect of any such undertaking or condition;
(v)    give the Sellers reasonable notice of and opportunity for them or any of their advisers to attend all material meetings and telephone calls with any Governmental Entity (save to the extent that the Governmental Entity expressly requests that the Sellers should not be present or represented at the meeting or part(s) of the meeting or call) and promptly provide copies of all written correspondence from any Governmental Entity to the Sellers; and

2




(vi)    provide the Sellers with drafts of all material written communications intended to be sent to any Governmental Entity, give the Sellers a reasonable opportunity to comment on them, take into account any such comments as are reasonable and provide the Sellers with final copies of all such communications.
(e)    Notwithstanding anything to the contrary in this Agreement, (i) following consultation with Parent, after giving due consideration to Parent’s views, acting reasonably, and in good faith, Buyer will control and lead all communications and strategy related to any filings, analyses, reviews, approvals, consents, submissions, or other dealings with any Governmental Entity under the HSR Act, Other Antitrust Laws or any Law regulating foreign investment in connection with the transactions contemplated by this Agreement, and (ii) under no circumstances will Buyer be required to agree to any behavioral or structural remedy with respect to the business, assets, services or products of Buyer and its Affiliates, in each case as they exist on the date of this Agreement.
7.2    French Business Employees; European Employees.
(a)    Sellers and Buyer acknowledge and agree that the French Services Employees and the French Artemis ND Employees shall automatically transfer to the Buyer or the applicable Buyer Designee(s) on the Closing Date according to the provisions of article L. 1224-1 of the French Labor Code (Code du Travail).
(b)    Buyer shall, or shall cause one of its Affiliates to, prior to the Closing, when required by Sellers (and not before) on reasonable notice (which time required by Sellers will be after the exercise of the Put Option), offer comparable employment to each European Employee effective as of the Closing Date on not less favorable terms and conditions than those applied by the applicable member of the Seller Group and with continuity of employment (reprise d’ancienneté) (the “European Employment Offer”). European Employees will have a three-week reflection period to accept or decline the European Employment Offer as from its receipt.
(c)    If such European Employment Offer is accepted, Buyer, the applicable member of the Seller Group and the European Employee shall enter into an appropriate agreement to record the voluntary transfer on the Closing Date, in substantially the form attached as Exhibit F hereto. Each European Employee who accepts such offer shall be employed by Buyer or its applicable Buyer Designee with effect from the Closing Date, and such employment shall be subject to and in accordance with the terms of applicable Law. In the event a European Employment Offer is not formally accepted, on the expiry of the three-week reflection period as described in Section 7.2(b), the applicable member of the Seller Group will keep the applicable European Employee(s) on its payroll and neither Buyer nor any of its Affiliates shall have any obligation with respect to such European Employee(s).
(d)    If the European Employment Offer is not made by Buyer or an Affiliate thereof in accordance with Section 7.2(b), Buyer shall bear solely and entirely all responsibility for and all Liability arising out of or in connection with any Seller’s termination

3




of the contract of employment of the applicable European Employee(s), provided that such termination occurred within a period of sixty (60) days following the Closing Date.
(e)    If the European Employment Offer is accepted, Buyer shall, or shall cause its Affiliates to, assume all obligations with respect to the European Employee on the Closing Date, including all salaries and other benefits (including paid leave, thirteen month salaries, expenses, profit sharing, social security contributions and retirement indemnities, whether immediately payable or not). Notwithstanding the generality of the foregoing, Buyer shall, or shall cause its Affiliates to, ensure that all such Transferred Employees who were notified of their target bonuses for the year in which the Closing occurs receive cash bonus opportunities for such year at least equal to the annual target bonus to which they were entitled for such year immediately prior to the Closing Date (less the amount of any Pro-Rated Bonuses).
(f)    If, as a result of the transactions contemplated by this Agreement, it is found or alleged that the employment of any employee other than a Business Employee (including any Excluded Employee) has transferred to Buyer or any of its Affiliates or in any way engages any automatic transfer pursuant to article L. 1224-1 of the French Labor Code (Code du Travail) and Council Directive 2001/23/EC as implemented into local legislation, or by virtue of a definitive court decision, Sellers shall indemnify Buyer against all Losses that Buyer or any of its Affiliates may suffer or incur in respect of the employment or termination of such employee.
(g)    The Parties expressly agree that all salaries and other benefits, including paid leave, thirteen month salaries, expenses, social insurance (including social security contributions) and retirement indemnities related to the French Business Employees shall be taken on by Buyer or the applicable Buyer Designee(s) as of the Closing Date. Sellers and Buyer further agree that (i) with effect from the Closing Date, Buyer or its applicable Buyer Designee(s) shall bear all of the consequences of whatsoever nature which may arise from any breach of the employment contracts of any French Business Employee transferred pursuant to this Agreement, and/or the payment of any amount due and any costs related to any French Business Employee, arising from any event or action originating after the Closing Date and (ii) Buyer or its applicable Buyer Designee(s) shall bear all the consequences of whatsoever nature that may arise from the termination after the Closing Date of the employment contracts of any French Business Employee (whether by way of redundancy or otherwise) including those attributable to the period of service of such employee prior to the Closing Date.
(h)    The Parties agree that the transfer of the employment contracts of the French Business Employees listed in Schedule 7.2(h), who are protected employees under French law (the “Protected Employees”), is subject to the prior authorization of the labor inspector (inspecteur du travail). The transfer of the Protected Employees will take effect as of the Closing Date provided that Services and Artemis ND have obtained at this date the necessary authorization from the labor inspector (inspecteur du travail). If Services and/or Artemis ND have not obtained the authorization from the labor inspector (inspecteur du

4




travail) as at the Closing Date, the employment contracts of the Protected Employees will be transferred to Buyer or the applicable Buyer Designee on the first business day following (i) the day on which the transfer is authorized by the labor inspector (inspecteur du travail); or (ii) if the labor inspector (inspecteur du travail) refuses the transfer, the day on which the transfer is authorized by the French administration or a French court. Sellers shall not be liable for any difficulties to operate the Business as currently being conducted due to the absence of any Protected Employee. Subject to the previous sentence, Sellers shall hold harmless and indemnify Buyer and its Affiliates against any Liabilities owing to any Protected Employees whose transfer is refused. If the labor inspector refuses the transfer of a Protected Employee, Seller shall remain employer of such Protected Employees.
(i)    Sellers will, and will cause their Affiliates to, reasonably cooperate with Buyer and its Affiliates in connection with any consultation conducted by Buyer or a Buyer Designee with an employee representative body prior to the Closing. Paragraph 3.2 of the offer letter, dated as of the Put Option Date and with respect to the transactions contemplated hereby, will apply to the foregoing obligation, mutatis mutandis. In any jurisdiction where both a member of the Seller Group, on the one hand, and Buyer or a Buyer Designee, on the other hand, conduct a consultation with an employee representative body, such parties will use their reasonable best efforts to coordinate the timing of such consultations and the information provided in connection therewith.
7.3    U.S. Employees.
(a)    No fewer than ten (10) days prior to the Closing, Sellers shall deliver to Buyer an updated version of the Business Employees Schedule; provided, that no changes may be made to the list of Excluded Employees on such Business Employee Schedule without the written consent of Buyer and provided further, that Business Employees may only be removed from the Business Employee Schedule (i) in the event that a Business Employee’s employment was terminated (A) by such former Business Employee, (B) by the applicable member of the Seller Group for cause, or (C) due to death or disability, or (ii) with the written consent of Buyer. Prior to the Closing, Sellers shall have transferred the employment of all Excluded Employees from the Purchased Companies to another member of the Seller Group. As of the Closing Date, Buyer shall, and Buyer shall cause its Affiliates to: (i) cause the Purchased Companies to continue to employ all of their employees; and (ii) at least fifteen (15) days prior to the Closing Date, offer employment to each other U.S. Employee who is not employed by a Purchased Company as indicated on the Business Employees Schedule, subject to the terms of this Section 7.3. Such employment of, or offers of employment made by Buyer or its Affiliates to, the U.S. Employees shall, subject to the other terms of this Section 7.3, be effective as of the Closing Date and shall be in a job or position and location that is substantially similar to the job or position and location in effect for such Business Employee immediately prior to the Closing Date, and (A) with total compensation and benefits having an aggregate value at least substantially similar to the total compensation and benefits to which they were entitled immediately prior to the Closing Date (excluding any equity-based compensation other than Colleague Equity Bonus Targets (as set forth on the Business Employee Schedule), post-employment health or welfare

5




benefits, payments or benefits payable on account of a change in control, or tax gross-ups) and (B) with Make-Whole Compensation as described in Section 7.3(c). Buyer shall provide Parent with draft copies of the template of the offer agreements contemplated above, along with templates of any documentation provided to Business Employees in connection with such offers, for Parent’s review and comment at least five (5) Business Days prior to providing such offers to the Business Employees. Notwithstanding the foregoing, following the Closing Date, Buyer and its Affiliates shall provide each U.S. Transferred Employee, as of the Closing Date, with cash compensation (including cash bonus opportunity) and benefits (excluding any equity-based compensation, post-employment health or welfare benefits, payments or benefits payable on account of a change in control, or tax gross-ups) at least as favorable as such cash compensation and benefits provided to similarly-situated employees of Buyer and its Affiliates. The obligation of Buyer and its Affiliates to provide the conditions of employment relating to pay and employee benefits in accordance with this Section 7.3(a) shall continue for a period ending not earlier than one year following the Closing Date.
(b)    Notwithstanding the foregoing, such employment of, or offers of employment made by Buyer or its Affiliates to, the U.S. Employees in accordance with Section 7.3(a), shall be subject to each U.S. Employee’s successful completion of the standard pre-employment screenings of Buyer or its Affiliates, including standard background and drug screenings. Prior to the Closing, Sellers shall use commercially reasonable efforts to provide Buyer and its Affiliates with any information reasonably requested by Buyer to allow for the transition of the Business Employees to Buyer or its Affiliates as of the Closing Date. Without limiting the foregoing, to the extent permitted by applicable law, Sellers will and will cause their Affiliates to (i) cooperate with Buyer and its Affiliates to provide any employee information for each Transferred Employee within fifteen (15) days following the Put Option Date to the extent necessary to permit Buyer to integrate and migrate any of the Transferred Employees onto Buyer’s or one of its Affiliate’s payroll and HR systems as of the Closing Date, (ii) provide Buyer and its Affiliates access to historical payroll information for the Transferred Employees, as and to the extent necessary to allow Buyer and its Affiliates to comply with applicable Law within ten (10) Business Days following the Closing Date, and (iii) deliver to Buyer and its Affiliates electronic employee files, as and to the extent necessary to allow Buyer and its Affiliates to comply with applicable Law within ten (10) Business Days following the Closing Date. Employee files should, to the extent permitted by applicable law, include all relevant documentation such as I-9, historic performance ratings, prior employee investigations or performance issues, if applicable, to the extent such files exist. Electronic files should be in a format that meets local guidelines for saving and filing employee information. In addition, Sellers and Buyer will, and will cause their Affiliates to, use commercially reasonable efforts to: (A) hold a full-day meeting to map out the transition of the Transferred Employees (other than the French Business Employees) into their roles with Buyer and its Affiliates within three (3) Business Days following the Put Option Date, which meeting will be attended by the human resources business partners, Rewards team, and may also be attended by other key personnel of Sellers, Buyer, and their Affiliates, as mutually agreed between the Parties and (B) hold a full-day meeting to map out human resources integration within two (2) Business

6




Days following the Put Option Date, which meeting will be attended by the human resources business partners, payroll, commissions, HRIS, Rewards team, and may also be attended by other key personnel of Sellers, Buyer, and their Affiliates, as mutually agreed between the Parties.
(c)    Without limiting the generality of the foregoing, (i) Buyer and its Affiliates shall have in effect for at least one (1) year following the Closing Date severance plans, practices and policies applicable to U.S. Transferred Employees on the Closing Date that are at least as favorable as the severance plans, practices and policies in effect for similarly-situated employees of Buyer and its Affiliates; (ii) Buyer shall, or shall cause its Affiliates to, ensure that all U.S. Transferred Employees who were notified of their target bonuses for the year in which the Closing occurs receive cash bonus opportunities for such year at least equal to the annual target bonus to which they were entitled for such year immediately prior to the Closing Date (less the amount of any Pro-Rated Bonuses); and (iii) Buyer shall, or shall cause one of its Affiliates to, provide each U.S. Transferred Employee who holds unvested equity awards with Parent as of immediately prior to the Closing Date (each, an “Unvested Equity Award”), as set forth on Section 7.3(c) of the Seller Disclosure Schedule, with “Make-Whole Compensation” (as defined below) in accordance with Buyer’s usual schedule for granting equity awards to similarly situated employees of Buyer and its Affiliates. With respect to any Unvested Equity Award set forth on Section 7.3(c) of the Seller Disclosure Schedule, “Make-Whole Compensation” means one or more types of compensation, which may be either cash-based or equity-based, vested or unvested, that provides the U.S. Transferred Employee with an aggregate economic value at least equal to the value of the applicable Unvested Equity Award. The value of any Unvested Equity Awards that are (1) in the form of restricted stock, restricted stock units or performance share units shall be determined based on the trading price of Parent common stock as of the close of trading on the business day immediately prior to the Closing Date and (2) in the form of stock options shall be determined based on the intrinsic value (i.e., spread value) of the stock options based on the difference between the applicable exercise price and the trading price of Parent common stock as of the close of trading on the business day immediately prior to the Closing Date. For the avoidance of doubt, Buyer’s obligation to provide “Make-Whole Compensation” under this Section 7.3(c) shall be limited to the amounts payable with respect to the Unvested Equity Awards to the U.S. Transferred Employees set forth on Section 7.3(c) of the Seller Disclosure Schedule. Section 7.3(c) of the Seller Disclosure Schedule sets forth, for each such U.S. Transferred Employee having an Unvested Equity Award: (i) the type of award, (ii) the total number of shares underlying the award, (iii) the applicable vesting and payment terms and schedules, (iv) in the case of awards that are in the form of stock options, the applicable exercise price, and (v) the value of the applicable Unvested Equity Award.
(d)    Coverage for all U.S. Transferred Employees and their respective spouses and dependents under all employee welfare benefit plans (within the meaning of Section 3(1) of ERISA) provided by Seller or the Seller Group shall cease to be effective immediately prior to the Closing Date. All claims incurred with respect to U.S. Transferred Employees and their eligible spouses and dependents on and after the Closing Date for

7




welfare benefits shall be the responsibility of the welfare benefit plans provided by Buyer. Claims incurred with respect to U.S. Transferred Employees and their eligible spouses and dependents for welfare benefits prior to the Closing Date shall be the responsibility of the welfare benefit plans of Seller. For purposes of this Section 7.3(d), a claim will be deemed “incurred” on the date that the event that gives rise to the claim occurs (for purposes of life insurance, accident and disability benefits) or on the date that treatment, services or products are provided (in the case of healthcare benefits).
(e)    U.S. Transferred Employees shall be provided credit by Buyer for all service with Sellers and the Seller Group, to the same extent as such service was credited for such purpose by Sellers and the Seller Group, under all employee benefit plans, programs, policies and benefits of Buyer or its Affiliates for purposes of eligibility and vesting and benefit accrual (other than with respect to any defined benefit pension and/or retiree medical benefits), but only to the extent such service crediting does not result in the duplication of benefits, and excluding defined benefit and retiree medical benefit accruals.
(f)    Buyer shall, and shall cause its Affiliates to, use commercially reasonable efforts to waive limitations on benefits relating to any pre-existing conditions of the U.S. Transferred Employees and their eligible spouses and dependents. Buyer shall, and shall cause its Affiliates to, use commercially reasonable efforts to recognize for purposes of annual deductible and out-of-pocket limits under their health plans applicable to U.S. Transferred Employees, deductible and out-of-pocket expenses paid by U.S. Transferred Employees and their respective spouses and dependents under Sellers’ or any of their Affiliates’ health plans in the calendar year in which the Closing Date occurs.
(g)    Each U.S. Transferred Employee who is a participant in the Integra LifeSciences Corporation 401(k) Trust (the “Seller 401(k) Plan”) shall cease to be an active participant under such plan effective as of the Closing Date. Effective as of the Closing Date, Buyer shall have in effect a defined contribution plan that is qualified under Section 401(a) of the Code and that includes a qualified cash or deferred arrangement within the meaning of Section 401(k) of the Code (the “Buyer 401(k) Plan”) in which U.S. Transferred Employees (other than those primarily employed outside the U.S.) shall be eligible to participate. As soon as practicable following the Closing Date, Buyer shall permit each U.S. Transferred Employee who participates in the Seller 401(k) Plan to elect to make a direct rollover of such U.S. Transferred Employee’s account balance under the Seller 401(k) Plan. Such transfer shall be subject to Sellers’ receipt from Buyer of a current determination letter from the Internal Revenue Service that the Buyer 401(k) Plan is qualified under Sections 401(a) and 401(k) of the Code. Following any such direct rollover, Buyer and its Affiliates shall assume all liabilities of Sellers and their Affiliates under the Seller 401(k) Plan to provide benefits to or on behalf of the U.S. Transferred Employees to the extent of the account balances so rolled over, and neither the Seller 401(k) Plan nor Sellers or their Affiliates shall have any obligation to Buyer or any Affiliate of Buyer or with respect to the applicable U.S. Transferred Employees with respect thereto. For the avoidance of doubt, neither the Seller 401(k) Plan, any other 401(k) plan sponsored by a Purchased Company or any Affiliate of a Purchased Company, nor any portion of such 401(k) plan will transfer

8




to Buyer or any Affiliate thereof, by operation of Law or otherwise, in connection with the Closing, except pursuant to a direct rollover, as described above.
(h)    Accrued entitlements, including vacation days for U.S. Transferred Employees as of the Closing Date, will not be subject to any applicable annual maximum rollover limitations contained in the vacation or paid-time off policies of Buyer and its Affiliates for the one-year period following the Closing Date.
(i)    In the case of U.S. Transferred Employees primarily employed outside the U.S., Buyer and its Affiliates shall, in addition to meeting the requirements of this Section 7.3, comply with any additional obligations or standards arising under applicable Laws governing the terms and conditions of their employment or severance of employment in connection with the transactions contemplated by this Agreement. In particular, Buyer and its Affiliates shall comply with any and all obligations on them triggered by applicable Laws to inform and/or consult with employee representative bodies.
(j)    Buyer shall be solely responsible for any Liabilities under the WARN Act, or under any other Laws that provide employees similar protections, resulting from actions taken by Buyer and its Affiliates on or after the Closing Date.
(k)    Buyer shall be solely responsible for compliance with the requirements of COBRA, including, without limitation, the provisions of continuation coverage with respect to all U.S. Transferred Employees (other than those primarily employed outside the U.S.), and their spouses and dependents, for whom a qualifying event occurs on or after the Closing Date. For purposes of this Section 7.3(k), the terms “continuation coverage” and “qualifying event” shall have the meanings ascribed to them in COBRA.
(l)    Buyer shall have in effect, or cause to be in effect, as of the Closing Date, flexible spending reimbursement accounts that are substantially equivalent in all material respects to the flexible spending reimbursement accounts in which the U.S. Transferred Employees are eligible to participate as of the Put Option Date, under a cafeteria plan designed to meet the requirements under Section 125 of the Code (the “Buyer FSAs”) in which the U.S. Transferred Employees (other than those primarily employed outside the U.S.) shall be eligible to participate beginning on the Closing Date. Buyer shall, subject to Sellers or their third party record-keeper providing sufficient records, allow the elections of such U.S. Transferred Employees in effect immediately prior to the Closing under the flexible spending reimbursement accounts under the cafeteria plans in which such employees are eligible to participate as of the Put Option Date (the “Seller FSAs”) to continue under the Buyer FSAs until the end of the 2020 calendar year.
(m)    As soon as practicable following the Closing Date, Sellers shall cause to be transferred to Buyer an amount in cash equal to the excess of the aggregate accumulated contributions to the flexible spending reimbursement accounts under the Seller FSAs made through the Closing Date during the year in which the Closing Date occurs by the U.S. Transferred Employees (other than those primarily employed outside the U.S.) over the

9




aggregate reimbursement payouts made for such year from such accounts to such employees through the Closing Date, together with all relevant records; provided, however, that, if the aggregate reimbursement payouts from the flexible spending reimbursement accounts under the Seller FSAs made through the Closing Date during the year in which the Closing Date occurs to U.S. Transferred Employees (other than those primarily employed outside the U.S.) exceed the aggregate accumulated contributions for such year to such accounts for such employees through the Closing Date, Buyer shall cause such excess to be transferred to Sellers as soon as practicable following the Closing Date. Buyer shall cause such amounts to be credited to each such employee’s corresponding accounts under the Buyer FSAs in which such employees participate following the Closing Date. On and after the Closing Date, Buyer shall assume and be solely responsible for all claims for reimbursement by such U.S. Transferred Employees that have not been paid in full as of the Closing Date. The foregoing shall include claims incurred but unpaid prior to the Closing Date, provided Sellers have provided to Buyer sufficient records to enable Buyer to administer and pay such claims. Any claims under the Buyer FSAs shall be administered and paid pursuant to and under the terms of the Buyer FSAs. Sellers and Buyer agree to cooperate in good faith regarding administration and payment of claims under Buyer FSAs.
(n)    Sellers acknowledge and agree that any and all restrictive covenants, including post-employment restrictive covenants, contained in any employment or other agreement between any Seller or any of their respective Affiliates and any Transferred Employee shall not be enforceable against such Transferred Employee or Buyer and its Affiliates, to the extent the asserted restrictive covenant violation arises out of the Transferred Employee’s provision of services to Buyer and its Affiliates following acceptance of an offer of employment with Buyer or its Affiliate as provided in Section 7.2 or this Section 7.3.
(o)    Nothing in this Agreement, express or implied, shall: (i) confer upon any Business Employee, or any Representative of any such employee, any rights or remedies, including any right to employment or continued employment for any period or terms of employment, for any nature whatsoever except as set forth in Section 7.2 or Section 7.3; or (ii) constitute or be deemed to constitute an amendment to any Benefit Plan or other employee benefit plan for any purpose.
7.4    Taxes.
(a)    Transfer Taxes. All transfer, documentary, sales, use, stamp, registration, value added, goods and services and other similar Taxes and fees (including any penalties and interest) incurred in connection with the transactions contemplated by this Agreement and the Ancillary Agreements, including all droits d’enregistrement under the laws of France, shall be paid fifty percent (50%) by Buyer and fifty percent (50%) by the Seller Group when due, and Buyer will, at its own expense, file all necessary Tax Returns and other documentation with respect to all such transfer, documentary, sales, use, stamp, registration and other Taxes and fees, and, if required by applicable Law, Sellers and Buyer will join in the execution of any such Tax Returns and other documentation if required. Parent will pay or cause to be paid to Buyer the share of Taxes to be borne by the Seller

10




Group pursuant to this Section 7.4(a) within five (5) Business Days of becoming due. No fewer than fifteen (15) Business Days before the Closing Date, Parent, on behalf of Sellers and such other members of the Seller Group as are selling Purchased Assets, shall provide written notice to Buyer of the amount of any Transfer Taxes due (with reasonable specificity as to the reason for and amount of such Transfer Tax). Buyer and Sellers shall use reasonable best efforts to cooperate with all other Parties, as reasonably requested, with respect to the filing of any Tax Return or conduct of any claim relating to any available refund of any amount paid pursuant to this Section 7.4(a). Each of the Sellers and Buyer shall reasonably cooperate and provide to other Parties such information as reasonably necessary to determine whether any Transfer Taxes are so required to be paid.
(b)    Tax Returns.
(i)    Entity Tax Returns. Parent shall prepare, or cause to be prepared, and file or cause to be filed, all Tax Returns of or including a Purchased Company for all taxable periods ending on or prior to the Closing Date which are required to be filed before, on or after the Closing Date (any such return, a “Pre-Closing Tax Return”). In no circumstance will Parent be required to provide Buyer with a Pre-Closing Tax Return that includes information about an entity other than a Purchased Company, (including without limitation an Affiliated Group Tax Return as defined in paragraph Section 7.4(e) below). Instead, Parent shall prepare, or cause to be prepared, a pro-forma version of any such Pre-Closing Tax Return that reflects Purchased Company data on a stand-alone basis (a “Pro-Forma Tax Return”). Parent shall provide Buyer with such Pre-Closing Tax Return or Pro-Forma Tax Return, as the case may be, for Buyer’s review and comment no later than ten (10) Business Days prior to the due date for filing the Pre-Closing Tax Return to which it relates (or, if the related Pre-Closing Tax Return is due to be filed less than ten (10) Business Days following the date hereof, then within such reasonable time as may be necessary to allow Buyer an adequate opportunity to review the Pro-Forma Tax Return and provide any comments). If Buyer does not provide any comments within five (5) Business Days of receiving the Pre-Closing Tax Return or Pro-Forma Tax Return, as the case may be, from Parent (or within a shorter time period, as may be applicable under the circumstances) prior to the due date for such Pre-Closing Tax Return, Buyer will be deemed to have accepted such Pre-Closing Tax Return or Pro-Forma Tax Return, as the case may be. Parent shall pay the amount due with respect to all Tax Returns described in this Section 7.4(b)(i).
(ii)    Asset Tax Returns. Parent shall prepare, or cause to be prepared, and file or cause to be filed, all Tax Returns with respect to the Purchased Assets for any Pre-Closing Tax Period that are required to be filed before, on or after the Closing Date (any such return, a “Pre-Closing Asset Return”). In no circumstance will Parent be required to provide Buyer with any Pre-Closing Asset Return to the extent it includes information about assets other than the Purchased Assets. In such a case, Parent shall prepare, or cause to be prepared, a pro-forma version of any such Pre-Closing Asset Return that reflects data relating to Purchased Assets only (a “Pro-Forma Asset Return”). Parent shall provide Buyer with such Pro-Forma Asset Return for Buyer’s review and comment no later than ten (10) Business Days prior to the due date for filing the Pre-Closing Asset Return to

11




which it relates (or, if the related Pre-Closing Asset Return is due to be filed less than ten (10) Business Days following the date hereof, then within such reasonable time as may be necessary to allow Buyer an adequate opportunity to review the Pro-Forma Asset Return and provide any comments). If Buyer does not provide any comments within five (5) Business Days of receiving the Pro-Forma Asset Return from Parent (or within a shorter time period, as may be applicable under the circumstances) prior to the due date for such Pre-Closing Asset Return, Buyer will be deemed to have accepted such Pro-Forma Asset Return. Parent shall pay the amount due with respect to all Tax Returns described in this Section 7.4(b)(ii).
(iii)    All Tax Returns required to be prepared by Parent pursuant to Section 7.4(b)(i) and (ii) must be prepared in accordance with past practices, unless otherwise required by Law or under this Agreement; provided, that Parent shall consider reasonable comments provided by Buyer pursuant to Section 7.4(b)(i) and (ii). Parent and Buyer shall cooperate in good faith in resolving any disagreements with respect to any Tax Returns prepared by Parent pursuant to Section 7.4(b)(i) and (ii).
(iv)    Buyer shall prepare, or cause to be prepared, and file, or cause to be filed, any Tax Returns of the Purchased Companies or any Tax Returns with respect to the Purchased Assets for any Straddle Period (any such Tax Return, “Straddle Period Tax Return”) and all such Straddle Period Tax Returns must be prepared in accordance with past practice, unless otherwise required by Law or under this Agreement. Buyer shall submit drafts of such Straddle Period Tax Returns to Parent for its review and comment not later than fifteen (15) Business Days prior to the due date (taking into account any extensions thereof) for filing such Straddle Period Tax Returns. Parent will provide any comments to Buyer as promptly as practicable (and not later than ten (10) Business Days after receiving any such Tax Returns) and Buyer shall reasonably consider all such comments, and if Parent does not provide any comments within ten (10) Business Days, Parent will be deemed to have accepted such Tax Returns. If a Straddle Period Tax Return is due to be filed in less than forty-five (45) days following the Closing Date (an “Imminent Tax Return”), Buyer will use its reasonable best efforts to submit drafts of such Imminent Tax Return to Parent for its review and comment no later than ten (10) days prior to the due date and Parent will use its reasonable best efforts to deliver comments by a time that allows Buyer an opportunity to include such comments in such Imminent Tax Return before it is due to be filed. If Buyer is unable to submit a draft Imminent Tax Return to Parent for its review at least ten (10) days prior to the due date, and if Parent objects to the Imminent Tax Return as filed, the Imminent Tax Return will be submitted to the Independent Accounting Firm for review and resolution. The Parties agree to promptly settle any amounts due based on the Independent Accounting Firm’s conclusion. Any fees imposed by the Independent Accounting Firm to resolve such dispute shall be borne fifty percent (50%) by Buyer and fifty percent (50%) by Parent. Parent and Buyer shall cooperate in good faith in resolving any disagreements regarding any Straddle Period Tax Returns (including Imminent Tax Returns) prepared by Buyer pursuant to this Section 7.4(b)(iv). Buyer shall pay the amount due with respect to all Tax Returns described in this Section 7.4(b)(iv), and Parent shall pay amounts attributable

12




to the Pre-Closing Tax Period (as determined in Section 7.4(c), below) to Buyer within three (3) Business Days prior to the date any such Tax Returns are filed.
(v)    Buyer and its Affiliates shall be liable for any Asset Level Taxes attributable to the Post-Closing Tax Period.
(c)    For all purposes of this Agreement (including, for the avoidance of doubt, Section 7.4(b)), the amount of Taxes (including Asset Level Taxes) allocable to the portion of a Straddle Period ending on the Closing Date shall be deemed to be: (i) in the case of real or personal property Taxes or similar Taxes imposed on a periodic basis, the amount of such Taxes for the entire Straddle Period multiplied by a fraction, the numerator of which is the number of calendar days in the portion of the Straddle Period ending on and including the Closing Date and the denominator of which is the number of calendar days in the entire relevant Straddle Period, and (ii) in the case of Taxes not described in (i) above (such as franchise Taxes, Taxes that are based upon or related to income or receipts, based upon production or occupancy or imposed in connection with any sale or other transfer or assignment of property (real or personal, tangible or intangible)), the amount of any such Taxes shall be determined as if such taxable period ended as of the end of the Closing Date. For the avoidance of doubt, the Parties shall not make a ratable allocation election under Section 1.1502-76(b)(2)(ii)(D) of the Treasury Regulations.
(d)    Buyer and Parent and their Affiliates agree to furnish or cause to be furnished to each other, upon request, as promptly as practicable, such information and assistance relating to the Purchased Companies, the Business, the Purchased Assets and Assumed Liabilities (including access to books and records) as is reasonably necessary for the filing of all Tax Returns, the making of any election relating to Taxes, the preparation for any audit by any Governmental Entity, and the prosecution or defense of any Action relating to any Tax. Any expenses incurred in furnishing such information or assistance shall be borne by the Party requesting it. Notwithstanding anything to the contrary in this Agreement, Buyer shall only be granted access to the Tax information, books and records concerning or relating to the Purchased Companies, the Business, or the Purchased Assets and not to any information, books or records relating to any consolidated, fiscal unity, unitary, combined or similar Tax Return (each an “Affiliated Group Tax Return”); provided, however, that with respect to any information reported on an Affiliated Group Tax Return with respect to the Purchased Companies, Buyer may, in accordance with this Section 7.4(e), be granted access to a Pro-Forma Tax Return.
(e)    Post-Closing Actions.
(i)    Except with the written permission of Parent, Buyer shall not, and shall not permit any of its Affiliates (including, after the Closing for the avoidance of doubt, the Purchased Companies) to: (A) voluntarily approach any Governmental Entity regarding any Taxes or Tax Returns of, or related to, the Purchased companies or the Purchased Assets for any Pre-Closing Tax Period or Straddle Period; (B) file (except as set forth in Section 7.4(b)), amend, refile or otherwise modify (or grant an extension of any statute of limitation with respect to) any Tax Return relating in whole or in part to a Purchased

13




Company or any Purchased Asset (or a group the parent of which is Parent) with respect to any Pre-Closing Tax Period or Straddle Period; or (C) change any accounting method or adopt any convention with respect to the Purchased Companies or the Purchased Assets that shifts, or is reasonably expected to shift, taxable income or Tax liability from a Post-Closing Tax Period to a Pre-Closing Tax Period or shift, or reasonably expected to shift, deductions or losses from a Pre-Closing Tax Period to a Post-Closing Tax Period.
(ii)    Buyer shall not make or cause there to be made any election under Section 338 or 336(e) of the Code (or any comparable applicable provision of state, local or foreign Tax Laws) with respect to the transactions contemplated by this Agreement, including with respect to Buyer’s or a Buyer Designee’s purchase of the ISC Shares. Buyer shall not make or cause to be made any extraordinary transaction, event, or effect as of the Closing Date that could reasonably be expected to increase the amount of Taxes directly imposed on Sellers or their Affiliates or for which Sellers are required to indemnify Buyer or its Affiliates or otherwise economically bear under this Agreement.
(iii)    Except with the written permission of Buyer or as contemplated herein, Parent (or any of its Affiliates) shall not (A) amend any Tax Return for any Pre-Closing Tax Period of a Purchased Company or with respect to any of the Purchased Assets, (B) take any action (or fail to take any action) before the Closing that is outside the ordinary course of business that would increase Buyer’s or any of its Affiliates’ (including the Purchased Companies after the Closing) Tax liability for any Post-Closing Tax Period (or portion of a Straddle Period ending after the Closing Date), or (C) change any accounting method or adopt any convention with respect to a Purchased Company or the Purchased Assets that shifts, or is reasonably expected to shift, taxable income or Tax liability from a Pre-Closing Tax Period to a Post-Closing Tax Period or shifts, or reasonably expected to shift, deductions or losses from a Post-Closing Tax Period to a Pre-Closing Tax Period.
(iv)    To the extent that any share of Ascension is a “loss share” (within the meaning of Treasury Regulations Section 1.1502-35(d)(2)(i)), and Parent reasonably determines that it will not be entitled to a Tax benefit from any portion of the loss attributable to such loss share, Parent will make a valid and timely election under Treasury Regulations Section 1.1502-36(d)(6) and (e)(5) to reduce the adjusted Tax basis in all such shares of Ascension so as to preserve to the maximum extent possible the Tax Attributes (including any net operating loss) of Ascension.
(f)    Refunds. Except to the extent taken into account in calculation of the Estimated Closing Working Capital pursuant to Section 2.6 or Closing Working Capital pursuant to Section 2.7, if after the Closing Date, the Buyer or any of its Affiliates receives a refund of any Tax that is attributable to a Pre-Closing Tax Period relating to a Purchased Company or a Purchased Asset, then Buyer shall promptly pay to Parent the amount of such refund together with any interest thereon. If there is a subsequent reduction by a Governmental Entity (or by virtue of a change in applicable Tax Law), of any amounts with respect to which a payment has been made to Parent pursuant to this Section 7.4(g), then

14




Parent shall pay Buyer (or a Person as directed by Buyer) an amount equal to such reduction, plus any interest or penalties imposed by a Governmental Entity with respect thereto.
(g)    Tax Contests.
(i)    Notwithstanding anything to the contrary herein, Parent shall have the exclusive right to control any pending or threatened audit, claim, demand or proceeding by a Governmental Entity involving a Purchased Company for any Pre-Closing Tax Period (except to the extent any Pre-Closing Tax Period is part of any Straddle Period) or any Affiliated Group Tax Return filed by Parent or any of its other Affiliates.
(ii)    Buyer shall promptly notify Parent in writing upon receipt by Buyer or its Affiliates of a Third-Party Claim relating to any pending or threatened audit, claim, demand or proceeding by a Governmental Entity involving a Purchased Company or any of its Subsidiaries or the Purchased Assets to the extent that any such Third-Party Claim relates to Taxes with respect to which Sellers may be liable, including pursuant to this Agreement. With respect to Third-Party Claims not subject to Section 7.4(h)(i), Parent shall have the right to control any Third-Party Claim that is for any Pre-Closing Tax Period other than a Straddle Period. Buyer and Seller shall have the right to jointly control any Third-Party Claim pertaining to a Straddle Period. Each of Parent and Buyer shall not abandon, settle or otherwise resolve any Third-Party Claim for a Straddle Period or that is not subject to Section 7.4(h)(i) but is with respect to a Pre-Closing Tax Period without the other Party’s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed. With respect to Third-Party Claims that are subject to Section 7.4(h)(i), Parent shall not abandon, settle or otherwise resolve any such Third-Party Claim without the Buyer’s prior written consent if such Third-Party Claim is reasonably expected to result in an increase in Buyer’s or any of its Affiliates’ (including the Purchased Companies after the Closing) Tax liability for any Post-Closing Tax Period, including a portion of a Straddle Period that begins after the Closing Date.
(h)    Tax Indemnity.
(i)    Parent and its Affiliates shall indemnify Buyer and its Affiliates (including, after the Closing Date, the Purchased Companies) and hold them harmless from, against and in respect of (A) all Liability for all Taxes of the Purchased Companies or with respect to the Purchased Assets for all Pre-Closing Tax Periods, (B) all Liability for Taxes of the Purchased Companies attributable to any Tax election with respect to any of the Purchased Companies to change any method of accounting filed and effective prior to the Closing Date, including elections described in Section 4.6(l) of the Seller Disclosure Schedule, (C) Taxes described in Section 2.10 which were not withheld by Buyer, and (D) Taxes resulting from any breach by Sellers of any representations in Section 4.6. Notwithstanding anything to the contrary in this Agreement, Buyer and its Affiliates will not be entitled to indemnification for (1) Taxes that were taken into account in the calculation of the Estimated Closing Working Capital or Estimated Closing Indebtedness pursuant to Section 2.6 or Closing Working Capital or Closing Indebtedness pursuant to Section 2.7, (2) Taxes that were actually recovered from a Person other than Buyer, Parent or their

15




respective Affiliates or a Purchased Company, (3) Taxes that result from Buyer undertaking any of the Post-Closing Actions described in Section 7.4(e)(i) or (ii), except with the written permission of Parent, or (4) Taxes directly attributable to and resulting from any extraordinary transactions or actions taken by Buyer, its Affiliates or a Purchased Company outside of the ordinary course of business that occur on the Closing Date after the Closing.
(ii)    Payment by the indemnitor of any amount of Tax described in Section 7.4(h)(i) shall be made within forty-five (45) days following written notice by the indemnitee. In the case of a Tax that is contested in accordance with the provisions of Section 7.4(h), payment of the Tax to the indemnitee shall not be considered to be due earlier than the date such Third-Party Claim is resolved. Buyer and Sellers agree to treat any amounts payable pursuant to this Section 7.4(h) as an adjustment to the Final Purchase Price for federal, state, territory, local and foreign Tax purposes, unless otherwise required by applicable Law.
(iii)    Payments pursuant to this Section 7.4(h) shall be limited to the Final Purchase Price, except with respect to payments arising pursuant to Treasury Regulations Section 1.1502-6, with respect to which there shall be no limitations as to the amount for which Parent or any of its Affiliates may be liable to Buyer under this Section 7.4(h).
(iv)    The indemnification obligations set forth in this Section 7.4(h) shall survive until sixty (60) days following the expiration of the applicable statutes of limitations in respect of the relevant Taxes.
7.5    Discharge of Business Obligations After Closing. From and after the Closing, if any member of the Seller Group or any of their respective Affiliates receives or collects any funds constituting a Purchased Asset or proceeds thereof, Parent shall cause such member of the Seller Group to remit such funds to Buyer within five (5) Business Days after its receipt thereof. From and after the Closing, if Buyer receives or collects any funds constituting an Excluded Asset or proceeds thereof, Buyer shall remit any such funds to the relevant member of the Seller Group within five (5) Business Days after its receipt thereof.
7.6    Access to Books and Records. Each of Sellers and Buyer shall, and shall cause their respective Affiliates to, preserve until the seventh (7th) anniversary of the Closing Date all records in existence as of the Closing and possessed by such Party relating to any of the assets, Liabilities or business of the Business prior to the Closing. After the Closing Date, where there is a legitimate business purpose, such Party shall, subject to the last sentence of Section 7.4(e), provide the other Party with reasonable access, upon prior reasonable written request specifying the need therefor, during regular business hours, to (a) the officers and employees of such Party and (b) the books of account and records of such Party in existence as of the Closing, but, in each case, only to the extent relating to the assets, Liabilities or business of the Business prior to the Closing, and the other Party and its representatives shall have the right to make copies of such books and records at their sole cost; provided, however, that the foregoing right of access shall not (a) be exercisable in such a manner as to interfere unreasonably with the normal operations and business of such

16




Party, (b) apply in connection with disputes between the Parties, or (c) extend to any information that is subject to attorney-client or similar privilege. Such records may nevertheless be destroyed by a Party if such Party sends to the other Party written notice of its intent to destroy records, specifying the contents of the records to be destroyed. Such records may then be destroyed after the thirtieth (30th) day after such notice is given unless the other Party objects to the destruction in which case the Party seeking to destroy the records shall deliver such records to the objecting Party at the objecting Party’s cost. For the avoidance of doubt, any books and records subject to this Section 7.6 shall not include Tax Returns (i) of Buyer and its pre-Closing Affiliates for any Tax period or (ii) of a Purchased Company or with respect to the Purchased Assets, in each case for any Post-Closing Tax Period; provided, however, that such books and records shall include pro-forma Tax Returns solely of a Purchased Company or with respect to the Purchased Assets for any Post-Closing Tax Period.
7.7    Further Assurances. Buyer and Parent shall, and Parent shall cause the other members of the Seller Group to, execute such documents and other instruments and take such further actions as may be reasonably required or desirable to carry out the provisions of this Agreement and the Ancillary Agreements and to consummate the transactions contemplated hereby and thereby. Upon the terms and subject to the conditions hereof, Buyer and Parent shall each use its respective reasonable best efforts to take or cause to be taken all actions and to do or cause to be done all other things necessary, proper or advisable to consummate and make effective as promptly as practicable the transactions contemplated by this Agreement and the Ancillary Agreements. From time to time after the Closing, at Buyer’s request and expense, Sellers shall execute, and Sellers shall cause each other relevant member of the Seller Group to, acknowledge and deliver to Buyer such other instruments of conveyance and transfer as Buyer may reasonably require in order to vest more effectively in Buyer (or if applicable, a Buyer Designee), or to put Buyer (or if applicable, a Buyer Designee) more fully in possession of, any of the Purchased Assets.
7.8    Local Transfer Agreements.
(a)    The Parties do not intend this Agreement to transfer title to the Purchased Assets, or to constitute the assumption of any Assumed Liabilities, in any jurisdiction in which such transfer or assumption is required by applicable Law to be made pursuant to a Local Transfer Agreement, and such Purchased Assets or Assumed Liabilities, as applicable, shall only be transferred or assumed by the applicable Local Transfer Agreement (which transfers and assumptions shall, except as otherwise expressly set forth herein, be on an “as-is,” “where-is” basis, without representation or warranty of any kind or nature).
(b)     Notwithstanding the generality of Section 7.8(a), to the extent that the provisions of a Local Transfer Agreement are inconsistent with, or (except to the extent they implement a transfer in accordance with this Agreement) additional to, the provisions of this Agreement (or do not fully give effect to the provisions of this Agreement with respect to the transfer of the Purchased Assets or the assumption of Assumed Liabilities): (i) the

17




provisions of this Agreement shall prevail; and (ii) so far as permissible under applicable Law of the relevant jurisdiction, Parent and Buyer shall cause the provisions of the relevant Local Transfer Agreement to be adjusted, to the extent necessary to give effect to the provisions of this Agreement.
(c)    Each Party hereto shall not, and shall cause its respective Affiliates not to, bring any claim (including for breach of any warranty, representation, undertaking, covenant or indemnity relating to the transactions contemplated by this Agreement) against the other Parties or any of its Affiliates in respect of or based upon any of the Local Transfer Agreements, except to the extent necessary to enforce any transfer of the Purchased Assets or the assumption of Assumed Liabilities sold to or assumed by Buyer or its Buyer Designee(s) hereunder in a manner consistent with the terms of this Agreement.
7.9    French Lease. Prior to the Closing, Sellers shall use commercially reasonable efforts to (a) cause Artemis ND to enter into the French Lease Agreement and (b) secure all necessary approvals to assign the French Lease Agreement to Buyer or the applicable Buyer Designee(s) at Closing as an Assigned Contract.
7.10    Public Announcements. Sellers and the other members of the Seller Group, on the one hand, and Buyer and its Affiliates, on the other hand, each shall (a) consult with each other before issuing any press release or otherwise making any public statement with respect to the transactions contemplated by this Agreement, (b) provide to the other party for review a copy of any such press release or public statement and (c) not issue any such press release or make any such public statement prior to such consultation and review and the receipt of the prior consent of the other party to this Agreement, unless required by applicable Law or regulations of any applicable stock exchange, in which case, the party required to issue the press release or make the public statement shall, prior to issuing such press release or making such public statement, use its commercially reasonable efforts to allow the other party reasonable time to comment on such release or statement to the extent practicable. Notwithstanding anything in the foregoing to the contrary, nothing in this Section 7.10 shall limit any Party’s right to make public statements about its actions under Section 9.1 without prior consultation with the other Party.
7.11    Confidentiality.
(a)    Effective upon the Closing, the Confidentiality Agreement will terminate with respect to information related to the Business; provided, however, that Buyer acknowledges that any and all other information provided to it by or on behalf of Parent or its Affiliates or their Representatives concerning Parent or any of its Affiliates (other than related to the Business) will remain subject to the terms and conditions of the Confidentiality Agreement after the Closing Date.
(b)    For a period of five (5) years after the Closing Date, Parent will, and will cause its Subsidiaries and their respective directors, officers, employees and other Representatives to, subject to clause (c) below, keep confidential and not disclose to any Person, any Confidential Information. For purposes of this Agreement, “Confidential

18




Information” means any non-public information to the extent related to the Business, other than information which (i) is or becomes generally available to the public other than as a result of a disclosure by Parent or any of its Subsidiaries or any of their respective directors, officers, employees or other Representatives, or (ii) is disclosed by Parent or a Subsidiary thereof pursuant to applicable Law.
(c)    In the event that Parent or a Subsidiary thereof is requested or required (by deposition, interrogatories, requests for information or documents in legal proceedings, subpoenas, civil investigative demand or similar process), in connection with any proceeding, to disclose any Confidential Information, Parent will, to the extent legally permissible, give Buyer prompt written notice of such request or requirement so that Buyer may seek an appropriate protective order or other remedy or waive compliance with the provisions of ‎Section 7.11(b), and Parent will reasonably cooperate with Buyer to obtain such protective order upon Buyer’s request and at Buyer’s expense. If, in the absence of a protective order or the receipt of a waiver hereunder, Parent or any of its Subsidiaries is nonetheless compelled or advised by legal counsel to disclose Confidential Information to or at the direction of any Governmental Entity, Parent or such Subsidiary may disclose such specifically requested Confidential Information to or at the direction of such Governmental Entity only after first notifying Buyer in writing of such disclosure (to the extent legally permissible) and, upon Buyer’s request, after using its reasonable best efforts to obtain assurances that confidential treatment will be accorded to such information.
7.12    Release of Guaranties. Parent shall, and shall cause its Affiliates to, use commercially reasonable efforts to cause each Seller Guaranty to be released and cancelled at or prior to the Closing. If Parent is not able to release and cancel any Seller Guaranty, then Parent shall indemnify, defend and hold harmless Buyer and Buyer’s Affiliates (including the Purchased Companies) for all Liabilities or expenses that arise or are incurred by Buyer or Buyer’s Affiliates (including the Purchased Companies) in connection with such Seller Guaranty.
7.13    Termination of Affiliate Arrangements. Prior to the Closing, Parent will cause all Affiliate Arrangements (and all other Contracts or transactions that would have been Affiliate Arrangements had they existed as of the Put Option Date) to be settled (irrespective of the terms of payment) or terminated and canceled without any further Liability to, or obligation of, any Purchased Company, from and after the Closing.
7.14    Restrictive Covenants.
(a)    Non-Competition. During the period commencing on the Closing Date and ending on the eighteen (18)-month anniversary of the Closing Date, Parent shall not, and shall cause its Affiliates not to, either directly or indirectly as a stockholder, investor, member, partner or otherwise, own, manage, operate or otherwise engage in any business in competition with the Restricted Business in any jurisdiction in the world (each, a “Competing Activity”); provided, that the foregoing shall not prohibit (i) the acquisition, holding of investments or direct or indirect ownership of any publicly-traded securities of any Person engaged in a Competing Activity, so long as (A) such ownership interest

19




represents not more than five percent (5%) of the aggregate voting power of such Person and (B) neither Parent nor any of its Affiliates actively participates in the management or operation of such Person; (ii) owning, engaging in, conducting or operating any business of Parent and its Affiliates as of the Put Option Date, other than the Restricted Business; or (iii) the acquisition of any business or Person (whether by stock or asset acquisition, merger, consolidation or otherwise) for which Competing Activities account for less than fifteen percent (15%) of the revenue of such Person or business. “Restricted Business” means the Business, as conducted by the Seller Group, including any reasonable extensions thereof and any Products currently planned or under development; provided, that the “Restricted Business” will not include the design, development, marketing, promotion, distribution, manufacturing, inspection, packaging or sale of any biologics product.
(b)    Non-Solicitation. During the period commencing on the Closing Date and ending on the eighteen (18)-month anniversary of the Closing Date, Parent and its Affiliates will not hire (whether as an employee, consultant or otherwise) directly or indirectly solicit or seek to induce any (i) Business Employee whose annual base salary at the relevant time is $100,000 or more or (ii) sales representative of the Business to leave his or her employment or position with Buyer or any of its Affiliates; provided that the foregoing shall not prohibit Parent or its Affiliates (A) from hiring or engaging any person who responds to a general solicitation or (B) hiring, engaging or soliciting any Person who was no longer employed or engaged by Buyer or its Affiliates at the time Parent or its Affiliates initially solicited such Person.
(c)    The Parties acknowledge and agree that the restrictions contained in this Section 7.14 are reasonable in scope and duration in light of the nature, size and location of the Business, and the Parties further acknowledge that the restrictions contained in this Section 7.14 are necessary to protect Buyer’s significant investment in the Business, including its goodwill. It is the desire and intent of the Parties that the provisions of this Section 7.14 be enforced to the fullest extent permissible under applicable Law. If all or part of this Section 7.14 is held invalid, illegal or incapable of being enforced by any Law or public policy, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect. If any part of this Section 7.14 is held to be excessively broad as to duration, scope, activity or subject, such part will be construed by limiting and reducing it so as to be enforceable to the maximum extent permissible under applicable Law or public policy.
7.15    Wrong Pockets.
(a)    If, following the Closing, Buyer, Parent, or any of their respective Affiliates identifies (i) any asset held by a member of the Seller Group that is a Purchased Asset; or (ii) any asset held by Buyer or a Buyer Designee that is an Excluded Asset (in each case, a “Wrong Pocket Asset”), then Parent or Buyer, as the case may be, will notify the other in writing.
(b)    As soon as reasonably practicable following notification under Section 7.15(a), (i) in the case of a Wrong Pocket Asset in the possession of a member of

20




the Seller Group, Parent will, or will cause the applicable member of the Seller Group to, transfer the Wrong Pocket Asset to Buyer or the applicable Buyer Designee(s), for no consideration, and (ii) in the case of a Wrong Pocket Asset in the possession of Buyer or a Buyer Designee, Buyer will, or will cause its applicable Buyer Designee to, transfer the Wrong Pocket Asset to a member of the Seller Group, as Parent directs, for no consideration.
7.16    License. Parent, on behalf of itself and the other Retained Companies, grants to Buyer and its Affiliates a non-exclusive, royalty-free, irrevocable, fully-paid-up, worldwide license under any patent owned by Parent or any other Retained Company on the Closing Date or that claims priority to such a patent solely to the extent necessary for Buyer and its Affiliates to continue to make, use, sell or offer to sell a Product that is being sold by the Business on the Closing Date or any evolution thereof.
7.17    Post-Closing Reporting. Following the Closing, Parent will make, or cause to be made, all required disclosures, filings and reports pursuant to the Physician Payments Sunshine Act (42 U.S.C. § 1320a-7h), and any similar state Laws, with respect to any pre-Closing payments made by the Seller Group, including the payment of the purchase price under the ISC Purchase Agreement.
ARTICLE VIII

CONDITIONS TO CLOSING
8.1    Conditions to Obligations of Buyer and Sellers. The obligations of Buyer and Sellers to consummate the transactions contemplated by this Agreement are subject to the satisfaction on or prior to the Closing Date of the following conditions:
(a)    The waiting period applicable to the consummation of the transactions contemplated by this Agreement under the HSR Act and any applicable waiting periods under the Other Antitrust Laws shall have expired or been terminated and any approvals, clearances or waivers under Other Antitrust Laws shall have been obtained.
(b)    No temporary restraining order, preliminary or permanent injunction or other Order preventing the consummation of the transactions contemplated by this Agreement shall be in effect. No Law shall have been enacted or shall be deemed applicable to the transactions contemplated by this Agreement which makes the consummation of such transactions illegal.
(c)    In accordance with Articles L. 151-3 et seq. and R. 151-1 et. seq. of the French Monetary and Financial Code (Code Monétaire et Financier), the request for authorization of the purchase of the French Services Business and the French Artemis ND Business shall have been filed by the Buyer with the Direction Générale du Trésor of the French Ministry of Economy and any approvals, clearances or waivers with respect to the purchase of the French Services Business and the French Artemis ND Business by the Buyer shall have been obtained.

21




8.2    Conditions to Obligation of Buyer. The obligation of Buyer to consummate the transactions contemplated by this Agreement is subject to the satisfaction (or waiver by Buyer in its sole discretion) of the following further conditions:
(a)    (i) The representations and warranties of Parent set forth in this Agreement (other than the Fundamental Representations), disregarding all materiality, Material Adverse Effect or similar qualifiers contained therein, shall have been true and correct at and as of the Put Option Date and shall be true and correct at and as of the Closing Date as if made at and as of the Closing Date, except to the extent that such representations and warranties refer specifically to an earlier date, in which case such representations and warranties shall have been true and correct as of such earlier date, except, in each case, to the extent that any such failures to be so true and correct, whether individually or in the aggregate, have not had, and would not be reasonably expected have, a Material Adverse Effect; and (ii) the Fundamental Representations shall have been true and correct in all but de minimis respects at and as of the Put Option Date and shall be true and correct in all but de minimis respects at and as of the Closing Date as if made at and as of the Closing Date, except to the extent that such Fundamental Representations refer specifically to an earlier date, in which case such Fundamental Representations shall have been true and correct in all but de minimis respects as of such earlier date.
(b)    Sellers shall have performed or complied in all material respects with all obligations and covenants required by this Agreement to be performed or complied with by Sellers at or prior to the Closing.
(c)    Buyer shall have received a certificate dated the Closing Date signed on behalf of Parent by an officer of Parent to the effect that the conditions set forth in Sections 8.2(a), 8.2(b) and 8.2(d) have been satisfied (the “Seller Closing Certificate”).
(d)    There shall not have occurred a Material Adverse Effect since the Put Option Date.
(e)    Sellers shall have delivered to Buyer all agreements and other documents required to be delivered by Sellers to Buyer pursuant to Section 3.2 of this Agreement.
(f)    Sellers shall have delivered to Buyer the consent of the landlord under the Lease for the Austin, Texas facility with respect to the assignment of such Lease.
(g)    Artemis ND shall have entered into the French Lease Agreement and delivered to Buyer the consent of the landlord thereunder with respect to the assignment of the French Lease Agreement to Buyer or a Buyer Designee, as applicable, at the Closing.
(h)    Design Freeze (as defined in the License and Development Agreement) shall have occurred, and the transactions contemplated by the ISC Purchase Agreement shall have been consummated in accordance with the terms thereof following Design Freeze.

1




8.3    Conditions to Obligation of Sellers. The obligation of Sellers to consummate the transactions contemplated by this Agreement is subject to the satisfaction (or waiver by Parent in its sole discretion) of the following further conditions:
(a)    The representations and warranties of Buyer set forth in this Agreement shall have been true and correct at and as of the Put Option Date and shall be true and correct (disregarding all materiality or similar qualifiers contained therein) at and as of the Closing Date as if made at and as of the Closing Date, except to the extent that such representations and warranties refer specifically to an earlier date, in which case such representations and warranties shall have been true and correct as of such earlier date; except, in each case, to the extent that any such failures to be so true and correct, whether individually or in the aggregate, have not had, and would not be reasonably expected have, a material adverse effect on Buyer’s ability to perform its obligations hereunder.
(b)    Buyer shall have performed or complied in all material respects with all obligations and covenants required by this Agreement to be performed or complied with by Buyer at or prior to the Closing.
(c)    Sellers shall have received a certificate dated the Closing Date signed on behalf of Buyer by an officer of Buyer to the effect that the conditions set forth in Section 8.3(a) and 8.3(b) have been satisfied (the “Buyer Closing Certificate”).
(a)    (d)    Buyer shall have delivered to Sellers all agreements and other documents required to be delivered by Buyer to Seller pursuant to Section 3.3 of this Agreement.
ARTICLE IX

TERMINATION
9.1    Termination.
(a)    This Agreement may be terminated at any time prior to the Closing:
(i)    by mutual written consent of Buyer and Parent;
(ii)    by Buyer or Parent if:
(A)    the Closing does not occur on or before four (4) months after the execution of this Agreement (the “Outside Date”); provided that the Outside Date can be extended by Parent or Buyer to a date that is no later than six (6) months after the initial Outside Date if the conditions set forth in Section 8.1(a) or Section 8.1(c) are not satisfied; provided further that the right to terminate this Agreement under this clause (ii)(A) shall not be available to any Party whose breach of a representation, warranty, covenant or agreement under this Agreement has been the cause of or resulted in the failure of the Closing to occur on or before such date; or

2




(B)    a Governmental Entity shall have issued an Order or taken any other action, in any case having the effect of permanently restraining, enjoining or otherwise prohibiting the transactions contemplated by this Agreement, which Order or other action is final and non-appealable;
(iii)    by Buyer if:
(A)    any condition to the obligations of Buyer hereunder becomes incapable of fulfillment other than as a result of a breach by Buyer of any covenant or agreement contained in this Agreement, and such condition is not waived by Buyer; or
(B)    there has been a breach by any Seller of any representation, warranty, covenant or agreement contained in this Agreement, or if any representation or warranty of Parent shall have become untrue, in either case such that the conditions set forth in Sections 8.2(a) or 8.2(b) cannot not be satisfied; or
(iv)    by Sellers if:
(A)    any condition to the obligations of Sellers hereunder becomes incapable of fulfillment other than as a result of a breach by Sellers of any covenant or agreement contained in this Agreement, and such condition is not waived by Sellers; or
(B)    there has been a breach by Buyer of any representation, warranty, covenant or agreement contained in this Agreement, or if any representation or warranty of Buyer shall have become untrue, in either case such that the conditions set forth in Sections 8.3(a) or 8.3(b) cannot not be satisfied.
(b)    The Party desiring to terminate this Agreement pursuant to clause (ii), (iii) or (iv) of Section 9.1(a) shall give written notice of such termination to the other Party hereto.
9.2    Effect of Termination. In the event of termination of this Agreement as provided in Section 9.1, this Agreement shall immediately become null and void and there shall be no Liability or obligation on the part of Sellers or Buyer or their respective officers, directors, stockholders or Affiliates, except as set forth in Section 9.3. Notwithstanding the foregoing, the provisions of Article I, this Article IX and Article XI will survive any termination of this Agreement and will remain in effect.
9.3    Remedies. Any Party terminating this Agreement pursuant to Section 9.1 shall have the right to recover damages sustained by such Party as a result of any breach by the other Party of any representation, warranty, covenant or agreement contained in this Agreement or Fraud; provided, however, that the Party seeking relief is not in breach of any representation, warranty, covenant or agreement contained in this Agreement under circumstances which would have permitted the other Party to terminate the Agreement under Section 9.1.

1




ARTICLE X

INDEMNIFICATION
10.1    Survival. The representations and warranties made by Parent and Buyer herein (other than the representations and warranties in Section 4.6, the survival of which is subject to Section 7.4(h)(iv)) and the covenants of the Parties herein to be performed prior to the Closing will not be extinguished by the Closing, but will survive the Closing until, and all claims for indemnification in connection therewith must be asserted not later than, eighteen (18) months following the Closing Date; provided, that each of the Fundamental Representations will survive the Closing for, and all claims for indemnification must be asserted not later than, six (6) years following the Closing Date, and the representations and warranties set forth in Section 4.13 will survive the Closing until sixty (60) days following the expiration of applicable statutes of limitations. Except as provided in Section 7.4(h)(iv), the covenants of the Parties contained herein that are required to be performed after the Closing will survive until fully performed or fulfilled; provided, that all claims for indemnification in connection with Section 10.3(c) relating to Taxes must be asserted not later than sixty (60) days following the expiration of any statute of limitations applicable to the rights of any Person to bring any claim with respect to such matters. Notwithstanding the foregoing, if, prior to the close of business on the last day a claim for indemnification may be asserted hereunder, the Indemnifying Party shall have been properly notified in writing of a claim for indemnity hereunder and such claim shall not have been finally resolved or disposed of at such date, such claim will continue to survive and will remain a basis for indemnity hereunder until such claim is finally resolved or disposed of in accordance with the terms hereof.
10.2    Indemnification Obligations of Parent. Except as otherwise provided for in Section 7.4(h), from and after the Closing, Parent will indemnify and hold harmless the Buyer Indemnified Parties from and against, and compensate, reimburse and pay the Buyer Indemnified Parties for, any and all Losses arising out of or relating to:
(a)    any inaccuracy in or breach of any representation or warranty set forth in Article IV of this Agreement;
(b)    any breach of any covenant, agreement or undertaking made by a Seller in this Agreement;
(c)    any product liability claim with respect to any Product sold by the Business prior to the Closing; and
(d)    any Excluded Liability.
The Losses of the Buyer Indemnified Parties described in this Section 10.2 and the items described in Section 7.4(h)(i) as to which the Buyer Indemnified Parties are entitled to indemnification are collectively referred to as “Buyer Losses.”

1




10.3    Indemnification Obligations of Buyer. From and after the Closing, Buyer will indemnify and hold harmless the Parent Indemnified Parties from and against, and compensate, reimburse and pay the Parent Indemnified Parties for, any and all Losses arising out of or relating to:
(a)    any inaccuracy in or breach of any representation or warranty set forth in Article V of this Agreement;
(b)    any breach of any covenant, agreement or undertaking made by Buyer in this Agreement; and
(c)    any Assumed Liability.
The Losses of the Parent Indemnified Parties described in this Section 10.3 as to which the Parent Indemnified Parties are entitled to indemnification are collectively referred to as “Parent Losses.”
10.4    Indemnification Procedure. Except as otherwise provided in Section 7.4(h):
(a)    Promptly following receipt by an Indemnified Party of notice by a third party (including any Governmental Entity) of any complaint, dispute or claim or the commencement of any Action with respect to which such Indemnified Party may be entitled to indemnification pursuant hereto (a “Third-Party Claim”), such Indemnified Party will provide written notice thereof to the Indemnifying Party; provided, that the failure to so notify the Indemnifying Party will not limit the Indemnified Party’s right to indemnification under this Article X or Section 7.4 unless, and only to the extent that, such failure to so notify the Indemnifying Party results in the forfeiture of rights and defenses otherwise available to the Indemnifying Party with respect to such Third-Party Claim. The Indemnifying Party will have the right, upon written notice delivered to the Indemnified Party within thirty (30) days thereafter, to assume the defense of such Third-Party Claim, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of the fees and disbursements of such counsel. In the event, however, that the Indemnifying Party declines or fails to assume the defense of such Third-Party Claim on the terms provided above or to employ counsel reasonably satisfactory to the Indemnified Party, in either case within such thirty (30) day period, then any Buyer Losses or Parent Losses (as the case may be) will include the reasonable fees and disbursements of counsel for the Indemnified Party as incurred. Notwithstanding anything to the contrary contained in this Section 10.4(a), the Indemnified Party will control such Third-Party Claim, solely to the extent (i) the Third-Party Claim arises in connection with any criminal proceeding, action, indictment, investigation or allegation against the Indemnified Party, (ii) the Third-Party Claim seeks material injunctive or other equitable relief against the Indemnified Party, (iii) the Third-Party Claim, if adversely determined, would have a material adverse effect on the financial condition, business or operations of Parent and its Affiliates, taken as a whole, on the one hand, or on the Business as conducted by Buyer and its Affiliates, taken as a whole, on the other hand, or (iv) an actual or readily apparent conflict of interest exists between the Indemnifying Party and the Indemnified Party with respect to the Third-Party

2




Claim that precludes effective joint representation. In any Third-Party Claim for which indemnification is being sought hereunder, the Indemnified Party or the Indemnifying Party, whichever is not assuming the defense of such Third-Party Claim, will have the right to reasonably participate in such matter and to retain its own counsel at such Person’s own expense. The Indemnifying Party or the Indemnified Party (as the case may be) will at all times use reasonable efforts to keep the Indemnifying Party or Indemnified Party (as the case may be) reasonably apprised of the status of the defense of any matter the defense of which it is maintaining and to cooperate in good faith with each other with respect to the defense of any such matter.
(b)    No Indemnified Party may settle or compromise any Third-Party Claim or consent to the entry of any judgment with respect to which indemnification is being sought hereunder without the prior written consent of the Indemnifying Party (which may not be unreasonably withheld or delayed), unless the Indemnifying Party fails to assume and maintain diligently the defense of such Third-Party Claim pursuant to Section 10.4(a). The Indemnifying Party may not, without the prior written consent of the Indemnified Party, settle or compromise any Third-Party Claim or consent to the entry of any judgment with respect to which indemnification is being sought hereunder unless such settlement, compromise or consent (i) includes an unconditional release of the Indemnified Party and its officers, directors, employees and Affiliates from all Liability arising out of, or related to, such Third-Party Claim, (ii) does not contain any admission or statement suggesting any wrongdoing or Liability on behalf of the Indemnified Party or any of the Indemnified Party’s Affiliates, and (iii) does not contain any equitable order, judgment or term that in any manner affects, restrains or interferes with the business of the Indemnified Party or any of its Affiliates.
(c)    In the event an Indemnified Party claims a right to payment pursuant to this Article X or Section 7.4(h) with respect to any matter not involving a Third-Party Claim (a “Direct Claim”), such Indemnified Party will send written notice of such claim to the Indemnifying Party (a “Notice of Claim”). Such Notice of Claim will specify the basis for such Direct Claim. The failure by any Indemnified Party so to notify the Indemnifying Party shall not limit the Indemnified Party’s right to indemnification with respect to any Direct Claim made pursuant to this Section 10.4(c), it being understood that Notices of Claim in respect of a breach of a representation or warranty must be delivered prior to the expiration of the survival period for such representation or warranty under Section 10.1 or Section 7.4(h)(iv), as applicable. In the event the Indemnifying Party does not notify the Indemnified Party within fifteen (15) Business Days following its receipt of such Notice of Claim that the Indemnifying Party disputes the Indemnified Party’s right to indemnification under this Article X or Section 7.4(h) or the amount thereof, the Indemnified Party will be conclusively entitled to the amount set forth in such Notice of Claim. In the event the Indemnifying Party has timely disputed the Indemnified Party’s right to indemnification under this Article X or Section 7.4(h) or the amount thereof, the Indemnified Party and the Indemnifying Party will, as promptly as reasonably practicable, establish the merits and amount of such Direct Claim (by mutual agreement, litigation or otherwise).

3




10.5     Liability Limitations.
(a)    Notwithstanding anything in this Article X to the contrary, no Buyer Indemnified Party will be entitled to indemnification for any Buyer Losses pursuant to Section 10.2(a) unless and until the aggregate of all such indemnifiable Buyer Losses exceeds on a cumulative basis an amount equal to one percent (1%) of Base Purchase Price (the “Basket Amount”), in which case the Buyer Indemnified Parties shall be entitled to indemnification pursuant to Section 10.2(a) for all Buyer Losses, including the Basket Amount; provided, however, that the limitations set forth in this Section 10.5(a) will not apply to any claim arising out of or related to Fraud, a breach of any Fundamental Representation, or claims for indemnification pursuant to Section 7.4(h)(i).
(b)    The maximum amount of indemnifiable Buyer Losses that may be recovered by the Buyer Indemnified Parties pursuant to Section 10.2(a) will be an aggregate amount equal to 10% of Base Purchase Price; provided, however, that the limitations set forth in this Section 10.5(b) will not apply to any claim arising out of or related to Fraud, a breach of any Fundamental Representation, or claims for indemnification pursuant to Section 7.4(h)(i).
(c)    The maximum amount of indemnifiable Buyer Losses that may be recovered by the Buyer Indemnified Parties pursuant to Section 10.2 will be an aggregate amount equal to the Final Purchase Price.
(d)    No Party will have any Liability under this Agreement for, and Buyer Losses and Parent Losses will not include, any punitive or exemplary damages, except to the extent awarded to a third party in connection with a Third-Party Claim for which a Party is entitled to indemnification hereunder.
(e)    The amount of any Losses for which indemnification is provided pursuant to this Article X will be calculated net of any insurance proceeds, indemnification payments, contribution payments or reimbursements actually received by the Indemnified Party with respect to such Losses or any of the circumstances giving rise thereto. In connection therewith, if, at any time following any indemnification payment made by an Indemnifying Party pursuant to this Agreement, the Indemnified Party receives any insurance proceeds, indemnification payments, contribution payments or reimbursements relating to the circumstances giving rise to such indemnification payment, the Indemnified Party will promptly remit to the Indemnifying Party such proceeds, payments or reimbursements in an amount not to exceed the amount of the corresponding indemnification payment made by the Indemnifying Party. The Indemnified Party will use (and will cause its Affiliates to use) commercially reasonably efforts to collect the proceeds of any available insurance that would have the effect of reducing any Losses (in which case the net proceeds thereof will reduce the Losses). For the avoidance of doubt, seeking recovery of Losses under any insurance policy will not be a condition to an Indemnified Party pursuing a claim for indemnification hereunder.

4




(f)    Notwithstanding anything to the contrary in this Agreement, any amounts for indemnification payable under this Agreement will be paid without duplication and in no event will any Party be indemnified under different provisions of this Agreement for Losses that have already been paid or otherwise taken into account under this Agreement.
(g)    To the extent required by Law, the Indemnified Party shall use commercially reasonable efforts to mitigate any Losses with respect to which it may be entitled to seek indemnification pursuant to this Agreement.
10.6    Exclusive Remedy. The Parties agree that, excluding (a) the remedies provided in Section 2.7 and (b) actions grounded in Fraud, and (c) actions arising under the Transition Services Agreement, from and after the Closing Date, the indemnities provided in this Article X and Section 7.4(h) will constitute the sole and exclusive remedy of any Indemnified Party for damages arising out of, resulting from or incurred in connection with any claims related to this Agreement or arising out of the transactions contemplated hereby; provided, however, that this exclusive remedy for damages does not preclude a Party from bringing an action for specific performance or other equitable remedy pursuant to Section 11.13.
10.7    Materiality. Notwithstanding anything contained herein to the contrary, for purposes of determining the amount of Losses that are the subject matter of a claim for indemnification hereunder, including under Section 7.4(h)(i) (but not for purposes of determining whether there has been a breach of a representation or warranty), each representation and warranty in this Agreement (other than Section 4.14(a)) and the Seller Disclosure Schedule will be read without regard and without giving effect to the terms “material” or “Material Adverse Effect” or similar phrases contained in such representation or warranty which have the effect of making such representation and warranty less restrictive (as if such word or qualification were deleted from such representation and warranty).
ARTICLE XI

MISCELLANEOUS
11.1    Notices. Except as otherwise expressly provided herein, all notices, demands and other communications to be given or delivered under or by reason of the provisions of this Agreement shall be in writing and shall be deemed to have been given (a) when personally delivered, (b) when transmitted by electronic mail (provided that no delivery failure notice is received), (c) the day following the day (except if not a Business Day, then the next Business Day) on which the same has been delivered prepaid to a reputable national overnight air courier service or (d) the third (3rd) Business Day following the day on which the same is sent by certified or registered mail, postage prepaid, in each case to the respective Parties at the address set forth below, or at such other address as such Party may specify by written notice to the other Party hereto:

5




If to Buyer, to:
Smith & Nephew USD Limited
150 Minuteman Road
Andover, MA 01810
Attn: Chief Legal and Compliance Officer
Email: Company.secretary@smith-nephew.com

With a required copy to (which shall not constitute notice):

Jones Day
1420 Peachtree Street, N.E., Suite 800
        Atlanta, GA 30309
Attn: Ken Boehner
Email: kboehner@jonesday.com

If to Parent or any Seller, to:

Integra LifeSciences Holdings Corporation
1100 Campus Road
Princeton, NJ 08540
Attn: Eric Schwartz
Email: eric.schwartz@integralife.com

; and
Integra LifeSciences Holdings Corporation
1100 Campus Road
Princeton, NJ 08540
Attn: Andrea Caruso
Email: andrea.caruso@integralife.com

With a required copy to (which shall not constitute notice):
        
Morgan, Lewis & Bockius LLP
1701 Market Street
Philadelphia, PA 19103-29219
Attn: Benjamin R. Wills
Email: benjamin.wills@morganlewis.com

11.2    Amendments and Waivers.
(a)    Any provision of this Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and is signed, in the case of an amendment, by each Party to this Agreement, or in the case of a waiver, by the Party against whom the waiver is to be effective.





(b)    No failure or delay by any Party in exercising any right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege.
(c)    To the maximum extent permitted by Law, (i) no waiver that may be given by a Party shall be applicable except in the specific instance for which it was given and (ii) no notice to or demand on one Party shall be deemed to be a waiver of any obligation of such Party or the right of the Party giving such notice or demand to take further action without notice or demand.
11.3    Expenses. Each Party shall bear its own costs and expenses in connection with this Agreement, the Ancillary Agreements and the transactions contemplated hereby and thereby, including all legal, accounting, financial advisory, consulting and all other fees and expenses of third parties, whether or not the transactions contemplated by this Agreement are consummated.
11.4    Bulk Sales Act. Buyer hereby waives compliance by Sellers with respect to any applicable “bulk-sale,” “bulk-transfer,” or similar Laws of any jurisdiction in connection with the transfer or sale to Buyer of the Purchased Assets. Buyer agrees not to file the Notice of Sale, Transfer or Assignment in Bulk provided for by New Jersey P.L. 2007, Chapter 100 (commonly referred to as the Bulk Sales Act) in connection with this Agreement.
11.5    Successors and Assigns. This Agreement may not be assigned by any Party hereto without the prior written consent of the other Parties; provided, that prior to the Closing and upon prior written notice to Parent, Buyer may assign to its Buyer Designee(s) its rights hereunder to purchase the ISC Shares, the Ascension Shares or the Purchased Assets, its obligation to assume any Assumed Liabilities, and its rights and obligations with respect to the offer of employment to, and the transfer of employment of, certain Business Employees. Notwithstanding any such assignment, Buyer shall remain liable to Parent for all obligations due to Parent under this Agreement unless and until expressly released by Parent. Subject to the foregoing, all of the terms and provisions of this Agreement shall inure to the benefit of and be binding upon the Parties hereto and their respective executors, heirs, personal representatives, successors and assigns.
11.6    Governing Law. This Agreement shall be governed by and interpreted and enforced in accordance with the Laws of the State of Delaware, without giving effect to any choice of Law or conflict of Laws rules or provisions (whether of the State of Delaware or any other jurisdiction) that would cause the application of the Laws of any jurisdiction other than the State of Delaware.
11.7    Consent to Jurisdiction. Each Party hereto irrevocably submits to the exclusive jurisdiction of the Delaware Court of Chancery and any state appellate court therefrom within the State of Delaware (unless the Delaware Court of Chancery shall decline to accept jurisdiction over a particular matter, in which case, in any Delaware state or federal court within the State of Delaware), for the purposes of any Action arising out of this





Agreement or the Ancillary Agreements or any transaction contemplated hereby or thereby, and agrees to commence any such Action only in such courts. Each Party further agrees that service of any process, summons, notice or document by registered mail to such Party’s respective address set forth herein shall be effective service of process for any such Action. Each Party irrevocably and unconditionally waives any objection to the laying of venue of any Action arising out of this Agreement, the Ancillary Agreements or the transactions contemplated hereby or thereby in such courts, and hereby irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such Action brought in any such court has been brought in an inconvenient forum. EACH PARTY HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE ANCILLARY AGREEMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY AND THEREBY OR THE ACTIONS OF SUCH PARTY IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT HEREOF AND THEREOF.
11.8    Counterparts. This Agreement and any amendments hereto may be executed in counterparts, including by electronic transmission in .pdf format, each of which shall be deemed to be an original, but all of which shall be considered one and the same instrument.
11.9    Third Party Beneficiaries. No provision of this Agreement is intended to confer upon any Person other than the Parties hereto any rights or remedies hereunder, other than the Persons entitled to indemnification pursuant to Section 7.4(h) and Article X.
11.10    Entire Agreement. This Agreement, the Ancillary Agreements, the Schedules, the Seller Disclosure Schedule and the Exhibits, documents, instruments and agreements specifically referred to herein or therein or delivered pursuant hereto or thereto set forth the entire understanding of the Parties hereto with respect to the transactions contemplated by this Agreement. All Schedules and Exhibits referred to herein are intended to be and hereby are specifically made a part of this Agreement. Any and all previous agreements and understandings between or among the Parties regarding the subject matter hereof, whether written or oral, are superseded by this Agreement, except for the Confidentiality Agreement which shall continue in effect to the extent provided by Section 7.11.
11.11    Captions. All captions contained in this Agreement are for convenience of reference only, do not form a part of this Agreement and shall not affect in any way the meaning or interpretation of this Agreement.
11.12    Severability. Any provision of this Agreement which is invalid or unenforceable in any jurisdiction shall be ineffective to the extent of such invalidity or unenforceability without invalidating or rendering unenforceable the remaining provisions hereof, and any such invalidity or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.





11.13    Specific Performance. The Parties agree that irreparable damage would occur if any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached or threatened to be breached and that an award of money damages would be inadequate in such event. Accordingly, it is acknowledged that the Parties shall be entitled to equitable relief, without proof of actual damages, including an Order for specific performance to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, in addition to any other remedy to which they are entitled at law or in equity as a remedy for any such breach or threatened breach. Each Party further agrees that neither the other Party nor any other Person shall be required to obtain, furnish or post any bond or similar instrument in connection with or as a condition to obtaining any remedy referred to in this Section 11.13, and each Party hereto irrevocably waives any right it may have to require the obtaining, furnishing or posting of any such bond or similar instrument. Each Party further agrees that the only permitted objection that it may raise in response to any action for equitable relief is that it contests the existence of a breach or threatened breach of this Agreement.
11.14    Disclosure Schedule. The Seller Disclosure Schedule, Schedules and Exhibits attached to this Agreement shall be construed with and as an integral part of this Agreement to the same extent as if the same had been set forth verbatim herein. Any capitalized terms used in any Exhibit or Schedule or in the Seller Disclosure Schedule but not otherwise defined therein shall be defined as set forth in this Agreement. The Seller Disclosure Schedule has been arranged for purposes of convenience in separately titled Sections corresponding to the Sections of this Agreement, however, each Section of the Seller Disclosure Schedule shall be deemed to incorporate by reference all information disclosed in any other Section of the Seller Disclosure Schedule to the extent it is reasonably apparent on the face of such information that the disclosure of such matter is applicable to such other Section of the Seller Disclosure Schedule. The inclusion of information in the Seller Disclosure Schedule shall not be construed as an admission that such information is material to any of members of the Seller Group. In addition, matters reflected in the Seller Disclosure Schedule are not necessarily limited to matters required by this Agreement to be reflected in the Seller Disclosure Schedule. Such additional matters are set forth for informational purposes only and do not necessarily include other matters of a similar nature. Neither the specifications of any dollar amount in any representation, warranty or covenant contained in this Agreement nor the inclusion of any specific item in the Seller Disclosure Schedule is intended to imply that such amount, or higher or lower amounts, or the item so included or other items, are or are not material, and no Party shall use the fact of the setting forth of any such amount or the inclusion of any such item in any dispute or controversy between the parties as to whether any obligation, item or matter not described herein or included in the Seller Disclosure Schedule is or is not material for purposes of this Agreement. Further, neither the specification of any item or matter in any representation, warranty or covenant contained in this Agreement nor the inclusion of any specific item in the Seller Disclosure Schedule is intended to imply that such item or matter, or other items or matters, are or are not in the ordinary course of business, and no Party shall use the fact of setting forth or the inclusion of any such items or matter in any dispute or controversy between the Parties as to whether any obligation, item or matter not described herein or included in the





Seller Disclosure Schedule is or is not in the ordinary course of business for purposes of this Agreement.
11.15    Interpretation.
(a)    The meaning assigned to each term defined herein shall be equally applicable to both the singular and the plural forms of such term and vice versa, and words denoting either gender shall include both genders as the context requires. Where a word or phrase is defined herein, each of its other grammatical forms shall have a corresponding meaning.
(b)    The terms “hereof,” “herein” and “herewith” and words of similar import shall, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular provision of this Agreement.
(c)    When a reference is made in this Agreement to an Article, Section, paragraph, Exhibit or Schedule, such reference is to an Article, Section, paragraph, Exhibit or Schedule to this Agreement unless otherwise specified.
(d)    The word “include,” “includes,” and “including” when used in this Agreement shall be deemed to be followed by the words “without limitation,” unless otherwise specified. As used herein, the word “or” is not exclusive and will be interpreted to mean and/or.
(e)    A reference to any Party to this Agreement or any other agreement or document shall include such Party’s predecessors, successors and permitted assigns.
(f)    Reference to any Law means such Law as amended, modified, codified, replaced or reenacted, and all rules and regulations promulgated thereunder.
(g)    The Parties have participated jointly in the negotiation and drafting of this Agreement and the Ancillary Agreements. Any rule of construction or interpretation otherwise requiring this Agreement or the Ancillary Agreements to be construed or interpreted against any Party by virtue of the authorship of this Agreement or the Ancillary Agreements shall not apply to the construction and interpretation hereof and thereof.
(h)    All accounting terms used and not defined herein shall have the respective meanings given to them under GAAP.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]





IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized officers as of the date first above written.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION


By: _______________________
Name:
Title:

INTEGRA LIFESCIENCES SERVICES (FRANCE) SAS


By: _______________________
Name:
Title:

NEWDEAL SAS

By: _______________________
Name:
Title:






IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized officers as of the date first above written.


SMITH & NEPHEW USD LIMITED


By: _______________________
Name:
Title:






EX-31.1 3 iart-20200930xexx311.htm EXHIBIT 31.1 Exhibit
Exhibit 31.1
Certification of Principal Executive Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Peter J. Arduini, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Integra LifeSciences Holdings Corporation;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
(a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
Date:
October 29, 2020
/s/ Peter J. Arduini
 
 
Peter J. Arduini
 
 
President and Chief Executive Officer


EX-31.2 4 iart-20200930xexx312.htm EXHIBIT 31.2 Exhibit
Exhibit 31.2
Certification of Principal Financial Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Carrie L. Anderson, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Integra LifeSciences Holdings Corporation;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
(a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:
October 29, 2020
/s/ Carrie L. Anderson
 
 
Carrie L. Anderson
 
 
Executive Vice President and Chief Financial Officer


EX-32.1 5 iart-20200930xexx321.htm EXHIBIT 32.1 Exhibit
Exhibit 32.1
Certification of Principal Executive Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
I, Peter J. Arduini, President and Chief Executive Officer of Integra LifeSciences Holdings Corporation (the “Company”), hereby certify that, to my knowledge:
1.
The Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2020 (the “Report”) fully complies with the requirement of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:
October 29, 2020
/s/ Peter J. Arduini
 
 
Peter J. Arduini
 
 
President and Chief Executive Officer


EX-32.2 6 iart-20200930xexx322.htm EXHIBIT 32.2 Exhibit
Exhibit 32.2
Certification of Principal Financial Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
I, Carrie L. Anderson, Corporate Vice President and Chief Financial Officer of Integra LifeSciences Holdings Corporation (the “Company”), hereby certify that, to my knowledge:
1.
The Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2020 (the “Report”) fully complies with the requirement of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:
October 29, 2020
/s/ Carrie L. Anderson
 
 
Carrie L. Anderson
 
 
Executive Vice President and Chief Financial Officer


EX-101.SCH 7 iart-20200930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2102100 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE - Assets and Liabilities Held For Sale (Details) link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - BASIS OF PRESENTATION (Policies) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - BUSINESS DEVELOPMENT link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - BUSINESS DEVELOPMENT - Asset Acquisition, Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - BUSINESS DEVELOPMENT - Business Combination, Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - BUSINESS DEVELOPMENT - Business Combination, Schedule of Purchase Price Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - BUSINESS DEVELOPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - COMMITMENTS AND CONTINGENCIES - Fair Value Contingent Consideration, Balance Information (Details) link:presentationLink link:calculationLink link:definitionLink 2417403 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 2415404 - Disclosure - COMPREHENSIVE INCOME (LOSS) - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - COMPREHENSIVE INCOME (LOSS) - Schedule of Changes in Accumulated Other Comprehensive Income by Component (Details) link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - COMPREHENSIVE INCOME (LOSS) - Schedule of Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - COMPREHENSIVE INCOME (LOSS) (Tables) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1002501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDER'S EQUITY (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1004001 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDER'S EQUITY (UNAUDITED) (PARENTHETICAL) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME / (LOSS) (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - DEBT - Contractual Maturity Table (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - DEBT - Maximum Total Leverage Ratio Table (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - DEBT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - DERIVATIVE INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 2408407 - Disclosure - DERIVATIVE INSTRUMENTS - Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 2408406 - Disclosure - DERIVATIVE INSTRUMENTS - Fair Value of Derivative Instruments By Balance Sheet Location (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - DERIVATIVE INSTRUMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Cross Currency Swap Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 2408405 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Net Investment Hedges Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - DERIVATIVE INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - DOCUMENT AND ENTITY INFORMATION link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Components of Company's Identifiable Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2413403 - Disclosure - INCOME TAXES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - INCOME TAXES - Summary of Effective Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - INVENTORIES - Schedule of Net Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - LEASES AND RELATED PARTY LEASES link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases, After Adoption of 842 (Details) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases, After Adoption of 842 (Details) link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - LEASES AND RELATED PARTY LEASES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - LEASES AND RELATED PARTY LEASES - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - LEASES AND RELATED PARTY LEASES - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - LEASES AND RELATED PARTY LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - NET INCOME (LOSS) PER SHARE link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - NET INCOME (LOSS) PER SHARE - Basic and Diluted Net Income Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - NET INCOME (LOSS) PER SHARE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - RETIREMENT PLANS link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - RETIREMENT PLANS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative, Revenue Remaining Performance Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Changes in Contract Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2404405 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Revenues Disaggregated by Major Source (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Net Sales and Profit by Reportable Segment (Details) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2416404 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Total Revenue by Major Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 2409401 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - TREASURY STOCK link:presentationLink link:calculationLink link:definitionLink 2412401 - Disclosure - TREASURY STOCK - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 iart-20200930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 iart-20200930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 iart-20200930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Share-based Payment Arrangement [Abstract] STOCK-BASED COMPENSATION Share-based Payment Arrangement [Text Block] Treasury Stock Transactions, Excluding Value of Shares Reissued [Abstract] Class of Treasury Stock [Table] Class of Treasury Stock [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Convertible Debt Convertible Debt [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Certain Purchasers Certain Purchasers [Member] Certain Purchasers [Member] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Treasury stock (in shares) Treasury Stock, Common, Shares Treasury stock Treasury Stock, Common, Value Treasury stock, average cost per share (in dollars per share) Treasury Stock Acquired, Average Cost Per Share Stock repurchase program, authorized amount (up to) Stock Repurchase Program, Authorized Amount Stock repurchased during period (in shares) Stock Repurchased During Period, Shares Net proceeds from offering of convertible senior notes Proceeds from Convertible Debt Accelerated share repurchase program, payment Accelerated Share Repurchases, Settlement (Payment) or Receipt Accelerated shares repurchased, amount Stock Repurchased During Period, Value Accelerated share repurchases, percentage of expected total repurchased Accelerated Share Repurchases, Percentage Of Expected Total Repurchased Accelerated Share Repurchases, Percentage Of Expected Total Repurchased Remaining amount under share repurchase Stock Repurchase Program, Remaining Authorized Repurchase Amount Leases [Abstract] Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Related Parties Related Parties [Member] Related Parties [Member] Third Parties Third Parties [Member] Third Parties [Member] Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] 2020 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year 2021 Lessee, Operating Lease, Liability, to be Paid, Year One 2022 Lessee, Operating Lease, Liability, to be Paid, Year Two 2023 Lessee, Operating Lease, Liability, to be Paid, Year Three 2024 Lessee, Operating Lease, Liability, to be Paid, Year Four Thereafter Lessee, Operating Lease, Liability, To Be Paid, After Year Four Lessee, Operating Lease, Liability, To Be Paid, After Year Four Total minimum lease payments Lessee, Operating Lease, Liability, to be Paid Less: Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Total lease liabilities Operating Lease, Liability Less: Current lease liabilities Operating Lease, Liability, Current Long-term lease liabilities Operating Lease, Liability, Noncurrent Segment Reporting [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] United States UNITED STATES Europe Europe [Member] Asia Pacific Asia Pacific [Member] Rest of World Rest Of World [Member] Revenues from rest of the world. Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Total Revenues Revenue from Contract with Customer, Excluding Assessed Tax Goodwill and Intangible Assets Disclosure [Abstract] Goodwill, impairment Goodwill, Impairment Loss Intangible assets, indefinite lives, discount rate Intangible Assets, Indefinite Life, Discount Rate, Percentage Intangible Assets, Indefinite Life, Discount Rate, Percentage Intangible assets, indefinite lives, impairment Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Expected annual amortization expense, remainder of 2020 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Expected annual amortization expense, in 2021 Finite-Lived Intangible Asset, Expected Amortization, Year One Expected annual amortization expense, in 2022 Finite-Lived Intangible Asset, Expected Amortization, Year Two Expected annual amortization expense, in 2023 Finite-Lived Intangible Asset, Expected Amortization, Year Three Expected annual amortization expense, in 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Four Expected annual amortization expense, in 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Five Expected annual amortization expense, thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Income Statement [Abstract] Total revenue, net Costs and expenses: Costs and Expenses [Abstract] Cost of goods sold Cost of Goods and Services Sold Research and development Research and Development Expense (Excluding Acquired in Process Cost) In-process research and development Research and Development in Process Selling, general and administrative Selling, General and Administrative Expense Intangible asset amortization Amortization of Intangible Assets Total costs and expenses Costs and Expenses Operating income (loss) Operating Income (Loss) Interest income Investment Income, Interest Interest expense Interest Expense Other income, net Other Nonoperating Income (Expense) Income (loss) before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Provision (benefit) for income taxes Income Tax Expense (Benefit) Net income (loss) Net Income (Loss) Attributable to Parent Net income (loss) per share Earnings Per Share [Abstract] Basic (in dollars per share) Earnings Per Share, Basic Diluted (in dollars per share) Earnings Per Share, Diluted Weighted average common shares outstanding (See Note 14): Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Comprehensive income (loss) (See Note 15) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Equity [Abstract] Schedule of Comprehensive Income (Loss) Comprehensive Income (Loss) [Table Text Block] Schedule of Changes in Accumulated Other Comprehensive Loss by Component Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Senior Credit Facility Senior Credit Facility [Member] Senior Credit Facility. Term Loan Facility Term Loan Facility [Member] Term Loan Facility [Member] 2025 Notes Two Thousand Twenty Five Senior Convertible Notes [Member] Two Thousand Twenty Five Senior Convertible Notes [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Secured Debt Secured Debt [Member] Revolving Credit Facility Revolving Credit Facility [Member] Standby Letters of Credit Standby Letters of Credit [Member] Swingline Loans Swingline Loan [Member] Swingline Loan [Member] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Eurodollar Eurodollar [Member] Overnight Federal Funds Fed Funds Effective Rate Overnight Index Swap Rate [Member] One Month Eurodollar Rate One Month Eurodollar Rate [Member] One Month Eurodollar Rate [Member] Option Indexed to Issuer's Equity [Axis] Option Indexed to Issuer's Equity [Axis] Option Indexed to Issuer's Equity, Type [Domain] Option Indexed to Issuer's Equity, Type [Domain] Call Option Call Option [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Maximum consolidated total leverage ratio Debt Instrument, Covenant, Maximum Leverage Ratio Debt Instrument, Covenant, Maximum Leverage Ratio Interest rates available Debt Instrument, Basis Spread on Variable Rate Line of credit, commitment fee percentage Line of Credit Facility, Commitment Fee Percentage Incremental financing costs capitalized Debt Issuance Costs, Gross Previously capitalized financing costs, written-off Write off of Deferred Debt Issuance Cost Incremental financing cost expense Amortization of Debt Issuance Costs Line of credit facility outstanding Long-term Line of Credit Weighted average interest rate on debt Debt, Weighted Average Interest Rate Term loan component of senior credit facility Secured Debt, Current Line of credit facility, fair value of amount outstanding Line of Credit Facility, Fair Value of Amount Outstanding Letters of credit outstanding Letters of Credit Outstanding, Amount Convertible notes, maximum borrowing capacity Debt Instrument, Face Amount Convertible notes, interest rate Debt Instrument, Interest Rate, Stated Percentage Debt proceeds, classified as equity at time of offering Debt Instrument, Convertible, Carrying Amount of Equity Component Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Carrying amount, liability component Convertible Debt, Noncurrent Unamortized discount Debt Instrument, Unamortized Discount Fair value Debt Instrument, Fair Value Disclosure Initial conversion rate Debt Instrument, Convertible, Conversion Ratio Initial conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Maximum selling price of the company's common stock of the conversion price Debt Instrument, Maximum Selling Price Of Common Stock Of The Conversion Price During Period Debt Instrument, Maximum Selling Price Of Common Stock Of The Conversion Price During Period Maximum average conversion value of notes Debt Instrument, Maximum Average Conversion Value Of Notes Debt Instrument, Maximum Average Conversion Value Of Notes Redemption price, percentage Debt Instrument, Redemption Price, Percentage Cost of call transactions Payments For Option Index To Issuers Equity Payments For Options Indexed to Issuer's Equity Proceeds from warrant transactions Proceeds from Issuance of Warrants Initial strike price (in dollars per share) Option Indexed to Issuer's Equity, Strike Price Warrant strike price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Cash interest Interest Expense, Debt, Excluding Amortization Amortization of discount Amortization of Debt Discount (Premium) Interest expense Interest Expense, Debt Securitization program outstanding borrowings, maximum limit Transferor's Interests In Transferred Financial Assets, Maximum Investment Limit Transferor's Interests In Transferred Financial Assets, Maximum Investment Limit Securitization program, term Debt, Accounts Receivable Securitization, Term Debt, Accounts Receivable Securitization, Term Long-term borrowings under securitization facility Secured Long-Term Debt, Securitization Program, Noncurrent Secured Long-Term Debt, Securitization Program, Noncurrent Weighted average interest rate, accounts receivable securitization revolving loan facility Debt, Weighted Average Interest Rate, From Securitization Debt, Weighted Average Interest Rate, From Securitization Securitization facility, outstanding borrowings, fair value Securitization Facility, Fair Value Of Amount Outstanding Securitization Facility, Fair Value Of Amount Outstanding Revenue from Contract with Customer [Abstract] Revenue, Initial Application Period Cumulative Effect Transition [Table] Revenue, Initial Application Period Cumulative Effect Transition [Table] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Manufacturing period for products shipped with no alternative use and right of payment for performance Revenue From Contract With Customer, Products Shipped With No Alternative Use And Right Of Payment For Performance, Manufacturing Period Revenue From Contract With Customer, Products Shipped With No Alternative Use And Right Of Payment For Performance, Manufacturing Period Number of days from shipment to issue a credit Return Policy, Issue Of Credit, Number Of Days From Shipment Return Policy, Issue of Credit, Number of Days from Shipment Short-term portion of contract liability Contract with Customer, Liability, Current Long-term portion of contract liability Contract with Customer, Liability, Noncurrent Product warranty period (up to) Revenue, Product Warranty Period Revenue, Product Warranty Period Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] Codman Specialty Surgical Codman Specialty Surgical [Member] Codman Specialty Surgical [Member] Orthopedics and Tissue Technologies Orthopedics and Tissue Technologies [Member] Orthopedics and Tissue Technologies [Member] Consolidation Items [Axis] Consolidation Items [Axis] Operating Activities [Domain] Consolidation Items [Domain] Operating Segments Operating Segments [Member] Corporate and other Corporate, Non-Segment [Member] Segment Net Sales Segment Reporting Information, Operating Income (Loss) [Abstract] Segment Profit Segment Reporting Information, Profit (Loss) [Abstract] Operating income Amortization TREASURY STOCK Treasury Stock [Text Block] Business Combinations [Abstract] Schedule of Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Income Tax Disclosure [Abstract] INCOME TAXES Income Tax Disclosure [Text Block] Statement of Financial Position [Abstract] Trade accounts receivable, allowance Accounts Receivable, Allowance for Credit Loss, Current Preferred stock, authorized shares (in shares) Preferred Stock, Shares Authorized Preferred stock, outstanding shares (in shares) Preferred Stock, Shares Outstanding Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, authorized shares (in shares) Common Stock, Shares Authorized Common stock, issued shares (in shares) Common Stock, Shares, Issued Treasury stock, shares (in shares) Treasury Stock, Shares Derivative Instruments and Hedging Activities Disclosure [Abstract] Schedule of Derivative Instruments Schedule of Derivative Instruments [Table Text Block] Schedule of Fair Value and Presentation of Derivatives Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Effect of Derivative Instruments Designated as Cash Flow Hedges on Statements of Operations Derivative Instruments, Gain (Loss) [Table Text Block] Retirement Benefits [Abstract] Net periodic benefit costs Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Service cost component Defined Benefit Plan, Service Cost Estimated fair value of plan assets Defined Benefit Plan, Plan Assets, Amount Defer payment and taxation, base salary, percentage (up to) Defined Benefit Plan, Defer Payment And Taxation, Base Salary, Percentage Defined Benefit Plan, Defer Payment And Taxation, Base Salary, Percentage Defer payment and taxation, bonus and other eligible cash compensation, percentage (up to) Defined Benefit Plan, Defer Payment And Taxation, Bonus And Other Compensation, Percentage Defined Benefit Plan, Defer Payment And Taxation, Bonus And Other Compensation, Percentage Deferred compensation plan, fair value of assets Deferred Compensation Plan Assets Schedule of Net Sales and Profit by Segments Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of Geographic Revenue by Area Schedule of Changes in Contract Assets and Contract Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Schedule Of Asset Acquisition [Table] Schedule Of Asset Acquisition [Table] Schedule Of Asset Acquisition [Table] Asset Acquisition [Axis] Asset Acquisition [Axis] Asset Acquisition [Axis] Asset Acquisition [Domain] Asset Acquisition [Domain] [Domain] for Asset Acquisition [Axis] Rebound Rebound Therapeutics Corporation [Member] Rebound Therapeutics Corporation [Member] ISC Integrated Shoulder Collaboration, Inc. [Member] Integrated Shoulder Collaboration, Inc. [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] In-Process Research and Development Expense In Process Research and Development [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Cash and Cash Equivalents Cash and Cash Equivalents [Member] Deferred Tax Asset Deferred Tax Asset [Member] Deferred Tax Asset [Member] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Enabling technology license Licensing Agreements [Member] Consortium of Focused Orthopedists, LLC Consortium of Focused Orthopedists, LLC [Member] Consortium of Focused Orthopedists, LLC [Member] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Disposal Group, Disposed of by Sale, Not Discontinued Operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Scenario [Axis] Scenario [Axis] Scenario [Domain] Scenario [Domain] Forecast Forecast [Member] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] Smith & Nephew USD Limited Smith & Nephew USD Limited [Member] Smith & Nephew USD Limited [Member] Schedule Of Asset Acquisition [Line Items] Schedule Of Asset Acquisition [Line Items] [Line Items] for Schedule Of Asset Acquisition [Table] Upfront payment Asset Acquisition, Consideration Transferred Asset Acquisition, Consideration Transferred Contingent development milestone payments commitment (up to) Asset Acquisition, Maximum Contingent Development Milestone Payments, If Circumstances Met Asset Acquisition, Maximum Contingent Development Milestone Payments Number of assets acquired Asset Acquisition, Number Of Assets Acquired Asset Acquisition, Number Of Assets Acquired Remaining net assets acquired Asset Acquisition, Assets Acquired And Liabilities Assumed, Net Asset Acquisition, Assets Acquired And Liabilities Assumed, Net Development milestone Asset Acquisition, Development Milestone Payment To Be Paid Asset Acquisition, Development Milestone Payment Upfront payment, intangible assets Payments to Acquire Intangible Assets Option to acquire, period subsequent to first commercial sale Asset Acquisition, Option To Acquire, Period Subsequent To Commercial Sale, If Circumstances Met Asset Acquisition, Option To Acquire, Period Subsequent To Commercial Sale, If Circumstances Met Maximum future purchase price, if circumstances met (not to exceed) Asset Acquisition, Maximum Future Consideration Transferred, If Circumstances Met Asset Acquisition, Maximum Future Consideration Transferred, If Circumstances Met Research and development Research and Development Expense Sale of Extremity Orthopedics business, product development payment Disposal Group, Including Discontinued Operation, Payment Related To Product Development Disposal Group, Including Discontinued Operation, Payment Related To Product Development Schedule of Long-term Debt Maximum Leverage Ratios Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Contractual Repayments of Long-Term Debt Schedule of Maturities of Long-term Debt [Table Text Block] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Treasury Stock Treasury Stock [Member] Additional Paid-In Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Retained Earnings Retained Earnings [Member] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance Beginning of Period, Shares (in shares) Shares, Issued Balance, Beginning of Period Stockholders' Equity Attributable to Parent Balance, Beginning of Period, Treasury Stock, Shares (in shares) Net income (loss) Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Issuance of common stock through employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common stock through employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock for vesting of share based awards, net of shares withheld for taxes (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Issuance of common stock for vesting of share based awards, net of shares withheld for taxes Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Share-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Share repurchase and equity component of the convertible note issuance, net (in shares) Stock Issued During Period, Shares, Treasury Stock Reissued Share repurchase and equity component of the convertible note issuance, net Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt Accelerated shares repurchased (in shares) Accelerated shares repurchased Balance End of Period, Shares (in shares) Balance, End of Period Balance, End of Period, Treasury Stock, Shares (in shares) Discontinued Operations and Disposal Groups [Abstract] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Sale of Extremity Orthopedics business, disposition price Disposal Group, Including Discontinued Operation, Consideration Statement of Cash Flows [Abstract] OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Net income Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Other Depreciation and Amortization Non-cash in-process research and development expense Noncash Or Part Noncash, In Process Research And Development Noncash Or Part Noncash, In Process Research And Development Non-cash impairment charges Impairment of Intangible Assets, Finite-lived Income tax expense (benefit) Deferred Income Tax Expense (Benefit) Share-based compensation Share-based Payment Arrangement, Noncash Expense Amortization of debt issuance costs and expenses associated with debt refinancing Amortization Of Debt Issuance Costs And Debt Refinanced Fees Amortization Of Debt Issuance Costs And Debt Refinanced Fees Non-cash lease expense Operating Lease, Right-of-Use Asset, Amortization Expense Accretion of bond issuance discount Accretion Expense Loss on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Change in fair value of contingent consideration and others Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Changes in assets and liabilities: Changes In Assets And Liabilities [Abstract] Changes In Assets And Liabilities [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Other non-current assets Increase (Decrease) in Other Operating Assets Accounts payable, accrued expenses and other current liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Contract liabilities Increase (Decrease) in Contract with Customer, Liability Other non-current liabilities Increase (Decrease) in Other Noncurrent Liabilities Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Acquired in-process research and development milestone Payments To Acquire In Process Research And Development Milestone Payments To Acquire In Process Research And Development Milestone Proceeds from note receivable Proceeds from Collection of Notes Receivable Proceeds from sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment Cash (paid) provided for business acquisitions, net of cash acquired Payments For (Proceeds From) Business Acquisitions Payments For (Proceeds From) Business Acquisitions Acquired in-process research and development Payments to Acquire in Process Research and Development Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from borrowings of long-term indebtedness Proceeds from Issuance of Secured Debt Payments on debt Repayments of Secured Debt Purchase of option hedge on convertible notes Proceeds from convertible notes issuance Proceeds from sale of stock purchase warrants Payment of debt issuance costs Payments of Debt Issuance Costs Purchases of treasury stock Payments for Repurchase of Common Stock Proceeds from exercised stock options Proceeds from Stock Options Exercised Cash taxes paid in net equity settlement Payment, Tax Withholding, Share-based Payment Arrangement Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash and cash equivalents at beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents at end of period REVENUES FROM CONTRACTS WITH CUSTOMERS Revenue from Contract with Customer [Text Block] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Other income (expense) Other Expense [Member] Interest income Interest Income [Member] Gains and Losses on Derivatives Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Loss reclassified from accumulated other comprehensive loss Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent SEGMENT AND GEOGRAPHIC INFORMATION Segment Reporting Disclosure [Text Block] Schedule of Fair Values of Assets and Liabilities Held For Sale Disposal Groups, Including Discontinued Operations [Table Text Block] Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Derivative [Table] Derivative [Table] Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Cash Flow Hedges Cash Flow Hedging [Member] Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] Swap One Swap One [Member] Swap One [Member] Swap Two Swap Two [Member] Swap Two [Member] Swap Three Swap Three [Member] Swap Three [Member] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Codman Codman [Member] Codman [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Cross-currency swap Cross Currency Interest Rate Contract [Member] Position [Axis] Position [Axis] Position [Domain] Position [Domain] Long Long [Member] Short Short [Member] Derivative [Line Items] Derivative [Line Items] Fixed Rate Derivative, Fixed Interest Rate Aggregate Notional Amount Derivative, Notional Amount Fair Value Asset (Liability) Derivative, Fair Value, Net Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Affiliated Entity Affiliated Entity [Member] Property Subject to or Available for Operating Lease [Axis] Property Subject to or Available for Operating Lease [Axis] Property Subject to or Available for Operating Lease [Domain] Property Subject to or Available for Operating Lease [Domain] Five Year Option Lease From November 1, 2029 Through October 31, 2034 Five Year Option Lease Period One [Member] Five-Year Option Lease Period One Five Year Option Lease From November 1, 2034 Through October 31, 2039 Five Year Option Lease Period Two [Member] Five-Year Option Lease Period Two Number of renewal options (or more) Lessee, Operating Lease, Number Of Renewal Options Lessee, Operating Lease, Number Of Renewal Options Operating lease expense Operating Lease, Expense Percent of manufacturing facility owned by corporation whose shareholders are trusts whose beneficiaries include family members of company's former director Percent Of Manufacturing Facility Owned By Corporation Whose Shareholders Are Trusts, Whose Beneficiaries Include Family Members Of Company's Former Director Percent Of Manufacturing Facility Owned By Corporation Whose Shareholders Are Trusts, Whose Beneficiaries Include Family Members Of Company's Former Director Annual rate of lease agreement Annual Rate Of Lease Agreement Annual rate of lease agreement. Option to extend lease, years Option To Extend Lease, Years Option to extend lease, years. Period for extended lease Lessee, Operating Lease, Option to Extend DEBT Debt Disclosure [Text Block] Contract Asset Change In Contract With Customer, Asset [Roll Forward] Change In Contract With Customer, Asset [Roll Forward] Contract asset, Beginning of period Contract with Customer, Asset, after Allowance for Credit Loss Transferred to trade receivable of contract asset included in beginning of the year contract asset Contract with Customer, Asset, Reclassified to Receivable Contract asset, net of transferred to trade receivables on contracts during the period Contract With Customer, Asset, Net Of Reclassified To Receivable Contract With Customer, Asset, Net Of Reclassified To Receivable Contract asset, End of Period Contract Liability Change In Contract With Customer, Liability [Roll Forward] Change In Contract With Customer, Liability [Roll Forward] Contract liability, Beginning of Period Contract with Customer, Liability Recognition of revenue included in beginning of year contract liability Contract with Customer, Liability, Revenue Recognized Contract liability, net of revenue recognized on contracts during the period Contract with Customer, Liability, Net Of Revenue Recognized Contract with Customer, Liability, Net Of Revenue Recognized Foreign currency translation Contract With Customer, Liability, Increase (Decrease) From Foreign Currency Translation Contract With Customer, Liability, Increase (Decrease) From Foreign Currency Translation Contract liability, End of Period Prepaid and other current assets Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current Other assets Disposal Group, Including Discontinued Operation, Other Assets Deferred tax assets Disposal Group, Including Discontinued Operation, Deferred Tax Assets Intangible assets Disposal Group, Including Discontinued Operation, Intangible Assets Property, plant and equipment, net Disposal Group, Including Discontinued Operation, Property, Plant and Equipment Goodwill Disposal Group, Including Discontinued Operation, Goodwill Inventories Disposal Group, Including Discontinued Operation, Inventory Total assets held for sale Disposal Group, Including Discontinued Operation, Assets Other liabilities Disposal Group, Including Discontinued Operation, Other Liabilities Current portion of lease liability - operating leases Disposal Group, Including Discontinued Operation, Operating Lease, Liability, Current Disposal Group, Including Discontinued Operation, Operating Lease, Liability, Current Accrued compensation Disposal Group, Including Discontinued Operation, Accrued Compensation Disposal Group, Including Discontinued Operation, Accrued Compensation Deferred tax liabilities Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities Lease liability - operating leases Disposal Group, Including Discontinued Operation, Operating Lease, Liability, Noncurrent Disposal Group, Including Discontinued Operation, Operating Lease, Liability, Noncurrent Total liabilities held for sale Disposal Group, Including Discontinued Operation, Liabilities Basic net income (loss) per share: Earnings Per Share, Basic [Abstract] Weighted average common shares outstanding - Basic (in shares) Basic net income (loss) per common share (in dollars per share) Diluted net income (loss) per share: Earnings Per Share, Diluted [Abstract] Effect of dilutive securities: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Stock options and restricted stock (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Weighted average common shares for diluted earnings per share (in shares) Diluted net income (loss) per common share (in dollars per share) ASSETS AND LIABILITIES HELD FOR SALE Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Net Investment Hedges Net Investment Hedging [Member] Cross Currency Interest Rate Swap One Cross Currency Interest Rate Contract One [Member] Cross Currency Interest Rate Contract One [Member] Cross Currency Interest Rate Swap Two Cross Currency Interest Rate Contract Two [Member] Cross Currency Interest Rate Contract Two [Member] Cross Currency Interest Rate Swap Three Cross Currency Interest Rate Contract Three [Member] Cross Currency Interest Rate Contract Three [Member] Cross Currency Interest Rate Swap Four Cross Currency Interest Rate Contract Four [Member] Cross Currency Interest Rate Contract Four [Member] Cross Currency Interest Rate Swap Five Cross Currency Interest Rate Contract Five [Member] Cross Currency Interest Rate Contract Five [Member] Cross Currency Interest Rate Swap Accounting Standards Update [Extensible List] Accounting Standards Update [Extensible List] Current notional amount Gain (loss) recorded in other income, net Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Gain (loss) recorded in AOCL, change in fair value Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Gain reclassified into other income Gain (Loss) on Derivative Instruments, Net, Pretax Gain expected to be reclassified to earnings in the next twelve months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Gain (loss) recorded, net investment hedge, change in fair value Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax 3-Month USD LIBOR Three Month USD LIBOR [Member] Three Month USD LIBOR [Member] 1-Month USD LIBOR One Month USD LIBOR [Member] One Month USD LIBOR [Member] Interest Rate Swap Designated February 6, 2017 Tranche 1 Interest Rate Swap Designated February 6, 2017 Tranche 1 [Member] Interest Rate Swap Designated February 6, 2017 Tranche 1 [Member] Interest Rate Swap Designated February 6, 2017 Tranche 2 Interest Rate Swap Designated February 6, 2017 Tranche 2 [Member] Interest Rate Swap Designated February 6, 2017 Tranche 2 [Member] Interest Rate Swap Designated March 27, 2017 Interest Rate Swap Designated March 27, 2017 [Member] Interest Rate Swap Designated March 27, 2017 [Member] Interest Rate Swap Designated December 13, 2017 Tranche 1 Interest Rate Swap Designated December 13, 2017 Tranche 1 [Member] Interest Rate Swap Designated December 13, 2017 Tranche 1 [Member] Interest Rate Swap Designated December 13, 2017 Tranche 2 Interest Rate Swap Designated December 13, 2017 Tranche 2 [Member] Interest Rate Swap Designated December 13, 2017 Tranche 2 [Member] Interest Rate Swap Designated December 13, 2017 Tranche 3 Interest Rate Swap Designated December 13, 2017 Tranche 3 [Member] Interest Rate Swap Designated December 13, 2017 Tranche 3 [Member] Interest Rate Swap Designated December 13, 2017 Tranche 4 Interest Rate Swap Designated December 13, 2017 Tranche 4 [Member] Interest Rate Swap Designated December 13, 2017 Tranche 4 [Member] Interest Rate Swap Designated December 13, 2017 Tranche 5 Interest Rate Swap Designated December 13, 2017 Tranche 5 [Member] Interest Rate Swap Designated December 13, 2017 Tranche 5 [Member] Interest Rate Swap Designated October 10, 2018 Tranche 1 Interest Rate Swap Designated October 10, 2018 Tranche 1 [Member] Interest Rate Swap Designated October 10, 2018 Tranche 1 [Member] Interest Rate Swap Designated October 10, 2018 Tranche 2 Interest Rate Swap Designated October 10, 2018 Tranche 2 [Member] Interest Rate Swap Designated October 10, 2018 Tranche 2 [Member] Interest Rate Swap Designated October 10, 2018 Tranche 3 Interest Rate Swap Designated October 10, 2018 Tranche 3 [Member] Interest Rate Swap Designated October 10, 2018 Tranche 3 [Member] Interest Rate Swap Designated December 18, 2018 Tranche 1 Interest Rate Swap Designated December 18, 2018 Tranche 1 [Member] Interest Rate Swap Designated December 18, 2018 Tranche 1 [Member] Interest Rate Swap Designated December 18, 2018 Tranche 2 Interest Rate Swap Designated December 18, 2018 Tranche 2 [Member] Interest Rate Swap Designated December 18, 2018 Tranche 2 [Member] Notional Amount Fixed Interest Rate Estimated Fair Value, Asset (Liability) RETIREMENT PLANS Retirement Benefits [Text Block] Income Tax Contingency [Table] Income Tax Contingency [Table] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Foreign Tax Authority Foreign Tax Authority [Member] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Ministry of the Economy, Finance and Industry, France Ministry of the Economy, Finance and Industry, France [Member] Swiss Federal Tax Administration (FTA) Swiss Federal Tax Administration (FTA) [Member] Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Effective income tax rate reconciliation, tax expense, sale of Extremity Orthopedic business Effective Income Tax Rate Reconciliation, Disposition of Business, Amount Effective income tax rate reconciliation, tax benefit, reversal of valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Effective income tax rate reconciliation, in-process research and development (IPR&D) expense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount Federal tax credit Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount Effective income tax rate reconciliation, tax benefit, federal tax holiday Effective Income Tax Rate Reconciliation, Tax Holiday, Amount Basic and Diluted Net Income (Loss) Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Effective Income Tax Rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Performance Shares and Restricted Units Performance Shares and Restricted Units [Member] Performance Shares and Restricted Units Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Shares excluded from computation as their effect would be antidilutive (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Shares included in computation (in shares) Additional EPS Shares Additional shares included in the basic and diluted calculation from their date of issuance because no further consideration is due related to the issuance of the underlying common shares Cover [Abstract] Document Type Document Type Document Quarterly Report Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address Entity Address, Address Line One Entity City Entity Address, City or Town Entity State Entity Address, State or Province Entity Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Smaller Reporting Company Entity Small Business Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Bankruptcy Proceedings, Reporting Current Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Arkis Arkis BioSciences Inc. [Member] Arkis BioSciences Inc. [Member] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Development Milestones Milestone Payment One [Member] Milestone Payment One [Member] Commercial Sales Milestones Milestone Payment Two [Member] Milestone Payment Two [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Purchase price of business combination Business Combination, Consideration Transferred Contingent consideration, liability (up to) Business Combination, Contingent Consideration, Liability Contingent consideration, fair value Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability Acquired intangible assets, discount rate Acquired Finite-lived Intangible Assets, Discount Rate Acquired Finite-lived Intangible Assets, Discount Rate LEASES AND RELATED PARTY LEASES Lessee, Operating Leases [Text Block] Reported tax rate Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Expected performance obligation through 2020, percentage Revenue, Remaining Performance Obligation, Percentage Performance obligations expected to be satisfied, expected timing Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Cash paid for amounts included in the measurement of lease liabilities: Cash Flow, Lessee [Abstract] Cash Flow, Lessee [Abstract] Operating cash flows from operating leases Operating Lease, Payments ROU assets obtained in exchange for lease liabilities: Right Of Use Asset Obtained In Exchange For Lease Liability [Abstract] Right Of Use Asset Obtained In Exchange For Lease Liability [Abstract] Operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Interest rate swap Interest Rate Swap [Member] Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Other assets Other Assets [Member] Accrued expenses and other current liabilities Accrued Expenses And Other Current Liabilities [Member] Accrued expenses and other current liabilities. Other liabilities Other Liabilities [Member] Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Total derivatives designated as hedges — Assets Derivative Asset, Fair Value, Gross Asset Total derivatives designated as hedges — Liabilities Derivative Liability, Fair Value, Gross Liability Schedule of Changes in Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of Indefinite-Lived Intangible Assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] CerebroFlo developed technology Developed Technology Rights [Member] Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Property, plant and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Deferred tax assets Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Intangible assets: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract] Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Goodwill Goodwill Total assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill Accounts payable, accrued expenses and other liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accounts Payable, Accrued Expenses And Other Liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accounts Payable, Accrued Expenses And Other Liabilities Contingent consideration Deferred tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Weighted Average Life Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Schedule of Goodwill [Table] Schedule of Goodwill [Table] Codman Specialty Surgical Goodwill [Line Items] Goodwill [Line Items] Goodwill [Roll Forward] Goodwill [Roll Forward] Beginning of Period Transfer to assets held for sale (See Note 2. Assets Held for Sale) Goodwill, Transfers Foreign currency translation Goodwill, Foreign Currency Translation Gain (Loss) End of Period Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Completed technology Completed Technology [Member] Completed technology. Customer relationships Customer Relationships [Member] Trademarks/brand names Trademarks Brand Names [Member] Trademarks Brand Names. Supplier relationships Supplier Relation Ships [Member] Supplier Relation Ships [Member] All other All Other [Member] All Other [Member] Transfer to assets held for sale (See Note 2. Assets Held for Sale) Transfer To Assets Held For Sale [Member] Transfer To Assets Held For Sale [Member] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Codman tradename Trade Names [Member] IPR&D Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Weighted Average Life Finite-Lived Intangible Asset, Useful Life Cost Cost Of Definite And Indefinite Lived Intangible Assets Gross Excluding Goodwill Cost Of Definite And Indefinite Lived Intangible Assets Gross Excluding Goodwill. Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Net Definite And Indefinite Lived Intangible Assets Net Excluding Goodwill Definite And Indefinite Lived Intangible Assets Net Excluding Goodwill. Other indefinite-lived intangible assets Other Indefinite-lived Intangible Assets Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table] Derivative Instruments, Gain (Loss) [Table] Derivative, by Nature [Axis] Derivative, Name [Domain] Interest rate swap Interest expense Interest Expense [Member] Other income (expense),net Other Nonoperating Income (Expense) [Member] Interest income Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Amount of Gain (Loss) Recognized in AOCL Amount of Gain (Loss) Reclassified from AOCL into Earnings Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Organization, Consolidation and Presentation of Financial Statements [Abstract] BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] COMPREHENSIVE INCOME (LOSS) Comprehensive Income (Loss) Note [Text Block] Supplemental Balance Sheet Information Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Supplemental Cash Flow Information Cash Flow, Lessee [Table Text Block] Cash Flow, Lessee [Table Text Block] Schedule of Operating Lease Maturities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Derma Sciences Derma Sciences [Member] Derma Sciences [Member] Liability Class [Axis] Liability Class [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Contingent Consideration Liability Contingent Consideration Liability [Member] Contingent Consideration Liability [Member] Fair Value, Inputs, Level 3 Fair Value, Inputs, Level 3 [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Balance, Beginning of Period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Loss from change in fair value of contingent consideration liabilities Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Additions from acquisition of Arkis Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Balance, End of Period Loss Contingencies [Table] Loss Contingencies [Table] BioD Earnout Payments and Medihoney Earnout Payments BioD Earnout Payments and Medihoney Earnout Payments [Member] BioD Earnout Payments and Medihoney Earnout Payments [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Payment for contingent consideration Payment for Contingent Consideration Liability, Financing Activities Number of contingent liabilities remaining Business Combination, Contingent Consideration, Number Of Liabilities Business Combination, Contingent Consideration, Number Of Liabilities Contingent consideration, maximum undiscounted payment amount Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Contingent consideration, estimated fair value Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Leased facilities Building [Member] Leased vehicles Vehicles [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Weighted average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Remainder of 2020 Long-Term Debt, Maturity, Remainder of Fiscal Year 2021 Long-Term Debt, Maturity, Year One 2022 Long-Term Debt, Maturity, Year Two 2023 Long-Term Debt, Maturity, Year Three 2024 Long-Term Debt, Maturity, Year Four 2025 Long-Term Debt, Maturity, Year Five Principal Repayment Long-term Debt Inventory, Net [Abstract] Schedule of Inventories, Net Schedule of Inventory, Current [Table Text Block] Schedule of Contingent Consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] DERIVATIVE INSTRUMENTS Derivative Instruments and Hedging Activities Disclosure [Text Block] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Change in unrealized loss on derivatives, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Pension liability adjustment, net of tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Comprehensive income (loss), net Number of reportable segments Number of Reportable Segments Number of products offered (more than) Segment Reporting Information, Number Of Products Offered Number of products sold by a segment Defined Benefit Pension Items Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Foreign Currency Items Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Total Accumulated Other Comprehensive Income (Loss) [Roll Forward] Other comprehensive income (loss) OCI, before Reclassifications, Net of Tax, Attributable to Parent Less: Amounts reclassified from accumulated other comprehensive loss Net current-period other comprehensive income (loss) INVENTORIES Inventory Disclosure [Text Block] Debt Covenant Period [Axis] Debt Covenant Period [Axis] Debt Covenant Period [Axis] Debt Covenant Period [Domain] Debt Covenant Period [Domain] [Domain] for Debt Covenant Period [Axis] Execution of July 2020 Amendment through June 30, 2021 Debt Covenant Period 6 [Member] Debt Covenant Period 6 [Member] September 30, 2021 through June 30, 2022 Debt Covenant Period 7 [Member] Debt Covenant Period 7 [Member] September 30, 2022 through June 30, 2023 Debt Covenant Period 8 [Member] Debt Covenant Period 8 [Member] September 30, 2023 and the last day of each fiscal quarter thereafter Debt Covenant Period 9 [Member] Debt Covenant Period 9 [Member] Maximum Consolidated Total Leverage Ratio Basis Of Presentation Basis of Accounting, Policy [Policy Text Block] Recently Issued Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Summary of Accounting Policies on Revenue Recognition and Shipping and Handling Fees Revenue from Contract with Customer [Policy Text Block] Product Warranties Extended Product Warranty, Policy [Policy Text Block] Taxes Collected from Customers Revenue, Transaction Price Measurement, Tax Exclusion [Policy Text Block] BUSINESS DEVELOPMENT Business Combination And Asset Acquisition Disclosure [Text Block] Business Combination And Asset Acquisition Disclosure [Text Block] Finished goods Inventory, Finished Goods, Net of Reserves Work in process Inventory, Work in Process, Net of Reserves Raw materials Inventory, Raw Materials and Purchased Parts, Net of Reserves Transfer to assets held for sale (See Note 2. Assets Held for Sale) Inventory, Transfer To Assets Held For Sale Inventory, Transfer To Assets Held For Sale Inventories, net Inventory, Net Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Neurosurgery Neurosurgery [Member] Neurosurgery [Member] Instruments Instruments [Member] Instruments [Member] Wound Reconstruction and Care Regenerative Skin And Wound [Member] Regenerative Skin And Wound [Member] Extremity Orthopedics Extremity Orthopedics [Member] Extremity Orthopedics [Member] Private Label Private Label [Member] Private Label [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Trade accounts receivable, net of allowances of $6,727 and $4,303 Accounts Receivable, after Allowance for Credit Loss, Current Inventories, net Assets held for sale Disposal Group, Including Discontinued Operation, Assets, Current Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property, plant and equipment, net Property, Plant and Equipment, Net Right of use asset - operating leases Operating Lease, Right-of-Use Asset Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Deferred tax assets, net Deferred Income Tax Assets, Net Other assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Current portion of borrowings under senior credit facility Current portion of lease liability - operating leases Accounts payable, trade Accounts Payable, Trade, Current Contract liabilities Accrued compensation Employee-related Liabilities, Current Liabilities held for sale Disposal Group, Including Discontinued Operation, Liabilities, Current Accrued expenses and other current liabilities Accrued Liabilities, Current Total current liabilities Liabilities, Current Long-term borrowings under senior credit facility Secured Long-term Debt, Noncurrent Long-term convertible securities Lease liability - operating leases Deferred tax liabilities Deferred Income Tax Liabilities, Net Other liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock; no par value; 15,000 authorized shares; none outstanding Preferred Stock, Value, Issued Common stock; $0.01 par value; 240,000 authorized shares; 89,191 and 88,735 issued at September 30, 2020 and December 31, 2019, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Treasury stock, at cost; 4,915 shares and 2,865 shares at September 30, 2020 and December 31, 2019, respectively Treasury Stock, Value Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Retained earnings Retained Earnings (Accumulated Deficit) Total stockholders’ equity Total liabilities and stockholders’ equity Liabilities and Equity GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] NET INCOME (LOSS) PER SHARE Earnings Per Share [Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Stock Options Share-based Payment Arrangement, Option [Member] Restricted Stock Restricted Stock [Member] Performance Stock and Restricted Stock Awards Performance Stock And Restricted Stock Awards [Member] Performance Stock And Restricted Stock Awards [Member] Performance Stock Performance Shares [Member] Title of Individual [Axis] Title of Individual [Axis] Title of Individual [Domain] Title of Individual [Domain] Directors Director [Member] Employees Employee [Member] Employee [Member] Directors and Certain Executive Officers Directors and Certain Executive Officers [Member] Directors and Certain Executive Officers [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based compensation arrangement by share-based payment award, number of plans Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans Stock options exercisable, vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Total unrecognized compensation costs Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Weighted-average period for cost recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Grants in period, net of forfeitures (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Options, weighted average grant date fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Requisite service periods of awards Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period Awards granted during the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Other than options, weighted average grant date fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value EX-101.PRE 11 iart-20200930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 iart-2020093010q_htm.xml IDEA: XBRL DOCUMENT 0000917520 2020-01-01 2020-09-30 0000917520 2020-10-27 0000917520 2019-01-01 2019-09-30 0000917520 2020-07-01 2020-09-30 0000917520 2019-07-01 2019-09-30 0000917520 2020-09-30 0000917520 2019-12-31 0000917520 2018-12-31 0000917520 2019-09-30 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000917520 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0000917520 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000917520 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000917520 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000917520 us-gaap:RetainedEarningsMember 2019-09-30 0000917520 2019-04-01 2019-06-30 0000917520 us-gaap:CommonStockMember 2019-03-31 0000917520 2019-01-01 2019-03-31 0000917520 us-gaap:TreasuryStockMember 2019-04-01 2019-06-30 0000917520 2019-06-30 0000917520 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0000917520 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000917520 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000917520 us-gaap:CommonStockMember 2019-09-30 0000917520 us-gaap:TreasuryStockMember 2019-09-30 0000917520 us-gaap:RetainedEarningsMember 2019-06-30 0000917520 us-gaap:RetainedEarningsMember 2018-12-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000917520 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000917520 us-gaap:CommonStockMember 2018-12-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000917520 us-gaap:TreasuryStockMember 2019-03-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000917520 us-gaap:TreasuryStockMember 2019-06-30 0000917520 us-gaap:CommonStockMember 2019-06-30 0000917520 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000917520 us-gaap:TreasuryStockMember 2018-12-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000917520 us-gaap:RetainedEarningsMember 2019-03-31 0000917520 2019-03-31 0000917520 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000917520 2020-01-01 2020-03-31 0000917520 2020-04-01 2020-06-30 0000917520 us-gaap:CommonStockMember 2020-09-30 0000917520 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000917520 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000917520 us-gaap:TreasuryStockMember 2020-06-30 0000917520 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0000917520 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0000917520 us-gaap:TreasuryStockMember 2020-04-01 2020-06-30 0000917520 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000917520 us-gaap:TreasuryStockMember 2019-12-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000917520 us-gaap:RetainedEarningsMember 2020-09-30 0000917520 us-gaap:CommonStockMember 2019-12-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000917520 us-gaap:CommonStockMember 2020-03-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000917520 us-gaap:CommonStockMember 2020-06-30 0000917520 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000917520 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000917520 us-gaap:RetainedEarningsMember 2020-03-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000917520 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0000917520 us-gaap:TreasuryStockMember 2020-03-31 0000917520 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-12-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000917520 us-gaap:RetainedEarningsMember 2020-06-30 0000917520 2020-03-31 0000917520 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000917520 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000917520 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0000917520 us-gaap:TreasuryStockMember 2020-09-30 0000917520 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000917520 us-gaap:RetainedEarningsMember 2019-12-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000917520 2020-06-30 0000917520 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000917520 2019-01-01 2019-12-31 0000917520 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember iart:SmithNephewUSDLimitedMember 2020-09-30 0000917520 srt:ScenarioForecastMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember iart:SmithNephewUSDLimitedMember us-gaap:SubsequentEventMember 2020-12-31 0000917520 iart:ConsortiumofFocusedOrthopedistsLLCMember srt:ScenarioForecastMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember iart:SmithNephewUSDLimitedMember us-gaap:SubsequentEventMember 2020-12-31 2020-12-31 0000917520 iart:IntegratedShoulderCollaborationInc.Member 2019-01-01 2019-03-31 0000917520 iart:ArkisBioSciencesInc.Member 2019-07-29 0000917520 iart:ReboundTherapeuticsCorporationMember 2019-01-01 2019-12-31 0000917520 us-gaap:LicensingAgreementsMember iart:IntegratedShoulderCollaborationInc.Member 2019-01-04 2019-01-04 0000917520 iart:ArkisBioSciencesInc.Member 2019-07-29 2019-07-29 0000917520 us-gaap:InProcessResearchAndDevelopmentMember iart:ReboundTherapeuticsCorporationMember 2019-09-09 2019-09-09 0000917520 iart:ReboundTherapeuticsCorporationMember 2019-09-09 2019-09-09 0000917520 iart:ArkisBioSciencesInc.Member 2020-09-30 0000917520 iart:DeferredTaxAssetMember iart:ReboundTherapeuticsCorporationMember 2019-09-09 2019-09-09 0000917520 us-gaap:CashAndCashEquivalentsMember iart:ReboundTherapeuticsCorporationMember 2019-09-09 2019-09-09 0000917520 iart:ReboundTherapeuticsCorporationMember 2019-12-31 0000917520 iart:ArkisBioSciencesInc.Member iart:MilestonePaymentOneMember 2019-07-29 0000917520 iart:ArkisBioSciencesInc.Member iart:MilestonePaymentTwoMember 2019-07-29 0000917520 iart:ReboundTherapeuticsCorporationMember 2019-09-09 0000917520 iart:IntegratedShoulderCollaborationInc.Member 2019-01-04 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:LicensingAgreementsMember 2019-07-29 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:DevelopedTechnologyRightsMember 2019-07-29 2019-07-29 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:LicensingAgreementsMember 2019-07-29 2019-07-29 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:DevelopedTechnologyRightsMember 2019-07-29 0000917520 2020-10-01 2020-09-30 0000917520 srt:MaximumMember 2020-01-01 2020-09-30 0000917520 iart:RegenerativeSkinAndWoundMember iart:OrthopedicsandTissueTechnologiesMember 2020-01-01 2020-09-30 0000917520 iart:InstrumentsMember iart:CodmanSpecialtySurgicalMember 2020-01-01 2020-09-30 0000917520 iart:RegenerativeSkinAndWoundMember iart:OrthopedicsandTissueTechnologiesMember 2019-01-01 2019-09-30 0000917520 iart:NeurosurgeryMember iart:CodmanSpecialtySurgicalMember 2019-07-01 2019-09-30 0000917520 iart:RegenerativeSkinAndWoundMember iart:OrthopedicsandTissueTechnologiesMember 2020-07-01 2020-09-30 0000917520 iart:CodmanSpecialtySurgicalMember 2020-07-01 2020-09-30 0000917520 iart:OrthopedicsandTissueTechnologiesMember 2020-01-01 2020-09-30 0000917520 iart:NeurosurgeryMember iart:CodmanSpecialtySurgicalMember 2020-01-01 2020-09-30 0000917520 iart:NeurosurgeryMember iart:CodmanSpecialtySurgicalMember 2020-07-01 2020-09-30 0000917520 iart:ExtremityOrthopedicsMember iart:OrthopedicsandTissueTechnologiesMember 2020-07-01 2020-09-30 0000917520 iart:InstrumentsMember iart:CodmanSpecialtySurgicalMember 2019-07-01 2019-09-30 0000917520 iart:OrthopedicsandTissueTechnologiesMember 2019-01-01 2019-09-30 0000917520 iart:CodmanSpecialtySurgicalMember 2020-01-01 2020-09-30 0000917520 iart:PrivateLabelMember iart:OrthopedicsandTissueTechnologiesMember 2019-07-01 2019-09-30 0000917520 iart:RegenerativeSkinAndWoundMember iart:OrthopedicsandTissueTechnologiesMember 2019-07-01 2019-09-30 0000917520 iart:PrivateLabelMember iart:OrthopedicsandTissueTechnologiesMember 2020-07-01 2020-09-30 0000917520 iart:ExtremityOrthopedicsMember iart:OrthopedicsandTissueTechnologiesMember 2019-07-01 2019-09-30 0000917520 iart:PrivateLabelMember iart:OrthopedicsandTissueTechnologiesMember 2019-01-01 2019-09-30 0000917520 iart:InstrumentsMember iart:CodmanSpecialtySurgicalMember 2019-01-01 2019-09-30 0000917520 iart:OrthopedicsandTissueTechnologiesMember 2019-07-01 2019-09-30 0000917520 iart:ExtremityOrthopedicsMember iart:OrthopedicsandTissueTechnologiesMember 2020-01-01 2020-09-30 0000917520 iart:InstrumentsMember iart:CodmanSpecialtySurgicalMember 2020-07-01 2020-09-30 0000917520 iart:CodmanSpecialtySurgicalMember 2019-07-01 2019-09-30 0000917520 iart:NeurosurgeryMember iart:CodmanSpecialtySurgicalMember 2019-01-01 2019-09-30 0000917520 iart:CodmanSpecialtySurgicalMember 2019-01-01 2019-09-30 0000917520 iart:OrthopedicsandTissueTechnologiesMember 2020-07-01 2020-09-30 0000917520 iart:PrivateLabelMember iart:OrthopedicsandTissueTechnologiesMember 2020-01-01 2020-09-30 0000917520 iart:ExtremityOrthopedicsMember iart:OrthopedicsandTissueTechnologiesMember 2019-01-01 2019-09-30 0000917520 srt:MinimumMember 2020-01-01 2020-09-30 0000917520 us-gaap:CustomerRelationshipsMember 2019-12-31 0000917520 us-gaap:CustomerRelationshipsMember 2019-01-01 2019-12-31 0000917520 iart:CompletedTechnologyMember 2019-12-31 0000917520 iart:CompletedTechnologyMember 2019-01-01 2019-12-31 0000917520 iart:SupplierRelationShipsMember 2019-12-31 0000917520 iart:SupplierRelationShipsMember 2019-01-01 2019-12-31 0000917520 iart:TrademarksBrandNamesMember 2019-12-31 0000917520 iart:TrademarksBrandNamesMember 2019-01-01 2019-12-31 0000917520 us-gaap:TradeNamesMember 2019-12-31 0000917520 iart:AllOtherMember 2019-12-31 0000917520 iart:AllOtherMember 2019-01-01 2019-12-31 0000917520 iart:OrthopedicsandTissueTechnologiesMember 2019-12-31 0000917520 iart:OrthopedicsandTissueTechnologiesMember 2020-09-30 0000917520 iart:CodmanSpecialtySurgicalMember 2020-09-30 0000917520 iart:CodmanSpecialtySurgicalMember 2019-12-31 0000917520 iart:AllOtherMember 2020-01-01 2020-09-30 0000917520 iart:SupplierRelationShipsMember 2020-09-30 0000917520 iart:TransferToAssetsHeldForSaleMember 2020-09-30 0000917520 iart:TrademarksBrandNamesMember 2020-01-01 2020-09-30 0000917520 iart:AllOtherMember 2020-09-30 0000917520 iart:CompletedTechnologyMember 2020-09-30 0000917520 us-gaap:CustomerRelationshipsMember 2020-09-30 0000917520 iart:TrademarksBrandNamesMember 2020-09-30 0000917520 us-gaap:TradeNamesMember 2020-09-30 0000917520 iart:SupplierRelationShipsMember 2020-01-01 2020-09-30 0000917520 us-gaap:CustomerRelationshipsMember 2020-01-01 2020-09-30 0000917520 iart:CompletedTechnologyMember 2020-01-01 2020-09-30 0000917520 us-gaap:InProcessResearchAndDevelopmentMember 2020-09-30 0000917520 us-gaap:InProcessResearchAndDevelopmentMember 2019-12-31 0000917520 us-gaap:StandbyLettersOfCreditMember iart:SeniorCreditFacilityMember 2020-09-30 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-01-01 2020-09-30 0000917520 iart:SeniorCreditFacilityMember 2020-02-03 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-09-30 0000917520 us-gaap:SecuredDebtMember iart:TermLoanFacilityMember 2020-02-03 0000917520 us-gaap:RevolvingCreditFacilityMember 2019-12-31 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember us-gaap:CallOptionMember 2020-01-01 2020-09-30 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-02-04 0000917520 us-gaap:SecuredDebtMember iart:TermLoanFacilityMember 2020-09-30 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember us-gaap:CallOptionMember 2020-02-04 2020-02-04 0000917520 srt:MinimumMember iart:SeniorCreditFacilityMember us-gaap:EurodollarMember 2020-01-01 2020-09-30 0000917520 srt:MinimumMember iart:SeniorCreditFacilityMember 2020-01-01 2020-09-30 0000917520 us-gaap:RevolvingCreditFacilityMember 2020-09-30 0000917520 us-gaap:SecuredDebtMember iart:TermLoanFacilityMember 2019-12-31 0000917520 us-gaap:FairValueInputsLevel2Member 2020-09-30 0000917520 iart:SeniorCreditFacilityMember us-gaap:FederalFundsEffectiveSwapRateMember 2020-01-01 2020-09-30 0000917520 iart:SeniorCreditFacilityMember iart:OneMonthEurodollarRateMember 2020-01-01 2020-09-30 0000917520 us-gaap:StandbyLettersOfCreditMember 2020-02-03 0000917520 srt:MaximumMember iart:SeniorCreditFacilityMember us-gaap:EurodollarMember 2020-01-01 2020-09-30 0000917520 us-gaap:RevolvingCreditFacilityMember us-gaap:FairValueInputsLevel2Member 2020-09-30 0000917520 us-gaap:StandbyLettersOfCreditMember iart:SeniorCreditFacilityMember 2019-12-31 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-02-04 2020-02-04 0000917520 us-gaap:SecuredDebtMember iart:TermLoanFacilityMember us-gaap:FairValueInputsLevel2Member 2020-09-30 0000917520 srt:MaximumMember iart:SeniorCreditFacilityMember 2020-01-01 2020-09-30 0000917520 iart:SeniorCreditFacilityMember 2020-07-01 2020-09-30 0000917520 iart:SwinglineLoanMember 2020-02-03 0000917520 us-gaap:RevolvingCreditFacilityMember 2020-02-03 0000917520 iart:SeniorCreditFacilityMember 2020-01-01 2020-03-31 0000917520 2018-10-01 2018-12-31 0000917520 iart:SeniorCreditFacilityMember iart:DebtCovenantPeriod8Member 2020-07-14 0000917520 iart:SeniorCreditFacilityMember iart:DebtCovenantPeriod6Member 2020-07-14 0000917520 iart:SeniorCreditFacilityMember iart:DebtCovenantPeriod7Member 2020-07-14 0000917520 iart:SeniorCreditFacilityMember iart:DebtCovenantPeriod9Member 2020-07-14 0000917520 us-gaap:OtherAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 us-gaap:OtherAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-09-30 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:ShortMember 2017-10-02 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-07-01 2019-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-09-30 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-07-01 2020-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-07-01 2019-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-07-01 2020-09-30 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SubsequentEventMember 2020-10-02 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:LongMember 2017-10-02 0000917520 iart:SwapTwoMember iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:SwapTwoMember iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-09-30 0000917520 iart:SwapThreeMember iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 iart:SwapOneMember iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-09-30 0000917520 iart:SwapThreeMember iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-09-30 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:SwapOneMember iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-09-30 0000917520 iart:SwapOneMember iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 iart:SwapOneMember iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:SwapThreeMember iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-09-30 0000917520 iart:SwapTwoMember iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-09-30 0000917520 iart:SwapTwoMember iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 iart:SwapThreeMember iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-01-01 2020-09-30 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-07-01 2019-09-30 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-07-01 2020-09-30 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-06-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-06-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2020-01-01 2020-09-30 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-07-01 2019-09-30 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2019-07-01 2019-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2019-06-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-09-30 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2020-09-30 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-06-30 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-07-01 2020-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2019-12-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-06-30 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-09-30 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2020-07-01 2020-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-09-30 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2019-01-01 2019-09-30 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2019-09-30 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2019-07-01 2019-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2020-06-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2020-07-01 2020-09-30 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-12-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2018-12-31 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:CrossCurrencyInterestRateContractFourMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractFourMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractFiveMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractFiveMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractFiveMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractFiveMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractFourMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:CrossCurrencyInterestRateContractFourMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche5Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche3Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedDecember182018Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2019-12-31 0000917520 iart:InterestRateSwapDesignatedDecember182018Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedFebruary62017Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:ThreeMonthUSDLIBORMember 2019-12-31 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche5Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2019-12-31 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2019-12-31 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche4Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2019-12-31 0000917520 iart:InterestRateSwapDesignatedDecember182018Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2019-12-31 0000917520 iart:InterestRateSwapDesignatedFebruary62017Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:ThreeMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedDecember182018Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche4Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche3Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2019-12-31 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche3Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2019-12-31 0000917520 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche3Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedFebruary62017Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2019-12-31 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedFebruary62017Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2019-12-31 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedMarch272017Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2019-12-31 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2019-12-31 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2020-09-30 0000917520 iart:InterestRateSwapDesignatedMarch272017Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2019-12-31 0000917520 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000917520 iart:PerformanceStockAndRestrictedStockAwardsMember 2020-01-01 2020-09-30 0000917520 srt:DirectorMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000917520 us-gaap:RestrictedStockMember 2020-01-01 2020-09-30 0000917520 us-gaap:EmployeeStockOptionMember 2020-09-30 0000917520 us-gaap:PerformanceSharesMember 2020-01-01 2020-09-30 0000917520 us-gaap:RestrictedStockMember 2020-09-30 0000917520 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000917520 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000917520 iart:EmployeeMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000917520 srt:MaximumMember iart:DirectorsandCertainExecutiveOfficersMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000917520 srt:MinimumMember iart:DirectorsandCertainExecutiveOfficersMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000917520 2019-05-01 2019-05-31 0000917520 iart:ThirdPartiesMember 2020-09-30 0000917520 iart:RelatedPartiesMember 2020-09-30 0000917520 us-gaap:BuildingMember 2020-09-30 0000917520 us-gaap:VehiclesMember 2020-09-30 0000917520 iart:FiveYearOptionLeasePeriodOneMember srt:AffiliatedEntityMember 2020-01-01 2020-09-30 0000917520 iart:FiveYearOptionLeasePeriodTwoMember srt:AffiliatedEntityMember 2020-01-01 2020-09-30 0000917520 srt:AffiliatedEntityMember 2020-01-01 2020-09-30 0000917520 srt:AffiliatedEntityMember 2019-01-01 2019-09-30 0000917520 2020-02-05 2020-02-05 0000917520 2018-12-11 0000917520 us-gaap:ConvertibleDebtMember 2020-01-01 2020-09-30 0000917520 2020-02-05 0000917520 2020-06-01 2020-06-30 0000917520 iart:CertainPurchasersMember us-gaap:ConvertibleDebtMember 2020-01-01 2020-09-30 0000917520 us-gaap:ForeignCountryMember us-gaap:SwissFederalTaxAdministrationFTAMember 2019-01-01 2019-09-30 0000917520 us-gaap:ForeignCountryMember us-gaap:SwissFederalTaxAdministrationFTAMember 2019-01-01 2019-03-31 0000917520 iart:ReboundTherapeuticsCorporationMember 2019-07-01 2019-09-30 0000917520 us-gaap:ForeignCountryMember us-gaap:MinistryOfTheEconomyFinanceAndIndustryFranceMember 2020-07-01 2020-09-30 0000917520 iart:ReboundTherapeuticsCorporationMember 2019-01-01 2019-09-30 0000917520 iart:PerformanceSharesandRestrictedUnitsMember 2020-09-30 0000917520 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-09-30 0000917520 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-09-30 0000917520 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000917520 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0000917520 us-gaap:AccumulatedTranslationAdjustmentMember 2020-09-30 0000917520 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000917520 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-09-30 0000917520 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-09-30 0000917520 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-09-30 0000917520 us-gaap:InterestIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-09-30 0000917520 us-gaap:OtherExpenseMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-09-30 0000917520 country:US 2020-07-01 2020-09-30 0000917520 srt:EuropeMember 2019-07-01 2019-09-30 0000917520 srt:AsiaPacificMember 2020-07-01 2020-09-30 0000917520 iart:RestOfWorldMember 2019-01-01 2019-09-30 0000917520 srt:AsiaPacificMember 2019-07-01 2019-09-30 0000917520 iart:RestOfWorldMember 2020-01-01 2020-09-30 0000917520 country:US 2019-07-01 2019-09-30 0000917520 srt:EuropeMember 2019-01-01 2019-09-30 0000917520 srt:EuropeMember 2020-07-01 2020-09-30 0000917520 country:US 2019-01-01 2019-09-30 0000917520 iart:RestOfWorldMember 2019-07-01 2019-09-30 0000917520 srt:AsiaPacificMember 2019-01-01 2019-09-30 0000917520 country:US 2020-01-01 2020-09-30 0000917520 srt:EuropeMember 2020-01-01 2020-09-30 0000917520 iart:RestOfWorldMember 2020-07-01 2020-09-30 0000917520 srt:AsiaPacificMember 2020-01-01 2020-09-30 0000917520 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-09-30 0000917520 us-gaap:OperatingSegmentsMember iart:CodmanSpecialtySurgicalMember 2020-07-01 2020-09-30 0000917520 us-gaap:OperatingSegmentsMember iart:OrthopedicsandTissueTechnologiesMember 2019-07-01 2019-09-30 0000917520 us-gaap:CorporateNonSegmentMember 2020-07-01 2020-09-30 0000917520 us-gaap:OperatingSegmentsMember iart:CodmanSpecialtySurgicalMember 2020-01-01 2020-09-30 0000917520 us-gaap:OperatingSegmentsMember iart:OrthopedicsandTissueTechnologiesMember 2020-07-01 2020-09-30 0000917520 us-gaap:OperatingSegmentsMember 2020-07-01 2020-09-30 0000917520 us-gaap:CorporateNonSegmentMember 2019-07-01 2019-09-30 0000917520 us-gaap:OperatingSegmentsMember iart:OrthopedicsandTissueTechnologiesMember 2019-01-01 2019-09-30 0000917520 us-gaap:OperatingSegmentsMember iart:OrthopedicsandTissueTechnologiesMember 2020-01-01 2020-09-30 0000917520 us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0000917520 us-gaap:OperatingSegmentsMember 2020-01-01 2020-09-30 0000917520 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-09-30 0000917520 us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0000917520 us-gaap:OperatingSegmentsMember iart:CodmanSpecialtySurgicalMember 2019-07-01 2019-09-30 0000917520 us-gaap:OperatingSegmentsMember iart:CodmanSpecialtySurgicalMember 2019-01-01 2019-09-30 0000917520 iart:DermaSciencesMember 2020-09-30 0000917520 iart:DermaSciencesMember iart:BioDEarnoutPaymentsandMedihoneyEarnoutPaymentsMember 2020-01-01 2020-09-30 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2019-12-31 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2020-01-01 2020-09-30 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2020-09-30 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2019-12-31 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2020-01-01 2020-09-30 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2020-09-30 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2019-01-01 2019-09-30 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2018-12-31 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2019-09-30 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2018-12-31 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2019-09-30 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2019-01-01 2019-09-30 pure iart:asset iso4217:CHF iso4217:USD shares iso4217:USD shares iart:plan iso4217:GBP iart:liability iart:renewal_option iart:Segment iso4217:EUR iart:product false --12-31 Q3 2020 0000917520 P3Y 5.50 5.00 4.50 4.00 P1M us-gaap:AccountingStandardsUpdate201613Member 4303000 6727000 0.01 0.01 240000000 240000000 88735000 89191000 877500000 200000 1000000 15000000 15000000 0 0 P3M P6Y 2865000 4915000 10-Q true 2020-09-30 false 0-26224 INTEGRA LIFESCIENCES HOLDINGS CORP DE 51-0317849 1100 Campus Road 08540 Princeton NJ 609 275-0500 Common Stock, Par Value $.01 Per Share IART NASDAQ Yes Yes Large Accelerated Filer false false false false 84272671 370232000 379095000 983221000 1122430000 134811000 142636000 373765000 415219000 19460000 19003000 55202000 54957000 0 59889000 0 59889000 150076000 173098000 432136000 513345000 8343000 5056000 23393000 21340000 312690000 399682000 884496000 1064750000 57542000 -20587000 98725000 57680000 2273000 2913000 7124000 8051000 20796000 13962000 54230000 40495000 2492000 4127000 2985000 8461000 41511000 -27509000 54604000 33697000 9174000 101000 13456000 -1185000 32337000 -27610000 41148000 34882000 0.38 -0.32 0.49 0.41 0.38 -0.32 0.48 0.40 84325000 85688000 84745000 85536000 84752000 85688000 85303000 86581000 43548000 -46521000 25637000 -7288000 396279000 198911000 218184000 275296000 307839000 316054000 159977000 0 69817000 67907000 1152096000 858168000 294439000 337404000 84916000 94530000 973685000 1031591000 919556000 954280000 8150000 12623000 20679000 14644000 3453521000 3303240000 22500000 45000000 12518000 12253000 50254000 113090000 4875000 4772000 71712000 79385000 12349000 0 80938000 76809000 255146000 331309000 944102000 1198561000 92300000 104500000 469898000 0 88778000 97504000 27780000 36553000 177530000 118077000 2055534000 1886504000 0 0 892000 887000 1284711000 1213620000 235224000 119943000 -91913000 -76402000 439521000 398574000 1397987000 1416736000 3453521000 3303240000 41148000 34882000 89853000 81584000 0 59889000 0 5764000 4784000 -10536000 14333000 15744000 10499000 4084000 2172000 3473000 11075000 0 -559000 -844000 -45000 10000 -57863000 17519000 45531000 30553000 865000 8162000 -10868000 -6650000 -67178000 366000 -548000 -1395000 -5417000 -2876000 123570000 142249000 30463000 47343000 5000000 0 0 752000 3311000 36000 0 30509000 0 64995000 -32152000 -142059000 151300000 215800000 441000000 143250000 104248000 0 575000000 0 44563000 0 24347000 0 100000000 0 3821000 6948000 4686000 6272000 100403000 73226000 5547000 -4273000 197368000 69143000 198911000 138838000 396279000 207981000 88735000 887000 2865000 -119943000 1213620000 -76402000 398574000 1416736000 9180000 9180000 -28187000 -28187000 13000 694000 694000 357000 2000 10000 476000 -3217000 -2739000 3781000 3781000 135000 -7632000 42538000 34906000 1304000 75407000 16961000 92368000 -200000 -200000 89105000 889000 4294000 -202506000 1240455000 -104589000 407553000 1341802000 -369000 -369000 1464000 1464000 84000 3000 -35000 1282000 1250000 4948000 4948000 621000 32685000 -32685000 0 89189000 892000 4915000 -235226000 1279370000 -103125000 407184000 1349095000 32337000 32337000 11212000 11212000 2000 2000 -69000 -67000 5410000 5410000 89191000 892000 4915000 -235224000 1284711000 -91913000 439521000 1397987000 88044000 880000 2881000 -120615000 1192601000 -45443000 348373000 1375796000 32756000 32756000 -11236000 -11236000 17000 716000 716000 243000 2000 12000 506000 -5629000 -5121000 4119000 4119000 88304000 882000 2869000 -120109000 1191807000 -56679000 381129000 1397030000 29736000 29736000 -12021000 -12021000 47000 1000 2000 405000 408000 5798000 5798000 88351000 883000 2869000 -120107000 1198010000 -68700000 410865000 1420951000 -27610000 -27610000 -18915000 -18915000 338000 3000 6000 4665000 4674000 5874000 5874000 88689000 886000 2869000 -120101000 1208549000 -87615000 383255000 1384974000 BASIS OF PRESENTATION<div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">General</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The terms “we,” “our,” “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the opinion of management, the </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, statement of changes in shareholder's equity, results of operations and cash flows of the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> included in the Company’s Annual Report on Form 10-K. The </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States. Operating results for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> month period ended </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results to be expected for the entire year.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements is in conformity with generally accepted accounting principles in the United States ("GAAP") which requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of derivative instruments, valuation of the equity component of convertible debt instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates. The novel coronavirus (“COVID-19”) pandemic and the resulting adverse impacts to global economic conditions, as well as our operations, may impact future estimates including, but not limited to, inventory valuations, fair value measurements, goodwill and long-lived asset impairments, the effectiveness of the Company’s hedging instruments, deferred tax valuation allowances, and allowances for doubtful accounts receivable.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Risks and Uncertainties</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company's business is highly uncertain and difficult to predict, as the responses to the pandemic and information is rapidly evolving. From late March, the Company's customers diverted resources to treat COVID-19 patients and deferred or canceled elective or non-emergent surgical procedures, all of which impacted hospitals' abilities to meet their obligations, including to the Company. Beginning in May 2020 and through the end of the third quarter of 2020, procedural volumes relevant to the Company’s products steadily increased and, in some geographic areas, began to approach normalized levels. However, on-going uncertainty persists about the continuing sustainability of those procedural volumes as virus outbreaks constrain healthcare networks. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is possible that it could cause a local and/or global economic recession. Such economic disruption has had an adverse effect on the Company's business as customers curtailed and reduced capital and overall spending. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and the economy as a whole. The magnitude and overall effectiveness of these actions remains uncertain. The severity of the impact of the COVID-19 pandemic on the Company's business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company's customers, all of which are uncertain and cannot be predicted with certainty. The Company's future results of operations and liquidity could be adversely impacted by delays in payments of outstanding receivable amounts beyond normal payment terms, supply chain disruptions and uncertain demand, and the impact of any initiatives or programs that the Company may undertake to address financial and operations challenges faced by its customers. The COVID-19 pandemic continues to cause a financial strain on healthcare systems which varies by location, and as a result we do not expect the same level of spending in the fourth quarter that we experienced last year. Even after the COVID-19 pandemic and government responses thereto have subsided, residual economic and other effects may have an impact on the demand for post-pandemic surgery levels that are difficult to predict. If the downturn is more severe and prolonged than currently expected, the Company may need to take further steps to reduce costs. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Recently Issued Accounting Standards</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326)</span><span style="font-family:inherit;font-size:10pt;">:</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Measurement of Credit Losses on Financial Instruments.</span><span style="font-family:inherit;font-size:10pt;"> The ASU is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financial assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. The ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted this guidance on January 1, 2020 using a modified retrospective transition method which requires a cumulative-effect adjustment to the opening balance of retained earnings to be recognized on the date of adoption with no change to financial results reported in prior periods. The cumulative-effect adjustment recorded on January 1, 2020, is not material. The adoption of this ASU did not have a significant impact on the Company's consolidated financial statements and related disclosures.</span></div><div style="line-height:120%;padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's exposure to credit losses may increase if its customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. Although the Company has historically not experienced significant credit losses, it is possible that there could be an adverse impact as hospital's cash flows are impacted by their response to the COVID-19 pandemic. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-14, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation-Retirement Benefits-Defined Benefit Plans-General (Subtopic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans.</span><span style="font-family:inherit;font-size:10pt;"> The new guidance modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans, including removing certain previous disclosure requirements, adding certain new disclosure requirements, and clarifying certain other disclosure requirements. The ASU will be effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Early adoption is permitted. The adoption is not expected to have a material impact on the Company's consolidated financial statements and related disclosures.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> In August 2018, the FASB issued ASU No. 2018-15, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40)</span><span style="font-family:inherit;font-size:10pt;">, relating to a customer's accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement that is hosted by a vendor (e.g., a service contract). Under the new guidance, a customer will apply the same criteria for capitalizing implementation costs as it would for an arrangement that has a software license. The new guidance also prescribes the balance sheet, income statement, and cash flow classification of the capitalized implementation costs and related amortization expense, and requires additional quantitative and qualitative disclosures. The ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted this guidance on January 1, 2020 using a prospective transition method. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements and related disclosures.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the FASB issued ASU No. 2019-12,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Income Taxes: Simplifying the Accounting for Income Taxes</span><span style="font-family:inherit;font-size:10pt;"> intended to simplify the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The Company is currently assessing the impact of this standard on its financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2020, the FASB issued ASU 2020-04, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Reference Rate Reform</span><span style="font-family:inherit;font-size:10pt;">, which provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. This amendment applies to all entities, subject to meeting certain criteria, that have contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This ASU is effective immediately and may be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before December 31, 2022. The Company is currently assessing the impact that this ASU will have on its consolidated financial statements and related disclosures.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:10pt;">In August 2020, the FASB issued ASU No. 2020-06 </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Debt-</span><span style="font-family:inherit;font-size:11pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40)-Accounting For Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="font-family:inherit;font-size:10pt;"> . The guidance simplifies accounting for convertible instruments by removing major </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify. The guidance also simplifies the diluted net income per share calculation in certain areas. The ASU will be effective for annual and interim periods beginning after December 15, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact of this standard on its consolidated financial statements and related disclosures.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There are no other recently issued accounting pronouncements that are expected to have any significant effect on the Company's financial position, results of operations or cash flows.</span></div> BASIS OF PRESENTATION<div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">General</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The terms “we,” “our,” “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the opinion of management, the </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, statement of changes in shareholder's equity, results of operations and cash flows of the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> included in the Company’s Annual Report on Form 10-K. The </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States. Operating results for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> month period ended </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results to be expected for the entire year.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements is in conformity with generally accepted accounting principles in the United States ("GAAP") which requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of derivative instruments, valuation of the equity component of convertible debt instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates. The novel coronavirus (“COVID-19”) pandemic and the resulting adverse impacts to global economic conditions, as well as our operations, may impact future estimates including, but not limited to, inventory valuations, fair value measurements, goodwill and long-lived asset impairments, the effectiveness of the Company’s hedging instruments, deferred tax valuation allowances, and allowances for doubtful accounts receivable.</span></div> <div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Recently Issued Accounting Standards</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326)</span><span style="font-family:inherit;font-size:10pt;">:</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Measurement of Credit Losses on Financial Instruments.</span><span style="font-family:inherit;font-size:10pt;"> The ASU is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financial assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. The ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted this guidance on January 1, 2020 using a modified retrospective transition method which requires a cumulative-effect adjustment to the opening balance of retained earnings to be recognized on the date of adoption with no change to financial results reported in prior periods. The cumulative-effect adjustment recorded on January 1, 2020, is not material. The adoption of this ASU did not have a significant impact on the Company's consolidated financial statements and related disclosures.</span></div><div style="line-height:120%;padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's exposure to credit losses may increase if its customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. Although the Company has historically not experienced significant credit losses, it is possible that there could be an adverse impact as hospital's cash flows are impacted by their response to the COVID-19 pandemic. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-14, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation-Retirement Benefits-Defined Benefit Plans-General (Subtopic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans.</span><span style="font-family:inherit;font-size:10pt;"> The new guidance modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans, including removing certain previous disclosure requirements, adding certain new disclosure requirements, and clarifying certain other disclosure requirements. The ASU will be effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Early adoption is permitted. The adoption is not expected to have a material impact on the Company's consolidated financial statements and related disclosures.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> In August 2018, the FASB issued ASU No. 2018-15, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40)</span><span style="font-family:inherit;font-size:10pt;">, relating to a customer's accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement that is hosted by a vendor (e.g., a service contract). Under the new guidance, a customer will apply the same criteria for capitalizing implementation costs as it would for an arrangement that has a software license. The new guidance also prescribes the balance sheet, income statement, and cash flow classification of the capitalized implementation costs and related amortization expense, and requires additional quantitative and qualitative disclosures. The ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted this guidance on January 1, 2020 using a prospective transition method. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements and related disclosures.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the FASB issued ASU No. 2019-12,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Income Taxes: Simplifying the Accounting for Income Taxes</span><span style="font-family:inherit;font-size:10pt;"> intended to simplify the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The Company is currently assessing the impact of this standard on its financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2020, the FASB issued ASU 2020-04, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Reference Rate Reform</span><span style="font-family:inherit;font-size:10pt;">, which provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. This amendment applies to all entities, subject to meeting certain criteria, that have contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This ASU is effective immediately and may be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before December 31, 2022. The Company is currently assessing the impact that this ASU will have on its consolidated financial statements and related disclosures.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:10pt;">In August 2020, the FASB issued ASU No. 2020-06 </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Debt-</span><span style="font-family:inherit;font-size:11pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40)-Accounting For Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="font-family:inherit;font-size:10pt;"> . The guidance simplifies accounting for convertible instruments by removing major </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify. The guidance also simplifies the diluted net income per share calculation in certain areas. The ASU will be effective for annual and interim periods beginning after December 15, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact of this standard on its consolidated financial statements and related disclosures.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There are no other recently issued accounting pronouncements that are expected to have any significant effect on the Company's financial position, results of operations or cash flows.</span></div> ASSETS AND LIABILITIES HELD FOR SALE<div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On September 29, 2020, the Company and certain of its subsidiaries entered into an agreement to sell its Extremity Orthopedics business to Smith &amp; Nephew USD Limited for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$240 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash. The transaction includes the sale of the Company’s upper and lower Extremity Orthopedics product portfolio, including ankle and shoulder arthroplasty and hand and wrist product lines. In connection with the transaction, the Company will pay </span><span style="font-family:inherit;font-size:10pt;"><span>$41.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the Consortium of Focused Orthopedists, LLC (“CFO”) pursuant to the terms of certain agreements between Integra and CFO relating to the development of shoulder arthroplasty products. The transaction is expected to close at or around the end of 2020, subject to the satisfaction of customary conditions, including regulatory approvals and consultation with employee representative bodies.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company considered the assets and liabilities associated with the Extremity Orthopedics business to be accounted as held-for-sale as the six criteria under ASC 260 were met during the third quarter of 2020. Upon designation of the assets and liabilities as held for sale, the Company recorded the assets at the lower of their carrying value or their estimated fair value, less estimated costs to sell. Goodwill was allocated to the assets and liabilities held for sale using the relative fair value method of the Extremity Orthopedics business to the Company's Orthopedics and Tissue Technologies reporting unit. The fair value of the business less costs to sell exceeded the related carrying value. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Extremity Orthopedics business was treated as a single disposal group and presented separately in the condensed consolidated balance sheet as assets and liabilities held for sale as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">. These balances are presented as current assets and liabilities as they are expected to be sold within twelve months. The major classes of assets and liabilities classified as a held for sale consisted of the following as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> (amounts in thousands):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:59.06432748538012%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:31%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prepaid and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>748</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,448</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6,927</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13,332</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Property, plant and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>36,714</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>47,117</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>50,691</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total assets held for sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>159,977</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>241</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current portion of lease liability - operating leases</span></div><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,060</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued compensation </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,584</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3,035</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Lease liability - operating leases</span></div><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6,429</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total liabilities held for sale</span></div><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12,349</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 240000000 41500000 The major classes of assets and liabilities classified as a held for sale consisted of the following as of <span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> (amounts in thousands):</span><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:59.06432748538012%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:31%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prepaid and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>748</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,448</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6,927</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13,332</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Property, plant and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>36,714</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>47,117</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>50,691</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total assets held for sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>159,977</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>241</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current portion of lease liability - operating leases</span></div><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,060</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued compensation </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,584</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3,035</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Lease liability - operating leases</span></div><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6,429</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total liabilities held for sale</span></div><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12,349</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 748000 4448000 6927000 13332000 36714000 47117000 50691000 159977000 241000 1060000 1584000 3035000 6429000 12349000 BUSINESS DEVELOPMENT<div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Arkis BioSciences Inc.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July 29, 2019, the Company acquired Arkis BioSciences Inc. ("Arkis") for an acquisition purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$30.6</span></span><span style="font-family:inherit;font-size:10pt;"> million (the "Arkis Acquisition") plus contingent consideration of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$25.5</span></span><span style="font-family:inherit;font-size:10pt;"> million, that may be payable based on the successful completion of certain development and commercial milestones. The contingent consideration had an acquisition date fair value of </span><span style="font-family:inherit;font-size:10pt;"><span>$13.1</span></span><span style="font-family:inherit;font-size:10pt;"> million. Arkis was a privately-held company that marketed the CerebroFlo® external ventricular drainage (EVD) catheter with Endexo® technology, a permanent additive designed to reduce the potential for catheter obstruction due to thrombus formation. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Assets Acquired and Liabilities Assumed at Fair Value</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Arkis Acquisition has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination to be recognized at their fair values as of the acquisition date. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the final fair values of the assets acquired and liabilities assumed at the acquisition date:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Final Valuation as of </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Life</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Dollars in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>751</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>457</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,697</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CerebroFlo developed technology </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15 years</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Enabling technology license</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,980</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14 years</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,153</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,228</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable, accrued expenses and other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,926</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,603</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">     Net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>30,599</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangible Assets</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated fair value of the intangible assets was determined using the income approach, which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each asset (including net revenues, cost of sales, R&amp;D costs, selling and marketing costs, and working capital/contributory asset charges), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, and competitive trends impacting the asset and each cash flow stream.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company used a discount rate of </span><span style="font-family:inherit;font-size:10pt;"><span>14.5%</span></span><span style="font-family:inherit;font-size:10pt;"> to arrive at the present value for the acquired intangible assets to reflect the rate of return a market participant would expect to earn and incremental commercial uncertainty in the cash flow projections. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results.  </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company allocated goodwill related to the Arkis Acquisition to the Codman Specialty Surgical segment. Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected revenue and cost synergies of the combined company and assembled workforce. One of the key factors that contributes to the recognition of goodwill, and a driver for the Company's acquisition of Arkis, is the planned expansion of the Endexo technology with the existing products within the Codman Specialty Surgical segment. Goodwill recognized as a result of this acquisition is non-deductible for income tax purposes. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contingent Consideration</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determines the acquisition date fair value of contingent consideration obligations based on a probability-weighted income approach derived from revenue estimates and a probability assessment with respect to the likelihood of achieving contingent obligations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined using the fair value concepts in ASC 820. The resultant probability-weighted cash flows are discounted using an appropriate effective annual interest rate. At each reporting date, the contingent consideration obligation will be revalued to estimated fair value and changes in fair value will be reflected as income or expense in the Company's consolidated statement of operations. Changes in the fair value of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of revenue estimates and changes in probability assumptions with respect to the likelihood of achieving the various contingent payment obligations. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of the acquisition, the Company is required to pay the former shareholders of Arkis up to </span><span style="font-family:inherit;font-size:10pt;"><span>$25.5</span></span><span style="font-family:inherit;font-size:10pt;"> million based on the timing of certain development milestones of </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0</span></span><span style="font-family:inherit;font-size:10pt;"> million and commercial sales milestones of </span><span style="font-family:inherit;font-size:10pt;"><span>$15.5</span></span><span style="font-family:inherit;font-size:10pt;"> million, respectively. The Company used a probability weighted income approach to calculate the fair value of the contingent consideration that considered the possible outcomes of scenarios related to each specified milestone. The Company estimated the fair value of the contingent consideration to be </span><span style="font-family:inherit;font-size:10pt;"><span>$13.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> at the acquisition date. The estimated fair value as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$14.2</span></span><span style="font-family:inherit;font-size:10pt;"> million. This amount is included in other liabilities at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> in the consolidated balance sheets of the Company.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred Tax Liabilities</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities result from identifiable intangible assets’ fair value adjustments. These adjustments create excess book basis over tax basis which is tax-effected by the statutory tax rates of applicable jurisdictions.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The pro forma results are not presented for this acquisition as they are not material.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Rebound Therapeutics Corporation</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On September 9, 2019, the Company acquired Rebound Therapeutics Corporation (“Rebound”), developers of a single-use medical device known as the AURORA Surgiscope® System ("Aurora") which enables minimally invasive access, using optics and illumination, for visualization, diagnostic and therapeutic use in neurosurgery (the “Rebound transaction”). Under the terms of the Rebound transaction, the Company made an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$67.1</span></span><span style="font-family:inherit;font-size:10pt;"> million and are committed to pay up to </span><span style="font-family:inherit;font-size:10pt;"><span>$35.0</span></span><span style="font-family:inherit;font-size:10pt;"> million of contingent development milestones upon achievement of certain regulatory milestones. The acquisition of Rebound was primarily concentrated in </span><span style="font-family:inherit;font-size:10pt;text-align:left;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> single identifiable asset and thus, for accounting purposes, the Company has concluded that the acquired assets do not meet the accounting definition of a business. The initial payment was allocated primarily to Aurora, resulting in a </span><span style="font-family:inherit;font-size:10pt;"><span>$59.9</span></span><span style="font-family:inherit;font-size:10pt;"> million in-process research and development (IPR&amp;D) expense. The balance of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$7.2</span></span><span style="font-family:inherit;font-size:10pt;"> million, which included </span><span style="font-family:inherit;font-size:10pt;"><span>$2.1</span></span><span style="font-family:inherit;font-size:10pt;"> million of cash and cash equivalents and a net deferred tax asset of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.2</span></span><span style="font-family:inherit;font-size:10pt;"> million, was allocated to the remaining net assets acquired. The deferred tax asset primarily resulted from a federal net operating loss carry forward. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the fourth quarter of 2019, the Company achieved the first developmental milestone which triggered a </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0</span></span><span style="font-family:inherit;font-size:10pt;"> million obligation to be paid to former shareholders of Rebound. The Company recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0</span></span><span style="font-family:inherit;font-size:10pt;"> million as IPR&amp;D expense in the consolidated statements of operations during the year ended December 31, 2019. The obligation was included in accrued expenses and other current liabilities at December 31, 2019 in the consolidated balance sheets. The milestone was paid during the first quarter of 2020.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Integrated Shoulder Collaboration, Inc.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 4, 2019, the Company entered into a licensing agreement with Integrated Shoulder Collaboration, Inc ("ISC"). Under the terms of the agreement, the Company paid ISC </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7</span></span><span style="font-family:inherit;font-size:10pt;"> million for the exclusive, worldwide license to commercialize its short stem and stemless shoulder system. A patent related to short stem and stemless shoulder systems was issued to ISC during the first quarter of 2019. ISC is eligible to receive royalties on sales of the short stem and stemless shoulder system. The Company has the option to acquire ISC at a date </span><span style="font-family:inherit;font-size:10pt;"><span>four years</span></span><span style="font-family:inherit;font-size:10pt;"> subsequent to the first commercial sale, which becomes mandatory upon the achievement of a certain sales thresholds of the short stem and stemless shoulder system, for an amount not to exceed </span><span style="font-family:inherit;font-size:10pt;"><span>$80.0</span></span><span style="font-family:inherit;font-size:10pt;"> million. The transaction was accounted for as an asset acquisition as the Company concluded that it acquired primarily </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> asset. During the quarter ended March 31, 2019, the total upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7</span></span><span style="font-family:inherit;font-size:10pt;"> million was expensed as a component of research and development expense and the future milestone and option payments will be recorded if the corresponding events become probable.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the sale of the Company's Extremity Orthopedic business, the Company will pay </span><span style="font-family:inherit;font-size:10pt;"><span>$41.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> to CFO pursuant to the terms of certain agreements between Integra and CFO relating to the sale of shares of ISC which includes the development of shoulder arthroplasty products effectively terminating our licensing agreement with ISC. See Note 2,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Assets and Liabilities Held for Sale, for details of the transaction.</span></div> 30600000 25500000 13100000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the final fair values of the assets acquired and liabilities assumed at the acquisition date:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Final Valuation as of </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Life</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Dollars in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>751</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>457</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,697</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CerebroFlo developed technology </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15 years</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Enabling technology license</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,980</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14 years</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,153</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,228</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable, accrued expenses and other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,926</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,603</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">     Net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>30,599</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 90000 751000 457000 1697000 20100000 P15Y 1980000 P14Y 27153000 52228000 2926000 13100000 5603000 30599000 0.145 25500000 10000000.0 15500000 13100000 14200000 67100000 35000000.0 1 59900000 7200000 2100000 4200000 5000000.0 5000000.0 1700000 P4Y 80000000.0 1 1700000 41500000 REVENUES FROM CONTRACTS WITH CUSTOMERS <div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Summary of Accounting Policies on Revenue Recognition</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue, net, includes product sales, product royalties and other revenues, such as fees received for services. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For products shipped with FOB shipping point terms, the control of the product passes to the customer at the time of shipment. For shipments in which the control of the product is transferred when the customer receives the product, the Company recognizes revenue upon receipt by the customer. Certain products that the Company produces for private label customers have no alternative use and the Company has a right of payment for performance to date. Revenues from those products are recognized over the period </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">that the Company manufactures these products, which is typically </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>three months</span></span><span style="font-family:inherit;font-size:10pt;">. The Company uses the input method to measure the manufacturing activities completed to date, which depicts the progress of the Company's performance obligation of transferring control of goods being manufactured for private label customers.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and distributors, and also from inventory physically held by field sales representatives. For these types of product sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized.   </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues from sale of products and services are evidenced by either a contract with the customer or a valid purchase order and an invoice which includes all relevant terms of sale. For product sales, invoices are generally issued upon the transfer of control (or upon the completion of the manufacturing in the case of the private label transactions recognized over time) and are typically payable thirty days after the invoice date. The Company performs a review of each specific customer's creditworthiness and ability to pay prior to acceptance as a customer. Further, the Company performs periodic reviews of its customers' creditworthiness prospectively. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Performance Obligations</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders, or invoices. The Company has no significant multi-element contracts with customers.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Significant Judgments</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company and the Company's strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information, and expected sales trends. Differences between actual reported licensee sales and those that were estimated are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company estimates returns, price concessions, and discount allowances using the expected value method based on historical trends and other known factors. Rebate allowances are estimated using the most likely method based on each customer contract. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's return policy, as set forth in its product catalogs and sales invoices, requires review and authorization in advance prior to the return of product. Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally </span><span style="font-family:inherit;font-size:10pt;"><span>ninety days</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less. The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Contract Asset and Liability</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues recognized from the Company's private label business that are not invoiced to the customers as a result of recognizing revenue over time are recorded as a contract asset included in the prepaid expenses and other current assets account in the consolidated balance sheet. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other operating revenues may include fees received under service agreements. Non-refundable fees received under multiple-period service agreements are recognized as revenue as the Company satisfies the performance obligations to the other party. A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the changes in the contract asset and liability balances for the </span><span style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">: </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Contract Asset</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract asset, January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,680</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transferred to trade receivable of contract asset included</span></div><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     in beginning of the year contract asset </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,680</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract asset, net of transferred to trade receivables on contracts during the period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,653</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract asset, September 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,653</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Contract Liability</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract liability, January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,946</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recognition of revenue included in beginning of year contract liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract liability, net of revenue recognized on contracts during the period</span></div><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,631</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(42</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract liability, September 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,385</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the short-term portion of the contract liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and the long-term portion of </span><span style="font-family:inherit;font-size:10pt;"><span>$6.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> were included in accrued expenses and other current liabilities and other liabilities in the consolidated balance sheet.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company is expected to recognize approximately </span><span style="font-family:inherit;font-size:10pt;"><span>43%</span></span><span style="font-family:inherit;font-size:10pt;"> of unsatisfied (or partially unsatisfied) performance obligations as revenue through 2020, with the remaining balance to be recognized in 2021 and thereafter.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Shipping and Handling Fees</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in the cost of goods sold. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Product Warranties</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of the Company's medical devices, including monitoring systems and neurosurgical systems, are designed to operate over long periods of time. These products are sold with warranties which may extend for up to </span><span style="font-family:inherit;font-size:10pt;"><span>two years</span></span><span style="font-family:inherit;font-size:10pt;"> from the date of purchase. The warranties are not considered a separate performance obligation. The Company estimates its product warranties using the expected value method based on historical trends and other known factors. The Company includes them in accrued expenses and other current liabilities in the consolidated balance sheet.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Taxes Collected from Customers</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company elected to exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Disaggregated Revenue</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents revenues disaggregated by the major sources of revenues for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> (amounts in thousands):</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.4296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Neurosurgery</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>189,674</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195,330</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>516,048</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>567,779</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Instruments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,649</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,654</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>124,493</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>169,031</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Codman Specialty Surgical</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>239,323</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>252,984</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>640,541</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>736,810</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wound Reconstruction and Care</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82,115</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82,213</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210,673</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>239,458</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Extremity Orthopedics</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,922</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,852</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,556</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,299</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Private Label</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,872</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,046</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,451</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,863</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Orthopedics and Tissue Technologies</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130,909</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>126,111</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>342,680</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>385,620</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>370,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>379,095</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>983,221</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,122,430</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior period amounts were reclassified between categories within the Codman Specialty Surgical segment to conform to the current period presentation.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Note 16, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Segment and Geographical Information</span><span style="font-family:inherit;font-size:10pt;">, for details of revenues based on the location of the customer.</span></div> <div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Summary of Accounting Policies on Revenue Recognition</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue, net, includes product sales, product royalties and other revenues, such as fees received for services. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For products shipped with FOB shipping point terms, the control of the product passes to the customer at the time of shipment. For shipments in which the control of the product is transferred when the customer receives the product, the Company recognizes revenue upon receipt by the customer. Certain products that the Company produces for private label customers have no alternative use and the Company has a right of payment for performance to date. Revenues from those products are recognized over the period </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">that the Company manufactures these products, which is typically </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>three months</span></span><span style="font-family:inherit;font-size:10pt;">. The Company uses the input method to measure the manufacturing activities completed to date, which depicts the progress of the Company's performance obligation of transferring control of goods being manufactured for private label customers.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and distributors, and also from inventory physically held by field sales representatives. For these types of product sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized.   </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues from sale of products and services are evidenced by either a contract with the customer or a valid purchase order and an invoice which includes all relevant terms of sale. For product sales, invoices are generally issued upon the transfer of control (or upon the completion of the manufacturing in the case of the private label transactions recognized over time) and are typically payable thirty days after the invoice date. The Company performs a review of each specific customer's creditworthiness and ability to pay prior to acceptance as a customer. Further, the Company performs periodic reviews of its customers' creditworthiness prospectively. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Performance Obligations</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders, or invoices. The Company has no significant multi-element contracts with customers.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Significant Judgments</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company and the Company's strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information, and expected sales trends. Differences between actual reported licensee sales and those that were estimated are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company estimates returns, price concessions, and discount allowances using the expected value method based on historical trends and other known factors. Rebate allowances are estimated using the most likely method based on each customer contract. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's return policy, as set forth in its product catalogs and sales invoices, requires review and authorization in advance prior to the return of product. Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally </span><span style="font-family:inherit;font-size:10pt;"><span>ninety days</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less. The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Contract Asset and Liability</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues recognized from the Company's private label business that are not invoiced to the customers as a result of recognizing revenue over time are recorded as a contract asset included in the prepaid expenses and other current assets account in the consolidated balance sheet. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other operating revenues may include fees received under service agreements. Non-refundable fees received under multiple-period service agreements are recognized as revenue as the Company satisfies the performance obligations to the other party. A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Shipping and Handling Fees</span></div>The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in the cost of goods sold. P3M P90D <div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the changes in the contract asset and liability balances for the </span><span style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">: </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Contract Asset</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract asset, January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,680</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transferred to trade receivable of contract asset included</span></div><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     in beginning of the year contract asset </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,680</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract asset, net of transferred to trade receivables on contracts during the period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,653</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract asset, September 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,653</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Contract Liability</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract liability, January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,946</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recognition of revenue included in beginning of year contract liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract liability, net of revenue recognized on contracts during the period</span></div><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,631</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(42</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract liability, September 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,385</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 8680000 8680000 6653000 6653000 11946000 3150000 2631000 -42000 11385000 4900000 6500000 0.43 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Product Warranties</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of the Company's medical devices, including monitoring systems and neurosurgical systems, are designed to operate over long periods of time. These products are sold with warranties which may extend for up to </span><span style="font-family:inherit;font-size:10pt;"><span>two years</span></span><span style="font-family:inherit;font-size:10pt;"> from the date of purchase. The warranties are not considered a separate performance obligation. The Company estimates its product warranties using the expected value method based on historical trends and other known factors. The Company includes them in accrued expenses and other current liabilities in the consolidated balance sheet.</span></div> P2Y <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Taxes Collected from Customers</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company elected to exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents revenues disaggregated by the major sources of revenues for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> (amounts in thousands):</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.4296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Neurosurgery</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>189,674</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195,330</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>516,048</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>567,779</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Instruments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,649</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,654</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>124,493</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>169,031</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Codman Specialty Surgical</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>239,323</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>252,984</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>640,541</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>736,810</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wound Reconstruction and Care</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82,115</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82,213</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210,673</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>239,458</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Extremity Orthopedics</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,922</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,852</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,556</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,299</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Private Label</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,872</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,046</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,451</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,863</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Orthopedics and Tissue Technologies</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130,909</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>126,111</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>342,680</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>385,620</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>370,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>379,095</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>983,221</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,122,430</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 189674000 195330000 516048000 567779000 49649000 57654000 124493000 169031000 239323000 252984000 640541000 736810000 82115000 82213000 210673000 239458000 21922000 20852000 54556000 65299000 26872000 23046000 77451000 80863000 130909000 126111000 342680000 385620000 370232000 379095000 983221000 1122430000 INVENTORIES<div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories, net consisted of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>223,726</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>201,870</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,037</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,333</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,767</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,851</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transfer to assets held for sale (See Note 2. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Assets Held for Sale</span><span style="font-family:inherit;font-size:10pt;">)</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(50,691</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventories</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>307,839</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>316,054</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories, net consisted of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>223,726</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>201,870</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,037</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,333</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,767</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,851</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transfer to assets held for sale (See Note 2. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Assets Held for Sale</span><span style="font-family:inherit;font-size:10pt;">)</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(50,691</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventories</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>307,839</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>316,054</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 223726000 201870000 57037000 48333000 77767000 65851000 50691000 0 307839000 316054000 GOODWILL AND OTHER INTANGIBLE ASSETS<div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in the carrying amount of goodwill for the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;">-month period ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Codman Specialty </span></div><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Surgical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Orthopedics and</span></div><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Tissue Technologies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">(In thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Goodwill at December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>653,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>300,780</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>954,280</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Transfer to assets held for sale (See Note 2. </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Assets Held for Sale</span><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(47,117</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(47,117</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign currency translation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>8,928</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>3,465</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>12,393</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Goodwill at September 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>662,428</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>257,128</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>919,556</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of the Company’s identifiable intangible assets were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:50%;"/><td style="width:9%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">September 30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">(Dollars in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Completed technology</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>19 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>891,554</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(250,609</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>640,945</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Customer relationships</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>12 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>223,512</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(138,989</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>84,523</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Trademarks/brand names</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>28 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>104,404</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(31,425</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>72,979</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Codman tradename</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Indefinite</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>167,013</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>167,013</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Supplier relationships</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>27 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>34,721</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(19,018</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>15,703</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">All other</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>4 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>11,101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(5,247</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>5,854</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Transfer to assets held for sale (See Note 2. </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Assets Held for Sale</span><span style="font-family:inherit;font-size:9.5pt;">)</span></div><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(39,821</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>26,489</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(13,332</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1,392,484</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(418,799</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>973,685</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:43%;"/><td style="width:12%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">(Dollars in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Completed technology</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>19 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>880,623</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(213,702</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>666,921</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Customer relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>12 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>222,575</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(119,393</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>103,182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Trademarks/brand names</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>28 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>103,873</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(28,514</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>75,359</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Codman tradename</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Indefinite</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>163,126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>163,126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Supplier relationships</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>27 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>34,721</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(17,947</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>16,774</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">All other</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> (1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>4 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>10,869</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(4,640</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>6,229</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1,415,787</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(384,196</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1,031,591</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, all other included IPR&amp;D of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0</span></span><span style="font-family:inherit;font-size:10pt;"> million, which was indefinite-lived. At September 30, 2020, this IPR&amp;D asset was presented separately as "assets held for sale" in conjunction with the sale of the Extremity Orthopedics business which is expected to be sold within twelve months. See Note 2, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Assets and Liabilities Held for Sale</span><span style="font-family:inherit;font-size:10pt;">, for details.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill and Intangible Assets with Indefinite Lives </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company tests goodwill and intangible assets with indefinite lives for impairment annually in the third quarter in accordance with ASC Topic 350. Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit or indefinite lived intangible asset below its carrying amount. The carrying value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including reporting unit specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of a reporting unit is less than its carrying amount, including goodwill. The Company may elect to bypass this qualitative evaluation for some or all of its reporting units and perform a quantitative test. During the third quarter of 2020, the Company began with the qualitative evaluation, which was sufficient to find </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> impairment.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For intangible assets with indefinite lives, the Company elected to bypass the qualitative evaluation for its Codman tradename intangible asset and perform a quantitative test during the third quarter 2020. In performing this test, the Company utilized a discount rate of </span><span style="font-family:inherit;font-size:10pt;"><span>11.5%</span></span><span style="font-family:inherit;font-size:10pt;">. The assumptions used in evaluating the Codman tradename for impairment are subject to change and are tracked against historical results by management. Based on the results of the quantitative test, the Company recorded </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> impairment to the Codman tradename intangible asset.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Based on quarter-end exchange rates, amortization expense (including amounts reported in cost of product revenues) is expected to be approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$15.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the remainder of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$62.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2021</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$59.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2022</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$58.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2023</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$58.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2024</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$58.4</span></span><span style="font-family:inherit;font-size:10pt;"> million in 2025 and </span><span style="font-family:inherit;font-size:10pt;"><span>$494.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> thereafter.</span></div> <div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in the carrying amount of goodwill for the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;">-month period ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Codman Specialty </span></div><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Surgical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Orthopedics and</span></div><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Tissue Technologies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">(In thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Goodwill at December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>653,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>300,780</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>954,280</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Transfer to assets held for sale (See Note 2. </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Assets Held for Sale</span><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(47,117</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(47,117</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Foreign currency translation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>8,928</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>3,465</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>12,393</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Goodwill at September 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>662,428</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>257,128</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>919,556</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 653500000 300780000 954280000 0 -47117000 -47117000 8928000 3465000 12393000 662428000 257128000 919556000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of the Company’s identifiable intangible assets were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:50%;"/><td style="width:9%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">September 30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">(Dollars in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Completed technology</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>19 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>891,554</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(250,609</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>640,945</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Customer relationships</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>12 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>223,512</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(138,989</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>84,523</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Trademarks/brand names</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>28 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>104,404</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(31,425</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>72,979</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Codman tradename</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Indefinite</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>167,013</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>167,013</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Supplier relationships</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>27 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>34,721</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(19,018</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>15,703</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">All other</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>4 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>11,101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(5,247</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>5,854</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Transfer to assets held for sale (See Note 2. </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Assets Held for Sale</span><span style="font-family:inherit;font-size:9.5pt;">)</span></div><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(39,821</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>26,489</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(13,332</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1,392,484</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(418,799</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>973,685</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:43%;"/><td style="width:12%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">(Dollars in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Completed technology</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>19 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>880,623</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(213,702</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>666,921</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Customer relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>12 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>222,575</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(119,393</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>103,182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Trademarks/brand names</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>28 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>103,873</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(28,514</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>75,359</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Codman tradename</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Indefinite</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>163,126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>163,126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Supplier relationships</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>27 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>34,721</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(17,947</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>16,774</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">All other</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> (1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>4 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>10,869</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(4,640</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>6,229</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1,415,787</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(384,196</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1,031,591</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, all other included IPR&amp;D of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0</span></span><span style="font-family:inherit;font-size:10pt;"> million, which was indefinite-lived. At September 30, 2020, this IPR&amp;D asset was presented separately as "assets held for sale" in conjunction with the sale of the Extremity Orthopedics business which is expected to be sold within twelve months. See Note 2, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Assets and Liabilities Held for Sale</span><span style="font-family:inherit;font-size:10pt;">, for details.</span></div> <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of the Company’s identifiable intangible assets were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:50%;"/><td style="width:9%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">September 30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">(Dollars in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Completed technology</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>19 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>891,554</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(250,609</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>640,945</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Customer relationships</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>12 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>223,512</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(138,989</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>84,523</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Trademarks/brand names</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>28 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>104,404</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(31,425</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>72,979</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Codman tradename</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Indefinite</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>167,013</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>167,013</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Supplier relationships</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>27 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>34,721</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(19,018</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>15,703</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">All other</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>4 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>11,101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(5,247</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>5,854</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Transfer to assets held for sale (See Note 2. </span><span style="font-family:inherit;font-size:9.5pt;font-style:italic;">Assets Held for Sale</span><span style="font-family:inherit;font-size:9.5pt;">)</span></div><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(39,821</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>26,489</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(13,332</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1,392,484</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(418,799</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>973,685</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:43%;"/><td style="width:12%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">(Dollars in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Completed technology</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>19 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>880,623</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(213,702</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>666,921</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Customer relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>12 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>222,575</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(119,393</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>103,182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Trademarks/brand names</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>28 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>103,873</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(28,514</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>75,359</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Codman tradename</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Indefinite</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>163,126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>163,126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Supplier relationships</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>27 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>34,721</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(17,947</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>16,774</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">All other</span><span style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> (1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>4 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>10,869</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(4,640</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>6,229</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1,415,787</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>(384,196</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span>1,031,591</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, all other included IPR&amp;D of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0</span></span><span style="font-family:inherit;font-size:10pt;"> million, which was indefinite-lived. At September 30, 2020, this IPR&amp;D asset was presented separately as "assets held for sale" in conjunction with the sale of the Extremity Orthopedics business which is expected to be sold within twelve months. See Note 2, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Assets and Liabilities Held for Sale</span><span style="font-family:inherit;font-size:10pt;">, for details.</span></div> P19Y 891554000 250609000 640945000 P12Y 223512000 138989000 84523000 P28Y 104404000 31425000 72979000 167013000 167013000 P27Y 34721000 19018000 15703000 P4Y 11101000 5247000 5854000 -39821000 -26489000 -13332000 1392484000 418799000 973685000 P19Y 880623000 213702000 666921000 P12Y 222575000 119393000 103182000 P28Y 103873000 28514000 75359000 163126000 163126000 P27Y 34721000 17947000 16774000 P4Y 10869000 4640000 6229000 1415787000 384196000 1031591000 1000000.0 0 0.115 0 15700000 62100000 59700000 58900000 58400000 58400000 494900000 DEBT <div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Amendment to the Sixth Amended and Restated Senior Credit Agreement</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 3, 2020, the Company entered into the sixth amendment and restatement (the "February 2020 Amendment") of its Senior Credit Facility (the "Senior Credit Facility") with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. The February 2020 Amendment extended the maturity date to February 3, 2025. The Company continues to have the aggregate principal amount of up to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 billion</span></span><span style="font-family:inherit;font-size:10pt;"> available to it through the following facilities: (i) a </span><span style="font-family:inherit;font-size:10pt;"><span>$877.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> Term Loan facility, and (ii) a </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 billion</span></span><span style="font-family:inherit;font-size:10pt;"> revolving credit facility, which includes a </span><span style="font-family:inherit;font-size:10pt;"><span>$60 million</span></span><span style="font-family:inherit;font-size:10pt;"> sublimit for the issuance of standby letters of credit and a </span><span style="font-family:inherit;font-size:10pt;"><span>$60 million</span></span><span style="font-family:inherit;font-size:10pt;"> sublimit for swingline loans. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July 14, 2020, the Company entered into an amendment (the "July 2020 Amendment") to the February 2020 Amendment of the Senior Credit Facility to increase financial flexibility in light of the unprecedented impact and uncertainty of the COVID-19 pandemic on the global economy. The July 2020 amendment does not increase the Company’s total indebtedness.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the July 14, 2020 amendment, the Company’s maximum consolidated total leverage ratio in the financial covenants (as defined in the Senior Credit Facility) was modified to the following:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:657px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:501px;"/><td style="width:5px;"/><td style="width:150px;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Maximum Consolidated Total Leverage Ratio</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Execution of July 2020 Amendment through June 30, 2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.50 to 1.00</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2021 through June 30, 2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.00 to 1.00</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2022 through June 30, 2023<br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.50 to 1.00<br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2023 and the last day of each fiscal quarter thereafter<br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.00 to 1.00<br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Borrowings under the Senior Credit Facility bear interest, at the Company’s option, at a rate equal to the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">i.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the Eurodollar Rate (as defined in the amendment and restatement) in effect from time to time plus the applicable rate (ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>1.00%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>2.25%</span></span><span style="font-family:inherit;font-size:10pt;">), or </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">ii.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the highest of: </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">1.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the weighted average overnight Federal funds rate, as published by the Federal Reserve Bank of New York, plus </span><span style="font-family:inherit;font-size:10pt;"><span>0.50%</span></span><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">2.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the prime lending rate of Bank of America, N.A. or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">3.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the one-month Eurodollar Rate plus </span><span style="font-family:inherit;font-size:10pt;"><span>1.00%</span></span><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The applicable rates are based on the Company’s consolidated total leverage ratio (defined as the ratio of (a) consolidated funded indebtedness as of such date less cash that is not subject to any restriction on the use or investment thereof to (b) consolidated EBITDA as defined by the July 2020 amendment, for the period of four consecutive fiscal quarters ending on such date).</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company will pay an annual commitment fee (ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>0.15%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>0.30%</span></span><span style="font-family:inherit;font-size:10pt;">), based on the Company's consolidated total leverage ratio, on the amount available for borrowing under the revolving credit facility.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Senior Credit Facility is collateralized by substantially all of the assets of the Company’s U.S. subsidiaries, excluding intangible assets. The Senior Credit Facility is subject to various financial and negative covenants and at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company was in compliance with all such covenants. In connection with the February 2020 Amendment, the Company capitalized </span><span style="font-family:inherit;font-size:10pt;"><span>$4.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> of financing costs in connection with modification of the Senior Credit Facility and wrote off </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> of previously capitalized financing costs during the first quarter of 2020. In connection with the July 2020 amendment, the Company expensed </span><span style="font-family:inherit;font-size:10pt;"><span>$3.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> of incremental financing costs in connection with the modification of the Senior Credit Facility during the third quarter of 2020.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$97.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$375.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding, respectively, under the revolving credit component of the Senior Credit Facility at weighted average interest rates of </span><span style="font-family:inherit;font-size:10pt;"><span>1.5%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>3.2%</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. At </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$877.5</span></span><span style="font-family:inherit;font-size:10pt;"> million outstanding, respectively, under the Term Loan component of the Senior Credit Facility at a weighted average interest rate of </span><span style="font-family:inherit;font-size:10pt;"><span>1.5%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>3.2%</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. At </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$22.5</span></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">million of the Term Loan component of the Senior Credit Facility is classified as current on the consolidated balance sheet as the first mandatory repayment is due June 30, 2021. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of outstanding borrowings of the Senior Credit Facility's revolving credit and Term Loan components at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$94.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$853.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. These fair values were determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable inputs that reflect unadjusted quoted prices for identical assets or liabilities. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Letters of credit outstanding as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:10pt;">. There were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> amounts drawn as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual repayments of the Term Loan component of the Senior Credit Facility are due as follows:</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:77%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Quarter Ended September 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Principal Repayment</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remainder of 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,875</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>669,375</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>877,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The outstanding balance of the revolving credit component of the Senior Credit Facility is due on February 3, 2025. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Convertible Senior Notes</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 4, 2020, the Company issued </span><span style="font-family:inherit;font-size:10pt;"><span>$575.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of its </span><span style="font-family:inherit;font-size:10pt;"><span>0.5%</span></span><span style="font-family:inherit;font-size:10pt;"> Convertible Senior Notes due 2025 (the "2025 Notes"). The 2025 Notes will mature on August 15, 2025 and bear interest at a rate of </span><span style="font-family:inherit;font-size:10pt;"><span>0.5%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum payable semi-annually in arrears, unless earlier converted, repurchased or redeemed in accordance with the terms of the Notes. The portion of debt proceeds that was classified as equity at the time of the offering was </span><span style="font-family:inherit;font-size:10pt;"><span>$104.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, and that amount is being amortized to interest expense using the effective interest method through August 2025. The effective interest rate implicit in the liability component is </span><span style="font-family:inherit;font-size:10pt;"><span>4.2%</span></span><span style="font-family:inherit;font-size:10pt;">. In connection with this offering, the Company capitalized </span><span style="font-family:inherit;font-size:10pt;"><span>$13.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> of financing fees. At </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the carrying amount of the liability component was </span><span style="font-family:inherit;font-size:10pt;"><span>$481.5</span></span><span style="font-family:inherit;font-size:10pt;"> million, the remaining unamortized discount was </span><span style="font-family:inherit;font-size:10pt;"><span>$93.5</span></span><span style="font-family:inherit;font-size:10pt;"> million, and the principal amount outstanding was </span><span style="font-family:inherit;font-size:10pt;"><span>$575.0</span></span><span style="font-family:inherit;font-size:10pt;"> million. The fair value of the 2025 Notes at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$541.8 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The 2025 Notes are senior, unsecured obligations of the Company, and are convertible into cash and shares of its common stock based on initial conversion rate, subject to adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>13.5739</span></span><span style="font-family:inherit;font-size:10pt;"> shares per </span><span style="font-family:inherit;font-size:10pt;">$1,000</span><span style="font-family:inherit;font-size:10pt;"> principal amounts of the 2025 Notes (which represents an initial conversion price of </span><span style="font-family:inherit;font-size:10pt;"><span>$73.67</span></span><span style="font-family:inherit;font-size:10pt;"> per share). The 2025 Notes convert only in the following circumstances: (1) if the closing price of the Company's common stock has been at least </span><span style="font-family:inherit;font-size:10pt;"><span>130%</span></span><span style="font-family:inherit;font-size:10pt;"> of the conversion price during the period; (2) if the average trading price per $1000 principal amount of the 2025 Notes is less than or equal to </span><span style="font-family:inherit;font-size:10pt;"><span>98%</span></span><span style="font-family:inherit;font-size:10pt;"> of the average conversion value of the 2025 Notes during a period as defined in the indenture; (3) at any time on or after February 20, 2023; or (4) if specified corporate transactions occur. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, none of these conditions existed with respect to the 2025 Notes and as a result the 2025 Notes are classified as long term.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Holders of the Notes will have the right to require the Company to repurchase for cash all or a portion of their Notes at </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of their principal amount, plus any accrued and unpaid interest, upon the occurrence of a fundamental change (as defined in the indenture relating to the Notes). The Company will also be required to increase the conversion rate for holders who convert their Notes in connection with certain fundamental changes occurring prior to the maturity date or following delivery by the Company of a notice of redemption.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the issuance of the 2025 Notes, the Company entered into call transactions and warrant transactions, primarily with affiliates of the initial purchasers of the 2025 Notes (the “hedge participants”). The cost of the call transactions was </span><span style="font-family:inherit;font-size:10pt;"><span>$104.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the 2025 Notes. The Company received </span><span style="font-family:inherit;font-size:10pt;"><span>$44.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> of proceeds from the warrant transactions for the 2025 Notes. The call transactions involved purchasing call options from the hedge participants, and the warrant transactions involved selling call options to the hedge participants with a higher strike price than the purchased call options. The initial strike price of the call transactions was </span><span style="font-family:inherit;font-size:10pt;"><span>$73.67</span></span><span style="font-family:inherit;font-size:10pt;">, subject to anti-dilution adjustments substantially similar to those in the 2025 </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Notes. The initial strike price of the warrant transactions was </span><span style="font-family:inherit;font-size:10pt;"><span>$113.34</span></span><span style="font-family:inherit;font-size:10pt;"> for the 2025 Notes, subject to customary anti-dilution adjustments.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized cash interest related to the contractual interest coupon of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.9</span></span><span style="font-family:inherit;font-size:10pt;"> million and amortization of the discount on the liability component of </span><span style="font-family:inherit;font-size:10pt;"><span>$11.1</span></span><span style="font-family:inherit;font-size:10pt;"> million for a total interest charge of </span><span style="font-family:inherit;font-size:10pt;"><span>$13.0</span></span><span style="font-family:inherit;font-size:10pt;"> million on the 2025 Notes.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Securitization Facility</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the fourth quarter of 2018, the Company entered into an accounts receivable securitization facility (the "Securitization Facility") under which accounts receivable of certain domestic subsidiaries are sold on a non-recourse basis to a special purpose entity (“SPE”), which is a bankruptcy-remote, consolidated subsidiary of the Company. Accordingly, the assets of the SPE are not available to satisfy the obligations of the Company or any of its subsidiaries. From time to time, the SPE may finance such accounts receivable with a revolving loan facility secured by a pledge of such accounts receivable. The amount of outstanding borrowings on the Securitization Facility at any one time is limited to </span><span style="font-family:inherit;font-size:10pt;"><span>$150.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Securitization Facility Agreement ("Securitization Agreement") is for an initial three-year term and may be extended. The Securitization Agreement governing the Securitization Facility contains certain covenants and termination events. An occurrence of an event of default or a termination event under this Securitization Agreement may give rise to the right of its counterparty to terminate this facility. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company was in compliance with the covenants and none of the termination events had occurred. At </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>$92.3</span></span><span style="font-family:inherit;font-size:10pt;"> million and </span><span style="font-family:inherit;font-size:10pt;"><span>$104.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of outstanding borrowings under its Securitization Facility at a weighted average interest rate of </span><span style="font-family:inherit;font-size:10pt;"><span>1.4%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>2.8%</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><span style="font-family:inherit;font-size:10pt;">The fair value of the outstanding borrowing of the Securitization Facility at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$92.8 million</span></span>. 2200000000 877500000 1300000000 60000000 60000000 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the July 14, 2020 amendment, the Company’s maximum consolidated total leverage ratio in the financial covenants (as defined in the Senior Credit Facility) was modified to the following:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:657px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:501px;"/><td style="width:5px;"/><td style="width:150px;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Maximum Consolidated Total Leverage Ratio</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Execution of July 2020 Amendment through June 30, 2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.50 to 1.00</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2021 through June 30, 2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.00 to 1.00</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2022 through June 30, 2023<br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.50 to 1.00<br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2023 and the last day of each fiscal quarter thereafter<br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.00 to 1.00<br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.0100 0.0225 0.0050 0.0100 0.0015 0.0030 4600000 1200000 3300000 97500000 375000000.0 0.015 0.032 877500000 0.015 0.032 22500000 94600000 853700000 1600000 800000 0 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual repayments of the Term Loan component of the Senior Credit Facility are due as follows:</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:77%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Quarter Ended September 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Principal Repayment</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remainder of 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,875</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>669,375</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>877,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 33750000 45000000 61875000 67500000 669375000 877500000 575000000.0 0.005 0.005 104500000 0.042 13200000 481500000 93500000 575000000.0 541800000 13.5739 73.67 1.30 0.98 1 104200000 44500000 73.67 113.34 1900000 11100000 13000000.0 150000000.0 92300000 104500000 0.014 0.028 92800000 DERIVATIVE INSTRUMENTS <div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Rate Hedging</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s interest rate risk relates to U.S. dollar denominated variable interest rate borrowings. The Company uses interest rate swap derivative instruments to manage earnings and cash flow exposure resulting from changes in interest rates. These interest rate swaps apply a fixed interest rate on a portion of the Company's expected LIBOR-indexed floating-rate borrowings. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company held the following interest rate swaps as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (dollar amounts in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;padding-left:12px;text-indent:-12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">September 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">September 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Hedged Item</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Notional Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Notional Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Designation Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Effective Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Termination Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Fixed Interest Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Asset (Liability)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">3-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>50,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">February 6, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">June 30, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">June 30, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1.834</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">1-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>100,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">February 6, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">June 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">June 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1.652</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">1-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>100,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>100,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">March 27, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">June 30, 2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1.971</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1,377</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(581</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">1-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>150,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>150,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 13, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 31, 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2.201</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(6,901</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(2,880</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">1-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>150,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>150,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 13, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">January 1, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 31, 2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2.201</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(6,922</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(2,880</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">1-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>100,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>100,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 13, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">July 1, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">June 30, 2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2.423</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(8,454</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(3,517</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">1-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>50,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>50,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 13, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">July 1, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">June 30, 2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2.423</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(4,064</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1,778</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">1-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>200,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>200,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 13, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 31, 2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2.313</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(18,188</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(6,595</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">1-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>75,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>75,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">October 10, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">July 1, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">June 30, 2025</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>3.220</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(10,608</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(5,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">1-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>75,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>75,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">October 10, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">July 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">June 30, 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>3.199</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(10,871</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(5,747</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">1-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>75,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>75,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">October 10, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">July 1, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">June 30, 2025</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>3.209</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(10,586</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(5,807</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">1-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>100,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>100,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 18, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 30, 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 31, 2027</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2.885</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(11,282</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(4,930</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">1-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>100,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>100,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 18, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 30, 2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 31, 2027</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2.867</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(11,127</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(4,691</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Total interest rate derivatives designated as cash flow hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1,175,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1,325,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(100,380</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(45,145</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has designated these derivative instruments as cash flow hedges. The Company assesses the effectiveness of these derivative instruments and has recorded the changes in the fair value of the derivative instrument designated as a cash flow hedge as unrealized gains or losses in accumulated other comprehensive loss (“AOCL”), net of tax, until the hedged item affected earnings, at which point any gain or loss was reclassified to earnings. If the hedged cash flow does not occur, or if it becomes probable that it will not occur, the Company will reclassify the remaining amount of any gain or loss on the related cash flow hedge recorded in AOCL to interest expense at that time.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Hedging</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time the Company enters into foreign currency hedge contracts intended to protect the U.S. dollar value of certain forecasted foreign currency denominated transactions. The Company assesses the effectiveness of the contracts that are designated as hedging instruments. The changes in fair value of foreign currency cash flow hedges are recorded in AOCL, net of tax, until the hedged item affects earnings. Once the related hedged item affects earnings, the Company reclassifies amounts recorded in AOCL to earnings. If the hedged forecasted transaction does not occur, or if it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. For contracts not designated as hedging instruments, the changes in fair value of the contracts are recognized in other income (expense), net in the consolidated statements of operation, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The success of the Company’s hedging program depends, in part, on forecasts of certain activity denominated in foreign currency. The Company may experience unanticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activities during periods of currency volatility. In addition, changes in currency exchange rates related to any unhedged transactions may affect earnings and cash flows. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cross-Currency Rate Swaps</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 2, 2017, the Company entered into cross-currency swap agreements to convert a notional amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$300.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> equivalent to </span><span style="font-family:inherit;font-size:10pt;"><span>291.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> of CHF denominated intercompany loans into U.S. dollars. The CHF-denominated intercompany loans were the result of the purchase of intellectual property by a subsidiary in Switzerland as part of an acquisition. The objective of these cross-currency swaps is to reduce volatility of earnings and cash flows associated with changes in the foreign currency exchange rate. Under the terms of these contracts, which have been designated as cash flow hedges, the Company will make interest payments in Swiss Francs and receive interest in U.S. dollars. Upon the maturity of these contracts, the Company will pay the principal amount of the loans in Swiss Francs and receive U.S. dollars from the counterparties.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company held the following cross-currency rate swaps as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (dollar amounts in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:21%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Termination Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fixed Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate Notional Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Asset (Liability)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pay CHF</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 2, 2017</span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 2, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.75%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CHF</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,565</span></span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(101</span></span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receive U.S.$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.38%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,333</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pay CHF</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 2, 2017</span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 2, 2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.85%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CHF</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,533</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,003</span></span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(119</span></span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receive U.S.$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.46%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pay CHF</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 2, 2017</span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 2, 2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.95%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CHF</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,598</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,167</span></span></div></td><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(289</span></span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receive U.S.$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.52%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,735</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(509</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 2, 2020 in accordance with the termination date, the Company settled a cross-currency swap designated as a cash flow hedge of an intercompany loan with an aggregate notional amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$33.3 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The cross- currency swaps are carried on the consolidated balance sheet at fair value, and changes in the fair values are recorded as unrealized gains or losses in AOCL. For the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded losses of </span><span style="font-family:inherit;font-size:10pt;"><span>$6.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$12.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in other income, net related to change in fair value related to the foreign currency rate translation to offset the gains recognized on the intercompany loans. For the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded gains of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in other income, net related to change in fair value related to the foreign currency rate translation to offset the losses recognized on the intercompany loans.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded a loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$6.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and a gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> in AOCL, respectively, related to change in fair value of the cross-currency swaps. For the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded gains of </span><span style="font-family:inherit;font-size:10pt;"><span>$9.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$15.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> in AOCL, respectively, related to change in fair value of the cross-currency swaps.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded gains of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps. For the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded gains of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$5.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated gain that is expected to be reclassified to other income (expense), net from AOCL as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> within the next twelve months is </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company does not expect any gains or losses will be reclassified into earnings as a result of the discontinuance of these cash flow hedges because the original forecasted transaction will not occur.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Investment Hedges</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company manages certain foreign exchange risks through a variety of strategies, including hedging. The Company is exposed to foreign exchange risk from its international operations through foreign currency purchases, net investments in foreign subsidiaries, and foreign currency assets and liabilities created in the normal course of business. On October 1, 2018, the Company entered into cross-currency swap agreements designated as net investment hedges to partially offset the effects of foreign currency on foreign subsidiaries.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company held the following cross-currency rate swaps designated as net investment hedges as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively (dollar amounts in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:14%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:2%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Termination Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fixed Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate Notional Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Asset (Liability)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pay EUR</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 3, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EUR</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,859</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>589</span></span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,459</span></span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receive U.S.$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.01%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pay EUR</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 3, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EUR</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,760</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,443</span></span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,087</span></span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receive U.S.$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.57%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pay EUR</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 3, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2025</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EUR</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,820</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,398</span></span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,032</span></span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receive U.S.$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.19%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pay GBP</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 3, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2025</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.67%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GBP</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>128,284</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,580</span></span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(154</span></span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receive U.S.$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.71%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>167,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pay CHF</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 3, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2025</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CHF</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>165,172</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,828</span></span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,221</span></span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receive GBP</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.67%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GBP</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>128,284</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,182</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,645</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The cross-currency swaps were carried on the consolidated balance sheet at fair value and changes in the fair values were recorded as unrealized gains or losses in AOCL. For the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$11.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and a gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.1</span></span><span style="font-family:inherit;font-size:10pt;"> million in AOCL related to the change in fair value of the cross-currency swaps. For the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded gains of </span><span style="font-family:inherit;font-size:10pt;"><span>$17.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$26.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> in AOCL related to the change in fair value of the cross-currency swaps.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded gains of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$6.6</span></span><span style="font-family:inherit;font-size:10pt;"> million in interest income included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps. For the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded gains of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$7.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in interest income included in the consolidation statements of operations related to the interest rate differential of the cross-currency swaps.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated gain that is expected to be reclassified to interest income from AOCL as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> within the next twelve months is </span><span style="font-family:inherit;font-size:10pt;"><span>$7.7 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Counterparty Credit Risk</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company manages its concentration of counterparty credit risk on its derivative instruments by limiting acceptable counterparties to a group of major financial institutions with investment grade credit ratings, and by actively monitoring their credit ratings and outstanding positions on an ongoing basis. Therefore, the Company considers the credit risk of the counterparties to be low. Furthermore, none of the Company’s derivative transactions are subject to collateral or other security arrangements, and none contain provisions that depend upon the Company’s credit ratings from any credit rating agency.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Derivative Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has classified all of its derivative instruments within Level 2 of the fair value hierarchy because observable inputs are available for substantially the full term of the derivative instruments. The fair values of the interest rate swaps and cross-currency swaps were developed using a market approach based on publicly available market yield curves and the terms of the swap. The Company performs ongoing assessments of counterparty credit risk. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the fair value for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value as of</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Location on Balance Sheet </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivatives designated as hedges — Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Cash Flow Hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,608</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,032</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Net Investment Hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,717</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,952</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Net Investment Hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,071</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,465</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total derivatives designated as hedges — Assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,396</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,461</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivatives designated as hedges — Liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses and other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Cash Flow Hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,324</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,635</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,565</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Cash Flow Hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78,056</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,522</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,777</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,440</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Net Investment Hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,605</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,772</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total derivatives designated as hedges — Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122,327</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,470</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company classifies derivative assets and liabilities as non-current based on the cash flows expected to be incurred within the following 12 months.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following presents the effect of derivative instruments designated as cash flow hedges on the accompanying condensed consolidated statement of operations during the </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">: </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance in AOCL</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Beginning of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gain (Loss)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Recognized in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">AOCL</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount of Gain (Loss)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Reclassified from</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">AOCL into</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance in AOCL</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">End of Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Location in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Statements of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operations</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;text-decoration:underline;">Cash Flow Hedges</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate swap</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(102,128</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(3,971</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(5,718</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(100,381</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest expense</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cross-currency swap</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>5,843</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(6,272</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(5,353</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4,924</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other income (expense),net</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;text-decoration:underline;">Net Investment Hedges</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cross-currency swap</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>22,223</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(11,254</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,202</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>8,767</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(74,062</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(21,497</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(8,869</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(86,690</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;text-decoration:underline;">Cash Flow Hedges</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate swap</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(43,161</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(13,788</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>237</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(57,186</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest expense</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cross-currency swap</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(2,284</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>9,661</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>7,520</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(143</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other income (expense),net</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;text-decoration:underline;">Net Investment Hedges</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cross-currency swap</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4,054</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>17,136</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,489</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>18,701</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(41,391</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>13,009</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>10,246</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(38,628</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance in AOCL</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Beginning of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gain (Loss)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Recognized in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">AOCL</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount of Gain (Loss)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Reclassified from</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">AOCL into</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance in AOCL</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">End of Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Location in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Statements of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operations</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;text-decoration:underline;">Cash Flow Hedges</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate swap</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(45,146</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(65,608</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(10,373</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(100,381</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest expense</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cross-currency swap</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>177</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(2,688</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(7,435</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4,924</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other income (expense),net</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;text-decoration:underline;">Net Investment Hedges</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cross-currency swap</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>10,229</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>5,102</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6,564</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>8,767</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(34,740</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(63,194</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(11,244</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(86,690</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended September 30, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;text-decoration:underline;">Cash Flow Hedges</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate swap</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>619</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(54,841</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,964</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(57,186</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest expense</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cross-currency swap</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(6,190</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>15,418</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>9,371</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(143</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other income (expense), net</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;text-decoration:underline;">Net Investment Hedges</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cross-currency swap</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(632</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>26,558</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>7,225</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>18,701</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(6,203</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(12,865</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>19,560</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(38,628</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 50000000 0.01834 0 -2000 0 100000000 0.01652 0 12000 100000000 100000000 0.01971 -1377000 -581000 150000000 150000000 0.02201 -6901000 -2880000 150000000 150000000 0.02201 -6922000 -2880000 100000000 100000000 0.02423 -8454000 -3517000 50000000 50000000 0.02423 -4064000 -1778000 200000000 200000000 0.02313 -18188000 -6595000 75000000 75000000 0.03220 -10608000 -5750000 75000000 75000000 0.03199 -10871000 -5747000 75000000 75000000 0.03209 -10586000 -5807000 100000000 100000000 0.02885 -11282000 -4930000 100000000 100000000 0.02867 -11127000 -4691000 1175000000 1325000000 -100380000 -45145000 300000000.0 291200000 0.0175 32355000 -1565000 -101000 0.0438 33333000 0.0185 48533000 -2003000 -119000 0.0446 50000000 0.0195 145598000 -4167000 -289000 0.0452 150000000 -7735000 -509000 33300000 -6900000 -12000000.0 5700000 3900000 -6300000 2700000 9700000 15400000 1500000 4500000 1800000 5500000 3000000.0 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company held the following cross-currency rate swaps designated as net investment hedges as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively (dollar amounts in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:14%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:2%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Termination Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fixed Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate Notional Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Asset (Liability)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pay EUR</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 3, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EUR</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,859</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>589</span></span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,459</span></span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receive U.S.$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.01%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pay EUR</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 3, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EUR</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,760</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,443</span></span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,087</span></span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receive U.S.$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.57%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pay EUR</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 3, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2025</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EUR</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,820</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,398</span></span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,032</span></span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receive U.S.$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.19%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pay GBP</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 3, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2025</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.67%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GBP</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>128,284</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,580</span></span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(154</span></span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receive U.S.$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.71%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>167,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pay CHF</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 3, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2025</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CHF</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>165,172</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,828</span></span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,221</span></span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receive GBP</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.67%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GBP</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>128,284</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,182</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,645</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company held the following cross-currency rate swaps as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (dollar amounts in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:21%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Termination Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fixed Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate Notional Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Asset (Liability)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pay CHF</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 2, 2017</span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 2, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.75%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CHF</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,565</span></span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(101</span></span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receive U.S.$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.38%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,333</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pay CHF</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 2, 2017</span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 2, 2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.85%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CHF</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,533</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,003</span></span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(119</span></span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receive U.S.$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.46%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pay CHF</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 2, 2017</span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 2, 2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.95%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CHF</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,598</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,167</span></span></div></td><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(289</span></span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receive U.S.$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.52%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,735</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(509</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company held the following interest rate swaps as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (dollar amounts in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;padding-left:12px;text-indent:-12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">September 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">September 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Hedged Item</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Notional Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Notional Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Designation Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Effective Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Termination Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Fixed Interest Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Asset (Liability)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">3-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>50,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">February 6, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">June 30, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">June 30, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1.834</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">1-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>100,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">February 6, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">June 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">June 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1.652</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">1-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>100,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>100,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">March 27, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">June 30, 2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1.971</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1,377</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(581</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">1-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>150,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>150,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 13, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 31, 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2.201</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(6,901</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(2,880</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">1-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>150,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>150,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 13, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">January 1, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 31, 2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2.201</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(6,922</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(2,880</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">1-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>100,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>100,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 13, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">July 1, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">June 30, 2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2.423</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(8,454</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(3,517</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">1-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>50,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>50,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 13, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">July 1, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">June 30, 2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2.423</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(4,064</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1,778</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">1-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>200,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>200,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 13, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 31, 2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2.313</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(18,188</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(6,595</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">1-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>75,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>75,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">October 10, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">July 1, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">June 30, 2025</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>3.220</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(10,608</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(5,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">1-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>75,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>75,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">October 10, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">July 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">June 30, 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>3.199</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(10,871</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(5,747</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">1-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>75,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>75,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">October 10, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">July 1, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">June 30, 2025</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>3.209</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(10,586</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(5,807</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">1-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>100,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>100,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 18, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 30, 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 31, 2027</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2.885</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(11,282</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(4,930</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">1-month USD LIBOR Loan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>100,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>100,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 18, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 30, 2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">December 31, 2027</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2.867</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(11,127</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(4,691</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Total interest rate derivatives designated as cash flow hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1,175,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1,325,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(100,380</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(45,145</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 44859000 589000 2459000 0.0301 52000000 0 51760000 2443000 3087000 0.0257 60000000 0 38820000 2398000 2032000 0.0219 45000000 0.0167 128284000 8580000 -154000 0.0271 167500000 0 165172000 -6828000 1221000 0.0167 128284000 7182000 8645000 -11300000 5100000 17100000 26600000 2200000 6600000 2500000 7200000 7700000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the fair value for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value as of</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Location on Balance Sheet </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivatives designated as hedges — Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Cash Flow Hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,608</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,032</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Net Investment Hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,717</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,952</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Net Investment Hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,071</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,465</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total derivatives designated as hedges — Assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,396</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,461</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivatives designated as hedges — Liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses and other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Cash Flow Hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,324</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,635</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,565</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Cash Flow Hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78,056</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,522</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,777</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,440</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">Net Investment Hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swap</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,605</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,772</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total derivatives designated as hedges — Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122,327</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,470</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company classifies derivative assets and liabilities as non-current based on the cash flows expected to be incurred within the following 12 months.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 12000 4608000 5032000 7717000 7952000 9071000 3465000 21396000 16461000 22324000 6635000 1565000 101000 78056000 38522000 10777000 5440000 9605000 2772000 122327000 53470000 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following presents the effect of derivative instruments designated as cash flow hedges on the accompanying condensed consolidated statement of operations during the </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">: </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance in AOCL</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Beginning of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gain (Loss)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Recognized in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">AOCL</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount of Gain (Loss)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Reclassified from</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">AOCL into</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance in AOCL</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">End of Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Location in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Statements of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operations</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;text-decoration:underline;">Cash Flow Hedges</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate swap</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(102,128</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(3,971</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(5,718</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(100,381</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest expense</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cross-currency swap</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>5,843</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(6,272</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(5,353</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4,924</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other income (expense),net</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;text-decoration:underline;">Net Investment Hedges</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cross-currency swap</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>22,223</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(11,254</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,202</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>8,767</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(74,062</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(21,497</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(8,869</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(86,690</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;text-decoration:underline;">Cash Flow Hedges</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate swap</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(43,161</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(13,788</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>237</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(57,186</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest expense</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cross-currency swap</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(2,284</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>9,661</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>7,520</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(143</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other income (expense),net</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;text-decoration:underline;">Net Investment Hedges</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cross-currency swap</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4,054</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>17,136</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,489</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>18,701</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(41,391</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>13,009</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>10,246</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(38,628</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance in AOCL</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Beginning of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gain (Loss)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Recognized in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">AOCL</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount of Gain (Loss)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Reclassified from</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">AOCL into</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance in AOCL</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">End of Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Location in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Statements of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operations</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;text-decoration:underline;">Cash Flow Hedges</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate swap</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(45,146</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(65,608</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(10,373</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(100,381</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest expense</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cross-currency swap</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>177</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(2,688</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(7,435</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4,924</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other income (expense),net</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;text-decoration:underline;">Net Investment Hedges</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cross-currency swap</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>10,229</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>5,102</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6,564</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>8,767</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(34,740</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(63,194</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(11,244</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(86,690</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended September 30, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;text-decoration:underline;">Cash Flow Hedges</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate swap</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>619</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(54,841</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,964</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(57,186</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest expense</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cross-currency swap</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(6,190</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>15,418</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>9,371</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(143</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other income (expense), net</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;text-decoration:underline;">Net Investment Hedges</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cross-currency swap</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(632</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>26,558</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>7,225</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>18,701</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(6,203</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(12,865</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>19,560</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(38,628</span></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -102128000 -3971000 -5718000 -100381000 5843000 -6272000 -5353000 4924000 22223000 -11254000 2202000 8767000 -74062000 -21497000 -8869000 -86690000 -43161000 -13788000 237000 -57186000 -2284000 9661000 7520000 -143000 4054000 17136000 2489000 18701000 -41391000 13009000 10246000 -38628000 -45146000 -65608000 -10373000 -100381000 177000 -2688000 -7435000 4924000 10229000 5102000 6564000 8767000 -34740000 -63194000 -11244000 -86690000 619000 -54841000 2964000 -57186000 -6190000 15418000 9371000 -143000 -632000 26558000 7225000 18701000 -6203000 -12865000 19560000 -38628000 STOCK-BASED COMPENSATION<div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company had stock options, restricted stock awards, performance stock units, contract stock awards and restricted stock unit awards outstanding under </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> plans, the 2001 Equity Incentive Plan (the “2001 Plan”) and the 2003 Equity Incentive Plan (the “2003 Plan,” and collectively, the “Plans”). </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options issued under the Plans become exercisable over specified periods, generally within </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>four years</span></span><span style="font-family:inherit;font-size:10pt;"> from the date of grant for officers and employees, and within </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;"> from date of grant for directors and generally expire </span><span style="font-family:inherit;font-size:10pt;"><span>eight years</span></span><span style="font-family:inherit;font-size:10pt;"> from the grant </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">date for employees, and from </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">six</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;"> for directors and certain executive officers. The Company values stock option grants using the binomial distribution model. Restricted stock issued under the Plans vests over specified periods, generally </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>three years</span></span><span style="font-family:inherit;font-size:10pt;"> after the date of grant. The vesting of performance stock issued under the Plans is subject to service and performance conditions.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Stock Options</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, there were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$6.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation costs related to unvested stock options. These costs are expected to be recognized over a weighted-average period of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>three years</span></span><span style="font-family:inherit;font-size:10pt;">. There were </span><span style="font-family:inherit;font-size:10pt;"><span>348,587</span></span><span style="font-family:inherit;font-size:10pt;"> stock options granted during the </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">. For the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the weighted average grant date fair value for stock options was </span><span style="font-family:inherit;font-size:10pt;"><span>$13.03</span></span><span style="font-family:inherit;font-size:10pt;"> per option.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Awards of Restricted Stock and Performance Stock</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Performance stock and restricted stock awards generally have requisite service periods of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>three years</span></span><span style="font-family:inherit;font-size:10pt;">. Performance stock units are subject to graded vesting conditions based on revenue goals of the Company. The Company expenses the fair value of restricted stock awards on a straight-line basis over the requisite service period. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, there was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$27.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation costs related to these unvested awards. The Company expects to recognize these costs over a weighted-average period of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>two years</span></span><span style="font-family:inherit;font-size:10pt;">. The Company granted </span><span style="font-family:inherit;font-size:10pt;"><span>322,485</span></span><span style="font-family:inherit;font-size:10pt;"> restricted stock awards and </span><span style="font-family:inherit;font-size:10pt;"><span>180,875</span></span><span style="font-family:inherit;font-size:10pt;"> performance stock awards during the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">. For the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the weighted average grant date fair value for restricted stock awards and performance stock units was </span><span style="font-family:inherit;font-size:10pt;"><span>$44.08</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$43.39</span></span><span style="font-family:inherit;font-size:10pt;"> per award, respectively.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also maintains an Employee Stock Purchase Plan (the “ESPP”), which provides eligible employees with the opportunity to acquire shares of common stock at periodic intervals by means of accumulated payroll deductions. The ESPP is a non-compensatory plan based on its terms.</span></div> 2 P4Y P1Y P8Y P10Y P3Y 6000000.0 P3Y 348587 13.03 P3Y 27500000 P2Y 322485 180875 44.08 43.39 RETIREMENT PLANS<div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company maintains defined benefit pension plans that cover certain employees in France, Japan, Germany and Switzerland.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net periodic benefit costs for the Company’s defined benefit pension plans for the three and </span><span style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0</span></span><span style="font-family:inherit;font-size:10pt;"> million, respectively. The components of the net periodic benefit costs other than the service cost component of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.9</span></span><span style="font-family:inherit;font-size:10pt;"> million for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, respectively, are included in other income (expense), net in the consolidated statements of operations.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net periodic benefit costs for the Company’s defined benefit pension plans for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0</span></span><span style="font-family:inherit;font-size:10pt;"> million and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.1</span></span><span style="font-family:inherit;font-size:10pt;"> million, respectively. The components of the net periodic benefit costs other than the service cost component of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, are included in other income (expense), net in the consolidated statements of operations.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated fair values of plan assets were </span><span style="font-family:inherit;font-size:10pt;"><span>$33.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$30.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. The net plan assets of the pension plans are invested in common trusts as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. Common trusts are classified as Level 2 in the fair value hierarchy. The fair value of common trusts is valued at the net asset value based on the fair values of the underlying investments of the trusts as determined by the sponsor of the trusts. The investment strategy of the Company's defined benefit plans is both to meet the liabilities of the plans as they fall due and to maximize the return on invested assets within an appropriate risk profile.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred Compensation Plan</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2019, the Company adopted the Integra LifeSciences Deferred Compensation Plan (the “Plan”). Under the Plan, certain employees of the Company may defer the payment and taxation of up to </span><span style="font-family:inherit;font-size:10pt;"><span>75%</span></span><span style="font-family:inherit;font-size:10pt;"> of their base salary and up to </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of bonus amounts and other eligible cash compensation. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the first quarter of 2020, employees participating in the Plan began to defer their compensation. This deferred compensation is invested in funds offered under the Plan and is valued based on Level 1 measurements in the fair value hierarchy. The purpose of the Plan is to retain key employees by providing them with an opportunity to defer a portion of their compensation as elected by the participant in accordance with the Plan. Any amounts set aside to defray the liabilities assumed by the Company will remain the general assets of the Company until such amounts are distributed to the participants. Assets of the Company's deferred compensation plan are included in Other current assets and recorded at fair value based on their quoted market prices. The fair value of these assets at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7</span></span><span style="font-family:inherit;font-size:10pt;"> million. Offsetting liabilities relating to the deferred compensation plan are included in Other liabilities.</span></div> 1000000.0 3000000.0 1000000.0 2900000 1000000.0 2100000 700000 2000000.0 33200000 30800000 0.75 1 1700000 LEASES AND RELATED PARTY LEASES<div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company leases administrative, manufacturing, research and distribution facilities and vehicles through operating lease agreements. The Company has no finance leases as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">. Many of the Company's leases include both lease (e.g., fixed payments including rent) and non-lease components (e.g., common-area or other maintenance costs). For vehicles, the Company has elected the practical expedient to group lease and non-lease components. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Most facility leases include </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> or more options to renew. The exercise of lease renewal options is typically at the Company's sole discretion, therefore, the majority of renewals to extend the lease terms are not included in the Right of Use ("ROU") assets and lease liabilities as they are not reasonably certain of exercise. The Company regularly evaluates renewal options and when they are reasonably certain of exercise, the renewal period is included in the lease term.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As most of the Company's leases do not provide an implicit rate, the Company uses a collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease expense for the </span><span style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, was </span><span style="font-family:inherit;font-size:10pt;"><span>$14.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$14.2</span></span><span style="font-family:inherit;font-size:10pt;"> million respectively, which includes </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, in related party operating lease expense. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental balance sheet information related to operating leases at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:81%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands, except lease term and discount rate)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term (in years):</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leased facilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leased vehicles</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average discount rate:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leased facilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leased vehicles</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to leases for the </span><span style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.890625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:66%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,976</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,680</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ROU assets obtained in exchange for lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,007</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,860</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum lease payments under operating leases at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Related Parties</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Third Parties</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,742</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,816</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,209</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,505</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,224</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,520</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,782</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,078</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,996</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,292</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,426</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,176</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total minimum lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,684</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>137,703</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,387</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Imputed interest</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,091</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101,296</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Current lease liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,518</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term lease liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,778</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Related Party Leases </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company leases its manufacturing facility in Plainsboro, New Jersey, from a general partnership that is </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> owned by a corporation whose shareholders are trusts, whose beneficiaries include family members of the Company’s principal stockholder and former director. The term of the current lease agreement is through October 31, 2029 at an annual rate of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> per year. The current lease agreement also provides (i) a </span><span style="font-family:inherit;font-size:10pt;"><span>5</span></span><span style="font-family:inherit;font-size:10pt;">-year renewal option for the Company to extend the lease from </span><span style="font-family:inherit;font-size:10pt;"><span>November 1, 2029 through October 31, 2034</span></span><span style="font-family:inherit;font-size:10pt;"> at the fair market rental rate of the premises, and (ii) another </span><span style="font-family:inherit;font-size:10pt;"><span>5</span></span><span style="font-family:inherit;font-size:10pt;">-year renewal option to extend the lease from </span><span style="font-family:inherit;font-size:10pt;"><span>November 1, 2034 through October 31, 2039</span></span><span style="font-family:inherit;font-size:10pt;"> at the fair market rental rate of the premises.</span></div> 1 14600000 14200000 200000 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental balance sheet information related to operating leases at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:81%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands, except lease term and discount rate)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term (in years):</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leased facilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leased vehicles</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average discount rate:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leased facilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leased vehicles</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> P11Y9M18D P1Y4M24D 0.046 0.022 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to leases for the </span><span style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.890625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:66%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,976</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,680</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ROU assets obtained in exchange for lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,007</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,860</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 10976000 10680000 6007000 41860000 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum lease payments under operating leases at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Related Parties</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Third Parties</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,742</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,816</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,209</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,505</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,224</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,520</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,782</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,078</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,996</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,292</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,426</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,176</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total minimum lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,684</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>137,703</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,387</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Imputed interest</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,091</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101,296</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Current lease liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,518</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term lease liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,778</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 74000 3742000 3816000 296000 13209000 13505000 296000 13224000 13520000 296000 10782000 11078000 296000 9996000 10292000 1426000 86750000 88176000 2684000 137703000 140387000 39091000 101296000 12518000 88778000 0.50 300000 P5Y November 1, 2029 through October 31, 2034 P5Y November 1, 2034 through October 31, 2039 TREASURY STOCK<div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span>4.9</span></span><span style="font-family:inherit;font-size:10pt;"> million and </span><span style="font-family:inherit;font-size:10pt;"><span>2.9</span></span><span style="font-family:inherit;font-size:10pt;"> million shares of treasury stock outstanding with a cost of </span><span style="font-family:inherit;font-size:10pt;"><span>$235.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$119.9</span></span><span style="font-family:inherit;font-size:10pt;"> million, at a weighted average cost per share of </span><span style="font-family:inherit;font-size:10pt;"><span>$47.86</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$41.87</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 11, 2018, the board of directors of the Company (the “Board”) authorized the Company to repurchase up to </span><span style="font-family:inherit;font-size:10pt;"><span>$225.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company’s common stock. The program allows the Company to repurchase its shares opportunistically from time to time. The repurchase authorization expires in December 2020. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company repurchased </span><span style="font-family:inherit;font-size:10pt;"><span>2.1</span></span><span style="font-family:inherit;font-size:10pt;"> million shares of Integra’s common stock as part of the existing share repurchase authorization. The Company utilized </span><span style="font-family:inherit;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of net proceeds from the offering of the Convertible Senior Notes to execute the share repurchase transactions. This included </span><span style="font-family:inherit;font-size:10pt;"><span>$7.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> from certain purchasers of the convertible notes in conjunction with the closing of the offering. On February 5, 2020, the Company entered into a </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;"><span>$92.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> accelerated share repurchase ("ASR") to complete the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of share repurchase. The Company received </span><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span><span style="font-family:inherit;font-size:10pt;"> million shares at inception of the ASR, which represented approximately </span><span style="font-family:inherit;font-size:10pt;"><span>80%</span></span><span style="font-family:inherit;font-size:10pt;"> of the expected total shares. Upon settlement of the ASR in June 2020, the Company received an additional </span><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span><span style="font-family:inherit;font-size:10pt;"> million shares determined using the volume-weighted average price of the Company's common stock during the term of the transaction. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has </span><span style="font-family:inherit;font-size:10pt;"><span>$125.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> remaining under the share repurchase of its Common Stock. The price and timing of any future purchases under the share repurchase program will depend on factors such as levels of cash generation from operations, the volume of stock option exercises by employees, cash requirements for acquisitions, dividends, economic and market conditions and stock price.</span></div> 4900000 2900000 235200000 119900000 47.86 41.87 225000000.0 2100000 100000000.0 7600000 -92400000 100000000.0 1300000 0.80 600000 125000000.0 INCOME TAXES<span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a summary of the Company's effective tax rate:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:85.3515625%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reported tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s effective income tax rates for the </span><span style="font-family:inherit;font-size:10pt;">three months ended September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>22.1%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>(0.4)%</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. For the </span><span style="font-family:inherit;font-size:10pt;">three months ended September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the primary drivers of the higher tax rate are the jurisdictional mix of income along with a </span><span style="font-family:inherit;font-size:10pt;"><span>$4.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> recognition of a deferred tax liability related to an outside tax basis from the sale of the Extremity Orthopedics business, offset by a </span><span style="font-family:inherit;font-size:10pt;"><span>$3.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> benefit from the reversal of the French valuation allowance. For the three months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the rate was primarily driven by the impact of the Rebound transaction, which resulted in a </span><span style="font-family:inherit;font-size:10pt;"><span>$59.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> IPR&amp;D expense. This amount was not deductible for tax purposes.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's effective income tax rates for the </span><span style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>24.6%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>(3.5)%</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. For the </span><span style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the primary drivers of the higher tax rate are the jurisdictional mix of income along with a </span><span style="font-family:inherit;font-size:10pt;"><span>$4.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> recognition of a deferred tax liability related to an outside tax basis from the sale of the Extremity Orthopedics business. For the </span><span style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the primary driver of the tax rate is the impact of the Rebound transaction, which resulted in a </span><span style="font-family:inherit;font-size:10pt;"><span>$59.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> IPR&amp;D expense. This amount is not deductible for tax purposes. This was offset by a tax benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>$10.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to a federal tax holiday in Switzerland, which was finalized during the quarter ended March 31, 2019. The Company received a federal tax credit in Switzerland of </span><span style="font-family:inherit;font-size:10pt;"><span>12 million</span></span><span style="font-family:inherit;font-size:10pt;"> CHF, which may be used over a seven year period, ending in 2024. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company has not provided deferred income taxes on unrepatriated earnings from foreign subsidiaries as they are deemed indefinitely reinvested. Such taxes would primarily be attributable to foreign withholding taxes and local income taxes when such earnings are distributed. As such, the Company has determined the tax impact of repatriating these earnings would not be material as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">. The Company does not anticipate the need to repatriate earnings from foreign subsidiaries as a result of the impact of the COVID-19 pandemic. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 27, 2020, the Coronavirus Aid Relief, and Economic Security Act (CARES Act) was signed into law. The CARES Act included certain income tax provisions for corporations and individuals, among other provisions. The Company does not expect the CARES Act provisions to have a significant impact on the Company's income taxes. The Company continues to monitor the issuance of new legislation, regulations, and case law that may impact federal, state, and international tax positions.</span></div> <div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a summary of the Company's effective tax rate:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:85.3515625%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reported tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.221 -0.004 0.246 -0.035 0.221 -0.004 4200000 -3200000 59900000 0.246 -0.035 4200000 59900000 10800000 12000000 NET INCOME (LOSS) PER SHARE<div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net income (loss) per share was as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:86.1328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:12px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands, except per share amounts)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands, except per share amounts)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Basic net income (loss) per share:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,337</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27,610</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,148</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,882</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,325</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,688</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,745</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,536</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income (loss) per common share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.49</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Diluted net income (loss) per share:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,337</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27,610</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,148</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,882</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding — Basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,325</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,688</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,745</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,536</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options and restricted stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>427</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>558</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares for diluted earnings per share</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,752</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,688</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,303</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86,581</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income (loss) per common share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.48</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>0.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively that are issuable through exercise of dilutive securities were not included in the computation of diluted net income (loss) per share because their effect would have been anti-dilutive. </span></div><span style="font-family:inherit;font-size:10pt;">Performance Shares and Restricted Units that entitle the holders to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>0.5 million</span></span> shares of common stock are included in the basic and diluted weighted average shares outstanding calculation from their date of issuance because no further consideration is due related to the issuance of the underlying common shares. <div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net income (loss) per share was as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:86.1328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:12px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands, except per share amounts)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands, except per share amounts)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Basic net income (loss) per share:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,337</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27,610</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,148</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,882</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,325</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,688</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,745</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,536</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income (loss) per common share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.49</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Diluted net income (loss) per share:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,337</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27,610</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,148</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,882</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding — Basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,325</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,688</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,745</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,536</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options and restricted stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>427</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>558</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares for diluted earnings per share</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,752</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,688</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,303</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86,581</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income (loss) per common share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.48</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 32337000 -27610000 41148000 34882000 84325000 85688000 84745000 85536000 0.38 -0.32 0.49 0.41 32337000 -27610000 41148000 34882000 84325000 85688000 84745000 85536000 427000 0 558000 1045000 84752000 85688000 85303000 86581000 0.38 -0.32 0.48 0.40 300000 600000 500000 COMPREHENSIVE INCOME (LOSS)<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive income (loss) was as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:86.328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,337</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27,610</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,148</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,882</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,181</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18,651</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,801</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17,960</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in unrealized loss on derivatives, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,679</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(775</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39,814</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24,714</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pension liability adjustment, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(291</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>515</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(498</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive income (loss), net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,548</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(46,521</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,637</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,288</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in accumulated other comprehensive loss by component between </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> are presented in the table below, net of tax:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:54%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains and Losses on Derivatives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Defined Benefit Pension Items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign Currency Items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at January 1, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(26,625</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,709</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(40,068</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(76,402</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(48,429</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(498</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,801</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24,126</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Amounts reclassified from accumulated other comprehensive loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,615</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,615</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net current-period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39,814</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(498</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,801</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,511</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at September 30, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(66,439</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,207</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,267</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(91,913</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company reclassified a loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.9 million</span></span> from accumulated other comprehensive loss to other income (expense), net and interest income, respectively. <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive income (loss) was as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:86.328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,337</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27,610</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,148</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,882</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,181</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18,651</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,801</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17,960</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in unrealized loss on derivatives, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,679</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(775</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39,814</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24,714</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pension liability adjustment, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(291</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>515</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(498</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive income (loss), net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,548</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(46,521</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,637</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,288</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 32337000 -27610000 41148000 34882000 21181000 -18651000 24801000 -17960000 -9679000 -775000 -39814000 -24714000 291000 -515000 498000 -504000 43548000 -46521000 25637000 -7288000 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in accumulated other comprehensive loss by component between </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> are presented in the table below, net of tax:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:54%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains and Losses on Derivatives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Defined Benefit Pension Items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign Currency Items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at January 1, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(26,625</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,709</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(40,068</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(76,402</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(48,429</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(498</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,801</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24,126</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Amounts reclassified from accumulated other comprehensive loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,615</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,615</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net current-period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39,814</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(498</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,801</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,511</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at September 30, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(66,439</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,207</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,267</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(91,913</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -26625000 -9709000 -40068000 -76402000 -48429000 -498000 24801000 -24126000 -8615000 0 0 -8615000 -39814000 -498000 24801000 -15511000 -66439000 -10207000 -15267000 -91913000 -5700000 -2900000 SEGMENT AND GEOGRAPHIC INFORMATION<div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company internally manages </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> global reportable segments and reports the results of its businesses to its chief operating decision maker. The </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> reportable segments and their activities are described below.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Codman Specialty Surgical segment includes (i) the Neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment and (ii) the instruments business, which sells more than </span><span style="font-family:inherit;font-size:10pt;"><span>40,000</span></span><span style="font-family:inherit;font-size:10pt;"> instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Orthopedics and Tissue Technologies segment includes such offerings as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair products.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Corporate and other category includes (i) various executive, finance, human resource, information systems and legal functions, (ii) brand management, and (iii) share-based compensation costs.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The operating results of the various reportable segments as presented are not comparable to one another because (i) certain operating segments are more dependent than others on corporate functions for unallocated general and administrative and/or operational manufacturing functions and (ii) the Company does not allocate certain manufacturing costs and general and administrative costs to the operating segment results. Net sales and profit by each reportable segment for the </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:90.8203125%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:51%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Net Sales</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Codman Specialty Surgical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>239,323</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>252,984</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>640,541</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>736,810</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Orthopedics and Tissue Technologies</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130,909</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>126,111</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>342,680</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>385,620</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>370,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>379,095</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>983,221</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,122,430</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Profit </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Codman Specialty Surgical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>97,061</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101,129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>249,552</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>291,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Orthopedics and Tissue Technologies</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,132</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,383</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>110,091</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112,664</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Segment profit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>147,193</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>131,512</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>359,643</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>404,414</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,343</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,056)</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(23,393</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21,340)</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(81,308</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(147,043</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>(237,525</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(325,394</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,542</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20,587</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98,725</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,680</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company does not allocate any assets to the reportable segments. No asset information is reported to the chief operating decision maker and disclosed in the financial information for each segment.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company attributes revenues to geographic areas based on the location of the customer. Total revenue by major geographic area consisted of the following:</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:90.0390625%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>266,477</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>266,280</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>695,179</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>796,397</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,995</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,242</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>123,917</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>148,753</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asia Pacific</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,473</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,079</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113,934</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114,810</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rest of World</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,287</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,494</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,191</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,470</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>370,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>379,095</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>983,221</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,122,430</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2 2 40000 Net sales and profit by each reportable segment for the <span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:90.8203125%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:51%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Net Sales</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Codman Specialty Surgical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>239,323</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>252,984</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>640,541</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>736,810</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Orthopedics and Tissue Technologies</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130,909</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>126,111</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>342,680</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>385,620</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>370,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>379,095</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>983,221</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,122,430</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Profit </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Codman Specialty Surgical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>97,061</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101,129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>249,552</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>291,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Orthopedics and Tissue Technologies</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,132</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,383</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>110,091</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112,664</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Segment profit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>147,193</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>131,512</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>359,643</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>404,414</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,343</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,056)</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(23,393</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21,340)</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(81,308</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(147,043</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>(237,525</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(325,394</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,542</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20,587</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98,725</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,680</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Total revenue by major geographic area consisted of the following:<div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:90.0390625%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>266,477</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>266,280</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>695,179</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>796,397</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,995</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,242</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>123,917</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>148,753</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asia Pacific</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,473</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,079</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113,934</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114,810</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rest of World</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,287</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,494</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,191</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,470</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>370,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>379,095</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>983,221</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,122,430</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 239323000 252984000 640541000 736810000 130909000 126111000 342680000 385620000 370232000 379095000 983221000 1122430000 97061000 101129000 249552000 291750000 50132000 30383000 110091000 112664000 147193000 131512000 359643000 404414000 8343000 5056000 23393000 21340000 -81308000 -147043000 -237525000 -325394000 57542000 -20587000 98725000 57680000 266477000 266280000 695179000 796397000 45995000 49242000 123917000 148753000 40473000 42079000 113934000 114810000 17287000 21494000 50191000 62470000 370232000 379095000 983221000 1122430000 COMMITMENTS AND CONTINGENCIES<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In consideration for certain technology, manufacturing, distribution, and selling rights and licenses granted to the Company, the Company has agreed to pay royalties on sales of certain products that it sells. The royalty payments that the Company made under these agreements were not significant for any of the periods presented.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is subject to various claims, lawsuits and proceedings in the ordinary course of the Company's business, including claims by current or former employees, distributors and competitors and with respect to its products and product liability claims, lawsuits and proceedings, some of which have been settled by the Company. In the opinion of management, such claims are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material, adverse effect on the Company's financial condition. However, it is possible that the Company's results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accrues for loss contingencies when it is deemed probable that a loss has been incurred and that loss is estimable. The amounts accrued are based on the full amount of the estimated loss before considering insurance proceeds and do not include an estimate for legal fees expected to be incurred in connection with the loss contingency. The Company consistently accrues legal fees expected to be incurred in connection with loss contingencies as those fees are incurred by outside counsel as a period cost.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Contingent Consideration</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determined the fair value of contingent consideration during the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> month period ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> to reflect the change in estimates, additions, payments, transfers and the time value of money during the period. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the </span><span style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> is as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:17%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contingent Consideration Liability Related to Acquisition of Arkis (See Note 3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contingent Consideration</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> Liability Related to Acquisition of Derma Sciences</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Location in Financial Statements</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Long-term</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Long-term</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,210</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>230</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss from change in fair value of contingent consideration liabilities </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of September 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,165</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>230</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:17%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contingent Consideration Liability Related to Acquisition of Arkis (See Note 3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contingent Consideration</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> Liability Related to Acquisition of Derma Sciences</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Location in Financial Statements</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Long-term</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Long-term</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of January 1, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>230</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions from acquisition of Arkis</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>230</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Derma Sciences</span></div><span style="font-family:inherit;font-size:10pt;">The Company assumed contingent consideration incurred by Derma Sciences, Inc. ("Derma Sciences") related to its acquisitions of BioD and the intellectual property related to Medihoney products. The Company accounted for the contingent liabilities by recording their fair value on the date of the acquisition based on a probability weighted income approach. The Company has already paid </span><span style="font-family:inherit;font-size:10pt;"><span>$33.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to the aforementioned contingent liabilities. </span><span style="font-family:inherit;font-size:10pt;"><span>One</span></span><span style="font-family:inherit;font-size:10pt;"> contingent liability remains which relates to net sales of Medihoney products exceeding certain amounts defined in the agreement between the Company and Derma Sciences. The potential maximum undiscounted payment amounts to </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. The estimated fair value as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span>. <div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the </span><span style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> is as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:17%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contingent Consideration Liability Related to Acquisition of Arkis (See Note 3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contingent Consideration</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> Liability Related to Acquisition of Derma Sciences</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Location in Financial Statements</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Long-term</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Long-term</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,210</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>230</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss from change in fair value of contingent consideration liabilities </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of September 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,165</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>230</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:17%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contingent Consideration Liability Related to Acquisition of Arkis (See Note 3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contingent Consideration</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> Liability Related to Acquisition of Derma Sciences</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Location in Financial Statements</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Long-term</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Long-term</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of January 1, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>230</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions from acquisition of Arkis</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>230</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 14210000 230000 -45000 0 14165000 230000 0 230000 13100000 0 13100000 230000 33300000 1 3000000.0 200000 2913000 13962000 4127000 101000 0.221 -0.004 XML 13 R1.htm IDEA: XBRL DOCUMENT v3.20.2
DOCUMENT AND ENTITY INFORMATION - shares
9 Months Ended
Sep. 30, 2020
Oct. 27, 2020
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2020  
Document Transition Report false  
Entity File Number 0-26224  
Entity Registrant Name INTEGRA LIFESCIENCES HOLDINGS CORP  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 51-0317849  
Entity Address 1100 Campus Road  
Entity City Princeton  
Entity State NJ  
Entity Postal Zip Code 08540  
City Area Code 609  
Local Phone Number 275-0500  
Title of 12(b) Security Common Stock, Par Value $.01 Per Share  
Trading Symbol IART  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Smaller Reporting Company false  
Emerging Growth Company false  
Entity Shell Company false  
Entity Bankruptcy Proceedings, Reporting Current false  
Entity Common Stock, Shares Outstanding (in shares)   84,272,671
Amendment Flag false  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q3  
Entity Central Index Key 0000917520  
Current Fiscal Year End Date --12-31  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME / (LOSS) (UNAUDITED) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Income Statement [Abstract]        
Total revenue, net $ 370,232 $ 379,095 $ 983,221 $ 1,122,430
Costs and expenses:        
Cost of goods sold 134,811 142,636 373,765 415,219
Research and development 19,460 19,003 55,202 54,957
In-process research and development 0 59,889 0 59,889
Selling, general and administrative 150,076 173,098 432,136 513,345
Intangible asset amortization 8,343 5,056 23,393 21,340
Total costs and expenses 312,690 399,682 884,496 1,064,750
Operating income (loss) 57,542 (20,587) 98,725 57,680
Interest income 2,273 2,913 7,124 8,051
Interest expense (20,796) (13,962) (54,230) (40,495)
Other income, net 2,492 4,127 2,985 8,461
Income (loss) before income taxes 41,511 (27,509) 54,604 33,697
Provision (benefit) for income taxes 9,174 101 13,456 (1,185)
Net income (loss) $ 32,337 $ (27,610) $ 41,148 $ 34,882
Net income (loss) per share        
Basic (in dollars per share) $ 0.38 $ (0.32) $ 0.49 $ 0.41
Diluted (in dollars per share) $ 0.38 $ (0.32) $ 0.48 $ 0.40
Weighted average common shares outstanding (See Note 14):        
Basic (in shares) 84,325 85,688 84,745 85,536
Diluted (in shares) 84,752 85,688 85,303 86,581
Comprehensive income (loss) (See Note 15) $ 43,548 $ (46,521) $ 25,637 $ (7,288)
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 396,279 $ 198,911
Trade accounts receivable, net of allowances of $6,727 and $4,303 218,184 275,296
Inventories, net 307,839 316,054
Assets held for sale 159,977 0
Prepaid expenses and other current assets 69,817 67,907
Total current assets 1,152,096 858,168
Property, plant and equipment, net 294,439 337,404
Right of use asset - operating leases 84,916 94,530
Intangible assets, net 973,685 1,031,591
Goodwill 919,556 954,280
Deferred tax assets, net 8,150 12,623
Other assets 20,679 14,644
Total assets 3,453,521 3,303,240
Current liabilities:    
Current portion of borrowings under senior credit facility 22,500 45,000
Current portion of lease liability - operating leases 12,518 12,253
Accounts payable, trade 50,254 113,090
Contract liabilities 4,875 4,772
Accrued compensation 71,712 79,385
Liabilities held for sale 12,349 0
Accrued expenses and other current liabilities 80,938 76,809
Total current liabilities 255,146 331,309
Long-term borrowings under senior credit facility 944,102 1,198,561
Long-term borrowings under securitization facility 92,300 104,500
Long-term convertible securities 469,898 0
Lease liability - operating leases 88,778 97,504
Deferred tax liabilities 27,780 36,553
Other liabilities 177,530 118,077
Total liabilities 2,055,534 1,886,504
Stockholders’ equity:    
Preferred stock; no par value; 15,000 authorized shares; none outstanding 0 0
Common stock; $0.01 par value; 240,000 authorized shares; 89,191 and 88,735 issued at September 30, 2020 and December 31, 2019, respectively 892 887
Additional paid-in capital 1,284,711 1,213,620
Treasury stock, at cost; 4,915 shares and 2,865 shares at September 30, 2020 and December 31, 2019, respectively (235,224) (119,943)
Accumulated other comprehensive loss (91,913) (76,402)
Retained earnings 439,521 398,574
Total stockholders’ equity 1,397,987 1,416,736
Total liabilities and stockholders’ equity $ 3,453,521 $ 3,303,240
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]    
Trade accounts receivable, allowance $ 6,727 $ 4,303
Preferred stock, authorized shares (in shares) 15,000,000 15,000,000
Preferred stock, outstanding shares (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, authorized shares (in shares) 240,000,000 240,000,000
Common stock, issued shares (in shares) 89,191,000 88,735,000
Treasury stock, shares (in shares) 4,915,000 2,865,000
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
OPERATING ACTIVITIES:    
Net income $ 41,148 $ 34,882
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 89,853 81,584
Non-cash in-process research and development expense 0 59,889
Non-cash impairment charges 0 5,764
Income tax expense (benefit) 4,784 (10,536)
Share-based compensation 14,333 15,744
Amortization of debt issuance costs and expenses associated with debt refinancing 10,499 4,084
Non-cash lease expense 2,172 3,473
Accretion of bond issuance discount 11,075 0
Loss on disposal of property and equipment 559 844
Change in fair value of contingent consideration and others (45) 10
Changes in assets and liabilities:    
Accounts receivable 57,863 (17,519)
Inventories (45,531) (30,553)
Prepaid expenses and other current assets (865) (8,162)
Other non-current assets 10,868 6,650
Accounts payable, accrued expenses and other current liabilities (67,178) 366
Contract liabilities (548) (1,395)
Other non-current liabilities (5,417) (2,876)
Net cash provided by operating activities 123,570 142,249
INVESTING ACTIVITIES:    
Purchases of property and equipment (30,463) (47,343)
Acquired in-process research and development milestone (5,000) 0
Proceeds from note receivable 0 752
Proceeds from sale of property and equipment 3,311 36
Cash (paid) provided for business acquisitions, net of cash acquired 0 (30,509)
Acquired in-process research and development 0 (64,995)
Net cash used in investing activities (32,152) (142,059)
FINANCING ACTIVITIES:    
Proceeds from borrowings of long-term indebtedness 151,300 215,800
Payments on debt (441,000) (143,250)
Purchase of option hedge on convertible notes (104,248) 0
Proceeds from convertible notes issuance 575,000 0
Proceeds from sale of stock purchase warrants 44,563 0
Payment of debt issuance costs (24,347) 0
Purchases of treasury stock (100,000) 0
Proceeds from exercised stock options 3,821 6,948
Cash taxes paid in net equity settlement (4,686) (6,272)
Net cash provided by financing activities 100,403 73,226
Effect of exchange rate changes on cash and cash equivalents 5,547 (4,273)
Net increase in cash and cash equivalents 197,368 69,143
Cash and cash equivalents at beginning of period 198,911 138,838
Cash and cash equivalents at end of period $ 396,279 $ 207,981
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDER'S EQUITY (UNAUDITED) - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Treasury Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Retained Earnings
Retained Earnings
Cumulative Effect, Period of Adoption, Adjustment
Balance Beginning of Period, Shares (in shares) at Dec. 31, 2018     88,044,000          
Balance, Beginning of Period at Dec. 31, 2018 $ 1,375,796   $ 880 $ (120,615) $ 1,192,601 $ (45,443) $ 348,373  
Balance, Beginning of Period, Treasury Stock, Shares (in shares) at Dec. 31, 2018       (2,881,000)        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) 32,756           32,756  
Other comprehensive income (loss), net of tax (11,236)         (11,236)    
Issuance of common stock through employee stock purchase plan (in shares)     17,000          
Issuance of common stock through employee stock purchase plan 716       716      
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes (in shares)     243,000 12,000        
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes (5,121)   $ 2 $ 506 (5,629)      
Share-based compensation 4,119       4,119      
Balance End of Period, Shares (in shares) at Mar. 31, 2019     88,304,000          
Balance, End of Period at Mar. 31, 2019 1,397,030   $ 882 $ (120,109) 1,191,807 (56,679) 381,129  
Balance, End of Period, Treasury Stock, Shares (in shares) at Mar. 31, 2019       (2,869,000)        
Balance Beginning of Period, Shares (in shares) at Dec. 31, 2018     88,044,000          
Balance, Beginning of Period at Dec. 31, 2018 1,375,796   $ 880 $ (120,615) 1,192,601 (45,443) 348,373  
Balance, Beginning of Period, Treasury Stock, Shares (in shares) at Dec. 31, 2018       (2,881,000)        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) 34,882              
Balance End of Period, Shares (in shares) at Sep. 30, 2019     88,689,000          
Balance, End of Period at Sep. 30, 2019 1,384,974   $ 886 $ (120,101) 1,208,549 (87,615) 383,255  
Balance, End of Period, Treasury Stock, Shares (in shares) at Sep. 30, 2019       (2,869,000)        
Balance Beginning of Period, Shares (in shares) at Mar. 31, 2019     88,304,000          
Balance, Beginning of Period at Mar. 31, 2019 1,397,030   $ 882 $ (120,109) 1,191,807 (56,679) 381,129  
Balance, Beginning of Period, Treasury Stock, Shares (in shares) at Mar. 31, 2019       (2,869,000)        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) 29,736           29,736  
Other comprehensive income (loss), net of tax (12,021)         (12,021)    
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes (in shares)     47,000          
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes 408   $ 1 $ 2 405      
Share-based compensation 5,798       5,798      
Balance End of Period, Shares (in shares) at Jun. 30, 2019     88,351,000          
Balance, End of Period at Jun. 30, 2019 1,420,951   $ 883 $ (120,107) 1,198,010 (68,700) 410,865  
Balance, End of Period, Treasury Stock, Shares (in shares) at Jun. 30, 2019       (2,869,000)        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) (27,610)           (27,610)  
Other comprehensive income (loss), net of tax (18,915)         (18,915)    
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes (in shares)     338,000          
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes 4,674   $ 3 $ 6 4,665      
Share-based compensation 5,874       5,874      
Balance End of Period, Shares (in shares) at Sep. 30, 2019     88,689,000          
Balance, End of Period at Sep. 30, 2019 1,384,974   $ 886 $ (120,101) 1,208,549 (87,615) 383,255  
Balance, End of Period, Treasury Stock, Shares (in shares) at Sep. 30, 2019       (2,869,000)        
Balance Beginning of Period, Shares (in shares) at Dec. 31, 2019     88,735,000          
Balance, Beginning of Period at Dec. 31, 2019 $ 1,416,736 $ (200) $ 887 $ (119,943) 1,213,620 (76,402) 398,574 $ (200)
Balance, Beginning of Period, Treasury Stock, Shares (in shares) at Dec. 31, 2019 (2,865,000)     (2,865,000)        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) $ 9,180           9,180  
Other comprehensive income (loss), net of tax (28,187)         (28,187)    
Issuance of common stock through employee stock purchase plan (in shares)     13,000          
Issuance of common stock through employee stock purchase plan 694       694      
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes (in shares)     357,000 10,000        
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes (2,739)   $ 2 $ 476 (3,217)      
Share-based compensation 3,781       3,781      
Share repurchase and equity component of the convertible note issuance, net (in shares)       (135,000)        
Share repurchase and equity component of the convertible note issuance, net 34,906     $ (7,632) 42,538      
Accelerated shares repurchased (in shares)       (1,304,000)        
Accelerated shares repurchased (92,368)     $ (75,407) (16,961)      
Balance End of Period, Shares (in shares) at Mar. 31, 2020     89,105,000          
Balance, End of Period at Mar. 31, 2020 1,341,802   $ 889 $ (202,506) 1,240,455 (104,589) 407,553  
Balance, End of Period, Treasury Stock, Shares (in shares) at Mar. 31, 2020       (4,294,000)        
Balance Beginning of Period, Shares (in shares) at Dec. 31, 2019     88,735,000          
Balance, Beginning of Period at Dec. 31, 2019 $ 1,416,736 $ (200) $ 887 $ (119,943) 1,213,620 (76,402) 398,574 $ (200)
Balance, Beginning of Period, Treasury Stock, Shares (in shares) at Dec. 31, 2019 (2,865,000)     (2,865,000)        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) $ 41,148              
Other comprehensive income (loss), net of tax $ (15,511)              
Accelerated shares repurchased (in shares) (2,100,000)              
Balance End of Period, Shares (in shares) at Sep. 30, 2020     89,191,000          
Balance, End of Period at Sep. 30, 2020 $ 1,397,987   $ 892 $ (235,224) 1,284,711 (91,913) 439,521  
Balance, End of Period, Treasury Stock, Shares (in shares) at Sep. 30, 2020 (4,915,000)     (4,915,000)        
Balance Beginning of Period, Shares (in shares) at Mar. 31, 2020     89,105,000          
Balance, Beginning of Period at Mar. 31, 2020 $ 1,341,802   $ 889 $ (202,506) 1,240,455 (104,589) 407,553  
Balance, Beginning of Period, Treasury Stock, Shares (in shares) at Mar. 31, 2020       (4,294,000)        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) (369)           (369)  
Other comprehensive income (loss), net of tax 1,464         1,464    
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes (in shares)     84,000          
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes 1,250   $ 3 $ (35) 1,282      
Share-based compensation 4,948       4,948      
Accelerated shares repurchased (in shares)       (621,000)        
Accelerated shares repurchased 0     $ (32,685) 32,685      
Balance End of Period, Shares (in shares) at Jun. 30, 2020     89,189,000          
Balance, End of Period at Jun. 30, 2020 1,349,095   $ 892 $ (235,226) 1,279,370 (103,125) 407,184  
Balance, End of Period, Treasury Stock, Shares (in shares) at Jun. 30, 2020       (4,915,000)        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) 32,337           32,337  
Other comprehensive income (loss), net of tax 11,212         11,212    
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes (in shares)     2,000          
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes (67)     $ 2 (69)      
Share-based compensation 5,410       5,410      
Balance End of Period, Shares (in shares) at Sep. 30, 2020     89,191,000          
Balance, End of Period at Sep. 30, 2020 $ 1,397,987   $ 892 $ (235,224) $ 1,284,711 $ (91,913) $ 439,521  
Balance, End of Period, Treasury Stock, Shares (in shares) at Sep. 30, 2020 (4,915,000)     (4,915,000)        
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDER'S EQUITY (UNAUDITED) (PARENTHETICAL)
12 Months Ended
Dec. 31, 2019
Statement of Stockholders' Equity [Abstract]  
Accounting Standards Update [Extensible List] us-gaap:AccountingStandardsUpdate201613Member
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.20.2
BASIS OF PRESENTATION
9 Months Ended
Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BASIS OF PRESENTATION BASIS OF PRESENTATION
General
The terms “we,” “our,” “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise.
In the opinion of management, the September 30, 2020 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, statement of changes in shareholder's equity, results of operations and cash flows of the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K. The December 31, 2019 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States. Operating results for the three and nine month period ended September 30, 2020 are not necessarily indicative of the results to be expected for the entire year.
The preparation of consolidated financial statements is in conformity with generally accepted accounting principles in the United States ("GAAP") which requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of derivative instruments, valuation of the equity component of convertible debt instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates. The novel coronavirus (“COVID-19”) pandemic and the resulting adverse impacts to global economic conditions, as well as our operations, may impact future estimates including, but not limited to, inventory valuations, fair value measurements, goodwill and long-lived asset impairments, the effectiveness of the Company’s hedging instruments, deferred tax valuation allowances, and allowances for doubtful accounts receivable.
Risks and Uncertainties
The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company's business is highly uncertain and difficult to predict, as the responses to the pandemic and information is rapidly evolving. From late March, the Company's customers diverted resources to treat COVID-19 patients and deferred or canceled elective or non-emergent surgical procedures, all of which impacted hospitals' abilities to meet their obligations, including to the Company. Beginning in May 2020 and through the end of the third quarter of 2020, procedural volumes relevant to the Company’s products steadily increased and, in some geographic areas, began to approach normalized levels. However, on-going uncertainty persists about the continuing sustainability of those procedural volumes as virus outbreaks constrain healthcare networks. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is possible that it could cause a local and/or global economic recession. Such economic disruption has had an adverse effect on the Company's business as customers curtailed and reduced capital and overall spending. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and the economy as a whole. The magnitude and overall effectiveness of these actions remains uncertain. The severity of the impact of the COVID-19 pandemic on the Company's business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company's customers, all of which are uncertain and cannot be predicted with certainty. The Company's future results of operations and liquidity could be adversely impacted by delays in payments of outstanding receivable amounts beyond normal payment terms, supply chain disruptions and uncertain demand, and the impact of any initiatives or programs that the Company may undertake to address financial and operations challenges faced by its customers. The COVID-19 pandemic continues to cause a financial strain on healthcare systems which varies by location, and as a result we do not expect the same level of spending in the fourth quarter that we experienced last year. Even after the COVID-19 pandemic and government responses thereto have subsided, residual economic and other effects may have an impact on the demand for post-pandemic surgery levels that are difficult to predict. If the downturn is more severe and prolonged than currently expected, the Company may need to take further steps to reduce costs.


Recently Issued Accounting Standards
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The ASU is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financial assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. The ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted this guidance on January 1, 2020 using a modified retrospective transition method which requires a cumulative-effect adjustment to the opening balance of retained earnings to be recognized on the date of adoption with no change to financial results reported in prior periods. The cumulative-effect adjustment recorded on January 1, 2020, is not material. The adoption of this ASU did not have a significant impact on the Company's consolidated financial statements and related disclosures.
The Company's exposure to credit losses may increase if its customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. Although the Company has historically not experienced significant credit losses, it is possible that there could be an adverse impact as hospital's cash flows are impacted by their response to the COVID-19 pandemic.
In August 2018, the FASB issued ASU 2018-14, Compensation-Retirement Benefits-Defined Benefit Plans-General (Subtopic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans. The new guidance modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans, including removing certain previous disclosure requirements, adding certain new disclosure requirements, and clarifying certain other disclosure requirements. The ASU will be effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Early adoption is permitted. The adoption is not expected to have a material impact on the Company's consolidated financial statements and related disclosures.
In August 2018, the FASB issued ASU No. 2018-15, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40), relating to a customer's accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement that is hosted by a vendor (e.g., a service contract). Under the new guidance, a customer will apply the same criteria for capitalizing implementation costs as it would for an arrangement that has a software license. The new guidance also prescribes the balance sheet, income statement, and cash flow classification of the capitalized implementation costs and related amortization expense, and requires additional quantitative and qualitative disclosures. The ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted this guidance on January 1, 2020 using a prospective transition method. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements and related disclosures.
In December 2019, the FASB issued ASU No. 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes intended to simplify the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The Company is currently assessing the impact of this standard on its financial condition and results of operations.
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform, which provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. This amendment applies to all entities, subject to meeting certain criteria, that have contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This ASU is effective immediately and may be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before December 31, 2022. The Company is currently assessing the impact that this ASU will have on its consolidated financial statements and related disclosures.

In August 2020, the FASB issued ASU No. 2020-06 Debt- Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40)-Accounting For Convertible Instruments and Contracts in an Entity's Own Equity . The guidance simplifies accounting for convertible instruments by removing major
separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify. The guidance also simplifies the diluted net income per share calculation in certain areas. The ASU will be effective for annual and interim periods beginning after December 15, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact of this standard on its consolidated financial statements and related disclosures.
There are no other recently issued accounting pronouncements that are expected to have any significant effect on the Company's financial position, results of operations or cash flows.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.20.2
ASSETS AND LIABILITIES HELD FOR SALE
9 Months Ended
Sep. 30, 2020
Discontinued Operations and Disposal Groups [Abstract]  
ASSETS AND LIABILITIES HELD FOR SALE ASSETS AND LIABILITIES HELD FOR SALE
On September 29, 2020, the Company and certain of its subsidiaries entered into an agreement to sell its Extremity Orthopedics business to Smith & Nephew USD Limited for approximately $240 million in cash. The transaction includes the sale of the Company’s upper and lower Extremity Orthopedics product portfolio, including ankle and shoulder arthroplasty and hand and wrist product lines. In connection with the transaction, the Company will pay $41.5 million to the Consortium of Focused Orthopedists, LLC (“CFO”) pursuant to the terms of certain agreements between Integra and CFO relating to the development of shoulder arthroplasty products. The transaction is expected to close at or around the end of 2020, subject to the satisfaction of customary conditions, including regulatory approvals and consultation with employee representative bodies.
The Company considered the assets and liabilities associated with the Extremity Orthopedics business to be accounted as held-for-sale as the six criteria under ASC 260 were met during the third quarter of 2020. Upon designation of the assets and liabilities as held for sale, the Company recorded the assets at the lower of their carrying value or their estimated fair value, less estimated costs to sell. Goodwill was allocated to the assets and liabilities held for sale using the relative fair value method of the Extremity Orthopedics business to the Company's Orthopedics and Tissue Technologies reporting unit. The fair value of the business less costs to sell exceeded the related carrying value.

The Extremity Orthopedics business was treated as a single disposal group and presented separately in the condensed consolidated balance sheet as assets and liabilities held for sale as of September 30, 2020. These balances are presented as current assets and liabilities as they are expected to be sold within twelve months. The major classes of assets and liabilities classified as a held for sale consisted of the following as of September 30, 2020 (amounts in thousands):
Prepaid and other current assets
$
748

Other assets
4,448

Deferred tax assets
6,927

Intangible assets
13,332

Property, plant and equipment, net
36,714

Goodwill
47,117

Inventories
50,691

Total assets held for sale
$
159,977

Other liabilities
241

Current portion of lease liability - operating leases

1,060

Accrued compensation
1,584

Deferred tax liabilities
3,035

Lease liability - operating leases

6,429

Total liabilities held for sale

$
12,349


XML 22 R10.htm IDEA: XBRL DOCUMENT v3.20.2
BUSINESS DEVELOPMENT
9 Months Ended
Sep. 30, 2020
Business Combinations [Abstract]  
BUSINESS DEVELOPMENT BUSINESS DEVELOPMENT
Arkis BioSciences Inc.
On July 29, 2019, the Company acquired Arkis BioSciences Inc. ("Arkis") for an acquisition purchase price of $30.6 million (the "Arkis Acquisition") plus contingent consideration of up to $25.5 million, that may be payable based on the successful completion of certain development and commercial milestones. The contingent consideration had an acquisition date fair value of $13.1 million. Arkis was a privately-held company that marketed the CerebroFlo® external ventricular drainage (EVD) catheter with Endexo® technology, a permanent additive designed to reduce the potential for catheter obstruction due to thrombus formation.
Assets Acquired and Liabilities Assumed at Fair Value
The Arkis Acquisition has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination to be recognized at their fair values as of the acquisition date.
The following table summarizes the final fair values of the assets acquired and liabilities assumed at the acquisition date:
 
Final Valuation as of
September 30, 2019
 
Weighted Average Life
 
(Dollars in thousands)
 
 
Cash
$
90

 
 
Other current assets
751

 
 
Property, plant and equipment
457

 
 
Deferred tax assets
1,697

 
 
Intangible assets:
 
 
 
CerebroFlo developed technology
20,100

 
15 years
Enabling technology license
1,980

 
14 years
Goodwill
27,153

 
 
Total assets acquired
52,228

 
 
 
 
 
 
Accounts payable, accrued expenses and other liabilities
2,926

 
 
Contingent consideration
13,100

 
 
Deferred tax liabilities
5,603

 
 
     Net assets acquired
$
30,599

 
 

Intangible Assets
The estimated fair value of the intangible assets was determined using the income approach, which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each asset (including net revenues, cost of sales, R&D costs, selling and marketing costs, and working capital/contributory asset charges), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, and competitive trends impacting the asset and each cash flow stream.
The Company used a discount rate of 14.5% to arrive at the present value for the acquired intangible assets to reflect the rate of return a market participant would expect to earn and incremental commercial uncertainty in the cash flow projections. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results.  
Goodwill
The Company allocated goodwill related to the Arkis Acquisition to the Codman Specialty Surgical segment. Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected revenue and cost synergies of the combined company and assembled workforce. One of the key factors that contributes to the recognition of goodwill, and a driver for the Company's acquisition of Arkis, is the planned expansion of the Endexo technology with the existing products within the Codman Specialty Surgical segment. Goodwill recognized as a result of this acquisition is non-deductible for income tax purposes.
Contingent Consideration
The Company determines the acquisition date fair value of contingent consideration obligations based on a probability-weighted income approach derived from revenue estimates and a probability assessment with respect to the likelihood of achieving contingent obligations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined using the fair value concepts in ASC 820. The resultant probability-weighted cash flows are discounted using an appropriate effective annual interest rate. At each reporting date, the contingent consideration obligation will be revalued to estimated fair value and changes in fair value will be reflected as income or expense in the Company's consolidated statement of operations. Changes in the fair value of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of revenue estimates and changes in probability assumptions with respect to the likelihood of achieving the various contingent payment obligations.
As part of the acquisition, the Company is required to pay the former shareholders of Arkis up to $25.5 million based on the timing of certain development milestones of $10.0 million and commercial sales milestones of $15.5 million, respectively. The Company used a probability weighted income approach to calculate the fair value of the contingent consideration that considered the possible outcomes of scenarios related to each specified milestone. The Company estimated the fair value of the contingent consideration to be $13.1 million at the acquisition date. The estimated fair value as of September 30, 2020 was $14.2 million. This amount is included in other liabilities at September 30, 2020 in the consolidated balance sheets of the Company.
Deferred Tax Liabilities
Deferred tax liabilities result from identifiable intangible assets’ fair value adjustments. These adjustments create excess book basis over tax basis which is tax-effected by the statutory tax rates of applicable jurisdictions.
The pro forma results are not presented for this acquisition as they are not material.
Rebound Therapeutics Corporation
On September 9, 2019, the Company acquired Rebound Therapeutics Corporation (“Rebound”), developers of a single-use medical device known as the AURORA Surgiscope® System ("Aurora") which enables minimally invasive access, using optics and illumination, for visualization, diagnostic and therapeutic use in neurosurgery (the “Rebound transaction”). Under the terms of the Rebound transaction, the Company made an upfront payment of $67.1 million and are committed to pay up to $35.0 million of contingent development milestones upon achievement of certain regulatory milestones. The acquisition of Rebound was primarily concentrated in one single identifiable asset and thus, for accounting purposes, the Company has concluded that the acquired assets do not meet the accounting definition of a business. The initial payment was allocated primarily to Aurora, resulting in a $59.9 million in-process research and development (IPR&D) expense. The balance of approximately $7.2 million, which included $2.1 million of cash and cash equivalents and a net deferred tax asset of $4.2 million, was allocated to the remaining net assets acquired. The deferred tax asset primarily resulted from a federal net operating loss carry forward.
During the fourth quarter of 2019, the Company achieved the first developmental milestone which triggered a $5.0 million obligation to be paid to former shareholders of Rebound. The Company recorded $5.0 million as IPR&D expense in the consolidated statements of operations during the year ended December 31, 2019. The obligation was included in accrued expenses and other current liabilities at December 31, 2019 in the consolidated balance sheets. The milestone was paid during the first quarter of 2020.
Integrated Shoulder Collaboration, Inc.
On January 4, 2019, the Company entered into a licensing agreement with Integrated Shoulder Collaboration, Inc ("ISC"). Under the terms of the agreement, the Company paid ISC $1.7 million for the exclusive, worldwide license to commercialize its short stem and stemless shoulder system. A patent related to short stem and stemless shoulder systems was issued to ISC during the first quarter of 2019. ISC is eligible to receive royalties on sales of the short stem and stemless shoulder system. The Company has the option to acquire ISC at a date four years subsequent to the first commercial sale, which becomes mandatory upon the achievement of a certain sales thresholds of the short stem and stemless shoulder system, for an amount not to exceed $80.0 million. The transaction was accounted for as an asset acquisition as the Company concluded that it acquired primarily one asset. During the quarter ended March 31, 2019, the total upfront payment of $1.7 million was expensed as a component of research and development expense and the future milestone and option payments will be recorded if the corresponding events become probable.
In connection with the sale of the Company's Extremity Orthopedic business, the Company will pay $41.5 million to CFO pursuant to the terms of certain agreements between Integra and CFO relating to the sale of shares of ISC which includes the development of shoulder arthroplasty products effectively terminating our licensing agreement with ISC. See Note 2, Assets and Liabilities Held for Sale, for details of the transaction.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.20.2
REVENUES FROM CONTRACTS WITH CUSTOMERS
9 Months Ended
Sep. 30, 2020
Revenue from Contract with Customer [Abstract]  
REVENUES FROM CONTRACTS WITH CUSTOMERS REVENUES FROM CONTRACTS WITH CUSTOMERS
Summary of Accounting Policies on Revenue Recognition
Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services.
Total revenue, net, includes product sales, product royalties and other revenues, such as fees received for services.
For products shipped with FOB shipping point terms, the control of the product passes to the customer at the time of shipment. For shipments in which the control of the product is transferred when the customer receives the product, the Company recognizes revenue upon receipt by the customer. Certain products that the Company produces for private label customers have no alternative use and the Company has a right of payment for performance to date. Revenues from those products are recognized over the period
that the Company manufactures these products, which is typically one to three months. The Company uses the input method to measure the manufacturing activities completed to date, which depicts the progress of the Company's performance obligation of transferring control of goods being manufactured for private label customers.
A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and distributors, and also from inventory physically held by field sales representatives. For these types of product sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized.   
Revenues from sale of products and services are evidenced by either a contract with the customer or a valid purchase order and an invoice which includes all relevant terms of sale. For product sales, invoices are generally issued upon the transfer of control (or upon the completion of the manufacturing in the case of the private label transactions recognized over time) and are typically payable thirty days after the invoice date. The Company performs a review of each specific customer's creditworthiness and ability to pay prior to acceptance as a customer. Further, the Company performs periodic reviews of its customers' creditworthiness prospectively.
Performance Obligations
The Company's performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders, or invoices. The Company has no significant multi-element contracts with customers.
Significant Judgments
Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company and the Company's strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information, and expected sales trends. Differences between actual reported licensee sales and those that were estimated are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant.
The Company estimates returns, price concessions, and discount allowances using the expected value method based on historical trends and other known factors. Rebate allowances are estimated using the most likely method based on each customer contract.
The Company's return policy, as set forth in its product catalogs and sales invoices, requires review and authorization in advance prior to the return of product. Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally ninety days.
The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less. The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.
Contract Asset and Liability
Revenues recognized from the Company's private label business that are not invoiced to the customers as a result of recognizing revenue over time are recorded as a contract asset included in the prepaid expenses and other current assets account in the consolidated balance sheet.
Other operating revenues may include fees received under service agreements. Non-refundable fees received under multiple-period service agreements are recognized as revenue as the Company satisfies the performance obligations to the other party. A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability.











The following table summarizes the changes in the contract asset and liability balances for the nine months ended September 30, 2020:
Contract Asset
 
Contract asset, January 1, 2020
$
8,680

Transferred to trade receivable of contract asset included
     in beginning of the year contract asset
(8,680
)
Contract asset, net of transferred to trade receivables on contracts during the period
6,653

Contract asset, September 30, 2020
$
6,653

 
 
Contract Liability
 
Contract liability, January 1, 2020
$
11,946

Recognition of revenue included in beginning of year contract liability
(3,150
)
Contract liability, net of revenue recognized on contracts during the period

2,631

Foreign currency translation
(42
)
Contract liability, September 30, 2020
$
11,385


At September 30, 2020, the short-term portion of the contract liability of $4.9 million and the long-term portion of $6.5 million were included in accrued expenses and other current liabilities and other liabilities in the consolidated balance sheet.
As of September 30, 2020, the Company is expected to recognize approximately 43% of unsatisfied (or partially unsatisfied) performance obligations as revenue through 2020, with the remaining balance to be recognized in 2021 and thereafter.
Shipping and Handling Fees
The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in the cost of goods sold.
Product Warranties
Certain of the Company's medical devices, including monitoring systems and neurosurgical systems, are designed to operate over long periods of time. These products are sold with warranties which may extend for up to two years from the date of purchase. The warranties are not considered a separate performance obligation. The Company estimates its product warranties using the expected value method based on historical trends and other known factors. The Company includes them in accrued expenses and other current liabilities in the consolidated balance sheet.
Taxes Collected from Customers
The Company elected to exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer.












Disaggregated Revenue
The following table presents revenues disaggregated by the major sources of revenues for the three and nine months ended September 30, 2020 and 2019 (amounts in thousands):
 
Three Months Ended September 30, 2020
Three Months Ended September 30, 2019
 
Nine Months Ended September 30, 2020
Nine Months Ended September 30, 2019
 
 
 
 
 
Neurosurgery
$
189,674

$
195,330

 
$
516,048

$
567,779

Instruments
49,649

57,654

 
124,493

169,031

Total Codman Specialty Surgical
239,323

252,984

 
640,541

736,810

 
 
 
 
 
 
Wound Reconstruction and Care
82,115

82,213

 
210,673

239,458

Extremity Orthopedics
21,922

20,852

 
54,556

65,299

Private Label
26,872

23,046

 
77,451

80,863

Total Orthopedics and Tissue Technologies
130,909

126,111

 
342,680

385,620

Total revenue
$
370,232

$
379,095

 
$
983,221

$
1,122,430


Prior period amounts were reclassified between categories within the Codman Specialty Surgical segment to conform to the current period presentation.
See Note 16, Segment and Geographical Information, for details of revenues based on the location of the customer.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.20.2
INVENTORIES
9 Months Ended
Sep. 30, 2020
Inventory, Net [Abstract]  
INVENTORIES INVENTORIES
Inventories, net consisted of the following:
 
September 30, 2020
 
December 31, 2019
 
(In thousands)
Finished goods
$
223,726

 
$
201,870

Work in process
57,037

 
48,333

Raw materials
77,767

 
$
65,851

Transfer to assets held for sale (See Note 2. Assets Held for Sale)

(50,691
)
 

Total inventories
$
307,839

 
$
316,054


XML 25 R13.htm IDEA: XBRL DOCUMENT v3.20.2
GOODWILL AND OTHER INTANGIBLE ASSETS
9 Months Ended
Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS
Goodwill
Changes in the carrying amount of goodwill for the nine-month period ended September 30, 2020 were as follows:
 
Codman Specialty
Surgical
 
Orthopedics and
Tissue Technologies
 
Total
 
(In thousands)
Goodwill at December 31, 2019
$
653,500

 
$
300,780

 
$
954,280

Transfer to assets held for sale (See Note 2. Assets Held for Sale)

 
(47,117
)
 
(47,117
)
Foreign currency translation
8,928

 
3,465

 
12,393

Goodwill at September 30, 2020
$
662,428

 
$
257,128

 
$
919,556








The components of the Company’s identifiable intangible assets were as follows:
 
September 30, 2020
 
Weighted
Average
Life
 
Cost
 
Accumulated
Amortization
 
Net
 
(Dollars in thousands)
Completed technology
19 years
 
$
891,554

 
$
(250,609
)
 
$
640,945

Customer relationships
12 years
 
223,512

 
(138,989
)
 
84,523

Trademarks/brand names
28 years
 
104,404

 
(31,425
)
 
72,979

Codman tradename
Indefinite
 
167,013

 

 
167,013

Supplier relationships
27 years
 
34,721

 
(19,018
)
 
15,703

All other(1)
4 years
 
11,101

 
(5,247
)
 
5,854

Transfer to assets held for sale (See Note 2. Assets Held for Sale)

 
 
(39,821
)
 
26,489

 
(13,332
)
 
 
 
$
1,392,484

 
$
(418,799
)
 
$
973,685


 
December 31, 2019
 
Weighted
Average
Life
 
Cost
 
Accumulated
Amortization
 
Net
 
(Dollars in thousands)
Completed technology
19 years
 
$
880,623

 
$
(213,702
)
 
$
666,921

Customer relationships
12 years
 
222,575

 
(119,393
)
 
103,182

Trademarks/brand names
28 years
 
103,873

 
(28,514
)
 
75,359

Codman tradename
Indefinite
 
163,126

 

 
163,126

Supplier relationships
27 years
 
34,721

 
(17,947
)
 
16,774

All other (1)
4 years
 
10,869

 
(4,640
)
 
6,229

 
 
 
$
1,415,787

 
$
(384,196
)
 
$
1,031,591


(1)
At September 30, 2020 and December 31, 2019, all other included IPR&D of $1.0 million, which was indefinite-lived. At September 30, 2020, this IPR&D asset was presented separately as "assets held for sale" in conjunction with the sale of the Extremity Orthopedics business which is expected to be sold within twelve months. See Note 2, Assets and Liabilities Held for Sale, for details.
Goodwill and Intangible Assets with Indefinite Lives

The Company tests goodwill and intangible assets with indefinite lives for impairment annually in the third quarter in accordance with ASC Topic 350. Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit or indefinite lived intangible asset below its carrying amount. The carrying value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units.

The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including reporting unit specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of a reporting unit is less than its carrying amount, including goodwill. The Company may elect to bypass this qualitative evaluation for some or all of its reporting units and perform a quantitative test. During the third quarter of 2020, the Company began with the qualitative evaluation, which was sufficient to find no impairment.

For intangible assets with indefinite lives, the Company elected to bypass the qualitative evaluation for its Codman tradename intangible asset and perform a quantitative test during the third quarter 2020. In performing this test, the Company utilized a discount rate of 11.5%. The assumptions used in evaluating the Codman tradename for impairment are subject to change and are tracked against historical results by management. Based on the results of the quantitative test, the Company recorded no impairment to the Codman tradename intangible asset.

Based on quarter-end exchange rates, amortization expense (including amounts reported in cost of product revenues) is expected to be approximately $15.7 million for the remainder of 2020, $62.1 million in 2021, $59.7 million in 2022, $58.9 million in 2023, $58.4 million in 2024, $58.4 million in 2025 and $494.9 million thereafter.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.20.2
DEBT
9 Months Ended
Sep. 30, 2020
Debt Disclosure [Abstract]  
DEBT DEBT
Amendment to the Sixth Amended and Restated Senior Credit Agreement
On February 3, 2020, the Company entered into the sixth amendment and restatement (the "February 2020 Amendment") of its Senior Credit Facility (the "Senior Credit Facility") with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. The February 2020 Amendment extended the maturity date to February 3, 2025. The Company continues to have the aggregate principal amount of up to approximately $2.2 billion available to it through the following facilities: (i) a $877.5 million Term Loan facility, and (ii) a $1.3 billion revolving credit facility, which includes a $60 million sublimit for the issuance of standby letters of credit and a $60 million sublimit for swingline loans.

On July 14, 2020, the Company entered into an amendment (the "July 2020 Amendment") to the February 2020 Amendment of the Senior Credit Facility to increase financial flexibility in light of the unprecedented impact and uncertainty of the COVID-19 pandemic on the global economy. The July 2020 amendment does not increase the Company’s total indebtedness.
In connection with the July 14, 2020 amendment, the Company’s maximum consolidated total leverage ratio in the financial covenants (as defined in the Senior Credit Facility) was modified to the following:
Fiscal Quarter
 
Maximum Consolidated Total Leverage Ratio
 
 
 
Execution of July 2020 Amendment through June 30, 2021
 
5.50 to 1.00
September 30, 2021 through June 30, 2022
 
5.00 to 1.00
September 30, 2022 through June 30, 2023
 
4.50 to 1.00
September 30, 2023 and the last day of each fiscal quarter thereafter
 
4.00 to 1.00

Borrowings under the Senior Credit Facility bear interest, at the Company’s option, at a rate equal to the following:
i.
the Eurodollar Rate (as defined in the amendment and restatement) in effect from time to time plus the applicable rate (ranging from 1.00% to 2.25%), or
ii.
the highest of:
1.
the weighted average overnight Federal funds rate, as published by the Federal Reserve Bank of New York, plus 0.50%
2.
the prime lending rate of Bank of America, N.A. or
3.
the one-month Eurodollar Rate plus 1.00%

The applicable rates are based on the Company’s consolidated total leverage ratio (defined as the ratio of (a) consolidated funded indebtedness as of such date less cash that is not subject to any restriction on the use or investment thereof to (b) consolidated EBITDA as defined by the July 2020 amendment, for the period of four consecutive fiscal quarters ending on such date).
The Company will pay an annual commitment fee (ranging from 0.15% to 0.30%), based on the Company's consolidated total leverage ratio, on the amount available for borrowing under the revolving credit facility.
The Senior Credit Facility is collateralized by substantially all of the assets of the Company’s U.S. subsidiaries, excluding intangible assets. The Senior Credit Facility is subject to various financial and negative covenants and at September 30, 2020, the Company was in compliance with all such covenants. In connection with the February 2020 Amendment, the Company capitalized $4.6 million of financing costs in connection with modification of the Senior Credit Facility and wrote off $1.2 million of previously capitalized financing costs during the first quarter of 2020. In connection with the July 2020 amendment, the Company expensed $3.3 million of incremental financing costs in connection with the modification of the Senior Credit Facility during the third quarter of 2020.
At September 30, 2020 and December 31, 2019, there was $97.5 million and $375.0 million outstanding, respectively, under the revolving credit component of the Senior Credit Facility at weighted average interest rates of 1.5% and 3.2%, respectively. At September 30, 2020 and December 31, 2019, there was $877.5 million outstanding, respectively, under the Term Loan component of the Senior Credit Facility at a weighted average interest rate of 1.5% and 3.2%, respectively. At September 30, 2020, $22.5
million of the Term Loan component of the Senior Credit Facility is classified as current on the consolidated balance sheet as the first mandatory repayment is due June 30, 2021.
The fair value of outstanding borrowings of the Senior Credit Facility's revolving credit and Term Loan components at September 30, 2020 were $94.6 million and $853.7 million, respectively. These fair values were determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable inputs that reflect unadjusted quoted prices for identical assets or liabilities.
Letters of credit outstanding as of September 30, 2020 and December 31, 2019 totaled $1.6 million and $0.8 million. There were no amounts drawn as of September 30, 2020.
Contractual repayments of the Term Loan component of the Senior Credit Facility are due as follows:
Quarter Ended September 30, 2020
 
Principal Repayment
 
 
(In thousands)
Remainder of 2020
 
$

2021
 
33,750

2022
 
45,000

2023
 
61,875

2024
 
67,500

2025
 
669,375

 
 
$
877,500


The outstanding balance of the revolving credit component of the Senior Credit Facility is due on February 3, 2025.
Convertible Senior Notes
On February 4, 2020, the Company issued $575.0 million aggregate principal amount of its 0.5% Convertible Senior Notes due 2025 (the "2025 Notes"). The 2025 Notes will mature on August 15, 2025 and bear interest at a rate of 0.5% per annum payable semi-annually in arrears, unless earlier converted, repurchased or redeemed in accordance with the terms of the Notes. The portion of debt proceeds that was classified as equity at the time of the offering was $104.5 million, and that amount is being amortized to interest expense using the effective interest method through August 2025. The effective interest rate implicit in the liability component is 4.2%. In connection with this offering, the Company capitalized $13.2 million of financing fees. At September 30, 2020, the carrying amount of the liability component was $481.5 million, the remaining unamortized discount was $93.5 million, and the principal amount outstanding was $575.0 million. The fair value of the 2025 Notes at September 30, 2020 was $541.8 million.
The 2025 Notes are senior, unsecured obligations of the Company, and are convertible into cash and shares of its common stock based on initial conversion rate, subject to adjustment of 13.5739 shares per $1,000 principal amounts of the 2025 Notes (which represents an initial conversion price of $73.67 per share). The 2025 Notes convert only in the following circumstances: (1) if the closing price of the Company's common stock has been at least 130% of the conversion price during the period; (2) if the average trading price per $1000 principal amount of the 2025 Notes is less than or equal to 98% of the average conversion value of the 2025 Notes during a period as defined in the indenture; (3) at any time on or after February 20, 2023; or (4) if specified corporate transactions occur. As of September 30, 2020, none of these conditions existed with respect to the 2025 Notes and as a result the 2025 Notes are classified as long term.
Holders of the Notes will have the right to require the Company to repurchase for cash all or a portion of their Notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of a fundamental change (as defined in the indenture relating to the Notes). The Company will also be required to increase the conversion rate for holders who convert their Notes in connection with certain fundamental changes occurring prior to the maturity date or following delivery by the Company of a notice of redemption.

In connection with the issuance of the 2025 Notes, the Company entered into call transactions and warrant transactions, primarily with affiliates of the initial purchasers of the 2025 Notes (the “hedge participants”). The cost of the call transactions was $104.2 million for the 2025 Notes. The Company received $44.5 million of proceeds from the warrant transactions for the 2025 Notes. The call transactions involved purchasing call options from the hedge participants, and the warrant transactions involved selling call options to the hedge participants with a higher strike price than the purchased call options. The initial strike price of the call transactions was $73.67, subject to anti-dilution adjustments substantially similar to those in the 2025
Notes. The initial strike price of the warrant transactions was $113.34 for the 2025 Notes, subject to customary anti-dilution adjustments.
During the nine months ended September 30, 2020, the Company recognized cash interest related to the contractual interest coupon of $1.9 million and amortization of the discount on the liability component of $11.1 million for a total interest charge of $13.0 million on the 2025 Notes.
Securitization Facility
During the fourth quarter of 2018, the Company entered into an accounts receivable securitization facility (the "Securitization Facility") under which accounts receivable of certain domestic subsidiaries are sold on a non-recourse basis to a special purpose entity (“SPE”), which is a bankruptcy-remote, consolidated subsidiary of the Company. Accordingly, the assets of the SPE are not available to satisfy the obligations of the Company or any of its subsidiaries. From time to time, the SPE may finance such accounts receivable with a revolving loan facility secured by a pledge of such accounts receivable. The amount of outstanding borrowings on the Securitization Facility at any one time is limited to $150.0 million. The Securitization Facility Agreement ("Securitization Agreement") is for an initial three-year term and may be extended. The Securitization Agreement governing the Securitization Facility contains certain covenants and termination events. An occurrence of an event of default or a termination event under this Securitization Agreement may give rise to the right of its counterparty to terminate this facility. As of September 30, 2020, the Company was in compliance with the covenants and none of the termination events had occurred. At September 30, 2020 and December 31, 2019, the Company had $92.3 million and $104.5 million, respectively, of outstanding borrowings under its Securitization Facility at a weighted average interest rate of 1.4% and 2.8%, respectively.
The fair value of the outstanding borrowing of the Securitization Facility at September 30, 2020 was $92.8 million.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.20.2
DERIVATIVE INSTRUMENTS
9 Months Ended
Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
DERIVATIVE INSTRUMENTS DERIVATIVE INSTRUMENTS
Interest Rate Hedging
The Company’s interest rate risk relates to U.S. dollar denominated variable interest rate borrowings. The Company uses interest rate swap derivative instruments to manage earnings and cash flow exposure resulting from changes in interest rates. These interest rate swaps apply a fixed interest rate on a portion of the Company's expected LIBOR-indexed floating-rate borrowings.
The Company held the following interest rate swaps as of September 30, 2020 and December 31, 2019 (dollar amounts in thousands):
 
 
September 30, 2020
 
December 31, 2019
 
 
 
 
 
 
 
 
 
September 30, 2020
 
December 31, 2019
Hedged Item
 
Notional Amount
 
Notional Amount
 
Designation Date
 
Effective Date
 
Termination Date
 
Fixed Interest Rate
 
Estimated Fair Value
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Asset (Liability)
3-month USD LIBOR Loan
 

 
50,000

 
February 6, 2017
 
June 30, 2017
 
June 30, 2020
 
1.834
%
 
$

 
$
(2
)
1-month USD LIBOR Loan
 

 
100,000

 
February 6, 2017
 
June 30, 2017
 
June 30, 2020
 
1.652
%
 

 
12

1-month USD LIBOR Loan
 
100,000

 
100,000

 
March 27, 2017
 
December 31, 2017
 
June 30, 2021
 
1.971
%
 
(1,377
)
 
(581
)
1-month USD LIBOR Loan
 
150,000

 
150,000

 
December 13, 2017
 
January 1, 2018
 
December 31, 2022
 
2.201
%
 
(6,901
)
 
(2,880
)
1-month USD LIBOR Loan
 
150,000

 
150,000

 
December 13, 2017
 
January 1, 2018
 
December 31, 2022
 
2.201
%
 
(6,922
)
 
(2,880
)
1-month USD LIBOR Loan
 
100,000

 
100,000

 
December 13, 2017
 
July 1, 2019
 
June 30, 2024
 
2.423
%
 
(8,454
)
 
(3,517
)
1-month USD LIBOR Loan
 
50,000

 
50,000

 
December 13, 2017
 
July 1, 2019
 
June 30, 2024
 
2.423
%
 
(4,064
)
 
(1,778
)
1-month USD LIBOR Loan
 
200,000

 
200,000

 
December 13, 2017
 
January 1, 2018
 
December 31, 2024
 
2.313
%
 
(18,188
)
 
(6,595
)
1-month USD LIBOR Loan
 
75,000

 
75,000

 
October 10, 2018
 
July 1, 2020
 
June 30, 2025
 
3.220
%
 
(10,608
)
 
(5,750
)
1-month USD LIBOR Loan
 
75,000

 
75,000

 
October 10, 2018
 
July 1, 2020
 
June 30, 2025
 
3.199
%
 
(10,871
)
 
(5,747
)
1-month USD LIBOR Loan
 
75,000

 
75,000

 
October 10, 2018
 
July 1, 2020
 
June 30, 2025
 
3.209
%
 
(10,586
)
 
(5,807
)
1-month USD LIBOR Loan
 
100,000

 
100,000

 
December 18, 2018
 
December 30, 2022
 
December 31, 2027
 
2.885
%
 
(11,282
)
 
(4,930
)
1-month USD LIBOR Loan
 
100,000

 
100,000

 
December 18, 2018
 
December 30, 2022
 
December 31, 2027
 
2.867
%
 
(11,127
)
 
(4,691
)
Total interest rate derivatives designated as cash flow hedge
 
$
1,175,000

 
$
1,325,000

 
 
 
 
 
 
 
 
 
$
(100,380
)
 
$
(45,145
)

The Company has designated these derivative instruments as cash flow hedges. The Company assesses the effectiveness of these derivative instruments and has recorded the changes in the fair value of the derivative instrument designated as a cash flow hedge as unrealized gains or losses in accumulated other comprehensive loss (“AOCL”), net of tax, until the hedged item affected earnings, at which point any gain or loss was reclassified to earnings. If the hedged cash flow does not occur, or if it becomes probable that it will not occur, the Company will reclassify the remaining amount of any gain or loss on the related cash flow hedge recorded in AOCL to interest expense at that time.
Foreign Currency Hedging
From time to time the Company enters into foreign currency hedge contracts intended to protect the U.S. dollar value of certain forecasted foreign currency denominated transactions. The Company assesses the effectiveness of the contracts that are designated as hedging instruments. The changes in fair value of foreign currency cash flow hedges are recorded in AOCL, net of tax, until the hedged item affects earnings. Once the related hedged item affects earnings, the Company reclassifies amounts recorded in AOCL to earnings. If the hedged forecasted transaction does not occur, or if it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. For contracts not designated as hedging instruments, the changes in fair value of the contracts are recognized in other income (expense), net in the consolidated statements of operation, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities.
The success of the Company’s hedging program depends, in part, on forecasts of certain activity denominated in foreign currency. The Company may experience unanticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activities during periods of currency volatility. In addition, changes in currency exchange rates related to any unhedged transactions may affect earnings and cash flows.
Cross-Currency Rate Swaps
On October 2, 2017, the Company entered into cross-currency swap agreements to convert a notional amount of $300.0 million equivalent to 291.2 million of CHF denominated intercompany loans into U.S. dollars. The CHF-denominated intercompany loans were the result of the purchase of intellectual property by a subsidiary in Switzerland as part of an acquisition. The objective of these cross-currency swaps is to reduce volatility of earnings and cash flows associated with changes in the foreign currency exchange rate. Under the terms of these contracts, which have been designated as cash flow hedges, the Company will make interest payments in Swiss Francs and receive interest in U.S. dollars. Upon the maturity of these contracts, the Company will pay the principal amount of the loans in Swiss Francs and receive U.S. dollars from the counterparties.
The Company held the following cross-currency rate swaps as of September 30, 2020 and December 31, 2019 (dollar amounts in thousands):
 
 
 
 
 
 
 
 
 
 
 
September 30, 2020
 
December 31, 2019
 
 
Effective Date
 
Termination Date
 
Fixed Rate
 
Aggregate Notional Amount
 
Fair Value
Asset (Liability)
 
 
 
 
 
 
 
 
 
 
 
 
 
Pay CHF
 
October 2, 2017
 
October 2, 2020
 
1.75%
 
CHF
32,355

 
$
(1,565
)
 
$
(101
)
Receive U.S.$
 
 
4.38%
 
$
33,333

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pay CHF
 
October 2, 2017
 
October 2, 2021
 
1.85%
 
CHF
48,533

 
(2,003
)
 
(119
)
Receive U.S.$
 
 
4.46%
 
$
50,000

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pay CHF
 
October 2, 2017
 
October 2, 2022
 
1.95%
 
CHF
145,598

 
(4,167
)
 
(289
)
Receive U.S.$
 
 
4.52%
 
$
150,000

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total
 
 
 
 
 
 
 
 
 
 
$
(7,735
)
 
$
(509
)


On October 2, 2020 in accordance with the termination date, the Company settled a cross-currency swap designated as a cash flow hedge of an intercompany loan with an aggregate notional amount of $33.3 million.
The cross- currency swaps are carried on the consolidated balance sheet at fair value, and changes in the fair values are recorded as unrealized gains or losses in AOCL. For the three and nine months ended September 30, 2020, the Company recorded losses of $6.9 million and $12.0 million, respectively, in other income, net related to change in fair value related to the foreign currency rate translation to offset the gains recognized on the intercompany loans. For the three and nine months ended September 30, 2019, the Company recorded gains of $5.7 million and $3.9 million, respectively, in other income, net related to change in fair value related to the foreign currency rate translation to offset the losses recognized on the intercompany loans.
For the three and nine months ended September 30, 2020, the Company recorded a loss of $6.3 million and a gain of $2.7 million in AOCL, respectively, related to change in fair value of the cross-currency swaps. For the three and nine months ended September 30, 2019, the Company recorded gains of $9.7 million and $15.4 million in AOCL, respectively, related to change in fair value of the cross-currency swaps.
For the three and nine months ended September 30, 2020, the Company recorded gains of $1.5 million and $4.5 million, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps. For the three and nine months ended September 30, 2019, the Company recorded gains of $1.8 million and
$5.5 million, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps.
The estimated gain that is expected to be reclassified to other income (expense), net from AOCL as of September 30, 2020 within the next twelve months is $3.0 million. As of September 30, 2020, the Company does not expect any gains or losses will be reclassified into earnings as a result of the discontinuance of these cash flow hedges because the original forecasted transaction will not occur.
Net Investment Hedges
The Company manages certain foreign exchange risks through a variety of strategies, including hedging. The Company is exposed to foreign exchange risk from its international operations through foreign currency purchases, net investments in foreign subsidiaries, and foreign currency assets and liabilities created in the normal course of business. On October 1, 2018, the Company entered into cross-currency swap agreements designated as net investment hedges to partially offset the effects of foreign currency on foreign subsidiaries.
The Company held the following cross-currency rate swaps designated as net investment hedges as of September 30, 2020 and December 31, 2019, respectively (dollar amounts in thousands):
 
 
 
 
 
 
 
 
 
 
 
September 30, 2020
 
December 31, 2019
 
 
Effective Date
 
Termination Date
 
Fixed Rate
 
Aggregate Notional Amount
 
Fair Value
Asset (Liability)
 
 
 
 
 
 
 
 
 
 
 
 
 
Pay EUR
 
October 3, 2018
 
September 30, 2021
 
—%
 
EUR
44,859

 
$
589

 
$
2,459

Receive U.S.$
 
 
 
3.01%
 
$
52,000

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pay EUR
 
October 3, 2018
 
September 30, 2023
 
—%
 
EUR
51,760

 
2,443

 
3,087

Receive U.S.$
 
 
 
2.57%
 
$
60,000

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pay EUR
 
October 3, 2018
 
September 30, 2025
 
—%
 
EUR
38,820

 
2,398

 
2,032

Receive U.S.$
 
 
 
2.19%
 
$
45,000

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pay GBP
 
October 3, 2018
 
September 30, 2025
 
1.67%
 
GBP
128,284

 
8,580

 
(154
)
Receive U.S.$
 
 
 
2.71%
 
$
167,500

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pay CHF
 
October 3, 2018
 
September 30, 2025
 
—%
 
CHF
165,172

 
(6,828
)
 
1,221

Receive GBP
 
 
 
1.67%
 
GBP
128,284

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total
 
 
 
 
 
 
 
 
 
 
$
7,182

 
$
8,645


The cross-currency swaps were carried on the consolidated balance sheet at fair value and changes in the fair values were recorded as unrealized gains or losses in AOCL. For the three and nine months ended September 30, 2020, the Company recorded loss of $11.3 million and a gain of $5.1 million in AOCL related to the change in fair value of the cross-currency swaps. For the three and nine months ended September 30, 2019, the Company recorded gains of $17.1 million and $26.6 million in AOCL related to the change in fair value of the cross-currency swaps.
For the three and nine months ended September 30, 2020, the Company recorded gains of $2.2 million and $6.6 million in interest income included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps. For the three and nine months ended September 30, 2019, the Company recorded gains of $2.5 million and $7.2 million, respectively, in interest income included in the consolidation statements of operations related to the interest rate differential of the cross-currency swaps.
The estimated gain that is expected to be reclassified to interest income from AOCL as of September 30, 2020 within the next twelve months is $7.7 million.
Counterparty Credit Risk
The Company manages its concentration of counterparty credit risk on its derivative instruments by limiting acceptable counterparties to a group of major financial institutions with investment grade credit ratings, and by actively monitoring their credit ratings and outstanding positions on an ongoing basis. Therefore, the Company considers the credit risk of the counterparties to be low. Furthermore, none of the Company’s derivative transactions are subject to collateral or other security arrangements, and none contain provisions that depend upon the Company’s credit ratings from any credit rating agency.
Fair Value of Derivative Instruments
The Company has classified all of its derivative instruments within Level 2 of the fair value hierarchy because observable inputs are available for substantially the full term of the derivative instruments. The fair values of the interest rate swaps and cross-currency swaps were developed using a market approach based on publicly available market yield curves and the terms of the swap. The Company performs ongoing assessments of counterparty credit risk.

The following table summarizes the fair value for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of September 30, 2020 and December 31, 2019:
 
 
Fair Value as of
Location on Balance Sheet (1):
 
September 30, 2020
 
December 31, 2019
 
 
(In thousands)
Derivatives designated as hedges — Assets:
 
 
 
 
Prepaid expenses and other current assets
 
 
 
 
Cash Flow Hedges
 
 
 
 
Interest rate swap
 
$

 
$
12

Cross-currency swap
 
4,608

 
5,032

Net Investment Hedges
 
 
 
 
Cross-currency swap
 
7,717

 
7,952

Other assets
 
 
 
 
Net Investment Hedges
 
 
 
 
Cross-currency swap
 
9,071

 
3,465

Total derivatives designated as hedges — Assets
 
$
21,396

 
$
16,461

 
 
 
 
 
Derivatives designated as hedges — Liabilities:
 
 
 
 
Accrued expenses and other current liabilities
 
 
 
 
Cash Flow Hedges
 
 
 
 
Interest rate swap
 
$
22,324

 
$
6,635

Cross-currency swap
 
1,565

 
101

Other liabilities
 
 
 
 
Cash Flow Hedges
 
 
 
 
Interest rate swap
 
78,056

 
38,522

Cross-currency swap
 
10,777

 
5,440

Net Investment Hedges
 
 
 
 
Cross-currency swap
 
9,605

 
2,772

Total derivatives designated as hedges — Liabilities
 
$
122,327

 
$
53,470

 
(1) 
The Company classifies derivative assets and liabilities as non-current based on the cash flows expected to be incurred within the following 12 months.

The following presents the effect of derivative instruments designated as cash flow hedges on the accompanying condensed consolidated statement of operations during the three and nine months ended September 30, 2020 and 2019:
 
Balance in AOCL
Beginning of
Quarter
 
Amount of
Gain (Loss)
Recognized in
AOCL
 
Amount of Gain (Loss)
Reclassified from
AOCL into
Earnings
 
Balance in AOCL
End of Quarter
 
Location in
Statements of
Operations
 
(In thousands)
Three Months Ended September 30, 2020
 
 
 
 
 
 
 
 
 
Cash Flow Hedges
 
 
 
 
 
 
 
 
 
Interest rate swap
$
(102,128
)
 
$
(3,971
)
 
$
(5,718
)
 
$
(100,381
)
 
Interest expense
Cross-currency swap
5,843

 
(6,272
)
 
(5,353
)
 
4,924

 
Other income (expense),net
Net Investment Hedges
 
 
 
 
 
 
 
 
 
Cross-currency swap
22,223

 
(11,254
)
 
2,202

 
8,767

 
Interest income
 
$
(74,062
)
 
$
(21,497
)
 
$
(8,869
)
 
$
(86,690
)
 
 
Three Months Ended September 30, 2019
 
 
 
 
 
 
 
 
 
Cash Flow Hedges
 
 
 
 
 
 
 
 
 
Interest rate swap
$
(43,161
)
 
$
(13,788
)
 
$
237

 
$
(57,186
)
 
Interest expense
Cross-currency swap
(2,284
)
 
9,661

 
7,520

 
(143
)
 
Other income (expense),net
Net Investment Hedges
 
 
 
 
 
 
 
 
 
Cross-currency swap
4,054

 
17,136

 
2,489

 
18,701

 
Interest income
 
$
(41,391
)
 
$
13,009

 
$
10,246

 
$
(38,628
)
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance in AOCL
Beginning of
Year
 
Amount of
Gain (Loss)
Recognized in
AOCL
 
Amount of Gain (Loss)
Reclassified from
AOCL into
Earnings
 
Balance in AOCL
End of Quarter
 
Location in
Statements of
Operations
 
(In thousands)
Nine Months Ended September 30, 2020
 
 
 
 
 
 
 
 
 
Cash Flow Hedges
 
 
 
 
 
 
 
 
 
Interest rate swap
$
(45,146
)
 
$
(65,608
)
 
$
(10,373
)
 
$
(100,381
)
 
Interest expense
Cross-currency swap
177

 
(2,688
)
 
(7,435
)
 
4,924

 
Other income (expense),net
Net Investment Hedges
 
 
 
 
 
 
 
 
 
Cross-currency swap
10,229

 
5,102

 
6,564

 
8,767

 
Interest income
 
$
(34,740
)
 
$
(63,194
)
 
$
(11,244
)
 
$
(86,690
)
 
 
Nine months ended September 30, 2019
 
 
 
 
 
 
 
 
 
Cash Flow Hedges
 
 
 
 
 
 
 
 
 
Interest rate swap
$
619

 
$
(54,841
)
 
$
2,964

 
$
(57,186
)
 
Interest expense
Cross-currency swap
(6,190
)
 
15,418

 
9,371

 
(143
)
 
Other income (expense), net
Net Investment Hedges
 
 
 
 
 
 
 
 
 
Cross-currency swap
(632
)
 
26,558

 
7,225

 
18,701

 
Interest income
 
$
(6,203
)
 
$
(12,865
)
 
$
19,560

 
$
(38,628
)
 
 

XML 28 R16.htm IDEA: XBRL DOCUMENT v3.20.2
STOCK-BASED COMPENSATION
9 Months Ended
Sep. 30, 2020
Share-based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION
As of September 30, 2020, the Company had stock options, restricted stock awards, performance stock units, contract stock awards and restricted stock unit awards outstanding under two plans, the 2001 Equity Incentive Plan (the “2001 Plan”) and the 2003 Equity Incentive Plan (the “2003 Plan,” and collectively, the “Plans”).
Stock options issued under the Plans become exercisable over specified periods, generally within four years from the date of grant for officers and employees, and within one year from date of grant for directors and generally expire eight years from the grant
date for employees, and from six to ten years for directors and certain executive officers. The Company values stock option grants using the binomial distribution model. Restricted stock issued under the Plans vests over specified periods, generally three years after the date of grant. The vesting of performance stock issued under the Plans is subject to service and performance conditions.
Stock Options
As of September 30, 2020, there were approximately $6.0 million of total unrecognized compensation costs related to unvested stock options. These costs are expected to be recognized over a weighted-average period of approximately three years. There were 348,587 stock options granted during the nine months ended September 30, 2020. For the nine months ended September 30, 2020, the weighted average grant date fair value for stock options was $13.03 per option.
Awards of Restricted Stock and Performance Stock
Performance stock and restricted stock awards generally have requisite service periods of three years. Performance stock units are subject to graded vesting conditions based on revenue goals of the Company. The Company expenses the fair value of restricted stock awards on a straight-line basis over the requisite service period. As of September 30, 2020, there was approximately $27.5 million of total unrecognized compensation costs related to these unvested awards. The Company expects to recognize these costs over a weighted-average period of approximately two years. The Company granted 322,485 restricted stock awards and 180,875 performance stock awards during the nine months ended September 30, 2020. For the nine months ended September 30, 2020, the weighted average grant date fair value for restricted stock awards and performance stock units was $44.08 and $43.39 per award, respectively.
The Company also maintains an Employee Stock Purchase Plan (the “ESPP”), which provides eligible employees with the opportunity to acquire shares of common stock at periodic intervals by means of accumulated payroll deductions. The ESPP is a non-compensatory plan based on its terms.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.20.2
RETIREMENT PLANS
9 Months Ended
Sep. 30, 2020
Retirement Benefits [Abstract]  
RETIREMENT PLANS RETIREMENT PLANS
The Company maintains defined benefit pension plans that cover certain employees in France, Japan, Germany and Switzerland.
Net periodic benefit costs for the Company’s defined benefit pension plans for the three and nine months ended September 30, 2020 were $1.0 million and $3.0 million, respectively. The components of the net periodic benefit costs other than the service cost component of $1.0 million and $2.9 million for the three and nine months ended September 30, 2020, respectively, are included in other income (expense), net in the consolidated statements of operations.
Net periodic benefit costs for the Company’s defined benefit pension plans for the three and nine months ended September 30, 2019 was $1.0 million and $2.1 million, respectively. The components of the net periodic benefit costs other than the service cost component of $0.7 million and $2.0 million for the three and nine months ended September 30, 2019, respectively, are included in other income (expense), net in the consolidated statements of operations.
The estimated fair values of plan assets were $33.2 million and $30.8 million as of September 30, 2020 and December 31, 2019, respectively. The net plan assets of the pension plans are invested in common trusts as of September 30, 2020 and December 31, 2019. Common trusts are classified as Level 2 in the fair value hierarchy. The fair value of common trusts is valued at the net asset value based on the fair values of the underlying investments of the trusts as determined by the sponsor of the trusts. The investment strategy of the Company's defined benefit plans is both to meet the liabilities of the plans as they fall due and to maximize the return on invested assets within an appropriate risk profile.
Deferred Compensation Plan
In May 2019, the Company adopted the Integra LifeSciences Deferred Compensation Plan (the “Plan”). Under the Plan, certain employees of the Company may defer the payment and taxation of up to 75% of their base salary and up to 100% of bonus amounts and other eligible cash compensation.
During the first quarter of 2020, employees participating in the Plan began to defer their compensation. This deferred compensation is invested in funds offered under the Plan and is valued based on Level 1 measurements in the fair value hierarchy. The purpose of the Plan is to retain key employees by providing them with an opportunity to defer a portion of their compensation as elected by the participant in accordance with the Plan. Any amounts set aside to defray the liabilities assumed by the Company will remain the general assets of the Company until such amounts are distributed to the participants. Assets of the Company's deferred compensation plan are included in Other current assets and recorded at fair value based on their quoted market prices. The fair value of these assets at September 30, 2020 was $1.7 million. Offsetting liabilities relating to the deferred compensation plan are included in Other liabilities.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.20.2
LEASES AND RELATED PARTY LEASES
9 Months Ended
Sep. 30, 2020
Leases [Abstract]  
LEASES AND RELATED PARTY LEASES LEASES AND RELATED PARTY LEASES
The Company leases administrative, manufacturing, research and distribution facilities and vehicles through operating lease agreements. The Company has no finance leases as of September 30, 2020. Many of the Company's leases include both lease (e.g., fixed payments including rent) and non-lease components (e.g., common-area or other maintenance costs). For vehicles, the Company has elected the practical expedient to group lease and non-lease components. 
Most facility leases include one or more options to renew. The exercise of lease renewal options is typically at the Company's sole discretion, therefore, the majority of renewals to extend the lease terms are not included in the Right of Use ("ROU") assets and lease liabilities as they are not reasonably certain of exercise. The Company regularly evaluates renewal options and when they are reasonably certain of exercise, the renewal period is included in the lease term.
As most of the Company's leases do not provide an implicit rate, the Company uses a collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments.
Total operating lease expense for the nine months ended September 30, 2020 and September 30, 2019, was $14.6 million and $14.2 million respectively, which includes $0.2 million, in related party operating lease expense.
Supplemental balance sheet information related to operating leases at September 30, 2020 were as follows:
 
September 30, 2020
 
(In thousands, except lease term and discount rate)
Weighted average remaining lease term (in years):
 
 
 
Leased facilities
11.8

Leased vehicles
1.4

 
 
Weighted average discount rate:
 
Leased facilities
4.6
%
Leased vehicles
2.2
%

Supplemental cash flow information related to leases for the nine months ended September 30, 2020 and September 30, 2019 were as follows:
 
September 30, 2020
 
September 30, 2019
 
(In thousands)
 
(In thousands)
Cash paid for amounts included in the measurement of lease liabilities:
 
 
 
Operating cash flows from operating leases
$
10,976

 
$
10,680

 
 
 
 
ROU assets obtained in exchange for lease liabilities:
 
 
 
Operating leases
$
6,007

 
$
41,860












Future minimum lease payments under operating leases at September 30, 2020 were as follows:
 
Related Parties
 
Third Parties
 
Total
 
(In thousands)
2020
$
74

 
$
3,742

 
$
3,816

2021
296

 
13,209

 
13,505

2022
296

 
13,224

 
13,520

2023
296

 
10,782

 
11,078

2024
296

 
9,996

 
10,292

Thereafter
1,426

 
86,750

 
88,176

Total minimum lease payments
$
2,684

 
$
137,703

 
$
140,387

Less: Imputed interest
 
 
 
 
39,091

Total lease liabilities
 
 
 
 
101,296

Less: Current lease liabilities
 
 
 
 
12,518

Long-term lease liabilities
 
 
 
 
88,778


Related Party Leases
The Company leases its manufacturing facility in Plainsboro, New Jersey, from a general partnership that is 50% owned by a corporation whose shareholders are trusts, whose beneficiaries include family members of the Company’s principal stockholder and former director. The term of the current lease agreement is through October 31, 2029 at an annual rate of approximately $0.3 million per year. The current lease agreement also provides (i) a 5-year renewal option for the Company to extend the lease from November 1, 2029 through October 31, 2034 at the fair market rental rate of the premises, and (ii) another 5-year renewal option to extend the lease from November 1, 2034 through October 31, 2039 at the fair market rental rate of the premises.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.20.2
TREASURY STOCK
9 Months Ended
Sep. 30, 2020
Treasury Stock Transactions, Excluding Value of Shares Reissued [Abstract]  
TREASURY STOCK TREASURY STOCK
As of September 30, 2020 and December 31, 2019, there were 4.9 million and 2.9 million shares of treasury stock outstanding with a cost of $235.2 million and $119.9 million, at a weighted average cost per share of $47.86 and $41.87, respectively.
On December 11, 2018, the board of directors of the Company (the “Board”) authorized the Company to repurchase up to $225.0 million of the Company’s common stock. The program allows the Company to repurchase its shares opportunistically from time to time. The repurchase authorization expires in December 2020.

During the nine months ended September 30, 2020, the Company repurchased 2.1 million shares of Integra’s common stock as part of the existing share repurchase authorization. The Company utilized $100.0 million of net proceeds from the offering of the Convertible Senior Notes to execute the share repurchase transactions. This included $7.6 million from certain purchasers of the convertible notes in conjunction with the closing of the offering. On February 5, 2020, the Company entered into a
$92.4 million accelerated share repurchase ("ASR") to complete the remaining $100.0 million of share repurchase. The Company received 1.3 million shares at inception of the ASR, which represented approximately 80% of the expected total shares. Upon settlement of the ASR in June 2020, the Company received an additional 0.6 million shares determined using the volume-weighted average price of the Company's common stock during the term of the transaction.

The Company has $125.0 million remaining under the share repurchase of its Common Stock. The price and timing of any future purchases under the share repurchase program will depend on factors such as levels of cash generation from operations, the volume of stock option exercises by employees, cash requirements for acquisitions, dividends, economic and market conditions and stock price.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.20.2
INCOME TAXES
9 Months Ended
Sep. 30, 2020
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The following table provides a summary of the Company's effective tax rate:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2020
 
2019
 
2020
 
2019
Reported tax rate
22.1
%
 
(0.4
)%
 
24.6
%
 
(3.5
)%


The Company’s effective income tax rates for the three months ended September 30, 2020 and 2019 were 22.1% and (0.4)%, respectively. For the three months ended September 30, 2020, the primary drivers of the higher tax rate are the jurisdictional mix of income along with a $4.2 million recognition of a deferred tax liability related to an outside tax basis from the sale of the Extremity Orthopedics business, offset by a $3.2 million benefit from the reversal of the French valuation allowance. For the three months ended September 30, 2019, the rate was primarily driven by the impact of the Rebound transaction, which resulted in a $59.9 million IPR&D expense. This amount was not deductible for tax purposes.

The Company's effective income tax rates for the nine months ended September 30, 2020 and September 30, 2019 were 24.6% and (3.5)%, respectively. For the nine months ended September 30, 2020, the primary drivers of the higher tax rate are the jurisdictional mix of income along with a $4.2 million recognition of a deferred tax liability related to an outside tax basis from the sale of the Extremity Orthopedics business. For the nine months ended September 30, 2019, the primary driver of the tax rate is the impact of the Rebound transaction, which resulted in a $59.9 million IPR&D expense. This amount is not deductible for tax purposes. This was offset by a tax benefit of $10.8 million related to a federal tax holiday in Switzerland, which was finalized during the quarter ended March 31, 2019. The Company received a federal tax credit in Switzerland of 12 million CHF, which may be used over a seven year period, ending in 2024.
As of September 30, 2020, the Company has not provided deferred income taxes on unrepatriated earnings from foreign subsidiaries as they are deemed indefinitely reinvested. Such taxes would primarily be attributable to foreign withholding taxes and local income taxes when such earnings are distributed. As such, the Company has determined the tax impact of repatriating these earnings would not be material as of September 30, 2020. The Company does not anticipate the need to repatriate earnings from foreign subsidiaries as a result of the impact of the COVID-19 pandemic.
On March 27, 2020, the Coronavirus Aid Relief, and Economic Security Act (CARES Act) was signed into law. The CARES Act included certain income tax provisions for corporations and individuals, among other provisions. The Company does not expect the CARES Act provisions to have a significant impact on the Company's income taxes. The Company continues to monitor the issuance of new legislation, regulations, and case law that may impact federal, state, and international tax positions.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.20.2
NET INCOME (LOSS) PER SHARE
9 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]  
NET INCOME (LOSS) PER SHARE NET INCOME (LOSS) PER SHARE
Basic and diluted net income (loss) per share was as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2020
 
2019
 
2020
 
2019
 
(In thousands, except per share amounts)
 
(In thousands, except per share amounts)
Basic net income (loss) per share:
 
 
 
 
 
 
 
Net income (loss)
$
32,337

 
$
(27,610
)
 
$
41,148

 
$
34,882

Weighted average common shares outstanding
84,325

 
85,688

 
84,745

 
85,536

Basic net income (loss) per common share
$
0.38

 
$
(0.32
)
 
$
0.49

 
$
0.41

 
 
 
 
 
 
 
 
Diluted net income (loss) per share:
 
 
 
 
 
 
 
Net income (loss)
$
32,337

 
$
(27,610
)
 
$
41,148

 
$
34,882

 
 
 
 
 
 
 
 
Weighted average common shares outstanding — Basic
84,325

 
85,688

 
84,745

 
85,536

Effect of dilutive securities:
 
 
 
 
 
 
 
Stock options and restricted stock
427

 

 
558

 
1,045

Weighted average common shares for diluted earnings per share
84,752

 
85,688

 
85,303

 
86,581

 
 
 
 
 
 
 
 
Diluted net income (loss) per common share
$
0.38

 
$
(0.32
)
 
$
0.48

 
$
0.40



Common stock of approximately 0.3 million and 0.6 million shares at September 30, 2020, and 2019, respectively that are issuable through exercise of dilutive securities were not included in the computation of diluted net income (loss) per share because their effect would have been anti-dilutive.
Performance Shares and Restricted Units that entitle the holders to approximately 0.5 million shares of common stock are included in the basic and diluted weighted average shares outstanding calculation from their date of issuance because no further consideration is due related to the issuance of the underlying common shares.
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.20.2
COMPREHENSIVE INCOME (LOSS)
9 Months Ended
Sep. 30, 2020
Equity [Abstract]  
COMPREHENSIVE INCOME (LOSS) COMPREHENSIVE INCOME (LOSS)

Comprehensive income (loss) was as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2020
 
2019
 
2020
 
2019
 
(In thousands)
 
(In thousands)
Net income (loss)
$
32,337

 
$
(27,610
)
 
$
41,148

 
$
34,882

Foreign currency translation adjustment
21,181

 
(18,651
)
 
24,801

 
(17,960
)
Change in unrealized loss on derivatives, net of tax
(9,679
)
 
(775
)
 
(39,814
)
 
(24,714
)
Pension liability adjustment, net of tax
(291
)
 
515

 
(498
)
 
504

Comprehensive income (loss), net
$
43,548

 
$
(46,521
)
 
$
25,637

 
$
(7,288
)

Changes in accumulated other comprehensive loss by component between December 31, 2019 and September 30, 2020 are presented in the table below, net of tax:
 
 
Gains and Losses on Derivatives
 
Defined Benefit Pension Items
 
Foreign Currency Items
 
Total
 
 
(In thousands)
Balance at January 1, 2020
 
$
(26,625
)
 
$
(9,709
)
 
$
(40,068
)
 
$
(76,402
)
Other comprehensive income (loss)
 
(48,429
)
 
(498
)
 
24,801

 
(24,126
)
Less: Amounts reclassified from accumulated other comprehensive loss
 
(8,615
)
 

 

 
(8,615
)
Net current-period other comprehensive income (loss)
 
(39,814
)
 
(498
)
 
24,801

 
(15,511
)
Balance at September 30, 2020
 
$
(66,439
)
 
$
(10,207
)
 
$
(15,267
)
 
$
(91,913
)

For the nine months ended September 30, 2020, the Company reclassified a loss of $5.7 million and $2.9 million from accumulated other comprehensive loss to other income (expense), net and interest income, respectively.
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.20.2
SEGMENT AND GEOGRAPHIC INFORMATION
9 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
SEGMENT AND GEOGRAPHIC INFORMATION SEGMENT AND GEOGRAPHIC INFORMATION
The Company internally manages two global reportable segments and reports the results of its businesses to its chief operating decision maker. The two reportable segments and their activities are described below.
The Codman Specialty Surgical segment includes (i) the Neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment and (ii) the instruments business, which sells more than 40,000 instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices.
The Orthopedics and Tissue Technologies segment includes such offerings as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair products.
The Corporate and other category includes (i) various executive, finance, human resource, information systems and legal functions, (ii) brand management, and (iii) share-based compensation costs.
The operating results of the various reportable segments as presented are not comparable to one another because (i) certain operating segments are more dependent than others on corporate functions for unallocated general and administrative and/or operational manufacturing functions and (ii) the Company does not allocate certain manufacturing costs and general and administrative costs to the operating segment results. Net sales and profit by each reportable segment for the three and nine months ended September 30, 2020 and 2019 are as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2020
 
2019
 
2020
 
2019
 
(In thousands)
 
(In thousands)
Segment Net Sales
 
 
 
 
 
 
 
Codman Specialty Surgical
$
239,323

 
$
252,984

 
$
640,541

 
$
736,810

Orthopedics and Tissue Technologies 
130,909

 
126,111

 
342,680

 
385,620

Total revenues
$
370,232

 
$
379,095

 
$
983,221

 
$
1,122,430

Segment Profit
 
 
 
 
 
 
 
Codman Specialty Surgical
$
97,061

 
$
101,129

 
$
249,552

 
$
291,750

Orthopedics and Tissue Technologies 
50,132

 
30,383

 
110,091

 
112,664

Segment profit
147,193

 
131,512

 
359,643

 
$
404,414

Amortization
(8,343
)
 
(5,056)

 
$
(23,393
)
 
(21,340)

Corporate and other
(81,308
)
 
(147,043
)
 
(237,525
)
 
(325,394
)
Operating income
$
57,542

 
$
(20,587
)
 
$
98,725

 
$
57,680


The Company does not allocate any assets to the reportable segments. No asset information is reported to the chief operating decision maker and disclosed in the financial information for each segment.
The Company attributes revenues to geographic areas based on the location of the customer. Total revenue by major geographic area consisted of the following:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2020
 
2019
 
2020
 
2019
 
(In thousands)
 
(In thousands)
United States
$
266,477

 
$
266,280

 
$
695,179

 
$
796,397

Europe
45,995

 
49,242

 
123,917

 
148,753

Asia Pacific
40,473

 
42,079

 
113,934

 
114,810

Rest of World
17,287

 
21,494

 
50,191

 
62,470

Total Revenues
$
370,232

 
$
379,095

 
$
983,221

 
$
1,122,430


XML 36 R24.htm IDEA: XBRL DOCUMENT v3.20.2
COMMITMENTS AND CONTINGENCIES
9 Months Ended
Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
In consideration for certain technology, manufacturing, distribution, and selling rights and licenses granted to the Company, the Company has agreed to pay royalties on sales of certain products that it sells. The royalty payments that the Company made under these agreements were not significant for any of the periods presented.
The Company is subject to various claims, lawsuits and proceedings in the ordinary course of the Company's business, including claims by current or former employees, distributors and competitors and with respect to its products and product liability claims, lawsuits and proceedings, some of which have been settled by the Company. In the opinion of management, such claims are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material, adverse effect on the Company's financial condition. However, it is possible that the Company's results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies.
The Company accrues for loss contingencies when it is deemed probable that a loss has been incurred and that loss is estimable. The amounts accrued are based on the full amount of the estimated loss before considering insurance proceeds and do not include an estimate for legal fees expected to be incurred in connection with the loss contingency. The Company consistently accrues legal fees expected to be incurred in connection with loss contingencies as those fees are incurred by outside counsel as a period cost.




Contingent Consideration
The Company determined the fair value of contingent consideration during the nine month period ended September 30, 2020 and September 30, 2019 to reflect the change in estimates, additions, payments, transfers and the time value of money during the period.
A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the nine months ended September 30, 2020 and September 30, 2019 is as follows (in thousands):
Nine Months Ended September 30, 2020
Contingent Consideration Liability Related to Acquisition of Arkis (See Note 3)
 
Contingent Consideration
 Liability Related to Acquisition of Derma Sciences
Location in Financial Statements
 
Long-term
 
Long-term
 
Balance as of January 1, 2020
$
14,210

 
$
230

 
Loss from change in fair value of contingent consideration liabilities
(45
)
 

Research and development
Balance as of September 30, 2020
$
14,165

 
$
230

 

Nine Months Ended September 30, 2019
Contingent Consideration Liability Related to Acquisition of Arkis (See Note 3)
 
Contingent Consideration
 Liability Related to Acquisition of Derma Sciences
Location in Financial Statements
 
Long-term
 
Long-term
 
Balance as of January 1, 2019
$

 
$
230

 
Additions from acquisition of Arkis
13,100

 

 
Balance as of September 30, 2019
$
13,100

 
$
230

 

Derma Sciences
The Company assumed contingent consideration incurred by Derma Sciences, Inc. ("Derma Sciences") related to its acquisitions of BioD and the intellectual property related to Medihoney products. The Company accounted for the contingent liabilities by recording their fair value on the date of the acquisition based on a probability weighted income approach. The Company has already paid $33.3 million related to the aforementioned contingent liabilities. One contingent liability remains which relates to net sales of Medihoney products exceeding certain amounts defined in the agreement between the Company and Derma Sciences. The potential maximum undiscounted payment amounts to $3.0 million. The estimated fair value as of September 30, 2020 and September 30, 2019 was $0.2 million.
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.20.2
BASIS OF PRESENTATION (Policies)
9 Months Ended
Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis Of Presentation BASIS OF PRESENTATION
General
The terms “we,” “our,” “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise.
In the opinion of management, the September 30, 2020 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, statement of changes in shareholder's equity, results of operations and cash flows of the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K. The December 31, 2019 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States. Operating results for the three and nine month period ended September 30, 2020 are not necessarily indicative of the results to be expected for the entire year.
The preparation of consolidated financial statements is in conformity with generally accepted accounting principles in the United States ("GAAP") which requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of derivative instruments, valuation of the equity component of convertible debt instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates. The novel coronavirus (“COVID-19”) pandemic and the resulting adverse impacts to global economic conditions, as well as our operations, may impact future estimates including, but not limited to, inventory valuations, fair value measurements, goodwill and long-lived asset impairments, the effectiveness of the Company’s hedging instruments, deferred tax valuation allowances, and allowances for doubtful accounts receivable.
Recently Issued Accounting Standards


Recently Issued Accounting Standards
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The ASU is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financial assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. The ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted this guidance on January 1, 2020 using a modified retrospective transition method which requires a cumulative-effect adjustment to the opening balance of retained earnings to be recognized on the date of adoption with no change to financial results reported in prior periods. The cumulative-effect adjustment recorded on January 1, 2020, is not material. The adoption of this ASU did not have a significant impact on the Company's consolidated financial statements and related disclosures.
The Company's exposure to credit losses may increase if its customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. Although the Company has historically not experienced significant credit losses, it is possible that there could be an adverse impact as hospital's cash flows are impacted by their response to the COVID-19 pandemic.
In August 2018, the FASB issued ASU 2018-14, Compensation-Retirement Benefits-Defined Benefit Plans-General (Subtopic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans. The new guidance modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans, including removing certain previous disclosure requirements, adding certain new disclosure requirements, and clarifying certain other disclosure requirements. The ASU will be effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Early adoption is permitted. The adoption is not expected to have a material impact on the Company's consolidated financial statements and related disclosures.
In August 2018, the FASB issued ASU No. 2018-15, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40), relating to a customer's accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement that is hosted by a vendor (e.g., a service contract). Under the new guidance, a customer will apply the same criteria for capitalizing implementation costs as it would for an arrangement that has a software license. The new guidance also prescribes the balance sheet, income statement, and cash flow classification of the capitalized implementation costs and related amortization expense, and requires additional quantitative and qualitative disclosures. The ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted this guidance on January 1, 2020 using a prospective transition method. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements and related disclosures.
In December 2019, the FASB issued ASU No. 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes intended to simplify the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The Company is currently assessing the impact of this standard on its financial condition and results of operations.
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform, which provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. This amendment applies to all entities, subject to meeting certain criteria, that have contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This ASU is effective immediately and may be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before December 31, 2022. The Company is currently assessing the impact that this ASU will have on its consolidated financial statements and related disclosures.

In August 2020, the FASB issued ASU No. 2020-06 Debt- Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40)-Accounting For Convertible Instruments and Contracts in an Entity's Own Equity . The guidance simplifies accounting for convertible instruments by removing major
separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify. The guidance also simplifies the diluted net income per share calculation in certain areas. The ASU will be effective for annual and interim periods beginning after December 15, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact of this standard on its consolidated financial statements and related disclosures.
There are no other recently issued accounting pronouncements that are expected to have any significant effect on the Company's financial position, results of operations or cash flows.
Summary of Accounting Policies on Revenue Recognition and Shipping and Handling Fees
Summary of Accounting Policies on Revenue Recognition
Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services.
Total revenue, net, includes product sales, product royalties and other revenues, such as fees received for services.
For products shipped with FOB shipping point terms, the control of the product passes to the customer at the time of shipment. For shipments in which the control of the product is transferred when the customer receives the product, the Company recognizes revenue upon receipt by the customer. Certain products that the Company produces for private label customers have no alternative use and the Company has a right of payment for performance to date. Revenues from those products are recognized over the period
that the Company manufactures these products, which is typically one to three months. The Company uses the input method to measure the manufacturing activities completed to date, which depicts the progress of the Company's performance obligation of transferring control of goods being manufactured for private label customers.
A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and distributors, and also from inventory physically held by field sales representatives. For these types of product sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized.   
Revenues from sale of products and services are evidenced by either a contract with the customer or a valid purchase order and an invoice which includes all relevant terms of sale. For product sales, invoices are generally issued upon the transfer of control (or upon the completion of the manufacturing in the case of the private label transactions recognized over time) and are typically payable thirty days after the invoice date. The Company performs a review of each specific customer's creditworthiness and ability to pay prior to acceptance as a customer. Further, the Company performs periodic reviews of its customers' creditworthiness prospectively.
Performance Obligations
The Company's performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders, or invoices. The Company has no significant multi-element contracts with customers.
Significant Judgments
Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company and the Company's strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information, and expected sales trends. Differences between actual reported licensee sales and those that were estimated are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant.
The Company estimates returns, price concessions, and discount allowances using the expected value method based on historical trends and other known factors. Rebate allowances are estimated using the most likely method based on each customer contract.
The Company's return policy, as set forth in its product catalogs and sales invoices, requires review and authorization in advance prior to the return of product. Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally ninety days.
The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less. The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.
Contract Asset and Liability
Revenues recognized from the Company's private label business that are not invoiced to the customers as a result of recognizing revenue over time are recorded as a contract asset included in the prepaid expenses and other current assets account in the consolidated balance sheet.
Other operating revenues may include fees received under service agreements. Non-refundable fees received under multiple-period service agreements are recognized as revenue as the Company satisfies the performance obligations to the other party. A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability.











Shipping and Handling Fees
The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in the cost of goods sold.
Product Warranties
Product Warranties
Certain of the Company's medical devices, including monitoring systems and neurosurgical systems, are designed to operate over long periods of time. These products are sold with warranties which may extend for up to two years from the date of purchase. The warranties are not considered a separate performance obligation. The Company estimates its product warranties using the expected value method based on historical trends and other known factors. The Company includes them in accrued expenses and other current liabilities in the consolidated balance sheet.
Taxes Collected from Customers
Taxes Collected from Customers
The Company elected to exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer.












XML 38 R26.htm IDEA: XBRL DOCUMENT v3.20.2
ASSETS AND LIABILITIES HELD FOR SALE (Tables)
9 Months Ended
Sep. 30, 2020
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Fair Values of Assets and Liabilities Held For Sale The major classes of assets and liabilities classified as a held for sale consisted of the following as of September 30, 2020 (amounts in thousands):
Prepaid and other current assets
$
748

Other assets
4,448

Deferred tax assets
6,927

Intangible assets
13,332

Property, plant and equipment, net
36,714

Goodwill
47,117

Inventories
50,691

Total assets held for sale
$
159,977

Other liabilities
241

Current portion of lease liability - operating leases

1,060

Accrued compensation
1,584

Deferred tax liabilities
3,035

Lease liability - operating leases

6,429

Total liabilities held for sale

$
12,349


XML 39 R27.htm IDEA: XBRL DOCUMENT v3.20.2
BUSINESS DEVELOPMENT (Tables)
9 Months Ended
Sep. 30, 2020
Business Combinations [Abstract]  
Schedule of Assets Acquired and Liabilities Assumed
The following table summarizes the final fair values of the assets acquired and liabilities assumed at the acquisition date:
 
Final Valuation as of
September 30, 2019
 
Weighted Average Life
 
(Dollars in thousands)
 
 
Cash
$
90

 
 
Other current assets
751

 
 
Property, plant and equipment
457

 
 
Deferred tax assets
1,697

 
 
Intangible assets:
 
 
 
CerebroFlo developed technology
20,100

 
15 years
Enabling technology license
1,980

 
14 years
Goodwill
27,153

 
 
Total assets acquired
52,228

 
 
 
 
 
 
Accounts payable, accrued expenses and other liabilities
2,926

 
 
Contingent consideration
13,100

 
 
Deferred tax liabilities
5,603

 
 
     Net assets acquired
$
30,599

 
 

XML 40 R28.htm IDEA: XBRL DOCUMENT v3.20.2
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
9 Months Ended
Sep. 30, 2020
Revenue from Contract with Customer [Abstract]  
Schedule of Changes in Contract Assets and Contract Liabilities
The following table summarizes the changes in the contract asset and liability balances for the nine months ended September 30, 2020:
Contract Asset
 
Contract asset, January 1, 2020
$
8,680

Transferred to trade receivable of contract asset included
     in beginning of the year contract asset
(8,680
)
Contract asset, net of transferred to trade receivables on contracts during the period
6,653

Contract asset, September 30, 2020
$
6,653

 
 
Contract Liability
 
Contract liability, January 1, 2020
$
11,946

Recognition of revenue included in beginning of year contract liability
(3,150
)
Contract liability, net of revenue recognized on contracts during the period

2,631

Foreign currency translation
(42
)
Contract liability, September 30, 2020
$
11,385


Schedule of Disaggregation of Revenue
The following table presents revenues disaggregated by the major sources of revenues for the three and nine months ended September 30, 2020 and 2019 (amounts in thousands):
 
Three Months Ended September 30, 2020
Three Months Ended September 30, 2019
 
Nine Months Ended September 30, 2020
Nine Months Ended September 30, 2019
 
 
 
 
 
Neurosurgery
$
189,674

$
195,330

 
$
516,048

$
567,779

Instruments
49,649

57,654

 
124,493

169,031

Total Codman Specialty Surgical
239,323

252,984

 
640,541

736,810

 
 
 
 
 
 
Wound Reconstruction and Care
82,115

82,213

 
210,673

239,458

Extremity Orthopedics
21,922

20,852

 
54,556

65,299

Private Label
26,872

23,046

 
77,451

80,863

Total Orthopedics and Tissue Technologies
130,909

126,111

 
342,680

385,620

Total revenue
$
370,232

$
379,095

 
$
983,221

$
1,122,430


XML 41 R29.htm IDEA: XBRL DOCUMENT v3.20.2
INVENTORIES (Tables)
9 Months Ended
Sep. 30, 2020
Inventory, Net [Abstract]  
Schedule of Inventories, Net
Inventories, net consisted of the following:
 
September 30, 2020
 
December 31, 2019
 
(In thousands)
Finished goods
$
223,726

 
$
201,870

Work in process
57,037

 
48,333

Raw materials
77,767

 
$
65,851

Transfer to assets held for sale (See Note 2. Assets Held for Sale)

(50,691
)
 

Total inventories
$
307,839

 
$
316,054



XML 42 R30.htm IDEA: XBRL DOCUMENT v3.20.2
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)
9 Months Ended
Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Changes in Carrying Amount of Goodwill
Changes in the carrying amount of goodwill for the nine-month period ended September 30, 2020 were as follows:
 
Codman Specialty
Surgical
 
Orthopedics and
Tissue Technologies
 
Total
 
(In thousands)
Goodwill at December 31, 2019
$
653,500

 
$
300,780

 
$
954,280

Transfer to assets held for sale (See Note 2. Assets Held for Sale)

 
(47,117
)
 
(47,117
)
Foreign currency translation
8,928

 
3,465

 
12,393

Goodwill at September 30, 2020
$
662,428

 
$
257,128

 
$
919,556








Schedule of Finite-Lived Intangible Assets
The components of the Company’s identifiable intangible assets were as follows:
 
September 30, 2020
 
Weighted
Average
Life
 
Cost
 
Accumulated
Amortization
 
Net
 
(Dollars in thousands)
Completed technology
19 years
 
$
891,554

 
$
(250,609
)
 
$
640,945

Customer relationships
12 years
 
223,512

 
(138,989
)
 
84,523

Trademarks/brand names
28 years
 
104,404

 
(31,425
)
 
72,979

Codman tradename
Indefinite
 
167,013

 

 
167,013

Supplier relationships
27 years
 
34,721

 
(19,018
)
 
15,703

All other(1)
4 years
 
11,101

 
(5,247
)
 
5,854

Transfer to assets held for sale (See Note 2. Assets Held for Sale)

 
 
(39,821
)
 
26,489

 
(13,332
)
 
 
 
$
1,392,484

 
$
(418,799
)
 
$
973,685


 
December 31, 2019
 
Weighted
Average
Life
 
Cost
 
Accumulated
Amortization
 
Net
 
(Dollars in thousands)
Completed technology
19 years
 
$
880,623

 
$
(213,702
)
 
$
666,921

Customer relationships
12 years
 
222,575

 
(119,393
)
 
103,182

Trademarks/brand names
28 years
 
103,873

 
(28,514
)
 
75,359

Codman tradename
Indefinite
 
163,126

 

 
163,126

Supplier relationships
27 years
 
34,721

 
(17,947
)
 
16,774

All other (1)
4 years
 
10,869

 
(4,640
)
 
6,229

 
 
 
$
1,415,787

 
$
(384,196
)
 
$
1,031,591


(1)
At September 30, 2020 and December 31, 2019, all other included IPR&D of $1.0 million, which was indefinite-lived. At September 30, 2020, this IPR&D asset was presented separately as "assets held for sale" in conjunction with the sale of the Extremity Orthopedics business which is expected to be sold within twelve months. See Note 2, Assets and Liabilities Held for Sale, for details.
Schedule of Indefinite-Lived Intangible Assets
The components of the Company’s identifiable intangible assets were as follows:
 
September 30, 2020
 
Weighted
Average
Life
 
Cost
 
Accumulated
Amortization
 
Net
 
(Dollars in thousands)
Completed technology
19 years
 
$
891,554

 
$
(250,609
)
 
$
640,945

Customer relationships
12 years
 
223,512

 
(138,989
)
 
84,523

Trademarks/brand names
28 years
 
104,404

 
(31,425
)
 
72,979

Codman tradename
Indefinite
 
167,013

 

 
167,013

Supplier relationships
27 years
 
34,721

 
(19,018
)
 
15,703

All other(1)
4 years
 
11,101

 
(5,247
)
 
5,854

Transfer to assets held for sale (See Note 2. Assets Held for Sale)

 
 
(39,821
)
 
26,489

 
(13,332
)
 
 
 
$
1,392,484

 
$
(418,799
)
 
$
973,685


 
December 31, 2019
 
Weighted
Average
Life
 
Cost
 
Accumulated
Amortization
 
Net
 
(Dollars in thousands)
Completed technology
19 years
 
$
880,623

 
$
(213,702
)
 
$
666,921

Customer relationships
12 years
 
222,575

 
(119,393
)
 
103,182

Trademarks/brand names
28 years
 
103,873

 
(28,514
)
 
75,359

Codman tradename
Indefinite
 
163,126

 

 
163,126

Supplier relationships
27 years
 
34,721

 
(17,947
)
 
16,774

All other (1)
4 years
 
10,869

 
(4,640
)
 
6,229

 
 
 
$
1,415,787

 
$
(384,196
)
 
$
1,031,591


(1)
At September 30, 2020 and December 31, 2019, all other included IPR&D of $1.0 million, which was indefinite-lived. At September 30, 2020, this IPR&D asset was presented separately as "assets held for sale" in conjunction with the sale of the Extremity Orthopedics business which is expected to be sold within twelve months. See Note 2, Assets and Liabilities Held for Sale, for details.
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.20.2
DEBT (Tables)
9 Months Ended
Sep. 30, 2020
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Maximum Leverage Ratios
In connection with the July 14, 2020 amendment, the Company’s maximum consolidated total leverage ratio in the financial covenants (as defined in the Senior Credit Facility) was modified to the following:
Fiscal Quarter
 
Maximum Consolidated Total Leverage Ratio
 
 
 
Execution of July 2020 Amendment through June 30, 2021
 
5.50 to 1.00
September 30, 2021 through June 30, 2022
 
5.00 to 1.00
September 30, 2022 through June 30, 2023
 
4.50 to 1.00
September 30, 2023 and the last day of each fiscal quarter thereafter
 
4.00 to 1.00

Schedule of Contractual Repayments of Long-Term Debt
Contractual repayments of the Term Loan component of the Senior Credit Facility are due as follows:
Quarter Ended September 30, 2020
 
Principal Repayment
 
 
(In thousands)
Remainder of 2020
 
$

2021
 
33,750

2022
 
45,000

2023
 
61,875

2024
 
67,500

2025
 
669,375

 
 
$
877,500


XML 44 R32.htm IDEA: XBRL DOCUMENT v3.20.2
DERIVATIVE INSTRUMENTS (Tables)
9 Months Ended
Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Derivative Instruments
The Company held the following cross-currency rate swaps designated as net investment hedges as of September 30, 2020 and December 31, 2019, respectively (dollar amounts in thousands):
 
 
 
 
 
 
 
 
 
 
 
September 30, 2020
 
December 31, 2019
 
 
Effective Date
 
Termination Date
 
Fixed Rate
 
Aggregate Notional Amount
 
Fair Value
Asset (Liability)
 
 
 
 
 
 
 
 
 
 
 
 
 
Pay EUR
 
October 3, 2018
 
September 30, 2021
 
—%
 
EUR
44,859

 
$
589

 
$
2,459

Receive U.S.$
 
 
 
3.01%
 
$
52,000

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pay EUR
 
October 3, 2018
 
September 30, 2023
 
—%
 
EUR
51,760

 
2,443

 
3,087

Receive U.S.$
 
 
 
2.57%
 
$
60,000

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pay EUR
 
October 3, 2018
 
September 30, 2025
 
—%
 
EUR
38,820

 
2,398

 
2,032

Receive U.S.$
 
 
 
2.19%
 
$
45,000

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pay GBP
 
October 3, 2018
 
September 30, 2025
 
1.67%
 
GBP
128,284

 
8,580

 
(154
)
Receive U.S.$
 
 
 
2.71%
 
$
167,500

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pay CHF
 
October 3, 2018
 
September 30, 2025
 
—%
 
CHF
165,172

 
(6,828
)
 
1,221

Receive GBP
 
 
 
1.67%
 
GBP
128,284

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total
 
 
 
 
 
 
 
 
 
 
$
7,182

 
$
8,645


The Company held the following cross-currency rate swaps as of September 30, 2020 and December 31, 2019 (dollar amounts in thousands):
 
 
 
 
 
 
 
 
 
 
 
September 30, 2020
 
December 31, 2019
 
 
Effective Date
 
Termination Date
 
Fixed Rate
 
Aggregate Notional Amount
 
Fair Value
Asset (Liability)
 
 
 
 
 
 
 
 
 
 
 
 
 
Pay CHF
 
October 2, 2017
 
October 2, 2020
 
1.75%
 
CHF
32,355

 
$
(1,565
)
 
$
(101
)
Receive U.S.$
 
 
4.38%
 
$
33,333

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pay CHF
 
October 2, 2017
 
October 2, 2021
 
1.85%
 
CHF
48,533

 
(2,003
)
 
(119
)
Receive U.S.$
 
 
4.46%
 
$
50,000

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pay CHF
 
October 2, 2017
 
October 2, 2022
 
1.95%
 
CHF
145,598

 
(4,167
)
 
(289
)
Receive U.S.$
 
 
4.52%
 
$
150,000

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total
 
 
 
 
 
 
 
 
 
 
$
(7,735
)
 
$
(509
)

The Company held the following interest rate swaps as of September 30, 2020 and December 31, 2019 (dollar amounts in thousands):
 
 
September 30, 2020
 
December 31, 2019
 
 
 
 
 
 
 
 
 
September 30, 2020
 
December 31, 2019
Hedged Item
 
Notional Amount
 
Notional Amount
 
Designation Date
 
Effective Date
 
Termination Date
 
Fixed Interest Rate
 
Estimated Fair Value
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Asset (Liability)
3-month USD LIBOR Loan
 

 
50,000

 
February 6, 2017
 
June 30, 2017
 
June 30, 2020
 
1.834
%
 
$

 
$
(2
)
1-month USD LIBOR Loan
 

 
100,000

 
February 6, 2017
 
June 30, 2017
 
June 30, 2020
 
1.652
%
 

 
12

1-month USD LIBOR Loan
 
100,000

 
100,000

 
March 27, 2017
 
December 31, 2017
 
June 30, 2021
 
1.971
%
 
(1,377
)
 
(581
)
1-month USD LIBOR Loan
 
150,000

 
150,000

 
December 13, 2017
 
January 1, 2018
 
December 31, 2022
 
2.201
%
 
(6,901
)
 
(2,880
)
1-month USD LIBOR Loan
 
150,000

 
150,000

 
December 13, 2017
 
January 1, 2018
 
December 31, 2022
 
2.201
%
 
(6,922
)
 
(2,880
)
1-month USD LIBOR Loan
 
100,000

 
100,000

 
December 13, 2017
 
July 1, 2019
 
June 30, 2024
 
2.423
%
 
(8,454
)
 
(3,517
)
1-month USD LIBOR Loan
 
50,000

 
50,000

 
December 13, 2017
 
July 1, 2019
 
June 30, 2024
 
2.423
%
 
(4,064
)
 
(1,778
)
1-month USD LIBOR Loan
 
200,000

 
200,000

 
December 13, 2017
 
January 1, 2018
 
December 31, 2024
 
2.313
%
 
(18,188
)
 
(6,595
)
1-month USD LIBOR Loan
 
75,000

 
75,000

 
October 10, 2018
 
July 1, 2020
 
June 30, 2025
 
3.220
%
 
(10,608
)
 
(5,750
)
1-month USD LIBOR Loan
 
75,000

 
75,000

 
October 10, 2018
 
July 1, 2020
 
June 30, 2025
 
3.199
%
 
(10,871
)
 
(5,747
)
1-month USD LIBOR Loan
 
75,000

 
75,000

 
October 10, 2018
 
July 1, 2020
 
June 30, 2025
 
3.209
%
 
(10,586
)
 
(5,807
)
1-month USD LIBOR Loan
 
100,000

 
100,000

 
December 18, 2018
 
December 30, 2022
 
December 31, 2027
 
2.885
%
 
(11,282
)
 
(4,930
)
1-month USD LIBOR Loan
 
100,000

 
100,000

 
December 18, 2018
 
December 30, 2022
 
December 31, 2027
 
2.867
%
 
(11,127
)
 
(4,691
)
Total interest rate derivatives designated as cash flow hedge
 
$
1,175,000

 
$
1,325,000

 
 
 
 
 
 
 
 
 
$
(100,380
)
 
$
(45,145
)

Schedule of Fair Value and Presentation of Derivatives
The following table summarizes the fair value for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of September 30, 2020 and December 31, 2019:
 
 
Fair Value as of
Location on Balance Sheet (1):
 
September 30, 2020
 
December 31, 2019
 
 
(In thousands)
Derivatives designated as hedges — Assets:
 
 
 
 
Prepaid expenses and other current assets
 
 
 
 
Cash Flow Hedges
 
 
 
 
Interest rate swap
 
$

 
$
12

Cross-currency swap
 
4,608

 
5,032

Net Investment Hedges
 
 
 
 
Cross-currency swap
 
7,717

 
7,952

Other assets
 
 
 
 
Net Investment Hedges
 
 
 
 
Cross-currency swap
 
9,071

 
3,465

Total derivatives designated as hedges — Assets
 
$
21,396

 
$
16,461

 
 
 
 
 
Derivatives designated as hedges — Liabilities:
 
 
 
 
Accrued expenses and other current liabilities
 
 
 
 
Cash Flow Hedges
 
 
 
 
Interest rate swap
 
$
22,324

 
$
6,635

Cross-currency swap
 
1,565

 
101

Other liabilities
 
 
 
 
Cash Flow Hedges
 
 
 
 
Interest rate swap
 
78,056

 
38,522

Cross-currency swap
 
10,777

 
5,440

Net Investment Hedges
 
 
 
 
Cross-currency swap
 
9,605

 
2,772

Total derivatives designated as hedges — Liabilities
 
$
122,327

 
$
53,470

 
(1) 
The Company classifies derivative assets and liabilities as non-current based on the cash flows expected to be incurred within the following 12 months.

Effect of Derivative Instruments Designated as Cash Flow Hedges on Statements of Operations
The following presents the effect of derivative instruments designated as cash flow hedges on the accompanying condensed consolidated statement of operations during the three and nine months ended September 30, 2020 and 2019:
 
Balance in AOCL
Beginning of
Quarter
 
Amount of
Gain (Loss)
Recognized in
AOCL
 
Amount of Gain (Loss)
Reclassified from
AOCL into
Earnings
 
Balance in AOCL
End of Quarter
 
Location in
Statements of
Operations
 
(In thousands)
Three Months Ended September 30, 2020
 
 
 
 
 
 
 
 
 
Cash Flow Hedges
 
 
 
 
 
 
 
 
 
Interest rate swap
$
(102,128
)
 
$
(3,971
)
 
$
(5,718
)
 
$
(100,381
)
 
Interest expense
Cross-currency swap
5,843

 
(6,272
)
 
(5,353
)
 
4,924

 
Other income (expense),net
Net Investment Hedges
 
 
 
 
 
 
 
 
 
Cross-currency swap
22,223

 
(11,254
)
 
2,202

 
8,767

 
Interest income
 
$
(74,062
)
 
$
(21,497
)
 
$
(8,869
)
 
$
(86,690
)
 
 
Three Months Ended September 30, 2019
 
 
 
 
 
 
 
 
 
Cash Flow Hedges
 
 
 
 
 
 
 
 
 
Interest rate swap
$
(43,161
)
 
$
(13,788
)
 
$
237

 
$
(57,186
)
 
Interest expense
Cross-currency swap
(2,284
)
 
9,661

 
7,520

 
(143
)
 
Other income (expense),net
Net Investment Hedges
 
 
 
 
 
 
 
 
 
Cross-currency swap
4,054

 
17,136

 
2,489

 
18,701

 
Interest income
 
$
(41,391
)
 
$
13,009

 
$
10,246

 
$
(38,628
)
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance in AOCL
Beginning of
Year
 
Amount of
Gain (Loss)
Recognized in
AOCL
 
Amount of Gain (Loss)
Reclassified from
AOCL into
Earnings
 
Balance in AOCL
End of Quarter
 
Location in
Statements of
Operations
 
(In thousands)
Nine Months Ended September 30, 2020
 
 
 
 
 
 
 
 
 
Cash Flow Hedges
 
 
 
 
 
 
 
 
 
Interest rate swap
$
(45,146
)
 
$
(65,608
)
 
$
(10,373
)
 
$
(100,381
)
 
Interest expense
Cross-currency swap
177

 
(2,688
)
 
(7,435
)
 
4,924

 
Other income (expense),net
Net Investment Hedges
 
 
 
 
 
 
 
 
 
Cross-currency swap
10,229

 
5,102

 
6,564

 
8,767

 
Interest income
 
$
(34,740
)
 
$
(63,194
)
 
$
(11,244
)
 
$
(86,690
)
 
 
Nine months ended September 30, 2019
 
 
 
 
 
 
 
 
 
Cash Flow Hedges
 
 
 
 
 
 
 
 
 
Interest rate swap
$
619

 
$
(54,841
)
 
$
2,964

 
$
(57,186
)
 
Interest expense
Cross-currency swap
(6,190
)
 
15,418

 
9,371

 
(143
)
 
Other income (expense), net
Net Investment Hedges
 
 
 
 
 
 
 
 
 
Cross-currency swap
(632
)
 
26,558

 
7,225

 
18,701

 
Interest income
 
$
(6,203
)
 
$
(12,865
)
 
$
19,560

 
$
(38,628
)
 
 

XML 45 R33.htm IDEA: XBRL DOCUMENT v3.20.2
LEASES AND RELATED PARTY LEASES (Tables)
9 Months Ended
Sep. 30, 2020
Leases [Abstract]  
Supplemental Balance Sheet Information
Supplemental balance sheet information related to operating leases at September 30, 2020 were as follows:
 
September 30, 2020
 
(In thousands, except lease term and discount rate)
Weighted average remaining lease term (in years):
 
 
 
Leased facilities
11.8

Leased vehicles
1.4

 
 
Weighted average discount rate:
 
Leased facilities
4.6
%
Leased vehicles
2.2
%

Supplemental Cash Flow Information
Supplemental cash flow information related to leases for the nine months ended September 30, 2020 and September 30, 2019 were as follows:
 
September 30, 2020
 
September 30, 2019
 
(In thousands)
 
(In thousands)
Cash paid for amounts included in the measurement of lease liabilities:
 
 
 
Operating cash flows from operating leases
$
10,976

 
$
10,680

 
 
 
 
ROU assets obtained in exchange for lease liabilities:
 
 
 
Operating leases
$
6,007

 
$
41,860












Schedule of Operating Lease Maturities
Future minimum lease payments under operating leases at September 30, 2020 were as follows:
 
Related Parties
 
Third Parties
 
Total
 
(In thousands)
2020
$
74

 
$
3,742

 
$
3,816

2021
296

 
13,209

 
13,505

2022
296

 
13,224

 
13,520

2023
296

 
10,782

 
11,078

2024
296

 
9,996

 
10,292

Thereafter
1,426

 
86,750

 
88,176

Total minimum lease payments
$
2,684

 
$
137,703

 
$
140,387

Less: Imputed interest
 
 
 
 
39,091

Total lease liabilities
 
 
 
 
101,296

Less: Current lease liabilities
 
 
 
 
12,518

Long-term lease liabilities
 
 
 
 
88,778


XML 46 R34.htm IDEA: XBRL DOCUMENT v3.20.2
INCOME TAXES (Tables)
9 Months Ended
Sep. 30, 2020
Income Tax Disclosure [Abstract]  
Schedule of Effective Income Tax Rate
The following table provides a summary of the Company's effective tax rate:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2020
 
2019
 
2020
 
2019
Reported tax rate
22.1
%
 
(0.4
)%
 
24.6
%
 
(3.5
)%


XML 47 R35.htm IDEA: XBRL DOCUMENT v3.20.2
NET INCOME (LOSS) PER SHARE (Tables)
9 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]  
Basic and Diluted Net Income (Loss) Per Share
Basic and diluted net income (loss) per share was as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2020
 
2019
 
2020
 
2019
 
(In thousands, except per share amounts)
 
(In thousands, except per share amounts)
Basic net income (loss) per share:
 
 
 
 
 
 
 
Net income (loss)
$
32,337

 
$
(27,610
)
 
$
41,148

 
$
34,882

Weighted average common shares outstanding
84,325

 
85,688

 
84,745

 
85,536

Basic net income (loss) per common share
$
0.38

 
$
(0.32
)
 
$
0.49

 
$
0.41

 
 
 
 
 
 
 
 
Diluted net income (loss) per share:
 
 
 
 
 
 
 
Net income (loss)
$
32,337

 
$
(27,610
)
 
$
41,148

 
$
34,882

 
 
 
 
 
 
 
 
Weighted average common shares outstanding — Basic
84,325

 
85,688

 
84,745

 
85,536

Effect of dilutive securities:
 
 
 
 
 
 
 
Stock options and restricted stock
427

 

 
558

 
1,045

Weighted average common shares for diluted earnings per share
84,752

 
85,688

 
85,303

 
86,581

 
 
 
 
 
 
 
 
Diluted net income (loss) per common share
$
0.38

 
$
(0.32
)
 
$
0.48

 
$
0.40


XML 48 R36.htm IDEA: XBRL DOCUMENT v3.20.2
COMPREHENSIVE INCOME (LOSS) (Tables)
9 Months Ended
Sep. 30, 2020
Equity [Abstract]  
Schedule of Comprehensive Income (Loss)

Comprehensive income (loss) was as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2020
 
2019
 
2020
 
2019
 
(In thousands)
 
(In thousands)
Net income (loss)
$
32,337

 
$
(27,610
)
 
$
41,148

 
$
34,882

Foreign currency translation adjustment
21,181

 
(18,651
)
 
24,801

 
(17,960
)
Change in unrealized loss on derivatives, net of tax
(9,679
)
 
(775
)
 
(39,814
)
 
(24,714
)
Pension liability adjustment, net of tax
(291
)
 
515

 
(498
)
 
504

Comprehensive income (loss), net
$
43,548

 
$
(46,521
)
 
$
25,637

 
$
(7,288
)

Schedule of Changes in Accumulated Other Comprehensive Loss by Component
Changes in accumulated other comprehensive loss by component between December 31, 2019 and September 30, 2020 are presented in the table below, net of tax:
 
 
Gains and Losses on Derivatives
 
Defined Benefit Pension Items
 
Foreign Currency Items
 
Total
 
 
(In thousands)
Balance at January 1, 2020
 
$
(26,625
)
 
$
(9,709
)
 
$
(40,068
)
 
$
(76,402
)
Other comprehensive income (loss)
 
(48,429
)
 
(498
)
 
24,801

 
(24,126
)
Less: Amounts reclassified from accumulated other comprehensive loss
 
(8,615
)
 

 

 
(8,615
)
Net current-period other comprehensive income (loss)
 
(39,814
)
 
(498
)
 
24,801

 
(15,511
)
Balance at September 30, 2020
 
$
(66,439
)
 
$
(10,207
)
 
$
(15,267
)
 
$
(91,913
)

XML 49 R37.htm IDEA: XBRL DOCUMENT v3.20.2
SEGMENT AND GEOGRAPHIC INFORMATION (Tables)
9 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
Schedule of Net Sales and Profit by Segments Net sales and profit by each reportable segment for the three and nine months ended September 30, 2020 and 2019 are as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2020
 
2019
 
2020
 
2019
 
(In thousands)
 
(In thousands)
Segment Net Sales
 
 
 
 
 
 
 
Codman Specialty Surgical
$
239,323

 
$
252,984

 
$
640,541

 
$
736,810

Orthopedics and Tissue Technologies 
130,909

 
126,111

 
342,680

 
385,620

Total revenues
$
370,232

 
$
379,095

 
$
983,221

 
$
1,122,430

Segment Profit
 
 
 
 
 
 
 
Codman Specialty Surgical
$
97,061

 
$
101,129

 
$
249,552

 
$
291,750

Orthopedics and Tissue Technologies 
50,132

 
30,383

 
110,091

 
112,664

Segment profit
147,193

 
131,512

 
359,643

 
$
404,414

Amortization
(8,343
)
 
(5,056)

 
$
(23,393
)
 
(21,340)

Corporate and other
(81,308
)
 
(147,043
)
 
(237,525
)
 
(325,394
)
Operating income
$
57,542

 
$
(20,587
)
 
$
98,725

 
$
57,680


Total revenue by major geographic area consisted of the following:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2020
 
2019
 
2020
 
2019
 
(In thousands)
 
(In thousands)
United States
$
266,477

 
$
266,280

 
$
695,179

 
$
796,397

Europe
45,995

 
49,242

 
123,917

 
148,753

Asia Pacific
40,473

 
42,079

 
113,934

 
114,810

Rest of World
17,287

 
21,494

 
50,191

 
62,470

Total Revenues
$
370,232

 
$
379,095

 
$
983,221

 
$
1,122,430


Schedule of Geographic Revenue by Area Net sales and profit by each reportable segment for the three and nine months ended September 30, 2020 and 2019 are as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2020
 
2019
 
2020
 
2019
 
(In thousands)
 
(In thousands)
Segment Net Sales
 
 
 
 
 
 
 
Codman Specialty Surgical
$
239,323

 
$
252,984

 
$
640,541

 
$
736,810

Orthopedics and Tissue Technologies 
130,909

 
126,111

 
342,680

 
385,620

Total revenues
$
370,232

 
$
379,095

 
$
983,221

 
$
1,122,430

Segment Profit
 
 
 
 
 
 
 
Codman Specialty Surgical
$
97,061

 
$
101,129

 
$
249,552

 
$
291,750

Orthopedics and Tissue Technologies 
50,132

 
30,383

 
110,091

 
112,664

Segment profit
147,193

 
131,512

 
359,643

 
$
404,414

Amortization
(8,343
)
 
(5,056)

 
$
(23,393
)
 
(21,340)

Corporate and other
(81,308
)
 
(147,043
)
 
(237,525
)
 
(325,394
)
Operating income
$
57,542

 
$
(20,587
)
 
$
98,725

 
$
57,680


Total revenue by major geographic area consisted of the following:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2020
 
2019
 
2020
 
2019
 
(In thousands)
 
(In thousands)
United States
$
266,477

 
$
266,280

 
$
695,179

 
$
796,397

Europe
45,995

 
49,242

 
123,917

 
148,753

Asia Pacific
40,473

 
42,079

 
113,934

 
114,810

Rest of World
17,287

 
21,494

 
50,191

 
62,470

Total Revenues
$
370,232

 
$
379,095

 
$
983,221

 
$
1,122,430


XML 50 R38.htm IDEA: XBRL DOCUMENT v3.20.2
COMMITMENTS AND CONTINGENCIES (Tables)
9 Months Ended
Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Contingent Consideration
A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the nine months ended September 30, 2020 and September 30, 2019 is as follows (in thousands):
Nine Months Ended September 30, 2020
Contingent Consideration Liability Related to Acquisition of Arkis (See Note 3)
 
Contingent Consideration
 Liability Related to Acquisition of Derma Sciences
Location in Financial Statements
 
Long-term
 
Long-term
 
Balance as of January 1, 2020
$
14,210

 
$
230

 
Loss from change in fair value of contingent consideration liabilities
(45
)
 

Research and development
Balance as of September 30, 2020
$
14,165

 
$
230

 

Nine Months Ended September 30, 2019
Contingent Consideration Liability Related to Acquisition of Arkis (See Note 3)
 
Contingent Consideration
 Liability Related to Acquisition of Derma Sciences
Location in Financial Statements
 
Long-term
 
Long-term
 
Balance as of January 1, 2019
$

 
$
230

 
Additions from acquisition of Arkis
13,100

 

 
Balance as of September 30, 2019
$
13,100

 
$
230

 

XML 51 R39.htm IDEA: XBRL DOCUMENT v3.20.2
ASSETS AND LIABILITIES HELD FOR SALE - Narrative (Details) - Smith & Nephew USD Limited - Disposal Group, Disposed of by Sale, Not Discontinued Operations - Subsequent Event - Forecast
$ in Millions
Dec. 31, 2020
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Sale of Extremity Orthopedics business, disposition price $ 240.0
Consortium of Focused Orthopedists, LLC  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Sale of Extremity Orthopedics business, product development payment $ 41.5
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.20.2
ASSETS AND LIABILITIES HELD FOR SALE - Assets and Liabilities Held For Sale (Details) - Smith & Nephew USD Limited - Disposal Group, Disposed of by Sale, Not Discontinued Operations
$ in Thousands
Sep. 30, 2020
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Prepaid and other current assets $ 748
Other assets 4,448
Deferred tax assets 6,927
Intangible assets 13,332
Property, plant and equipment, net 36,714
Goodwill 47,117
Inventories 50,691
Total assets held for sale 159,977
Other liabilities 241
Current portion of lease liability - operating leases 1,060
Accrued compensation 1,584
Deferred tax liabilities 3,035
Lease liability - operating leases 6,429
Total liabilities held for sale $ 12,349
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.20.2
BUSINESS DEVELOPMENT - Business Combination, Narrative (Details) - Arkis - USD ($)
Jul. 29, 2019
Sep. 30, 2020
Business Acquisition [Line Items]    
Purchase price of business combination $ 30,600,000  
Contingent consideration, liability (up to) 25,500,000  
Contingent consideration, fair value $ 13,100,000 $ 14,200,000
Acquired intangible assets, discount rate 14.50%  
Development Milestones    
Business Acquisition [Line Items]    
Contingent consideration, liability (up to) $ 10,000,000.0  
Commercial Sales Milestones    
Business Acquisition [Line Items]    
Contingent consideration, liability (up to) $ 15,500,000  
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.20.2
BUSINESS DEVELOPMENT - Business Combination, Schedule of Purchase Price Allocation (Details) - USD ($)
$ in Thousands
Jul. 29, 2019
Sep. 30, 2020
Dec. 31, 2019
Intangible assets:      
Goodwill   $ 919,556 $ 954,280
Arkis      
Business Acquisition [Line Items]      
Cash $ 90    
Other current assets 751    
Property, plant and equipment 457    
Deferred tax assets 1,697    
Intangible assets:      
Goodwill 27,153    
Total assets acquired 52,228    
Accounts payable, accrued expenses and other liabilities 2,926    
Contingent consideration 13,100 $ 14,200  
Deferred tax liabilities 5,603    
Net assets acquired 30,599    
Arkis | CerebroFlo developed technology      
Intangible assets:      
Intangible assets $ 20,100    
Weighted Average Life 15 years    
Arkis | Enabling technology license      
Intangible assets:      
Intangible assets $ 1,980    
Weighted Average Life 14 years    
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.20.2
BUSINESS DEVELOPMENT - Asset Acquisition, Narrative (Details)
3 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2020
USD ($)
Sep. 09, 2019
USD ($)
asset
Jan. 04, 2019
USD ($)
asset
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Schedule Of Asset Acquisition [Line Items]                  
In-process research and development       $ 0 $ 59,889,000   $ 0 $ 59,889,000  
Consortium of Focused Orthopedists, LLC | Disposal Group, Disposed of by Sale, Not Discontinued Operations | Subsequent Event | Forecast | Smith & Nephew USD Limited                  
Schedule Of Asset Acquisition [Line Items]                  
Sale of Extremity Orthopedics business, product development payment $ 41,500,000                
Rebound                  
Schedule Of Asset Acquisition [Line Items]                  
Upfront payment   $ 67,100,000              
Contingent development milestone payments commitment (up to)   $ 35,000,000.0              
Number of assets acquired | asset   1              
Remaining net assets acquired   $ 7,200,000              
Development milestone                 $ 5,000,000.0
In-process research and development                 $ 5,000,000.0
Rebound | Cash and Cash Equivalents                  
Schedule Of Asset Acquisition [Line Items]                  
Remaining net assets acquired   2,100,000              
Rebound | Deferred Tax Asset                  
Schedule Of Asset Acquisition [Line Items]                  
Remaining net assets acquired   4,200,000              
Rebound | In-Process Research and Development Expense                  
Schedule Of Asset Acquisition [Line Items]                  
Upfront payment   $ 59,900,000              
ISC                  
Schedule Of Asset Acquisition [Line Items]                  
Number of assets acquired | asset     1            
Research and development           $ 1,700,000      
ISC | Enabling technology license                  
Schedule Of Asset Acquisition [Line Items]                  
Upfront payment, intangible assets     $ 1,700,000            
Option to acquire, period subsequent to first commercial sale     4 years            
Maximum future purchase price, if circumstances met (not to exceed)     $ 80,000,000.0            
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.20.2
REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2020
Dec. 31, 2019
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]    
Number of days from shipment to issue a credit 90 days  
Short-term portion of contract liability $ 4,875 $ 4,772
Long-term portion of contract liability $ 6,500  
Product warranty period (up to) 2 years  
Minimum    
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]    
Manufacturing period for products shipped with no alternative use and right of payment for performance 1 month  
Maximum    
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]    
Manufacturing period for products shipped with no alternative use and right of payment for performance 3 months  
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.20.2
REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative, Revenue Remaining Performance Obligation (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01
Sep. 30, 2020
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Expected performance obligation through 2020, percentage 43.00%
Performance obligations expected to be satisfied, expected timing 3 months
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.20.2
REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Changes in Contract Assets and Liabilities (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2020
USD ($)
Contract Asset  
Contract asset, Beginning of period $ 8,680
Transferred to trade receivable of contract asset included in beginning of the year contract asset (8,680)
Contract asset, net of transferred to trade receivables on contracts during the period 6,653
Contract asset, End of Period 6,653
Contract Liability  
Contract liability, Beginning of Period 11,946
Recognition of revenue included in beginning of year contract liability (3,150)
Contract liability, net of revenue recognized on contracts during the period 2,631
Foreign currency translation (42)
Contract liability, End of Period $ 11,385
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.20.2
REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Revenues Disaggregated by Major Source (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Disaggregation of Revenue [Line Items]        
Total Revenues $ 370,232 $ 379,095 $ 983,221 $ 1,122,430
Codman Specialty Surgical        
Disaggregation of Revenue [Line Items]        
Total Revenues 239,323 252,984 640,541 736,810
Codman Specialty Surgical | Neurosurgery        
Disaggregation of Revenue [Line Items]        
Total Revenues 189,674 195,330 516,048 567,779
Codman Specialty Surgical | Instruments        
Disaggregation of Revenue [Line Items]        
Total Revenues 49,649 57,654 124,493 169,031
Orthopedics and Tissue Technologies        
Disaggregation of Revenue [Line Items]        
Total Revenues 130,909 126,111 342,680 385,620
Orthopedics and Tissue Technologies | Wound Reconstruction and Care        
Disaggregation of Revenue [Line Items]        
Total Revenues 82,115 82,213 210,673 239,458
Orthopedics and Tissue Technologies | Extremity Orthopedics        
Disaggregation of Revenue [Line Items]        
Total Revenues 21,922 20,852 54,556 65,299
Orthopedics and Tissue Technologies | Private Label        
Disaggregation of Revenue [Line Items]        
Total Revenues $ 26,872 $ 23,046 $ 77,451 $ 80,863
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.20.2
INVENTORIES - Schedule of Net Inventories (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Inventory, Net [Abstract]    
Finished goods $ 223,726 $ 201,870
Work in process 57,037 48,333
Raw materials 77,767 65,851
Transfer to assets held for sale (See Note 2. Assets Held for Sale) (50,691) 0
Inventories, net $ 307,839 $ 316,054
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.20.2
GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2020
USD ($)
Goodwill [Roll Forward]  
Beginning of Period $ 954,280
Transfer to assets held for sale (See Note 2. Assets Held for Sale) (47,117)
Foreign currency translation 12,393
End of Period 919,556
Codman Specialty Surgical  
Goodwill [Roll Forward]  
Beginning of Period 653,500
Transfer to assets held for sale (See Note 2. Assets Held for Sale) 0
Foreign currency translation 8,928
End of Period 662,428
Orthopedics and Tissue Technologies  
Goodwill [Roll Forward]  
Beginning of Period 300,780
Transfer to assets held for sale (See Note 2. Assets Held for Sale) (47,117)
Foreign currency translation 3,465
End of Period $ 257,128
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.20.2
GOODWILL AND OTHER INTANGIBLE ASSETS - Components of Company's Identifiable Intangible Assets (Details) - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2020
Dec. 31, 2019
Acquired Finite-Lived Intangible Assets [Line Items]    
Cost $ 1,392,484 $ 1,415,787
Accumulated Amortization (418,799) (384,196)
Net 973,685 1,031,591
Codman tradename    
Acquired Finite-Lived Intangible Assets [Line Items]    
Cost 167,013 163,126
Net 167,013 163,126
IPR&D    
Acquired Finite-Lived Intangible Assets [Line Items]    
Other indefinite-lived intangible assets $ 1,000 $ 1,000
Completed technology    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life 19 years 19 years
Cost $ 891,554 $ 880,623
Accumulated Amortization (250,609) (213,702)
Net $ 640,945 $ 666,921
Customer relationships    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life 12 years 12 years
Cost $ 223,512 $ 222,575
Accumulated Amortization (138,989) (119,393)
Net $ 84,523 $ 103,182
Trademarks/brand names    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life 28 years 28 years
Cost $ 104,404 $ 103,873
Accumulated Amortization (31,425) (28,514)
Net $ 72,979 $ 75,359
Supplier relationships    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life 27 years 27 years
Cost $ 34,721 $ 34,721
Accumulated Amortization (19,018) (17,947)
Net $ 15,703 $ 16,774
All other    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life 4 years 4 years
Cost $ 11,101 $ 10,869
Accumulated Amortization (5,247) (4,640)
Net 5,854 $ 6,229
Transfer to assets held for sale (See Note 2. Assets Held for Sale)    
Acquired Finite-Lived Intangible Assets [Line Items]    
Cost (39,821)  
Accumulated Amortization 26,489  
Net $ (13,332)  
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.20.2
GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)
3 Months Ended
Sep. 30, 2020
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill, impairment $ 0
Intangible assets, indefinite lives, discount rate 11.50%
Intangible assets, indefinite lives, impairment $ 0
Expected annual amortization expense, remainder of 2020 15,700,000
Expected annual amortization expense, in 2021 62,100,000
Expected annual amortization expense, in 2022 59,700,000
Expected annual amortization expense, in 2023 58,900,000
Expected annual amortization expense, in 2024 58,400,000
Expected annual amortization expense, in 2025 58,400,000
Expected annual amortization expense, thereafter $ 494,900,000
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.20.2
DEBT - Narrative (Details)
3 Months Ended 9 Months Ended
Feb. 04, 2020
USD ($)
$ / shares
Sep. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Feb. 03, 2020
USD ($)
Dec. 31, 2019
USD ($)
Debt Instrument [Line Items]                
Term loan component of senior credit facility   $ 22,500,000     $ 22,500,000     $ 45,000,000
Carrying amount, liability component   469,898,000     469,898,000     0
Cost of call transactions         104,248,000 $ 0    
Proceeds from warrant transactions         44,563,000 $ 0    
Securitization program outstanding borrowings, maximum limit       $ 150,000,000.0        
Securitization program, term       3 years        
Long-term borrowings under securitization facility   $ 92,300,000     $ 92,300,000     $ 104,500,000
Weighted average interest rate, accounts receivable securitization revolving loan facility   1.40%     1.40%     2.80%
Fair Value, Inputs, Level 2                
Debt Instrument [Line Items]                
Securitization facility, outstanding borrowings, fair value   $ 92,800,000     $ 92,800,000      
Revolving Credit Facility                
Debt Instrument [Line Items]                
Maximum borrowing capacity             $ 1,300,000,000  
Line of credit facility outstanding   $ 97,500,000     $ 97,500,000     $ 375,000,000.0
Weighted average interest rate on debt   1.50%     1.50%     3.20%
Revolving Credit Facility | Fair Value, Inputs, Level 2                
Debt Instrument [Line Items]                
Line of credit facility, fair value of amount outstanding   $ 94,600,000     $ 94,600,000      
Standby Letters of Credit                
Debt Instrument [Line Items]                
Maximum borrowing capacity             60,000,000  
Swingline Loans                
Debt Instrument [Line Items]                
Maximum borrowing capacity             60,000,000  
Senior Credit Facility                
Debt Instrument [Line Items]                
Maximum borrowing capacity             2,200,000,000  
Incremental financing costs capitalized             4,600,000  
Previously capitalized financing costs, written-off     $ 1,200,000          
Incremental financing cost expense   3,300,000            
Senior Credit Facility | Overnight Federal Funds                
Debt Instrument [Line Items]                
Interest rates available         0.50%      
Senior Credit Facility | One Month Eurodollar Rate                
Debt Instrument [Line Items]                
Interest rates available         1.00%      
Senior Credit Facility | Minimum                
Debt Instrument [Line Items]                
Line of credit, commitment fee percentage         0.15%      
Senior Credit Facility | Minimum | Eurodollar                
Debt Instrument [Line Items]                
Interest rates available         1.00%      
Senior Credit Facility | Maximum                
Debt Instrument [Line Items]                
Line of credit, commitment fee percentage         0.30%      
Senior Credit Facility | Maximum | Eurodollar                
Debt Instrument [Line Items]                
Interest rates available         2.25%      
Senior Credit Facility | Standby Letters of Credit                
Debt Instrument [Line Items]                
Line of credit facility outstanding   0     $ 0      
Letters of credit outstanding   1,600,000     1,600,000     $ 800,000
Term Loan Facility | Secured Debt                
Debt Instrument [Line Items]                
Maximum borrowing capacity             $ 877,500,000  
Line of credit facility outstanding   $ 877,500,000     $ 877,500,000     $ 877,500,000
Weighted average interest rate on debt   1.50%     1.50%     3.20%
Term loan component of senior credit facility   $ 22,500,000     $ 22,500,000      
Term Loan Facility | Secured Debt | Fair Value, Inputs, Level 2                
Debt Instrument [Line Items]                
Line of credit facility, fair value of amount outstanding   853,700,000     853,700,000      
2025 Notes | Convertible Debt                
Debt Instrument [Line Items]                
Incremental financing costs capitalized $ 13,200,000              
Convertible notes, maximum borrowing capacity $ 575,000,000.0 575,000,000.0     575,000,000.0      
Convertible notes, interest rate 0.50%              
Debt proceeds, classified as equity at time of offering $ 104,500,000              
Effective interest rate 4.20%              
Carrying amount, liability component   481,500,000     481,500,000      
Unamortized discount   93,500,000     93,500,000      
Fair value   $ 541,800,000     541,800,000      
Initial conversion rate 13.5739              
Initial conversion price (in dollars per share) | $ / shares $ 73.67              
Maximum selling price of the company's common stock of the conversion price 130.00%              
Maximum average conversion value of notes 98.00%              
Redemption price, percentage 100.00%              
Warrant strike price (in dollars per share) | $ / shares $ 113.34              
Cash interest         1,900,000      
Amortization of discount         11,100,000      
Interest expense         13,000,000.0      
2025 Notes | Convertible Debt | Call Option                
Debt Instrument [Line Items]                
Cost of call transactions         104,200,000      
Proceeds from warrant transactions         $ 44,500,000      
Initial strike price (in dollars per share) | $ / shares $ 73.67              
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.20.2
DEBT - Maximum Total Leverage Ratio Table (Details) - Senior Credit Facility
Jul. 14, 2020
Execution of July 2020 Amendment through June 30, 2021  
Debt Instrument [Line Items]  
Maximum Consolidated Total Leverage Ratio 5.50
September 30, 2021 through June 30, 2022  
Debt Instrument [Line Items]  
Maximum Consolidated Total Leverage Ratio 5.00
September 30, 2022 through June 30, 2023  
Debt Instrument [Line Items]  
Maximum Consolidated Total Leverage Ratio 4.50
September 30, 2023 and the last day of each fiscal quarter thereafter  
Debt Instrument [Line Items]  
Maximum Consolidated Total Leverage Ratio 4.00
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.20.2
DEBT - Contractual Maturity Table (Details)
$ in Thousands
Sep. 30, 2020
USD ($)
Debt Disclosure [Abstract]  
Remainder of 2020 $ 0
2021 33,750
2022 45,000
2023 61,875
2024 67,500
2025 669,375
Principal Repayment $ 877,500
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.20.2
DERIVATIVE INSTRUMENTS - Schedule of Derivatives (Details) - Cash Flow Hedges - Designated as Hedging Instrument - USD ($)
Sep. 30, 2020
Dec. 31, 2019
Derivative [Line Items]    
Notional Amount $ 1,175,000,000 $ 1,325,000,000
Estimated Fair Value, Asset (Liability) (100,380,000) (45,145,000)
3-Month USD LIBOR | Interest Rate Swap Designated February 6, 2017 Tranche 1    
Derivative [Line Items]    
Notional Amount $ 0 50,000,000
Fixed Interest Rate 1.834%  
Estimated Fair Value, Asset (Liability) $ 0 (2,000)
1-Month USD LIBOR | Interest Rate Swap Designated February 6, 2017 Tranche 2    
Derivative [Line Items]    
Notional Amount $ 0 100,000,000
Fixed Interest Rate 1.652%  
Estimated Fair Value, Asset (Liability) $ 0 12,000
1-Month USD LIBOR | Interest Rate Swap Designated March 27, 2017    
Derivative [Line Items]    
Notional Amount $ 100,000,000 100,000,000
Fixed Interest Rate 1.971%  
Estimated Fair Value, Asset (Liability) $ (1,377,000) (581,000)
1-Month USD LIBOR | Interest Rate Swap Designated December 13, 2017 Tranche 1    
Derivative [Line Items]    
Notional Amount $ 150,000,000 150,000,000
Fixed Interest Rate 2.201%  
Estimated Fair Value, Asset (Liability) $ (6,901,000) (2,880,000)
1-Month USD LIBOR | Interest Rate Swap Designated December 13, 2017 Tranche 2    
Derivative [Line Items]    
Notional Amount $ 150,000,000 150,000,000
Fixed Interest Rate 2.201%  
Estimated Fair Value, Asset (Liability) $ (6,922,000) (2,880,000)
1-Month USD LIBOR | Interest Rate Swap Designated December 13, 2017 Tranche 3    
Derivative [Line Items]    
Notional Amount $ 100,000,000 100,000,000
Fixed Interest Rate 2.423%  
Estimated Fair Value, Asset (Liability) $ (8,454,000) (3,517,000)
1-Month USD LIBOR | Interest Rate Swap Designated December 13, 2017 Tranche 4    
Derivative [Line Items]    
Notional Amount $ 50,000,000 50,000,000
Fixed Interest Rate 2.423%  
Estimated Fair Value, Asset (Liability) $ (4,064,000) (1,778,000)
1-Month USD LIBOR | Interest Rate Swap Designated December 13, 2017 Tranche 5    
Derivative [Line Items]    
Notional Amount $ 200,000,000 200,000,000
Fixed Interest Rate 2.313%  
Estimated Fair Value, Asset (Liability) $ (18,188,000) (6,595,000)
1-Month USD LIBOR | Interest Rate Swap Designated October 10, 2018 Tranche 1    
Derivative [Line Items]    
Notional Amount $ 75,000,000 75,000,000
Fixed Interest Rate 3.22%  
Estimated Fair Value, Asset (Liability) $ (10,608,000) (5,750,000)
1-Month USD LIBOR | Interest Rate Swap Designated October 10, 2018 Tranche 2    
Derivative [Line Items]    
Notional Amount $ 75,000,000 75,000,000
Fixed Interest Rate 3.199%  
Estimated Fair Value, Asset (Liability) $ (10,871,000) (5,747,000)
1-Month USD LIBOR | Interest Rate Swap Designated October 10, 2018 Tranche 3    
Derivative [Line Items]    
Notional Amount $ 75,000,000 75,000,000
Fixed Interest Rate 3.209%  
Estimated Fair Value, Asset (Liability) $ (10,586,000) (5,807,000)
1-Month USD LIBOR | Interest Rate Swap Designated December 18, 2018 Tranche 1    
Derivative [Line Items]    
Notional Amount $ 100,000,000 100,000,000
Fixed Interest Rate 2.885%  
Estimated Fair Value, Asset (Liability) $ (11,282,000) (4,930,000)
1-Month USD LIBOR | Interest Rate Swap Designated December 18, 2018 Tranche 2    
Derivative [Line Items]    
Notional Amount $ 100,000,000 100,000,000
Fixed Interest Rate 2.867%  
Estimated Fair Value, Asset (Liability) $ (11,127,000) $ (4,691,000)
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.20.2
DERIVATIVE INSTRUMENTS - Narrative (Details)
3 Months Ended 9 Months Ended
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Oct. 02, 2020
USD ($)
Dec. 31, 2019
USD ($)
Oct. 02, 2017
CHF (SFr)
Oct. 02, 2017
USD ($)
Designated as Hedging Instrument                
Derivative [Line Items]                
Gain (loss) recorded in AOCL, change in fair value $ (21,497,000) $ 13,009,000 $ (63,194,000) $ (12,865,000)        
Cash Flow Hedges | Designated as Hedging Instrument                
Derivative [Line Items]                
Current notional amount 1,175,000,000   1,175,000,000     $ 1,325,000,000    
Cross-currency swap | Net Investment Hedges | Designated as Hedging Instrument                
Derivative [Line Items]                
Gain reclassified into other income 2,200,000 2,500,000 6,600,000 7,200,000        
Gain expected to be reclassified to earnings in the next twelve months 7,700,000   7,700,000          
Gain (loss) recorded, net investment hedge, change in fair value (11,300,000) 17,100,000 5,100,000 26,600,000        
Cross-currency swap | Codman | Cash Flow Hedges | Designated as Hedging Instrument                
Derivative [Line Items]                
Gain (loss) recorded in other income, net (6,900,000) 5,700,000 (12,000,000.0) 3,900,000        
Gain (loss) recorded in AOCL, change in fair value (6,300,000) 9,700,000 2,700,000 15,400,000        
Gain reclassified into other income 1,500,000 $ 1,800,000 4,500,000 $ 5,500,000        
Gain expected to be reclassified to earnings in the next twelve months $ 3,000,000.0   $ 3,000,000.0          
Cross-currency swap | Codman | Cash Flow Hedges | Subsequent Event | Designated as Hedging Instrument                
Derivative [Line Items]                
Current notional amount         $ 33,300,000      
Cross-currency swap | Short | Codman                
Derivative [Line Items]                
Current notional amount               $ 300,000,000.0
Cross-currency swap | Long | Codman                
Derivative [Line Items]                
Current notional amount | SFr             SFr 291,200,000  
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.20.2
DERIVATIVE INSTRUMENTS - Schedule of Cross Currency Swap Derivatives (Details)
Sep. 30, 2020
CHF (SFr)
Sep. 30, 2020
USD ($)
Dec. 31, 2019
USD ($)
Oct. 02, 2017
CHF (SFr)
Oct. 02, 2017
USD ($)
Codman | Cross-currency swap | Long          
Derivative [Line Items]          
Aggregate Notional Amount | SFr       SFr 291,200,000  
Codman | Cross-currency swap | Short          
Derivative [Line Items]          
Aggregate Notional Amount         $ 300,000,000.0
Cash Flow Hedges | Designated as Hedging Instrument          
Derivative [Line Items]          
Aggregate Notional Amount   $ 1,175,000,000 $ 1,325,000,000    
Fair Value Asset (Liability)   (100,380,000) (45,145,000)    
Cash Flow Hedges | Designated as Hedging Instrument | Codman | Cross-currency swap          
Derivative [Line Items]          
Fair Value Asset (Liability)   (7,735,000) (509,000)    
Cash Flow Hedges | Swap One | Designated as Hedging Instrument | Codman | Cross-currency swap          
Derivative [Line Items]          
Fair Value Asset (Liability)   $ (1,565,000) (101,000)    
Cash Flow Hedges | Swap One | Designated as Hedging Instrument | Codman | Cross-currency swap | Long          
Derivative [Line Items]          
Fixed Rate 1.75% 1.75%      
Aggregate Notional Amount | SFr SFr 32,355,000        
Cash Flow Hedges | Swap One | Designated as Hedging Instrument | Codman | Cross-currency swap | Short          
Derivative [Line Items]          
Fixed Rate 4.38% 4.38%      
Aggregate Notional Amount   $ 33,333,000      
Cash Flow Hedges | Swap Two | Designated as Hedging Instrument | Codman | Cross-currency swap          
Derivative [Line Items]          
Fair Value Asset (Liability)   $ (2,003,000) (119,000)    
Cash Flow Hedges | Swap Two | Designated as Hedging Instrument | Codman | Cross-currency swap | Long          
Derivative [Line Items]          
Fixed Rate 1.85% 1.85%      
Aggregate Notional Amount | SFr SFr 48,533,000        
Cash Flow Hedges | Swap Two | Designated as Hedging Instrument | Codman | Cross-currency swap | Short          
Derivative [Line Items]          
Fixed Rate 4.46% 4.46%      
Aggregate Notional Amount   $ 50,000,000      
Cash Flow Hedges | Swap Three | Designated as Hedging Instrument | Codman | Cross-currency swap          
Derivative [Line Items]          
Fair Value Asset (Liability)   $ (4,167,000) $ (289,000)    
Cash Flow Hedges | Swap Three | Designated as Hedging Instrument | Codman | Cross-currency swap | Long          
Derivative [Line Items]          
Fixed Rate 1.95% 1.95%      
Aggregate Notional Amount | SFr SFr 145,598,000        
Cash Flow Hedges | Swap Three | Designated as Hedging Instrument | Codman | Cross-currency swap | Short          
Derivative [Line Items]          
Fixed Rate 4.52% 4.52%      
Aggregate Notional Amount   $ 150,000,000      
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.20.2
DERIVATIVE INSTRUMENTS - Schedule of Net Investment Hedges Derivatives (Details) - Designated as Hedging Instrument - Net Investment Hedges
€ in Thousands, £ in Thousands, SFr in Thousands, $ in Thousands
Sep. 30, 2020
CHF (SFr)
Sep. 30, 2020
USD ($)
Sep. 30, 2020
GBP (£)
Sep. 30, 2020
EUR (€)
Dec. 31, 2019
USD ($)
Cross Currency Interest Rate Swap One          
Derivative [Line Items]          
Fair Value Asset (Liability)   $ 589     $ 2,459
Cross Currency Interest Rate Swap One | Long          
Derivative [Line Items]          
Fixed Rate 0.00% 0.00% 0.00% 0.00%  
Aggregate Notional Amount | €       € 44,859  
Cross Currency Interest Rate Swap One | Short          
Derivative [Line Items]          
Fixed Rate 3.01% 3.01% 3.01% 3.01%  
Aggregate Notional Amount   $ 52,000      
Cross Currency Interest Rate Swap Two          
Derivative [Line Items]          
Fair Value Asset (Liability)   $ 2,443     3,087
Cross Currency Interest Rate Swap Two | Long          
Derivative [Line Items]          
Fixed Rate 0.00% 0.00% 0.00% 0.00%  
Aggregate Notional Amount | €       € 51,760  
Cross Currency Interest Rate Swap Two | Short          
Derivative [Line Items]          
Fixed Rate 2.57% 2.57% 2.57% 2.57%  
Aggregate Notional Amount   $ 60,000      
Cross Currency Interest Rate Swap Three          
Derivative [Line Items]          
Fair Value Asset (Liability)   $ 2,398     2,032
Cross Currency Interest Rate Swap Three | Long          
Derivative [Line Items]          
Fixed Rate 0.00% 0.00% 0.00% 0.00%  
Aggregate Notional Amount | €       € 38,820  
Cross Currency Interest Rate Swap Three | Short          
Derivative [Line Items]          
Fixed Rate 2.19% 2.19% 2.19% 2.19%  
Aggregate Notional Amount   $ 45,000      
Cross Currency Interest Rate Swap Four          
Derivative [Line Items]          
Fair Value Asset (Liability)   $ 8,580     (154)
Cross Currency Interest Rate Swap Four | Long          
Derivative [Line Items]          
Fixed Rate 1.67% 1.67% 1.67% 1.67%  
Aggregate Notional Amount | £     £ 128,284    
Cross Currency Interest Rate Swap Four | Short          
Derivative [Line Items]          
Fixed Rate 2.71% 2.71% 2.71% 2.71%  
Aggregate Notional Amount   $ 167,500      
Cross Currency Interest Rate Swap Five          
Derivative [Line Items]          
Fair Value Asset (Liability)   $ (6,828)     1,221
Cross Currency Interest Rate Swap Five | Long          
Derivative [Line Items]          
Fixed Rate 0.00% 0.00% 0.00% 0.00%  
Aggregate Notional Amount | SFr SFr 165,172        
Cross Currency Interest Rate Swap Five | Short          
Derivative [Line Items]          
Fixed Rate 1.67% 1.67% 1.67% 1.67%  
Aggregate Notional Amount | £     £ 128,284    
Cross Currency Interest Rate Swap          
Derivative [Line Items]          
Fair Value Asset (Liability)   $ 7,182     $ 8,645
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.20.2
DERIVATIVE INSTRUMENTS - Fair Value of Derivative Instruments By Balance Sheet Location (Details) - Designated as Hedging Instrument - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Derivatives, Fair Value [Line Items]    
Total derivatives designated as hedges — Assets $ 21,396 $ 16,461
Total derivatives designated as hedges — Liabilities 122,327 53,470
Interest rate swap | Prepaid expenses and other current assets    
Derivatives, Fair Value [Line Items]    
Total derivatives designated as hedges — Assets 0 12
Interest rate swap | Accrued expenses and other current liabilities    
Derivatives, Fair Value [Line Items]    
Total derivatives designated as hedges — Liabilities 22,324 6,635
Interest rate swap | Other liabilities    
Derivatives, Fair Value [Line Items]    
Total derivatives designated as hedges — Liabilities 78,056 38,522
Cross-currency swap | Prepaid expenses and other current assets    
Derivatives, Fair Value [Line Items]    
Total derivatives designated as hedges — Assets 4,608 5,032
Cross-currency swap | Accrued expenses and other current liabilities    
Derivatives, Fair Value [Line Items]    
Total derivatives designated as hedges — Liabilities 1,565 101
Cross-currency swap | Other liabilities    
Derivatives, Fair Value [Line Items]    
Total derivatives designated as hedges — Liabilities 10,777 5,440
Cross-currency swap | Net Investment Hedges | Prepaid expenses and other current assets    
Derivatives, Fair Value [Line Items]    
Total derivatives designated as hedges — Assets 7,717 7,952
Cross-currency swap | Net Investment Hedges | Other assets    
Derivatives, Fair Value [Line Items]    
Total derivatives designated as hedges — Assets 9,071 3,465
Cross-currency swap | Net Investment Hedges | Other liabilities    
Derivatives, Fair Value [Line Items]    
Total derivatives designated as hedges — Liabilities $ 9,605 $ 2,772
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.20.2
DERIVATIVE INSTRUMENTS - Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Derivative Instruments, Gain (Loss) [Roll Forward]        
Balance, Beginning of Period $ 1,349,095 $ 1,420,951 $ 1,416,736 $ 1,375,796
Balance, End of Period 1,397,987 1,384,974 1,397,987 1,384,974
Accumulated Other Comprehensive Loss        
Derivative Instruments, Gain (Loss) [Roll Forward]        
Balance, Beginning of Period (103,125) (68,700) (76,402) (45,443)
Balance, End of Period (91,913) (87,615) (91,913) (87,615)
Designated as Hedging Instrument        
Derivative Instruments, Gain (Loss) [Roll Forward]        
Amount of Gain (Loss) Recognized in AOCL (21,497) 13,009 (63,194) (12,865)
Amount of Gain (Loss) Reclassified from AOCL into Earnings (8,869) 10,246 (11,244) 19,560
Designated as Hedging Instrument | Accumulated Other Comprehensive Loss        
Derivative Instruments, Gain (Loss) [Roll Forward]        
Balance, Beginning of Period (74,062) (41,391) (34,740) (6,203)
Balance, End of Period (86,690) (38,628) (86,690) (38,628)
Designated as Hedging Instrument | Interest rate swap | Cash Flow Hedges | Interest expense        
Derivative Instruments, Gain (Loss) [Roll Forward]        
Balance, Beginning of Period (102,128) (43,161) (45,146) 619
Amount of Gain (Loss) Recognized in AOCL (3,971) (13,788) (65,608) (54,841)
Amount of Gain (Loss) Reclassified from AOCL into Earnings (5,718) 237 (10,373) 2,964
Balance, End of Period (100,381) (57,186) (100,381) (57,186)
Designated as Hedging Instrument | Cross-currency swap | Cash Flow Hedges | Other income (expense),net        
Derivative Instruments, Gain (Loss) [Roll Forward]        
Balance, Beginning of Period 5,843 (2,284) 177 (6,190)
Amount of Gain (Loss) Recognized in AOCL (6,272) 9,661 (2,688) 15,418
Amount of Gain (Loss) Reclassified from AOCL into Earnings (5,353) 7,520 (7,435) 9,371
Balance, End of Period 4,924 (143) 4,924 (143)
Designated as Hedging Instrument | Cross-currency swap | Net Investment Hedges | Interest income        
Derivative Instruments, Gain (Loss) [Roll Forward]        
Balance, Beginning of Period 22,223 4,054 10,229 (632)
Amount of Gain (Loss) Recognized in AOCL (11,254) 17,136 5,102 26,558
Amount of Gain (Loss) Reclassified from AOCL into Earnings 2,202 2,489 6,564 7,225
Balance, End of Period $ 8,767 $ 18,701 $ 8,767 $ 18,701
XML 73 R61.htm IDEA: XBRL DOCUMENT v3.20.2
STOCK-BASED COMPENSATION - Narrative (Details)
$ / shares in Units, $ in Millions
9 Months Ended
Sep. 30, 2020
USD ($)
plan
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Share-based compensation arrangement by share-based payment award, number of plans | plan 2
Grants in period, net of forfeitures (in shares) | shares 348,587
Options, weighted average grant date fair value (in dollars per share) | $ / shares $ 13.03
Stock Options  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Total unrecognized compensation costs | $ $ 6.0
Weighted-average period for cost recognition 3 years
Stock Options | Directors  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Stock options exercisable, vesting period 1 year
Stock Options | Employees  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Expiration period 8 years
Restricted Stock  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Stock options exercisable, vesting period 3 years
Total unrecognized compensation costs | $ $ 27.5
Weighted-average period for cost recognition 2 years
Awards granted during the period (in shares) | shares 322,485
Other than options, weighted average grant date fair value (in dollars per share) | $ / shares $ 44.08
Performance Stock and Restricted Stock Awards  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Requisite service periods of awards 3 years
Performance Stock  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Awards granted during the period (in shares) | shares 180,875
Other than options, weighted average grant date fair value (in dollars per share) | $ / shares $ 43.39
Minimum | Stock Options | Directors and Certain Executive Officers  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Expiration period 6 years
Maximum | Stock Options  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Stock options exercisable, vesting period 4 years
Maximum | Stock Options | Directors and Certain Executive Officers  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Expiration period 10 years
XML 74 R62.htm IDEA: XBRL DOCUMENT v3.20.2
RETIREMENT PLANS - Narrative (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 9 Months Ended
May 31, 2019
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Retirement Benefits [Abstract]            
Net periodic benefit costs   $ 1.0 $ 1.0 $ 3.0 $ 2.1  
Service cost component   1.0 $ 0.7 2.9 $ 2.0  
Estimated fair value of plan assets   33.2   33.2   $ 30.8
Defer payment and taxation, base salary, percentage (up to) 75.00%          
Defer payment and taxation, bonus and other eligible cash compensation, percentage (up to) 100.00%          
Deferred compensation plan, fair value of assets   $ 1.7   $ 1.7    
XML 75 R63.htm IDEA: XBRL DOCUMENT v3.20.2
LEASES AND RELATED PARTY LEASES - Narrative (Details)
$ in Millions
9 Months Ended
Sep. 30, 2020
USD ($)
renewal_option
Sep. 30, 2019
USD ($)
Operating Leased Assets [Line Items]    
Number of renewal options (or more) | renewal_option 1  
Operating lease expense $ 14.6 $ 14.2
Affiliated Entity    
Operating Leased Assets [Line Items]    
Operating lease expense $ 0.2 $ 0.2
Percent of manufacturing facility owned by corporation whose shareholders are trusts whose beneficiaries include family members of company's former director 50.00%  
Annual rate of lease agreement $ 0.3  
Affiliated Entity | Five Year Option Lease From November 1, 2029 Through October 31, 2034    
Operating Leased Assets [Line Items]    
Option to extend lease, years 5 years  
Period for extended lease November 1, 2029 through October 31, 2034  
Affiliated Entity | Five Year Option Lease From November 1, 2034 Through October 31, 2039    
Operating Leased Assets [Line Items]    
Option to extend lease, years 5 years  
Period for extended lease November 1, 2034 through October 31, 2039  
XML 76 R64.htm IDEA: XBRL DOCUMENT v3.20.2
LEASES AND RELATED PARTY LEASES - Supplemental Balance Sheet Information (Details)
Sep. 30, 2020
Leased facilities  
Lessee, Lease, Description [Line Items]  
Weighted average remaining lease term (in years) 11 years 9 months 18 days
Weighted average discount rate 4.60%
Leased vehicles  
Lessee, Lease, Description [Line Items]  
Weighted average remaining lease term (in years) 1 year 4 months 24 days
Weighted average discount rate 2.20%
XML 77 R65.htm IDEA: XBRL DOCUMENT v3.20.2
LEASES AND RELATED PARTY LEASES - Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2020
Dec. 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:    
Operating cash flows from operating leases $ 10,976 $ 10,680
ROU assets obtained in exchange for lease liabilities:    
Operating leases $ 6,007 $ 41,860
XML 78 R66.htm IDEA: XBRL DOCUMENT v3.20.2
LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases, After Adoption of 842 (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Operating Leased Assets [Line Items]    
2020 $ 3,816  
2021 13,505  
2022 13,520  
2023 11,078  
2024 10,292  
Thereafter 88,176  
Total minimum lease payments 140,387  
Less: Imputed interest 39,091  
Total lease liabilities 101,296  
Less: Current lease liabilities 12,518 $ 12,253
Long-term lease liabilities 88,778 $ 97,504
Related Parties    
Operating Leased Assets [Line Items]    
2020 74  
2021 296  
2022 296  
2023 296  
2024 296  
Thereafter 1,426  
Total minimum lease payments 2,684  
Third Parties    
Operating Leased Assets [Line Items]    
2020 3,742  
2021 13,209  
2022 13,224  
2023 10,782  
2024 9,996  
Thereafter 86,750  
Total minimum lease payments $ 137,703  
XML 79 R67.htm IDEA: XBRL DOCUMENT v3.20.2
TREASURY STOCK - Narrative (Details) - USD ($)
$ / shares in Units, shares in Millions
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 05, 2020
Jun. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Dec. 11, 2018
Equity, Class of Treasury Stock [Line Items]                
Treasury stock (in shares)         4.9   2.9  
Treasury stock         $ 235,200,000   $ 119,900,000  
Treasury stock, average cost per share (in dollars per share)         $ 47.86   $ 41.87  
Stock repurchase program, authorized amount (up to)               $ 225,000,000.0
Stock repurchased during period (in shares) 1.3 0.6     2.1      
Net proceeds from offering of convertible senior notes         $ 575,000,000 $ 0    
Accelerated share repurchase program, payment $ 92,400,000              
Accelerated shares repurchased, amount $ 100,000,000.0   $ 0 $ 92,368,000        
Accelerated share repurchases, percentage of expected total repurchased 80.00%              
Remaining amount under share repurchase         125,000,000.0      
Convertible Debt                
Equity, Class of Treasury Stock [Line Items]                
Net proceeds from offering of convertible senior notes         100,000,000.0      
Convertible Debt | Certain Purchasers                
Equity, Class of Treasury Stock [Line Items]                
Net proceeds from offering of convertible senior notes         $ 7,600,000      
XML 80 R68.htm IDEA: XBRL DOCUMENT v3.20.2
INCOME TAXES - Summary of Effective Tax Rate (Details)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Income Tax Disclosure [Abstract]        
Reported tax rate 22.10% (0.40%) 24.60% (3.50%)
XML 81 R69.htm IDEA: XBRL DOCUMENT v3.20.2
INCOME TAXES - Narrative (Details)
SFr in Millions, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
CHF (SFr)
Sep. 30, 2019
USD ($)
Income Tax Contingency [Line Items]            
Effective income tax rate 22.10% (0.40%)   24.60% (3.50%) (3.50%)
Effective income tax rate reconciliation, tax expense, sale of Extremity Orthopedic business $ 4.2     $ 4.2    
Rebound            
Income Tax Contingency [Line Items]            
Effective income tax rate reconciliation, in-process research and development (IPR&D) expense   $ 59.9       $ 59.9
Foreign Tax Authority | Ministry of the Economy, Finance and Industry, France            
Income Tax Contingency [Line Items]            
Effective income tax rate reconciliation, tax benefit, reversal of valuation allowance $ 3.2          
Foreign Tax Authority | Swiss Federal Tax Administration (FTA)            
Income Tax Contingency [Line Items]            
Federal tax credit     $ 10.8      
Effective income tax rate reconciliation, tax benefit, federal tax holiday | SFr         SFr 12  
XML 82 R70.htm IDEA: XBRL DOCUMENT v3.20.2
NET INCOME (LOSS) PER SHARE - Basic and Diluted Net Income Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Sep. 30, 2020
Sep. 30, 2019
Basic net income (loss) per share:                
Net income (loss) $ 32,337 $ (369) $ 9,180 $ (27,610) $ 29,736 $ 32,756 $ 41,148 $ 34,882
Weighted average common shares outstanding - Basic (in shares) 84,325     85,688     84,745 85,536
Basic net income (loss) per common share (in dollars per share) $ 0.38     $ (0.32)     $ 0.49 $ 0.41
Diluted net income (loss) per share:                
Net income (loss) $ 32,337 $ (369) $ 9,180 $ (27,610) $ 29,736 $ 32,756 $ 41,148 $ 34,882
Weighted average common shares outstanding - Basic (in shares) 84,325     85,688     84,745 85,536
Effect of dilutive securities:                
Stock options and restricted stock (in shares) 427     0     558 1,045
Weighted average common shares for diluted earnings per share (in shares) 84,752     85,688     85,303 86,581
Diluted net income (loss) per common share (in dollars per share) $ 0.38     $ (0.32)     $ 0.48 $ 0.40
XML 83 R71.htm IDEA: XBRL DOCUMENT v3.20.2
NET INCOME (LOSS) PER SHARE - Narrative (Details) - shares
shares in Millions
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Shares excluded from computation as their effect would be antidilutive (in shares) 0.3 0.6
Performance Shares and Restricted Units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Shares included in computation (in shares) 0.5  
XML 84 R72.htm IDEA: XBRL DOCUMENT v3.20.2
COMPREHENSIVE INCOME (LOSS) - Schedule of Comprehensive Income (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Sep. 30, 2020
Sep. 30, 2019
Equity [Abstract]                
Net income (loss) $ 32,337 $ (369) $ 9,180 $ (27,610) $ 29,736 $ 32,756 $ 41,148 $ 34,882
Foreign currency translation adjustment 21,181     (18,651)     24,801 (17,960)
Change in unrealized loss on derivatives, net of tax (9,679)     (775)     (39,814) (24,714)
Pension liability adjustment, net of tax (291)     515     (498) 504
Comprehensive income (loss), net $ 43,548     $ (46,521)     $ 25,637 $ (7,288)
XML 85 R73.htm IDEA: XBRL DOCUMENT v3.20.2
COMPREHENSIVE INCOME (LOSS) - Schedule of Changes in Accumulated Other Comprehensive Income by Component (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Sep. 30, 2020
Accumulated Other Comprehensive Income (Loss) [Roll Forward]              
Balance, Beginning of Period $ 1,349,095 $ 1,341,802 $ 1,416,736 $ 1,420,951 $ 1,397,030 $ 1,375,796 $ 1,416,736
Other comprehensive income (loss)             (24,126)
Less: Amounts reclassified from accumulated other comprehensive loss             (8,615)
Net current-period other comprehensive income (loss) 11,212 1,464 (28,187) (18,915) (12,021) (11,236) (15,511)
Balance, End of Period 1,397,987 1,349,095 1,341,802 1,384,974 1,420,951 1,397,030 1,397,987
Gains and Losses on Derivatives              
Accumulated Other Comprehensive Income (Loss) [Roll Forward]              
Balance, Beginning of Period     (26,625)       (26,625)
Other comprehensive income (loss)             (48,429)
Less: Amounts reclassified from accumulated other comprehensive loss             (8,615)
Net current-period other comprehensive income (loss)             (39,814)
Balance, End of Period (66,439)           (66,439)
Defined Benefit Pension Items              
Accumulated Other Comprehensive Income (Loss) [Roll Forward]              
Balance, Beginning of Period     (9,709)       (9,709)
Other comprehensive income (loss)             (498)
Less: Amounts reclassified from accumulated other comprehensive loss             0
Net current-period other comprehensive income (loss)             (498)
Balance, End of Period (10,207)           (10,207)
Foreign Currency Items              
Accumulated Other Comprehensive Income (Loss) [Roll Forward]              
Balance, Beginning of Period     (40,068)       (40,068)
Other comprehensive income (loss)             24,801
Less: Amounts reclassified from accumulated other comprehensive loss             0
Net current-period other comprehensive income (loss)             24,801
Balance, End of Period (15,267)           (15,267)
Total              
Accumulated Other Comprehensive Income (Loss) [Roll Forward]              
Balance, Beginning of Period (103,125) (104,589) (76,402) (68,700) (56,679) (45,443) (76,402)
Net current-period other comprehensive income (loss) 11,212 1,464 (28,187) (18,915) (12,021) (11,236)  
Balance, End of Period $ (91,913) $ (103,125) $ (104,589) $ (87,615) $ (68,700) $ (56,679) $ (91,913)
XML 86 R74.htm IDEA: XBRL DOCUMENT v3.20.2
COMPREHENSIVE INCOME (LOSS) - Narrative (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2020
USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Loss reclassified from accumulated other comprehensive loss $ 8,615
Gains and Losses on Derivatives  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Loss reclassified from accumulated other comprehensive loss 8,615
Other income (expense) | Gains and Losses on Derivatives  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Loss reclassified from accumulated other comprehensive loss 5,700
Interest income | Gains and Losses on Derivatives  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Loss reclassified from accumulated other comprehensive loss $ 2,900
XML 87 R75.htm IDEA: XBRL DOCUMENT v3.20.2
SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)
9 Months Ended
Sep. 30, 2020
Segment
product
Segment Reporting Information [Line Items]  
Number of reportable segments | Segment 2
Codman Specialty Surgical  
Segment Reporting Information [Line Items]  
Number of products offered (more than) | product 40,000
XML 88 R76.htm IDEA: XBRL DOCUMENT v3.20.2
SEGMENT AND GEOGRAPHIC INFORMATION - Net Sales and Profit by Reportable Segment (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Segment Net Sales        
Total Revenues $ 370,232 $ 379,095 $ 983,221 $ 1,122,430
Segment Profit        
Operating income 57,542 (20,587) 98,725 57,680
Amortization (8,343) (5,056) (23,393) (21,340)
Operating Segments        
Segment Profit        
Operating income 147,193 131,512 359,643 404,414
Corporate and other        
Segment Profit        
Operating income (81,308) (147,043) (237,525) (325,394)
Codman Specialty Surgical        
Segment Net Sales        
Total Revenues 239,323 252,984 640,541 736,810
Codman Specialty Surgical | Operating Segments        
Segment Profit        
Operating income 97,061 101,129 249,552 291,750
Orthopedics and Tissue Technologies        
Segment Net Sales        
Total Revenues 130,909 126,111 342,680 385,620
Orthopedics and Tissue Technologies | Operating Segments        
Segment Profit        
Operating income $ 50,132 $ 30,383 $ 110,091 $ 112,664
XML 89 R77.htm IDEA: XBRL DOCUMENT v3.20.2
SEGMENT AND GEOGRAPHIC INFORMATION - Total Revenue by Major Geographic Area (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Segment Reporting Information [Line Items]        
Total Revenues $ 370,232 $ 379,095 $ 983,221 $ 1,122,430
United States        
Segment Reporting Information [Line Items]        
Total Revenues 266,477 266,280 695,179 796,397
Europe        
Segment Reporting Information [Line Items]        
Total Revenues 45,995 49,242 123,917 148,753
Asia Pacific        
Segment Reporting Information [Line Items]        
Total Revenues 40,473 42,079 113,934 114,810
Rest of World        
Segment Reporting Information [Line Items]        
Total Revenues $ 17,287 $ 21,494 $ 50,191 $ 62,470
XML 90 R78.htm IDEA: XBRL DOCUMENT v3.20.2
COMMITMENTS AND CONTINGENCIES - Fair Value Contingent Consideration, Balance Information (Details) - Contingent Consideration Liability - Fair Value, Inputs, Level 3 - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Arkis    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, Beginning of Period $ 14,210 $ 0
Loss from change in fair value of contingent consideration liabilities (45)  
Additions from acquisition of Arkis   13,100
Balance, End of Period 14,165 13,100
Derma Sciences    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, Beginning of Period 230 230
Loss from change in fair value of contingent consideration liabilities 0  
Additions from acquisition of Arkis   0
Balance, End of Period $ 230 $ 230
XML 91 R79.htm IDEA: XBRL DOCUMENT v3.20.2
COMMITMENTS AND CONTINGENCIES - Narrative (Details) - Derma Sciences
9 Months Ended
Sep. 30, 2020
USD ($)
liability
Loss Contingencies [Line Items]  
Number of contingent liabilities remaining | liability 1
Contingent consideration, maximum undiscounted payment amount $ 3,000,000.0
Contingent consideration, estimated fair value 200,000
BioD Earnout Payments and Medihoney Earnout Payments  
Loss Contingencies [Line Items]  
Payment for contingent consideration $ 33,300,000
EXCEL 92 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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

H:':_MA-_@]U_7=)PL_M'(K7R0FH%+HBFGEF!**7"R2BS MANO 2LL$QBL]8 KQ,(O"*:]7\%UM4@I?7Z%6+&]@UJ5'%&P]2XL48T- M\L_OS?*'A'6O,K\_M5BOL\M7L^M_VL>N5^Z#>$/0EP7H*PVE<@II(!2%U$E@ MA(9$R]CGR7BX ?2+0JXE^T7:6%W?UFCQ"=?*Z%H)GS?&C(/$^".#\;=!ZH\; MH1H"6&"UAAY :P!F@ 41G4N I2+.8.;6PJ< MJJ2^4Z#$0<1#P*KB(8[@C-IK;%@-)&X8D+IH*J0UA=I*Y("E F@!,#3($26I M%%#LX!WUG(O3[6T MX%$*=1"4A#K/"*4. Z0@Y0YIXBV3% '!B30D:KM +6T=CW M&K?\$>#3T2N@$.$BNH@K*;RBC 3(8HHKBYF1"K*@A!KG-F%5/1S-)P99M7 S M-TIH@SZO1Q]2H ]Q/J",@E(10X'FRAO.-1+4"*$41K5WG3;H\SP[6)6BTKNA MSXEDA%?F 3WF\)V33:B$D)7"%#VDV E#%;#4&"(T(<1:RXCV &M7 Y_IWV(; M>L0C9I\T5K^GTZ))HVR@JQ;0)7@IK29(FI#X\!]-'3:"*P.8]LS#< '4P?/: M0%<#70UTU7/B>_ /9>R>SQ[Q)@.XUA/?P_;/&E)-782PH8!:3_PM',2P[HMP MM+M?!VD585ZJO2:(],@A&5-,+!,*64P="N(J4-*)>KB43U9@W*CK0RQ1[]3Y96':^M>:J"G_M"#2]5I#/;6.2JY!X(BRS71G!(G/&1!QW:V M!G[N!GH:Z#D1Z#F&/,9%1R7$35[J8>_G?[7[1<9X[G86-9EMLYN5A!$@5)/Y M'OI^UD*X*\5?"^^@$)P$]9)0I;44#GEI"0[_\%IMLA:^H5NXD>]V\A"CL[!L M3:KQ,0+4$6BB6WP;6!2^#:A(#%JA <(X-0!J9S0E-/S/<@=E)=E^#6C5RLUCMP&N@X N@@@14D7;K6V6A)" 95$2&Z-U\A*[(6@0M7*+=M 5Q4E MGEM"5&E5.Q3H:ERQ34S.*<3D;,%^#.;8[ZQ13A(>M&M&(:):$>>@@AP@B@C< MP8.R7V'UM&M3O*<'I4D:;%"L%BA&2B$H4DLL)-)(,:HH$A8S3[WP0GF"4!V: M7S**P<#PQ M9R2'QG %/ V_T!%;G#(28V>59?7WF9\8_E7A,T=-?]$&!4\>!3$MW.]!XM-0 M2J(%H< "!1F$Q%D.H8+>U:M.>(."-72_'SP*-EV6FTBJVD+Y%B1GL*@8+KE% M!& *-:I0SI;$+LJ0$CFN@A=X@1+ZO![R!G@9ZC@]ZCB_7LLF$/O3]_*]);\$#+6LR MU68K=Z^E36HRUT/?RSI(=:P4G6TP9) YB8G5E'*DK;;60DT0\1AK76//\(D) M=CMYA@G"1YZ,TZ1 'RI8;7%D,%(X,C2$'#J-+%2&0D^TYIA+A:SW#!KAZ^_. M/3'0VMF1(5J$DB.'KB8%^EBAB[$Y=%F&!-< JICTT^K-?(*00D5QP'1*ND4 MWQC2Z@1=N$5AE?7Y#P6ZFA3H)@#G% )PMF"_+!JR(&RDISZJV0'^J59.0ZRP MHHX[)R6OJ]>6G#3B/]]UTN0.-B!VE"#&81%Z(B4 7EAJ(= 402T8?[.97X*UN=O]HI-92 MP#17B!@!"!.646V@@,W! P_>[^[1,37&ODWSZH;)*^&#IBXM\(X+B\2FD@\U<96?&/[M[&\B+<"J=)4? M% HVF<\-"LY04/(Y"A)'"!"$2$8YY1A(8014FC)HJ18;Q;^:>-T;%'P9"L(6 MYZ)!P2;SN0F@.H JLU(+E#1_88@2*@$6D$ J&12,8$ 0-(@YP#RIJX^='K2 M^/U\]Q-JT@\;Z*D1])!2^ Y3W#"%-?>$JG"9,2\LLU 8AL4NX3O[%1T;Z&F@ MY_B@YQC2*YO,Y^/:SZ8']#'MYMIBVDT"]!$)=Z78;$6UD88J;K6CWD%I)2.> MV)AD* G<5"'VO1W$)R;?[>0@QK!)@#Y*@#H"372+/T."PI^!A1(>&2B\4500 M*94G'D#" 43 FPW-].KBU3TQT-K=GR%:4%3IT*@C=C49T,>*74C,L8MRZI"5 MEG/O*&9&0LXM](0X:A%2E11O: QJ=<(NUJ*2GB!T;7>YW@=\Z:5-!G03B+,? M6JB#EBUIJ0,!)A)I[;#PF#)C9&S^S"4RQ 1=V]:A"?1E9SR(@ ^B\6X*^/"D M ?_Y'A1.F]S!!L..$<-XT4L*>J654XP#[ZEC7#/I"26 82ZTY'4H@-U@6(-A M#8:]8.+O+(=7Y;&:\OW4_PB:_K^G1@!+Z<\(-)M_2IN_E/Y,F]U_I]VO@ F!RT&FKR_ M!@5/'@59T=P%8FJE(,)K(2D#7%@OH"3:6,X\8JI6'O<&!7='0=KBM&G[_!I/ M_&DYW$\"XG?8V5JH\:(HYH,!I99P[510XPT0@B.HB)'89\G0&[ITO:O[')TT M?+^CZZFV'J8&>.H//! 4<3LHZ-'":H(P$E1)H#S@$DA%(2$&J T2Y+OZO!O@ M:8#GZ(#G/>77NCFJF^VLQ796X79NMK(F6UF!$[G9RYJ*=*50;& -](!" 6C MP$M)*7(2*RZX$11NJ&;SWB[A$Y/J=G()0RDK= G7T=S7Y#L?9\Y@4#D+#X8F M5 CDK63&4X2A $(IY;S1#'($*^F:VF!6C3P802<0')Y@SF #7<< 7;+H/.(8 M-IYA#H%$%%NH '#,Q"+\P!*M1>V=KPUTO=CY2II^SS6,LZZ9\_6T V^.->HZ MB*V%BJT1GX;#&LPK,&P>LKA=7,B-P1PH 309#N? M].8WV&;PB3?F_7]HF)K;ME M.X,J7=L'E>+29#LW>7Y3W,.@<#5AHK04F&I+%?7":PJ98-1K)[U0OEY5P1OX MJ\1+3@5K$OT:%#QU%$1%)Q<&J5(6J@"#G&(A@P@(E$=8>J<,,QN\+C5QN#OM6SZ*I5O%BWQ-L^JTVT%,CZ&&E_EK,&<8ULB #\):6&F#&.FH<@R8 M33UJWK[53LV>A:BDZV"3_%PW M@#K^#$*""X>&"V#%%> DVL$\99( RPUR <6(TFI3:_IW;/9\PJ"UNU\7MI! M)YA#V,6 7Q:6&GP XB E@A%"/M$1 0R6H$@829T"MG+$-=E6 7:0E<96& MM4.!KB;]N8G$:5('"2\U7R%8&LJX%A#3< 8():$ FDAF*>&N#NG/:Q'_M M> MO*<3I4D>;%"L%B@FBR@4(:%1UD H :=8(.Z]R0P%'00$[^*$;"C@."GB]Y[JA@&.17VDIBMI *YFF6B!&**%6 M$$JQ%TYSC,)_:Y(,W8BPN_JZ624I,$TV].%CW0GG 5)6N)X,U1 AHC AAKL MM+):4JHI4,1B4DG7TP;_ZN1Z@K %49,)V,#@R<.@($4ZM((:0LF4]H(:PB21 M2@!+*"2.:+\IUK$F'O@&!E_J@6>RRM8)!X^"MC-N]I#OELV08*#"0U(QM1N'?,S).VJ.D$S@BB M1HZ5\-?;^^+V 36K6/N"Q6F N 'B=P!B3$J--(+B0AAC$&G*(-.<$*D)Q8(R M[/$.D61;-9>C V*,&B ^;9FVF5\SOV9^S?R:^;UKKE;-YGJ:\VO4BJ-3*[;X M1IB4)=^(M1 M CFA+4BJ+*1S&CB>.9W_]>AU==I;TT(Z!/7DJ($=2< M*T<5M]*2('2YR,#$&VT^P0]KIGM]ER9F.[=%1VW1*(W_BX])TMO;.,K?TW[X+AG<;GEV_R8;RS#M1"+,1I)T[MK] M\)+PP^SC;<"9Y/<(--/'K7_8DF>^O3SH^.6D/TS#AOT[_.1;0)PPOF'2&V1C M#R]K=SJ3^TDO>\(@O&<8@.S^89C>I?U1?%?\9?+Q__R'0 C\I"[-Y^R?\*#:__1"B\9=WO9.+/WWB3=<7J?M+-U"9_2]K ?J&C42MKCY/M=MW.7 M/ RZ8?QQ*>.H9H-*ON<+TPOKV[WMQL49S.\^2\YOR^\H)GLS"+/I#\)XPG2& MK?BT[FT80_(UK/%]N/8P''R-O!5N#R,(%[YW>[WR'>/2WF;7YH-XS*X-T_LP MS#"*I)WY!N+,5P8_Z$]_FZ_G\F;,-SS<$I=)'^\1"6/(T+E(UQW+U/ MSY[!S#.NS_ZY,77DPV;FKX"-5UHJ9G_>#66A_2S]]#>3XVZ?V;1C2C^W> M]_;C*#+NW7 ZFTU#W)0.\\I!9Q^_Y^_X.NC=A$><7UR[G[^HY/.Y=U?FW%T8 M=Y7\]?*S/;_X^2HQEU]^N?RBKL\O+Q8G^_X#O[B\#B.]ODQ^O5"_VO-K9\-H M+ZR[N,K_=77Y^=RJ^+4_OU 7YEQ]3JZNPQ=_+!]6 ML[DNT-UV^ 8>*$^P0$!""@360%##%?5(&A?^CAD+\W>J\8MOQUNH^YV.MOQC M_/F/W7%X=F?=OOG!,'SN)V8R'*;]SF,R%=.>3U_O=G#[X> ^@ZJ(9?G?)2#- M2#T>,^'B[722G=DDQYEQ.Q7:?\F1_P U^.P\]G#?CV[.@L W^NU2R=B M)XB*$7GC4P/,1K1=>4%0+@?WW>EA/VSW1[DH^M*#O#3$#)C;PW3IV+W+MZM\ MR.?O*!WJBP?ZREB7A8WL+>Z.U MI]A3)W1I>TH[\ ;']>L/Z=)L%L_B)+!IB1;B8+:206M9MEN5ZXHGSK;\6S\3 MUN*0,X&LVX^+DGR<2@A3R6LJ*(;;,]TE&\1H'/[*A&>5[\YY316MZ7Y)W4]4;9OR^CN2QE/MJ?KH%4Y#%"45JN,31_/7?;H D MN&@E01(D.Y6RS0W Z3[].?LYG6YGY'GC[ "0*IS'X;C=GCO8$P8*&BWD/U<; MZ+GOVR"[\]OK%_S:;Z)?D?ML,&J%]9BR]' >A@)?_]$9+6+.!)[F5W<1>NZR MAT+M&W3R<$;'O9>?>2023R<'37_P('L<6^"#O.@7"Q&B49SYZ\W=SX]N#2> MS5XE[LW []^'F; /^?Y)J&L8-IZ\=[]<])+)#+H$%=TC>&M5XA>\[S>[71 Z MXXJAIS')O@WR"42%;_1[P>GC#=?>)/-J#KFGR_%V;T+QN_]\P1](YV8 N48 M-Q)SP*AE2A-AH;!$:0J5U,_X Y]+& M.0/YWXM<+H)DW3H^'G:!20_#-FYSD?@&])"VPK[\IL[S$*]6TZD@I) MK!*8(FB5M-HQS*'"_M\*G@BO?.I/_=!SK-*^O5F/59"$9ZL-C&MC%0\FYF_I MDG#V=+T%48M:#PT+5 M"[_J!FLVB%RO8'@9Z]6%KU[F>:WDZ[!S[3?U(0C12Z^E_=MK6X6$'A9Z1ZG& M>D$]8X/RR?I?_UE:*Y7+\1'(]8056.MA>>RUC$J0AU\](6J#FM=O=PIZ"ZUQ MV3VYK#4N2/RSY+>@,!;?]&MU-^<2G6F[K8D;\#;SC_\U:"?/%AD-'U'Y[[+? M\\I_=I\]E&*E7$.OY:6A'K"DS.L]>>DYG7S;?VEQIW^[G^BZGD6]%E2NSLHS MKSR#OVNYU5YQ"IK;O/P*[T\YZ^E'FG^,Y*8PIPNU?AP>->S^JG[]LK=%"4XP MU)QP)*BE5C#IN#(.0F>-;;\J*O'6SN;:E)I9\Y]_/N]80UNYYK@AJ[ M=!:*JK;R0&3#C?2+R_Q^M-I%":R/3X$?UO[U8PU]H%S_8=Y/?"U3>[\X\OWQ MT#_D\,>?ZO5YSOU^(=(.ENHO_8.WIZ\?69&K3O \G.??DR]]+UF7G_8N&WCCL'R\;#SJ3]\HHX[%.]\[ MUZ-;_VU/_"2\V Y+>3_,?YK^X^?E8.*[6:GI+'L0RG=/5Z*6]T#PAY_?K<1/ M)_=_YJ,U?P;6^AE?ZU?LZ8_D6A=$NURJ-6_VNI^]7)A\[/F7)T+?8LK#:G[" ML=-_[/3%_3UN^N+^'C=])["_KV^'=/QK<>KTSW@!-Y 7GC,SQ5L70SR>6/." MP7]:R'CRW#!UN"3+OI8W]9 Z'H8X:?J.EU*'Y\,@BX$R8-&:C)^T^3]-.']5JX[A"UID%17$_4N]&J>*0UTAIIC;1& M6D^&UE=KS4=&]RG1&O?X^&D]R3U^M:&PK[&/=;6U_9P]A$SV./1G@?!!__L+ M4>ZF3?UR?9M?C[OYQ8W[U[@S>O@U']WV_8__ M\#\-!3ZK[^;YN;]O51D7:FG#V*S%*K:&%-,UO!/<&D5_JW-HY^O^7IA$"\_X M:J^X:D)KLT]EA*/5%HYK4]X Y73[1+X*N(Q<.KS99U M:-W?5C_1T;@^(ZT! N'YUL48LDHB$,N0E48)2AT%4"BDH780"LXY@<+6UH,^ MRH9]RX9:V^NW*'LC]-=WPK8R\'?M(Q<'GT>Y<2)R0U1RPR@CN$3^#V$HID)P MDE(HO!7!K'9(Q.'**<+OVJ'N, M6QCC&!V)TN&("&]B'9P\G;3M2&HD-9(:28VD1E*/@=17-P4\+K)/B-0F%H'% M'8X[O",SZ- #=;'*+Q9TQ2J_R!3/5?G!B X-)7QO<6R"P"RJ ITE0A&1&BLH M841 JIAT",HP"9$_,PMQ]W'LJ^_]&%@YB"H_$:O\#AF.8I5?[9"+Z0QRE24 MIM@X_S_5F$JLA7 <$4<R(M\VO\B.B16,<^VC%P[P+=C\F3$.*&PBM M=%:;LE0Z 4@*-846*17Z5%C,(3!0P>=TUGT5Q44HW7]Q VH!\$:D/*7RA@BS M$68QX7.N 6H 8AA:0R'51$B:2JH%2P5$0J:T@35D$6;W#[,P3$B*(!MKR&(- M6>-]/B=+^-Y\[Q161=J"4IXR3BV2E#*N%2*0,:V$,9 2#*+O_? EZQYJR B+ MSO<#QJ-80U8SXL[U--4 IY9RHQ1W%",BD8.,0\&X=9PK&%WO)PBW:]>04= " M $3?>Y0.1T1XK"&+I$92(ZF1U$AJ)#62&FO(X@['"J.XPR>VPR<3J(LU9+%< M*-:01:9XKH8,171H*.%[BV-S(*N"!FPX-41+1@7%RBK_/Q(I5P RSO1S0RIV M'\>^'>2Q/=]A5)')6$5VR( 4J\AJ!UU$JEEQ1BKFG-78&8J-UA@@R@#3)-21 ML095D47$/8 Z,DAHB\K5[M,QF'T<$F*]"H?^X#H?3*F"]W\FPWZW\ME6 M%<2FA[+Y51(1J&,I&N94SLVB5Q Y8ATFB@I-%<;4$&RP)L "*)M8BA:!N % MC$0L1HO%:+$8[1!<1R=+^-Z<^ )478E&Q(BV2&DF-I$92(ZF1U$AJK$B+.QSKE>(.[VZ' M)RD7X3>K^1:-6).3">5=]4=9-UK'D?!(>"0\$AX)CX0?&^&O-M".>1$BX8\2 MOI#[C+TN?MT??^WF,V5\G05XL0>RL21G5B-!4ICHEBE@J'$!*48%KJ]Z($?%]I??R%L>K1<(;A+LW/C]O MROK=+\"L57FQ\0+MS1,3Y5:46\V56[226Y09J @2#BE+I>%*RY0A("4$2$*! M:BMVB7)K7W*+@C>6I42I]6(ARU]&F:=Y^GXM^69^A\+!Z?3&6;E%![)>.T^^=T:WR>@V3_SQONN4 M)RNY]@>I5;QK^G?^E@_),!^-NOEUDB7M@ H?VA-82(;?LWM_E*:G+\F&X3O^ M*"=!=B>W_BSF2?\F\<_="1#2GERPV_?O%#?W?V??O@WR;_[W26^2%YMD16)L M^.5T_=8$[O]\ ;AY5:5(G&1 .:RXP89+#:2 &!$L=6JE WJ]=-Z)E>&W : ( MV>LEWUZ.OP[S?XU#OO,?_H^KA_M\,0]W\?.W9.2R9X$>X[/5D:.)Y[NN_\<2 MXK^90<^2UV/#/*X+#^)S6/'/\7#4N7FH)3KGCWQYP).%$^X/]YODHR4;)C==EDC^",M/R1_PZ:=]FO6_Y,,!/ M^''U<7GM01X@J020<6^0>]+^[5]]\[PX3/H#CQ?#8?EK=6$^G26I?R]<9^W% M'X64^.+)>GZMU[Y,2\\_-J7N+>YD M%;>/JK)J="0IX1 2JHG6U% L)<58IXS85'"=KC0ZNO!//@A//LAO\]ZPP"8O M-?( 2?. DT]QZDO>[F;#8>?&:U;A673N#W1^E?VYI#;;$HC_?F4C#->E.=-Y M''V-YLS.5C7GNO"T.,W;9FPQ5_T#54I=JAA@%$ @%+)&(\8X!L:FZ:X9^Q^1 ML??(V!"=K1;NU,79+0_AP_N\'5:R^] *8K ?N,G_(W!0*^EYH3L(R^A!?M2? M"-OPM4K.SG]>2&#/2YZN2M /@@+N=[$W++D,8351CR&36H8@5=Q2I(0"6@+ ,$J- M9!BLM,C:)HA!&:7S]D#L.7?6V6JSJP,2RA!6SE=C!6"044((ID(JK:PCCE*G M/4=3OA(TW#8_1Z&\!W[&6U0RFR"*)V;Q6/(F;\_KT!AMX:!L M^:Q@@QUH"[AJ>*"L]:@*L9":4FJEM@80YA4(C(&D:,5#^F9T+=%T&6-5[SJ: M\XVT>M@6W:/%@60*8>IY&S'"!,-[STAC#QPPYM6CJ246Y&"E#LM! 4.2B.X<4*FP%OD M2L,]L'04FGM@:4C/R$%)S6@@-T*NUV\@[TJN,U;U.9?$82"8YM++=:*UT4"E M"AF+N"-\)20X/?D7O4>!X3P??1[DHVCZ-@G?SE8+%@Y)9//*F\-!:KU-2XD4 MB$JM%,720,0 3U/#[4I7_LVX-4KC/7 KV2*WOLH3[O_='0'_[GECH :U'L&E!R[^O!U,+W*??\?LAO_2#]EW>_9P]#?ZB^W M@PDUKZPGJ&LN0?'R>WF/K_WNM;_$Q_,K]]'&^5B'$%A_\_.+*/^G51?+;N?K-?KQRUC_MN77GE^6_ M+B\^?;0JO)U^/%?GYJ/ZE%Q>^3=^=>=7E\G[V<]^3-Y/^"R_7BYOF=*ZP'=+ MC%G XI6G^3+OYL6Y^ !2;S>0T&Q<0@H$UD!0PQ5-D33._QU*EF;W5*,W_YR\ MP-U[,W5?*3BJ+$S$@Z4%F2(:.J65$P93!"F$5NJ4K%3;;28XHA*[E_2D526V MU(!.19-="SIKK@OQ3^VW8S11#_VS9GY-O$K[9UBXDL*O11W'Q#];OC6_CLG[ M\.7>,/^Q7-&;0?^N<.>%HH]-M,VZ'4I%8=IDFWM^09/1][S[1S[5XCW56U:, M9564)ID@U&$)B4NIHEPC+A1$6AH.*14K,R86$.,Q/_I57\]YT?-K.Q[X8WON MR83HUX+ V"FC,="'MYA4?I:H9AV[13_N=3\?AGK0"<(DX;WE=X53]"B5KY;O#?+EL=>BOW,[&_H/PH_Z@ MX_?8XW2(0OEO%I 7,O0F)[AXE/"X_;8'[^9'%L_=4;^VNU'562/TM6L MF:3 D>%>"YJOYCC$HTP6MJF=#T9!)$W3*/,_)T&@@0>8H=^]07_\[=:SP1_9 MH)./'L*.^Y/JS^ZW3CYL322[7_!BW_W?9\G\;4HAUQ^6 NW1FY2BK#,:E@*^ MA(L@TRM%8/H4*[F>]^.!O](P/$BI9DR7NZAVG'Y]./XZ[%QW @'#LJ!RY4+^ M .3^1^&S;B?[VNEZ7 ZKXPW(4:6V] +8=#V\CP?#@O>_3K#\+)DK%H>%9TDL MGLC"%)L>L,?JP+-O@WRB!2V6A"\2-CU>_BKW7F!XY:?[,)_>FGNMJ%UJ4BM$ M]A]?DJ7S5B+FNE2O!PM+=?OOW=X_8:X1C*8P#(#6 M(HF$ME!22E/.=*@.^U!YW?WG@%H'B>".4DPDQ0*&OP0!T%GSK&&G!"<8:DXX M$M12*YCT]IQQ$#KC!)4?P#NOJ+6S^^#2&(SS6LV\;9SAV[Q[/OX&)5PM<"4$98_#HE^(!_]N=_+I?[WS MW!]>^P=O3U\_LCY7G3O/*.?Y]^1+W\N0Y:>]RP9>")2/EXU'_>D;99.5XIWO MG>O1[4]2G@E F.#TAVE3E798T?MA_M/T'ROGY]VLS_>L3R:4[YYN U[>"I(? M?IY^:>6S9SY"3W_VS$=KWDVL]2M:]P77_&@]FI];Q?7V9>YGC9J<50/P-WKZ MP3[I6^P M=J5Z=CI/W;ZXOX>-WUQ?X^;OA/8W]=W;3_^M3AU^E\]GFD?:_&< MM2G>NACB\=2 F1<@678 G!8HGCPC3!TPR;+OI:GSC:,6<%S(OPLF=X6_O?-' MGMALE,>-/YF-OYKK^1NW_J2V/NW\F5\G7TYVTT]>LU&SGMO3YM5)V;WZ0 [) MOOB%[X%?]@ /H7:V&$7Q9!AP)TP:4AJ2]Y\FZ0P/3PX/:(KZ':=%1U(CJ9'4 M2&HD]8A(?;6V?%QDGQ"I<8>/G=13W.%7VP8[G@1@(IC32AL%&7(*8/#,M-H00IBOTGRA:/39 M$M"RAY/JKJV[8^QO!S?ZY6=OKFI_[TEG/UHKUQ^495,DIF M%:,?T&+)Z+_S0?\Z&]X&MA<(HI]7*D9_6"H5;>J!B$A0X]SJ!JB#VR?R56@W M-[/-8HD5=< *32A13/@WI%7 :"FL,RM=:E\WXC5"W090EX\'3P_C?JZU'6D) M6NL8[J=8?^O6VV.SJQN'44U5V=>A=7];_9_;-E :#\<,5G")*\%7"K>B+8O,W5$WHB\ M$7EWAKRXFD"B$(.$L=1(GE),A2)<6Z=U"H!_^UFS_]7("^7?243>&I 7MSR[ ET:@[])^N;B82?&N%[\\LS7@EH"3@R"# ' M64JE M*F2J6<2\P!@'1ED''TR]?LK+J\[0]61?A;'/.KO1QA=,T?,!C4IJSO M7=@WQ!Z1J'+,(T:P @"E"E!B@4@AU<(PC4#JJ%Z9G!0=\]O'NK4=1:@%P&K? MVNB9C]A\N(3',J-(:B0UDAI)C:1&4B.I=55CO.2?/RZR3XC44ZRWB3M\[&2? M3' N5E2=>"%-K*B*C/!X116.O-!0PO<6N16\&O##L(16J=205%#(I'(4""*- MP9P0(U8FDNXUCOC<#O22H=#5D)>?&0HL@ MHY@I0:BB(>N.,:HA8TTL0#I,'*LG#9[@DTF#CU 5H4K":A"\4$QQC0PR'%,L MG4#40O_"IJF&(*T%JNJNV#E9J,(M(/C)0-7)! 5BQ>-!" Q3I%,$C-.(L&9UTCI,R;SCBAUT1E>%>'3]-ISP6+&S M/;CCE3UB)%8*1E%+D-#06.V%2S@%,28.:+9X0V*U;M8-%2Z 8 MNSU6>(ZI\!/\$I6^9IQ+94P0I@=#)@ M=3+!@5BY@$CXJ1&^-_\OHK"R)[!T#J94IP10:8CD@F/#&)8B?N<*SMB#M\8CM\,@&Z4+WS M5_TYFL"G6K01JWDM(-8&"&TDTY09;FU(#B'2(L-09#E/* M:=JL>3MI?SPXNG#&QL4[2P$->,9BW\5#!H/: IL-T B;$;TEK!I:8:%EEC A MC2,48*H=YP0(21$ 3L@&16]/!^V^?;U?*W8+D6@A06+P]DCA.6;$3_"+5PH; MHI@"R+CU8$655@)[*#-<02.5%)0VL7SG0)&LANP2T:+BC\7D7?J%/5 MQ_#5:=Z$X^L"NA]/.:@0JWX.P7$0"3\UPO?F-Z:D6LH<5X0P M( VWE@H)X7-=!*+?N*E%/QQ&Q_$!HT$L^JD9[^AA\5(3'HI](:B0UDAI)C:1&4B.IL>@G[G L M"8D[?&([?#+QN5#T8_Z61A/X5&L]8M%/9(18]'-8#L&]!6\YQE4P@VFIN2"8 M.4PEIEH"13DGC$,I'!/-"M[Z'Q]=/"-.[(E0L(VP9@/TP6;$;CD15:Z*%% : M82&4A&I")$N-98I*9E(N#6]0[/9DL*Y]>[-FZ):V(']CC_D8NCT8>(YI]%, M8Y6^AK!4"B%J#"0T-< #%R$,$0UQ*J1Z3E_;7\W/84)9G6GTK"50[:-[CB>1 M/L+<*<#<"R@GYE!.I@0K))PVCBH(!2*8"RDP PH+5DME8^W%0L>-4Z#5N:,E/[!5UX&@0>T75CGAD+DYFF,5<46]\.*HU4 Z MPE%J*7*I?:[(,3J.MP9WL5E4]!Q'PF/13R0UDAI)C:1&4B.ID=18]!-W.):$ MQ!T^T1T^F?C<57^4=:,!' F/A$?"(^&1\$CXL1'^:AOLF!M:[IK-:%\:7U> MY)SGUFFMY=AE\)H!RF?!:T,I-11@F#I,7>H$ML 11JF0G$+V3-73-HH&IE]Z M,9)]@%'L&K)I>0N*6HN:UCX(^SWT:P>V-S[XFXF,-ZQ:E"=1GAR,/.&LFN4B MN6$:0$JTI42F2AI(D1&:BU08*G=;GA'ER0MSIQBA49X\7\_QEU'F29B^7\NU MRP4_]YLYZ+07B.MV>OF'B3<<(O##,B*()7 -K^<6Y)_CX:AS\U"+"_DV3]KA MV'QH3\Y-,OR>W0^3[_[P).UL,.CDUXG'@E'XHC\$8M_R8=(I?UM].KGV(&\';KA.LJ%G\4'N2?NW M?_7-'[]ATA\D7?]0Y<_5A?ETEJ3^O7"AZ2*_F=31[2 O'ZWGEW_MRR1W_IW; M89+WPL.O?9E9FYY27D]Z]8"UK]#E7_)V-QL..S<>I IP[5U?97\NB1);FB9_O[)1FCPC3>A,FK!7 M#@:#9WA%JB2>F[K^'TO2Y>VG+)S3K$"#[;,O!&BN/X@F*;2 $Z I$4XRP<(L M8),RJ4"ZHMGLBGW_$=GW]>S[#-?2LQ<+5=<0"2733X65A]]N(2-'_5)N%J(P M?#HG(SU7CYX0OJMPP6V"J56@(L M59IH1PQ$UFGM .=DI>1\>L O>H^>?W^J/P_R4307MPQ*9ZNAK$.2G[CR;*0I MY09JH T7%# A$$8X#8%4)+C2*SV)-F/ *!7K8<#'A&*=!E]GLM+^'T$Y"G]U MQP$B.X\X38QT $[^_?YH%S<9:DZNZC_/$^N.S4.L]XW!B2(F2U0!3(&H59-/'J8T"^16VJY0%Q>)^WPR)V'UIODVV!V;8L MW)IF.(;0J:?";\QH(D/\LV=^K;S8^S.L8TGQUR+4.7&&E&\M+^O-H']7&M?9 M9F*H;N,O^=X9W4[VNN?/=#+ZGG?_R*?2W5.Z9\+CJJKOIYS4^77=CSP''+NR83HUX+ F.:X M72Q;;3=6%Y:M 18!&=B6\BS*E^'K/W5&_MKM\IWOY6-\[7>O_45-Z Z5#^ZS MP>@A,8/\NC-* B\UBY02]Z8J]%W6RXHD#X_Y_J"$?H0EZ <8:\\3U"X)&GB" M0CI)^,'UC,\]$,X8/?GZD'0[=YV1IR3)VFT/:2$S9_YJ'7]'#Z-9$I*,[L.M M[K)_>LOGIM/+>NT@1\+U.J-Q*7X"B/EWID?"_RJ[SFP](/B^_WQR N]7ECTY'[2M6H8R/-+VN]]ZX?WOV;#CK?, M_*H-"L_XH@T2)&C'+\1P(O?F%FDB"E?(]@+%0YFW]<:#X*"_*Z[I#]',[3JY M=C$+AO^\L,Y^=WK#\JQY"@9Y,AQ__:<75>&Z[7XWB.E!$,.#I!^NG0QS+X0[ M?ONRP2#X>8L=*M>JN&, QR#X[@?]/SK#XJJ%#+S.[[WIEXSO)YE#RX^TM):% M "R68_[]Q+.61\RELQP@(]RVTQMGI3%?O%WF7RT?D=5>F>^>/T(UG ^$EAZX M^/-V,+W(O2?KP]=!GOW^(;OQC_13UOV>/0S]K?YR.YA0\]PC;J'_YR-H]/'\ MROWUBTH^?4S=I?GHSHV[3/YV\=O/@YQ=7 M_DFO+I+?SM5O]N.5L_YISZT[ORS_=7GQZ:-5X>WTX[DZ-Q_5I^3RRK_QJSN_ MNDS>SW[V8_)^PF?Y]7++^BFM"WRWQ)B%+G/E:;[,NWEQY#Z %*B48(& A!0( MK(&@ABN:(FF<__L#*?6-XIYJ].:?TQ>XNS&R+F0!)_\]C155"D\RI_$T6>[= M>D5]3J?/NH7I\HQ0FRC2GW(O6Q(T1>JYD-EMQR/OH'W[X/&]G8V'?F&^#O/! M'X7LZ_3NO:0I #O[(^MTBS>], GP'010L)V\R"HN.?;/XL_6W?0>CS]0(9 6 MDC(G7U\TSLIM D[?V/-P/"]3VTGCP>\@)O?=B(6O?!A%8)I'> MC[]ZAO!/6E$Q^>Y#)^_ZFXP'7DH7]PO/$LB8/5BX8_G4TTWP!F90+X=Q=RZ>=.T,?>Y=0D MO[A)I\K1M+WF+!,_@(SN]MN_OWL$LG2J'8<<*F$5Q98HJ3"'% KK)!+0?@!5 M40"GQF+)M4XME09I;AU!J:$P3-G2_NES;QCN\%YC^Z93I8>., M_8TZ%F"4QE0R=L3_EZ_G*]8*QV%\0)!&4- M\,0&R;O=R:?_]0Z\*U[[QVQ/7S]"X57GSG/.>?X]^=+WUM+RTW[O7(]N?Y+R M3 #"!*<_3&LD"FW\?IC_-/W'S\L5$>]F36YF1>+RW=,M<,H[,?'#S],O+7\& MU_L(UW[%C6^VUT:H3U>NB+>BEFA^*ZL:0/E5_0_X2_T/%HJ25JN+UEF+)_=U MQ7Q9:V>?UXL+Z;!1=ZLMK,A+W%'_BGSJMR<.I5ZB)_+SLB@Y>KML>>(6_V_O(?!.AS?K^&M?.*!?CKQL_Y2K[K=F'0%])[.7 MM>IU8-O0)=]*?OA!<;GK4%Y0^*Y^\E3D@^!'"FE>V? V"A6^>]\T+_V2E$X085GJ\96E8WM41PQ M+6):S9A&JR9VS!@D%4Z%%)0:B201E#AM$92((0KKP;2%!KT1TYX=-WX,F%:K MX=Y!2$Y?2=*4CT2&K MCF\M8FT$[I(6 Z+.SN=/\7-C]P<)0[0%<*T#?1H'0^MX+0\O='.>CY*JM<+Z\9MCPMYCCU;&O3P> M6J,!&S7'D]<<&9OS$P)%D,92$NB518HE-S#T-*6KR- MA[ZG;[&U#]>DYK*:)JB8%2+%@AMH*398&BB@,%R9% .F5P;E[L)W6-@,T7*N MV7*6+@/A"YW.\/V?R75_')K6 M;M+J[,G57*\YWCX+>5Y#U>WSEB2=^QK:^48Q')2[N_DGD M?,:VOK$%9O,RPSC@;!9&@1P(8JG&W$&JN%-,09A2)*1EDCCPQC#*U#_SL&Z* M:B<;C/YG8OP\4?(YYP,ZUD:8"+4P(L>0QA71+:+;CM%-TBJ!QW(H%;..&DZ= M,AI@ICS840"4U/JM>:_/H-OK*L@ MMT)[M+7^A%/,I'$"(">8E$ )?H3:Y$$VVH0M6FN10/-Z?$0P.E$PPF0&1E1# MK2201GD#%Q$MD=92<2IEZK3CY/B4O\,$(U!K-F/CH.BXXM)ENZ$8>CZ5<&7< MR^.A-8:>8^@Y!A]CZ#GN?@P]GYQP/]I&'QS-3324#E#%@#." >H04\)B@D!J MC(6&DYT[X!::?9Q :(.+%J!U5DXWUH,6L>$@L(%7S;VU=@QY/, (0.HT4MPX MA&B*TM10:G;N#SLU;,"B15&<B,)]XJ ')*HO.0:6Q@U[EXHI*G"K@ M()1*<>(E;!\0T2NTZT*!"B_,XKR7BSO'A#I[+MP",$&929KF15%@C))/: M*2LY%MS9MS:7;91*=Y"X0UN$@*.&G3C"]%2MY&,/C\6]/!Y:HX4:-<6H*8K* M0D4IHP"D%&KA* =:*NM "G&*12I(6J/SK_D6ZHFT IV2,.DP599((J +=7<$4H&EW9)* MWP@1 (L.";4&>%YL@]W(;M=[@8=5?(P#!R)X-A\\:54EMG0"/"DN$5XK5&JP\3.0LO^RRCS3SI[O_AS[G%"/.C#M/LW M C]L&G1Z'*R*9TC:>;<[.5G_]0Z\*U[[;[6GKQ^YR57GSFO*Y_GWY$O_+NO] MG*P2OVA&?.][^Q:KX]UKEZ>X_P)^@O*F:YSM\?TS9M SS\#O M1^]^>0]_]*L]OE]#3(3+OT#P'+_^ZF#9J]L\,?T[_[.'I-W-AL/. M3:>PDZ: X^VD,/FM: L\5XT9S"=_IC],>P1_S8;>IO)(./(7;(<"J"!ZAT5; MX78PMT;]Y&N>='K%#ZZ3[YW1;:?\]DV_Z[_J-R^!J%RY._^4M\.SET[2_<@^N@TRY?!_#N],99"8C%U\H?+N/"W'.W\^"9 M>8E/:J !X24"BC]O!].+W&??\@]?!WGV^X?LQC_23UGW>_8P#.?\=C"AYI6L M/*%I&];_Q_,K]]'&^ M2.S^'_S\XLH_Z=5%\MNY^LU^O'+6/^VY=>>7Y;\N+SY]M"J\G7X\5^?FH_J4 M7%[Y-WYUYU>7R?O9SWY,WD_X++_^\;$M7>:[!49=5#!L:9W]XVK%W+MLW^;7 MX^Z"FO*(6_!C[W+D%8[PWL5-VNEEO78GZW[V.GI0('KM_,K?2W?[[=_?%>I4 M>'F9=_-"9_A N&(*&2R,@]0A*8USRH'42<4=3O$',-.XF';2(JD83"75'"I& M_:\UYRE#)K7P79)[[>4^G*W!.']74#U_'!^Y.TB!2@D6"$A(01C))ZCABJ;( M/X?_^P-]X5 NZ;'+@5[Q.$#5A.\5P-X/\F'8DP)W\YL;3U[2OYE'^TZU<4O. MLAFH3]UF$[#/VNU2?H0;^'6\#OTF0MB@5VA?Q<^'TYT/=^O?YV4BC+_#>!!^ M%2XS9<\W4CCQHTXTO.5,&\_,(NQ!9"@^+=TRKP1&-F/\PIS(N?P6<^>NZSVC_:Z)VY9KU.F5?ZL+\^E)Q-S)4^7?.KU>D+G] MF[T^R-_'V@H9>WV<5:2*A_,D#V?Y=X-.R=1)>9W<#/IW>S\DWF(>]??Z%"X;!(E^HCDK M)W]"B>CH.O M1?LKT1KR7;;"V=JVOO\8G.#]\3#K72^K1F_;VH:,VJYK8:X*E_NOII-L! YA0F M& K5G/L1_WV[[?]KE>GA^Y?XZ>*IU&MSW^73X+ M^#S:)65*ZF0>XMM*',.C^/=>: 2,6A").HH=7\OP%3YM<@3J.=&/Q3Y.UJ:/ M4'WH4,TJJ+: IH@Y1#E U @J3.H48)H J01)W3)4EV-6^W?W@_S60TV!G@&? M FC.0V(^0]+939-T*MW?97]^>[1(JR_7]D(]/L">MR2O)9!LA'F(\Q' MF-\KS(LYF$\IUQ!R 0"A@*4"":F(H H!*P5.-X;Y%8 /E=,1XIL(\;3%8=3D M(\1'B#]TB/=H7O6QLPQ3H1@T4"LJ-512<>ZXY%Z/-X^TIGZETP5'H-Z?TP6T ML(C:>(3JVF($30\1Y.59JBV3I+%!D5>/G'BY0?D&PGHW0NP%&8:KV:I>9 '+ M:>I-$TTQ@@*DR@G$G%,IM53M)G"PXW[AC1)JA>%WWN]-VMB$JX4?K27CGK5! M!,'',,/UV(/4QX% +ZG1%,S%+AE$D O#-:0& 8FU18I:!:C1$AZ$0SP"6#T M]AHEG;50/5,4E@[1H6OB$?@. ?AX!7S<")NBU #-'45&:8HT0I!X&"1(HI4A MJ$US$4?0VQWHT1:FM:AO$?0BZ.W:WI25O\C]4$@B&<^"&6%,@ J MYIRDW$E)7*JT5-P AY@$1QGSWLF,[+6RN*LRAA2OI\2<>WCXNI'M.06OY#8GZ602L M1@ 6KP +42HX!5QJA:GB4J8:"9HB Z12$+&CC$V?#.R(%F<\PLY!P,[A!Z1G M]35E3/I@.ODW::,71YK@^S^3Z_XXS&/=9*;)DZLYN5LQ_75E>DH32VE?6IU- M:FW76XQ=^E4PX%52F4/"BVDF)).4A4+<5*8IILY88"5=\:N\V:%;HP2Z?>"R%ZXHFJWQW?C;KCD4V91_9X'3EJ U9E9OSF+OLEGL<\3O%;I[,;+ MLQGROV&]HEB(8N$PQ *JQ(+6C @O&)!5E%K-M$H9\=8=(5A#P5?B?#MVMV\N M5.H$?P1;1-9B'T7PC^ ?P3^"_Q[ GU3@GP*A(.4TM?YCSK2 V$L# *4V$DBQ M.?BO'WUH%O"+EF RXG[$_8C[$?9F&NOC*5*.9", >HE@N)(( >8H) ( MM8K[;P[BG(8O2+ 6DR"*A9V)A9-S\A\[X<:!S%#&>5''3E_!S V,56WRU+L,*M&Y86XXU&=S;;!0AFK&M;(:LU0ZJC51$J\35((RCE?> MWZ0?@EN0U3GH9ZTH50,#48IZWA%A=USL6,&!PQ^!0Q^ 4(1G,03+% EJ9"&EW,VE%0 M.\A8BAV$2-$=9L5&^-TB_#Y7Z(%C%7S$T(BA;]1C206BAA !32I"F3&U""KD M'$).IEJ35.JURHT#&D8HW-N =MZ"@D5--*)HH[W'-<(4P# :@F5 NK&3/6>BGE )#WUQ+R-]!T%?C*J_V7NP#?.A"4Y4,3?8#ENJH%,$ 6>HLD!HZ2 UCB"1 M0BC6S?]J=E#]9.9$D1:H9_QF]'\V#<]/&\$XK-*"I() $".<8U0)H[320CI. M"%.8R#1&Q$\7_R!O05Q++FP$P B 30+ N90@R:$Q'%MH%*>.(AW&K[-4&HM3 M9:V*UN$N7S M;< J-7I\N*HL3J.S>[-FHBO$5\CO@HYUYA7IQ0A!Q1"5E)#G;2:R11PPIF' M6+Y2Q[%#/WXSL!6T$*DUF!>Q-6)KQ-;#Q=;GW0T2S/7KA5YEE9)HQ+2@1AD) ML-0I8 9B"%R*-@X4G(:[ 8L60W6VN8WNAJ/V\1X)?8URUM^6LVN+#.RF5#EF4P.N>/6] M9*.OWO[W5]!9-^NU\W*-.KWR;W5A/BVNUZZ?*O_6Z?7\VB3]F[T^R#_R;-!0 M:(PG8[M;K^[ZX]ZH7*(]\W?_6\U^XGN+%7A]G%:;B MX3S)PUG^W:!3,@E%YM?)S:!_M_=#DG1ZH_Y>G\)E@R#.GVCF%(_KD1_79FJ9 MKG?M]__]A+1K?]\3#K72^K1D>WM8_0?][IY(AWRME ME_G]J$@?2#!H)0B$/MH;R>UC%P1'0%_BT1C;%5E!&L;)"*T< T)PIJM:= M(T[>UC-NODW>A(QZ/-B5U:_/0"&W!>BJ#E]CZT">?';KDB"C:+!0E%8H: M+"VU"J.4 4J,%!83:H"22EK+W>9=A]_6#0:!O^-_O+7S<,3@^C"8T18#=58& M1PR.&!PQ>!6#687!3B&.#2&< J_'IEJFR&C %&;:.2)7--DM=HR)^+MG_(6@ MA7F=8X$C_D;\C?B[BK]"S/#7,DR%8M! K:C4T"N_G#LNN1+$D)2LXTD(0!I1 M='\HZF%4U-E/-\+H\<+H_ES/DVGH<.!Z4T2G85QM=YO]CEBA96TW&DEA%?'H7; 8YMABC% *-MU(_*U7!\1 M">M!PMNZT<,/4X,I7/-QJUQ'*9<&0FITD1RQ!S4*E48 MD31E37<=1_S<'7[R%L$TXF?$SV/'SQ?@D\^9TX!(8R#2#&'*4R:T3C'DB@H+ MC4OY;CR_$02W;DZ3ED0D&M1'"F:[ ["=^T>+\S$9/YJ\G_B+?VSU\E%M&=H' M6)YWGH^2:G9R/35Z1WL.CH>^N)?'0U_[ ;9A/C3! M#6*812@ZA56G!.)!8ILX 3M8=8M[LJ+K7H2L5NA&^@"G-ZTP] M>V'@)*IUF&\T_IL"Z"<-80*R"L(,Y "G2A&): JTA(AISBAE@AM%5W)88S#] M= "0MB! $?\B_AT;_N$JDD,!TMH8B2W"%!DBG;%&&F&0LE)#'0/AIXE]K$59 M#/Q$[#LZ[*,5]B%*!:> 2ZTP55S*5"-!4V2 5,KK@4<9Q3X9!!,MSF(N^+$B MV!&'KF=53F7TNFG=^!NUT0O31_#]G\EU?_RUFV\T?F1RT?"-U7DF#2P=?O4B MU$[S+K-WA00SP2U3[C2&4A!MJ0%"2\N](#=..*0<62O];,'O7*,$G,F^\L;! M=.KW@LA>N*)JM\=WXVZXY%,65OV)K9BT. %U9K:^EA/?E.&ZS_.X5OKK-D!I M=>7>L"P1LB-D[P&R):P@&W,K)/6@+32@V&,V21WW)I>FF*5(RSW[V3<'_%J; MB>$6E+5X7R(P1V".P!R!>0F8<07,3$.7:LU#QQZJ+=)<"J.!LY!!2DVZQP! MLT 9PA8B$90C*$=0CJ"\#5"FL.JL!K!4*0>2,4 %)HHC@1Q@@D(BE%@KL6XA M,G$:#@[!6DQ&!T?LA79:])W"L-Z[?C&L-W]T6"^4^N)>1OH.@[U0:&NQM6._& MV?*[C"^]M,?-KFF! +*JH%EH(2%3T$J-J ! (ZT@WXM>C0'#Z_-D(\;O1R-'+1E[8D2HCE#=1)T$H2XE88Z0(42C N,M"%*0;XC1WZC4$VT2<>@6_[L]IIB\!: M)A-/@**Q?I.(8(> 8',=QFQJK+$":@]K%$HE%6940,*82S&MH5W-EKV]$;VV MCEZRA7DM<;X(7A&\-C<=\5RS+8FUH(1!:H2EE M!O 69(J>-A$(RKX%$J&( ,>TX==HJ8"2'4FLJ+*!F M/>=%T^/>QS65Z74]SNL HV;Y]]?*'NX\*ZY^H%6(O2&-^.L-40V.*H4K*0A) A89A E&FH:0J9 M(JD42@BG48QOGR9D\19"-")61*QF():L$ M2;I@W_Y@)8TFTDYI(*R!7Q#*9 MKF;D'$5,^V1P!XH6!S&;YC" 9^?T-7G$[M&Z6_CV+Y@@4&(H"(4*28.Y3JE-)5)26+RQ1_5F M\^6)$\NB6(AB85$LD$HL2"8P=-Q(1B65#@CC;3DE%'+*<8=7Q,*.7><-FSZ) M6H+5XIF)Z!_1/Z)_1/_=N_,HJ\!?2\H@QH(8B:BE6FH.K.;,*",H8'J/ 8C= M ?]S>"];E-72#&!C0*OEE.V^55D$\ C@$ 04RDET8AI03UL2X"E M3@$S$$/@TI40\IL#,J?AU<&BQ5 M22)1L3_I].B3);P(U?QEE'D>G[Y?BY;A M3V3 ITYOG$V.9'E&SSW"##KM!7I#[=Z'VW),,43@ARUI/L4?68'*0X0, Y)1 MY'1*"0/*0 >!YDIHH9&4_@)_R>9^^.2CSAW+?XZ'H\[-P^9/7[Q<'-O\V/XU MX+'D6?)_%O9UQ3Y H+ /EN69[0S;W?YP/,@O;H*D\&*BX),BF)]?F_YP-+R\ MS0:YSH;Y]>?LH8C]7_DKZZZ7A.^*70PO+_-N7H#^!\51B@DF*:* D,E20G2 MJ=]C:; 1X$-5XJ\$@U11Y/_G%$NKK?-O8 *%X3QUH)2MGG>]>!R]^3[P79)[ M,78?0'LPSM_]N//)_@]$;++Q<1^.T(=\6PH>GGP MRLGH"*QYRW>_M!*O$R6!T[/>0W*;!7'C^3CIWQ>I*ZTD!-0]#WC>GWR2?<\& MU_Z#>R\+@@+4:^>33X+ZY#]H3Y)F%KZ?9+WKU6N%7TR_T!^/AB/_+;]+25$Y MO>XZON"WP 1 DA,BJT@FQ]!2S(60D#)HO?[+D(2*<8P=T#.O12<;C'ZJ#O\\ M/*C!(.M]*Y11_;""#RI0Z ^3W[:+F\_=K#=<]5?,\&BFA-[[+\YKH1_/TYD: M"A:TSP_#O!TTT.]>:QOFO7>_C+[W7](]W[RH27B>8+5[#GW\LN&!R ?RZ"^#BW=;D"L4%_$$IH.*/ MO/M0/L_DZ\723N]UEKQ>*NT-,"[G#UO2&0X]($ZX/]!5$)1\S8LN"_F?^:#= M&0:-* F:6#*\][QQT_&_\&>QTP^'\EO>RP=9M_N0?.^,;CN]K6+1PC&;RMG% M4T:K$68.*X",IH8#1P6R@A C-2#0&*V46ZT 6_>@%7_\MX<:OWV?BX6!3QZW M_QD.1O_S)5RQL!G#JU^S/SMWX[LE6[.XZ-7#?;Y@6[J[^V[_(<^+;;PH=G%J M2RX?S^OQ8'8\;_KC0?*09X/ADY)VW4-Z,^C?%:QS'48#>F'TS:_7*#R-?W'3 M:7LSO3A#^>3)/<^$EYMQRZM8@;WT8NA/SK7XZP[8PO;&7C,Z0^VR1?^6!5LL1VN6.6(ZPE-)4M4 MV)'_>>\_V2XWD+E96\QKMP)IS5/*G55&<)%"; %T!,*58JMBJ[^^S U?E[G! M!;**+Y>\L XK!!U@MKW;Y(5".FT;)$I6>,E"+MXNS=9E23HG%8,0SP<_OZ": MUR S$5EZX.+/V\'T(O?9M_S#UT&>_?XA"^&AG[+N]^QA&"SGV\&$FE>:J!.: MMF&A?CR_^3=^ M=>=7E\G[V<]^3-[/C,!EGU_E%YGCNQH,S\9:C@4X!TQ>$LS%4=VF$C?L_+D^ MD(SZ^U8P>34?AC/KQ887&<9JBKQN:01QP/^!)78,@3W)D>>TRQ?DS%3G&'I. M,/E@E'5Z[L^\/0ZFS\5$F]NF#!KEO6U)H!7MHUW2%ZRK^>X**.Y]7QUW]Z3@]H.B^?:');^C!)AAON-"ARL-]9;7M_#']G]_:#OI87G MP_519@HA__F\-U16O2\$"A/EH54:$(H8$_Y/[?4G :@0S*V,69O)EI*U'\>4 M\WY1\)B7R#&\ZH^R[OSG(:YRWA_](_?PT>Y_Z_GG7Q:K'TM$65_2/1G=IS.W M*GN^5.-L-74K\8O?]?_8&'@\IX["JOC'',R6P*] M4;^11!(@S(2%=!D/%G4 M19]]@57#?/)UOQO%U*GVY#=?\V3N^H5TRY)2P\^O/V3^M3>?)F(N/%2M7/BL M()-5%@KS;W*J#%-84^F8Q%0Q;A3"J620LIWQ8"GI-5*FU*1I44?&!=?U:2D3,?370CO\^)*R M/@<0PW"YX>MB+RN9/T2TJ.#UAU\6SGBIE?@#[!EEJO1N4]#UO,1>_]'O_#NW MPR3WBL+U0;_3=9(E4M4?&C] J5^ M??X[+,]KX,CK*_YJQ5WG,0F]$I$@/GNYPG2-<+#7',H=/6R314W2#V[F'0.E M'1.LM,]S5EKQ;N.)???+YQ7C]-'LBTGB1>7)N/4GV7_M7^/.L.,/\=18G?@\ MMFU,O:PB4CS7ZTKH%!G.M+24RM0H2(45F"DG3 @@U>OK^#)=E(F&N:;3H_#J MS>U.P5"J=[WD!"E9V_1$_6ZW3W:OQ/RJ,_)D+H#P+9RMGJ>U_Y;\]N^SD=^7E M&F3^4T+FAB2GWBRTV%"F*!-$A\P01T1J 2.2':CYOXZG^WM_BX;_C$^FQN16 M/0!$5"Y&DJ:I(T R(2C50 $ #1$4$,L$L*M#L->5W66&X5R3MJ("Z.HVZ[W- M-[ AZ&SD3T"HY9>F?OW]*6D:5,6M,L),7>@Z#GJ@OV('W MB%< Y1 1&CC&N:/4*J0PX- 8X$U.@1@@^P*H]?U*F^O/F_BB"#D#+Y;%KA&U MWUQFO<03E?:"J0#&JRO6NI1*P@6&"&ONC26$O/1Z/%_UD'GB9:FV*5?@,RRW MXZ$L *6H8KJ?EHPTWUWY[I=Y[=PO93^YRSJ]D!\5L#&9VCL3-^7G\:!]ZYEG MM7[&77[^/*V':27?;SOMV\3;U8,7I]B^X-=Z&U3+X.FJ#V:6(S!J N)IW\$-\_7A^0N#RDPP8RL MBO"3^^QAT.]V/9]5-RE( 7^3N^5< MF25M5CXXXHE4IQQJH#1TOC3RI! EFL&Z:LK:U_!%-O(NX5@W9K6SZ'7 M0=$BK0"0S][0'>0COY\%^.2]_,:O:%7X^FPQ*U0&22 -I2FE5'GC#6!,4$H- M@HP".U?,RI7'26VT5?Z[@#LEG.466R X0QK99VM 7[S/2C'K%W?U\4N19)Q\ M_J3.+S%2X<>VWN>^E1X]_YP%_F^A"@-4SBG:'5=#%*=]C- M1*F?+%Y 3LA_?FGIIK\J??$;J2+!*%C4[6K*Q=EY+EL>3:A+ E.6$5.G8 MSEOQQ!AAB IE/4 ZI)A'@)0*+42Z4N]GRT6>X%$097ZG/D\V:O)N\-$]KL7\ M?3EBNI:7%VXSPVN;2NID]>=JFAFW4 ,%F2:4,(_"C"&EO=&B"$-FM>_!1JN_ M$J]>:_7Q(ZN_\:I/=F])!2P4CO:L8= T)-5[&AOZQ&M?J9*4Q^D% MFX>:5A$N[_3:W7%X2J]*E4A2SJA(WD_BW=X\"^#3*='%,T;1\8ZNKV2$%H+;$T:U(>/VA9&H&FH8O^32.H-#2GQ*4N$@%Y9J;B3D1*]D M0&VV^G7)I1?'09V\BB?G&F5 Q@P%J;*642Z4$AJD-C6:8JXD6>G&^49]H[Y3 M! M2"D<]]EPF(? [=;=3Q16T*FADY!2KZY02/T!5BH% M%&*#BV::DK]\CF=QL[)GFRJH>#PIL0[G!SY#!PRA%)(YSY]C5B&')"*4(B&9 M\%B*$"9>05'N%1#ZRJ7W8$KJ6'IPMAJ3KF_IFY5AO!DKV+P]_S"P5APM5;9" M09N#C8G>MF@&EH [27WM]*;AR-%@7-2\QB5_)G7)+*Z57\GI3(V0LS-,/N5^ M,Q(T%51S*3NW'2^8!NW;R4XM9N/!TA3CWN%2$PB]# M]Y=)$K9G_=%XT"L"VK,D[HFD++OQA3,0TJ_O!YV0.S7H#'\/T?N;3C=OOF)0 MO@Q?_ZDS\M=N%ZQ\DP\&GL[Y1)@B:V%MF#_[;9 EGSHW^66[D_?:GB^>IGDA4V.^2^I9\MM"$Y'6(R'9 M1:[UC/40^';RH_LRB:CDNNS/\I;^%^/[#3HVO93<6ZH!I*KSUDX!)03D"#NJ MJ17:.4N!(B2%2$.ST%9W50AS5GV;2FQ MJ;2RD-\O #_X/S&X'"**$XM]6HS(%@")1F"4BF6,L37W:U^;SR<)I[,GX#=;QX$J_9R M+;OW-="89'?]<1!08>=*\V^67]7.AK<+Q3P;M";>$=[9*O'[IC,8CI)_C?V^ MYX50#;I0:PZ*[K,PF*)SGXU*83W#+2]!OP5?6K^")L_FBPMQ==L9EA\/EBN> M.L,%%>_&:P0!]_Q75]HL%:M>J1PSW:)496#(0PN93:4*\:)>W/>'^11C MBQMT)E54!0S_[D5[1;]7.\J^A< V^KC91:DI1Q2E7PDPK% ML$D%150+HAXQZXN-7(#][3M2X".NZ+I"#&?)Q9/4E&769S_DM7? MS,1S%WM=5FN#^O'2I0=>HQ_O)$=7(NUJ/O/+(X$*Z;;?TI]_B67Y0^_-ZW3U[UR)\?$,0(08:3 ME*?040>%%$S"HJN%Y$XR,Y=3+16V@ENN4R0HE$ "K) PQ!\5D6IAGLVI?O$^ M*SG5GYRZ]#RBSFWRQ7TJ>.&S^G+UCZ3\8-,4Z]<\T";TO+;;\R.*]);2L;L% M-R39]5VGURE<4)T_\I9707KC&[^_A=9=.$7SH(\6NLQ""UO_I9GRU@L]-VX[ M[6[1+&/0'W^[G8:.@G0*=TJR;X.\5'L7*[YOO>+0ZWO=OE?HD=/':I;?]"SY M-3SKBH8X>=J)$"W=>G)_. %=98$/V(AH(M$^KPWZ=8Z' U_+(M IUNP/$BITN(+U;?01+SZ M4O1DN.X$?;5HG=+W5OYDJYYXJK.WCEC;17W*NU]^#5D1$W9\6-Z2+3DM&(8H M)V0N!99":QG4"A)#G2#202P H$2FV@KD%IP6CP'S="C3%V_B?,^ZD[JZUV1F M#LI?_$_9 FO-.4W]$!JO6U?U3'G7'^2S=FN%W>H?MD2 R12APK I66U"R=P4 MHF3T>8U% M8[;TN4^OZ$_OL-_+OGHBINY3?[DI^8MP.,B_C;O9((P^"59?-BI4^L5E*<;D MW.:]ZB[/WZ$UC89CIZ$U^M^L8R3]_>Z7UB_0(MZ-"_%13.;RGPV\#/UW06&[=+KX!?C:'PSZWPL0#L&, MA?!/IU<>DL+]\4?6Z18SKB:L-\/#N^!0+_S:12FY7[YI[&?JJKH/@K,W6K#< M)[^?"H/MN=[JU!B*7D#+LGR21K)Y;LYVJXPV"G;6GZBS31=)*8]8%?*@2'M% MG#$62L--&O[IB+(*N#3UKU9&4"P*(U=N\#;K B Y8X>993)9ZRI@P127 %HO M]SF@U@GEA",I)<8HGJ9R)?GXE6M=7X*>7^O5C)[:4HT7$]#*TNZ):-DZPU=E M9BGT2\:5DM(1Z@U3Z0TPX]\A5(F4LY5>SF]C^+FN%$7I^&>OQCU<#;+>L'RN MH7Z8_V0V9$7=W'BM(+SOO/$X>JBM"QS88HY6*TBT:7^WX"I_>$H"+,NP-[DI M"E6X=,&JWO6G2H$JU>.K('J?]58XY\UM+!&2R%"_U]HJZYAC!%+G;6\]YZU@ M5FIH!<. 8^JM=6F80UH0QS'DQ3R217=#XQQ#7B"-[^^[,QTFZY;M:&[S(I&S MTEKF^O(M;5K3(@;%9(E01]/M]K\/?WJ[-O2(ZO.DDW+N>@OSZ,'T]QVO?O3* MU_,W[(6%[2[<$H)R''TQ$=[KV]WNY-/"R JO/2'MZ>M'UN2J<^7.M,4:7[,J5L2]G] MZJ]:80A95")0,]A6?_JW3P0H$&A $" $45WM$A##&?;^[>'LH=LOAY=-QH/9 M%\-B0,4WW[N=\15<#8OQ)1XO#3\4^N[-*/\T^V.)!..(A_#_1=?:N-3_YQU] M-]_B?OKK=,#E*Q3^R\^SBQ9_P^J)WZJ?'GCVMWQ8N""FPROYZ.=[^T(6F&K^ M\Y3OYK\JUX:4&S.WU[&,P"60UZ>K;@?VMPX^?,@),EN#NY4E[YZ>ZW37IC/! M-S^2(@0[F14FKF^>.:ZI)JY>NE+J84_VX[K]W"JN3"Y?LO:? MT6O5[WR8%G5NM_/\\K*AH[E-WNDB[8*&WI]$0WTPB8WH1BW00]I 5'.>BYFC MNAW/_PL#?_$!LA, M51""ZO&3UP,XQ[ @:\(#VEM\*&S,_" M2 L(L%N1<+ MQ?\^C";9^#;&'L78U%A6\::LN[A4ZM!.NKVXG$\4YXY87L0'J&>*]=M9(K02GF-F@+1.<*)9:X^12 M99M7Y-'_G&[A\SSZD=7'HH_N_O[S[B$I"?NF+^^=2\2YU3KUS"!-,**26+Y4 ^9)R>RGS/09 M>&F:@K5%[?F)Q"VZ:MK60P?6ZTOQ94+>A"3JHO6_-)KYT6KFCP# 7&8FMY0Z M[\" 1I0CHI37R&*'I.;"!OI,4,E. 6!1-:\# ,CS411UDLH;08:_%N>@L^]K ML2D6+*671Q6X;'25@KZS:B0!98($;((+1/* M2+(DGMM9MZ]V%21-L\9BI39M@BS6#+1HJ M::CD'I540G#O/7YOE8ZVO$A[1F#WXG4>"L5I:*JAJ;IIZM#"NZ(YF]QDL.C1 M*IO5MEE,WYLK+52E5,[E)3YW8O$<$1X PQWZ_(YF+X_')WWG0ZT\-Z/DERW:O[ M_O=I3<25:@HLIJ55/G+Z3&G#EI9U'I/M7[#+,2NL#9B\<3"9JUC"'4(VI:E4 MGE#)76R6Y$7L(LZE-3JL"R:Q%'YM8"+4LSV2WC28[)6_]C4BY_9!4=WAO(]I MKD>YQ_OI*]T"HGT^^^.N#.^76'&H=$3D/]I76?]K61NF=A?$T>I6ASSQ9OKT)KRNTZ#^ ML-OZPA1K+$#9C+,99S/.9IS-.(]NG$L)\WO??D9LWG[FJ2$V762>'/CIJW61 MJ:&_2&P04EN3ESM]^K$TR+D, M*!F")EXIR8+D*/Z%I'=>X>!4X%X^V2GEV?1)+OE]/KA=* MNT][ AYJ_=655O0-92355$T5DVOFROCLGWYCAD)PDK MNP_OGA923V(E]=U5VVBH8+^HX.*J.VQHX,AI(':?V?>HJ5T1 <9;"*-YR\D[ M;SV"9H.SX31"*FJ#168,XITSPX(KEVE#KLV/SUCUAG\N'R.;$/C8LI8_FP:.9R"J\K:N7$4BGS#6VZ#Y3+6?>T M3;*#CMO=*VQZZR?U#3KM&)W47-]2*REAL6\9IIQ):BG'3 2$N$N1=.*5T:FP M NK&)MJ2;">5O!IX:N"I@:>7PA, PQT\(4R5L2X081471ED?/**IIM9XCLW6 ME:=:T$;AP\Z(/+1R"[#U^!4*?N\)]V%5U3I4*48!& \)S86B&G.I-$VQMY(\ MT"YC)>[SD_P4YG;Q/>]]RW\;Q/J ^V2X$%TGL^ZM!G @OX8F)%6O6LHDCFF+(-UP8\.->\*-7%2B,7"''$*. M>L\9MHIBS(S61@BEK%S/;EZ9&^MA+H[X(3#7,1T8D'WJ.K(G7"GG^KL9[X7W MA FD.0M44VZ"ESX@DJ;>N76Y,AJ(%]\'AZNG[I]1N5?,O*^R]!#965="5FOD M4LM=8*GGQFE#C$RUL81;)81>ZC>Q"W;>FJ9+FA.SAI\/CY\IKM+*J7?,$2FL MQX)[DAHM4DY3ZQ7\Q^.U_4E/\G--NC)I"E&],1\N/5I#E=)*AG+0?;5CEE') M.;%.<^V$I"&U@5G#^$8\=S7,\\-5BO=65AZ32'S#7,@KR6<9YZD.E&"-N+/2 M!N$05ZE56(D0-I-\:W/A=G19U)*JSO"*A@T;-MR$#645BXFQ"AA)HC6V( >Q M,I(*)#CW3C"GUO;:/L.&=7 5;B&I#H&KCLE=RQI[<(D==245@S>$,RV8TH(K MR4P(!BFMO$R%QV8CJ9@.)GL5$-WX:QO_SB'R,\.5>/5441H$5MZD7""E6*I9 M-#T-0T1:_2K\O!4E5[=TP\\-/Q\B/],J.0 I@UGJ.)9*<&*MLEX8*600*49> MK!UR]#0_UV.#$GW8(?Z'YK"]@._SHBS2ICRYA63H/6%-7HE:JJWF&"Q8XA / ME!A'>,I"*J3%P@=SKQWZDWQY,;#Y[UFW8^+:[Z/FC%N,U"IKGR&0O16Y1R59 M#Y>+925@F3:&:C+2K0DK_4$M6'B_6?B M-\RDNLI!\UYS9I$4-% >M#+:.R$<#I1ZI@+="I/6P7.JA6OMQ;?_NNY;=QD7 M!6\>*2JX,4A2 ,G.8!)KZ&TB11]=X_6Z1+]JKNQSZ[-),NUZR[%3E.-SN7X< MIRF22J5$!NXTTRDFJ:0&K'V24KKVT=@^61*D)52M499KT\_K\DKC\VN M '2 M.H%T+D\3IS$X71HPZQ1/M8)/J<0!XR"$,FRI7JR)1%M@+0!T@9( M&R"M%4CG4FP1HI)@ZH+!GA/N+5$:R,YYQ+'T=NWHD.V=.C'4HJK.AG.'AHN' M=F@52>Y3C\8;5? ]=!AS _)J]/)SY;=6;/0?##Z#W?LA< M@2M?MQ#$4V*(L4IS;+ B1!J%C0Y.2Q7PBV3N'_U.=]0N;)-.^-&&2\UU_+2] M4FNZA32N7_Z^=/OV1HP>AC]\J8W\IN7RC];Z.N")-[O?[/YQ1FR*N8"2@#V8 MQH@Z+"RG'AF-"%#6:H@]8@\G(+? M]L0B:7'<9/>^)=/TUT$<4CZ\;LS3QD!IS--F]QOS]!%Q/%?0$:<>4\>P"81P MZZUV0:4J8)N:E#!$5Q3'IX-^>\L26:F6K+7>QI[:J7\MFFK/OJ_EV??:V+^H M?;M8H.OX>1OMV\N/\?)/W3$\NUU^<[]19:3J:2/[[(ZL7]S,OER/^>?SRM_DY MI],IGWWOYQU[ZP;#F\&PV.K_NAJ,\O.K;)A? 4W!%,TPOQC"CHR*7RPLP&6W M#8\&I?&DW^Y-.GE:S*\,U1N=74[7>Y0"4N5#WQT"Y0T64T9\B7K_N/#_G +G M? #U[<4PZX_*A1C9V_E?BCC!&$!H+B]A"O'[ (0ZOET*%01T++ZHD)3< >D' M\B22/I#V]9<%&'WQ+B>#N-;)EUL@HW:UWLGWN*S):&[%$_@S&1=KWIK^_&5^ MV8%.BW5/REO]?_X\B6/X\2FY@P]O=&Z#:T7C0_K-\29+U M.\4*P)^=Z19]3"*[%/;!]%'M>PZT[.LPSV-$4J3V\14(AJ]7R1G<"6\O-0F* M6PELK$Z (V!YLC[@1R^!B>;QB=G-S7#P U9XG,.H-V27?WN&7VAU0,RH-Q)K M2X@.7#H+@)=28!J.N7:$^GO\8HHQ?X8QGET6.&=FL]X]!2\J OR.?L63Y(L^ M+@>Z)K"H/?AC8S(&]2:YS;,IM3Q&(3#@ 5#>X%NW P3[OOL34'T] #D5TDO[ M76EL7E-L$-?!.\D#1@;^E-8 /F+.1"KO[??935R>BT'X,<[[G6+'8Y;;8A.+ M!W;[]^$ UF)\>S[Y\B_@GXO!V=!\R[J]J)P ]MW7 ZOPYK3[K7A#^>+B1\#H M[J!SUL]+"JB;GN8HY<,H;W_J3(9Q P'FEA2?#8GC0WQN @21?P>^'Q0SC*^? MQZ5D/$CR8K&+;TO"*<3K5NF#H;D@3,Y 1)_ MOAGFUUW0XUJ%!'O?CXHO%]\'!XDOKX0GNG+8&\P81\8J&UL0,VVP%%XS+ UBFJ9O 4^V11P+>$+9 M8WBB7QE//BY[!.Y9P/^[^#HKR&"DM7!,$HS!Z.+(*RV#\XY+8A#EH%Y&$SI; MPS!6"X9Q_%R/Y^"^GP"3CU/7WWT:?X3J%@GX8@B$ TQ^'NV)Z%ZP/?CCW0/> MAE2F8*W2U'"EN1.I8BFHXDX& 0JXE/1#)94%)YJY0#7QB'M82NO!MD4L5M>D M0;J2)V _\HX9O_@]8!3GH#O?1'?5<)*_^^7B;^WT>)K]C! MY[TJ*[Q_8T+8CH?$%';CVEQVGM^,"_Z>&H"HT!K0!EP+.+[VW3YOSP^F0!:L MUWY<*R($V.+?XS];MD:%B;[^&R/RY=O_=1"W8P$5EKM2I?C7@?+ J6< M.*XP,Q9)+3A8B:FC6*@-5AOK_V#UK#;9YFJ7XRK$X71NI9\H&4S&HS'L1721 M?N^.KPJ_U6B\$5P\X[N9;D_EZE3<@@*%-/Q"N A28[#:J+(8P%5IM\KV_&?6 M6R-_;N6MH?SCKT*3MD^^8LJ+]\H(K0U M0>LH"5AJM9+<$:,1:*">+84"W=L1T_[O27<(VE(Y#P?3 %V_0*M'[8O[FU1= M_I /'3TM(>1']6S,[#XRA,15+[_4:\\98:"3M-0844\>Y0UAROA29O/[R M1P:I=_GQQ^>S>M=0B$!4W$2=]UO>NUTPF9Y2;[=P1'S63V;J7H)+34\5"EOR M99 -.Y%/9P<;BTH6L,VG@EFE#/%-8!"LLYL$ME3DJR._SW7!_'PZ^ M#K-KS,J,-WZ?"B-+J/Q@L:3Q ? RJ3T[3504CX1^73]%J$XR/G'6U"RE4 M*C#E <5-.?LDZ_4&WT=/;&H\%Y[I0C;XO^6 M#Y^[?48XI868_[CI#HN3NHI((\A^?,&A^7;"*+;\1E\>J<=E[L/C$]B-\=4H MR?N=? /@KMO*;-VC@VH7MVQWZ#G10BFA02$)QAZG(%F05EXPEPJBK61+2:L+ M/-TIU[GTW3UH@#PHTS>R09Y-4JW#!CF!*0"_/LC0238J B]FS)__B P*U%8J M9H\Q8\FJL\V>C+N] MZW"]]S'6.4]E;[H!4+F%N9*JZD,P0I9ZQ";DFM!KQN MYWEGE +FN$&_",WZTLM]_F6%(^@8XAM/\./5%[MW]N/"TVH[;\8(;1GK M^_DX(GFQ+E,POHJJ^&5>P,V=-+B;7W*>][N#87(Z& -A%4<$>7LRSHOKENAE M/.??CN32O8NQV#J=S!TC!"=#P$(S)CB58/D*SY$1A*0<:;0$"6O1R=.EMQP\ M(^OV?Y^NRW"T<";P*M0E/R[;$;715D%+[7+:RN=4=)U5L*M+&>*8-]TIS M$JRQ'/- 0DI3YG&Z=-JW'I\2F#S"'^!?BNIA5_2 4E8WNW;RJ&MV8]3T9#3S M*GP;]";7^8#PR[EY/#9&XR9>3\00><2<:GGKX MS%?Z'68$"W038^IB &]6.M%'$Q"20#.]_%O>*TRD=C:ZFN;$E*&^T9H:W$P_ MCEIS'%OH2.6Y\LW410I"*D9>Q92(''39P6T>PSJ+9P[SXO"D*']:!!!G\31E MU)T^%IBDVX'1P9\Y;/;@NMLNICX-\X*O2B ?%=^6KRT6:)4HK]TS_%U<64 V M!?5,ZA PIXB95*=$!6(QX\%@LN]Q90FF@*!KQ92=] &J\XOLA^^.HBT-1/MD M9!FH1$@Q'1 .F@>G#,98&V)2@BAE@G[NRWD%R8_R^?LJ[TQZ47>]O"P/&^^H(R;F?(X\WRZB36/,; QY?9)4."42!V,YQ#-Y#" $#QD62S MC:0K1A;.$BUK4B(N!_% K5"GX@94N3X9R(GKZ^CM6E+&\MEVPCT_BBC<3YLH M/W-7WTLU1[-@R2Z(NG[Y>?YQ_2CB>_<6!J,R][R<"]A5O>FOQ3E[_ S#;,\^ M/[!6%]UKF'O,&/T\N,Z6DO._=SOCJT^*?Z2@W@O"_S(KT]F&9=P. _N4!5 MT)_EVJE44JRLY\IJ2[&U+A6&,J70].,_E M[Y^&#X+F8H89(9@1 M(2WCC*16"V00XO&XU&F[%"VW"7Q@_5+X6"5(#CT0(]? R$K$\M-:.+)3=EI> MU1ZS#S!6B]PA+3P3AQ*<\YL7#/UI183&6LC@WK5>'^4=M.@Q[/CJI M 9]&AVG0HW8=9JZ0B=2>\=C&@B#**67&IP%KXSGH-3R$I>SI3768E\''*CH, M_<@;&*E1A]E2]>X5$\]K+)KT2 GQA0B8Y:+BLQL7A[WL[GHFJ*.&.1"Y,('B MWZMA%5+Q-?_P99AG?W[(+F%(G[+>]^QV%$_*KX;3V:RX\DLNO/HBSDY.+\+? M/IODUY,TG+N3<.K">?+WLU_]R>G?SA-W]OGWL\_FXN3L="V2V>+ 3\\N8*07 M9\D?I^8/?W(1/(SVU(?3\_*O\[-?3[R)7Z.R!T7 M,0/W,MCOG0>_9J6SC>J:;;6@6:D'*'*@KM#-DUAJ*&'SC!*FQ($[DG[:>!<6 M*MDDZ7Z#12N9%BOM%I&5G2$,N\I2O@+DC3']4^@K^P? ]_^:#+NC3K<]S6FZ M[OXH\@=*H,QZ@ZJPV]:*\1?T.%<,P4CKI276H5BRG4IIG6 "UH88JBE;ZJ93 MD>&]H%_?'=T,RG2 LTL;LX/RT4IPL&[N!]MFE;.R+\66R:"J=<"(#U3!+\K$,NR(*H^9H!@'Y@322W7] M'B$#=Y7UOP)4^>EZP05F!+,9Q83BX@H3HY2S?ON1DF?_,5%5:87?);-]83&MZ>78(>$XJLE=NTVX]C,_W. M2;\SB;_"TL$7+ZN=L)HINT7Z+;N3C"OZ&^81GF*)[I(&TV'>;U\EWV:[4E9C MBC/]F-Q![P,(6F_!H$TKP9;@^CT;37$X]EXID+@?N2=>T 7EM'V7>/HY_Q*- M^?G\PBK5>#3IC8NB#]MF.XFJ>H)!.T^E1ZD*DDE#>> 1?9W1#/Y#5F6[TT'< MG4F[J(L1\XO[H_QS/LJS8?L*:-G'_+#!S<,]4Z9*0EEOI&!64Z5V595(IFL' MK#+,;O+)&#!KKDE1;;5%^$,%)6OCBY/?/_^O[/KF9U]D+/=C48"RN$Q69"H6 MI-0?C)-J,4NC!0#]9@*372Y+OA>NCE>U_/Y]NS;?^8T7MWM+\Z.*L\(#AX M@0Q#*8[M.@UWUCNF#+&($JO14CG(+>G@_SA>'7Q>!>\^KX&7UT==?=Y54O#; MU.[=8DGX*?E4GA/,T]C%T#,,N,984(A8(!\FG/3*\J7"7H^0#WSA %JZX]'4 MK_$@E> =^D?.OW='HS3OQ/ZZ\<+.=>DP*8:;7I@:JY5^7&Z272.*5^B<7);3 M*8CE*A[ 9T6389CJ^'_R80]TP!D81?*Z[()\CB5MY@L5_?<$6!'0KL34WR)[ M)[/&-H_4F+O_WG:QS0NOK8%DGZ987K65P(X2E&K)2.!8*8>90$"Q7 MO0>:O MZO*%+_Y>+N'C2N?>TFK[ZO(>K8J52PYMCU+=W],9]5T#77[)DTFL@!WCJV(1 MASSZM8I^>S=%=;%6),%(E4!)H%.QEY3*>N7N5OM:>/QJZO^9UL[H5!I?Y=B( M9;'[0$C#_"8;#XL&>PEL2JP3-57U+DMB3D:3+Z )3EM$9X4R=%L8 9W8DS<^ M$QX/=%I4-(1;^M_R$3SM8W(>ZSJ5K_H^F/0Z<^Y-((IL#*_],BDK8P"JS5X7 M;8;82[HL 1)OCKC2&P!9WQ_^]ZN\7]:.NAMW,:K(,/'!<0BFK"ZUO#QS->!F MREZEX-VMR10L1WGUBG(F<75A#K&,(US72[+]ZG9V'\ [@[RDAPSL[-BQ>UK< MM9^7\J0B@14I()OJN#-E^+YJ[,[^\\1_P#J!EW? -FBOP]';9=^S_E3B$7F_ M%DE)AN!Y3\7C>_+#O"AED]L/.\/8G@G1B8\GMG/H?S^.=/A:B- M+H=9R>5>]GVZ#[-KJN+?L\K0UIJQL+-_ #^U[6M2RG>#>6N??!8*^R;WE$9QA_][+;SJ(*.]W5_D*U MG7DFO$]HLWBAXHDPPNYX:OV!5)O$4YFRY/KWI)=_[8YZ66DU#?.OD]ZLL%N< M:3O6C(/5@UNS<2%#ID.9JA\MV&L@UM9T68 %^]G4"5$LY-1T7ZGUYBL3XC-U MVYA@DBL*&CCQW((VXN!_J3#<>"$<\OM>MPVS=.4-,&HP)U3Y2I;$F MF*24R@!_H[!48>VUV>7=+\5R%"#6*1>D:$1-*745B %>K3UM(Z^J-+Q;GU32JTAC085FJVOI13; =+ <_KAYOK? M/;\ N>\SW=H6OS^)_NG!9)25;3M^Q#Y<FP(/VTH6XZZ#-0A04BST;WVX!3=8J=KC]>H8-_#3P\[;@YVGTF4O004(H&K#6 M(@1.C3,N4*:,2V6 [_!22MD**LS3Z;:KJC ,MS!;SM5J5)@&0QH,V0,,D16& M:$>(4XIR80R7G!M/A/>4:H6I\W2IPL0*&DP]&$)92ZGE++I#PI #.A)Y]\M_ M%>4BWM:5&8YNRRB_D=GU=H6ITVK>"?*;5F+,Q5K M45)G@?6]%>('(*L/GZWT7)T\QPAB*9->&\)6K&(K0ZB31 !OQ0+[*5=!$"V5#ISBE/HE[W$-TJH^MN(M M3NMLUK7'5MAKN'2VL !/1:+-&VN-T^<0G3Y:XLIQC @WVJ426QVSNCUVF.*@ ML$DU ,^2/'\PSWS%,_#9/?,H0^Y !CW30H(V7N3&B]P REX>A&M=58<(-/4J M14Y)R7GJP/!F@K 4Q^JPSM'E=C6K(^$,V@#[6;I:&LS[88MU\]MM)L&41I$ MV0=$H16B&.&-5X@(SBWG 2L2@C96>DR-2\7:#=U(\IRX\-#0I2]2BR> M%NTB^*:6:F5O)MUDA_,^IKDV>WSXI1[? QI@L7'5=/^_?,51S=- M_#]:\^F0)][L?K/[S>X?Y\2;W3^HB/C7*BJPEP[!-^/W(T=9(V!OSPC>.J(U M#+YO80N8''<"_^%$)#38T&!#S<+_*+/K&^'?,/BQ,/A1IK[O_WG]JWHT9LV\ M:FH[]O9=/#M RZ<1P[^ZW/!GE[0E; MW6]VO]G]_?#6XOV5_N?C0?O/9' 3=;11 EIB GK?>-AM1Q?N*/ZXH4*^TY[! M.U7801>O'$R!8Y%Z;W3PW&IL.$XQH=R$ ";QLN/VI-\>YM=Y?YSU7.$?+U5U M,X:E_S(99U]Z^<5@5G8A[_R>W<:+S7"8];\6]ZT4F;V!%L](K=W;GB&"QG3> M ]/Y@#F55ZY@SE@0 3F.)>&$&$6(])%9A?(:N:6(R&UPZF;^X?_)AX-.-KJ* MVUX:Q6$Q(@((9B0J=.[$KFU.;@.,43MJJ%3JW/P?@=//4H*ZVWK@;/W"Q:E MX?T]X7U6=2*TUGN-E59""BXQU]PSD0I& S:U([SH#42BB#>\WHOW(]&]1 M<;"6SFE$G6!.^48WH[TKH^#18NKIACXSMQBLT*K:(\RP YL MWL+D7'+#8)FA)3TU:U,=_W2KHVF++C^J12S]4G)=1X+)T6 MR'"AD6*8>F&)TIR$0/S:H-)T5MT.S3:=51LX>F-P]#0:*3Q7,=$33 A"S%C& M%596&$\#9AH9ERJVF8I3=R?$1L5I,*7!E/W$E+D*[(@)IPU/!<64(X^M28-V MBCAA+0]D?4S91G?5.NNP[Q^F%'Z;OQ9!HK/O:WEVN62GDVNXI7UO<*IXS0988-8%EZ\$? M"PS[XO4M$CVWNSMBOI<]80HL0F4MY9PIDP(HIJE0A# R*5>]EO:G96.IE?? MG>42)[7MSC3P.!NOOT?G^" %@97\'*P HEW=%H$H$>O@$9]/4JR7_DPW9WE#]2S23YGL-=_4'AZ"Z( M"?Z FXN([QE!W=W[=./+Y$O>SB:C^.Z\.TSRLHK*]\&DUTFNLF_Q][P/BS;N M?IB-Y&.R+%,BD7;[DZR4P\77)?0O8OX-5?KX;3V3PUQ.4Y;3SHXN-\?]-WOYR< M7H2_?3;)KR=I.'KR=C<#/SV[ M@)%>G"5_G)H__,E%\##:4Q].S\N_SL]^/?$F?IV>G)I3=V)^3?+^[K:?DO=3.LL[B[Z=V5P?H[OG= VUH&NH576-!>(OY,<%W'B>]_("3S]0 M&BC1QEJ;IMSHU#IFG)(F&!6X<^H#*4&^F)<9O_AVN@Y/@)0IQ$*_G2?G4YP& M9/Q<54WX \3+J 0IH(WNN,"G/+F"3EPO//J=C^I_F>#3L7 MMS>Y^=$=_3,^Y)]SBU4^ I:J6JEBH7XKI%1=0GDY*^L1H;R,O2]?_AHHF%;2 M'L1.>UZ;+@3<@ICZ$NNW%?0VDU#?%W.7'JBS#$O7GO3*,5Z"]C0561T@O_C6 M0HI&OCOC8==>5A?I7#1G[+R]XOIX-Q'@G5]H#0WCU MMY)AC,%^"HX*3@Q28$TI!O:53%-%D?A0*??628Z9]@9T?(Z)U!X63E ?#):, M6?PD1#_['K@]!]:_B0K0<)*#P7GVV^^?P]]!!I[\9TA.3N%S2-[_>G9^_M.2 MC7YOIY]GUE4&L\E MTH51Z18MW%Y).^_UIK\6[L#X&8;9GGU^8"TNNM<@-$[S[\GG 8CKQ=%^[W;& M5Y^4^$B)PH3_99;QT(9ER&Y&^:?9'S\O>OK>W051W4618?'N\1BK\DT<7C&[ M:/$W_/A/:JV[UOMIO7>1O9^77NFN5PU;?]R;K%[*\6KUX$>Y3[4LYCY7:' \6Y]Y>1O!,0>D\9Z"!G^^A1A/ M0D0N&9^K@V6XHE2)X#P/02LN@S)$&H.#"FBIPCML>.6@7S$?;JTB&92T**VS M6/O>AH,? , W_+TW:6H%@XLJ]56EQE/OD)>8X;! M'\Q->YS!5TE*([(E<)W1VX>3?=9 0P,-]8I^52$#$D+1@+46(7 :FW,'RI1Q MJ0SP'5[*[EA!]"_E=*S7I 6W<*TI8HWH;_C[./A;H8J_M2/$*46Y,(9+SHTG MPGM*M<+4>9IT8"QW;$S0E*Q>9$<]5C,?($JQ3T+T9]](K+Z@$*0M78DSI4G#<68Q3 M?2 N;KH7;KH5%W$GRG>;?N>BVA=SMRW UF>7%]F/WP?#XH=[[29^S^ QCZ1\ MU6/'$Q#F!U[L\ICSO0^;O9\VLQ6MZLGCX+ E@ELB&5=:*LN"QLY[+K$ '7O/ M^'L+9CQ6+<%WPNB'8]\WR/!6D>%I8. 5,% F$"'8:XXM=SS5V$@7B!3"*,7- MDA:^!X*_'BV?@):/&L'?L/=;9.]G!+^L^#MEA )S.ZMTRJWPECK-*&$$.%VE M4NP9?[_0BE])\,N6%CNIOO)V!/]!'?*[J]B!,"9K3OK#')[]/WDGB:?]"3!& M!^[YEL4Z *-645@@IDMF/S8$C3>,#;HR^J74"'F4"APP5TYIX1'2REE/L#)X M9:,@.N1<-KI* =[_GG>^YG_+NOWXI8GE"3[G[5XV&G4O81EG> &H4(]EOPH MZ):0NCF_.TS__A&PK)[STU&+8X4E3KQ5/-#4*,T8]9@QYPD8]J_!LELPUJ6L ML]%KP[ -P^Z48>F<8UVRE+M@,0Z&IY99[K'0J0@D%1H[\UHRMF8EF^J6PJSA MV89GWRK/SE7.\Z#].D>IHF7ZAKN2LC6S+.$M>21\NQQ M'(S_'HD1"+W7S;YT>]WQ[=QI>(W&\ %ZT+3"=VA@)#$!*TP$<=P:9["BFB)F M E%"VZ40],?0P.>7W7[>L7D?_AC_WLOZH_TY!=?-R5CC.G\QXS^3 /DF@>%) M7, (5<"@!&CR/!5%CW9%B&)**L0$#O#1B:4^S;L#ABU8Y!S7:9&O33G-6=I> M \);9/BG-0$,4K8Z3#-6$XJ,UK'BG'>&2!=BR4\A$$JI>UU5H*;H=KV3[B>- M*G!8G'^$J@"K5 %'&%8H6)*FFBNIC7*<,!00T=+!3Z^K"M3L-^"H3J?!VU,% M#NOP_/&JFX6+8.,=I;"CG<$D5LCF447K77TJK+4/NL=PN#0LQ91,:A MU%.1$LT%I@IPT0$I%6S)5?)0D>0IR&W3V\%HB]?;X^VYK7Y=ZFW2_QJ@ M.@:@>LZ24W-U1;@UDCH:/ J@L'FK';+1R\OC,0^G&R'5%MPO3+0XJ=5'N^JF MO\A >UWB/]+3V0;CC@CCGH8XC"J(8YKJP*7P6J=<<6Z4=%0"/BDFL%!+D=\O M5L9JRL/@+5%K(:5&&6N J@&J5P>J9Y0Q, FK3I7*:D*"MH(';I%1+I7,:V*" M%+VVG@KL>K[[#S8!YK-.QJ+])POM\6W@W[>'R=?\O'WV+MS[;Y\/F_/ MMU[%L?7J!MU/-VO66W^I*#")^/YWI!?Z25"&'N M ?>$\-ZV3,((;=@L2;Y[W-D_;9;$7J<'T-M[U_[UAWK5:N7[I'0?P/SVK%S_ MHXK5UBIZQZ#RLAMN5$OR(NO55UFO#54<)55,(PF2:2A!,HL%/P&UI*&)XZ2) M6:&\61&'AAB.F!@N!N.LMV^=7!K=:#M$COEQ-*M9F7C?>FJ7S7I%\_=LG/S? MK#_)AK<)ON]B:")8M\/BCR[6&SQK>&[?W_@9 Y7RSL,J7- I,SI%$G-!L$%< M!Z6EY,YR%99"]\_'@_:?5P [^7 4_GO2'=\N'"V<%$<+[)_3&_YY/LY FP+D M*Z]V,\?FR/SHCNZNFG,NSY*!3_/QO23A,I+WM\)[6&NZKV@)4FL23ZVQ_?MW M7-' 9@.;1PF;NH)-C8OR)5H9%;@SQJ::<(^MBTVYK%TJ7[)]V'PR1:)^U-0M MB>HL'M: 9@.:#6@>'F@R7-5(^X)Y*53X8.QACL*\.>6 M$BJVCWF/!6_5#WM2M!BJLV'4 63-KWF,@/;6XWKV0!3;:[26WC,4/X+2@)CQ MJIXGLS:PD#*-A>"!6LNTLH1K 5=;O-R5\JS=M3E@1[Y8[F\T"UE^48&/M^-N M9*K%2%-VNV'[M\OVLF)[H5B0W@7.@^ "=!I,.4'&[7?L+JNW M>E##\@W+[S)]DLTUQZ#<&X<9YIXBCAG2\/]@S#"$J3'"+9?TV1>.K\'7L\NV M64W"9<.RFTAI/M<=(XC8NDY*!:(9E'.LD?;,,P,,'*R3R]TQZN79FHMS8R*. M4I;6'<2U)9_"O9?@>/U\+M2'XIL:5NC7?#3ZE)AKF.9XE SO"#7O))?#P?5* MF7:-YWD]6#S(JH;/X2F;2\S&6*3"(V,+L)H"@1J M!NUN&7 ^_AV&->@6A483V,Q04:< MUD6E""R##-XM]S'=1RBJT1>8>[@7ZYDL(014$643:5FR"^="6T/11K[Y6TXK [)+P6$FK1+ROUP4Y#N M@^ZG)D2F/D!]R[A)JV)GQ'N34N8$LY)[CXT0AG-,L41,:+URWZRI5V?M9CEO MQZ=4>W?=52EM_[&WP8\-@Z;?0&Z%X!5X<.2)ETAH9 G'7!KF""&!.VL5\G+) M);U_X'%\$3EO+^^B08TW@!K/@(:L0,.!10;P@'T0B&-D-=: (D$'GP8KU'+0 M[MZ!QAL+ZFE*K#=<_TJZ@J[8'@<+]@437J2<.VR5QBHU@5H6M$ AW17;URG. M,6]Q7">K'HA$/\;*3W=%II/%^M*-*_NU&DX<4,;^LWU4#CRE7Y*Y7N_4($T) M9I0YGBIO<1JSOIB74:X@N4YZ:Y0.;\<')42+T5HKH6Q,7V]<9#7(W"!S@\QK M(?-78DNC5L:TP:3 M:W:X;[^99_P^D!S3S!!,>:!!T<%)P8I9[AB"AF9 MIHHB\8&4S */R#MF_.+;Z3K[E Z&15_(M=M,]F%!DVOX]FJ4Y/U.WGGBC.'% M#V\58XOLGO5O[V!F>''#>#E%"=?S8?,[U!8K(;"_..R M6IS MO;@CP4H?O'^;]:O=47JF:MW*93F5!.#/=@WJ=2>:&FHH:XX(5@Z$-@3 MZCF)G7GRT7A>SKX=^B$?EP\@'J&?9;GQIB$9#Z:_S:+F\Y+/ M?RJ[^T8*[TXW<'I)"W!T=!-'\RWOW7Y!*4<^Y@Q7X:S9WXR92=V,EI/AXOQL4%A^3-9M]YU\CF7_.;V(T1_^K M[X[:L &3X=,-O5./1:J-$X&G7&FAB.742*6==LH3.]?06P0MA=4D]2AP!6MK MO&&8L)0'BBA73RH'S[X'+_8#/P]_^RV<7B3FU"=_"V=_^VQ^__N)2TY.T[// MOYF+D[/39<5JGBR>I_15QK3)E,B[UZ>Q=[]%9@E(..F-"RVR"__S93("(BHZX@*NQF_:5]W\ M,AGT.D_BJ;]UQ%[81 MM H8^Z@-NA%(T:+M_J]"!.O0HK MAZO!J)Z!Q(7WWW?UL?*M:VR) EWW1;Y(&.G/+QOJ^M#<@95/SD'AZ6:]\6UR M/AE^C2.9$4[4BGH3H)'D??>G A1.\\DP2O:O^?#V#A):R?>K;OL*[@+" ./S M3?NNT#8<2PN7?$X^ K6?*N0R*N&4PPI00P#N]QX[E.L@]6@EAI03&.B MX)U=UPUIT7A.;;Z8K,(+8P@N)K_UF2 MX1T5SHAPR=Z9[O-J@/M0+Q6$:H?1UQPP@ M0J\&0*5CF$8KF7%$V>D5OHBYQ5FOE=P,.MUL/+PMJ?%;#K\"8<.5@\O+2,@? MG_,D-@A^T A^-AQ?@0+6Z;9+JKLH(?,B;U_U![W!URCFE["\P-=!9&!8G5%$ MVM&?W7YQ__?H8)_B:BOY,@ (CU__:P!XF5QV?TS-F>N;7A91KMLO@&]R SI@ M2>B#[_ 7X,$PORZ4C.E#O@ZSRPC0)>0/OY6/'>?]#CQN <:?I>E]L6N& ), M;L54ICX(^/AU,+R]+S>_92NYFD0)#*KV8#*, MG[L5Y":CVU%L*%\N;/XURK-)OX M6,E"ZH"LZ\_+M]9,(,%OHRN0I1^^9*.\ M4_A&\OZH?&Q[,%I:Y%T< JRURI5U,6>.1)J;+>J#VNX(B"D?13#M%%IN?S N MUB ;%A=&OU!!V>6N?A"U&-C?R27(JTFAH51/G2D?Y:#G#P,Z R"]..G9*Y/9E.X_JR"%XCE/C*B\ M"-9L?&\_9K RW9>U?4?MJ[PSZ>5GET]H'_9V^N.3_B1%0;NA"FLJ)%#*.(.Y<,1ZAKA(.0M"*OC/D\Z79]^SY$^*Q3U&H*24 M:PU =]D=)U]NDSP#)%ZFX()>RH.GA[U,S_N75AGC)E,D+V?HZ;'M])"U@ S0 MS@8EF<=9YL#SXZMA7B)J/#M;7RV[=^BV]F/N3NM*%MOXR&ZS0Y78P6N#5P-H M91&* !*^CSX][MBO#HZ7#HIG)\R+,F,._TL5=@?J#]$+>D+Q[]6P4F:_@O@; MYMF?'T#WR(>?LM[W['84%<^KX70V3PUQ>4[;<+J?G%Z$OWTVR:\G:3AW)^'4 MA?/D[V>_^I/3OYTG[NSS[V>?IP[G5>7U;@9^>G8!([TX2_XX-7_XDXO@8;2G M/IR>EW^=G_UZXDW\.CTY-:?NQ/R:G%_ %]&Q?IZ\O[OMI^3]'1 M!D949RQS M=%>#MMOI=85ED.=MEA4JR&2MT(DI_%(X$4T M\JJ(\7CDYUH+LB(IT%<@A1>LQ-:(8\UZ"X>$ L>[]7C1F&L$Q#Z2QGIA\PUD M-'2Q#WC2F!_;;E6XM1U]?Q)/&@>34=;O''W=ZR/9TI4B MYX_;'R8[S\4PP% MZ;8?6JGIV5<23Y'.XRG2IC+A:--[#WCBS>XWN]_L_G%.O-G]U72%^[-<#&3: M%YW@W2^/QF7O2/'=R]H3FXQ[-Y72R^AK):IB:AH3'6P(-!C/)=;6",<%,C3X M()A;:J#^.?^6]R=Y3&9U@R)"??Q?W?&5FXQ@BC%-.485PJ1-3,,9Y9V+[,?# M$=C_L9T([+4+HE/=HJ3.>A%;)]$C+GK>X,E>X8FJPA:1=!PK(I7!AG/&%<.> M>J=2SQ3'83MX@O7^X0DG+:WJ[.#4X$F#)T>")UI7^HGQU@F1HF ]!UU%6

  • -+@R7'@B<85GBB)B$P5(3)0S@.W MWG -UH[&R)L0Q-;TDSW#$TE%2^%GLTW? I[4>@I3D\NEANFND#BY08KVY.:) MM7HBSEO>C.>@;W+S"*4<=TOQI]&(5N5 D.*$(H&-(8QKK(Q/J4=I8,A*H@3? M%^_+'"T"*9:4.$^(M<$2IJBET?::CKR P/96/SI8%WF#&T_B!N=50VTGN'.2 MXI10KGUJ4ZVD#"053BE&'JA%^#I>EMWA!A$M7&N7O 8W&MPX#-R0505#:B5220(D1#U3.?AVOR>YP0_&6(,>-&X<5T7(Q&!?U^@K"?21^ M]04;6%=GEL-KP+*U6>\2'#&:]RFGB()%1HAEECO,#1'&4Z2-Y12LMJUZ<>K M,HE:A)*=MDIY5;)N#J8:!&L0#-&JMP5FB@M$K8=?N5/.PG]]RK1'B".P$K?I M3ZH%P70+:=X@V*MP^#+$O6!Q&OQK\.^5\&^N!K653%,LI6,IYU9J2VQ0%O-@ M,4),L6WZQ6K /ZUHBY#M>;\/!O\:#:Y!L -",%DA&/*<*>VHM YL4!XAC% 5 M"%+><;7%N.MZ$ RW,"$M1K?G47LS&-8DE2\DE?]>%B-N$@N;M-)F]YO=;W:_ MV?UF]P_O *Y)*7_#*188R^H\S((-XHC'%&G&59K:-"#G@_::6BMCED=%ZWK\>ND76K:0:+*Y MW@#(-E"S=U"CJX,KH[$C&'./B.2>(F,Q"-017+E9-@@C<*.HIX]0B;1A#),6>Z-1QL10\O;):\X^#P1K" M=(OS.D.)&JQIL.98L(966&.8=#BDW@@F>6J,46KX.GMV MEC7"40MO,=#Z+22--"<6JT#* 4*&I)4AA9QF#@5J#>4&,0W*#2 (%0(%ID5X M TZ;W26:H195=98E;2#A;4+"$6H9FE0)"@;C0M$('($]I*U@Q%OI-<&,%=W0 M]][WLKM:&!BUD&YJ8328TF#*(J907&&*L.0O ( .RUJQG MN>S6Q[)#3"$M(>HL9_SV,.6PPFUFT;4W173MADCRA@&!5H"@K)4B**$9V"5I M0!JE*0XN,-# A=&O%;=2!_LRV<*ZZ6YP8 )\=]D\N^5)7O4GH=JD@K(T92"C M%4;:2\]=X)90R56Z5.EN1[Z"6DI=XA;'6_ &[ED^RVX8=G]3CH]!B,JJ 8AR MCOO F;PFUOJ=;CBN&X)U@C1MR%$F^"&_8((756O M92*E%J=$^]3P-#56IDR0U DYH9W#1#!$&LQ?!!=?XXA#?7=+^9Z M '/ZGX)0CO'0[OW37,MPI8D;:9WW(E6<.(Y1JH@FVA&GO&5.+KO@YY?V[/*D M/\[Z7[M?>GG,*!\_;BC7P(6J16L5T\_N;$6P^R!'UFD^W_C##Y6#*9YW>%/D M&$H1\5PAKDP:',7 OUCH!P*87\K!]17TXBW$Q1('_[0%%MY;%?R0.;)^I]:K M;>]:Y6F>V]HW "MSS2@8 S5 ZN!B,XJ@I%5*([#W0Y"@]2];_.LH!O54F2&T M16OU@C>:P9O&H>/6#&2E&>#4.H4Q"C*6Q1/<"D5]\))2Q3C32_7OUM$,:F)A M#,K]?-UMW.F@/W64O-M6!G9':85C) MX0CFHY*_A\OR?,[%%FQ03"*./'4\!:%,N7-4!.](RBA9*N)8]V'W3E@^QJ*@ M>OUS1\/SV^"#MXH)K\KS%]WK?/3/T_S[/S\/KK/'%N59WI]SSE$K"?>,<,-% M/#TWCCOE?6 $(,"8]2J9O.#\3ZAL<5)GH?Y7Y>UGJ:"1Z\86>R(7VD\Z?##?ZZSB# M*H%W&+-TF61'4EHP'R1BN'>8W@V&Q6,EHFC[V,3D= ME%VK;GZ9#.[\I)%(1_':Z^S/?%A$2'6ZHW9O,()[ MNOWBGLMN/^O'&KKW'@Y_)7G6OIH-XN/]Q=_[I<[&XV'WRV2T6^7'Y'\O$%L!5Q2S3PMP# M[VD&:$9,W3ZH-.7G^3?V(T'W[KT HU(S*GFLG?=ZTU__S[NX0_ 9%J0]^_S8 MJ6QRFG]/'CR5_=[MC*\^:?0148T$X7^9P3)@=2^[&>6?9G_\O C"[^X.<>Y. M.+%X]_@93_DJIO_R\[LEV5+^AI_X":UW6_.R=5[V_ G=%H_G'Q?VZJ50JU8_ MG)?[=#C?!G3(AYO.O/ATOXOLQ=4PSY/?X(>K41( A3K)>7XS+HZ_$XI:3116 M0R2_G()(>AF-'"%>/-MG\Q788A?$$3UR1Q['M1];OY[YO$6ZP'IOI1Z AUE.?4U;>ACKX_Z9>S'5\-)K&R\^C8 \F/:5^/(UCX MCWXW>D"+(N>C'5%W4R9DMZ>$FHHJOPD[1+1E'%O.N65:4YA.R=PA*I-X@B :4&E!J0*DV4))51U5'4AHTY9YH MPY5(-7P,WOE86#TE;JGP2VV:TC]V"TI"\Q:6N@&E!I0:4-I+4-(5*"%AI2<< MZT \CV6HL/=8R[7#B:GZ%;7"B M;I%:*QTTG-APXB:IO3:LV+#B)JPH*E:,$E B*W4:*XQSIK5P.#CB=8"/]EM'V.[@&<8607=7'S-D854$ZV%/-K=:6"LRYQ
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end

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

  •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end XML 93 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 94 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 95 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 429 437 1 false 127 0 false 13 false false R1.htm 0001000 - Document - DOCUMENT AND ENTITY INFORMATION Sheet http://integralife.com/role/DocumentAndEntityInformation DOCUMENT AND ENTITY INFORMATION Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME / (LOSS) (UNAUDITED) Sheet http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME / (LOSS) (UNAUDITED) Statements 2 false false R3.htm 1002000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Sheet http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Statements 3 false false R4.htm 1002501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Sheet http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Statements 4 false false R5.htm 1003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 5 false false R6.htm 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDER'S EQUITY (UNAUDITED) Sheet http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDER'S EQUITY (UNAUDITED) Statements 6 false false R7.htm 1004001 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDER'S EQUITY (UNAUDITED) (PARENTHETICAL) Sheet http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnauditedParenthetical CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDER'S EQUITY (UNAUDITED) (PARENTHETICAL) Statements 7 false false R8.htm 2101100 - Disclosure - BASIS OF PRESENTATION Sheet http://integralife.com/role/BasisOfPresentation BASIS OF PRESENTATION Notes 8 false false R9.htm 2102100 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE Sheet http://integralife.com/role/AssetsAndLiabilitiesHeldForSale ASSETS AND LIABILITIES HELD FOR SALE Notes 9 false false R10.htm 2103100 - Disclosure - BUSINESS DEVELOPMENT Sheet http://integralife.com/role/BusinessDevelopment BUSINESS DEVELOPMENT Notes 10 false false R11.htm 2104100 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS Sheet http://integralife.com/role/RevenuesFromContractsWithCustomers REVENUES FROM CONTRACTS WITH CUSTOMERS Notes 11 false false R12.htm 2105100 - Disclosure - INVENTORIES Sheet http://integralife.com/role/Inventories INVENTORIES Notes 12 false false R13.htm 2106100 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Sheet http://integralife.com/role/GoodwillAndOtherIntangibleAssets GOODWILL AND OTHER INTANGIBLE ASSETS Notes 13 false false R14.htm 2107100 - Disclosure - DEBT Sheet http://integralife.com/role/Debt DEBT Notes 14 false false R15.htm 2108100 - Disclosure - DERIVATIVE INSTRUMENTS Sheet http://integralife.com/role/DerivativeInstruments DERIVATIVE INSTRUMENTS Notes 15 false false R16.htm 2109100 - Disclosure - STOCK-BASED COMPENSATION Sheet http://integralife.com/role/StockBasedCompensation STOCK-BASED COMPENSATION Notes 16 false false R17.htm 2110100 - Disclosure - RETIREMENT PLANS Sheet http://integralife.com/role/RetirementPlans RETIREMENT PLANS Notes 17 false false R18.htm 2111100 - Disclosure - LEASES AND RELATED PARTY LEASES Sheet http://integralife.com/role/LeasesAndRelatedPartyLeases LEASES AND RELATED PARTY LEASES Notes 18 false false R19.htm 2112100 - Disclosure - TREASURY STOCK Sheet http://integralife.com/role/TreasuryStock TREASURY STOCK Notes 19 false false R20.htm 2113100 - Disclosure - INCOME TAXES Sheet http://integralife.com/role/IncomeTaxes INCOME TAXES Notes 20 false false R21.htm 2114100 - Disclosure - NET INCOME (LOSS) PER SHARE Sheet http://integralife.com/role/NetIncomeLossPerShare NET INCOME (LOSS) PER SHARE Notes 21 false false R22.htm 2115100 - Disclosure - COMPREHENSIVE INCOME (LOSS) Sheet http://integralife.com/role/ComprehensiveIncomeLoss COMPREHENSIVE INCOME (LOSS) Notes 22 false false R23.htm 2116100 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION Sheet http://integralife.com/role/SegmentAndGeographicInformation SEGMENT AND GEOGRAPHIC INFORMATION Notes 23 false false R24.htm 2117100 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://integralife.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 24 false false R25.htm 2201201 - Disclosure - BASIS OF PRESENTATION (Policies) Sheet http://integralife.com/role/BasisOfPresentationPolicies BASIS OF PRESENTATION (Policies) Policies 25 false false R26.htm 2302301 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE (Tables) Sheet http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleTables ASSETS AND LIABILITIES HELD FOR SALE (Tables) Tables http://integralife.com/role/AssetsAndLiabilitiesHeldForSale 26 false false R27.htm 2303301 - Disclosure - BUSINESS DEVELOPMENT (Tables) Sheet http://integralife.com/role/BusinessDevelopmentTables BUSINESS DEVELOPMENT (Tables) Tables http://integralife.com/role/BusinessDevelopment 27 false false R28.htm 2304301 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables) Sheet http://integralife.com/role/RevenuesFromContractsWithCustomersTables REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables) Tables http://integralife.com/role/RevenuesFromContractsWithCustomers 28 false false R29.htm 2305301 - Disclosure - INVENTORIES (Tables) Sheet http://integralife.com/role/InventoriesTables INVENTORIES (Tables) Tables http://integralife.com/role/Inventories 29 false false R30.htm 2306301 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Sheet http://integralife.com/role/GoodwillAndOtherIntangibleAssetsTables GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Tables http://integralife.com/role/GoodwillAndOtherIntangibleAssets 30 false false R31.htm 2307301 - Disclosure - DEBT (Tables) Sheet http://integralife.com/role/DebtTables DEBT (Tables) Tables http://integralife.com/role/Debt 31 false false R32.htm 2308301 - Disclosure - DERIVATIVE INSTRUMENTS (Tables) Sheet http://integralife.com/role/DerivativeInstrumentsTables DERIVATIVE INSTRUMENTS (Tables) Tables http://integralife.com/role/DerivativeInstruments 32 false false R33.htm 2311301 - Disclosure - LEASES AND RELATED PARTY LEASES (Tables) Sheet http://integralife.com/role/LeasesAndRelatedPartyLeasesTables LEASES AND RELATED PARTY LEASES (Tables) Tables http://integralife.com/role/LeasesAndRelatedPartyLeases 33 false false R34.htm 2313301 - Disclosure - INCOME TAXES (Tables) Sheet http://integralife.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://integralife.com/role/IncomeTaxes 34 false false R35.htm 2314301 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables) Sheet http://integralife.com/role/NetIncomeLossPerShareTables NET INCOME (LOSS) PER SHARE (Tables) Tables http://integralife.com/role/NetIncomeLossPerShare 35 false false R36.htm 2315301 - Disclosure - COMPREHENSIVE INCOME (LOSS) (Tables) Sheet http://integralife.com/role/ComprehensiveIncomeLossTables COMPREHENSIVE INCOME (LOSS) (Tables) Tables http://integralife.com/role/ComprehensiveIncomeLoss 36 false false R37.htm 2316301 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables) Sheet http://integralife.com/role/SegmentAndGeographicInformationTables SEGMENT AND GEOGRAPHIC INFORMATION (Tables) Tables http://integralife.com/role/SegmentAndGeographicInformation 37 false false R38.htm 2317301 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://integralife.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://integralife.com/role/CommitmentsAndContingencies 38 false false R39.htm 2402402 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE - Narrative (Details) Sheet http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleNarrativeDetails ASSETS AND LIABILITIES HELD FOR SALE - Narrative (Details) Details 39 false false R40.htm 2402403 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE - Assets and Liabilities Held For Sale (Details) Sheet http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails ASSETS AND LIABILITIES HELD FOR SALE - Assets and Liabilities Held For Sale (Details) Details 40 false false R41.htm 2403402 - Disclosure - BUSINESS DEVELOPMENT - Business Combination, Narrative (Details) Sheet http://integralife.com/role/BusinessDevelopmentBusinessCombinationNarrativeDetails BUSINESS DEVELOPMENT - Business Combination, Narrative (Details) Details 41 false false R42.htm 2403403 - Disclosure - BUSINESS DEVELOPMENT - Business Combination, Schedule of Purchase Price Allocation (Details) Sheet http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails BUSINESS DEVELOPMENT - Business Combination, Schedule of Purchase Price Allocation (Details) Details 42 false false R43.htm 2403404 - Disclosure - BUSINESS DEVELOPMENT - Asset Acquisition, Narrative (Details) Sheet http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails BUSINESS DEVELOPMENT - Asset Acquisition, Narrative (Details) Details 43 false false R44.htm 2404402 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) Sheet http://integralife.com/role/RevenuesFromContractsWithCustomersNarrativeDetails REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) Details 44 false false R45.htm 2404403 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative, Revenue Remaining Performance Obligation (Details) Sheet http://integralife.com/role/RevenuesFromContractsWithCustomersNarrativeRevenueRemainingPerformanceObligationDetails REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative, Revenue Remaining Performance Obligation (Details) Details 45 false false R46.htm 2404404 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Changes in Contract Assets and Liabilities (Details) Sheet http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfChangesInContractAssetsAndLiabilitiesDetails REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Changes in Contract Assets and Liabilities (Details) Details 46 false false R47.htm 2404405 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Revenues Disaggregated by Major Source (Details) Sheet http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfRevenuesDisaggregatedByMajorSourceDetails REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Revenues Disaggregated by Major Source (Details) Details 47 false false R48.htm 2405402 - Disclosure - INVENTORIES - Schedule of Net Inventories (Details) Sheet http://integralife.com/role/InventoriesScheduleOfNetInventoriesDetails INVENTORIES - Schedule of Net Inventories (Details) Details 48 false false R49.htm 2406402 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details) Sheet http://integralife.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfChangesInCarryingAmountOfGoodwillDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details) Details 49 false false R50.htm 2406403 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Components of Company's Identifiable Intangible Assets (Details) Sheet http://integralife.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfCompanysIdentifiableIntangibleAssetsDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Components of Company's Identifiable Intangible Assets (Details) Details 50 false false R51.htm 2406404 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) Sheet http://integralife.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) Details 51 false false R52.htm 2407402 - Disclosure - DEBT - Narrative (Details) Sheet http://integralife.com/role/DebtNarrativeDetails DEBT - Narrative (Details) Details 52 false false R53.htm 2407403 - Disclosure - DEBT - Maximum Total Leverage Ratio Table (Details) Sheet http://integralife.com/role/DebtMaximumTotalLeverageRatioTableDetails DEBT - Maximum Total Leverage Ratio Table (Details) Details 53 false false R54.htm 2407404 - Disclosure - DEBT - Contractual Maturity Table (Details) Sheet http://integralife.com/role/DebtContractualMaturityTableDetails DEBT - Contractual Maturity Table (Details) Details 54 false false R55.htm 2408402 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Derivatives (Details) Sheet http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails DERIVATIVE INSTRUMENTS - Schedule of Derivatives (Details) Details 55 false false R56.htm 2408403 - Disclosure - DERIVATIVE INSTRUMENTS - Narrative (Details) Sheet http://integralife.com/role/DerivativeInstrumentsNarrativeDetails DERIVATIVE INSTRUMENTS - Narrative (Details) Details 56 false false R57.htm 2408404 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Cross Currency Swap Derivatives (Details) Sheet http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails DERIVATIVE INSTRUMENTS - Schedule of Cross Currency Swap Derivatives (Details) Details 57 false false R58.htm 2408405 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Net Investment Hedges Derivatives (Details) Sheet http://integralife.com/role/DerivativeInstrumentsScheduleOfNetInvestmentHedgesDerivativesDetails DERIVATIVE INSTRUMENTS - Schedule of Net Investment Hedges Derivatives (Details) Details 58 false false R59.htm 2408406 - Disclosure - DERIVATIVE INSTRUMENTS - Fair Value of Derivative Instruments By Balance Sheet Location (Details) Sheet http://integralife.com/role/DerivativeInstrumentsFairValueOfDerivativeInstrumentsByBalanceSheetLocationDetails DERIVATIVE INSTRUMENTS - Fair Value of Derivative Instruments By Balance Sheet Location (Details) Details 59 false false R60.htm 2408407 - Disclosure - DERIVATIVE INSTRUMENTS - Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations (Details) Sheet http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails DERIVATIVE INSTRUMENTS - Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations (Details) Details 60 false false R61.htm 2409401 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) Sheet http://integralife.com/role/StockBasedCompensationNarrativeDetails STOCK-BASED COMPENSATION - Narrative (Details) Details 61 false false R62.htm 2410401 - Disclosure - RETIREMENT PLANS - Narrative (Details) Sheet http://integralife.com/role/RetirementPlansNarrativeDetails RETIREMENT PLANS - Narrative (Details) Details 62 false false R63.htm 2411402 - Disclosure - LEASES AND RELATED PARTY LEASES - Narrative (Details) Sheet http://integralife.com/role/LeasesAndRelatedPartyLeasesNarrativeDetails LEASES AND RELATED PARTY LEASES - Narrative (Details) Details 63 false false R64.htm 2411403 - Disclosure - LEASES AND RELATED PARTY LEASES - Supplemental Balance Sheet Information (Details) Sheet http://integralife.com/role/LeasesAndRelatedPartyLeasesSupplementalBalanceSheetInformationDetails LEASES AND RELATED PARTY LEASES - Supplemental Balance Sheet Information (Details) Details 64 false false R65.htm 2411404 - Disclosure - LEASES AND RELATED PARTY LEASES - Supplemental Cash Flow Information (Details) Sheet http://integralife.com/role/LeasesAndRelatedPartyLeasesSupplementalCashFlowInformationDetails LEASES AND RELATED PARTY LEASES - Supplemental Cash Flow Information (Details) Details 65 false false R66.htm 2411405 - Disclosure - LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases, After Adoption of 842 (Details) Sheet http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases, After Adoption of 842 (Details) Details 66 false false R67.htm 2412401 - Disclosure - TREASURY STOCK - Narrative (Details) Sheet http://integralife.com/role/TreasuryStockNarrativeDetails TREASURY STOCK - Narrative (Details) Details 67 false false R68.htm 2413402 - Disclosure - INCOME TAXES - Summary of Effective Tax Rate (Details) Sheet http://integralife.com/role/IncomeTaxesSummaryOfEffectiveTaxRateDetails INCOME TAXES - Summary of Effective Tax Rate (Details) Details 68 false false R69.htm 2413403 - Disclosure - INCOME TAXES - Narrative (Details) Sheet http://integralife.com/role/IncomeTaxesNarrativeDetails INCOME TAXES - Narrative (Details) Details 69 false false R70.htm 2414402 - Disclosure - NET INCOME (LOSS) PER SHARE - Basic and Diluted Net Income Per Share (Details) Sheet http://integralife.com/role/NetIncomeLossPerShareBasicAndDilutedNetIncomePerShareDetails NET INCOME (LOSS) PER SHARE - Basic and Diluted Net Income Per Share (Details) Details http://integralife.com/role/NetIncomeLossPerShareTables 70 false false R71.htm 2414403 - Disclosure - NET INCOME (LOSS) PER SHARE - Narrative (Details) Sheet http://integralife.com/role/NetIncomeLossPerShareNarrativeDetails NET INCOME (LOSS) PER SHARE - Narrative (Details) Details http://integralife.com/role/NetIncomeLossPerShareTables 71 false false R72.htm 2415402 - Disclosure - COMPREHENSIVE INCOME (LOSS) - Schedule of Comprehensive Income (Details) Sheet http://integralife.com/role/ComprehensiveIncomeLossScheduleOfComprehensiveIncomeDetails COMPREHENSIVE INCOME (LOSS) - Schedule of Comprehensive Income (Details) Details http://integralife.com/role/ComprehensiveIncomeLossTables 72 false false R73.htm 2415403 - Disclosure - COMPREHENSIVE INCOME (LOSS) - Schedule of Changes in Accumulated Other Comprehensive Income by Component (Details) Sheet http://integralife.com/role/ComprehensiveIncomeLossScheduleOfChangesInAccumulatedOtherComprehensiveIncomeByComponentDetails COMPREHENSIVE INCOME (LOSS) - Schedule of Changes in Accumulated Other Comprehensive Income by Component (Details) Details http://integralife.com/role/ComprehensiveIncomeLossTables 73 false false R74.htm 2415404 - Disclosure - COMPREHENSIVE INCOME (LOSS) - Narrative (Details) Sheet http://integralife.com/role/ComprehensiveIncomeLossNarrativeDetails COMPREHENSIVE INCOME (LOSS) - Narrative (Details) Details http://integralife.com/role/ComprehensiveIncomeLossTables 74 false false R75.htm 2416402 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details) Sheet http://integralife.com/role/SegmentAndGeographicInformationNarrativeDetails SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details) Details 75 false false R76.htm 2416403 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Net Sales and Profit by Reportable Segment (Details) Sheet http://integralife.com/role/SegmentAndGeographicInformationNetSalesAndProfitByReportableSegmentDetails SEGMENT AND GEOGRAPHIC INFORMATION - Net Sales and Profit by Reportable Segment (Details) Details 76 false false R77.htm 2416404 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Total Revenue by Major Geographic Area (Details) Sheet http://integralife.com/role/SegmentAndGeographicInformationTotalRevenueByMajorGeographicAreaDetails SEGMENT AND GEOGRAPHIC INFORMATION - Total Revenue by Major Geographic Area (Details) Details 77 false false R78.htm 2417402 - Disclosure - COMMITMENTS AND CONTINGENCIES - Fair Value Contingent Consideration, Balance Information (Details) Sheet http://integralife.com/role/CommitmentsAndContingenciesFairValueContingentConsiderationBalanceInformationDetails COMMITMENTS AND CONTINGENCIES - Fair Value Contingent Consideration, Balance Information (Details) Details 78 false false R79.htm 2417403 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details) Sheet http://integralife.com/role/CommitmentsAndContingenciesNarrativeDetails COMMITMENTS AND CONTINGENCIES - Narrative (Details) Details 79 false false All Reports Book All Reports iart-2020093010q.htm iart-20200930.xsd iart-20200930_cal.xml iart-20200930_def.xml iart-20200930_lab.xml iart-20200930_pre.xml iart-20200930xexx21.htm iart-20200930xexx311.htm iart-20200930xexx312.htm iart-20200930xexx321.htm iart-20200930xexx322.htm http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/country/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true JSON 98 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "iart-2020093010q.htm": { "axisCustom": 2, "axisStandard": 38, "contextCount": 429, "dts": { "calculationLink": { "local": [ "iart-20200930_cal.xml" ] }, "definitionLink": { "local": [ "iart-20200930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "iart-2020093010q.htm" ] }, "labelLink": { "local": [ "iart-20200930_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "iart-20200930_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "iart-20200930.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 670, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 20, "http://integralife.com/20200930": 6, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 31 }, "keyCustom": 52, "keyStandard": 385, "memberCustom": 67, "memberStandard": 59, "nsprefix": "iart", "nsuri": "http://integralife.com/20200930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - DOCUMENT AND ENTITY INFORMATION", "role": "http://integralife.com/role/DocumentAndEntityInformation", "shortName": "DOCUMENT AND ENTITY INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "iart:BusinessCombinationAndAssetAcquisitionDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - BUSINESS DEVELOPMENT", "role": "http://integralife.com/role/BusinessDevelopment", "shortName": "BUSINESS DEVELOPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "iart:BusinessCombinationAndAssetAcquisitionDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS", "role": "http://integralife.com/role/RevenuesFromContractsWithCustomers", "shortName": "REVENUES FROM CONTRACTS WITH CUSTOMERS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - INVENTORIES", "role": "http://integralife.com/role/Inventories", "shortName": "INVENTORIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS", "role": "http://integralife.com/role/GoodwillAndOtherIntangibleAssets", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - DEBT", "role": "http://integralife.com/role/Debt", "shortName": "DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - DERIVATIVE INSTRUMENTS", "role": "http://integralife.com/role/DerivativeInstruments", "shortName": "DERIVATIVE INSTRUMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - STOCK-BASED COMPENSATION", "role": "http://integralife.com/role/StockBasedCompensation", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - RETIREMENT PLANS", "role": "http://integralife.com/role/RetirementPlans", "shortName": "RETIREMENT PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - LEASES AND RELATED PARTY LEASES", "role": "http://integralife.com/role/LeasesAndRelatedPartyLeases", "shortName": "LEASES AND RELATED PARTY LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - TREASURY STOCK", "role": "http://integralife.com/role/TreasuryStock", "shortName": "TREASURY STOCK", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME / (LOSS) (UNAUDITED)", "role": "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME / (LOSS) (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - INCOME TAXES", "role": "http://integralife.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - NET INCOME (LOSS) PER SHARE", "role": "http://integralife.com/role/NetIncomeLossPerShare", "shortName": "NET INCOME (LOSS) PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - COMPREHENSIVE INCOME (LOSS)", "role": "http://integralife.com/role/ComprehensiveIncomeLoss", "shortName": "COMPREHENSIVE INCOME (LOSS)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION", "role": "http://integralife.com/role/SegmentAndGeographicInformation", "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117100 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://integralife.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - BASIS OF PRESENTATION (Policies)", "role": "http://integralife.com/role/BasisOfPresentationPolicies", "shortName": "BASIS OF PRESENTATION (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302301 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE (Tables)", "role": "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleTables", "shortName": "ASSETS AND LIABILITIES HELD FOR SALE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - BUSINESS DEVELOPMENT (Tables)", "role": "http://integralife.com/role/BusinessDevelopmentTables", "shortName": "BUSINESS DEVELOPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)", "role": "http://integralife.com/role/RevenuesFromContractsWithCustomersTables", "shortName": "REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - INVENTORIES (Tables)", "role": "http://integralife.com/role/InventoriesTables", "shortName": "INVENTORIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "role": "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "role": "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsTables", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - DEBT (Tables)", "role": "http://integralife.com/role/DebtTables", "shortName": "DEBT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - DERIVATIVE INSTRUMENTS (Tables)", "role": "http://integralife.com/role/DerivativeInstrumentsTables", "shortName": "DERIVATIVE INSTRUMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "iart:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - LEASES AND RELATED PARTY LEASES (Tables)", "role": "http://integralife.com/role/LeasesAndRelatedPartyLeasesTables", "shortName": "LEASES AND RELATED PARTY LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "iart:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313301 - Disclosure - INCOME TAXES (Tables)", "role": "http://integralife.com/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314301 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables)", "role": "http://integralife.com/role/NetIncomeLossPerShareTables", "shortName": "NET INCOME (LOSS) PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315301 - Disclosure - COMPREHENSIVE INCOME (LOSS) (Tables)", "role": "http://integralife.com/role/ComprehensiveIncomeLossTables", "shortName": "COMPREHENSIVE INCOME (LOSS) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316301 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables)", "role": "http://integralife.com/role/SegmentAndGeographicInformationTables", "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317301 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "role": "http://integralife.com/role/CommitmentsAndContingenciesTables", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q4_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_iart_SmithNephewUSDLimitedMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402402 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE - Narrative (Details)", "role": "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleNarrativeDetails", "shortName": "ASSETS AND LIABILITIES HELD FOR SALE - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q4_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_iart_SmithNephewUSDLimitedMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1002501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)", "role": "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_iart_SmithNephewUSDLimitedMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402403 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE - Assets and Liabilities Held For Sale (Details)", "role": "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails", "shortName": "ASSETS AND LIABILITIES HELD FOR SALE - Assets and Liabilities Held For Sale (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_iart_SmithNephewUSDLimitedMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "D2019Q3Jul29-Jul29_us-gaap_BusinessAcquisitionAxis_iart_ArkisBioSciencesInc.Member", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - BUSINESS DEVELOPMENT - Business Combination, Narrative (Details)", "role": "http://integralife.com/role/BusinessDevelopmentBusinessCombinationNarrativeDetails", "shortName": "BUSINESS DEVELOPMENT - Business Combination, Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "D2019Q3Jul29-Jul29_us-gaap_BusinessAcquisitionAxis_iart_ArkisBioSciencesInc.Member", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - BUSINESS DEVELOPMENT - Business Combination, Schedule of Purchase Price Allocation (Details)", "role": "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails", "shortName": "BUSINESS DEVELOPMENT - Business Combination, Schedule of Purchase Price Allocation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "I2019Q3Jul29_us-gaap_BusinessAcquisitionAxis_iart_ArkisBioSciencesInc.Member", "decimals": "-3", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentInProcess", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403404 - Disclosure - BUSINESS DEVELOPMENT - Asset Acquisition, Narrative (Details)", "role": "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails", "shortName": "BUSINESS DEVELOPMENT - Asset Acquisition, Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "D2019Q3Sep09-Sep09_iart_AssetAcquisitionAxis_iart_ReboundTherapeuticsCorporationMember", "decimals": "-5", "lang": null, "name": "iart:AssetAcquisitionConsiderationTransferred", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "iart:ReturnPolicyIssueOfCreditNumberOfDaysFromShipment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative (Details)", "role": "http://integralife.com/role/RevenuesFromContractsWithCustomersNarrativeDetails", "shortName": "REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "iart:ReturnPolicyIssueOfCreditNumberOfDaysFromShipment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-10-01", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligationPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404403 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative, Revenue Remaining Performance Obligation (Details)", "role": "http://integralife.com/role/RevenuesFromContractsWithCustomersNarrativeRevenueRemainingPerformanceObligationDetails", "shortName": "REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative, Revenue Remaining Performance Obligation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-10-01", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligationPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404404 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Changes in Contract Assets and Liabilities (Details)", "role": "http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfChangesInContractAssetsAndLiabilitiesDetails", "shortName": "REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Changes in Contract Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404405 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Revenues Disaggregated by Major Source (Details)", "role": "http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfRevenuesDisaggregatedByMajorSourceDetails", "shortName": "REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Revenues Disaggregated by Major Source (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3QTD_srt_ProductOrServiceAxis_iart_NeurosurgeryMember_us-gaap_StatementBusinessSegmentsAxis_iart_CodmanSpecialtySurgicalMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - INVENTORIES - Schedule of Net Inventories (Details)", "role": "http://integralife.com/role/InventoriesScheduleOfNetInventoriesDetails", "shortName": "INVENTORIES - Schedule of Net Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details)", "role": "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfChangesInCarryingAmountOfGoodwillDetails", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": "-3", "lang": null, "name": "us-gaap:GoodwillTransfers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "role": "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3", "decimals": "-3", "first": true, "lang": null, "name": "iart:CostOfDefiniteAndIndefiniteLivedIntangibleAssetsGrossExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Components of Company's Identifiable Intangible Assets (Details)", "role": "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfCompanysIdentifiableIntangibleAssetsDetails", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Components of Company's Identifiable Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3", "decimals": "-3", "first": true, "lang": null, "name": "iart:CostOfDefiniteAndIndefiniteLivedIntangibleAssetsGrossExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3QTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406404 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)", "role": "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3QTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SecuredDebtCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - DEBT - Narrative (Details)", "role": "http://integralife.com/role/DebtNarrativeDetails", "shortName": "DEBT - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2018Q4", "decimals": "INF", "lang": null, "name": "iart:TransferorsInterestsInTransferredFinancialAssetsMaximumInvestmentLimit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - DEBT - Maximum Total Leverage Ratio Table (Details)", "role": "http://integralife.com/role/DebtMaximumTotalLeverageRatioTableDetails", "shortName": "DEBT - Maximum Total Leverage Ratio Table (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - DEBT - Contractual Maturity Table (Details)", "role": "http://integralife.com/role/DebtContractualMaturityTableDetails", "shortName": "DEBT - Contractual Maturity Table (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Derivatives (Details)", "role": "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails", "shortName": "DERIVATIVE INSTRUMENTS - Schedule of Derivatives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3_us-gaap_DerivativeInstrumentRiskAxis_iart_InterestRateSwapDesignatedFebruary62017Tranche1Member_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_VariableRateAxis_iart_ThreeMonthUSDLIBORMember", "decimals": "INF", "lang": null, "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3QTD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - DERIVATIVE INSTRUMENTS - Narrative (Details)", "role": "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails", "shortName": "DERIVATIVE INSTRUMENTS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CrossCurrencyInterestRateContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-5", "lang": null, "name": "us-gaap:GainLossOnDerivativeInstrumentsNetPretax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "I2017Q4Oct02_us-gaap_BusinessAcquisitionAxis_iart_CodmanMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CrossCurrencyInterestRateContractMember_us-gaap_PositionAxis_us-gaap_LongMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unitRef": "chf", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Cross Currency Swap Derivatives (Details)", "role": "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails", "shortName": "DERIVATIVE INSTRUMENTS - Schedule of Cross Currency Swap Derivatives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3_us-gaap_BusinessAcquisitionAxis_iart_CodmanMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CrossCurrencyInterestRateContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3_us-gaap_DerivativeInstrumentRiskAxis_iart_CrossCurrencyInterestRateContractOneMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408405 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Net Investment Hedges Derivatives (Details)", "role": "http://integralife.com/role/DerivativeInstrumentsScheduleOfNetInvestmentHedgesDerivativesDetails", "shortName": "DERIVATIVE INSTRUMENTS - Schedule of Net Investment Hedges Derivatives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3_us-gaap_DerivativeInstrumentRiskAxis_iart_CrossCurrencyInterestRateContractOneMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408406 - Disclosure - DERIVATIVE INSTRUMENTS - Fair Value of Derivative Instruments By Balance Sheet Location (Details)", "role": "http://integralife.com/role/DerivativeInstrumentsFairValueOfDerivativeInstrumentsByBalanceSheetLocationDetails", "shortName": "DERIVATIVE INSTRUMENTS - Fair Value of Derivative Instruments By Balance Sheet Location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDER'S EQUITY (UNAUDITED)", "role": "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDER'S EQUITY (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember", "decimals": "-3", "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408407 - Disclosure - DERIVATIVE INSTRUMENTS - Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations (Details)", "role": "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails", "shortName": "DERIVATIVE INSTRUMENTS - Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3QTD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": "INF", "first": true, "lang": null, "name": "iart:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans", "reportCount": 1, "unique": true, "unitRef": "plan", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409401 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)", "role": "http://integralife.com/role/StockBasedCompensationNarrativeDetails", "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": "INF", "first": true, "lang": null, "name": "iart:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans", "reportCount": 1, "unique": true, "unitRef": "plan", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410401 - Disclosure - RETIREMENT PLANS - Narrative (Details)", "role": "http://integralife.com/role/RetirementPlansNarrativeDetails", "shortName": "RETIREMENT PLANS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": "INF", "first": true, "lang": null, "name": "iart:LesseeOperatingLeaseNumberOfRenewalOptions", "reportCount": 1, "unique": true, "unitRef": "renewal_option", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411402 - Disclosure - LEASES AND RELATED PARTY LEASES - Narrative (Details)", "role": "http://integralife.com/role/LeasesAndRelatedPartyLeasesNarrativeDetails", "shortName": "LEASES AND RELATED PARTY LEASES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": "INF", "first": true, "lang": null, "name": "iart:LesseeOperatingLeaseNumberOfRenewalOptions", "reportCount": 1, "unique": true, "unitRef": "renewal_option", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "iart:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411403 - Disclosure - LEASES AND RELATED PARTY LEASES - Supplemental Balance Sheet Information (Details)", "role": "http://integralife.com/role/LeasesAndRelatedPartyLeasesSupplementalBalanceSheetInformationDetails", "shortName": "LEASES AND RELATED PARTY LEASES - Supplemental Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "iart:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "iart:CashFlowLesseeTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - LEASES AND RELATED PARTY LEASES - Supplemental Cash Flow Information (Details)", "role": "http://integralife.com/role/LeasesAndRelatedPartyLeasesSupplementalCashFlowInformationDetails", "shortName": "LEASES AND RELATED PARTY LEASES - Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "iart:CashFlowLesseeTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411405 - Disclosure - LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases, After Adoption of 842 (Details)", "role": "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details", "shortName": "LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases, After Adoption of 842 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:TreasuryStockCommonShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412401 - Disclosure - TREASURY STOCK - Narrative (Details)", "role": "http://integralife.com/role/TreasuryStockNarrativeDetails", "shortName": "TREASURY STOCK - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:TreasuryStockCommonShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3QTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413402 - Disclosure - INCOME TAXES - Summary of Effective Tax Rate (Details)", "role": "http://integralife.com/role/IncomeTaxesSummaryOfEffectiveTaxRateDetails", "shortName": "INCOME TAXES - Summary of Effective Tax Rate (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3QTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413403 - Disclosure - INCOME TAXES - Narrative (Details)", "role": "http://integralife.com/role/IncomeTaxesNarrativeDetails", "shortName": "INCOME TAXES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-5", "lang": null, "name": "us-gaap:IncomeTaxReconciliationDispositionOfBusiness", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1004001 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDER'S EQUITY (UNAUDITED) (PARENTHETICAL)", "role": "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnauditedParenthetical", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDER'S EQUITY (UNAUDITED) (PARENTHETICAL)", "subGroupType": "", "uniqueAnchor": null }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414402 - Disclosure - NET INCOME (LOSS) PER SHARE - Basic and Diluted Net Income Per Share (Details)", "role": "http://integralife.com/role/NetIncomeLossPerShareBasicAndDilutedNetIncomePerShareDetails", "shortName": "NET INCOME (LOSS) PER SHARE - Basic and Diluted Net Income Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-3", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414403 - Disclosure - NET INCOME (LOSS) PER SHARE - Narrative (Details)", "role": "http://integralife.com/role/NetIncomeLossPerShareNarrativeDetails", "shortName": "NET INCOME (LOSS) PER SHARE - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415402 - Disclosure - COMPREHENSIVE INCOME (LOSS) - Schedule of Comprehensive Income (Details)", "role": "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfComprehensiveIncomeDetails", "shortName": "COMPREHENSIVE INCOME (LOSS) - Schedule of Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415403 - Disclosure - COMPREHENSIVE INCOME (LOSS) - Schedule of Changes in Accumulated Other Comprehensive Income by Component (Details)", "role": "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfChangesInAccumulatedOtherComprehensiveIncomeByComponentDetails", "shortName": "COMPREHENSIVE INCOME (LOSS) - Schedule of Changes in Accumulated Other Comprehensive Income by Component (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": "-3", "lang": null, "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415404 - Disclosure - COMPREHENSIVE INCOME (LOSS) - Narrative (Details)", "role": "http://integralife.com/role/ComprehensiveIncomeLossNarrativeDetails", "shortName": "COMPREHENSIVE INCOME (LOSS) - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherExpenseMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember", "decimals": "-5", "lang": null, "name": "us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416402 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)", "role": "http://integralife.com/role/SegmentAndGeographicInformationNarrativeDetails", "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Segment", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416403 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Net Sales and Profit by Reportable Segment (Details)", "role": "http://integralife.com/role/SegmentAndGeographicInformationNetSalesAndProfitByReportableSegmentDetails", "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION - Net Sales and Profit by Reportable Segment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416404 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Total Revenue by Major Geographic Area (Details)", "role": "http://integralife.com/role/SegmentAndGeographicInformationTotalRevenueByMajorGeographicAreaDetails", "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION - Total Revenue by Major Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3QTD_srt_StatementGeographicalAxis_country_US", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2019Q4_us-gaap_BusinessAcquisitionAxis_iart_ArkisBioSciencesInc.Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_iart_ContingentConsiderationLiabilityMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417402 - Disclosure - COMMITMENTS AND CONTINGENCIES - Fair Value Contingent Consideration, Balance Information (Details)", "role": "http://integralife.com/role/CommitmentsAndContingenciesFairValueContingentConsiderationBalanceInformationDetails", "shortName": "COMMITMENTS AND CONTINGENCIES - Fair Value Contingent Consideration, Balance Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2019Q4_us-gaap_BusinessAcquisitionAxis_iart_ArkisBioSciencesInc.Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_iart_ContingentConsiderationLiabilityMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3_us-gaap_BusinessAcquisitionAxis_iart_DermaSciencesMember", "decimals": "INF", "first": true, "lang": null, "name": "iart:BusinessCombinationContingentConsiderationNumberOfLiabilities", "reportCount": 1, "unique": true, "unitRef": "liability", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417403 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)", "role": "http://integralife.com/role/CommitmentsAndContingenciesNarrativeDetails", "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FI2020Q3_us-gaap_BusinessAcquisitionAxis_iart_DermaSciencesMember", "decimals": "INF", "first": true, "lang": null, "name": "iart:BusinessCombinationContingentConsiderationNumberOfLiabilities", "reportCount": 1, "unique": true, "unitRef": "liability", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - BASIS OF PRESENTATION", "role": "http://integralife.com/role/BasisOfPresentation", "shortName": "BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - ASSETS AND LIABILITIES HELD FOR SALE", "role": "http://integralife.com/role/AssetsAndLiabilitiesHeldForSale", "shortName": "ASSETS AND LIABILITIES HELD FOR SALE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "iart-2020093010q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 127, "tag": { "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://integralife.com/role/SegmentAndGeographicInformationTotalRevenueByMajorGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r610" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r611" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity City" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity State" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r609" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current", "terseLabel": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r612" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r612" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r612" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r613" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r612" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r612" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r612" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Smaller Reporting Company" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r612" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r607" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r608" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://integralife.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "iart_AcceleratedShareRepurchasesPercentageOfExpectedTotalRepurchased": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accelerated Share Repurchases, Percentage Of Expected Total Repurchased", "label": "Accelerated Share Repurchases, Percentage Of Expected Total Repurchased", "terseLabel": "Accelerated share repurchases, percentage of expected total repurchased" } } }, "localname": "AcceleratedShareRepurchasesPercentageOfExpectedTotalRepurchased", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/TreasuryStockNarrativeDetails" ], "xbrltype": "percentItemType" }, "iart_AccruedExpensesAndOtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accrued expenses and other current liabilities.", "label": "Accrued Expenses And Other Current Liabilities [Member]", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedExpensesAndOtherCurrentLiabilitiesMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsFairValueOfDerivativeInstrumentsByBalanceSheetLocationDetails" ], "xbrltype": "domainItemType" }, "iart_AcquiredFinitelivedIntangibleAssetsDiscountRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Acquired Finite-lived Intangible Assets, Discount Rate", "label": "Acquired Finite-lived Intangible Assets, Discount Rate", "terseLabel": "Acquired intangible assets, discount rate" } } }, "localname": "AcquiredFinitelivedIntangibleAssetsDiscountRate", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationNarrativeDetails" ], "xbrltype": "percentItemType" }, "iart_AdditionalEPSShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Additional shares included in the basic and diluted calculation from their date of issuance because no further consideration is due related to the issuance of the underlying common shares", "label": "Additional EPS Shares", "terseLabel": "Shares included in computation (in shares)" } } }, "localname": "AdditionalEPSShares", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/NetIncomeLossPerShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "iart_AllOtherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All Other [Member]", "label": "All Other [Member]", "terseLabel": "All other" } } }, "localname": "AllOtherMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "iart_AmortizationOfDebtIssuanceCostsAndDebtRefinancedFees": { "auth_ref": [], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortization Of Debt Issuance Costs And Debt Refinanced Fees", "label": "Amortization Of Debt Issuance Costs And Debt Refinanced Fees", "terseLabel": "Amortization of debt issuance costs and expenses associated with debt refinancing" } } }, "localname": "AmortizationOfDebtIssuanceCostsAndDebtRefinancedFees", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "iart_AnnualRateOfLeaseAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Annual rate of lease agreement.", "label": "Annual Rate Of Lease Agreement", "terseLabel": "Annual rate of lease agreement" } } }, "localname": "AnnualRateOfLeaseAgreement", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_ArkisBioSciencesInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arkis BioSciences Inc. [Member]", "label": "Arkis BioSciences Inc. [Member]", "terseLabel": "Arkis" } } }, "localname": "ArkisBioSciencesInc.Member", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationNarrativeDetails", "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails", "http://integralife.com/role/CommitmentsAndContingenciesFairValueContingentConsiderationBalanceInformationDetails" ], "xbrltype": "domainItemType" }, "iart_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Assets Acquired And Liabilities Assumed, Net", "label": "Asset Acquisition, Assets Acquired And Liabilities Assumed, Net", "terseLabel": "Remaining net assets acquired" } } }, "localname": "AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_AssetAcquisitionAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails", "http://integralife.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "iart_AssetAcquisitionConsiderationTransferred": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Consideration Transferred", "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Upfront payment" } } }, "localname": "AssetAcquisitionConsiderationTransferred", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_AssetAcquisitionDevelopmentMilestonePaymentToBePaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Development Milestone Payment", "label": "Asset Acquisition, Development Milestone Payment To Be Paid", "terseLabel": "Development milestone" } } }, "localname": "AssetAcquisitionDevelopmentMilestonePaymentToBePaid", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_AssetAcquisitionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Asset Acquisition [Axis]", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails", "http://integralife.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_AssetAcquisitionMaximumContingentDevelopmentMilestonePaymentsIfCircumstancesMet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Maximum Contingent Development Milestone Payments", "label": "Asset Acquisition, Maximum Contingent Development Milestone Payments, If Circumstances Met", "terseLabel": "Contingent development milestone payments commitment (up to)" } } }, "localname": "AssetAcquisitionMaximumContingentDevelopmentMilestonePaymentsIfCircumstancesMet", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_AssetAcquisitionMaximumFutureConsiderationTransferredIfCircumstancesMet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Maximum Future Consideration Transferred, If Circumstances Met", "label": "Asset Acquisition, Maximum Future Consideration Transferred, If Circumstances Met", "terseLabel": "Maximum future purchase price, if circumstances met (not to exceed)" } } }, "localname": "AssetAcquisitionMaximumFutureConsiderationTransferredIfCircumstancesMet", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_AssetAcquisitionNumberOfAssetsAcquired": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Number Of Assets Acquired", "label": "Asset Acquisition, Number Of Assets Acquired", "terseLabel": "Number of assets acquired" } } }, "localname": "AssetAcquisitionNumberOfAssetsAcquired", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails" ], "xbrltype": "integerItemType" }, "iart_AssetAcquisitionOptionToAcquirePeriodSubsequentToCommercialSaleIfCircumstancesMet": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Option To Acquire, Period Subsequent To Commercial Sale, If Circumstances Met", "label": "Asset Acquisition, Option To Acquire, Period Subsequent To Commercial Sale, If Circumstances Met", "terseLabel": "Option to acquire, period subsequent to first commercial sale" } } }, "localname": "AssetAcquisitionOptionToAcquirePeriodSubsequentToCommercialSaleIfCircumstancesMet", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails" ], "xbrltype": "durationItemType" }, "iart_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assets And Liabilities, Lessee [Table Text Block]", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Supplemental Balance Sheet Information" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesTables" ], "xbrltype": "textBlockItemType" }, "iart_BioDEarnoutPaymentsandMedihoneyEarnoutPaymentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "BioD Earnout Payments and Medihoney Earnout Payments [Member]", "label": "BioD Earnout Payments and Medihoney Earnout Payments [Member]", "terseLabel": "BioD Earnout Payments and Medihoney Earnout Payments" } } }, "localname": "BioDEarnoutPaymentsandMedihoneyEarnoutPaymentsMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_BusinessCombinationAndAssetAcquisitionDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Combination And Asset Acquisition Disclosure [Text Block]", "label": "Business Combination And Asset Acquisition Disclosure [Text Block]", "terseLabel": "BUSINESS DEVELOPMENT" } } }, "localname": "BusinessCombinationAndAssetAcquisitionDisclosureTextBlock", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/BusinessDevelopment" ], "xbrltype": "textBlockItemType" }, "iart_BusinessCombinationContingentConsiderationNumberOfLiabilities": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Combination, Contingent Consideration, Number Of Liabilities", "label": "Business Combination, Contingent Consideration, Number Of Liabilities", "terseLabel": "Number of contingent liabilities remaining" } } }, "localname": "BusinessCombinationContingentConsiderationNumberOfLiabilities", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accounts Payable, Accrued Expenses And Other Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accounts Payable, Accrued Expenses And Other Liabilities", "terseLabel": "Accounts payable, accrued expenses and other liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredIncludingGoodwill": { "auth_ref": [], "calculation": { "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill", "totalLabel": "Total assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "iart_CashFlowLesseeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash Flow, Lessee [Abstract]", "label": "Cash Flow, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashFlowLesseeAbstract", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "iart_CashFlowLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash Flow, Lessee [Table Text Block]", "label": "Cash Flow, Lessee [Table Text Block]", "terseLabel": "Supplemental Cash Flow Information" } } }, "localname": "CashFlowLesseeTableTextBlock", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesTables" ], "xbrltype": "textBlockItemType" }, "iart_CertainPurchasersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Certain Purchasers [Member]", "label": "Certain Purchasers [Member]", "terseLabel": "Certain Purchasers" } } }, "localname": "CertainPurchasersMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/TreasuryStockNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_ChangeInContractWithCustomerAssetRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Change In Contract With Customer, Asset [Roll Forward]", "label": "Change In Contract With Customer, Asset [Roll Forward]", "terseLabel": "Contract Asset" } } }, "localname": "ChangeInContractWithCustomerAssetRollForward", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfChangesInContractAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "iart_ChangeInContractWithCustomerLiabilityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Change In Contract With Customer, Liability [Roll Forward]", "label": "Change In Contract With Customer, Liability [Roll Forward]", "terseLabel": "Contract Liability" } } }, "localname": "ChangeInContractWithCustomerLiabilityRollForward", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfChangesInContractAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "iart_ChangesInAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Changes In Assets And Liabilities [Abstract]", "label": "Changes In Assets And Liabilities [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "ChangesInAssetsAndLiabilitiesAbstract", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "iart_CodmanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Codman [Member]", "label": "Codman [Member]", "terseLabel": "Codman" } } }, "localname": "CodmanMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_CodmanSpecialtySurgicalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Codman Specialty Surgical [Member]", "label": "Codman Specialty Surgical [Member]", "terseLabel": "Codman Specialty Surgical", "verboseLabel": "Codman Specialty Surgical" } } }, "localname": "CodmanSpecialtySurgicalMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfChangesInCarryingAmountOfGoodwillDetails", "http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfRevenuesDisaggregatedByMajorSourceDetails", "http://integralife.com/role/SegmentAndGeographicInformationNarrativeDetails", "http://integralife.com/role/SegmentAndGeographicInformationNetSalesAndProfitByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "iart_CompletedTechnologyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Completed technology.", "label": "Completed Technology [Member]", "terseLabel": "Completed technology" } } }, "localname": "CompletedTechnologyMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "iart_ConsortiumofFocusedOrthopedistsLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Consortium of Focused Orthopedists, LLC [Member]", "label": "Consortium of Focused Orthopedists, LLC [Member]", "terseLabel": "Consortium of Focused Orthopedists, LLC" } } }, "localname": "ConsortiumofFocusedOrthopedistsLLCMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleNarrativeDetails", "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_ContingentConsiderationLiabilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contingent Consideration Liability [Member]", "label": "Contingent Consideration Liability [Member]", "terseLabel": "Contingent Consideration Liability" } } }, "localname": "ContingentConsiderationLiabilityMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/CommitmentsAndContingenciesFairValueContingentConsiderationBalanceInformationDetails" ], "xbrltype": "domainItemType" }, "iart_ContractWithCustomerAssetNetOfReclassifiedToReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Contract With Customer, Asset, Net Of Reclassified To Receivable", "label": "Contract With Customer, Asset, Net Of Reclassified To Receivable", "terseLabel": "Contract asset, net of transferred to trade receivables on contracts during the period" } } }, "localname": "ContractWithCustomerAssetNetOfReclassifiedToReceivable", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfChangesInContractAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "iart_ContractWithCustomerLiabilityIncreaseDecreaseFromForeignCurrencyTranslation": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contract With Customer, Liability, Increase (Decrease) From Foreign Currency Translation", "label": "Contract With Customer, Liability, Increase (Decrease) From Foreign Currency Translation", "terseLabel": "Foreign currency translation" } } }, "localname": "ContractWithCustomerLiabilityIncreaseDecreaseFromForeignCurrencyTranslation", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfChangesInContractAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "iart_ContractwithCustomerLiabilityNetOfRevenueRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contract with Customer, Liability, Net Of Revenue Recognized", "label": "Contract with Customer, Liability, Net Of Revenue Recognized", "terseLabel": "Contract liability, net of revenue recognized on contracts during the period" } } }, "localname": "ContractwithCustomerLiabilityNetOfRevenueRecognized", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfChangesInContractAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "iart_CostOfDefiniteAndIndefiniteLivedIntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "calculation": { "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfCompanysIdentifiableIntangibleAssetsDetails": { "order": 1.0, "parentTag": "iart_DefiniteAndIndefiniteLivedIntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cost Of Definite And Indefinite Lived Intangible Assets Gross Excluding Goodwill.", "label": "Cost Of Definite And Indefinite Lived Intangible Assets Gross Excluding Goodwill", "terseLabel": "Cost" } } }, "localname": "CostOfDefiniteAndIndefiniteLivedIntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "iart_CrossCurrencyInterestRateContractFiveMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cross Currency Interest Rate Contract Five [Member]", "label": "Cross Currency Interest Rate Contract Five [Member]", "terseLabel": "Cross Currency Interest Rate Swap Five" } } }, "localname": "CrossCurrencyInterestRateContractFiveMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_CrossCurrencyInterestRateContractFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cross Currency Interest Rate Contract Four [Member]", "label": "Cross Currency Interest Rate Contract Four [Member]", "terseLabel": "Cross Currency Interest Rate Swap Four" } } }, "localname": "CrossCurrencyInterestRateContractFourMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_CrossCurrencyInterestRateContractOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cross Currency Interest Rate Contract One [Member]", "label": "Cross Currency Interest Rate Contract One [Member]", "terseLabel": "Cross Currency Interest Rate Swap One" } } }, "localname": "CrossCurrencyInterestRateContractOneMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_CrossCurrencyInterestRateContractThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cross Currency Interest Rate Contract Three [Member]", "label": "Cross Currency Interest Rate Contract Three [Member]", "terseLabel": "Cross Currency Interest Rate Swap Three" } } }, "localname": "CrossCurrencyInterestRateContractThreeMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_CrossCurrencyInterestRateContractTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cross Currency Interest Rate Contract Two [Member]", "label": "Cross Currency Interest Rate Contract Two [Member]", "terseLabel": "Cross Currency Interest Rate Swap Two" } } }, "localname": "CrossCurrencyInterestRateContractTwoMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_DebtAccountsReceivableSecuritizationTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt, Accounts Receivable Securitization, Term", "label": "Debt, Accounts Receivable Securitization, Term", "terseLabel": "Securitization program, term" } } }, "localname": "DebtAccountsReceivableSecuritizationTerm", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "durationItemType" }, "iart_DebtCovenantPeriod6Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Covenant Period 6 [Member]", "label": "Debt Covenant Period 6 [Member]", "terseLabel": "Execution of July 2020 Amendment through June 30, 2021" } } }, "localname": "DebtCovenantPeriod6Member", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DebtMaximumTotalLeverageRatioTableDetails" ], "xbrltype": "domainItemType" }, "iart_DebtCovenantPeriod7Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Covenant Period 7 [Member]", "label": "Debt Covenant Period 7 [Member]", "terseLabel": "September 30, 2021 through June 30, 2022" } } }, "localname": "DebtCovenantPeriod7Member", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DebtMaximumTotalLeverageRatioTableDetails" ], "xbrltype": "domainItemType" }, "iart_DebtCovenantPeriod8Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Covenant Period 8 [Member]", "label": "Debt Covenant Period 8 [Member]", "terseLabel": "September 30, 2022 through June 30, 2023" } } }, "localname": "DebtCovenantPeriod8Member", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DebtMaximumTotalLeverageRatioTableDetails" ], "xbrltype": "domainItemType" }, "iart_DebtCovenantPeriod9Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Covenant Period 9 [Member]", "label": "Debt Covenant Period 9 [Member]", "terseLabel": "September 30, 2023 and the last day of each fiscal quarter thereafter" } } }, "localname": "DebtCovenantPeriod9Member", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DebtMaximumTotalLeverageRatioTableDetails" ], "xbrltype": "domainItemType" }, "iart_DebtCovenantPeriodAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Covenant Period [Axis]", "label": "Debt Covenant Period [Axis]", "terseLabel": "Debt Covenant Period [Axis]" } } }, "localname": "DebtCovenantPeriodAxis", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DebtMaximumTotalLeverageRatioTableDetails" ], "xbrltype": "stringItemType" }, "iart_DebtCovenantPeriodDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Debt Covenant Period [Axis]", "label": "Debt Covenant Period [Domain]", "terseLabel": "Debt Covenant Period [Domain]" } } }, "localname": "DebtCovenantPeriodDomain", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DebtMaximumTotalLeverageRatioTableDetails" ], "xbrltype": "domainItemType" }, "iart_DebtInstrumentCovenantMaximumLeverageRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Covenant, Maximum Leverage Ratio", "label": "Debt Instrument, Covenant, Maximum Leverage Ratio", "terseLabel": "Maximum Consolidated Total Leverage Ratio", "verboseLabel": "Maximum consolidated total leverage ratio" } } }, "localname": "DebtInstrumentCovenantMaximumLeverageRatio", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DebtMaximumTotalLeverageRatioTableDetails", "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "pureItemType" }, "iart_DebtInstrumentMaximumAverageConversionValueOfNotes": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Maximum Average Conversion Value Of Notes", "label": "Debt Instrument, Maximum Average Conversion Value Of Notes", "terseLabel": "Maximum average conversion value of notes" } } }, "localname": "DebtInstrumentMaximumAverageConversionValueOfNotes", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "iart_DebtInstrumentMaximumSellingPriceOfCommonStockOfTheConversionPriceDuringPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Maximum Selling Price Of Common Stock Of The Conversion Price During Period", "label": "Debt Instrument, Maximum Selling Price Of Common Stock Of The Conversion Price During Period", "terseLabel": "Maximum selling price of the company's common stock of the conversion price" } } }, "localname": "DebtInstrumentMaximumSellingPriceOfCommonStockOfTheConversionPriceDuringPeriod", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "iart_DebtWeightedAverageInterestRateFromSecuritization": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt, Weighted Average Interest Rate, From Securitization", "label": "Debt, Weighted Average Interest Rate, From Securitization", "terseLabel": "Weighted average interest rate, accounts receivable securitization revolving loan facility" } } }, "localname": "DebtWeightedAverageInterestRateFromSecuritization", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "iart_DeferredTaxAssetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Deferred Tax Asset [Member]", "label": "Deferred Tax Asset [Member]", "terseLabel": "Deferred Tax Asset" } } }, "localname": "DeferredTaxAssetMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_DefinedBenefitPlanDeferPaymentAndTaxationBaseSalaryPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Defined Benefit Plan, Defer Payment And Taxation, Base Salary, Percentage", "label": "Defined Benefit Plan, Defer Payment And Taxation, Base Salary, Percentage", "terseLabel": "Defer payment and taxation, base salary, percentage (up to)" } } }, "localname": "DefinedBenefitPlanDeferPaymentAndTaxationBaseSalaryPercentage", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/RetirementPlansNarrativeDetails" ], "xbrltype": "percentItemType" }, "iart_DefinedBenefitPlanDeferPaymentAndTaxationBonusAndOtherCompensationPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Defined Benefit Plan, Defer Payment And Taxation, Bonus And Other Compensation, Percentage", "label": "Defined Benefit Plan, Defer Payment And Taxation, Bonus And Other Compensation, Percentage", "terseLabel": "Defer payment and taxation, bonus and other eligible cash compensation, percentage (up to)" } } }, "localname": "DefinedBenefitPlanDeferPaymentAndTaxationBonusAndOtherCompensationPercentage", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/RetirementPlansNarrativeDetails" ], "xbrltype": "percentItemType" }, "iart_DefiniteAndIndefiniteLivedIntangibleAssetsNetExcludingGoodwill": { "auth_ref": [], "calculation": { "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfCompanysIdentifiableIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Definite And Indefinite Lived Intangible Assets Net Excluding Goodwill.", "label": "Definite And Indefinite Lived Intangible Assets Net Excluding Goodwill", "totalLabel": "Net" } } }, "localname": "DefiniteAndIndefiniteLivedIntangibleAssetsNetExcludingGoodwill", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "iart_DermaSciencesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Derma Sciences [Member]", "label": "Derma Sciences [Member]", "terseLabel": "Derma Sciences" } } }, "localname": "DermaSciencesMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/CommitmentsAndContingenciesFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_DirectorsandCertainExecutiveOfficersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Directors and Certain Executive Officers [Member]", "label": "Directors and Certain Executive Officers [Member]", "terseLabel": "Directors and Certain Executive Officers" } } }, "localname": "DirectorsandCertainExecutiveOfficersMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_DisposalGroupIncludingDiscontinuedOperationAccruedCompensation": { "auth_ref": [], "calculation": { "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Accrued Compensation", "label": "Disposal Group, Including Discontinued Operation, Accrued Compensation", "terseLabel": "Accrued compensation" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedCompensation", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "iart_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent": { "auth_ref": [], "calculation": { "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease, Liability, Current", "label": "Disposal Group, Including Discontinued Operation, Operating Lease, Liability, Current", "terseLabel": "Current portion of lease liability - operating leases" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "iart_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease, Liability, Noncurrent", "label": "Disposal Group, Including Discontinued Operation, Operating Lease, Liability, Noncurrent", "terseLabel": "Lease liability - operating leases" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "iart_DisposalGroupIncludingDiscontinuedOperationPaymentRelatedToProductDevelopment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Payment Related To Product Development", "label": "Disposal Group, Including Discontinued Operation, Payment Related To Product Development", "terseLabel": "Sale of Extremity Orthopedics business, product development payment" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPaymentRelatedToProductDevelopment", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleNarrativeDetails", "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_EmployeeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employee [Member]", "label": "Employee [Member]", "terseLabel": "Employees" } } }, "localname": "EmployeeMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_ExtremityOrthopedicsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extremity Orthopedics [Member]", "label": "Extremity Orthopedics [Member]", "terseLabel": "Extremity Orthopedics" } } }, "localname": "ExtremityOrthopedicsMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfRevenuesDisaggregatedByMajorSourceDetails" ], "xbrltype": "domainItemType" }, "iart_FiveYearOptionLeasePeriodOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Five-Year Option Lease Period One", "label": "Five Year Option Lease Period One [Member]", "terseLabel": "Five Year Option Lease From November 1, 2029 Through October 31, 2034" } } }, "localname": "FiveYearOptionLeasePeriodOneMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_FiveYearOptionLeasePeriodTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Five-Year Option Lease Period Two", "label": "Five Year Option Lease Period Two [Member]", "terseLabel": "Five Year Option Lease From November 1, 2034 Through October 31, 2039" } } }, "localname": "FiveYearOptionLeasePeriodTwoMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_InstrumentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Instruments [Member]", "label": "Instruments [Member]", "terseLabel": "Instruments" } } }, "localname": "InstrumentsMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfRevenuesDisaggregatedByMajorSourceDetails" ], "xbrltype": "domainItemType" }, "iart_IntangibleAssetsIndefiniteLifeDiscountRatePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible Assets, Indefinite Life, Discount Rate, Percentage", "label": "Intangible Assets, Indefinite Life, Discount Rate, Percentage", "terseLabel": "Intangible assets, indefinite lives, discount rate" } } }, "localname": "IntangibleAssetsIndefiniteLifeDiscountRatePercentage", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "percentItemType" }, "iart_IntegratedShoulderCollaborationInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Integrated Shoulder Collaboration, Inc. [Member]", "label": "Integrated Shoulder Collaboration, Inc. [Member]", "terseLabel": "ISC" } } }, "localname": "IntegratedShoulderCollaborationInc.Member", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_InterestRateSwapDesignatedDecember132017Tranche1Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Swap Designated December 13, 2017 Tranche 1 [Member]", "label": "Interest Rate Swap Designated December 13, 2017 Tranche 1 [Member]", "terseLabel": "Interest Rate Swap Designated December 13, 2017 Tranche 1" } } }, "localname": "InterestRateSwapDesignatedDecember132017Tranche1Member", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_InterestRateSwapDesignatedDecember132017Tranche2Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Swap Designated December 13, 2017 Tranche 2 [Member]", "label": "Interest Rate Swap Designated December 13, 2017 Tranche 2 [Member]", "terseLabel": "Interest Rate Swap Designated December 13, 2017 Tranche 2" } } }, "localname": "InterestRateSwapDesignatedDecember132017Tranche2Member", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_InterestRateSwapDesignatedDecember132017Tranche3Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Swap Designated December 13, 2017 Tranche 3 [Member]", "label": "Interest Rate Swap Designated December 13, 2017 Tranche 3 [Member]", "terseLabel": "Interest Rate Swap Designated December 13, 2017 Tranche 3" } } }, "localname": "InterestRateSwapDesignatedDecember132017Tranche3Member", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_InterestRateSwapDesignatedDecember132017Tranche4Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Swap Designated December 13, 2017 Tranche 4 [Member]", "label": "Interest Rate Swap Designated December 13, 2017 Tranche 4 [Member]", "terseLabel": "Interest Rate Swap Designated December 13, 2017 Tranche 4" } } }, "localname": "InterestRateSwapDesignatedDecember132017Tranche4Member", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_InterestRateSwapDesignatedDecember132017Tranche5Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Swap Designated December 13, 2017 Tranche 5 [Member]", "label": "Interest Rate Swap Designated December 13, 2017 Tranche 5 [Member]", "terseLabel": "Interest Rate Swap Designated December 13, 2017 Tranche 5" } } }, "localname": "InterestRateSwapDesignatedDecember132017Tranche5Member", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_InterestRateSwapDesignatedDecember182018Tranche1Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Swap Designated December 18, 2018 Tranche 1 [Member]", "label": "Interest Rate Swap Designated December 18, 2018 Tranche 1 [Member]", "terseLabel": "Interest Rate Swap Designated December 18, 2018 Tranche 1" } } }, "localname": "InterestRateSwapDesignatedDecember182018Tranche1Member", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_InterestRateSwapDesignatedDecember182018Tranche2Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Swap Designated December 18, 2018 Tranche 2 [Member]", "label": "Interest Rate Swap Designated December 18, 2018 Tranche 2 [Member]", "terseLabel": "Interest Rate Swap Designated December 18, 2018 Tranche 2" } } }, "localname": "InterestRateSwapDesignatedDecember182018Tranche2Member", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_InterestRateSwapDesignatedFebruary62017Tranche1Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Swap Designated February 6, 2017 Tranche 1 [Member]", "label": "Interest Rate Swap Designated February 6, 2017 Tranche 1 [Member]", "terseLabel": "Interest Rate Swap Designated February 6, 2017 Tranche 1" } } }, "localname": "InterestRateSwapDesignatedFebruary62017Tranche1Member", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_InterestRateSwapDesignatedFebruary62017Tranche2Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Swap Designated February 6, 2017 Tranche 2 [Member]", "label": "Interest Rate Swap Designated February 6, 2017 Tranche 2 [Member]", "terseLabel": "Interest Rate Swap Designated February 6, 2017 Tranche 2" } } }, "localname": "InterestRateSwapDesignatedFebruary62017Tranche2Member", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_InterestRateSwapDesignatedMarch272017Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Swap Designated March 27, 2017 [Member]", "label": "Interest Rate Swap Designated March 27, 2017 [Member]", "terseLabel": "Interest Rate Swap Designated March 27, 2017" } } }, "localname": "InterestRateSwapDesignatedMarch272017Member", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_InterestRateSwapDesignatedOctober102018Tranche1Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Swap Designated October 10, 2018 Tranche 1 [Member]", "label": "Interest Rate Swap Designated October 10, 2018 Tranche 1 [Member]", "terseLabel": "Interest Rate Swap Designated October 10, 2018 Tranche 1" } } }, "localname": "InterestRateSwapDesignatedOctober102018Tranche1Member", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_InterestRateSwapDesignatedOctober102018Tranche2Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Swap Designated October 10, 2018 Tranche 2 [Member]", "label": "Interest Rate Swap Designated October 10, 2018 Tranche 2 [Member]", "terseLabel": "Interest Rate Swap Designated October 10, 2018 Tranche 2" } } }, "localname": "InterestRateSwapDesignatedOctober102018Tranche2Member", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_InterestRateSwapDesignatedOctober102018Tranche3Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Swap Designated October 10, 2018 Tranche 3 [Member]", "label": "Interest Rate Swap Designated October 10, 2018 Tranche 3 [Member]", "terseLabel": "Interest Rate Swap Designated October 10, 2018 Tranche 3" } } }, "localname": "InterestRateSwapDesignatedOctober102018Tranche3Member", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_InventoryTransferToAssetsHeldForSale": { "auth_ref": [], "calculation": { "http://integralife.com/role/InventoriesScheduleOfNetInventoriesDetails": { "order": 4.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Inventory, Transfer To Assets Held For Sale", "label": "Inventory, Transfer To Assets Held For Sale", "negatedTerseLabel": "Transfer to assets held for sale (See Note 2. Assets Held for Sale)" } } }, "localname": "InventoryTransferToAssetsHeldForSale", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/InventoriesScheduleOfNetInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "iart_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four", "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details" ], "xbrltype": "monetaryItemType" }, "iart_LesseeOperatingLeaseNumberOfRenewalOptions": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Number Of Renewal Options", "label": "Lessee, Operating Lease, Number Of Renewal Options", "terseLabel": "Number of renewal options (or more)" } } }, "localname": "LesseeOperatingLeaseNumberOfRenewalOptions", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "iart_MilestonePaymentOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Milestone Payment One [Member]", "label": "Milestone Payment One [Member]", "terseLabel": "Development Milestones" } } }, "localname": "MilestonePaymentOneMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_MilestonePaymentTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Milestone Payment Two [Member]", "label": "Milestone Payment Two [Member]", "terseLabel": "Commercial Sales Milestones" } } }, "localname": "MilestonePaymentTwoMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_NeurosurgeryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Neurosurgery [Member]", "label": "Neurosurgery [Member]", "terseLabel": "Neurosurgery" } } }, "localname": "NeurosurgeryMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfRevenuesDisaggregatedByMajorSourceDetails" ], "xbrltype": "domainItemType" }, "iart_NoncashOrPartNoncashInProcessResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Noncash Or Part Noncash, In Process Research And Development", "label": "Noncash Or Part Noncash, In Process Research And Development", "terseLabel": "Non-cash in-process research and development expense" } } }, "localname": "NoncashOrPartNoncashInProcessResearchAndDevelopment", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "iart_OneMonthEurodollarRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "One Month Eurodollar Rate [Member]", "label": "One Month Eurodollar Rate [Member]", "terseLabel": "One Month Eurodollar Rate" } } }, "localname": "OneMonthEurodollarRateMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_OneMonthUSDLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "One Month USD LIBOR [Member]", "label": "One Month USD LIBOR [Member]", "terseLabel": "1-Month USD LIBOR" } } }, "localname": "OneMonthUSDLIBORMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_OptionToExtendLeaseYears": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Option to extend lease, years.", "label": "Option To Extend Lease, Years", "terseLabel": "Option to extend lease, years" } } }, "localname": "OptionToExtendLeaseYears", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "iart_OrthopedicsandTissueTechnologiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Orthopedics and Tissue Technologies [Member]", "label": "Orthopedics and Tissue Technologies [Member]", "terseLabel": "Orthopedics and Tissue Technologies" } } }, "localname": "OrthopedicsandTissueTechnologiesMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfChangesInCarryingAmountOfGoodwillDetails", "http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfRevenuesDisaggregatedByMajorSourceDetails", "http://integralife.com/role/SegmentAndGeographicInformationNetSalesAndProfitByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "iart_PaymentsForOptionIndexToIssuersEquity": { "auth_ref": [], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments For Options Indexed to Issuer's Equity", "label": "Payments For Option Index To Issuers Equity", "negatedLabel": "Purchase of option hedge on convertible notes", "terseLabel": "Cost of call transactions" } } }, "localname": "PaymentsForOptionIndexToIssuersEquity", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_PaymentsForProceedsFromBusinessAcquisitions": { "auth_ref": [], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments For (Proceeds From) Business Acquisitions", "label": "Payments For (Proceeds From) Business Acquisitions", "negatedLabel": "Cash (paid) provided for business acquisitions, net of cash acquired" } } }, "localname": "PaymentsForProceedsFromBusinessAcquisitions", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "iart_PaymentsToAcquireInProcessResearchAndDevelopmentMilestone": { "auth_ref": [], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments To Acquire In Process Research And Development Milestone", "label": "Payments To Acquire In Process Research And Development Milestone", "negatedLabel": "Acquired in-process research and development milestone" } } }, "localname": "PaymentsToAcquireInProcessResearchAndDevelopmentMilestone", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "iart_PercentOfManufacturingFacilityOwnedByCorporationWhoseShareholdersAreTrustsWhoseBeneficiariesIncludeFamilyMembersOfCompanysFormerDirector": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percent Of Manufacturing Facility Owned By Corporation Whose Shareholders Are Trusts, Whose Beneficiaries Include Family Members Of Company's Former Director", "label": "Percent Of Manufacturing Facility Owned By Corporation Whose Shareholders Are Trusts, Whose Beneficiaries Include Family Members Of Company's Former Director", "terseLabel": "Percent of manufacturing facility owned by corporation whose shareholders are trusts whose beneficiaries include family members of company's former director" } } }, "localname": "PercentOfManufacturingFacilityOwnedByCorporationWhoseShareholdersAreTrustsWhoseBeneficiariesIncludeFamilyMembersOfCompanysFormerDirector", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesNarrativeDetails" ], "xbrltype": "percentItemType" }, "iart_PerformanceSharesandRestrictedUnitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Performance Shares and Restricted Units", "label": "Performance Shares and Restricted Units [Member]", "terseLabel": "Performance Shares and Restricted Units" } } }, "localname": "PerformanceSharesandRestrictedUnitsMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/NetIncomeLossPerShareNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_PerformanceStockAndRestrictedStockAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Performance Stock And Restricted Stock Awards [Member]", "label": "Performance Stock And Restricted Stock Awards [Member]", "terseLabel": "Performance Stock and Restricted Stock Awards" } } }, "localname": "PerformanceStockAndRestrictedStockAwardsMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_PrivateLabelMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Private Label [Member]", "label": "Private Label [Member]", "terseLabel": "Private Label" } } }, "localname": "PrivateLabelMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfRevenuesDisaggregatedByMajorSourceDetails" ], "xbrltype": "domainItemType" }, "iart_ReboundTherapeuticsCorporationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Rebound Therapeutics Corporation [Member]", "label": "Rebound Therapeutics Corporation [Member]", "terseLabel": "Rebound" } } }, "localname": "ReboundTherapeuticsCorporationMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails", "http://integralife.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_RegenerativeSkinAndWoundMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Regenerative Skin And Wound [Member]", "label": "Regenerative Skin And Wound [Member]", "terseLabel": "Wound Reconstruction and Care" } } }, "localname": "RegenerativeSkinAndWoundMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfRevenuesDisaggregatedByMajorSourceDetails" ], "xbrltype": "domainItemType" }, "iart_RelatedPartiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Related Parties [Member]", "label": "Related Parties [Member]", "terseLabel": "Related Parties" } } }, "localname": "RelatedPartiesMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details" ], "xbrltype": "domainItemType" }, "iart_RestOfWorldMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenues from rest of the world.", "label": "Rest Of World [Member]", "terseLabel": "Rest of World" } } }, "localname": "RestOfWorldMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/SegmentAndGeographicInformationTotalRevenueByMajorGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "iart_ReturnPolicyIssueOfCreditNumberOfDaysFromShipment": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Return Policy, Issue of Credit, Number of Days from Shipment", "label": "Return Policy, Issue Of Credit, Number Of Days From Shipment", "terseLabel": "Number of days from shipment to issue a credit" } } }, "localname": "ReturnPolicyIssueOfCreditNumberOfDaysFromShipment", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersNarrativeDetails" ], "xbrltype": "durationItemType" }, "iart_RevenueFromContractWithCustomerProductsShippedWithNoAlternativeUseAndRightOfPaymentForPerformanceManufacturingPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue From Contract With Customer, Products Shipped With No Alternative Use And Right Of Payment For Performance, Manufacturing Period", "label": "Revenue From Contract With Customer, Products Shipped With No Alternative Use And Right Of Payment For Performance, Manufacturing Period", "terseLabel": "Manufacturing period for products shipped with no alternative use and right of payment for performance" } } }, "localname": "RevenueFromContractWithCustomerProductsShippedWithNoAlternativeUseAndRightOfPaymentForPerformanceManufacturingPeriod", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersNarrativeDetails" ], "xbrltype": "durationItemType" }, "iart_RevenueProductWarrantyPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue, Product Warranty Period", "label": "Revenue, Product Warranty Period", "terseLabel": "Product warranty period (up to)" } } }, "localname": "RevenueProductWarrantyPeriod", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersNarrativeDetails" ], "xbrltype": "durationItemType" }, "iart_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Right Of Use Asset Obtained In Exchange For Lease Liability [Abstract]", "label": "Right Of Use Asset Obtained In Exchange For Lease Liability [Abstract]", "terseLabel": "ROU assets obtained in exchange for lease liabilities:" } } }, "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "iart_ScheduleOfAssetAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Schedule Of Asset Acquisition [Table]", "label": "Schedule Of Asset Acquisition [Line Items]", "terseLabel": "Schedule Of Asset Acquisition [Line Items]" } } }, "localname": "ScheduleOfAssetAcquisitionLineItems", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails" ], "xbrltype": "stringItemType" }, "iart_ScheduleOfAssetAcquisitionTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Asset Acquisition [Table]", "label": "Schedule Of Asset Acquisition [Table]", "terseLabel": "Schedule Of Asset Acquisition [Table]" } } }, "localname": "ScheduleOfAssetAcquisitionTable", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails" ], "xbrltype": "stringItemType" }, "iart_SecuredLongTermDebtSecuritizationProgramNoncurrent": { "auth_ref": [], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Secured Long-Term Debt, Securitization Program, Noncurrent", "label": "Secured Long-Term Debt, Securitization Program, Noncurrent", "terseLabel": "Long-term borrowings under securitization facility" } } }, "localname": "SecuredLongTermDebtSecuritizationProgramNoncurrent", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_SecuritizationFacilityFairValueOfAmountOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Securitization Facility, Fair Value Of Amount Outstanding", "label": "Securitization Facility, Fair Value Of Amount Outstanding", "terseLabel": "Securitization facility, outstanding borrowings, fair value" } } }, "localname": "SecuritizationFacilityFairValueOfAmountOutstanding", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_SegmentReportingInformationNumberOfProductsOffered": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of products sold by a segment", "label": "Segment Reporting Information, Number Of Products Offered", "terseLabel": "Number of products offered (more than)" } } }, "localname": "SegmentReportingInformationNumberOfProductsOffered", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/SegmentAndGeographicInformationNarrativeDetails" ], "xbrltype": "integerItemType" }, "iart_SeniorCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Credit Facility.", "label": "Senior Credit Facility [Member]", "terseLabel": "Senior Credit Facility" } } }, "localname": "SeniorCreditFacilityMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DebtMaximumTotalLeverageRatioTableDetails", "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans", "terseLabel": "Share-based compensation arrangement by share-based payment award, number of plans" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "integerItemType" }, "iart_SmithNephewUSDLimitedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Smith & Nephew USD Limited [Member]", "label": "Smith & Nephew USD Limited [Member]", "terseLabel": "Smith & Nephew USD Limited" } } }, "localname": "SmithNephewUSDLimitedMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails", "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleNarrativeDetails", "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_SupplierRelationShipsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Supplier Relation Ships [Member]", "label": "Supplier Relation Ships [Member]", "terseLabel": "Supplier relationships" } } }, "localname": "SupplierRelationShipsMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "iart_SwapOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Swap One [Member]", "label": "Swap One [Member]", "terseLabel": "Swap One" } } }, "localname": "SwapOneMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_SwapThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Swap Three [Member]", "label": "Swap Three [Member]", "terseLabel": "Swap Three" } } }, "localname": "SwapThreeMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_SwapTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Swap Two [Member]", "label": "Swap Two [Member]", "terseLabel": "Swap Two" } } }, "localname": "SwapTwoMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_SwinglineLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Swingline Loan [Member]", "label": "Swingline Loan [Member]", "terseLabel": "Swingline Loans" } } }, "localname": "SwinglineLoanMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_TermLoanFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan Facility [Member]", "label": "Term Loan Facility [Member]", "terseLabel": "Term Loan Facility" } } }, "localname": "TermLoanFacilityMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_ThirdPartiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Third Parties [Member]", "label": "Third Parties [Member]", "verboseLabel": "Third Parties" } } }, "localname": "ThirdPartiesMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details" ], "xbrltype": "domainItemType" }, "iart_ThreeMonthUSDLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Three Month USD LIBOR [Member]", "label": "Three Month USD LIBOR [Member]", "terseLabel": "3-Month USD LIBOR" } } }, "localname": "ThreeMonthUSDLIBORMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_TrademarksBrandNamesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trademarks Brand Names.", "label": "Trademarks Brand Names [Member]", "terseLabel": "Trademarks/brand names" } } }, "localname": "TrademarksBrandNamesMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "iart_TransferToAssetsHeldForSaleMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Transfer To Assets Held For Sale [Member]", "label": "Transfer To Assets Held For Sale [Member]", "terseLabel": "Transfer to assets held for sale (See Note 2. Assets Held for Sale)" } } }, "localname": "TransferToAssetsHeldForSaleMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "iart_TransferorsInterestsInTransferredFinancialAssetsMaximumInvestmentLimit": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Transferor's Interests In Transferred Financial Assets, Maximum Investment Limit", "label": "Transferor's Interests In Transferred Financial Assets, Maximum Investment Limit", "terseLabel": "Securitization program outstanding borrowings, maximum limit" } } }, "localname": "TransferorsInterestsInTransferredFinancialAssetsMaximumInvestmentLimit", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_TwoThousandTwentyFiveSeniorConvertibleNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Thousand Twenty Five Senior Convertible Notes [Member]", "label": "Two Thousand Twenty Five Senior Convertible Notes [Member]", "terseLabel": "2025 Notes" } } }, "localname": "TwoThousandTwentyFiveSeniorConvertibleNotesMember", "nsuri": "http://integralife.com/20200930", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r343", "r514", "r515", "r517", "r605" ], "lang": { "en-US": { "role": { "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Entity" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "Asia Pacific" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/SegmentAndGeographicInformationTotalRevenueByMajorGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r162", "r175", "r176", "r177", "r178", "r180", "r182", "r186" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/SegmentAndGeographicInformationNetSalesAndProfitByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r162", "r175", "r176", "r177", "r178", "r180", "r182", "r186" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Operating Activities [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/SegmentAndGeographicInformationNetSalesAndProfitByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r64", "r120" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleNarrativeDetails", "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails", "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details", "http://integralife.com/role/TreasuryStockNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r127", "r134", "r205", "r381", "r382", "r383", "r402", "r403" ], "lang": { "en-US": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r127", "r134", "r205", "r381", "r382", "r383", "r402", "r403" ], "lang": { "en-US": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r127", "r134", "r205", "r381", "r382", "r383", "r402", "r403" ], "lang": { "en-US": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "label": "Director [Member]", "terseLabel": "Directors" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/SegmentAndGeographicInformationTotalRevenueByMajorGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r357", "r360", "r523", "r524", "r525", "r526", "r527", "r528", "r530", "r572", "r575" ], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails", "http://integralife.com/role/RevenuesFromContractsWithCustomersNarrativeDetails", "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r357", "r360", "r523", "r524", "r525", "r526", "r527", "r528", "r530", "r572", "r575" ], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails", "http://integralife.com/role/RevenuesFromContractsWithCustomersNarrativeDetails", "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r189", "r316", "r320", "r531", "r571", "r573" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfRevenuesDisaggregatedByMajorSourceDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r189", "r316", "r320", "r531", "r571", "r573" ], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfRevenuesDisaggregatedByMajorSourceDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r331", "r357", "r360", "r523", "r524", "r525", "r526", "r527", "r528", "r530", "r572", "r575" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails", "http://integralife.com/role/RevenuesFromContractsWithCustomersNarrativeDetails", "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r331", "r357", "r360", "r523", "r524", "r525", "r526", "r527", "r528", "r530", "r572", "r575" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails", "http://integralife.com/role/RevenuesFromContractsWithCustomersNarrativeDetails", "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleNarrativeDetails", "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails", "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details", "http://integralife.com/role/TreasuryStockNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r358" ], "lang": { "en-US": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleNarrativeDetails", "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r358" ], "lang": { "en-US": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleNarrativeDetails", "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r200" ], "lang": { "en-US": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r190", "r191", "r316", "r321", "r574", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603" ], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/SegmentAndGeographicInformationTotalRevenueByMajorGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r190", "r191", "r316", "r321", "r574", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/SegmentAndGeographicInformationTotalRevenueByMajorGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r256", "r358", "r519" ], "lang": { "en-US": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleNarrativeDetails", "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r195", "r516" ], "lang": { "en-US": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "Derivative Instruments, Gain (Loss) [Roll Forward]", "verboseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfChangesInAccumulatedOtherComprehensiveIncomeByComponentDetails", "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt": { "auth_ref": [ "r287" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement.", "label": "Accelerated Share Repurchases, Settlement (Payment) or Receipt", "negatedTerseLabel": "Accelerated share repurchase program, payment" } } }, "localname": "AcceleratedShareRepurchasesSettlementPaymentOrReceipt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/TreasuryStockNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r128", "r129", "r130", "r131", "r202", "r203", "r204", "r205", "r206", "r207", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r402", "r403", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587" ], "lang": { "en-US": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible List]", "terseLabel": "Accounting Standards Update [Extensible List]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnauditedParenthetical" ], "xbrltype": "extensibleListItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r22", "r49" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Trade, Current", "terseLabel": "Accounts payable, trade" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r19", "r31", "r196", "r197" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Trade accounts receivable, net of allowances of $6,727 and $4,303" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionExpense": { "auth_ref": [ "r248", "r249" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.", "label": "Accretion Expense", "terseLabel": "Accretion of bond issuance discount" } } }, "localname": "AccretionExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r52" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r69", "r74", "r76", "r437" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Defined Benefit Pension Items" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfChangesInAccumulatedOtherComprehensiveIncomeByComponentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r74", "r83", "r436" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Gains and Losses on Derivatives" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/ComprehensiveIncomeLossNarrativeDetails", "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfChangesInAccumulatedOtherComprehensiveIncomeByComponentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/ComprehensiveIncomeLossNarrativeDetails", "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfChangesInAccumulatedOtherComprehensiveIncomeByComponentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r34", "r72", "r73", "r74", "r562", "r583", "r587" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r487", "r488", "r489", "r490", "r491", "r493" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/ComprehensiveIncomeLossNarrativeDetails", "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfChangesInAccumulatedOtherComprehensiveIncomeByComponentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r71", "r74", "r76", "r124", "r125", "r126", "r437", "r578", "r579" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Total", "verboseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfChangesInAccumulatedOtherComprehensiveIncomeByComponentDetails", "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited", "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r67", "r74", "r76", "r437", "r488", "r489", "r490", "r491", "r493" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Items" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfChangesInAccumulatedOtherComprehensiveIncomeByComponentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Weighted Average Life" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r32" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r124", "r125", "r126", "r381", "r382", "r383" ], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": { "auth_ref": [ "r271" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.", "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt", "terseLabel": "Share repurchase and equity component of the convertible note issuance, net" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r362", "r364", "r385", "r386" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r38", "r198", "r208" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Trade accounts receivable, allowance" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r95", "r112", "r496" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r89", "r112", "r498" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Incremental financing cost expense" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r112", "r221", "r229" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 6.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "negatedTerseLabel": "Amortization", "terseLabel": "Intangible asset amortization" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited", "http://integralife.com/role/SegmentAndGeographicInformationNetSalesAndProfitByReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Shares excluded from computation as their effect would be antidilutive (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/NetIncomeLossPerShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/NetIncomeLossPerShareNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Assets": { "auth_ref": [ "r118", "r170", "r177", "r184", "r201", "r434", "r438", "r485", "r547", "r559" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r20", "r21", "r62", "r118", "r201", "r434", "r438", "r485" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r9", "r11", "r14", "r243" ], "calculation": { "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Assets", "totalLabel": "Total assets held for sale" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r0", "r1", "r9", "r11", "r14", "r237", "r243" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "terseLabel": "Assets held for sale" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r366", "r375" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/NetIncomeLossPerShareNarrativeDetails", "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsFairValueOfDerivativeInstrumentsByBalanceSheetLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r449", "r454" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsFairValueOfDerivativeInstrumentsByBalanceSheetLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis Of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Leased facilities" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r356", "r359" ], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationNarrativeDetails", "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails", "http://integralife.com/role/CommitmentsAndContingenciesFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r356", "r359", "r414", "r415" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationNarrativeDetails", "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails", "http://integralife.com/role/CommitmentsAndContingenciesFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationNarrativeDetails", "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r424", "r425", "r427" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Purchase price of business combination" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r111", "r430" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "verboseLabel": "Change in fair value of contingent consideration and others" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r429" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Contingent consideration, maximum undiscounted payment amount" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r423", "r426", "r428" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent consideration, liability (up to)", "verboseLabel": "Contingent consideration, estimated fair value" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationNarrativeDetails", "http://integralife.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r417" ], "calculation": { "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails": { "order": 1.0, "parentTag": "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "verboseLabel": "Cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability": { "auth_ref": [ "r416", "r417" ], "calculation": { "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability", "terseLabel": "Contingent consideration", "verboseLabel": "Contingent consideration, fair value" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationNarrativeDetails", "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "auth_ref": [ "r417" ], "calculation": { "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails": { "order": 2.0, "parentTag": "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "terseLabel": "Other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": { "auth_ref": [ "r417" ], "calculation": { "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails": { "order": 4.0, "parentTag": "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets", "terseLabel": "Deferred tax assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r417" ], "calculation": { "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "terseLabel": "Deferred tax liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]", "terseLabel": "Intangible assets:" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r416", "r417" ], "calculation": { "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails": { "order": 6.0, "parentTag": "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r416", "r417" ], "calculation": { "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails": { "order": 3.0, "parentTag": "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, plant and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r417" ], "calculation": { "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CallOptionMember": { "auth_ref": [ "r589", "r590", "r591", "r592", "r593", "r594" ], "lang": { "en-US": { "role": { "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option.", "label": "Call Option [Member]", "terseLabel": "Call Option" } } }, "localname": "CallOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r17", "r46", "r114" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r109", "r114", "r115" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r109", "r486" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r445" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedges" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails", "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r288", "r289", "r290", "r291" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/TreasuryStockNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r281" ], "lang": { "en-US": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrant strike price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r252", "r253", "r254", "r262" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r124", "r125" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r30" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r30" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized shares (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r30" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued shares (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r30" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock; $0.01 par value; 240,000 authorized shares; 89,191 and 88,735 issued at September 30, 2020 and December 31, 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r79", "r81", "r82", "r87", "r553", "r568" ], "calculation": { "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "terseLabel": "Comprehensive income (loss) (See Note 15)", "totalLabel": "Comprehensive income (loss), net" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfComprehensiveIncomeDetails", "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r86", "r98", "r552", "r567" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "COMPREHENSIVE INCOME (LOSS)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/ComprehensiveIncomeLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationNarrativeDetails", "http://integralife.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationNarrativeDetails", "http://integralife.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r298" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Schedule of Changes in Contract Assets and Contract Liabilities" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r294", "r296", "r317" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "periodEndLabel": "Contract asset, End of Period", "periodStartLabel": "Contract asset, Beginning of period" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfChangesInContractAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetReclassifiedToReceivable": { "auth_ref": [ "r297" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time from transfer to receivable due to right to consideration becoming unconditional.", "label": "Contract with Customer, Asset, Reclassified to Receivable", "negatedTerseLabel": "Transferred to trade receivable of contract asset included in beginning of the year contract asset" } } }, "localname": "ContractWithCustomerAssetReclassifiedToReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfChangesInContractAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r294", "r295", "r317" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Contract liability, End of Period", "periodStartLabel": "Contract liability, Beginning of Period" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfChangesInContractAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r294", "r295", "r317" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Contract liabilities", "verboseLabel": "Short-term portion of contract liability" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://integralife.com/role/RevenuesFromContractsWithCustomersNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r294", "r295", "r317" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Long-term portion of contract liability" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r318" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "negatedLabel": "Recognition of revenue included in beginning of year contract liability" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfChangesInContractAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r270" ], "lang": { "en-US": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Debt" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails", "http://integralife.com/role/TreasuryStockNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtNoncurrent": { "auth_ref": [ "r56" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.", "label": "Convertible Debt, Noncurrent", "terseLabel": "Long-term convertible securities", "verboseLabel": "Carrying amount, liability component" } } }, "localname": "ConvertibleDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r175", "r176", "r177", "r178", "r180", "r186", "r188" ], "lang": { "en-US": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate and other" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/SegmentAndGeographicInformationNetSalesAndProfitByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r91", "r531" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r90" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CrossCurrencyInterestRateContractMember": { "auth_ref": [ "r332", "r461" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.", "label": "Cross Currency Interest Rate Contract [Member]", "terseLabel": "Cross-currency swap", "verboseLabel": "Cross Currency Interest Rate Swap" } } }, "localname": "CrossCurrencyInterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails", "http://integralife.com/role/DerivativeInstrumentsFairValueOfDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r420" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "verboseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "DEBT" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r26", "r27", "r28", "r548", "r549", "r558" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtMaximumTotalLeverageRatioTableDetails", "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Interest rates available" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": { "auth_ref": [ "r272" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.", "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component", "terseLabel": "Debt proceeds, classified as equity at time of offering" } } }, "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r274" ], "lang": { "en-US": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Initial conversion price (in dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r55", "r281", "r282", "r284" ], "lang": { "en-US": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Initial conversion rate" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r497", "r499" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Convertible notes, maximum borrowing capacity" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r484" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Fair value" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r54", "r275", "r497" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r54" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Convertible notes, interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtMaximumTotalLeverageRatioTableDetails", "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r56" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtMaximumTotalLeverageRatioTableDetails", "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r556" ], "lang": { "en-US": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Redemption price, percentage" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r56", "r121", "r281", "r283", "r284", "r285", "r496", "r497", "r499", "r557" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtMaximumTotalLeverageRatioTableDetails", "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r496", "r499" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Unamortized discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtWeightedAverageInterestRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average interest rate of debt outstanding.", "label": "Debt, Weighted Average Interest Rate", "terseLabel": "Weighted average interest rate on debt" } } }, "localname": "DebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredCompensationPlanAssets": { "auth_ref": [ "r48" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.", "label": "Deferred Compensation Plan Assets", "terseLabel": "Deferred compensation plan, fair value of assets" } } }, "localname": "DeferredCompensationPlanAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/RetirementPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r498" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Incremental financing costs capitalized" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r389", "r390" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets, net" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r112", "r119", "r400", "r406", "r407", "r408" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Income tax expense (benefit)" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r389", "r390" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "auth_ref": [ "r330", "r332", "r334", "r335", "r351" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.", "label": "Defined Benefit Plan, Plan Assets, Amount", "terseLabel": "Estimated fair value of plan assets" } } }, "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/RetirementPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r340", "r349", "r351", "r352" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "terseLabel": "Net periodic benefit costs" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/RetirementPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r329", "r341", "r350", "r351", "r352" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "verboseLabel": "Service cost component" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/RetirementPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]", "verboseLabel": "Derivative, Name [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails", "http://integralife.com/role/DerivativeInstrumentsFairValueOfDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r63", "r65", "r452", "r529" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Total derivatives designated as hedges \u2014 Assets" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsFairValueOfDerivativeInstrumentsByBalanceSheetLocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r63", "r65", "r452", "r529" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "terseLabel": "Total derivatives designated as hedges \u2014 Liabilities" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsFairValueOfDerivativeInstrumentsByBalanceSheetLocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "auth_ref": [ "r484" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives.", "label": "Derivative, Fair Value, Net", "terseLabel": "Fair Value Asset (Liability)", "verboseLabel": "Estimated Fair Value, Asset (Liability)" } } }, "localname": "DerivativeFairValueOfDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative, Fixed Interest Rate", "terseLabel": "Fixed Interest Rate", "verboseLabel": "Fixed Rate" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r450", "r453", "r458", "r463" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]", "verboseLabel": "Derivative, by Nature [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails", "http://integralife.com/role/DerivativeInstrumentsFairValueOfDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r477" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "DERIVATIVE INSTRUMENTS" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r447", "r450", "r458" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails", "http://integralife.com/role/DerivativeInstrumentsFairValueOfDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r447", "r450", "r458", "r463", "r464", "r467", "r470" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r442", "r444" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "netLabel": "Aggregate Notional Amount", "terseLabel": "Current notional amount", "verboseLabel": "Notional Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r441", "r443", "r444", "r447", "r448", "r455", "r458", "r465", "r466", "r470" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsFairValueOfDerivativeInstrumentsByBalanceSheetLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r447" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails", "http://integralife.com/role/DerivativeInstrumentsFairValueOfDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r422" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "CerebroFlo developed technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DilutiveSecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]", "terseLabel": "Effect of dilutive securities:" } } }, "localname": "DilutiveSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/NetIncomeLossPerShareBasicAndDilutedNetIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfRevenuesDisaggregatedByMajorSourceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r316", "r320", "r321", "r322", "r323", "r324", "r325", "r326" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfRevenuesDisaggregatedByMajorSourceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r316" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r387" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails", "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleNarrativeDetails", "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails", "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleNarrativeDetails", "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r236", "r245" ], "lang": { "en-US": { "role": { "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations" } } }, "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails", "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleNarrativeDetails", "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Sale of Extremity Orthopedics business, disposition price" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets": { "auth_ref": [ "r0", "r1", "r9", "r243" ], "calculation": { "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as deferred tax assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Assets", "terseLabel": "Deferred tax assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities": { "auth_ref": [ "r0", "r1", "r9", "r243" ], "calculation": { "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities", "terseLabel": "Deferred tax liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": { "auth_ref": [ "r0", "r1", "r9", "r243" ], "calculation": { "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails": { "order": 7.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Goodwill", "terseLabel": "Goodwill" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": { "auth_ref": [ "r0", "r1", "r9", "r243" ], "calculation": { "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Intangible Assets", "terseLabel": "Intangible assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": { "auth_ref": [ "r0", "r1", "r9", "r243" ], "calculation": { "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails": { "order": 5.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Inventory", "terseLabel": "Inventories" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": { "auth_ref": [ "r0", "r1", "r9", "r243" ], "calculation": { "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Other Assets", "terseLabel": "Other assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": { "auth_ref": [ "r0", "r1", "r9", "r243" ], "calculation": { "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": { "auth_ref": [ "r0", "r1", "r9", "r237", "r243" ], "calculation": { "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current", "terseLabel": "Prepaid and other current assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": { "auth_ref": [ "r0", "r1", "r9", "r243" ], "calculation": { "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails": { "order": 6.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment", "terseLabel": "Property, plant and equipment, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r15", "r247" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "ASSETS AND LIABILITIES HELD FOR SALE" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSale" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r356", "r359" ], "lang": { "en-US": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails", "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleNarrativeDetails", "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "verboseLabel": "Net income (loss) per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r88", "r132", "r133", "r134", "r135", "r136", "r140", "r142", "r147", "r148", "r149", "r153", "r154", "r554", "r569" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Basic net income (loss) per common share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited", "http://integralife.com/role/NetIncomeLossPerShareBasicAndDilutedNetIncomePerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Basic net income (loss) per share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/NetIncomeLossPerShareBasicAndDilutedNetIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r88", "r132", "r133", "r134", "r135", "r136", "r142", "r147", "r148", "r149", "r153", "r154", "r554", "r569" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Diluted net income (loss) per common share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited", "http://integralife.com/role/NetIncomeLossPerShareBasicAndDilutedNetIncomePerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted net income (loss) per share:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/NetIncomeLossPerShareBasicAndDilutedNetIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r150", "r151", "r152", "r155" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "NET INCOME (LOSS) PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/NetIncomeLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r486" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r392" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate", "verboseLabel": "Reported tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/IncomeTaxesNarrativeDetails", "http://integralife.com/role/IncomeTaxesSummaryOfEffectiveTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r52" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r374" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Total unrecognized compensation costs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r374" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average period for cost recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r373" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/TreasuryStockNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r124", "r125", "r126", "r129", "r137", "r139", "r156", "r205", "r280", "r286", "r381", "r382", "r383", "r402", "r403", "r487", "r488", "r489", "r490", "r491", "r493", "r578", "r579", "r580" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/ComprehensiveIncomeLossNarrativeDetails", "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfChangesInAccumulatedOtherComprehensiveIncomeByComponentDetails", "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited", "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EurodollarMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.", "label": "Eurodollar [Member]", "terseLabel": "Eurodollar" } } }, "localname": "EurodollarMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExtendedProductWarrantyPolicy": { "auth_ref": [ "r116", "r255", "r266" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for extended product warranties and other guarantee contracts including the methodology for measuring the liability.", "label": "Extended Product Warranty, Policy [Policy Text Block]", "terseLabel": "Product Warranties" } } }, "localname": "ExtendedProductWarrantyPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r351", "r478", "r520", "r521", "r522" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CommitmentsAndContingenciesFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r482", "r483" ], "lang": { "en-US": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CommitmentsAndContingenciesFairValueContingentConsiderationBalanceInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r332", "r334", "r339", "r351", "r478", "r521" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r351", "r478", "r522" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CommitmentsAndContingenciesFairValueContingentConsiderationBalanceInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r479" ], "lang": { "en-US": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CommitmentsAndContingenciesFairValueContingentConsiderationBalanceInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CommitmentsAndContingenciesFairValueContingentConsiderationBalanceInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CommitmentsAndContingenciesFairValueContingentConsiderationBalanceInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r479", "r483" ], "lang": { "en-US": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CommitmentsAndContingenciesFairValueContingentConsiderationBalanceInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r479", "r483" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of Contingent Consideration" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r480" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "netLabel": "Loss from change in fair value of contingent consideration liabilities" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CommitmentsAndContingenciesFairValueContingentConsiderationBalanceInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r481" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "terseLabel": "Additions from acquisition of Arkis" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CommitmentsAndContingenciesFairValueContingentConsiderationBalanceInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r479" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Balance, End of Period", "periodStartLabel": "Balance, Beginning of Period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CommitmentsAndContingenciesFairValueContingentConsiderationBalanceInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r351", "r520", "r521", "r522" ], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CommitmentsAndContingenciesFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r449", "r455", "r467" ], "lang": { "en-US": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsFairValueOfDerivativeInstrumentsByBalanceSheetLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "auth_ref": [ "r468" ], "lang": { "en-US": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.", "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]", "terseLabel": "Overnight Federal Funds" } } }, "localname": "FederalFundsEffectiveSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Weighted Average Life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r228" ], "calculation": { "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfCompanysIdentifiableIntangibleAssetsDetails": { "order": 2.0, "parentTag": "iart_DefiniteAndIndefiniteLivedIntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "Expected annual amortization expense, thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r230" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "Expected annual amortization expense, in 2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "Expected annual amortization expense, remainder of 2020" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r230" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "Expected annual amortization expense, in 2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r230" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "Expected annual amortization expense, in 2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r230" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "Expected annual amortization expense, in 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r230" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "Expected annual amortization expense, in 2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r222", "r225", "r228", "r232", "r532", "r533" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails", "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails", "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r222", "r227" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails", "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails", "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign Tax Authority" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r450" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "terseLabel": "Gain reclassified into other income" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets": { "auth_ref": [ "r112", "r236", "r241" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "negatedLabel": "Loss on disposal of property and equipment" } } }, "localname": "GainLossOnDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r211", "r213", "r546" ], "calculation": { "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails": { "order": 5.0, "parentTag": "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 }, "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "End of Period", "periodStartLabel": "Beginning of Period", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails", "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfChangesInCarryingAmountOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r215" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency translation" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfChangesInCarryingAmountOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r112", "r212", "r214", "r218" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill, impairment" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfChangesInCarryingAmountOfGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfChangesInCarryingAmountOfGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillTransfers": { "auth_ref": [ "r216" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of transfers into (out of) an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Transfers", "terseLabel": "Transfer to assets held for sale (See Note 2. Assets Held for Sale)" } } }, "localname": "GoodwillTransfers", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfChangesInCarryingAmountOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r447", "r464" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails", "http://integralife.com/role/DerivativeInstrumentsFairValueOfDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r447" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails", "http://integralife.com/role/DerivativeInstrumentsFairValueOfDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r447" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails", "http://integralife.com/role/DerivativeInstrumentsFairValueOfDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r112", "r233" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-lived", "terseLabel": "Non-cash impairment charges" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r112", "r233" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "terseLabel": "Intangible assets, indefinite lives, impairment" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In-Process Research and Development Expense", "verboseLabel": "IPR&D" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails", "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r122", "r170", "r176", "r180", "r183", "r186" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r356", "r359" ], "lang": { "en-US": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails", "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleNarrativeDetails", "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails", "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r1", "r3", "r4", "r5", "r6", "r7", "r8", "r10", "r12", "r13", "r14", "r245", "r246" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails", "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails", "http://integralife.com/role/ComprehensiveIncomeLossNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails", "http://integralife.com/role/ComprehensiveIncomeLossNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r394" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r394" ], "lang": { "en-US": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Tax Contingency [Line Items]" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r395", "r396", "r398", "r401" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r393", "r397", "r399", "r404", "r409", "r411", "r412", "r413" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r119", "r138", "r139", "r168", "r391", "r405", "r410", "r570" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision (benefit) for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r392" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "negatedTerseLabel": "Effective income tax rate reconciliation, tax benefit, reversal of valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationDispositionOfBusiness": { "auth_ref": [ "r392" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the disposition of a business not qualifying as a discontinued operation.", "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Amount", "terseLabel": "Effective income tax rate reconciliation, tax expense, sale of Extremity Orthopedic business" } } }, "localname": "IncomeTaxReconciliationDispositionOfBusiness", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": { "auth_ref": [ "r392" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount", "terseLabel": "Effective income tax rate reconciliation, in-process research and development (IPR&D) expense" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsForeign": { "auth_ref": [ "r392" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount", "terseLabel": "Federal tax credit" } } }, "localname": "IncomeTaxReconciliationTaxCreditsForeign", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxHolidays": { "auth_ref": [ "r392" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income exempt from income tax because of a tax holiday.", "label": "Effective Income Tax Rate Reconciliation, Tax Holiday, Amount", "terseLabel": "Effective income tax rate reconciliation, tax benefit, federal tax holiday" } } }, "localname": "IncomeTaxReconciliationTaxHolidays", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r111" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable, accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r111" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r111" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Contract liabilities" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r111" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "terseLabel": "Other non-current liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r111" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other non-current assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r111" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r143", "r144", "r145", "r149" ], "calculation": { "http://integralife.com/role/NetIncomeLossPerShareBasicAndDilutedNetIncomePerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Stock options and restricted stock (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/NetIncomeLossPerShareBasicAndDilutedNetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r224", "r231" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r224", "r231" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r220", "r226" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r84", "r164", "r495", "r498", "r555" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r95", "r276" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r97" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Cash interest" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r462" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which reported facts about interest income have been included.", "label": "Interest Income [Member]", "terseLabel": "Interest income", "verboseLabel": "Interest income" } } }, "localname": "InterestIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/ComprehensiveIncomeLossNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "auth_ref": [ "r471" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "terseLabel": "Gain expected to be reclassified to earnings in the next twelve months" } } }, "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r460" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest rate swap", "verboseLabel": "Interest rate swap" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails", "http://integralife.com/role/DerivativeInstrumentsFairValueOfDerivativeInstrumentsByBalanceSheetLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r210" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "INVENTORIES" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r39", "r209" ], "calculation": { "http://integralife.com/role/InventoriesScheduleOfNetInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/InventoriesScheduleOfNetInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r18", "r61" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://integralife.com/role/InventoriesScheduleOfNetInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net", "totalLabel": "Inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://integralife.com/role/InventoriesScheduleOfNetInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory, Net [Abstract]" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryRawMaterialsAndPurchasedPartsNetOfReserves": { "auth_ref": [ "r41", "r209" ], "calculation": { "http://integralife.com/role/InventoriesScheduleOfNetInventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of items purchased for use as components of a finished product or pieces of machinery and equipment plus any items in their natural and unrefined state. This element may be used when the reporting entity combines raw materials and purchased parts into an aggregate amount.", "label": "Inventory, Raw Materials and Purchased Parts, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsAndPurchasedPartsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/InventoriesScheduleOfNetInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r40", "r209" ], "calculation": { "http://integralife.com/role/InventoriesScheduleOfNetInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/InventoriesScheduleOfNetInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r94", "r163" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r506" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r511" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Operating Lease Maturities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r511" ], "calculation": { "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842DetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r511" ], "calculation": { "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r511" ], "calculation": { "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r511" ], "calculation": { "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r511" ], "calculation": { "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r511" ], "calculation": { "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r511" ], "calculation": { "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842DetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r505" ], "lang": { "en-US": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee, Operating Lease, Option to Extend", "terseLabel": "Period for extended lease" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r513" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES AND RELATED PARTY LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of credit outstanding" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r51", "r118", "r178", "r201", "r435", "r438", "r439", "r485" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r37", "r118", "r201", "r485", "r550", "r564" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r53", "r118", "r201", "r435", "r438", "r439", "r485" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r9", "r11", "r14", "r243" ], "calculation": { "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "totalLabel": "Total liabilities held for sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r0", "r1", "r9", "r11", "r14", "r237", "r243" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "terseLabel": "Liabilities held for sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r421" ], "lang": { "en-US": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Enabling technology license" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails", "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r28", "r549", "r558" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Line of credit facility outstanding" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Line of credit, commitment fee percentage" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": { "auth_ref": [ "r484" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of the amount outstanding under the credit facility.", "label": "Line of Credit Facility, Fair Value of Amount Outstanding", "terseLabel": "Line of credit facility, fair value of amount outstanding" } } }, "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r50" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates an ownership position in, or purchase of, a security.", "label": "Long [Member]", "terseLabel": "Long" } } }, "localname": "LongMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r28", "r273", "r549", "r561" ], "calculation": { "http://integralife.com/role/DebtContractualMaturityTableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Principal Repayment" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtContractualMaturityTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r123", "r268" ], "calculation": { "http://integralife.com/role/DebtContractualMaturityTableDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtContractualMaturityTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r123", "r268" ], "calculation": { "http://integralife.com/role/DebtContractualMaturityTableDetails": { "order": 6.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtContractualMaturityTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r123", "r268" ], "calculation": { "http://integralife.com/role/DebtContractualMaturityTableDetails": { "order": 5.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtContractualMaturityTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r123", "r268" ], "calculation": { "http://integralife.com/role/DebtContractualMaturityTableDetails": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtContractualMaturityTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r123", "r268" ], "calculation": { "http://integralife.com/role/DebtContractualMaturityTableDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtContractualMaturityTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r123" ], "calculation": { "http://integralife.com/role/DebtContractualMaturityTableDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "Remainder of 2020" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtContractualMaturityTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r56" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails", "http://integralife.com/role/TreasuryStockNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r56", "r269" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails", "http://integralife.com/role/TreasuryStockNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r264", "r265" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the government of France.", "label": "Ministry of the Economy, Finance and Industry, France [Member]", "terseLabel": "Ministry of the Economy, Finance and Industry, France" } } }, "localname": "MinistryOfTheEconomyFinanceAndIndustryFranceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r109" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r109" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r109", "r110", "r113" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r14", "r77", "r80", "r85", "r113", "r118", "r128", "r132", "r133", "r134", "r135", "r138", "r139", "r146", "r170", "r176", "r180", "r183", "r186", "r201", "r485", "r551", "r566" ], "calculation": { "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfComprehensiveIncomeDetails", "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited", "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited", "http://integralife.com/role/NetIncomeLossPerShareBasicAndDilutedNetIncomePerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r446" ], "lang": { "en-US": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net Investment Hedges" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails", "http://integralife.com/role/DerivativeInstrumentsFairValueOfDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r158" ], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/SegmentAndGeographicInformationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "auth_ref": [ "r74", "r83" ], "calculation": { "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfChangesInAccumulatedOtherComprehensiveIncomeByComponentDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfChangesInAccumulatedOtherComprehensiveIncomeByComponentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r170", "r176", "r180", "r183", "r186" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income (loss)", "verboseLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited", "http://integralife.com/role/SegmentAndGeographicInformationNetSalesAndProfitByReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r503" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r502" ], "calculation": { "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842DetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r502" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "netLabel": "Less: Current lease liabilities", "verboseLabel": "Current portion of lease liability - operating leases" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r502" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "netLabel": "Long-term lease liabilities", "verboseLabel": "Lease liability - operating leases" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r504", "r507" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r501" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Right of use asset - operating leases" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r112" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Non-cash lease expense" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r510", "r512" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r509", "r512" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]", "terseLabel": "Operating Leased Assets [Line Items]" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details", "http://integralife.com/role/LeasesAndRelatedPartyLeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r175", "r176", "r177", "r178", "r180", "r186" ], "lang": { "en-US": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/SegmentAndGeographicInformationNetSalesAndProfitByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OptionIndexedToIssuersEquityEquityAxis": { "auth_ref": [ "r279", "r472", "r473", "r475" ], "lang": { "en-US": { "role": { "documentation": "Information by type of options indexed to an issuer's equity.", "label": "Option Indexed to Issuer's Equity [Axis]", "terseLabel": "Option Indexed to Issuer's Equity [Axis]" } } }, "localname": "OptionIndexedToIssuersEquityEquityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityStrikePrice1": { "auth_ref": [ "r278", "r474" ], "lang": { "en-US": { "role": { "documentation": "Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.", "label": "Option Indexed to Issuer's Equity, Strike Price", "terseLabel": "Initial strike price (in dollars per share)" } } }, "localname": "OptionIndexedToIssuersEquityStrikePrice1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "auth_ref": [ "r476" ], "lang": { "en-US": { "role": { "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.", "label": "Option Indexed to Issuer's Equity, Type [Domain]", "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]" } } }, "localname": "OptionIndexedToIssuersEquityTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r16", "r440" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "BASIS OF PRESENTATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r449", "r467" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsFairValueOfDerivativeInstrumentsByBalanceSheetLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r48" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r70", "r72", "r432", "r436" ], "calculation": { "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfComprehensiveIncomeDetails": { "order": 4.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "negatedTerseLabel": "Pension liability adjustment, net of tax" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r432", "r433", "r436" ], "calculation": { "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r72" ], "calculation": { "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfComprehensiveIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "terseLabel": "Change in unrealized loss on derivatives, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r68", "r72", "r451", "r456", "r469" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Gain (loss) recorded in AOCL, change in fair value", "verboseLabel": "Amount of Gain (Loss) Recognized in AOCL" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails", "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r72", "r75" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "terseLabel": "Amount of Gain (Loss) Reclassified from AOCL into Earnings" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r72", "r75", "r457" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "terseLabel": "Gain (loss) recorded in other income, net" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r459" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Gain (loss) recorded, net investment hedge, change in fair value" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r78", "r81", "r432", "r433", "r436" ], "calculation": { "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfChangesInAccumulatedOtherComprehensiveIncomeByComponentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income (loss), net of tax", "totalLabel": "Net current-period other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfChangesInAccumulatedOtherComprehensiveIncomeByComponentDetails", "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDepreciationAndAmortization": { "auth_ref": [ "r92", "r112", "r238" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.", "label": "Other Depreciation and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "OtherDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenseMember": { "auth_ref": [ "r462" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other expense.", "label": "Other Expense [Member]", "terseLabel": "Other income (expense)" } } }, "localname": "OtherExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/ComprehensiveIncomeLossNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill.", "label": "Other Indefinite-lived Intangible Assets", "terseLabel": "Other indefinite-lived intangible assets" } } }, "localname": "OtherIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesMember": { "auth_ref": [ "r449", "r467" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other liabilities.", "label": "Other Liabilities [Member]", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsFairValueOfDerivativeInstrumentsByBalanceSheetLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r57" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r96" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other income (expense),net" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r108" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "terseLabel": "Payment for contingent consideration" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r105" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Purchases of treasury stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r107" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r105" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Cash taxes paid in net equity settlement" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": { "auth_ref": [ "r101" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.", "label": "Payments to Acquire in Process Research and Development", "negatedLabel": "Acquired in-process research and development" } } }, "localname": "PaymentsToAcquireInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r102" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "terseLabel": "Upfront payment, intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r102" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r331", "r333", "r339", "r342", "r344", "r345", "r346", "r347", "r348", "r351", "r353", "r354", "r355", "r361" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "RETIREMENT PLANS" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/RetirementPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance Stock" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PositionAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by position taken for a security.", "label": "Position [Axis]", "terseLabel": "Position [Axis]" } } }, "localname": "PositionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PositionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates position taken for a security.", "label": "Position [Domain]", "terseLabel": "Position [Domain]" } } }, "localname": "PositionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r29" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized shares (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r29" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding shares (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r29" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock; no par value; 15,000 authorized shares; none outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r20", "r44", "r45" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsFairValueOfDerivativeInstrumentsByBalanceSheetLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromCollectionOfNotesReceivable": { "auth_ref": [ "r99" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from Collection of Notes Receivable", "terseLabel": "Proceeds from note receivable" } } }, "localname": "ProceedsFromCollectionOfNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r104" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from convertible notes issuance", "verboseLabel": "Net proceeds from offering of convertible senior notes" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://integralife.com/role/TreasuryStockNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "auth_ref": [ "r104" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.", "label": "Proceeds from Issuance of Secured Debt", "terseLabel": "Proceeds from borrowings of long-term indebtedness" } } }, "localname": "ProceedsFromIssuanceOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r103" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "terseLabel": "Proceeds from sale of stock purchase warrants", "verboseLabel": "Proceeds from warrant transactions" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r100" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of property and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r103", "r376" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercised stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r47", "r240" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r24", "r25", "r240", "r565" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r24", "r239" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis": { "auth_ref": [ "r500" ], "lang": { "en-US": { "role": { "documentation": "Information by property that could be leased or is available for lease.", "label": "Property Subject to or Available for Operating Lease [Axis]", "terseLabel": "Property Subject to or Available for Operating Lease [Axis]" } } }, "localname": "PropertySubjectToOrAvailableForOperatingLeaseAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain": { "auth_ref": [ "r500" ], "lang": { "en-US": { "role": { "documentation": "A descriptive title of whether the property is subject to or available for operating lease.", "label": "Property Subject to or Available for Operating Lease [Domain]", "terseLabel": "Property Subject to or Available for Operating Lease [Domain]" } } }, "localname": "PropertySubjectToOrAvailableForOperatingLeaseDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r74", "r83" ], "calculation": { "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfChangesInAccumulatedOtherComprehensiveIncomeByComponentDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "negatedLabel": "Loss reclassified from accumulated other comprehensive loss", "terseLabel": "Less: Amounts reclassified from accumulated other comprehensive loss" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/ComprehensiveIncomeLossNarrativeDetails", "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfChangesInAccumulatedOtherComprehensiveIncomeByComponentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r343", "r514", "r515" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r343", "r514", "r517", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfSecuredDebt": { "auth_ref": [ "r106" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.", "label": "Repayments of Secured Debt", "negatedTerseLabel": "Payments on debt" } } }, "localname": "RepaymentsOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r388", "r606" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r388" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentInProcess": { "auth_ref": [], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.", "label": "Research and Development in Process", "terseLabel": "In-process research and development" } } }, "localname": "ResearchAndDevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails", "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r33", "r286", "r384", "r563", "r582", "r587" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r124", "r125", "r126", "r129", "r137", "r139", "r205", "r381", "r382", "r383", "r402", "r403", "r578", "r580" ], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r161", "r162", "r175", "r181", "r182", "r189", "r190", "r193", "r315", "r316", "r531" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total Revenues", "verboseLabel": "Total revenue, net" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited", "http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfRevenuesDisaggregatedByMajorSourceDetails", "http://integralife.com/role/SegmentAndGeographicInformationNetSalesAndProfitByReportableSegmentDetails", "http://integralife.com/role/SegmentAndGeographicInformationTotalRevenueByMajorGeographicAreaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r117", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r328" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Summary of Accounting Policies on Revenue Recognition and Shipping and Handling Fees" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r298", "r299", "r300", "r301", "r302", "r303", "r305", "r306", "r319", "r328" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "REVENUES FROM CONTRACTS WITH CUSTOMERS" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomers" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]", "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]" } } }, "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": { "auth_ref": [ "r327" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.", "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]", "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]" } } }, "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersNarrativeRevenueRemainingPerformanceObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r304" ], "lang": { "en-US": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Performance obligations expected to be satisfied, expected timing" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersNarrativeRevenueRemainingPerformanceObligationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r304" ], "lang": { "en-US": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersNarrativeRevenueRemainingPerformanceObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersNarrativeRevenueRemainingPerformanceObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationPercentage": { "auth_ref": [ "r304" ], "lang": { "en-US": { "role": { "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Percentage", "terseLabel": "Expected performance obligation through 2020, percentage" } } }, "localname": "RevenueRemainingPerformanceObligationPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/RevenuesFromContractsWithCustomersNarrativeRevenueRemainingPerformanceObligationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RevenueTransactionPriceMeasurementTaxExclusionPolicyTextBlock": { "auth_ref": [ "r293" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for election to exclude from measurement of transaction price tax assessed by governmental authority that are both imposed on and concurrent with specific revenue-producing transaction, and collected from customer. Includes, but is not limited to, sales, use, value-added and excise tax.", "label": "Revenue, Transaction Price Measurement, Tax Exclusion [Policy Text Block]", "terseLabel": "Taxes Collected from Customers" } } }, "localname": "RevenueTransactionPriceMeasurementTaxExclusionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r508", "r512" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r74", "r492", "r493" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Changes in Accumulated Other Comprehensive Loss by Component" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/ComprehensiveIncomeLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/NetIncomeLossPerShareNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r414", "r415" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentBusinessCombinationNarrativeDetails", "http://integralife.com/role/BusinessDevelopmentBusinessCombinationScheduleOfPurchasePriceAllocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r66" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans.", "label": "Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/ComprehensiveIncomeLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r56", "r121", "r281", "r283", "r284", "r285", "r496", "r497", "r499", "r557" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt Maximum Leverage Ratios" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r450", "r458", "r464" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Effect of Derivative Instruments Designated as Cash Flow Hedges on Statements of Operations" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r455" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Schedule of Fair Value and Presentation of Derivatives" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r441", "r443", "r444", "r447", "r448", "r455", "r458", "r465", "r466" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Schedule of Derivative Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r1", "r3", "r4", "r5", "r6", "r7", "r8", "r10", "r12", "r13", "r14", "r245", "r246" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Schedule of Fair Values of Assets and Liabilities Held For Sale" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r149" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Basic and Diluted Net Income (Loss) Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/NetIncomeLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r392" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r222", "r227" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r217", "r219" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfChangesInCarryingAmountOfGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r217", "r219" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Changes in Carrying Amount of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r231", "r234" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r23", "r41", "r42", "r43" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories, Net" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r268" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of Contractual Repayments of Long-Term Debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule of Operating Leased Assets [Table]", "terseLabel": "Schedule of Operating Leased Assets [Table]" } } }, "localname": "ScheduleOfOperatingLeasedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesFutureMinimumLeasePaymentUnderOperatingLeasesAfterAdoptionOf842Details", "http://integralife.com/role/LeasesAndRelatedPartyLeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r418" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/BusinessDevelopmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r170", "r173", "r179", "r217" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/SegmentAndGeographicInformationNarrativeDetails", "http://integralife.com/role/SegmentAndGeographicInformationNetSalesAndProfitByReportableSegmentDetails", "http://integralife.com/role/SegmentAndGeographicInformationTotalRevenueByMajorGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r170", "r173", "r179", "r217" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Geographic Revenue by Area", "verboseLabel": "Schedule of Net Sales and Profit by Segments" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/SegmentAndGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r366", "r375" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SecuredDebtCurrent": { "auth_ref": [ "r26", "r548", "r560" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "Secured Debt, Current", "terseLabel": "Current portion of borrowings under senior credit facility", "verboseLabel": "Term loan component of senior credit facility" } } }, "localname": "SecuredDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SecuredLongTermDebt": { "auth_ref": [ "r56" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.", "label": "Secured Long-term Debt, Noncurrent", "terseLabel": "Long-term borrowings under senior credit facility" } } }, "localname": "SecuredLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r157", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r175", "r176", "r177", "r178", "r180", "r181", "r182", "r183", "r184", "r186", "r193", "r571" ], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfChangesInCarryingAmountOfGoodwillDetails", "http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfRevenuesDisaggregatedByMajorSourceDetails", "http://integralife.com/role/SegmentAndGeographicInformationNarrativeDetails", "http://integralife.com/role/SegmentAndGeographicInformationNetSalesAndProfitByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r157", "r159", "r160", "r170", "r174", "r180", "r184", "r185", "r186", "r187", "r189", "r192", "r193", "r194" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "SEGMENT AND GEOGRAPHIC INFORMATION" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/SegmentAndGeographicInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/SegmentAndGeographicInformationNarrativeDetails", "http://integralife.com/role/SegmentAndGeographicInformationNetSalesAndProfitByReportableSegmentDetails", "http://integralife.com/role/SegmentAndGeographicInformationTotalRevenueByMajorGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting Information, Operating Income (Loss) [Abstract]", "terseLabel": "Segment Net Sales" } } }, "localname": "SegmentReportingInformationOperatingIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/SegmentAndGeographicInformationNetSalesAndProfitByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingInformationProfitLossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting Information, Profit (Loss) [Abstract]", "terseLabel": "Segment Profit" } } }, "localname": "SegmentReportingInformationProfitLossAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/SegmentAndGeographicInformationNetSalesAndProfitByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r93" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r111" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r367" ], "lang": { "en-US": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period", "terseLabel": "Requisite service periods of awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r367" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Stock options exercisable, vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r371" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Awards granted during the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r371" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Other than options, weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r370" ], "lang": { "en-US": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Grants in period, net of forfeitures (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r372" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Options, weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r363", "r369" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/NetIncomeLossPerShareNarrativeDetails", "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r368" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r280" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance End of Period, Shares (in shares)", "periodStartLabel": "Balance Beginning of Period, Shares (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates the sale of a borrowed security or written option.", "label": "Short [Member]", "terseLabel": "Short" } } }, "localname": "ShortMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StandbyLettersOfCreditMember": { "auth_ref": [ "r263", "r267", "r431", "r588" ], "lang": { "en-US": { "role": { "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.", "label": "Standby Letters of Credit [Member]", "terseLabel": "Standby Letters of Credit" } } }, "localname": "StandbyLettersOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r2", "r157", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r175", "r176", "r177", "r178", "r180", "r181", "r182", "r183", "r184", "r186", "r193", "r217", "r244", "r250", "r251", "r571" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfChangesInCarryingAmountOfGoodwillDetails", "http://integralife.com/role/RevenuesFromContractsWithCustomersScheduleOfRevenuesDisaggregatedByMajorSourceDetails", "http://integralife.com/role/SegmentAndGeographicInformationNarrativeDetails", "http://integralife.com/role/SegmentAndGeographicInformationNetSalesAndProfitByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r59", "r124", "r125", "r126", "r129", "r137", "r139", "r156", "r205", "r280", "r286", "r381", "r382", "r383", "r402", "r403", "r487", "r488", "r489", "r490", "r491", "r493", "r578", "r579", "r580" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/ComprehensiveIncomeLossNarrativeDetails", "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfChangesInAccumulatedOtherComprehensiveIncomeByComponentDetails", "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited", "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r124", "r125", "r126", "r156", "r531" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r29", "r30", "r280", "r286" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock through employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r29", "r30", "r280", "r286" ], "lang": { "en-US": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock for vesting of share based awards, net of shares withheld for taxes (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": { "auth_ref": [ "r30", "r280", "r286" ], "lang": { "en-US": { "role": { "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.", "label": "Stock Issued During Period, Shares, Treasury Stock Reissued", "negatedTerseLabel": "Share repurchase and equity component of the convertible note issuance, net (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r29", "r30", "r280", "r286" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock through employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r29", "r30", "r286", "r365", "r372" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock for vesting of share based awards, net of shares withheld for taxes" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "verboseLabel": "Stock repurchase program, authorized amount (up to)" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/TreasuryStockNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Remaining amount under share repurchase" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/TreasuryStockNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r29", "r30", "r280", "r286" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedTerseLabel": "Accelerated shares repurchased (in shares)", "terseLabel": "Stock repurchased during period (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited", "http://integralife.com/role/TreasuryStockNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r29", "r30", "r280", "r286" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Accelerated shares repurchased", "terseLabel": "Accelerated shares repurchased, amount" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited", "http://integralife.com/role/TreasuryStockNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r30", "r35", "r36", "r118", "r199", "r201", "r485" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance, End of Period", "periodStartLabel": "Balance, Beginning of Period", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/ComprehensiveIncomeLossScheduleOfChangesInAccumulatedOtherComprehensiveIncomeByComponentDetails", "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited", "http://integralife.com/role/DerivativeInstrumentsEffectOfDerivativeInstrumentsDesignatedCashFlowHedgesOnStatementsOfOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r494", "r518" ], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleNarrativeDetails", "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r494", "r518" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleNarrativeDetails", "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r494", "r518" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/AssetsAndLiabilitiesHeldForSaleNarrativeDetails", "http://integralife.com/role/BusinessDevelopmentAssetAcquisitionNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SwissFederalTaxAdministrationFTAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the government of Switzerland.", "label": "Swiss Federal Tax Administration (FTA) [Member]", "terseLabel": "Swiss Federal Tax Administration (FTA)" } } }, "localname": "SwissFederalTaxAdministrationFTAMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r419" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Codman tradename" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r288" ], "lang": { "en-US": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Treasury Stock Acquired, Average Cost Per Share", "terseLabel": "Treasury stock, average cost per share (in dollars per share)" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/TreasuryStockNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r288" ], "lang": { "en-US": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "terseLabel": "Treasury stock (in shares)" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/TreasuryStockNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockCommonValue": { "auth_ref": [ "r60", "r288", "r291" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Value", "terseLabel": "Treasury stock" } } }, "localname": "TreasuryStockCommonValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/TreasuryStockNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r58", "r288" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r58", "r288" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "negatedPeriodEndLabel": "Balance, End of Period, Treasury Stock, Shares (in shares)", "negatedPeriodStartLabel": "Balance, Beginning of Period, Treasury Stock, Shares (in shares)", "terseLabel": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://integralife.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockTextBlock": { "auth_ref": [ "r292" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Treasury Stock [Text Block]", "terseLabel": "TREASURY STOCK" } } }, "localname": "TreasuryStockTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/TreasuryStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_TreasuryStockTransactionsExcludingValueOfSharesReissuedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Treasury Stock Transactions, Excluding Value of Shares Reissued [Abstract]" } } }, "localname": "TreasuryStockTransactionsExcludingValueOfSharesReissuedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r58", "r288", "r291" ], "calculation": { "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost; 4,915 shares and 2,865 shares at September 30, 2020 and December 31, 2019, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails", "http://integralife.com/role/DerivativeInstrumentsScheduleOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VehiclesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment used primarily for road transportation.", "label": "Vehicles [Member]", "terseLabel": "Leased vehicles" } } }, "localname": "VehiclesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/LeasesAndRelatedPartyLeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r141", "r149" ], "calculation": { "http://integralife.com/role/NetIncomeLossPerShareBasicAndDilutedNetIncomePerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average common shares for diluted earnings per share (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited", "http://integralife.com/role/NetIncomeLossPerShareBasicAndDilutedNetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average common shares outstanding (See Note 14):" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r140", "r149" ], "calculation": { "http://integralife.com/role/NetIncomeLossPerShareBasicAndDilutedNetIncomePerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average common shares outstanding - Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited", "http://integralife.com/role/NetIncomeLossPerShareBasicAndDilutedNetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "auth_ref": [ "r95" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.", "label": "Write off of Deferred Debt Issuance Cost", "verboseLabel": "Previously capitalized financing costs, written-off" } } }, "localname": "WriteOffOfDeferredDebtIssuanceCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://integralife.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" } }, "unitCount": 13 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r15": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r155": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r16": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r194": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r235": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r247": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r254": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r262": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121596127&loc=d3e12803-110250" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r277": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "63", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=117411753&loc=d3e23176-110880" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405686&loc=d3e22802-112653" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r292": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/subtopic&trid=2208821" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "32", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121321036&loc=SL82860478-203043" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r328": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4587-114921" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r361": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r387": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r413": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(6)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121607252&loc=SL5864739-113975" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90193-114008" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90198-114008" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90205-114008" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90205-114008" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519491&loc=d3e90476-114009" }, "r477": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121578510&loc=d3e41551-112718" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r513": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611282-123010" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611282-123010" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611282-123010" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column E)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611282-123010" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column F)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611282-123010" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611282-123010" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r607": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r608": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r609": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r611": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r612": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r613": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e526-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" } }, "version": "2.1" } ZIP 99 0000917520-20-000047-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000917520-20-000047-xbrl.zip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